| Score | Text |
|---|---|
| 0.9992 | DrugIsotretinoin teratogenicity. |
| 0.9175 | Isotretinoin Adverse-Effectteratogenicity . |
| Score | Text |
|---|---|
| 0.9966 | DrugNiacin maculopathy. |
| 0.9130 | Niacin Adverse-Effectmaculopathy . |
| Score | Text |
|---|---|
| 0.9989 | DrugAllopurinol hypersensitivity. |
| 0.8684 | Allopurinol Adverse-Effecthypersensitivity . |
| Score | Text |
|---|---|
| 0.9990 | DrugTamoxifen retinopathy. |
| 0.9154 | Tamoxifen Adverse-Effectretinopathy . |
| Score | Text |
|---|---|
| 0.9990 | DrugMetronidazole neuropathy. |
| 0.8735 | Metronidazole Adverse-Effectneuropathy . |
| Score | Text |
|---|---|
| 0.9986 | DrugCyclophosphamide pneumonitis. |
| 0.9015 | Cyclophosphamide Adverse-Effectpneumonitis . |
| Score | Text |
|---|---|
| 0.9985 | DrugGold nephropathy. |
| 0.8537 | Gold Adverse-Effectnephropathy . |
| Score | Text |
|---|---|
| 0.9995 | Ocular Drugethambutol toxicity. |
| 0.6846 | Adverse-EffectOcular ethambutol toxicity . |
| Score | Text |
|---|---|
| 0.9995 | DrugClozapine induced polyserositis. |
| 0.9981 | Clozapine induced Adverse-Effectpolyserositis . |
| Score | Text |
|---|---|
| 0.9981 | DrugSulfadiazine crystalluria revisited. |
| 0.8797 | Sulfadiazine Adverse-Effectcrystalluria revisited. |
| Score | Text |
|---|---|
| 0.9951 | Pulmonary Druggold toxicity. |
| 0.8257 | Adverse-EffectPulmonary gold toxicity . |
| Score | Text |
|---|---|
| 0.9996 | Anaphylaxis to Drugcalcitonin . |
| 0.9987 | Adverse-EffectAnaphylaxis to calcitonin. |
| Score | Text |
|---|---|
| 0.9996 | Dermatitis to Drugcaptopril . |
| 0.9988 | Adverse-EffectDermatitis to captopril. |
| Score | Text |
|---|---|
| 0.9986 | Severe Drugdapsone hypersensitivity syndrome. |
| 0.9151 | Severe dapsone Adverse-Effecthypersensitivity syndrome . |
| Score | Text |
|---|---|
| 0.9996 | Anisocoria from transdermal Drugscopolamine . |
| 0.9987 | Adverse-EffectAnisocoria from transdermal scopolamine. |
| Score | Text |
|---|---|
| 0.9996 | Priapism associated with Drugolanzapine . |
| 0.9986 | Adverse-EffectPriapism associated with olanzapine. |
| Score | Text |
|---|---|
| 0.9995 | Anaphylaxis to intrathecal Drugdiamorphine . |
| 0.9987 | Adverse-EffectAnaphylaxis to intrathecal diamorphine. |
| Score | Text |
|---|---|
| 0.9996 | DrugDiclofenac - associated hepatitis. |
| 0.9989 | Diclofenac - associated Adverse-Effecthepatitis . |
| Score | Text |
|---|---|
| 0.9995 | DrugCarbamazepine - induced hyperammonemia. |
| 0.9972 | Carbamazepine - induced Adverse-Effecthyperammonemia . |
| Score | Text |
|---|---|
| 0.9996 | DrugImidazoline intoxication in children. |
| 0.8091 | Adverse-EffectImidazoline intoxication in children. |
| Score | Text |
|---|---|
| 0.9995 | DrugGold - induced pneumonitis. |
| 0.9989 | Gold - induced Adverse-Effectpneumonitis . |
| Score | Text |
|---|---|
| 0.9995 | DrugCarbamazepine - induced tics. |
| 0.9986 | Carbamazepine - induced Adverse-Effecttics . |
| Score | Text |
|---|---|
| 0.9996 | Priapism associated with Drugzuclopenthixol . |
| 0.9987 | Adverse-EffectPriapism associated with zuclopenthixol. |
| Score | Text |
|---|---|
| 0.9994 | Delayed hypersensitivity to Drugflurbiprofen . |
| 0.9710 | Adverse-EffectDelayed hypersensitivity to flurbiprofen. |
| Score | Text |
|---|---|
| 0.9996 | Morphea after Drugbromocriptine therapy. |
| 0.9988 | Adverse-EffectMorphea after bromocriptine therapy. |
| Score | Text |
|---|---|
| 0.9996 | DrugAmpicillin - associated seizures. |
| 0.9988 | Ampicillin - associated Adverse-Effectseizures . |
| Score | Text |
|---|---|
| 0.9996 | DrugAtenolol - induced pseudolymphoma. |
| 0.9979 | Atenolol - induced Adverse-Effectpseudolymphoma . |
| Score | Text |
|---|---|
| 0.9995 | DrugLosartan - induced angioedema. |
| 0.9984 | Losartan - induced Adverse-Effectangioedema . |
| Score | Text |
|---|---|
| 0.9996 | DrugDisulfiram - induced hepatitis. |
| 0.9990 | Disulfiram - induced Adverse-Effecthepatitis . |
| Score | Text |
|---|---|
| 0.9996 | DrugMetoclopramide - induced parkinsonism. |
| 0.9985 | Metoclopramide - induced Adverse-Effectparkinsonism . |
| Score | Text |
|---|---|
| 0.9993 | DrugPhenylpropanolamine - induced psychosis. |
| 0.9986 | Phenylpropanolamine - induced Adverse-Effectpsychosis . |
| Score | Text |
|---|---|
| 0.9993 | DrugClofazimine induced nail changes. |
| 0.9910 | Clofazimine induced Adverse-Effectnail changes . |
| Score | Text |
|---|---|
| 0.9993 | DrugCiprofloxacin - induced psychosis. |
| 0.9986 | Ciprofloxacin - induced Adverse-Effectpsychosis . |
| Score | Text |
|---|---|
| 0.9995 | Jaundice induced by Drugstreptokinase . |
| 0.9988 | Adverse-EffectJaundice induced by streptokinase. |
| Score | Text |
|---|---|
| 0.9996 | Agranulocytosis during Drugclozapine therapy. |
| 0.9981 | Adverse-EffectAgranulocytosis during clozapine therapy. |
| Score | Text |
|---|---|
| 0.9993 | DrugHeparin - induced hyperkalemia. |
| 0.9983 | Heparin - induced Adverse-Effecthyperkalemia . |
| Score | Text |
|---|---|
| 0.9996 | Stupor from Druglamotrigine toxicity. |
| 0.9991 | Adverse-EffectStupor from lamotrigine toxicity. |
| Score | Text |
|---|---|
| 0.9996 | DrugCimetidine - induced fever. |
| 0.9964 | Cimetidine - induced Adverse-Effectfever . |
| Score | Text |
|---|---|
| 0.9996 | DrugVancomycin - induced vasculitis. |
| 0.9987 | Vancomycin - induced Adverse-Effectvasculitis . |
| Score | Text |
|---|---|
| 0.9997 | Gigantomastia induced by Drugbucillamine . |
| 0.9985 | Adverse-EffectGigantomastia induced by bucillamine. |
| Score | Text |
|---|---|
| 0.9996 | DrugIsoniazid - induced anaphylaxis. |
| 0.9986 | Isoniazid - induced Adverse-Effectanaphylaxis . |
| Score | Text |
|---|---|
| 0.9995 | DrugVincristine induced cranial polyneuropathy. |
| 0.9831 | Vincristine induced Adverse-Effectcranial polyneuropathy . |
| Score | Text |
|---|---|
| 0.9994 | DrugBromocriptine - induced schizophrenia. |
| 0.9974 | Bromocriptine - induced Adverse-Effectschizophrenia . |
| Score | Text |
|---|---|
| 0.9992 | Hepatic reactions to Drugcyclofenil . |
| 0.9916 | Adverse-EffectHepatic reactions to cyclofenil. |
| Score | Text |
|---|---|
| 0.9996 | DrugQuetiapine - induced myoclonus. |
| 0.9989 | Quetiapine - induced Adverse-Effectmyoclonus . |
| Score | Text |
|---|---|
| 0.9993 | DrugEnalaprilat induced acute parotitis. |
| 0.9859 | Enalaprilat induced Adverse-Effectacute parotitis . |
| Score | Text |
|---|---|
| 0.9996 | DrugTemsirolimus - induced glomerulopathy. |
| 0.9973 | Temsirolimus - induced Adverse-Effectglomerulopathy . |
| Score | Text |
|---|---|
| 0.9996 | Rhabdomyolysis following Drugclarithromycin monotherapy. |
| 0.9978 | Adverse-EffectRhabdomyolysis following clarithromycin monotherapy. |
| Score | Text |
|---|---|
| 0.9996 | DrugTaxane - induced glaucoma. |
| 0.9988 | Taxane - induced Adverse-Effectglaucoma . |
| Score | Text |
|---|---|
| 0.9996 | DrugFurosemide - associated fever. |
| 0.9961 | Furosemide - associated Adverse-Effectfever . |
| Score | Text |
|---|---|
| 0.9993 | DrugThalidomide neuropathy in childhood. |
| 0.8830 | Thalidomide Adverse-Effectneuropathy in childhood. |
| Score | Text |
|---|---|
| 0.9996 | Hepatitis following Drugcimetidine administration. |
| 0.9990 | Adverse-EffectHepatitis following cimetidine administration. |
| Score | Text |
|---|---|
| 0.9994 | DrugLansoprazole - induced thrombocytopenia. |
| 0.9967 | Lansoprazole - induced Adverse-Effectthrombocytopenia . |
| Score | Text |
|---|---|
| 0.9997 | DrugColchicine - induced rhabdomyolysis. |
| 0.9974 | Colchicine - induced Adverse-Effectrhabdomyolysis . |
| Score | Text |
|---|---|
| 0.9995 | Keratitis in Drugmethamphetamine abusers. |
| 0.9990 | Adverse-EffectKeratitis in methamphetamine abusers. |
| Score | Text |
|---|---|
| 0.9996 | Localized purpura associated with Druglamotrigine . |
| 0.9906 | Adverse-EffectLocalized purpura associated with lamotrigine. |
| Score | Text |
|---|---|
| 0.9991 | DrugCiprofloxacin - induced hemorrhagic vasculitis. |
| 0.9880 | Ciprofloxacin - induced Adverse-Effecthemorrhagic vasculitis . |
| Score | Text |
|---|---|
| 0.9992 | DrugCodeine intoxication in the neonate. |
| 0.8259 | Adverse-EffectCodeine intoxication in the neonate. |
| Score | Text |
|---|---|
| 0.9996 | Rosaceiform eruption induced by Drugerlotinib . |
| 0.9916 | Adverse-EffectRosaceiform eruption induced by erlotinib. |
| Score | Text |
|---|---|
| 0.9994 | DrugMethyldopa - induced liver injury. |
| 0.9917 | Methyldopa - induced Adverse-Effectliver injury . |
| Score | Text |
|---|---|
| 0.9989 | DrugAcetazolamide - accelerated anticonvulsant osteomalacia. |
| 0.9946 | Acetazolamide - accelerated anticonvulsant Adverse-Effectosteomalacia . |
| Score | Text |
|---|---|
| 0.9992 | DrugCephalexin rash in infectious mononucleosis. |
| 0.9128 | Adverse-EffectCephalexin rash in infectious mononucleosis. |
| Score | Text |
|---|---|
| 0.9991 | Adverse-EffectScleritis complicating zoledronic acid infusion. |
| 0.9793 | Scleritis complicating Drugzoledronic acid infusion. |
| Score | Text |
|---|---|
| 0.9996 | Seizures associated with Drugfluoxetine therapy. |
| 0.9992 | Adverse-EffectSeizures associated with fluoxetine therapy. |
| Score | Text |
|---|---|
| 0.9996 | Pulmonary fibrosis associated with Drugnabumetone . |
| 0.9892 | Adverse-EffectPulmonary fibrosis associated with nabumetone. |
| Score | Text |
|---|---|
| 0.9995 | Metabolic acidosis induced by Drugacetazolamide . |
| 0.9923 | Adverse-EffectMetabolic acidosis induced by acetazolamide. |
| Score | Text |
|---|---|
| 0.9995 | Probable Drugenoxaparin - induced hepatotoxicity. |
| 0.9976 | Probable enoxaparin - induced Adverse-Effecthepatotoxicity . |
| Score | Text |
|---|---|
| 0.9996 | Pulmonary toxicity associated with Drugerlotinib . |
| 0.9876 | Adverse-EffectPulmonary toxicity associated with erlotinib. |
| Score | Text |
|---|---|
| 0.9994 | Fixed drug eruption to Drugrofecoxib . |
| 0.9724 | Adverse-EffectFixed drug eruption to rofecoxib. |
| Score | Text |
|---|---|
| 0.9995 | DrugEnoxaparin - induced generalized exanthem. |
| 0.9856 | Enoxaparin - induced Adverse-Effectgeneralized exanthem . |
| Score | Text |
|---|---|
| 0.9992 | Biomicroscopy revealed Drugamiodarone corneal deposits. |
| 0.8692 | Biomicroscopy revealed amiodarone Adverse-Effectcorneal deposits . |
| Score | Text |
|---|---|
| 0.9995 | DrugAlbendazole - induced pseudomembranous colitis. |
| 0.9916 | Albendazole - induced Adverse-Effectpseudomembranous colitis . |
| Score | Text |
|---|---|
| 0.9997 | Catatonia associated with Drugdisulfiram therapy. |
| 0.9988 | Adverse-EffectCatatonia associated with disulfiram therapy. |
| Score | Text |
|---|---|
| 0.9993 | DrugPropylthiouracil - induced cutaneous vasculitis. |
| 0.9852 | Propylthiouracil - induced Adverse-Effectcutaneous vasculitis . |
| Score | Text |
|---|---|
| 0.9996 | Nodular scleritis following Drugalendronate therapy. |
| 0.9897 | Adverse-EffectNodular scleritis following alendronate therapy. |
| Score | Text |
|---|---|
| 0.9996 | Acute dystonia induced by Druglamivudine . |
| 0.9882 | Adverse-EffectAcute dystonia induced by lamivudine. |
| Score | Text |
|---|---|
| 0.9991 | Occult Drugquinine - induced thrombocytopenia. |
| 0.9969 | Occult quinine - induced Adverse-Effectthrombocytopenia . |
| Score | Text |
|---|---|
| 0.9979 | DrugProtamine - induced fatal anaphylaxis. |
| 0.9841 | Protamine - induced Adverse-Effectfatal anaphylaxis . |
| Score | Text |
|---|---|
| 0.9992 | DrugChlorpropamide - induced hemolytic anemia. |
| 0.9916 | Chlorpropamide - induced Adverse-Effecthemolytic anemia . |
| Score | Text |
|---|---|
| 0.9986 | Adverse-EffectParaplegia following intrathecal cytosine arabinoside. |
| 0.9755 | Paraplegia following intrathecal Drugcytosine arabinoside . |
| Score | Text |
|---|---|
| 0.9993 | Sarcoma complicating therapy with Drugcyclophosphamide . |
| 0.9992 | Adverse-EffectSarcoma complicating therapy with cyclophosphamide. |
| Score | Text |
|---|---|
| 0.9996 | DrugQuinine - induced hearing loss. |
| 0.9950 | Quinine - induced Adverse-Effecthearing loss . |
| Score | Text |
|---|---|
| 0.9994 | DrugGold - induced aplastic anemia. |
| 0.9925 | Gold - induced Adverse-Effectaplastic anemia . |
| Score | Text |
|---|---|
| 0.9995 | Tardive dyskinesia induced by Drugsulpiride . |
| 0.9903 | Adverse-EffectTardive dyskinesia induced by sulpiride. |
| Score | Text |
|---|---|
| 0.9994 | Intravenous Drugdiazepam exacerbated the seizures. |
| 0.9970 | Intravenous diazepam exacerbated the Adverse-Effectseizures . |
| Score | Text |
|---|---|
| 0.9996 | DrugEzetimibe - induced acute pancreatitis. |
| 0.9871 | Ezetimibe - induced Adverse-Effectacute pancreatitis . |
| Score | Text |
|---|---|
| 0.9995 | DrugCefuroxime - induced immune hemolysis. |
| 0.9865 | Cefuroxime - induced Adverse-Effectimmune hemolysis . |
| Score | Text |
|---|---|
| 0.9942 | Lamotrigine toxicity secondary to Drugsertraline . |
| 0.9941 | DrugLamotrigine toxicity secondary to sertraline. |
| 0.8827 | Adverse-EffectLamotrigine toxicity secondary to sertraline. |
| Score | Text |
|---|---|
| 0.9991 | DrugAzathioprine can cause severe myelosuppression. |
| 0.9377 | Azathioprine can cause severe Adverse-Effectmyelosuppression . |
| Score | Text |
|---|---|
| 0.9996 | Acute leukaemia during Drugtamoxifen therapy. |
| 0.9907 | Adverse-EffectAcute leukaemia during tamoxifen therapy. |
| Score | Text |
|---|---|
| 0.9995 | Vortex keratopathy associated with Drugatovaquone . |
| 0.9866 | Adverse-EffectVortex keratopathy associated with atovaquone. |
| Score | Text |
|---|---|
| 0.9995 | Paradoxical seizures in Drugphenytoin toxicity. |
| 0.9926 | Paradoxical Adverse-Effectseizures in phenytoin toxicity. |
| Score | Text |
|---|---|
| 0.9994 | Hepatic damage after Drugdanazol treatment. |
| 0.9935 | Adverse-EffectHepatic damage after danazol treatment. |
| Score | Text |
|---|---|
| 0.9994 | DrugInsulin - induced cardiac failure. |
| 0.9923 | Insulin - induced Adverse-Effectcardiac failure . |
| Score | Text |
|---|---|
| 0.9994 | Nail staining from Drughydroquinone cream. |
| 0.9901 | Adverse-EffectNail staining from hydroquinone cream. |
| Score | Text |
|---|---|
| 0.9996 | Delusional parasitosis associated with Drugphenelzine . |
| 0.9925 | Adverse-EffectDelusional parasitosis associated with phenelzine. |
| Score | Text |
|---|---|
| 0.9995 | DrugPiritrexim - induced pulmonary toxicity. |
| 0.9886 | Piritrexim - induced Adverse-Effectpulmonary toxicity . |
| Score | Text |
|---|---|
| 0.9991 | DrugPropecia - associated bilateral cataract. |
| 0.9873 | Propecia - associated Adverse-Effectbilateral cataract . |
| Score | Text |
|---|---|
| 0.9996 | DrugTerlipressin - induced ventricular arrhythmia. |
| 0.9863 | Terlipressin - induced Adverse-Effectventricular arrhythmia . |
| Score | Text |
|---|---|
| 0.9996 | Asterixis induced by Drugcarbamazepine therapy. |
| 0.9988 | Adverse-EffectAsterixis induced by carbamazepine therapy. |
| Score | Text |
|---|---|
| 0.9993 | Cardiorespiratory toxicity due to Drugmiconazole . |
| 0.9885 | Adverse-EffectCardiorespiratory toxicity due to miconazole. |
| Score | Text |
|---|---|
| 0.9995 | DrugNabumetone - associated interstitial nephritis. |
| 0.9875 | Nabumetone - associated Adverse-Effectinterstitial nephritis . |
| Score | Text |
|---|---|
| 0.9976 | Human insulin - induced Adverse-Effectlipoatrophy . |
| 0.9902 | DrugHuman insulin - induced lipoatrophy. |
| Score | Text |
|---|---|
| 0.9995 | DrugSulfasalazine - induced lupus erythematosus. |
| 0.9870 | Sulfasalazine - induced Adverse-Effectlupus erythematosus . |
| Score | Text |
|---|---|
| 0.9994 | Lichenoid drug eruption to Drugsalsalate . |
| 0.9832 | Adverse-EffectLichenoid drug eruption to salsalate. |
| Score | Text |
|---|---|
| 0.9995 | Uncontrolled headache induced by Drugoxcarbazepine . |
| 0.9938 | Uncontrolled Adverse-Effectheadache induced by oxcarbazepine. |
| Score | Text |
|---|---|
| 0.9995 | Intravenous Drugazithromycin - induced ototoxicity. |
| 0.9983 | Intravenous azithromycin - induced Adverse-Effectototoxicity . |
| Score | Text |
|---|---|
| 0.9996 | Fulminant hepatitis associated with Drugdisulfiram . |
| 0.9903 | Adverse-EffectFulminant hepatitis associated with disulfiram. |
| Score | Text |
|---|---|
| 0.9996 | Pulmonary toxicity secondary to Drugprocarbazine . |
| 0.9881 | Adverse-EffectPulmonary toxicity secondary to procarbazine. |
| Score | Text |
|---|---|
| 0.9995 | DrugMesalamine - induced hypersensitivity pneumonitis. |
| 0.9860 | Mesalamine - induced Adverse-Effecthypersensitivity pneumonitis . |
| Score | Text |
|---|---|
| 0.9996 | Psychotic disorder associated with Drugisoniazid . |
| 0.9937 | Adverse-EffectPsychotic disorder associated with isoniazid. |
| Score | Text |
|---|---|
| 0.9990 | DrugMagnesium toxicosis in two horses. |
| 0.8598 | Adverse-EffectMagnesium toxicosis in two horses. |
| Score | Text |
|---|---|
| 0.9996 | Seizures associated with Drugofloxacin therapy. |
| 0.9992 | Adverse-EffectSeizures associated with ofloxacin therapy. |
| Score | Text |
|---|---|
| 0.9995 | Pemphigus foliaceus induced by Drugrifampicin . |
| 0.9860 | Adverse-EffectPemphigus foliaceus induced by rifampicin. |
| Score | Text |
|---|---|
| 0.9995 | Anaphylactic reaction to Drugbacitracin ointment. |
| 0.9886 | Adverse-EffectAnaphylactic reaction to bacitracin ointment. |
| Score | Text |
|---|---|
| 0.9994 | DrugRifampicin - induced renal failure. |
| 0.9919 | Rifampicin - induced Adverse-Effectrenal failure . |
| Score | Text |
|---|---|
| 0.9994 | Intranasal Drugdesmopressin - induced hyponatremia. |
| 0.9984 | Intranasal desmopressin - induced Adverse-Effecthyponatremia . |
| Score | Text |
|---|---|
| 0.9995 | DrugChloroquine - induced bilateral ptosis. |
| 0.9925 | Chloroquine - induced Adverse-Effectbilateral ptosis . |
| Score | Text |
|---|---|
| 0.9995 | DrugDisopyramide - induced heart block. |
| 0.9934 | Disopyramide - induced Adverse-Effectheart block . |
| Score | Text |
|---|---|
| 0.9995 | DrugCarbamazepine - induced Diabetes mellitus. |
| 0.9899 | Carbamazepine - induced Adverse-EffectDiabetes mellitus . |
| Score | Text |
|---|---|
| 0.9996 | DrugEtoposide - related myocardial infarction. |
| 0.9889 | Etoposide - related Adverse-Effectmyocardial infarction . |
| Score | Text |
|---|---|
| 0.9995 | Myoclonic spasms following intrathecal Drugmorphine . |
| 0.9901 | Adverse-EffectMyoclonic spasms following intrathecal morphine. |
| Score | Text |
|---|---|
| 0.9996 | DrugMethotrexate - induced liver cirrhosis. |
| 0.9889 | Methotrexate - induced Adverse-Effectliver cirrhosis . |
| Score | Text |
|---|---|
| 0.9994 | DrugCefoxitin - associated renal failure. |
| 0.9914 | Cefoxitin - associated Adverse-Effectrenal failure . |
| Score | Text |
|---|---|
| 0.9996 | Acute psychosis associated with Druglevetiracetam . |
| 0.9887 | Adverse-EffectAcute psychosis associated with levetiracetam. |
| Score | Text |
|---|---|
| 0.9994 | Metastatic osteomyelitis following DrugBCG vaccination. |
| 0.9830 | Adverse-EffectMetastatic osteomyelitis following BCG vaccination. |
| Score | Text |
|---|---|
| 0.9997 | Atrial fibrillation after Drugvardenafil therapy. |
| 0.9919 | Adverse-EffectAtrial fibrillation after vardenafil therapy. |
| Score | Text |
|---|---|
| 0.9996 | Visual hallucinations associated with Drugzonisamide . |
| 0.9859 | Adverse-EffectVisual hallucinations associated with zonisamide. |
| Score | Text |
|---|---|
| 0.9995 | DrugGliclazide - induced acute hepatitis. |
| 0.9901 | Gliclazide - induced Adverse-Effectacute hepatitis . |
| Score | Text |
|---|---|
| 0.9995 | DrugRisperidone - induced tardive dyskinesia. |
| 0.9898 | Risperidone - induced Adverse-Effecttardive dyskinesia . |
| Score | Text |
|---|---|
| 0.9728 | Adverse-EffectAllergic contact dermatitis from 4 - chloro - 7 - nitrobenzofurazan. |
| 0.9455 | Allergic contact dermatitis from Drug4 - chloro - 7 - nitrobenzofurazan . |
| Score | Text |
|---|---|
| 0.9994 | DrugNitrendipine - induced gingival hyperplasia. |
| 0.9907 | Nitrendipine - induced Adverse-Effectgingival hyperplasia . |
| Score | Text |
|---|---|
| 0.9996 | DrugAdenosine - induced ventricular fibrillation. |
| 0.9879 | Adenosine - induced Adverse-Effectventricular fibrillation . |
| Score | Text |
|---|---|
| 0.9996 | Edema associated with Drugibuprofen therapy. |
| 0.9992 | Adverse-EffectEdema associated with ibuprofen therapy. |
| Score | Text |
|---|---|
| 0.9996 | DrugTegaserod - associated ischemic colitis. |
| 0.9928 | Tegaserod - associated Adverse-Effectischemic colitis . |
| Score | Text |
|---|---|
| 0.9992 | Progressive hypokalemia developed during Drugphosphate treatment. |
| 0.9885 | Adverse-EffectProgressive hypokalemia developed during phosphate treatment. |
| Score | Text |
|---|---|
| 0.9995 | Progressive pulmonary fibrosis complicating Drugcyclophosphamide therapy. |
| 0.9841 | Adverse-EffectProgressive pulmonary fibrosis complicating cyclophosphamide therapy. |
| Score | Text |
|---|---|
| 0.9994 | Cardiopulmonary arrest following intravenous Drugphenytoin loading. |
| 0.9930 | Adverse-EffectCardiopulmonary arrest following intravenous phenytoin loading. |
| Score | Text |
|---|---|
| 0.9996 | DrugQuetiapine - induced leucopenia and thrombocytopenia. |
| 0.9980 | Quetiapine - induced Adverse-Effectleucopenia and thrombocytopenia. |
| 0.9971 | Quetiapine - induced leucopenia and Adverse-Effectthrombocytopenia . |
| Score | Text |
|---|---|
| 0.9992 | A paradoxical ocular effect of Drugbrimonidine . |
| 0.9801 | A Adverse-Effectparadoxical ocular effect of brimonidine. |
| Score | Text |
|---|---|
| 0.9994 | Severe Drugvancomycin - induced anaphylactic reaction. |
| 0.9913 | Severe vancomycin - induced Adverse-Effectanaphylactic reaction . |
| Score | Text |
|---|---|
| 0.9996 | Fulminant hepatic failure associated with Drugbicalutamide . |
| 0.9851 | Adverse-EffectFulminant hepatic failure associated with bicalutamide. |
| Score | Text |
|---|---|
| 0.9995 | Tuberculous uveitis after treatment with Drugetanercept . |
| 0.9885 | Adverse-EffectTuberculous uveitis after treatment with etanercept. |
| Score | Text |
|---|---|
| 0.9995 | Cardiac arrest following use of Drugsumatriptan . |
| 0.9950 | Adverse-EffectCardiac arrest following use of sumatriptan. |
| Score | Text |
|---|---|
| 0.9995 | Early Drugritonavir - induced maculopapular eruption. |
| 0.9920 | Early ritonavir - induced Adverse-Effectmaculopapular eruption . |
| Score | Text |
|---|---|
| 0.9995 | DrugCarbamazepine - induced systemic lupus erythematosus. |
| 0.9776 | Carbamazepine - induced Adverse-Effectsystemic lupus erythematosus . |
| Score | Text |
|---|---|
| 0.9994 | DrugSalicylate - induced hepatotoxicity is reviewed. |
| 0.9966 | Salicylate - induced Adverse-Effecthepatotoxicity is reviewed. |
| Score | Text |
|---|---|
| 0.9979 | An unusual case of DrugEcstasy poisoning. |
| 0.9742 | An unusual case of Adverse-EffectEcstasy poisoning . |
| Score | Text |
|---|---|
| 0.9994 | Oculomotor disturbances associated with Drug5 - fluorouracil chemotherapy. |
| 0.9888 | Adverse-EffectOculomotor disturbances associated with 5 - fluorouracil chemotherapy. |
| Score | Text |
|---|---|
| 0.9986 | Does Drugacyclovir increase serum lithium levels? |
| 0.8128 | Does acyclovir Adverse-Effectincrease serum lithium levels ? |
| Score | Text |
|---|---|
| 0.9995 | Exacerbation of schizophrenia associated with Drugamantadine . |
| 0.9844 | Exacerbation of Adverse-Effectschizophrenia associated with amantadine. |
| Score | Text |
|---|---|
| 0.9994 | Diagnosis : Drugpractolol induced sclerosing peritonitis. |
| 0.9842 | Diagnosis : practolol induced Adverse-Effectsclerosing peritonitis . |
| Score | Text |
|---|---|
| 0.9996 | Erythema multiforme bullosum due to Drugrifampicin . |
| 0.9834 | Adverse-EffectErythema multiforme bullosum due to rifampicin. |
| Score | Text |
|---|---|
| 0.9993 | Suspected Drugciprofloxacin - induced interstitial nephritis. |
| 0.9870 | Suspected ciprofloxacin - induced Adverse-Effectinterstitial nephritis . |
| Score | Text |
|---|---|
| 0.9996 | Widespread cutaneous vasculitis associated with Drugdiltiazem . |
| 0.9874 | Widespread Adverse-Effectcutaneous vasculitis associated with diltiazem. |
| Score | Text |
|---|---|
| 0.9996 | Acute interstitial nephritis due to Drugpantoprazole . |
| 0.9783 | Adverse-EffectAcute interstitial nephritis due to pantoprazole. |
| Score | Text |
|---|---|
| 0.9824 | Allergic contact angioedema to Drugbenzoyl peroxide . |
| 0.9651 | Adverse-EffectAllergic contact angioedema to benzoyl peroxide. |
| Score | Text |
|---|---|
| 0.9881 | DrugDapsone syndrome in cutaneous lupus erythematosus. |
| 0.9275 | Adverse-EffectDapsone syndrome in cutaneous lupus erythematosus. |
| Score | Text |
|---|---|
| 0.9997 | Nonconvulsive status epilepticus due to Drugifosfamide . |
| 0.9792 | Adverse-EffectNonconvulsive status epilepticus due to ifosfamide. |
| Score | Text |
|---|---|
| 0.9994 | Persisent ocular hypertension following intravitreal Drugranibizumab . |
| 0.9847 | Adverse-EffectPersisent ocular hypertension following intravitreal ranibizumab. |
| Score | Text |
|---|---|
| 0.9995 | Trichiasis associated with Drugprostaglandin analog use. |
| 0.9989 | Adverse-EffectTrichiasis associated with prostaglandin analog use. |
| Score | Text |
|---|---|
| 0.9994 | Persistent light reactivity from systemic Drugquinine . |
| 0.9760 | Adverse-EffectPersistent light reactivity from systemic quinine. |
| Score | Text |
|---|---|
| 0.9995 | Interstitial granulomatous dermatitis associated with Drugdarifenacin . |
| 0.9794 | Adverse-EffectInterstitial granulomatous dermatitis associated with darifenacin. |
| Score | Text |
|---|---|
| 0.9995 | DrugIfosfamide - induced nonconvulsive status epilepticus. |
| 0.9824 | Ifosfamide - induced Adverse-Effectnonconvulsive status epilepticus . |
| Score | Text |
|---|---|
| 0.9995 | Nephrotic syndrome associated with Druglithium therapy. |
| 0.9941 | Adverse-EffectNephrotic syndrome associated with lithium therapy. |
| Score | Text |
|---|---|
| 0.9769 | Aminophylline hypersensitivity apparently due to Drugethylenediamine . |
| 0.9056 | DrugAminophylline hypersensitivity apparently due to ethylenediamine. |
| 0.7946 | Aminophylline Adverse-Effecthypersensitivity apparently due to ethylenediamine. |
| Adverse-EffectAminophylline hypersensitivity apparently due to ethylenediamine. | |
| Score | Text |
|---|---|
| 0.9993 | The 3 - week Drugsulphasalazine syndrome strikes again. |
| 0.8726 | The 3 - week Adverse-Effectsulphasalazine syndrome strikes again. |
| Score | Text |
|---|---|
| 0.9994 | DrugDoxycycline - induced photo - onycholysis. |
| 0.9803 | Doxycycline - induced Adverse-Effectphoto - onycholysis . |
| Score | Text |
|---|---|
| 0.9988 | DrugBleomycin pneumonitis potentiated by oxygen administration. |
| 0.8982 | Bleomycin Adverse-Effectpneumonitis potentiated by oxygen administration. |
| Score | Text |
|---|---|
| 0.9992 | Acute Drugvalproate ingestion induces symptomatic methemoglobinemia. |
| 0.9824 | Acute valproate ingestion induces Adverse-Effectsymptomatic methemoglobinemia . |
| Score | Text |
|---|---|
| 0.9994 | DrugMethotrexate induced sprue - like syndrome. |
| 0.9813 | Methotrexate induced Adverse-Effectsprue - like syndrome . |
| Score | Text |
|---|---|
| 0.9994 | Polymyositis after Drugpropylthiouracil treatment for hyperthyroidism. |
| 0.9986 | Adverse-EffectPolymyositis after propylthiouracil treatment for hyperthyroidism. |
| Score | Text |
|---|---|
| 0.9995 | Atrial fibrillation following Drugmethylprednisolone pulse therapy. |
| 0.9921 | Adverse-EffectAtrial fibrillation following methylprednisolone pulse therapy. |
| Score | Text |
|---|---|
| 0.9893 | Adverse-EffectOesophageal ulceration due to emepronium bromide. |
| 0.9820 | Oesophageal ulceration due to Drugemepronium bromide . |
| Score | Text |
|---|---|
| 0.9995 | DrugTroglitazone - induced fulminant hepatic failure. |
| 0.9852 | Troglitazone - induced Adverse-Effectfulminant hepatic failure . |
| Score | Text |
|---|---|
| 0.9828 | Adverse-EffectToxic epidermal necrolysis associated with interleukin - 2. |
| 0.9764 | Toxic epidermal necrolysis associated with Druginterleukin - 2 . |
| Score | Text |
|---|---|
| 0.9996 | DrugCaptopril - associated " pseudocholangitis '. |
| 0.9979 | Captopril - associated " Adverse-Effectpseudocholangitis '. |
| Score | Text |
|---|---|
| 0.9996 | Fulminant liver failure associated with Drugclarithromycin . |
| 0.9855 | Adverse-EffectFulminant liver failure associated with clarithromycin. |
| Score | Text |
|---|---|
| 0.9994 | DrugCefuroxime - induced acute renal failure. |
| 0.9829 | Cefuroxime - induced Adverse-Effectacute renal failure . |
| Score | Text |
|---|---|
| 0.9995 | Nail - changes induced by Drugpenicillamine . |
| 0.9877 | Adverse-EffectNail - changes induced by penicillamine. |
| Score | Text |
|---|---|
| 0.9987 | Adverse-EffectPsoriasis induced by interferon - alpha. |
| 0.9664 | Psoriasis induced by Druginterferon - alpha . |
| Score | Text |
|---|---|
| 0.9995 | DrugGentamicin - associated acute renal failure. |
| 0.9826 | Gentamicin - associated Adverse-Effectacute renal failure . |
| Score | Text |
|---|---|
| 0.9996 | Radiation recall pneumonitis induced by Druggemcitabine . |
| 0.9818 | Adverse-EffectRadiation recall pneumonitis induced by gemcitabine. |
| Score | Text |
|---|---|
| 0.9960 | Can magnesium sulfate therapy impact Adverse-Effectlactogenesis ? |
| 0.9624 | Can Drugmagnesium sulfate therapy impact lactogenesis? |
| Score | Text |
|---|---|
| 0.9982 | DrugSalicylate hepato toxicity in rheumatic fever. |
| 0.8475 | Salicylate Adverse-Effecthepato toxicity in rheumatic fever. |
| Score | Text |
|---|---|
| 0.9995 | Pemphigus vulgaris precipitated by Drugglibenclamide therapy. |
| 0.9918 | Adverse-EffectPemphigus vulgaris precipitated by glibenclamide therapy. |
| Score | Text |
|---|---|
| 0.9993 | DrugFlurbiprofen - associated acute tubulointerstitial nephritis. |
| 0.9814 | Flurbiprofen - associated Adverse-Effectacute tubulointerstitial nephritis . |
| Score | Text |
|---|---|
| 0.9980 | Fluorouracil for allergic reactions to Drugcapecitabine . |
| 0.9645 | Fluorouracil for Adverse-Effectallergic reactions to capecitabine. |
| Score | Text |
|---|---|
| 0.9987 | Chronic Drugfentanyl application induces adrenocortical insufficiency. |
| 0.9855 | Chronic fentanyl application induces Adverse-Effectadrenocortical insufficiency . |
| Score | Text |
|---|---|
| 0.9996 | Agranulocytosis and granulocytopenia associated with Drugquetiapine . |
| 0.9969 | Adverse-EffectAgranulocytosis and granulocytopenia associated with quetiapine. |
| 0.9964 | Agranulocytosis and Adverse-Effectgranulocytopenia associated with quetiapine. |
| Score | Text |
|---|---|
| 0.9840 | Treatment of Druglithium tremor with metoprolol. |
| 0.9713 | Treatment of lithium Adverse-Effecttremor with metoprolol. |
| Score | Text |
|---|---|
| 0.9995 | DrugBarbiturate - induced submassive hepatic necrosis. |
| 0.9841 | Barbiturate - induced Adverse-Effectsubmassive hepatic necrosis . |
| Score | Text |
|---|---|
| 0.9996 | Ulcerating enteritis associated with Drugflucytosine therapy. |
| 0.9907 | Adverse-EffectUlcerating enteritis associated with flucytosine therapy. |
| Score | Text |
|---|---|
| 0.9872 | Adverse-EffectExfoliative dermatitis secondary to tobramycin sulfate. |
| 0.9790 | Exfoliative dermatitis secondary to Drugtobramycin sulfate . |
| Score | Text |
|---|---|
| 0.9995 | Protease inhibitor - induced Drugcarbamazepine toxicity. |
| 0.8233 | Protease inhibitor - induced Adverse-Effectcarbamazepine toxicity . |
| Score | Text |
|---|---|
| 0.9745 | Severe hepatitis caused by Drugcyproterone acetate . |
| 0.9737 | Adverse-EffectSevere hepatitis caused by cyproterone acetate. |
| Score | Text |
|---|---|
| 0.9993 | DrugGabapentin withdrawal presenting as status epilepticus. |
| 0.9867 | Gabapentin withdrawal presenting as Adverse-Effectstatus epilepticus . |
| Score | Text |
|---|---|
| 0.9990 | DrugSuxamethonium apnoea terminated with commercial serumcholinesterase. |
| 0.9394 | Suxamethonium Adverse-Effectapnoea terminated with commercial serumcholinesterase. |
| Score | Text |
|---|---|
| 0.9996 | Transient hemiparesis caused by Drugphenytoin toxicity. |
| 0.9512 | Adverse-EffectTransient hemiparesis caused by phenytoin toxicity. |
| Score | Text |
|---|---|
| 0.9992 | Systemic corticosteroids in the Drugphenytoin hypersensitivity syndrome. |
| Systemic corticosteroids in the Adverse-Effectphenytoin hypersensitivity syndrome . | |
| Score | Text |
|---|---|
| 0.9959 | Adverse-EffectNeurotoxicity of intrathecal administration of amphotericin B. |
| 0.9796 | Neurotoxicity of intrathecal administration of Drugamphotericin B . |
| Score | Text |
|---|---|
| 0.9996 | Sustained monomorphic ventricular tachycardia after Drugadenosine infusion. |
| 0.9678 | Adverse-EffectSustained monomorphic ventricular tachycardia after adenosine infusion. |
| Score | Text |
|---|---|
| 0.9777 | Severe hepatocellular dysfunction following Drugcyproterone acetate therapy. |
| 0.9478 | Adverse-EffectSevere hepatocellular dysfunction following cyproterone acetate therapy. |
| Score | Text |
|---|---|
| 0.9994 | DrugBleomycin induced hyperpigmentation with yolk sac tumor. |
| 0.9927 | Bleomycin induced Adverse-Effecthyperpigmentation with yolk sac tumor. |
| Score | Text |
|---|---|
| 0.9995 | Atypical neuroleptic malignant syndrome associated with Drugolanzapine . |
| 0.9410 | Atypical Adverse-Effectneuroleptic malignant syndrome associated with olanzapine. |
| Score | Text |
|---|---|
| 0.9996 | Focal renal cortical necrosis associated with Drugzomepirac . |
| 0.9770 | Adverse-EffectFocal renal cortical necrosis associated with zomepirac. |
| Score | Text |
|---|---|
| 0.9990 | DrugCapecitabine - induced headache responding to diltiazem. |
| 0.9990 | Capecitabine - induced Adverse-Effectheadache responding to diltiazem. |
| Score | Text |
|---|---|
| 0.9996 | Acute coronary syndrome induced by Drugcapecitabine therapy. |
| 0.9886 | Adverse-EffectAcute coronary syndrome induced by capecitabine therapy. |
| Score | Text |
|---|---|
| 0.9989 | Acute Drugisoniazid neurotoxicity in an urban hospital. |
| 0.8502 | Acute isoniazid Adverse-Effectneurotoxicity in an urban hospital. |
| Score | Text |
|---|---|
| 0.9826 | Adverse-EffectInappropriate antidiuretic hormone following adenine arabinoside administration. |
| 0.9727 | Inappropriate antidiuretic hormone following Drugadenine arabinoside administration. |
| Score | Text |
|---|---|
| 0.9996 | Skin rash and splinter hemorrhages from Drugganciclovir . |
| 0.9876 | Adverse-EffectSkin rash and splinter hemorrhages from ganciclovir. |
| 0.9826 | Skin rash and Adverse-Effectsplinter hemorrhages from ganciclovir. |
| Score | Text |
|---|---|
| 0.9996 | Priapism as a complication of Drugheparin therapy. |
| 0.9991 | Adverse-EffectPriapism as a complication of heparin therapy. |
| Score | Text |
|---|---|
| 0.9985 | Thrombocytosis under Drugciprofloxacin and tazobactam / piperacillin. |
| 0.9983 | Thrombocytosis under ciprofloxacin and Drugtazobactam / piperacillin. |
| 0.9982 | Thrombocytosis under ciprofloxacin and tazobactam / Drugpiperacillin . |
| 0.9970 | Adverse-EffectThrombocytosis under ciprofloxacin and tazobactam / piperacillin. |
| Score | Text |
|---|---|
| 0.9996 | Nonoliguric acute renal failure after Drugcaptopril therapy. |
| 0.9785 | Adverse-EffectNonoliguric acute renal failure after captopril therapy. |
| Score | Text |
|---|---|
| 0.9996 | DrugCaptopril - induced acute reversible renal failure. |
| 0.9809 | Captopril - induced Adverse-Effectacute reversible renal failure . |
| Score | Text |
|---|---|
| 0.9996 | Gastro - oesophageal reflux associated with Drugnifedipine . |
| 0.9846 | Adverse-EffectGastro - oesophageal reflux associated with nifedipine. |
| Score | Text |
|---|---|
| 0.9994 | DrugIsoniazid associated, painful, bilateral gynaecomastia. |
| 0.9794 | Isoniazid associated, painful, Adverse-Effectbilateral gynaecomastia . |
| Score | Text |
|---|---|
| 0.9983 | Adverse-EffectPiloerection induced by replacing fluvoxamine with milnacipran. |
| 0.9973 | Piloerection induced by replacing fluvoxamine with Drugmilnacipran . |
| 0.9965 | Piloerection induced by replacing Drugfluvoxamine with milnacipran. |
| Score | Text |
|---|---|
| 0.9995 | Allergic and irritant contact dermatitis to Drugcalcipotriol . |
| 0.9707 | Allergic and Adverse-Effectirritant contact dermatitis to calcipotriol. |
| Score | Text |
|---|---|
| 0.9994 | Case studies in Drugheparin - induced thrombocytopenia. |
| 0.9967 | Case studies in heparin - induced Adverse-Effectthrombocytopenia . |
| Score | Text |
|---|---|
| 0.9981 | The bleeding resolved on discontinuation of DrugAPV . |
| 0.9886 | The Adverse-Effectbleeding resolved on discontinuation of APV. |
| Score | Text |
|---|---|
| 0.9968 | DIAGNOSIS : Interferon alpha - 2b - induced Adverse-Effectcardiomyopathy . |
| 0.9665 | DIAGNOSIS : DrugInterferon alpha - 2b - induced cardiomyopathy. |
| Score | Text |
|---|---|
| 0.9991 | Case study : adverse response to Drugclonidine . |
| 0.9725 | Case study : Adverse-Effectadverse response to clonidine. |
| Score | Text |
|---|---|
| 0.9994 | Syncope induced by Drugpropranolol in hypertrophic cardiomyopathy. |
| 0.9990 | Adverse-EffectSyncope induced by propranolol in hypertrophic cardiomyopathy. |
| Score | Text |
|---|---|
| 0.9992 | Prolonged severe cholestasis induced by Drugoxacillin derivatives. |
| 0.8619 | Prolonged Adverse-Effectsevere cholestasis induced by oxacillin derivatives. |
| Score | Text |
|---|---|
| 0.9996 | DrugLithium - induced Creutzfeldt - Jakob syndrome. |
| 0.9842 | Lithium - induced Adverse-EffectCreutzfeldt - Jakob syndrome . |
| Score | Text |
|---|---|
| 0.9989 | Adverse-EffectEctropion secondary to bolus injection of 5 - fluorouracil. |
| 0.9981 | Ectropion secondary to bolus injection of Drug5 - fluorouracil . |
| Score | Text |
|---|---|
| 0.9996 | DrugCarbamazepine - related hyponatremia following cardiopulmonary bypass. |
| 0.9973 | Carbamazepine - related Adverse-Effecthyponatremia following cardiopulmonary bypass. |
| Score | Text |
|---|---|
| 0.9982 | Clinical and morphological features of Druggold neuropathy. |
| 0.8720 | Clinical and morphological features of gold Adverse-Effectneuropathy . |
| Score | Text |
|---|---|
| 0.9996 | Sporadic rippling muscle disease unmasked by Drugsimvastatin . |
| 0.9816 | Adverse-EffectSporadic rippling muscle disease unmasked by simvastatin. |
| Score | Text |
|---|---|
| 0.9994 | Refractory hypoglycemia from ciprofloxacin and Drugglyburide interaction. |
| 0.9994 | Refractory hypoglycemia from Drugciprofloxacin and glyburide interaction. |
| 0.9810 | Adverse-EffectRefractory hypoglycemia from ciprofloxacin and glyburide interaction. |
| Score | Text |
|---|---|
| 0.9995 | Two patients had Drugampicillin - associated seizures. |
| 0.9985 | Two patients had ampicillin - associated Adverse-Effectseizures . |
| Score | Text |
|---|---|
| 0.9994 | Angioimmunoblastic lymphadenopathy with dysproteinemia following Drugdoxycycline administration. |
| 0.9740 | Adverse-EffectAngioimmunoblastic lymphadenopathy with dysproteinemia following doxycycline administration. |
| Score | Text |
|---|---|
| 0.9996 | DrugMethadone - induced myoclonus in advanced cancer. |
| 0.9987 | Methadone - induced Adverse-Effectmyoclonus in advanced cancer. |
| Score | Text |
|---|---|
| 0.9996 | Paradoxical cerebral cortical hyperexcitability following Drugflupirtine overdose. |
| 0.9732 | Adverse-EffectParadoxical cerebral cortical hyperexcitability following flupirtine overdose. |
| Score | Text |
|---|---|
| 0.9951 | Torsade de pointes during loading with Drugamiodarone . |
| 0.9876 | Adverse-EffectTorsade de pointes during loading with amiodarone. |
| Score | Text |
|---|---|
| 0.9993 | Severe abdominal pain in low dosage Drugclofazimine . |
| 0.6184 | Severe Adverse-Effectabdominal pain in low dosage clofazimine. |
| 0.6162 | Adverse-EffectSevere abdominal pain in low dosage clofazimine. |
| Score | Text |
|---|---|
| 0.9995 | Ischaemic colitis in a patient taking Drugmeloxicam . |
| 0.9926 | Adverse-EffectIschaemic colitis in a patient taking meloxicam. |
| Score | Text |
|---|---|
| 0.9995 | Probable Drugpropafenone - induced transient global amnesia. |
| 0.9839 | Probable propafenone - induced Adverse-Effecttransient global amnesia . |
| Score | Text |
|---|---|
| 0.9995 | Acute myocardial necrosis during administration of Drugamsacrine . |
| 0.9817 | Adverse-EffectAcute myocardial necrosis during administration of amsacrine. |
| Score | Text |
|---|---|
| 0.9991 | Generalized argyria after habitual use of DrugAgNO3 . |
| 0.9893 | Adverse-EffectGeneralized argyria after habitual use of AgNO3. |
| Score | Text |
|---|---|
| 0.9995 | Corneal endothelial dysfunction associated with Drugamantadine toxicity. |
| 0.9768 | Adverse-EffectCorneal endothelial dysfunction associated with amantadine toxicity. |
| Score | Text |
|---|---|
| 0.9996 | Reversible nonthrombocytopenic palpable purpura associated with Drugmetoclopramide . |
| 0.9076 | Reversible Adverse-Effectnonthrombocytopenic palpable purpura associated with metoclopramide. |
| Score | Text |
|---|---|
| 0.9974 | Methylphenidate and Drugdextroamphetamine - induced peripheral vasculopathy. |
| 0.9947 | DrugMethylphenidate and dextroamphetamine - induced peripheral vasculopathy. |
| 0.9866 | Methylphenidate and dextroamphetamine - induced Adverse-Effectperipheral vasculopathy . |
| Score | Text |
|---|---|
| 0.9996 | Pure red cell aplasia associated with Drugfenoprofen . |
| 0.9780 | Adverse-EffectPure red cell aplasia associated with fenoprofen. |
| Score | Text |
|---|---|
| 0.9995 | Cicatricial entropion associated with chronic Drugdipivefrin application. |
| 0.9903 | Adverse-EffectCicatricial entropion associated with chronic dipivefrin application. |
| Score | Text |
|---|---|
| 0.9995 | DrugLeflunomide - associated infections in rheumatoid arthritis. |
| 0.9958 | Leflunomide - associated Adverse-Effectinfections in rheumatoid arthritis. |
| Score | Text |
|---|---|
| 0.9994 | A possible case of Drugcarbamazepine induced pancreatitis. |
| 0.9981 | A possible case of carbamazepine induced Adverse-Effectpancreatitis . |
| Score | Text |
|---|---|
| 0.9993 | Lichen planus and acne provoked by Druggold . |
| 0.9982 | Lichen planus and Adverse-Effectacne provoked by gold. |
| 0.9891 | Adverse-EffectLichen planus and acne provoked by gold. |
| Score | Text |
|---|---|
| 0.9995 | Cutaneous mycobacterial infection post intravesical DrugBCG installation. |
| 0.9821 | Adverse-EffectCutaneous mycobacterial infection post intravesical BCG installation. |
| Score | Text |
|---|---|
| 0.9989 | An Drugamiodarone optic neuropathy has been described. |
| 0.9163 | An amiodarone Adverse-Effectoptic neuropathy has been described. |
| Score | Text |
|---|---|
| 0.9992 | Regression of thyrotoxic ophthalmopathy following Druglithium withdrawal. |
| 0.9597 | Regression of Adverse-Effectthyrotoxic ophthalmopathy following lithium withdrawal. |
| Score | Text |
|---|---|
| 0.9876 | Acute leukopenia associated with Drugsilver sulfadiazine therapy. |
| 0.9757 | Adverse-EffectAcute leukopenia associated with silver sulfadiazine therapy. |
| Score | Text |
|---|---|
| 0.9926 | Trimethoprim - sulfamethoxazole - induced Adverse-Effectaseptic meningitis . |
| 0.8475 | DrugTrimethoprim - sulfamethoxazole - induced aseptic meningitis. |
| Score | Text |
|---|---|
| 0.9991 | Unique behavioral change with Drugcinepazide in parkinsonism. |
| 0.9752 | Unique Adverse-Effectbehavioral change with cinepazide in parkinsonism. |
| Score | Text |
|---|---|
| 0.9995 | DrugIsoniazid induced gynaecomastia : a case report. |
| 0.9977 | Isoniazid induced Adverse-Effectgynaecomastia : a case report. |
| Score | Text |
|---|---|
| 0.9995 | Rapidly developing hyperglycemia during treatment with Drugolanzapine . |
| 0.9982 | Rapidly developing Adverse-Effecthyperglycemia during treatment with olanzapine. |
| Score | Text |
|---|---|
| 0.9978 | The disease predisposes to severe Drugvincristine neurotoxicity. |
| 0.8487 | The disease predisposes to severe vincristine Adverse-Effectneurotoxicity . |
| The disease predisposes to severe Adverse-Effectvincristine neurotoxicity . | |
| Score | Text |
|---|---|
| 0.9995 | Intrahepatic cholestasis and sicca complex after Drugthiabendazole . |
| 0.9854 | Intrahepatic cholestasis and Adverse-Effectsicca complex after thiabendazole. |
| 0.9843 | Adverse-EffectIntrahepatic cholestasis and sicca complex after thiabendazole. |
| Score | Text |
|---|---|
| 0.9995 | DrugNaproxen - associated sudden sensorineural hearing loss. |
| 0.9809 | Naproxen - associated Adverse-Effectsudden sensorineural hearing loss . |
| Score | Text |
|---|---|
| 0.9992 | Neonatal mydriasis : intravenous Druglidocaine adverse reaction. |
| 0.9740 | Neonatal Adverse-Effectmydriasis : intravenous lidocaine adverse reaction. |
| Score | Text |
|---|---|
| 0.9995 | Linear IgA bullous dermatosis occurring after Drugcarbamazepine . |
| 0.9775 | Adverse-EffectLinear IgA bullous dermatosis occurring after carbamazepine. |
| Score | Text |
|---|---|
| 0.9852 | Adverse-EffectBilateral anterior uveitis associated with clomiphene citrate. |
| 0.9764 | Bilateral anterior uveitis associated with Drugclomiphene citrate . |
| Score | Text |
|---|---|
| 0.9993 | DrugEthambutol toxicity manifesting as acute onset psychosis. |
| 0.9700 | Ethambutol toxicity manifesting as Adverse-Effectacute onset psychosis . |
| Score | Text |
|---|---|
| 0.9987 | A drug interaction between zafirlukast and Drugtheophylline . |
| 0.9987 | A drug interaction between Drugzafirlukast and theophylline. |
| 0.9765 | A Adverse-Effectdrug interaction between zafirlukast and theophylline. |
| Score | Text |
|---|---|
| 0.9995 | Recurrent hyponatremia associated with Drugcitalopram and mirtazapine. |
| 0.9995 | Recurrent hyponatremia associated with citalopram and Drugmirtazapine . |
| 0.9757 | Adverse-EffectRecurrent hyponatremia associated with citalopram and mirtazapine. |
| Score | Text |
|---|---|
| 0.9996 | Seizures associated with Drugfluoxetine therapy are uncommon. |
| 0.9992 | Adverse-EffectSeizures associated with fluoxetine therapy are uncommon. |
| Score | Text |
|---|---|
| 0.9995 | Spontaneous splenic infarction associated with Drugsumatriptan use. |
| 0.9859 | Adverse-EffectSpontaneous splenic infarction associated with sumatriptan use. |
| Score | Text |
|---|---|
| 0.9853 | Nicotinic acid - induced Adverse-Effectfulminant hepatic failure . |
| 0.9723 | DrugNicotinic acid - induced fulminant hepatic failure. |
| Score | Text |
|---|---|
| 0.9996 | DrugTriazolam - induced nocturnal bingeing with amnesia. |
| 0.9954 | Triazolam - induced nocturnal bingeing with Adverse-Effectamnesia . |
| 0.9835 | Triazolam - induced Adverse-Effectnocturnal bingeing with amnesia. |
| Score | Text |
|---|---|
| 0.9989 | Asthma and Adverse-Effecturticaria during disodium cromoglycate treatment. |
| 0.9988 | Adverse-EffectAsthma and urticaria during disodium cromoglycate treatment. |
| 0.9763 | Asthma and urticaria during Drugdisodium cromoglycate treatment. |
| Score | Text |
|---|---|
| 0.9996 | Cerebral and ocular toxicity induced by Drugdesferrioxamine . |
| 0.9707 | Adverse-EffectCerebral and ocular toxicity induced by desferrioxamine. |
| Score | Text |
|---|---|
| 0.9996 | Acute drug induced hepatitis due to Drugerlotinib . |
| 0.9988 | Acute drug induced Adverse-Effecthepatitis due to erlotinib. |
| Score | Text |
|---|---|
| 0.9995 | Panic anxiety after abrupt discontinuation of Drugmianserin . |
| 0.9894 | Adverse-EffectPanic anxiety after abrupt discontinuation of mianserin. |
| Score | Text |
|---|---|
| 0.9995 | One patient on Drugouabain also developed cardiomyopathy. |
| 0.9978 | One patient on ouabain also developed Adverse-Effectcardiomyopathy . |
| Score | Text |
|---|---|
| 0.9996 | DrugSotalol - induced bradycardia reversed by glucagon. |
| 0.9986 | Sotalol - induced Adverse-Effectbradycardia reversed by glucagon. |
| Score | Text |
|---|---|
| 0.9995 | DrugPilocarpine toxicity and the treatment of xerostomia. |
| 0.8849 | Adverse-EffectPilocarpine toxicity and the treatment of xerostomia. |
| Score | Text |
|---|---|
| 0.9990 | Probable early acute hepatitis with parenteral Drugamiodarone . |
| 0.9694 | Probable early Adverse-Effectacute hepatitis with parenteral amiodarone. |
| Score | Text |
|---|---|
| 0.9995 | Acute respiratory distress syndrome after Drugrituximab infusion. |
| 0.9731 | Adverse-EffectAcute respiratory distress syndrome after rituximab infusion. |
| Score | Text |
|---|---|
| 0.9895 | Adverse-EffectBromide intoxication secondary to pyridostigmine bromide therapy. |
| 0.9758 | Bromide intoxication secondary to Drugpyridostigmine bromide therapy. |
| Score | Text |
|---|---|
| 0.9993 | Acute generalized exanthematous pustulosis induced by Drugnimesulide . |
| 0.9739 | Adverse-EffectAcute generalized exanthematous pustulosis induced by nimesulide. |
| Score | Text |
|---|---|
| 0.9983 | DrugPhenytoin toxicity due to concomitant antituberculosis therapy. |
| 0.8911 | Adverse-EffectPhenytoin toxicity due to concomitant antituberculosis therapy. |
| Score | Text |
|---|---|
| 0.9993 | Unusual pigmentary changes associated with Drug5 - fluorouracil therapy. |
| 0.9824 | Unusual Adverse-Effectpigmentary changes associated with 5 - fluorouracil therapy. |
| Score | Text |
|---|---|
| 0.9818 | Juvenile absence epilepsy exacerbated by Drugvalproic acid . |
| 0.9745 | Adverse-EffectJuvenile absence epilepsy exacerbated by valproic acid. |
| Score | Text |
|---|---|
| 0.9989 | Interstitial pneumopathy and low - dosage Drugamiodarone . |
| 0.9831 | Adverse-EffectInterstitial pneumopathy and low - dosage amiodarone. |
| Score | Text |
|---|---|
| 0.9993 | DrugLevofloxacin - induced delirium with psychotic features. |
| 0.9098 | Levofloxacin - induced Adverse-Effectdelirium with psychotic features . |
| Score | Text |
|---|---|
| 0.9996 | Multifocal inflammatory leukoencephalopathy associated with Druglevamisole therapy. |
| 0.9686 | Adverse-EffectMultifocal inflammatory leukoencephalopathy associated with levamisole therapy. |
| Score | Text |
|---|---|
| 0.9985 | Prothipendylhydrochloride - induced Adverse-Effectpriapism : case report. |
| 0.9809 | DrugProthipendylhydrochloride - induced priapism : case report. |
| Score | Text |
|---|---|
| 0.9992 | DrugPravastatin is associated with myotonia in animals. |
| 0.9978 | Pravastatin is associated with Adverse-Effectmyotonia in animals. |
| Score | Text |
|---|---|
| 0.9995 | Hemodynamic collapse following Druglabetalol administration in preeclampsia. |
| 0.9935 | Adverse-EffectHemodynamic collapse following labetalol administration in preeclampsia. |
| Score | Text |
|---|---|
| 0.9995 | Severe serotonin syndrome induced by Drugmirtazapine monotherapy. |
| 0.8577 | Severe Adverse-Effectserotonin syndrome induced by mirtazapine monotherapy. |
| 0.7611 | Adverse-EffectSevere serotonin syndrome induced by mirtazapine monotherapy. |
| Score | Text |
|---|---|
| 0.9995 | DrugGemcitabine - induced rectus abdominus radiation recall. |
| 0.9668 | Gemcitabine - induced Adverse-Effectrectus abdominus radiation recall . |
| Score | Text |
|---|---|
| 0.9997 | Life - threatening hyponatremia caused by Drugvinblastine . |
| 0.9977 | Life - threatening Adverse-Effecthyponatremia caused by vinblastine. |
| Score | Text |
|---|---|
| 0.9884 | Long lasting Adverse-Effectrespiratory depression induced by morphine - 6 - glucuronide? |
| 0.9693 | Long lasting respiratory depression induced by Drugmorphine - 6 - glucuronide ? |
| Score | Text |
|---|---|
| 0.9992 | Glaucoma secondary to epithelial downgrowth and Drug5 - fluorouracil . |
| 0.9985 | Adverse-EffectGlaucoma secondary to epithelial downgrowth and 5 - fluorouracil. |
| Score | Text |
|---|---|
| 0.9996 | Drug - induced fever due to Drugdiltiazem . |
| 0.9944 | Drug - induced Adverse-Effectfever due to diltiazem. |
| Score | Text |
|---|---|
| 0.9996 | A case of mania associated with Drugfluoxetine . |
| 0.9985 | A case of Adverse-Effectmania associated with fluoxetine. |
| Score | Text |
|---|---|
| 0.9996 | DrugColchicine - induced myopathy in renal failure. |
| 0.9981 | Colchicine - induced Adverse-Effectmyopathy in renal failure. |
| Score | Text |
|---|---|
| 0.9995 | Life - threatening hyperkalemia induced by Drugarginine . |
| 0.9973 | Life - threatening Adverse-Effecthyperkalemia induced by arginine. |
| Score | Text |
|---|---|
| 0.9994 | Depressive symptoms disappeared after Druginterferon therapy was stopped. |
| 0.9877 | Adverse-EffectDepressive symptoms disappeared after interferon therapy was stopped. |
| Score | Text |
|---|---|
| 0.9994 | Eruptive epidermoid cysts resulting from treatment with Drugimiquimod . |
| 0.9812 | Adverse-EffectEruptive epidermoid cysts resulting from treatment with imiquimod. |
| Score | Text |
|---|---|
| 0.9996 | Deepening of lid sulcus from topical Drugbimatoprost therapy. |
| 0.9760 | Adverse-EffectDeepening of lid sulcus from topical bimatoprost therapy. |
| Score | Text |
|---|---|
| 0.9992 | We diagnosed this case as Drugdanazol induced thrombocytopenia. |
| 0.9971 | We diagnosed this case as danazol induced Adverse-Effectthrombocytopenia . |
| Score | Text |
|---|---|
| 0.9996 | DrugAliskiren - associated acute renal failure with hyperkalemia. |
| 0.9827 | Aliskiren - associated Adverse-Effectacute renal failure with hyperkalemia. |
| Score | Text |
|---|---|
| 0.9991 | DrugCiprofloxacin - induced renal insufficiency in cystic fibrosis. |
| 0.9897 | Ciprofloxacin - induced Adverse-Effectrenal insufficiency in cystic fibrosis. |
| Score | Text |
|---|---|
| 0.9996 | Fixed drug eruption in hands caused by Drugomeprazole . |
| 0.8925 | Fixed drug Adverse-Effecteruption in hands caused by omeprazole. |
| Score | Text |
|---|---|
| 0.9830 | Reversible cardiomyopathy caused by administration of Druginterferon alpha . |
| 0.9752 | Adverse-EffectReversible cardiomyopathy caused by administration of interferon alpha. |
| Score | Text |
|---|---|
| 0.9996 | DrugAlprazolam - induced mania : two clinical cases. |
| 0.9984 | Alprazolam - induced Adverse-Effectmania : two clinical cases. |
| Score | Text |
|---|---|
| 0.9995 | Fulminant hepatitis and lymphocyte sensitization due to Drugpropylthiouracil . |
| 0.9872 | Adverse-EffectFulminant hepatitis and lymphocyte sensitization due to propylthiouracil. |
| 0.7565 | Fulminant hepatitis and Adverse-Effectlymphocyte sensitization due to propylthiouracil. |
| Score | Text |
|---|---|
| 0.9815 | Theophylline intoxication following Drugviloxazine induced decrease in clearance. |
| 0.8728 | Adverse-EffectTheophylline intoxication following viloxazine induced decrease in clearance. |
| 0.7972 | DrugTheophylline intoxication following viloxazine induced decrease in clearance. |
| Theophylline intoxication following viloxazine induced Adverse-Effectdecrease in clearance . | |
| Score | Text |
|---|---|
| 0.9975 | Mycophenolate mofetil - induced Adverse-Effectneutropenia in liver transplantation. |
| 0.9544 | DrugMycophenolate mofetil - induced neutropenia in liver transplantation. |
| Score | Text |
|---|---|
| 0.9995 | Allergic contact dermatitis to compound tincture of Drugbenzoin . |
| 0.9645 | Adverse-EffectAllergic contact dermatitis to compound tincture of benzoin. |
| Score | Text |
|---|---|
| 0.9996 | Pulmonary infiltrates and skin pigmentation associated with Drugsulfasalazine . |
| 0.9772 | Pulmonary infiltrates and Adverse-Effectskin pigmentation associated with sulfasalazine. |
| 0.9641 | Adverse-EffectPulmonary infiltrates and skin pigmentation associated with sulfasalazine. |
| Score | Text |
|---|---|
| 0.9994 | Spindle coma in Drugbenzodiazepine toxicity : case report. |
| 0.9931 | Adverse-EffectSpindle coma in benzodiazepine toxicity : case report. |
| Score | Text |
|---|---|
| 0.9990 | DrugTiclopidine - induced marrow aplasia treated with cyclosporine. |
| 0.9920 | Ticlopidine - induced Adverse-Effectmarrow aplasia treated with cyclosporine. |
| Score | Text |
|---|---|
| 0.9996 | Priapism associated with Drugtrazodone therapy : case report. |
| 0.9988 | Adverse-EffectPriapism associated with trazodone therapy : case report. |
| Score | Text |
|---|---|
| 0.9995 | MR findings in Drugmethotrexate - induced CNS abnormalities. |
| 0.9890 | MR findings in methotrexate - induced Adverse-EffectCNS abnormalities . |
| Score | Text |
|---|---|
| 0.9987 | Reversible findings of restricted diffusion in Drug5 - fluorouracil neurotoxicity. |
| 0.9230 | Reversible findings of restricted diffusion in 5 - fluorouracil Adverse-Effectneurotoxicity . |
| Score | Text |
|---|---|
| 0.9992 | RESULTS : DrugBudesonide use can cause contact dermatitis. |
| 0.9891 | RESULTS : Budesonide use can cause Adverse-Effectcontact dermatitis . |
| Score | Text |
|---|---|
| 0.9888 | Adverse-EffectRestless legs syndrome due to interferon - alpha. |
| 0.9639 | Restless legs syndrome due to Druginterferon - alpha . |
| Score | Text |
|---|---|
| 0.9994 | A lethal complication of peripheral vein Drugvasopressin infusion. |
| 0.9872 | A Adverse-Effectlethal complication of peripheral vein vasopressin infusion. |
| Score | Text |
|---|---|
| 0.9993 | Allergic reaction to Druggemfibrozil manifesting as eosinophilic gastroenteritis. |
| 0.9847 | Allergic reaction to gemfibrozil manifesting as Adverse-Effecteosinophilic gastroenteritis . |
| Score | Text |
|---|---|
| 0.9995 | Progressive interstitial lung disease from prolonged Drugmethotrexate therapy. |
| 0.9816 | Adverse-EffectProgressive interstitial lung disease from prolonged methotrexate therapy. |
| Score | Text |
|---|---|
| 0.9996 | Angioedema and maculopapular eruptions associated with Drugcarbamazepine administration. |
| 0.9964 | Adverse-EffectAngioedema and maculopapular eruptions associated with carbamazepine administration. |
| 0.9894 | Angioedema and Adverse-Effectmaculopapular eruptions associated with carbamazepine administration. |
| Score | Text |
|---|---|
| 0.9996 | Fatal toxic epidermal necrolysis related to Druglamotrigine administration. |
| 0.9805 | Adverse-EffectFatal toxic epidermal necrolysis related to lamotrigine administration. |
| Score | Text |
|---|---|
| 0.9993 | DrugNitrofurantoin - induced acute liver damage in pregnancy. |
| 0.9877 | Nitrofurantoin - induced Adverse-Effectacute liver damage in pregnancy. |
| Score | Text |
|---|---|
| 0.9985 | DrugCyclophosphamide can rarely cause interstitial pneumonitis and fibrosis. |
| 0.9959 | Cyclophosphamide can rarely cause interstitial pneumonitis and Adverse-Effectfibrosis . |
| 0.9829 | Cyclophosphamide can rarely cause Adverse-Effectinterstitial pneumonitis and fibrosis. |
| Score | Text |
|---|---|
| 0.9995 | Acute bilateral phrenic neuropathy following treatment with Drugadalimumab . |
| 0.9380 | Adverse-EffectAcute bilateral phrenic neuropathy following treatment with adalimumab. |
| Score | Text |
|---|---|
| 0.9992 | DrugAmpicillin may aggravate clinical and experimental myasthenia gravis. |
| 0.9860 | Ampicillin may aggravate clinical and experimental Adverse-Effectmyasthenia gravis . |
| Score | Text |
|---|---|
| 0.9994 | The increased libido disappeared after Drugfluvoxamine was discontinued. |
| 0.9902 | The Adverse-Effectincreased libido disappeared after fluvoxamine was discontinued. |
| Score | Text |
|---|---|
| 0.9990 | DrugAmiodarone was discontinued, and thyrotoxicosis gradually abated. |
| 0.9948 | Amiodarone was discontinued, and Adverse-Effectthyrotoxicosis gradually abated. |
| Score | Text |
|---|---|
| 0.9996 | Visceral herpesvirus infections in leukemic patients receiving Drugcytarabine . |
| 0.9781 | Adverse-EffectVisceral herpesvirus infections in leukemic patients receiving cytarabine. |
| Score | Text |
|---|---|
| 0.9903 | Adverse-EffectBowel perforation associated with intraperitoneal chromic phosphate instillation. |
| 0.9821 | Bowel perforation associated with intraperitoneal Drugchromic phosphate instillation. |
| Score | Text |
|---|---|
| 0.9456 | DrugCo - trimoxazole red cell aplasia in leukaemia. |
| 0.8858 | Co - trimoxazole Adverse-Effectred cell aplasia in leukaemia. |
| Score | Text |
|---|---|
| 0.9995 | Recurrent hypotension immediately after seizures in Drugnortriptyline overdose. |
| 0.9845 | Recurrent hypotension immediately after Adverse-Effectseizures in nortriptyline overdose. |
| 0.9844 | Adverse-EffectRecurrent hypotension immediately after seizures in nortriptyline overdose. |
| Score | Text |
|---|---|
| 0.9997 | Nephropathy caused by Drugmethicillin therapy for staphylococcal septicemia. |
| 0.9981 | Adverse-EffectNephropathy caused by methicillin therapy for staphylococcal septicemia. |
| Score | Text |
|---|---|
| 0.9995 | DrugDapsone - induced erythroderma with Beau's lines. |
| 0.9979 | Dapsone - induced Adverse-Effecterythroderma with Beau's lines. |
| Score | Text |
|---|---|
| 0.9994 | Esophageal spasm following Drugpropranolol overdose relieved by glucagon. |
| 0.9897 | Adverse-EffectEsophageal spasm following propranolol overdose relieved by glucagon. |
| Score | Text |
|---|---|
| 0.9995 | DrugMetformin - associated lactic acidosis precipitated by diarrhea. |
| 0.9911 | Metformin - associated Adverse-Effectlactic acidosis precipitated by diarrhea. |
| Score | Text |
|---|---|
| 0.9996 | DrugAmoxapine - induced cognitive impairment in two patients. |
| 0.9885 | Amoxapine - induced Adverse-Effectcognitive impairment in two patients. |
| Score | Text |
|---|---|
| 0.9996 | First case of Drugivermectin - induced severe hepatitis. |
| 0.9902 | First case of ivermectin - induced Adverse-Effectsevere hepatitis . |
| Score | Text |
|---|---|
| 0.9994 | Acute sensorineural hearing loss following intravenous Drugketoralac administration. |
| 0.9819 | Adverse-EffectAcute sensorineural hearing loss following intravenous ketoralac administration. |
| Score | Text |
|---|---|
| 0.9993 | Leishmania infantum leishmaniasis in Drugcorticosteroid - - treated patients. |
| 0.9740 | Adverse-EffectLeishmania infantum leishmaniasis in corticosteroid - - treated patients. |
| Score | Text |
|---|---|
| 0.9991 | Methemoglobinemia : an occupational hazard of Drugphenylpropanolamine production. |
| 0.9976 | Adverse-EffectMethemoglobinemia : an occupational hazard of phenylpropanolamine production. |
| Score | Text |
|---|---|
| 0.9995 | DrugPentazocine - induced fibrous myopathy and localized neuropathy. |
| 0.9953 | Pentazocine - induced fibrous myopathy and localized Adverse-Effectneuropathy . |
| 0.9812 | Pentazocine - induced Adverse-Effectfibrous myopathy and localized neuropathy. |
| Score | Text |
|---|---|
| 0.9995 | Anaphylactoid reaction to 50 % solution of Drugdextrose . |
| 0.9899 | Adverse-EffectAnaphylactoid reaction to 50 % solution of dextrose. |
| Score | Text |
|---|---|
| 0.9995 | DrugLeflunomide - associated weight loss in rheumatoid arthritis. |
| 0.9934 | Leflunomide - associated Adverse-Effectweight loss in rheumatoid arthritis. |
| Score | Text |
|---|---|
| 0.9848 | Anterior ischemic optic neuropathy secondary to Druginterferon alfa . |
| 0.9740 | Adverse-EffectAnterior ischemic optic neuropathy secondary to interferon alfa. |
| Score | Text |
|---|---|
| 0.9990 | DrugPhenobarbital hepatotoxicity in an 8 - month - old infant. |
| 0.8816 | Phenobarbital Adverse-Effecthepatotoxicity in an 8 - month - old infant. |
| Score | Text |
|---|---|
| 0.9990 | We conclude peripheral neuropathy with Drug5 - FU is rare. |
| 0.9826 | We conclude Adverse-Effectperipheral neuropathy with 5 - FU is rare. |
| Score | Text |
|---|---|
| 0.9996 | PET scintigraphy of Drugetoposide - induced pulmonary toxicity. |
| 0.9901 | PET scintigraphy of etoposide - induced Adverse-Effectpulmonary toxicity . |
| Score | Text |
|---|---|
| 0.9995 | He had priapism following the use of Drugolanzapine . |
| 0.9982 | He had Adverse-Effectpriapism following the use of olanzapine. |
| Score | Text |
|---|---|
| 0.9989 | Anaphylaxis to Drugcisplatin following nine previous uncomplicated cycles. |
| 0.9985 | Adverse-EffectAnaphylaxis to cisplatin following nine previous uncomplicated cycles. |
| Score | Text |
|---|---|
| 0.9990 | BACKGROUND : Hypersensitivity reactions to Drugcyclosporine are rare. |
| 0.9737 | BACKGROUND : Adverse-EffectHypersensitivity reactions to cyclosporine are rare. |
| Score | Text |
|---|---|
| 0.9994 | Pulmonary oedema after Drughexoprenaline administration in preterm labour. |
| 0.9928 | Adverse-EffectPulmonary oedema after hexoprenaline administration in preterm labour. |
| Score | Text |
|---|---|
| 0.9941 | After abstinence from oolong tea his Adverse-Effectdelirium resolved. |
| 0.9630 | After abstinence from Drugoolong tea his delirium resolved. |
| Score | Text |
|---|---|
| 0.9995 | DrugQuinine induced coagulopathy - - a near fatal experience. |
| 0.9981 | Quinine induced Adverse-Effectcoagulopathy - - a near fatal experience. |
| Score | Text |
|---|---|
| 0.9996 | The pulmonary toxicity is probably induced by Drugpiritrexim . |
| 0.9859 | The Adverse-Effectpulmonary toxicity is probably induced by piritrexim. |
| Score | Text |
|---|---|
| 0.9995 | MR findings in Drugmethotrexate - induced CNS abnormalities. |
| 0.9890 | MR findings in methotrexate - induced Adverse-EffectCNS abnormalities . |
| Score | Text |
|---|---|
| 0.9996 | Osteomyelitis occurring during Druginfliximab treatment of severe psoriasis. |
| 0.9984 | Adverse-EffectOsteomyelitis occurring during infliximab treatment of severe psoriasis. |
| Score | Text |
|---|---|
| 0.9993 | She was thus diagnosed as having DrugAZ intoxication. |
| 0.9337 | She was thus diagnosed as having Adverse-EffectAZ intoxication . |
| Score | Text |
|---|---|
| 0.9989 | Renal failure associated with the use of Drugdextran - 40 . |
| 0.9947 | Adverse-EffectRenal failure associated with the use of dextran - 40. |
| Score | Text |
|---|---|
| 0.9995 | DrugAripiprazole - induced hiccups : a case report. |
| 0.9988 | Aripiprazole - induced Adverse-Effecthiccups : a case report. |
| Score | Text |
|---|---|
| 0.9996 | Rhabdomyolysis associated with the use of intravenous Drugvasopressin . |
| 0.9981 | Adverse-EffectRhabdomyolysis associated with the use of intravenous vasopressin. |
| Score | Text |
|---|---|
| 0.9995 | Other upper tract neoplasms after Drugcyclophosphamide are reviewed. |
| 0.9829 | Other Adverse-Effectupper tract neoplasms after cyclophosphamide are reviewed. |
| Score | Text |
|---|---|
| 0.9994 | DrugBisphosphonate - related osteonecrosis of the skull base. |
| 0.9795 | Bisphosphonate - related Adverse-Effectosteonecrosis of the skull base . |
| Score | Text |
|---|---|
| 0.9996 | Acute asthma associated with sustained - release Drugverapamil . |
| 0.9914 | Adverse-EffectAcute asthma associated with sustained - release verapamil. |
| Score | Text |
|---|---|
| 0.9995 | Erosion of psoriatic plaques after chronic Drugmethotrexate administration. |
| 0.9847 | Adverse-EffectErosion of psoriatic plaques after chronic methotrexate administration. |
| Score | Text |
|---|---|
| 0.9855 | We suspect that Drugnefazodone inhibits metabolism of tacrolimus. |
| 0.9470 | We suspect that nefazodone inhibits metabolism of Drugtacrolimus . |
| We suspect that nefazodone Adverse-Effectinhibits metabolism of tacrolimus . | |
| Score | Text |
|---|---|
| 0.9995 | Hyponatraemia developed after rechallenge with controlled release Drugcarbamazepine . |
| 0.9985 | Adverse-EffectHyponatraemia developed after rechallenge with controlled release carbamazepine. |
| Score | Text |
|---|---|
| 0.9994 | DrugTriiodothyronine - induced thyrotoxicosis in ophthalmic Graves disease. |
| 0.9972 | Triiodothyronine - induced Adverse-Effectthyrotoxicosis in ophthalmic Graves disease. |
| Score | Text |
|---|---|
| 0.9992 | DrugInsulin - induced lipoatrophy in type I diabetes. |
| 0.9975 | Insulin - induced Adverse-Effectlipoatrophy in type I diabetes. |
| Score | Text |
|---|---|
| 0.9995 | Optic neuropathy in Drugethambutol - treated renal tuberculosis. |
| 0.9873 | Adverse-EffectOptic neuropathy in ethambutol - treated renal tuberculosis. |
| Score | Text |
|---|---|
| 0.9996 | Localized dyskeratotic plaque with milia associated with Drugsorafenib . |
| 0.9953 | Localized dyskeratotic plaque with Adverse-Effectmilia associated with sorafenib. |
| 0.9754 | Adverse-EffectLocalized dyskeratotic plaque with milia associated with sorafenib. |
| Score | Text |
|---|---|
| 0.9903 | Adverse-EffectChoroidal hemorrhage associated with systemic tissue plasminogen activator. |
| 0.9452 | Choroidal hemorrhage associated with systemic Drugtissue plasminogen activator . |
| Score | Text |
|---|---|
| 0.9992 | Severe acute encephalopathy following inadvertent intrathecal Drugdoxorubicin administration. |
| 0.9346 | Adverse-EffectSevere acute encephalopathy following inadvertent intrathecal doxorubicin administration. |
| Score | Text |
|---|---|
| 0.9996 | Pulmonary lymphohistiocytic reactions temporally related to Drugetanercept therapy. |
| 0.9856 | Adverse-EffectPulmonary lymphohistiocytic reactions temporally related to etanercept therapy. |
| Score | Text |
|---|---|
| 0.9995 | A case of SIADH induced by Drugmizoribin administration. |
| 0.9977 | A case of Adverse-EffectSIADH induced by mizoribin administration. |
| Score | Text |
|---|---|
| 0.9993 | Photo - onycholysis caused by Drugolanzapine and aripiprazole. |
| 0.9993 | Photo - onycholysis caused by olanzapine and Drugaripiprazole . |
| 0.9798 | Adverse-EffectPhoto - onycholysis caused by olanzapine and aripiprazole. |
| Score | Text |
|---|---|
| 0.9995 | A woman developed delusional parasitosis when taking Drugphenelzine . |
| 0.9930 | A woman developed Adverse-Effectdelusional parasitosis when taking phenelzine. |
| Score | Text |
|---|---|
| 0.9907 | Adverse-EffectEosinophilic cystitis after bladder instillation with dimethyl sulfoxide. |
| 0.9676 | Eosinophilic cystitis after bladder instillation with Drugdimethyl sulfoxide . |
| Score | Text |
|---|---|
| 0.9990 | Transient asymptomatic bradycardia in patients on infusional Drug5 - fluorouracil . |
| 0.9631 | Adverse-EffectTransient asymptomatic bradycardia in patients on infusional 5 - fluorouracil. |
| Score | Text |
|---|---|
| 0.9997 | Easily reversible hypoxemia and hypotension induced by Drugnimodipine . |
| 0.9975 | Easily reversible hypoxemia and Adverse-Effecthypotension induced by nimodipine. |
| 0.9961 | Easily reversible Adverse-Effecthypoxemia and hypotension induced by nimodipine. |
| Score | Text |
|---|---|
| 0.9993 | DrugGelofusine allergy - - the need for identification jewellery. |
| 0.8328 | Adverse-EffectGelofusine allergy - - the need for identification jewellery. |
| Score | Text |
|---|---|
| 0.9995 | Disseminated salmonellosis in a patient treated with Drugtemozolomide . |
| 0.9887 | Adverse-EffectDisseminated salmonellosis in a patient treated with temozolomide. |
| Score | Text |
|---|---|
| 0.9990 | DrugEpoprostenol may be associated rarely with severe erythroderma. |
| 0.9769 | Epoprostenol may be associated rarely with severe Adverse-Effecterythroderma . |
| Score | Text |
|---|---|
| 0.9996 | Chromosome abnormalities after Drugchlorambucil therapy of polycythaemia vera. |
| 0.9875 | Adverse-EffectChromosome abnormalities after chlorambucil therapy of polycythaemia vera. |
| Score | Text |
|---|---|
| 0.9996 | Acute acoustic nerve palsy associated with Drugvincristine therapy. |
| 0.9828 | Adverse-EffectAcute acoustic nerve palsy associated with vincristine therapy. |
| Score | Text |
|---|---|
| 0.9996 | Case report of withdrawal dyskinesia associated with Drugamoxapine . |
| 0.9978 | Case report of withdrawal Adverse-Effectdyskinesia associated with amoxapine. |
| Score | Text |
|---|---|
| 0.9996 | Insulin - dependent diabetes mellitus associated with Drugdanazol . |
| 0.9686 | Adverse-EffectInsulin - dependent diabetes mellitus associated with danazol. |
| Score | Text |
|---|---|
| 0.9990 | Acute dystonic reaction with low - dose Drugpimozide . |
| 0.9858 | Adverse-EffectAcute dystonic reaction with low - dose pimozide. |
| Score | Text |
|---|---|
| 0.9995 | Falling backward in two elderly patients taking Drugbupropion . |
| 0.9889 | Adverse-EffectFalling backward in two elderly patients taking bupropion. |
| Score | Text |
|---|---|
| 0.9994 | Reversible Drugsirolimus - associated pneumonitis after heart transplantation. |
| 0.9977 | Reversible sirolimus - associated Adverse-Effectpneumonitis after heart transplantation. |
| Score | Text |
|---|---|
| 0.9990 | DrugRifampin - associated thrombocytopenia secondary to poor compliance. |
| 0.9959 | Rifampin - associated Adverse-Effectthrombocytopenia secondary to poor compliance. |
| Score | Text |
|---|---|
| 0.9995 | Inappropriate antidiuretic hormone secretion after high dose Drugvinblastine . |
| 0.9771 | Adverse-EffectInappropriate antidiuretic hormone secretion after high dose vinblastine. |
| Score | Text |
|---|---|
| 0.9996 | DrugClozapine - induced akathisia in children with schizophrenia. |
| 0.9983 | Clozapine - induced Adverse-Effectakathisia in children with schizophrenia. |
| Score | Text |
|---|---|
| 0.9995 | A fatal case of pancytopenia due to Druglevomepromazine . |
| 0.8997 | A Adverse-Effectfatal case of pancytopenia due to levomepromazine. |
| Score | Text |
|---|---|
| 0.9994 | Near fatal acute Drugcolchicine intoxication in a child. |
| 0.9802 | Adverse-EffectNear fatal acute colchicine intoxication in a child. |
| 0.5398 | Near fatal acute Adverse-Effectcolchicine intoxication in a child. |
| Score | Text |
|---|---|
| 0.9993 | DrugAtenolol induced memory impairment : a case report. |
| 0.9871 | Atenolol induced Adverse-Effectmemory impairment : a case report. |
| Score | Text |
|---|---|
| 0.9988 | After discontinuation of Drugdanazol the diabetes completely resolved. |
| 0.9892 | After discontinuation of danazol the Adverse-Effectdiabetes completely resolved. |
| Score | Text |
|---|---|
| 0.9993 | DrugMethotrexate pneumonitis in nonsurgical treatment of ectopic pregnancy. |
| 0.9225 | Methotrexate Adverse-Effectpneumonitis in nonsurgical treatment of ectopic pregnancy. |
| Score | Text |
|---|---|
| 0.9995 | Tardive dyskinesia in 2 patients treated with Drugziprasidone . |
| 0.9909 | Adverse-EffectTardive dyskinesia in 2 patients treated with ziprasidone. |
| Score | Text |
|---|---|
| 0.9994 | Encephalopathy and seizures induced by intravesical Drugalum irrigations. |
| 0.9986 | Encephalopathy and Adverse-Effectseizures induced by intravesical alum irrigations. |
| 0.9973 | Adverse-EffectEncephalopathy and seizures induced by intravesical alum irrigations. |
| Score | Text |
|---|---|
| 0.9994 | Life - threatening cranial dystonia following Drugtrihexyphenidyl withdrawal. |
| 0.9855 | Life - threatening Adverse-Effectcranial dystonia following trihexyphenidyl withdrawal. |
| Score | Text |
|---|---|
| 0.9994 | Flaccid quadriparesis was noted after discontinuation of Drugvecuronium . |
| 0.9789 | Adverse-EffectFlaccid quadriparesis was noted after discontinuation of vecuronium. |
| Score | Text |
|---|---|
| 0.9995 | DrugTheophylline intoxication mimicking diabetic ketoacidosis in a child. |
| 0.8871 | Adverse-EffectTheophylline intoxication mimicking diabetic ketoacidosis in a child. |
| Score | Text |
|---|---|
| 0.9995 | Intraventricular Drugnafcillin - induced seizures in a neonate. |
| 0.9987 | Intraventricular nafcillin - induced Adverse-Effectseizures in a neonate. |
| Score | Text |
|---|---|
| 0.9996 | Linear immunoglobulin A bullous dermatosis induced by Druggemcitabine . |
| 0.9745 | Adverse-EffectLinear immunoglobulin A bullous dermatosis induced by gemcitabine. |
| Score | Text |
|---|---|
| 0.9994 | Renal failure associated with Drugacetazolamide therapy for glaucoma. |
| 0.9927 | Adverse-EffectRenal failure associated with acetazolamide therapy for glaucoma. |
| Score | Text |
|---|---|
| 0.9994 | Gangrene of the fingertips after Drugbleomycin and methotrexate. |
| 0.9994 | Gangrene of the fingertips after bleomycin and Drugmethotrexate . |
| 0.9989 | Adverse-EffectGangrene of the fingertips after bleomycin and methotrexate. |
| Score | Text |
|---|---|
| 0.9991 | DrugFlucloxacillin - induced aplastic anaemia and liver failure. |
| 0.9920 | Flucloxacillin - induced Adverse-Effectaplastic anaemia and liver failure. |
| 0.9897 | Flucloxacillin - induced aplastic anaemia and Adverse-Effectliver failure . |
| Score | Text |
|---|---|
| 0.9990 | The course of delirium due to Druglithium intoxication. |
| 0.9959 | The course of Adverse-Effectdelirium due to lithium intoxication. |
| Score | Text |
|---|---|
| 0.9656 | Severe neurotoxicity with Drugmethyl G : CALGB experience. |
| 0.8321 | Adverse-EffectSevere neurotoxicity with methyl G : CALGB experience. |
| Score | Text |
|---|---|
| 0.9996 | Spontaneous bacterial peritonitis induced by intraarterial Drugvasopressin therapy. |
| 0.9790 | Spontaneous Adverse-Effectbacterial peritonitis induced by intraarterial vasopressin therapy. |
| 0.9815 | Adverse-EffectSpontaneous bacterial peritonitis induced by intraarterial vasopressin therapy. |
| Score | Text |
|---|---|
| 0.9989 | Their parkinsonism improved on discontinuation of Drugmetoclopramide therapy. |
| 0.9769 | Their Adverse-Effectparkinsonism improved on discontinuation of metoclopramide therapy. |
| Score | Text |
|---|---|
| 0.9975 | DrugLinezolid - induced dyserythropoiesis : chloramphenicol toxicity revisited. |
| 0.9959 | Linezolid - induced Adverse-Effectdyserythropoiesis : chloramphenicol toxicity revisited. |
| Score | Text |
|---|---|
| 0.9995 | DrugRifampin - induced hypothyroidism without underlying thyroid disease. |
| 0.9965 | Rifampin - induced Adverse-Effecthypothyroidism without underlying thyroid disease. |
| Score | Text |
|---|---|
| 0.9994 | Severe acidosis from Drugacetazolamide in a diabetic patient. |
| 0.9899 | Adverse-EffectSevere acidosis from acetazolamide in a diabetic patient. |
| Score | Text |
|---|---|
| 0.9993 | Acute pancreatitis associated with Drugdanazol treatment for endometriosis. |
| 0.9826 | Adverse-EffectAcute pancreatitis associated with danazol treatment for endometriosis. |
| Score | Text |
|---|---|
| 0.9996 | DrugSirolimus - associated hepatotoxicity in the kidney graft recipient. |
| 0.9960 | Sirolimus - associated Adverse-Effecthepatotoxicity in the kidney graft recipient. |
| Score | Text |
|---|---|
| 0.9991 | Transient Drugphenytoin induced IgA deficiency and permanent IgE increase. |
| 0.9898 | Transient phenytoin induced IgA deficiency and permanent Adverse-EffectIgE increase . |
| 0.9881 | Transient phenytoin induced Adverse-EffectIgA deficiency and permanent IgE increase. |
| Score | Text |
|---|---|
| 0.9993 | DrugMefloquine - associated hypoglycaemia in a cachectic AIDS patient. |
| 0.9966 | Mefloquine - associated Adverse-Effecthypoglycaemia in a cachectic AIDS patient. |
| Score | Text |
|---|---|
| 0.9993 | DrugLansoprazole - associated collagenous colitis : a case report. |
| 0.9902 | Lansoprazole - associated Adverse-Effectcollagenous colitis : a case report. |
| Score | Text |
|---|---|
| 0.9996 | DrugEnalapril - induced anemia in two kidney transplant recipients. |
| 0.9988 | Enalapril - induced Adverse-Effectanemia in two kidney transplant recipients. |
| Score | Text |
|---|---|
| 0.9909 | Transient leucopenia and Adverse-Effectthrombocytopenia associated with sodium nitroprusside infusion. |
| 0.9905 | Transient leucopenia and thrombocytopenia associated with Drugsodium nitroprusside infusion. |
| 0.6227 | Transient Adverse-Effectleucopenia and thrombocytopenia associated with sodium nitroprusside infusion. |
| Score | Text |
|---|---|
| 0.9996 | A case of Drugcolchicine - induced rhabdomyolysis is reported. |
| 0.9977 | A case of colchicine - induced Adverse-Effectrhabdomyolysis is reported. |
| Score | Text |
|---|---|
| 0.9996 | A diagnosis of Drugtrastuzumab - induced pneumonitis was made. |
| 0.9988 | A diagnosis of trastuzumab - induced Adverse-Effectpneumonitis was made. |
| Score | Text |
|---|---|
| 0.9983 | DrugAlprazolam withdrawal delirium unresponsive to diazepam : case report. |
| 0.9980 | Alprazolam withdrawal Adverse-Effectdelirium unresponsive to diazepam : case report. |
| Score | Text |
|---|---|
| 0.9996 | Abnormal retinal function associated with Drugisotretinoin therapy for acne. |
| 0.9829 | Adverse-EffectAbnormal retinal function associated with isotretinoin therapy for acne. |
| Score | Text |
|---|---|
| 0.9995 | Rupture of a cerebral aneurysm associated with Drugnifedipine treatment. |
| 0.9725 | Adverse-EffectRupture of a cerebral aneurysm associated with nifedipine treatment. |
| Score | Text |
|---|---|
| 0.9995 | Phantom limb pain as a manifestation of Drugpaclitaxel neurotoxicity. |
| 0.9787 | Adverse-EffectPhantom limb pain as a manifestation of paclitaxel neurotoxicity. |
| 0.8510 | Phantom limb pain as a manifestation of paclitaxel Adverse-Effectneurotoxicity . |
| Score | Text |
|---|---|
| 0.9993 | Papillary necrosis associated with the HIV protease inhibitor Drugindinavir . |
| 0.9890 | Adverse-EffectPapillary necrosis associated with the HIV protease inhibitor indinavir. |
| Score | Text |
|---|---|
| 0.9995 | DrugAmpicillin - induced interstitial nephritis with generalised exfoliative dermatitis. |
| 0.9876 | Ampicillin - induced Adverse-Effectinterstitial nephritis with generalised exfoliative dermatitis. |
| 0.9830 | Ampicillin - induced interstitial nephritis with Adverse-Effectgeneralised exfoliative dermatitis . |
| Score | Text |
|---|---|
| 0.9962 | Traumatic late flap dehiscence and Enterobacter keratitis following DrugLASIK . |
| 0.9853 | Traumatic late flap dehiscence and Adverse-EffectEnterobacter keratitis following LASIK. |
| 0.9695 | Adverse-EffectTraumatic late flap dehiscence and Enterobacter keratitis following LASIK. |
| Score | Text |
|---|---|
| 0.9991 | DrugOfloxacin : a probable cause of toxic epidermal necrolysis. |
| 0.9819 | Ofloxacin : a probable cause of Adverse-Effecttoxic epidermal necrolysis . |
| Score | Text |
|---|---|
| 0.9989 | DrugBisphosphonate induced osteochemonecrosis of the jaw mimicking a tumour. |
| 0.9786 | Bisphosphonate induced Adverse-Effectosteochemonecrosis of the jaw mimicking a tumour. |
| Score | Text |
|---|---|
| 0.9991 | This case report illustrates the neurotoxicity unique to DrugHDARAC . |
| 0.9963 | This case report illustrates the Adverse-Effectneurotoxicity unique to HDARAC. |
| Score | Text |
|---|---|
| 0.9995 | Three cases of Druggold - related neuropathy are reported. |
| 0.9980 | Three cases of gold - related Adverse-Effectneuropathy are reported. |
| Score | Text |
|---|---|
| 0.9983 | DrugPropranolol - induced hypertension in treatment of cocaine intoxication. |
| 0.9965 | Propranolol - induced Adverse-Effecthypertension in treatment of cocaine intoxication. |
| Score | Text |
|---|---|
| 0.9994 | Serotonin syndrome caused by interaction between Drugcitalopram and fentanyl. |
| 0.9993 | Serotonin syndrome caused by interaction between citalopram and Drugfentanyl . |
| 0.9936 | Adverse-EffectSerotonin syndrome caused by interaction between citalopram and fentanyl. |
| Score | Text |
|---|---|
| 0.9994 | Hepatotoxicity after high - dose Drugmethylprednisolone for demyelinating disease. |
| 0.9975 | Adverse-EffectHepatotoxicity after high - dose methylprednisolone for demyelinating disease. |
| Score | Text |
|---|---|
| 0.9996 | Accelerated nodulosis during Drugmethotrexate therapy for juvenile rheumatoid arthritis. |
| 0.9853 | Adverse-EffectAccelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis. |
| Score | Text |
|---|---|
| 0.9995 | Thrombotic thrombocytopenic purpura during Drugpenicillamine therapy in rheumatoid arthritis. |
| 0.9800 | Adverse-EffectThrombotic thrombocytopenic purpura during penicillamine therapy in rheumatoid arthritis. |
| Score | Text |
|---|---|
| 0.9995 | Acute respiratory depression as a complication of nebulised Drugmorphine . |
| 0.9754 | Adverse-EffectAcute respiratory depression as a complication of nebulised morphine. |
| Score | Text |
|---|---|
| 0.9992 | DrugCeftriaxone - induced fixed drug eruption : first report. |
| 0.9701 | Ceftriaxone - induced Adverse-Effectfixed drug eruption : first report. |
| Score | Text |
|---|---|
| 0.9896 | Adverse-EffectComeoscleral perforation after pterygium excision and intraoperative mitomycin C. |
| 0.9851 | Comeoscleral perforation after pterygium excision and intraoperative Drugmitomycin C . |
| Score | Text |
|---|---|
| 0.9995 | DrugIfosfamide is a known nephrotoxic drug with demonstrated tubulopathies. |
| 0.9983 | Ifosfamide is a known nephrotoxic drug with demonstrated Adverse-Effecttubulopathies . |
| Score | Text |
|---|---|
| 0.9991 | Hepatotoxicity associated with Drug6 - thioguanine therapy for Crohn's disease. |
| 0.9977 | Adverse-EffectHepatotoxicity associated with 6 - thioguanine therapy for Crohn's disease. |
| Score | Text |
|---|---|
| 0.9989 | Hepatotoxicity of Drughycanthone in patients with metastatic breast cancer. |
| 0.9955 | Adverse-EffectHepatotoxicity of hycanthone in patients with metastatic breast cancer. |
| Score | Text |
|---|---|
| 0.9992 | DrugDisulfiram encephalopathy as a cause of the catatonia syndrome. |
| 0.9913 | Disulfiram encephalopathy as a cause of the Adverse-Effectcatatonia syndrome . |
| 0.6384 | Disulfiram Adverse-Effectencephalopathy as a cause of the catatonia syndrome. |
| Score | Text |
|---|---|
| 0.9845 | Adverse-EffectSensorimotor polyneuropathy with 5 - aminosalicylic acid : a case report. |
| 0.9755 | Sensorimotor polyneuropathy with Drug5 - aminosalicylic acid : a case report. |
| Score | Text |
|---|---|
| 0.9784 | Delayed neurotoxicity of intraventricular Druginterleukin - 2 : a case report. |
| 0.8860 | Delayed Adverse-Effectneurotoxicity of intraventricular interleukin - 2 : a case report. |
| Score | Text |
|---|---|
| 0.9898 | Unusual hypersensitivity to Drugwarfarin in a critically ill patient. |
| 0.9097 | Unusual Adverse-Effecthypersensitivity to warfarin in a critically ill patient. |
| Score | Text |
|---|---|
| 0.9918 | Adverse-EffectVasomotor reactions after gold sodium thiomalate are well recognized. |
| 0.9659 | Vasomotor reactions after Druggold sodium thiomalate are well recognized. |
| Score | Text |
|---|---|
| 0.9996 | Intrahepatic cholestasis and cutaneous bullae associated with Drugglibenclamide therapy. |
| 0.9895 | Intrahepatic cholestasis and Adverse-Effectcutaneous bullae associated with glibenclamide therapy. |
| 0.9864 | Adverse-EffectIntrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy. |
| Score | Text |
|---|---|
| 0.9995 | DrugTrazodone - induced transient hypomanic symptoms and their management. |
| 0.9824 | Trazodone - induced Adverse-Effecttransient hypomanic symptoms and their management. |
| Score | Text |
|---|---|
| 0.9992 | Some patients develop hypersensitivity rash in response to DrugHCQ . |
| 0.9915 | Some patients develop Adverse-Effecthypersensitivity rash in response to HCQ. |
| Score | Text |
|---|---|
| 0.9991 | Possible recurrence of Drugamiodarone pulmonary toxicity following corticosteroid therapy. |
| 0.8646 | Possible recurrence of amiodarone Adverse-Effectpulmonary toxicity following corticosteroid therapy. |
| Score | Text |
|---|---|
| 0.9996 | Hepatotoxicity related to Drugitraconazole : report of three cases. |
| 0.9976 | Adverse-EffectHepatotoxicity related to itraconazole : report of three cases. |
| Score | Text |
|---|---|
| 0.9994 | Septic knee arthritis after intra - articular Drughyaluronate injection. |
| 0.9805 | Adverse-EffectSeptic knee arthritis after intra - articular hyaluronate injection. |
| Score | Text |
|---|---|
| 0.9786 | Adverse-EffectMultiple sclerosis - like disease secondary to alpha interferon. |
| 0.9148 | Multiple sclerosis - like disease secondary to Drugalpha interferon . |
| Score | Text |
|---|---|
| 0.9992 | The literature of Drugvincristine optic nerve toxicity is reviewed. |
| 0.8603 | The literature of vincristine Adverse-Effectoptic nerve toxicity is reviewed. |
| Score | Text |
|---|---|
| 0.9994 | An intertrigo - like eruption from pegylated liposomal Drugdoxorubicin . |
| 0.9816 | An Adverse-Effectintertrigo - like eruption from pegylated liposomal doxorubicin. |
| Score | Text |
|---|---|
| 0.9994 | Hypotension and sinus arrest with Drugnifedipine in pulmonary hypertension. |
| 0.9973 | Adverse-EffectHypotension and sinus arrest with nifedipine in pulmonary hypertension. |
| 0.9882 | Hypotension and Adverse-Effectsinus arrest with nifedipine in pulmonary hypertension. |
| Score | Text |
|---|---|
| 0.9995 | Liver transplantation for fulminant hepatitis related to Drugnevirapine therapy. |
| 0.9734 | Liver transplantation for Adverse-Effectfulminant hepatitis related to nevirapine therapy. |
| Score | Text |
|---|---|
| 0.9995 | Diabetes Mellitus was observed in a patient given Drugcarbamazepine . |
| 0.9892 | Adverse-EffectDiabetes Mellitus was observed in a patient given carbamazepine. |
| Score | Text |
|---|---|
| 0.9995 | DrugMethotrexate - induced papular eruption following treatment of psoriasis. |
| 0.9915 | Methotrexate - induced Adverse-Effectpapular eruption following treatment of psoriasis. |
| Score | Text |
|---|---|
| 0.9995 | Pulmonary hypertension during Druglithium therapy : clinical case study. |
| 0.9905 | Adverse-EffectPulmonary hypertension during lithium therapy : clinical case study. |
| Score | Text |
|---|---|
| 0.9992 | DrugClofazimine enteropathy in a pediatric bone marrow transplant recipient. |
| 0.9288 | Clofazimine Adverse-Effectenteropathy in a pediatric bone marrow transplant recipient. |
| Score | Text |
|---|---|
| 0.9994 | Cardiac arrest associated with Drugsulprostone use during caesarean section. |
| 0.9947 | Adverse-EffectCardiac arrest associated with sulprostone use during caesarean section. |
| Score | Text |
|---|---|
| 0.9996 | DrugPropafenone - induced ataxia : report of three cases. |
| 0.9987 | Propafenone - induced Adverse-Effectataxia : report of three cases. |
| Score | Text |
|---|---|
| 0.9995 | Disseminated muscular cysticercosis with myositis induced by Drugpraziquantel therapy. |
| 0.9793 | Disseminated muscular cysticercosis with Adverse-Effectmyositis induced by praziquantel therapy. |
| Score | Text |
|---|---|
| 0.9997 | We report a case of myoclonus induced by Drugquetiapine . |
| 0.9988 | We report a case of Adverse-Effectmyoclonus induced by quetiapine. |
| Score | Text |
|---|---|
| 0.9992 | Hepatopathy subsided after the cessation of Drugcarbamazepine and lynestrenol. |
| 0.9992 | Hepatopathy subsided after the cessation of carbamazepine and Druglynestrenol . |
| 0.9984 | Adverse-EffectHepatopathy subsided after the cessation of carbamazepine and lynestrenol. |
| Score | Text |
|---|---|
| 0.9992 | Large dose of Drugmethylphenidate may cause cataract and glaucoma. |
| 0.9987 | Large dose of methylphenidate may cause cataract and Adverse-Effectglaucoma . |
| 0.9986 | Large dose of methylphenidate may cause Adverse-Effectcataract and glaucoma. |
| Score | Text |
|---|---|
| 0.9995 | Syndrome of inappropriate antidiuretic hormone associated with Drugvinorelbine therapy. |
| 0.9441 | Adverse-EffectSyndrome of inappropriate antidiuretic hormone associated with vinorelbine therapy. |
| Score | Text |
|---|---|
| 0.9869 | Adverse-EffectAcute pancreatitis after long - term 5 - aminosalicylic acid therapy. |
| 0.9790 | Acute pancreatitis after long - term Drug5 - aminosalicylic acid therapy. |
| Score | Text |
|---|---|
| 0.9996 | DrugFoscarnet - induced severe hypomagnesemia and other electrolyte disorders. |
| 0.9925 | Foscarnet - induced severe hypomagnesemia and other Adverse-Effectelectrolyte disorders . |
| 0.9839 | Foscarnet - induced Adverse-Effectsevere hypomagnesemia and other electrolyte disorders. |
| Score | Text |
|---|---|
| 0.9992 | Anaphylactoid reaction to Drugmethylprednisolone pulsed therapy for multiple sclerosis. |
| 0.9899 | Adverse-EffectAnaphylactoid reaction to methylprednisolone pulsed therapy for multiple sclerosis. |
| Score | Text |
|---|---|
| 0.9973 | Simvastatin - induced Adverse-Effectrhabdomyolysis following cyclosporine treatment for uveitis. |
| 0.9880 | DrugSimvastatin - induced rhabdomyolysis following cyclosporine treatment for uveitis. |
| 0.9488 | Simvastatin - induced rhabdomyolysis following Drugcyclosporine treatment for uveitis. |
| Score | Text |
|---|---|
| 0.9991 | The spectrum of Drugnitrofurantoin lung injury continues to widen. |
| 0.8908 | The spectrum of nitrofurantoin Adverse-Effectlung injury continues to widen. |
| Score | Text |
|---|---|
| 0.9995 | Paradoxical ventricular tachycardia and fibrillation after intravenous Drugbretylium therapy. |
| 0.9943 | Paradoxical ventricular tachycardia and Adverse-Effectfibrillation after intravenous bretylium therapy. |
| 0.9754 | Adverse-EffectParadoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy. |
| Score | Text |
|---|---|
| 0.9995 | The patient developed grade 3 Drugcapecitabine - induced headache. |
| 0.9990 | The patient developed grade 3 capecitabine - induced Adverse-Effectheadache . |
| Score | Text |
|---|---|
| 0.9762 | Adverse-EffectEmbolia cutis medicamentosa following subcutaneous injection of glatiramer acetate. |
| 0.9726 | Embolia cutis medicamentosa following subcutaneous injection of Drugglatiramer acetate . |
| Score | Text |
|---|---|
| 0.9989 | These results indicate that Druglithium may cause biochemical hyperparathyroidism. |
| 0.9849 | These results indicate that lithium may cause Adverse-Effectbiochemical hyperparathyroidism . |
| Score | Text |
|---|---|
| 0.9995 | A new type of Drugminocycline - induced cutaneous hyperpigmentation. |
| 0.9897 | A new type of minocycline - induced Adverse-Effectcutaneous hyperpigmentation . |
| Score | Text |
|---|---|
| 0.9991 | Reversible corneal keratinization following trabeculectomy and treatment with Drug5 - fluorouracil . |
| 0.9826 | Adverse-EffectReversible corneal keratinization following trabeculectomy and treatment with 5 - fluorouracil. |
| Score | Text |
|---|---|
| 0.9993 | Acute endophthalmitis following intravitreal Drugbevacizumab ( Avastin ) injection. |
| 0.9991 | Acute endophthalmitis following intravitreal bevacizumab ( DrugAvastin ) injection. |
| 0.9840 | Adverse-EffectAcute endophthalmitis following intravitreal bevacizumab ( Avastin ) injection. |
| Score | Text |
|---|---|
| 0.9984 | Adverse-EffectCamptocormia , a new side effect of sodium valproate. |
| 0.9826 | Camptocormia, a new side effect of Drugsodium valproate . |
| Score | Text |
|---|---|
| 0.9991 | Histopathology of the thyroid in Drugamiodarone - induced hypothyroidism. |
| 0.9969 | Histopathology of the thyroid in amiodarone - induced Adverse-Effecthypothyroidism . |
| Score | Text |
|---|---|
| 0.9996 | Multiple seizures after Drugbupropion overdose in a small child. |
| 0.9896 | Adverse-EffectMultiple seizures after bupropion overdose in a small child. |
| Score | Text |
|---|---|
| 0.9982 | Successful challenge with Drugclozapine in a history of eosinophilia. |
| 0.9588 | Successful challenge with clozapine in a history of Adverse-Effecteosinophilia . |
| Score | Text |
|---|---|
| 0.9989 | A case of Drugpyridoxine - dependent seizures is reported. |
| 0.9942 | A case of pyridoxine - dependent Adverse-Effectseizures is reported. |
| Score | Text |
|---|---|
| 0.9996 | Systemic lupus erythematosus during Drugpenicillamine therapy for rheumatoid arthritis. |
| 0.9785 | Adverse-EffectSystemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis. |
| Score | Text |
|---|---|
| 0.9994 | Two fatal cases of poisoning by Drugparacetamol are described. |
| 0.8953 | Two Adverse-Effectfatal cases of poisoning by paracetamol are described. |
| Score | Text |
|---|---|
| 0.9995 | Nephrotic range pseudoproteinuria in a Drugtolmetin - treated patient. |
| 0.9758 | Adverse-EffectNephrotic range pseudoproteinuria in a tolmetin - treated patient. |
| Score | Text |
|---|---|
| 0.9997 | DrugCaptopril - related ( and - induced? ) asthma. |
| 0.9950 | Captopril - related ( and - induced? ) Adverse-Effectasthma . |
| Score | Text |
|---|---|
| 0.9828 | A case of noncardiogenic pulmonary edema by Drugethanolamine oleate . |
| 0.9818 | A case of Adverse-Effectnoncardiogenic pulmonary edema by ethanolamine oleate. |
| Score | Text |
|---|---|
| 0.9981 | Adverse-EffectHypercalcemia in an AIDS patient treated with growth hormone. |
| 0.9689 | Hypercalcemia in an AIDS patient treated with Druggrowth hormone . |
| Score | Text |
|---|---|
| 0.9995 | Systemic vasculitis complicating hairy cell leukaemia treatment with Drugcladribine . |
| 0.9909 | Adverse-EffectSystemic vasculitis complicating hairy cell leukaemia treatment with cladribine. |
| Score | Text |
|---|---|
| 0.9990 | DrugCephalosporins are most likely associated with Vitamin K deficiency. |
| 0.9862 | Cephalosporins are most likely associated with Adverse-EffectVitamin K deficiency . |
| Score | Text |
|---|---|
| 0.9995 | Reversible cholestasis with bile duct injury following Drugazathioprine therapy. |
| 0.9784 | Reversible cholestasis with Adverse-Effectbile duct injury following azathioprine therapy. |
| 0.8685 | Reversible Adverse-Effectcholestasis with bile duct injury following azathioprine therapy. |
| Score | Text |
|---|---|
| 0.9996 | Uveitis associated with Drugrifabutin therapy : a clinical alert. |
| 0.9987 | Adverse-EffectUveitis associated with rifabutin therapy : a clinical alert. |
| Score | Text |
|---|---|
| 0.9996 | DrugAmiodarone - induced thyrotoxicosis associated with thyrotropin receptor antibody. |
| 0.9972 | Amiodarone - induced Adverse-Effectthyrotoxicosis associated with thyrotropin receptor antibody. |
| 0.9799 | Amiodarone - induced thyrotoxicosis associated with Adverse-Effectthyrotropin receptor antibody . |
| Score | Text |
|---|---|
| 0.9996 | Peripheral neuropathy and cerebellar syndrome associated with Drugamiodarone therapy. |
| 0.9885 | Peripheral neuropathy and Adverse-Effectcerebellar syndrome associated with amiodarone therapy. |
| 0.9860 | Adverse-EffectPeripheral neuropathy and cerebellar syndrome associated with amiodarone therapy. |
| Score | Text |
|---|---|
| 0.9996 | A case of priapism associated with Drugtrazodone is described. |
| 0.9986 | A case of Adverse-Effectpriapism associated with trazodone is described. |
| Score | Text |
|---|---|
| 0.9995 | DISCUSSION : Electrolyte disorders associated with Drugfoscarnet are reviewed. |
| 0.9914 | DISCUSSION : Adverse-EffectElectrolyte disorders associated with foscarnet are reviewed. |
| Score | Text |
|---|---|
| 0.9995 | Myocardial ischemia associated with high - dose Drugcarmustine infusion. |
| 0.9901 | Adverse-EffectMyocardial ischemia associated with high - dose carmustine infusion. |
| Score | Text |
|---|---|
| 0.9990 | DrugMethylphenidate - associated enuresis in attention deficit hyperactivity disorder. |
| 0.9975 | Methylphenidate - associated Adverse-Effectenuresis in attention deficit hyperactivity disorder. |
| Score | Text |
|---|---|
| 0.9991 | Development of porphyria cutanea tarda after treatment with Drugcyclophosphamide . |
| 0.9860 | Development of Adverse-Effectporphyria cutanea tarda after treatment with cyclophosphamide. |
| Score | Text |
|---|---|
| 0.9996 | Acute reversible ataxo - myoclonic encephalopathy with Drugflecainide therapy. |
| 0.9269 | Adverse-EffectAcute reversible ataxo - myoclonic encephalopathy with flecainide therapy. |
| Score | Text |
|---|---|
| 0.9937 | Thus Drugcabergoline may cause similar pleuropulmonary abnormalities to bromocriptine. |
| 0.9864 | Thus cabergoline may cause similar pleuropulmonary abnormalities to Drugbromocriptine . |
| 0.9745 | Thus cabergoline may cause similar Adverse-Effectpleuropulmonary abnormalities to bromocriptine. |
| Score | Text |
|---|---|
| 0.9995 | High - grade atrioventricular block during Drugdipyridamole stress testing. |
| 0.9779 | Adverse-EffectHigh - grade atrioventricular block during dipyridamole stress testing. |
| Score | Text |
|---|---|
| 0.9992 | Disulfiram - like reactions with newer cephalosporins : Drugcefmenoxime . |
| 0.9832 | Adverse-EffectDisulfiram - like reactions with newer cephalosporins : cefmenoxime. |
| Score | Text |
|---|---|
| 0.9992 | We suggest discontinuing Druggemcitabine if radiation recall is observed. |
| 0.9891 | We suggest discontinuing gemcitabine if Adverse-Effectradiation recall is observed. |
| Score | Text |
|---|---|
| 0.9996 | DrugFluoxetine - induced akathisia : clinical and theoretical implications. |
| 0.9985 | Fluoxetine - induced Adverse-Effectakathisia : clinical and theoretical implications. |
| Score | Text |
|---|---|
| 0.9875 | The Adverse-Effectharlequin color change and association with prostaglandin E1. |
| 0.9821 | The harlequin color change and association with Drugprostaglandin E1 . |
| Score | Text |
|---|---|
| 0.9994 | Management and successful desensitization in Drugmethotrexate - induced anaphylaxis. |
| 0.9985 | Management and successful desensitization in methotrexate - induced Adverse-Effectanaphylaxis . |
| Score | Text |
|---|---|
| 0.9995 | Response of a Drugpromethazine - induced coma to flumazenil. |
| 0.9968 | Response of a promethazine - induced Adverse-Effectcoma to flumazenil. |
| Score | Text |
|---|---|
| 0.9994 | Multifocal electroretinographic abnormalities in Drugethambutol - induced visual loss. |
| 0.9950 | Multifocal electroretinographic abnormalities in ethambutol - induced Adverse-Effectvisual loss . |
| Score | Text |
|---|---|
| 0.9995 | Acute renal failure in a child associated with Drugacyclovir . |
| 0.9692 | Adverse-EffectAcute renal failure in a child associated with acyclovir. |
| Score | Text |
|---|---|
| 0.9994 | Withdrawal of DrugDepakote resulted in resolution of the effusion. |
| 0.9986 | Withdrawal of Depakote resulted in resolution of the Adverse-Effecteffusion . |
| Score | Text |
|---|---|
| 0.9995 | DrugDipyrone - induced granulocytopenia : a case for awareness. |
| 0.9969 | Dipyrone - induced Adverse-Effectgranulocytopenia : a case for awareness. |
| Score | Text |
|---|---|
| 0.9996 | The second patient exhibited sudden PLMS following Drugolanzapine injection. |
| 0.9943 | The second patient exhibited sudden Adverse-EffectPLMS following olanzapine injection. |
| Score | Text |
|---|---|
| 0.9994 | Fixed drug eruption of the scrotum due to Drugmethylphenidate . |
| 0.8606 | Adverse-EffectFixed drug eruption of the scrotum due to methylphenidate. |
| Score | Text |
|---|---|
| 0.9989 | Hepatotoxic effects in a child receiving valproate and Drugcarnitine . |
| 0.9989 | Hepatotoxic effects in a child receiving Drugvalproate and carnitine. |
| 0.9823 | Adverse-EffectHepatotoxic effects in a child receiving valproate and carnitine. |
| Score | Text |
|---|---|
| 0.9990 | Isoniazid and Drugethambutol as a cause of optic neuropathy. |
| 0.9990 | DrugIsoniazid and ethambutol as a cause of optic neuropathy. |
| 0.9857 | Isoniazid and ethambutol as a cause of Adverse-Effectoptic neuropathy . |
| Score | Text |
|---|---|
| 0.9660 | DrugAmphotericin B nephrotoxicity in humans decreased by salt repletion. |
| 0.6606 | Amphotericin B Adverse-Effectnephrotoxicity in humans decreased by salt repletion. |
| Score | Text |
|---|---|
| 0.9994 | DrugLevofloxacin induced polymorphic ventricular tachycardia with normal QT interval. |
| 0.9828 | Levofloxacin induced Adverse-Effectpolymorphic ventricular tachycardia with normal QT interval. |
| Score | Text |
|---|---|
| 0.9994 | Pulmonary edema as a delayed complication of Drugritodrine therapy. |
| 0.9918 | Adverse-EffectPulmonary edema as a delayed complication of ritodrine therapy. |
| Score | Text |
|---|---|
| 0.9995 | Toxicity related to Drugchloroquine treatment of resistant vivax malaria. |
| 0.9980 | Adverse-EffectToxicity related to chloroquine treatment of resistant vivax malaria. |
| Score | Text |
|---|---|
| 0.9974 | Carbamazepine toxicity induced by Drugclarithromycin coadministration in psychiatric patients. |
| 0.9955 | DrugCarbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients. |
| 0.8913 | Adverse-EffectCarbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients. |
| Score | Text |
|---|---|
| 0.9987 | Circulating anticoagulant in the Drugprocainamide - induced lupus syndrome. |
| 0.9937 | Circulating anticoagulant in the procainamide - induced Adverse-Effectlupus syndrome . |
| Score | Text |
|---|---|
| 0.9996 | Myotonia associated with sarcoidosis : marked exacerbation with Drugpravastatin . |
| 0.9987 | Adverse-EffectMyotonia associated with sarcoidosis : marked exacerbation with pravastatin. |
| Score | Text |
|---|---|
| 0.9551 | Gold nephropathy due to auranofin obscured by Drugtolmetin pseudoproteinuria. |
| 0.9245 | DrugGold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria. |
| 0.8911 | Gold nephropathy due to Drugauranofin obscured by tolmetin pseudoproteinuria. |
| 0.7560 | Gold Adverse-Effectnephropathy due to auranofin obscured by tolmetin pseudoproteinuria. |
| Adverse-EffectGold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria. | |
| Gold nephropathy due to auranofin obscured by tolmetin Adverse-Effectpseudoproteinuria . | |
| Score | Text |
|---|---|
| 0.9994 | DrugDoxycycline - induced hypoglycemia in a nondiabetic young man. |
| 0.9975 | Doxycycline - induced Adverse-Effecthypoglycemia in a nondiabetic young man. |
| Score | Text |
|---|---|
| 0.9996 | Tetany in a child with AIDS receiving intravenous Drugtobramycin . |
| 0.9991 | Adverse-EffectTetany in a child with AIDS receiving intravenous tobramycin. |
| Score | Text |
|---|---|
| 0.9987 | Case report : acute renal failure after administering intravenous Drugimmunoglobulin . |
| 0.9838 | Case report : Adverse-Effectacute renal failure after administering intravenous immunoglobulin. |
| Score | Text |
|---|---|
| 0.9983 | Adverse-EffectDyspnea possibly associated with controlled - release morphine sulfate tablets. |
| 0.9837 | Dyspnea possibly associated with controlled - release Drugmorphine sulfate tablets. |
| Score | Text |
|---|---|
| 0.9996 | Acute kidney injury caused by Drugzonisamide - induced hypersensitivity syndrome. |
| 0.9859 | Acute kidney injury caused by zonisamide - induced Adverse-Effecthypersensitivity syndrome . |
| 0.9661 | Adverse-EffectAcute kidney injury caused by zonisamide - induced hypersensitivity syndrome. |
| Score | Text |
|---|---|
| 0.9995 | The renal consequences of Drugindinavir - associated nephrotoxicity are uncertain. |
| 0.9951 | The renal consequences of indinavir - associated Adverse-Effectnephrotoxicity are uncertain. |
| Score | Text |
|---|---|
| 0.9993 | Occurrence of IDDM during Druginterferon therapy for chronic viral hepatitis. |
| 0.9975 | Occurrence of Adverse-EffectIDDM during interferon therapy for chronic viral hepatitis. |
| Score | Text |
|---|---|
| 0.9992 | A further case of anaphylactoid reaction to Drugmethylprednisolone is reported. |
| 0.9878 | A further case of Adverse-Effectanaphylactoid reaction to methylprednisolone is reported. |
| Score | Text |
|---|---|
| 0.9996 | Bull's - eye maculopathy associated with Drugquinacrine therapy for malaria. |
| 0.9631 | Adverse-EffectBull's - eye maculopathy associated with quinacrine therapy for malaria. |
| Score | Text |
|---|---|
| 0.9989 | Can Drugpropofol precipitate pancreatitis in patients with Cushing's syndrome? |
| 0.9952 | Can propofol precipitate Adverse-Effectpancreatitis in patients with Cushing's syndrome? |
| Score | Text |
|---|---|
| 0.9996 | DrugClonidine - induced bradycardia in patients with spinal cord injury. |
| 0.9983 | Clonidine - induced Adverse-Effectbradycardia in patients with spinal cord injury. |
| Score | Text |
|---|---|
| 0.9996 | Lymphoma developing in a patient with rheumatoid arthritis taking Drugmethotrexate . |
| 0.9984 | Adverse-EffectLymphoma developing in a patient with rheumatoid arthritis taking methotrexate. |
| Score | Text |
|---|---|
| 0.9942 | Amphotericin B overdose in pediatric patients with associated Adverse-Effectcardiac arrest . |
| 0.9713 | DrugAmphotericin B overdose in pediatric patients with associated cardiac arrest. |
| Score | Text |
|---|---|
| 0.9991 | DrugIsoniazid causing breast tissue enlargement has been very rarely reported. |
| 0.9769 | Isoniazid causing Adverse-Effectbreast tissue enlargement has been very rarely reported. |
| Score | Text |
|---|---|
| 0.9994 | Paradoxical pulmonary vasoconstriction induced by Drugnitroglycerin in idiopathic pulmonary hypertension. |
| 0.9409 | Adverse-EffectParadoxical pulmonary vasoconstriction induced by nitroglycerin in idiopathic pulmonary hypertension. |
| Score | Text |
|---|---|
| 0.9996 | However, recurrent staphylococcus aureus sepsis developed during DrugCyA therapy. |
| 0.9827 | However, recurrent Adverse-Effectstaphylococcus aureus sepsis developed during CyA therapy. |
| Score | Text |
|---|---|
| 0.9835 | Adverse-EffectNoncardiogenic pulmonary edema during intrabiliary infusion of mono - octanoin. |
| 0.9344 | Noncardiogenic pulmonary edema during intrabiliary infusion of Drugmono - octanoin . |
| Score | Text |
|---|---|
| 0.9990 | DrugMoxalactam is more likely to be associated with platelet dysfunction. |
| 0.9887 | Moxalactam is more likely to be associated with Adverse-Effectplatelet dysfunction . |
| Score | Text |
|---|---|
| 0.9995 | Severe Raynaud's phenomenon with Drugyohimbine therapy for erectile dysfunction. |
| 0.9648 | Adverse-EffectSevere Raynaud's phenomenon with yohimbine therapy for erectile dysfunction. |
| Score | Text |
|---|---|
| 0.9992 | Severe systemic hypersensitivity reaction to Drugibuprofen occurring after prolonged therapy. |
| 0.9765 | Adverse-EffectSevere systemic hypersensitivity reaction to ibuprofen occurring after prolonged therapy. |
| Score | Text |
|---|---|
| 0.9993 | Fatal Druggemcitabine - induced pulmonary toxicity in metastatic gallbladder adenocarcinoma. |
| 0.9891 | Fatal gemcitabine - induced Adverse-Effectpulmonary toxicity in metastatic gallbladder adenocarcinoma. |
| Score | Text |
|---|---|
| 0.9992 | Massive plasmocytosis due to Drugmethimazole - induced bone marrow toxicity. |
| 0.9815 | Massive plasmocytosis due to methimazole - induced Adverse-Effectbone marrow toxicity . |
| 0.9609 | Adverse-EffectMassive plasmocytosis due to methimazole - induced bone marrow toxicity. |
| Score | Text |
|---|---|
| 0.9947 | Ketanserin in the treatment of Drugprotamine - induced pulmonary hypertension. |
| 0.9897 | Ketanserin in the treatment of protamine - induced Adverse-Effectpulmonary hypertension . |
| Score | Text |
|---|---|
| 0.9969 | Adverse-EffectBradycardia and congestive heart failure associated with ocular timolol maleate. |
| 0.9864 | Bradycardia and Adverse-Effectcongestive heart failure associated with ocular timolol maleate. |
| 0.9779 | Bradycardia and congestive heart failure associated with ocular Drugtimolol maleate . |
| Score | Text |
|---|---|
| 0.9996 | Ulcerative proctitis in juvenile systemic lupus erythematosus after Drugibuprofen treatment. |
| 0.9889 | Adverse-EffectUlcerative proctitis in juvenile systemic lupus erythematosus after ibuprofen treatment. |
| Score | Text |
|---|---|
| 0.9994 | A patient developed cholestatic hepatitis while being treated with Drugnitrofurantoin . |
| 0.9907 | A patient developed Adverse-Effectcholestatic hepatitis while being treated with nitrofurantoin. |
| Score | Text |
|---|---|
| 0.9995 | DrugDorzolamide - induced choroidal detachment in a surgically untreated eye. |
| 0.9922 | Dorzolamide - induced Adverse-Effectchoroidal detachment in a surgically untreated eye. |
| Score | Text |
|---|---|
| 0.9860 | Mitomycin C - related Adverse-Effecthemolytic uremic syndrome in cancer patients. |
| 0.9835 | DrugMitomycin C - related hemolytic uremic syndrome in cancer patients. |
| Score | Text |
|---|---|
| 0.9928 | Possible Adverse-Effectserotonin syndrome associated with clomipramine after withdrawal of clozapine. |
| 0.9877 | Possible serotonin syndrome associated with Drugclomipramine after withdrawal of clozapine. |
| 0.9055 | Possible serotonin syndrome associated with clomipramine after withdrawal of Drugclozapine . |
| Score | Text |
|---|---|
| 0.9996 | A case of recall pneumonitis induced by Druggemcitabine is reported. |
| 0.9871 | A case of Adverse-Effectrecall pneumonitis induced by gemcitabine is reported. |
| Score | Text |
|---|---|
| 0.9996 | Myoglobinuria and acute renal failure associated with intravenous Drugvasopressin infusion. |
| 0.9972 | Adverse-EffectMyoglobinuria and acute renal failure associated with intravenous vasopressin infusion. |
| 0.9841 | Myoglobinuria and Adverse-Effectacute renal failure associated with intravenous vasopressin infusion. |
| Score | Text |
|---|---|
| 0.9985 | Amphotericin B - induced Adverse-Effectseizures in a patient with AIDS. |
| 0.9723 | DrugAmphotericin B - induced seizures in a patient with AIDS. |
| Score | Text |
|---|---|
| 0.9988 | The Drugallopurinol hypersensitivity syndrome is a rare adverse drug reaction. |
| 0.9321 | The allopurinol Adverse-Effecthypersensitivity syndrome is a rare adverse drug reaction. |
| Score | Text |
|---|---|
| 0.9992 | PURPOSE : We report an unusual paradoxical effect of Drugbrimonidine . |
| 0.9482 | PURPOSE : We report an unusual Adverse-Effectparadoxical effect of brimonidine. |
| Score | Text |
|---|---|
| 0.9995 | The most likely cause of such hyponatremic episode is Drugvinblastine . |
| 0.9857 | The most likely cause of such Adverse-Effecthyponatremic episode is vinblastine. |
| Score | Text |
|---|---|
| 0.9993 | DrugCefoxitin therapy for Mycobacterium fortuitum bacteremia with associated granulomatous hepatitis. |
| 0.9893 | Cefoxitin therapy for Mycobacterium fortuitum bacteremia with associated Adverse-Effectgranulomatous hepatitis . |
| Score | Text |
|---|---|
| 0.9993 | Acceleration of ventricular response to atrial flutter after intravenous Drugadenosine . |
| 0.9782 | Adverse-EffectAcceleration of ventricular response to atrial flutter after intravenous adenosine. |
| Score | Text |
|---|---|
| 0.9996 | We present a case of hypereosinophilia related to Drugzafirlukast therapy. |
| 0.9961 | We present a case of Adverse-Effecthypereosinophilia related to zafirlukast therapy. |
| Score | Text |
|---|---|
| 0.9943 | Adverse-EffectRenal damage associated with long term use of lithium carbonate. |
| 0.9844 | Renal damage associated with long term use of Druglithium carbonate . |
| Score | Text |
|---|---|
| 0.9980 | Reversible valproic acid - induced Adverse-Effectdementia : a case report. |
| 0.9766 | Reversible Drugvalproic acid - induced dementia : a case report. |
| Score | Text |
|---|---|
| 0.9994 | Severe hypo - alpha - lipoproteinemia during treatment with Drugrosiglitazone . |
| 0.8798 | Adverse-EffectSevere hypo - alpha - lipoproteinemia during treatment with rosiglitazone. |
| Score | Text |
|---|---|
| 0.9995 | Excluding other causes, DrugPentasa - associated pancytopenia was considered. |
| 0.9978 | Excluding other causes, Pentasa - associated Adverse-Effectpancytopenia was considered. |
| Score | Text |
|---|---|
| 0.9995 | Thrombo - embolic complication after Drugstreptokinase therapy of pulmonary emboli. |
| 0.9832 | Adverse-EffectThrombo - embolic complication after streptokinase therapy of pulmonary emboli. |
| Score | Text |
|---|---|
| 0.9995 | Development of persistent late onset asthma following treatment with Drugcaptopril . |
| 0.9309 | Development of Adverse-Effectpersistent late onset asthma following treatment with captopril. |
| Score | Text |
|---|---|
| 0.9838 | Amphotericin B - induced Adverse-Effectcutaneous leucocytoclastic vasculitis : case report. |
| 0.9727 | DrugAmphotericin B - induced cutaneous leucocytoclastic vasculitis : case report. |
| Score | Text |
|---|---|
| 0.9995 | DrugPropranolol - related bronchospasm in patients without history of asthma. |
| 0.9978 | Propranolol - related Adverse-Effectbronchospasm in patients without history of asthma. |
| Score | Text |
|---|---|
| 0.9972 | Trimethoprim - sulfamethoxazole - induced Adverse-Effecthepatotoxicity in a pediatric patient. |
| 0.8622 | DrugTrimethoprim - sulfamethoxazole - induced hepatotoxicity in a pediatric patient. |
| Score | Text |
|---|---|
| 0.9993 | Bronchiolitis obliterans organising pneumonia associated with the use of Drugnitrofurantoin . |
| 0.9792 | Adverse-EffectBronchiolitis obliterans organising pneumonia associated with the use of nitrofurantoin. |
| Score | Text |
|---|---|
| 0.9996 | Cerebral edema associated with DrugGliadel wafers : two case studies. |
| 0.9937 | Adverse-EffectCerebral edema associated with Gliadel wafers : two case studies. |
| Score | Text |
|---|---|
| 0.9995 | Agranulocytosis induced by Drugvancomycin in an ESRD patient on CAPD. |
| 0.9976 | Adverse-EffectAgranulocytosis induced by vancomycin in an ESRD patient on CAPD. |
| Score | Text |
|---|---|
| 0.9994 | DrugZidovudine induced pure red cell aplasia : a case report. |
| 0.9758 | Zidovudine induced Adverse-Effectpure red cell aplasia : a case report. |
| Score | Text |
|---|---|
| 0.9996 | Various case reports concerning Drugdapsone - induced agranulocytosis are reviewed. |
| 0.9983 | Various case reports concerning dapsone - induced Adverse-Effectagranulocytosis are reviewed. |
| Score | Text |
|---|---|
| 0.9993 | Neurotoxicity of Drugvalacyclovir in peritoneal dialysis : a pharmacokinetic study. |
| 0.9947 | Adverse-EffectNeurotoxicity of valacyclovir in peritoneal dialysis : a pharmacokinetic study. |
| Score | Text |
|---|---|
| 0.9995 | Recently, CD20 - negative tumors have been described after DrugRituximab therapy. |
| 0.9807 | Recently, Adverse-EffectCD20 - negative tumors have been described after Rituximab therapy. |
| Score | Text |
|---|---|
| 0.9994 | Cutaneous ulceration : an unusual complication of intravenous Drugpentamidine therapy. |
| 0.9920 | Adverse-EffectCutaneous ulceration : an unusual complication of intravenous pentamidine therapy. |
| Score | Text |
|---|---|
| 0.9995 | Aplastic anemia and agranulocytosis in patients using Drugmethazolamide for glaucoma. |
| 0.9968 | Aplastic anemia and Adverse-Effectagranulocytosis in patients using methazolamide for glaucoma. |
| 0.9914 | Adverse-EffectAplastic anemia and agranulocytosis in patients using methazolamide for glaucoma. |
| Score | Text |
|---|---|
| 0.9993 | Lethargy in a newborn : Druglithium toxicity or lab error? |
| 0.9979 | Adverse-EffectLethargy in a newborn : lithium toxicity or lab error? |
| Lethargy in a newborn : Adverse-Effectlithium toxicity or lab error? | |
| Score | Text |
|---|---|
| 0.9994 | DrugLevofloxacin - induced toxic epidermal necrolysis in an elderly patient. |
| 0.9844 | Levofloxacin - induced Adverse-Effecttoxic epidermal necrolysis in an elderly patient. |
| Score | Text |
|---|---|
| 0.9807 | Adverse-EffectMental nerve neuropathy as a result of hepatitis B vaccination. |
| 0.9671 | Mental nerve neuropathy as a result of Drughepatitis B vaccination . |
| Score | Text |
|---|---|
| 0.9995 | DrugMuzolimine - induced severe neuromyeloencephalopathy : report of seven cases. |
| 0.9630 | Muzolimine - induced Adverse-Effectsevere neuromyeloencephalopathy : report of seven cases. |
| Score | Text |
|---|---|
| 0.9982 | After Drug5 - ASA was discontinued, the polyneuropathy symptoms recovered gradually. |
| 0.9953 | After 5 - ASA was discontinued, the Adverse-Effectpolyneuropathy symptoms recovered gradually. |
| Score | Text |
|---|---|
| 0.9994 | DrugCimetidine is a rare cause of drug - induced fever. |
| 0.9967 | Cimetidine is a rare cause of drug - induced Adverse-Effectfever . |
| Score | Text |
|---|---|
| 0.9969 | He was later skin tested to confirm allergy to DrugMTX . |
| 0.9865 | He was later skin tested to confirm Adverse-Effectallergy to MTX. |
| Score | Text |
|---|---|
| 0.9996 | Secondary acute myeloid leukemia after Drugetoposide therapy for haemophagocytic lymphohistiocytosis. |
| 0.9425 | Secondary Adverse-Effectacute myeloid leukemia after etoposide therapy for haemophagocytic lymphohistiocytosis. |
| Score | Text |
|---|---|
| 0.9990 | DrugMinocycline as a cause of drug - induced autoimmune hepatitis. |
| 0.9875 | Minocycline as a cause of drug - induced Adverse-Effectautoimmune hepatitis . |
| Score | Text |
|---|---|
| 0.9993 | Macular infarction after endophthalmitis treated with vitrectomy and intravitreal Druggentamicin . |
| 0.9915 | Adverse-EffectMacular infarction after endophthalmitis treated with vitrectomy and intravitreal gentamicin. |
| Score | Text |
|---|---|
| 0.9994 | A 57 - year - old man developed morphea while taking Drugbromocriptine . |
| 0.9980 | A 57 - year - old man developed Adverse-Effectmorphea while taking bromocriptine. |
| Score | Text |
|---|---|
| 0.9994 | DrugMethotrexate is an effective but potentially toxic treatment for psoriasis. |
| Methotrexate is an effective but Adverse-Effectpotentially toxic treatment for psoriasis. | |
| Score | Text |
|---|---|
| 0.9913 | Isonicotinic acid hydrazide induced anagen effluvium and associated Adverse-Effectlichenoid eruption . |
| 0.9856 | Isonicotinic acid hydrazide induced Adverse-Effectanagen effluvium and associated lichenoid eruption. |
| 0.9583 | DrugIsonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption. |
| Score | Text |
|---|---|
| 0.9972 | Lovastatin - induced Adverse-Effectrhabdomyolysis possibly associated with clarithromycin and azithromycin. |
| 0.9945 | DrugLovastatin - induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. |
| 0.9851 | Lovastatin - induced rhabdomyolysis possibly associated with clarithromycin and Drugazithromycin . |
| 0.9763 | Lovastatin - induced rhabdomyolysis possibly associated with Drugclarithromycin and azithromycin. |
| Score | Text |
|---|---|
| 0.9995 | The occurrence of acute hepatitis is best known for Drugketoconazole . |
| 0.9202 | The occurrence of Adverse-Effectacute hepatitis is best known for ketoconazole. |
| The occurrence of acute Adverse-Effecthepatitis is best known for ketoconazole. | |
| Score | Text |
|---|---|
| 0.9995 | Our experience supports hemodialysis for ESRF patients with Drugatenolol toxicity. |
| 0.9105 | Our experience supports hemodialysis for ESRF patients with Adverse-Effectatenolol toxicity . |
| Score | Text |
|---|---|
| 0.9995 | Stevens - Johnson syndrome caused by the antiretroviral drug Drugnevirapine . |
| 0.9839 | Adverse-EffectStevens - Johnson syndrome caused by the antiretroviral drug nevirapine. |
| Score | Text |
|---|---|
| 0.9996 | DrugDasatinib - induced pleural effusions : a lymphatic network disorder? |
| 0.9869 | Dasatinib - induced Adverse-Effectpleural effusions : a lymphatic network disorder? |
| Score | Text |
|---|---|
| 0.9994 | Increasing the Drugolanzapine dosage severely aggravated the symptoms of RLS. |
| 0.9976 | Increasing the olanzapine dosage severely aggravated the symptoms of Adverse-EffectRLS . |
| Score | Text |
|---|---|
| 0.9990 | Hemodialysis was also shown to reverse Drugifosfamide - related neurotoxicity. |
| 0.9966 | Hemodialysis was also shown to reverse ifosfamide - related Adverse-Effectneurotoxicity . |
| Score | Text |
|---|---|
| 0.9994 | Neurologic toxicity associated with hepatic artery infusion HAI of DrugFUdR . |
| 0.9871 | Adverse-EffectNeurologic toxicity associated with hepatic artery infusion HAI of FUdR. |
| Score | Text |
|---|---|
| 0.9971 | Adverse-EffectPapilledema without peripheral neuropathy in a patient taking perhexiline maleate. |
| 0.9827 | Papilledema without peripheral neuropathy in a patient taking Drugperhexiline maleate . |
| Score | Text |
|---|---|
| 0.9994 | Sudden cardiac death due to hypersensitivity myocarditis during Drugclozapine treatment. |
| 0.9832 | Adverse-EffectSudden cardiac death due to hypersensitivity myocarditis during clozapine treatment. |
| 0.9737 | Sudden cardiac death due to Adverse-Effecthypersensitivity myocarditis during clozapine treatment. |
| Score | Text |
|---|---|
| 0.9996 | Marked elevation of serum creatine kinase associated with Drugolanzapine therapy. |
| 0.9775 | Marked Adverse-Effectelevation of serum creatine kinase associated with olanzapine therapy. |
| Score | Text |
|---|---|
| 0.9986 | DrugDoxorubicin cardiotoxicity : possible role of digoxin in its prevention. |
| 0.8813 | Doxorubicin Adverse-Effectcardiotoxicity : possible role of digoxin in its prevention. |
| Score | Text |
|---|---|
| 0.9992 | Paroxysmal supraventricular tachycardia during treatment with cisplatin and Drugetoposide combination. |
| 0.9992 | Paroxysmal supraventricular tachycardia during treatment with Drugcisplatin and etoposide combination. |
| 0.9742 | Adverse-EffectParoxysmal supraventricular tachycardia during treatment with cisplatin and etoposide combination. |
| Score | Text |
|---|---|
| 0.9996 | Fatal acute encephalomyelitis after a single dose of intrathecal Drugmethotrexate . |
| 0.9782 | Adverse-EffectFatal acute encephalomyelitis after a single dose of intrathecal methotrexate. |
| Score | Text |
|---|---|
| 0.9907 | Oxygen potentiation of bleomycin - induced Adverse-Effectpulmonary toxicity is discussed. |
| 0.9860 | Oxygen potentiation of Drugbleomycin - induced pulmonary toxicity is discussed. |
| 0.8774 | DrugOxygen potentiation of bleomycin - induced pulmonary toxicity is discussed. |
| Score | Text |
|---|---|
| 0.9986 | Allergy to Drugcloxacillin with normal tolerance to amoxicillin and cefuroxime. |
| 0.9731 | Adverse-EffectAllergy to cloxacillin with normal tolerance to amoxicillin and cefuroxime. |
| Score | Text |
|---|---|
| 0.9988 | DrugMagnesium tocolysis as the cause of urinary calculus during pregnancy. |
| 0.9923 | Magnesium tocolysis as the cause of Adverse-Effecturinary calculus during pregnancy. |
| Score | Text |
|---|---|
| 0.9992 | Hemorrhagic cystitis is a significant toxic effect of Drugcyclophosphamide therapy. |
| 0.9881 | Adverse-EffectHemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy. |
| Score | Text |
|---|---|
| 0.9992 | Hypokalemia after normal doses of neubulized Drugalbuterol ( salbutamol ). |
| 0.9991 | Hypokalemia after normal doses of neubulized albuterol ( Drugsalbutamol ). |
| 0.9989 | Adverse-EffectHypokalemia after normal doses of neubulized albuterol ( salbutamol ). |
| Score | Text |
|---|---|
| 0.9996 | Toxic hepatitis induced by Drugdisulfiram in a non - alcoholic. |
| 0.9895 | Adverse-EffectToxic hepatitis induced by disulfiram in a non - alcoholic. |
| Score | Text |
|---|---|
| 0.9987 | Acute renal failure during lisinopril and Druglosartan therapy for proteinuria. |
| 0.9985 | Acute renal failure during Druglisinopril and losartan therapy for proteinuria. |
| 0.9777 | Adverse-EffectAcute renal failure during lisinopril and losartan therapy for proteinuria. |
| Score | Text |
|---|---|
| 0.9995 | Hair loss associated with Drugparoxetine treatment : a case report. |
| 0.9939 | Adverse-EffectHair loss associated with paroxetine treatment : a case report. |
| Score | Text |
|---|---|
| 0.9994 | Severe diffuse interstitial pneumonitis induced by Drugcarmustine ( BCNU ). |
| 0.9994 | Severe diffuse interstitial pneumonitis induced by carmustine ( DrugBCNU ). |
| 0.9251 | Adverse-EffectSevere diffuse interstitial pneumonitis induced by carmustine ( BCNU ). |
| Score | Text |
|---|---|
| 0.9996 | The cough continued for the duration of therapy with Drugquinapril . |
| 0.9979 | The Adverse-Effectcough continued for the duration of therapy with quinapril. |
| Score | Text |
|---|---|
| 0.9827 | Adverse-EffectMulticentric hepatocellular carcinoma following phosphate diethylstilbestrol therapy for prostatic cancer. |
| 0.9597 | Multicentric hepatocellular carcinoma following Drugphosphate diethylstilbestrol therapy for prostatic cancer. |
| Score | Text |
|---|---|
| 0.9990 | Adverse-EffectCough induced by quinapril with resolution after changing to fosinopril. |
| 0.9990 | Cough induced by Drugquinapril with resolution after changing to fosinopril. |
| Score | Text |
|---|---|
| 0.9902 | Lipoid pneumonia : a silent complication of Drugmineral oil aspiration. |
| 0.9887 | Adverse-EffectLipoid pneumonia : a silent complication of mineral oil aspiration. |
| Score | Text |
|---|---|
| 0.9993 | Corneal edema recurred when the administration of Drugamantadine was resumed. |
| 0.9912 | Adverse-EffectCorneal edema recurred when the administration of amantadine was resumed. |
| Score | Text |
|---|---|
| 0.9994 | DrugFluphenazine - induced neuroleptic malignant syndrome in a schizophrenic patient. |
| 0.9858 | Fluphenazine - induced Adverse-Effectneuroleptic malignant syndrome in a schizophrenic patient. |
| Score | Text |
|---|---|
| 0.9988 | After stopping Drugindapamide , glucose tolerance impairing may be reversed. |
| 0.9777 | After stopping indapamide, Adverse-Effectglucose tolerance impairing may be reversed. |
| Score | Text |
|---|---|
| 0.9994 | Transient acute myopia resulting from Drugisotretinoin ( accutane ) therapy. |
| 0.9993 | Transient acute myopia resulting from isotretinoin ( Drugaccutane ) therapy. |
| 0.9625 | Adverse-EffectTransient acute myopia resulting from isotretinoin ( accutane ) therapy. |
| Score | Text |
|---|---|
| 0.9996 | Cardiac decompensation following Drugverapamil therapy in infants with supraventricular tachycardia. |
| 0.9912 | Adverse-EffectCardiac decompensation following verapamil therapy in infants with supraventricular tachycardia. |
| Score | Text |
|---|---|
| 0.9995 | Three patients developed proteinuria following Druggold therapy for rheumatoid arthritis. |
| 0.9990 | Three patients developed Adverse-Effectproteinuria following gold therapy for rheumatoid arthritis. |
| Score | Text |
|---|---|
| 0.9996 | Nephrotic syndrome related to systemic lupus erythematosus after Druggriseofulvin therapy. |
| 0.9912 | Adverse-EffectNephrotic syndrome related to systemic lupus erythematosus after griseofulvin therapy. |
| 0.9589 | Nephrotic syndrome related to Adverse-Effectsystemic lupus erythematosus after griseofulvin therapy. |
| Score | Text |
|---|---|
| 0.9996 | Colitis as a manifestation of Druginfliximab - associated disseminated cryptococcosis. |
| 0.9982 | Adverse-EffectColitis as a manifestation of infliximab - associated disseminated cryptococcosis. |
| 0.9842 | Colitis as a manifestation of infliximab - associated Adverse-Effectdisseminated cryptococcosis . |
| Score | Text |
|---|---|
| 0.9995 | DrugGabapentin - induced mood changes with hypomanic features in adults. |
| 0.9893 | Gabapentin - induced mood changes with Adverse-Effecthypomanic features in adults. |
| 0.9868 | Gabapentin - induced Adverse-Effectmood changes with hypomanic features in adults. |
| Score | Text |
|---|---|
| 0.9994 | Discontinuation of the Drugitraconazole caused resolution of the drug eruption. |
| 0.9891 | Discontinuation of the itraconazole caused resolution of the Adverse-Effectdrug eruption . |
| Score | Text |
|---|---|
| 0.9984 | DrugTacrolimus ( FK506 ) - induced mutism after liver transplant. |
| 0.9983 | Tacrolimus ( FK506 ) - induced Adverse-Effectmutism after liver transplant. |
| 0.9977 | Tacrolimus ( DrugFK506 ) - induced mutism after liver transplant. |
| Score | Text |
|---|---|
| 0.9993 | DrugCarbamazepine induced right bundle branch block in a Greenlandic patient. |
| 0.9827 | Carbamazepine induced Adverse-Effectright bundle branch block in a Greenlandic patient. |
| Score | Text |
|---|---|
| 0.9996 | Angioedema and dysphagia caused by contact allergy to inhaled Drugbudesonide . |
| 0.9985 | Angioedema and Adverse-Effectdysphagia caused by contact allergy to inhaled budesonide. |
| 0.9983 | Adverse-EffectAngioedema and dysphagia caused by contact allergy to inhaled budesonide. |
| Score | Text |
|---|---|
| 0.9944 | Apparent Drugcyclophosphamide ( cytoxan ) embryopathy : a distinct phenotype? |
| 0.9623 | Apparent cyclophosphamide ( cytoxan ) Adverse-Effectembryopathy : a distinct phenotype? |
| Score | Text |
|---|---|
| 0.9990 | One patient had MRI T2 abnormalities compatible with Drugcyclosporin neurotoxicity. |
| 0.9608 | One patient had Adverse-EffectMRI T2 abnormalities compatible with cyclosporin neurotoxicity. |
| 0.9078 | One patient had MRI T2 abnormalities compatible with cyclosporin Adverse-Effectneurotoxicity . |
| Score | Text |
|---|---|
| 0.9995 | Acute renal failure in a patient receiving treatment with Drugsuramin . |
| 0.9686 | Adverse-EffectAcute renal failure in a patient receiving treatment with suramin. |
| Score | Text |
|---|---|
| 0.9990 | DrugCarboplatin hypersensitivity presenting as coronary vasospasm - a case report. |
| 0.9870 | Carboplatin hypersensitivity presenting as Adverse-Effectcoronary vasospasm - a case report. |
| Score | Text |
|---|---|
| 0.9995 | Severe symptomatic hyponatremia during Drugsibutramine therapy : a case report. |
| 0.9573 | Adverse-EffectSevere symptomatic hyponatremia during sibutramine therapy : a case report. |
| Score | Text |
|---|---|
| 0.9994 | DrugPhenytoin toxicity : an easily missed cause of cerebellar syndrome. |
| 0.9915 | Phenytoin toxicity : an easily missed cause of Adverse-Effectcerebellar syndrome . |
| Score | Text |
|---|---|
| 0.9995 | This pattern is suggestive of renal toxicity due to Drugtobramycin . |
| 0.9868 | This pattern is suggestive of Adverse-Effectrenal toxicity due to tobramycin. |
| Score | Text |
|---|---|
| 0.9995 | Delay of corneal wound healing in patients treated with Drugcolchicine . |
| 0.9521 | Adverse-EffectDelay of corneal wound healing in patients treated with colchicine. |
| Score | Text |
|---|---|
| 0.9994 | DrugWarfarin - associated thoracic aortic dissection in an elderly woman. |
| 0.9854 | Warfarin - associated Adverse-Effectthoracic aortic dissection in an elderly woman. |
| Score | Text |
|---|---|
| 0.9992 | Hypersensitivity to Drugzonisamide was confirmed by the skin patch test. |
| 0.9875 | Adverse-EffectHypersensitivity to zonisamide was confirmed by the skin patch test. |
| Score | Text |
|---|---|
| 0.9994 | DrugPseudoephedrine - induced hemorrhage associated with a cerebral vascular malformation. |
| 0.9983 | Pseudoephedrine - induced Adverse-Effecthemorrhage associated with a cerebral vascular malformation. |
| 0.9821 | Pseudoephedrine - induced hemorrhage associated with a Adverse-Effectcerebral vascular malformation . |
| Score | Text |
|---|---|
| 0.9996 | A case of acute cardiomyopathy and pericarditis associated with Drugmethylphenidate . |
| 0.9972 | A case of acute cardiomyopathy and Adverse-Effectpericarditis associated with methylphenidate. |
| 0.9837 | A case of Adverse-Effectacute cardiomyopathy and pericarditis associated with methylphenidate. |
| Score | Text |
|---|---|
| 0.9993 | Syncope in a 65 - year - old woman after Drugnitrate ingestion. |
| 0.9985 | Adverse-EffectSyncope in a 65 - year - old woman after nitrate ingestion. |
| Score | Text |
|---|---|
| 0.9994 | DIAGNOSIS : Sustained ventricular tachycardia possibly owing to Drugthalidomide treatment. |
| 0.9783 | DIAGNOSIS : Adverse-EffectSustained ventricular tachycardia possibly owing to thalidomide treatment. |
| Score | Text |
|---|---|
| 0.9991 | Acute lung injury associated with 5 - fluorouracil and Drugoxaliplatinum combined chemotherapy. |
| 0.9990 | Acute lung injury associated with Drug5 - fluorouracil and oxaliplatinum combined chemotherapy. |
| 0.9876 | Adverse-EffectAcute lung injury associated with 5 - fluorouracil and oxaliplatinum combined chemotherapy. |
| Score | Text |
|---|---|
| 0.9995 | Cardiac toxicity related to DrugBCNU has not been described well. |
| 0.9910 | Adverse-EffectCardiac toxicity related to BCNU has not been described well. |
| Score | Text |
|---|---|
| 0.9992 | DrugCiprofloxacin - induced hemorrhagic vasculitis is a rare side effect. |
| 0.9887 | Ciprofloxacin - induced Adverse-Effecthemorrhagic vasculitis is a rare side effect. |
| Score | Text |
|---|---|
| 0.9992 | An immediate hemolytic reaction induced by repeated administration of Drugoxaliplatin . |
| 0.9915 | An immediate Adverse-Effecthemolytic reaction induced by repeated administration of oxaliplatin. |
| Score | Text |
|---|---|
| 0.9993 | DrugAcyclovir neurotoxicity : clinical experience and review of the literature. |
| 0.8794 | Acyclovir Adverse-Effectneurotoxicity : clinical experience and review of the literature. |
| Score | Text |
|---|---|
| 0.9703 | Adverse-EffectAcute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection. |
| 0.9693 | Acute syphilitic posterior placoid chorioretinitis following intravitreal Drugtriamcinolone acetonide injection. |
| Score | Text |
|---|---|
| 0.9995 | DrugRisperidone - induced obsessive - compulsive symptoms in two children. |
| 0.9853 | Risperidone - induced Adverse-Effectobsessive - compulsive symptoms in two children. |
| Score | Text |
|---|---|
| 0.9993 | Fibrosis of corpus cavernosum after intracavernous injection of Drugphentolamine / papaverine. |
| 0.9993 | Fibrosis of corpus cavernosum after intracavernous injection of phentolamine / Drugpapaverine . |
| 0.9451 | Adverse-EffectFibrosis of corpus cavernosum after intracavernous injection of phentolamine / papaverine. |
| Score | Text |
|---|---|
| 0.9954 | This eruption appears to be a distinct cutaneous toxicity of DrugPLD . |
| 0.9939 | This Adverse-Effecteruption appears to be a distinct cutaneous toxicity of PLD. |
| Score | Text |
|---|---|
| 0.9996 | Erosion of psoriatic plaques : an early sign of Drugmethotrexate toxicity. |
| 0.9824 | Adverse-EffectErosion of psoriatic plaques : an early sign of methotrexate toxicity. |
| Erosion of psoriatic plaques : an early sign of Adverse-Effectmethotrexate toxicity . | |
| Score | Text |
|---|---|
| 0.9992 | After nine previous uncomplicated cycles she developed severe anaphylaxis to Drugcisplatin . |
| 0.9859 | After nine previous uncomplicated cycles she developed severe Adverse-Effectanaphylaxis to cisplatin. |
| Score | Text |
|---|---|
| 0.9996 | DrugColchicine - induced myopathy in a teenager with familial Mediterranean fever. |
| 0.9987 | Colchicine - induced Adverse-Effectmyopathy in a teenager with familial Mediterranean fever. |
| Score | Text |
|---|---|
| 0.9995 | DrugIbopamine - induced reversible leukopenia during treatment for congestive heart failure. |
| 0.9642 | Ibopamine - induced reversible Adverse-Effectleukopenia during treatment for congestive heart failure. |
| Score | Text |
|---|---|
| 0.9994 | We also describe a case of Drugtimolol - induced ocular pemphigoid. |
| 0.9725 | We also describe a case of timolol - induced Adverse-Effectocular pemphigoid . |
| Score | Text |
|---|---|
| 0.9991 | Acute aluminum toxicity after continuous intravesical Drugalum irrigation for hemorrhagic cystitis. |
| 0.9436 | Adverse-EffectAcute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis. |
| Acute Adverse-Effectaluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis. | |
| Score | Text |
|---|---|
| 0.9996 | Only a few reports of overt jaundice are associated with Drugstreptokinase . |
| 0.9970 | Only a few reports of overt Adverse-Effectjaundice are associated with streptokinase. |
| Score | Text |
|---|---|
| 0.9996 | Sensory neuropathy revealing necrotizing vasculitis during Druginfliximab therapy for rheumatoid arthritis. |
| 0.9866 | Adverse-EffectSensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. |
| 0.9122 | Sensory neuropathy revealing Adverse-Effectnecrotizing vasculitis during infliximab therapy for rheumatoid arthritis. |
| Score | Text |
|---|---|
| 0.9996 | Electrical proarrhythmia with Drugprocainamide : a new ICD - drug interaction. |
| 0.9820 | Adverse-EffectElectrical proarrhythmia with procainamide : a new ICD - drug interaction. |
| Score | Text |
|---|---|
| 0.9884 | Adverse-EffectLivedo reticularis associated with interferon alpha therapy in two melanoma patients. |
| 0.9867 | Livedo reticularis associated with Druginterferon alpha therapy in two melanoma patients. |
| Score | Text |
|---|---|
| 0.9991 | The association of Drugphenothiazine overdose and respiratory distress syndrome merits consideration. |
| 0.9842 | The association of phenothiazine overdose and Adverse-Effectrespiratory distress syndrome merits consideration. |
| Score | Text |
|---|---|
| 0.9976 | Adverse-EffectMethemoglobinemia associated with dermal application of benzocaine cream in a cat. |
| 0.9962 | Methemoglobinemia associated with dermal application of Drugbenzocaine cream in a cat. |
| Score | Text |
|---|---|
| 0.9990 | When the Drugtrazodone was reduced, the involuntary movements promptly ceased. |
| 0.9883 | When the trazodone was reduced, the Adverse-Effectinvoluntary movements promptly ceased. |
| Score | Text |
|---|---|
| 0.9995 | DrugAnastrozole - associated sclerosing glomerulonephritis in a patient with breast cancer. |
| 0.9840 | Anastrozole - associated Adverse-Effectsclerosing glomerulonephritis in a patient with breast cancer. |
| Score | Text |
|---|---|
| 0.9993 | Transfusion haemosiderosis inspite of regular use of Drugdesferrioxamine : case report. |
| 0.9823 | Adverse-EffectTransfusion haemosiderosis inspite of regular use of desferrioxamine : case report. |
| Score | Text |
|---|---|
| 0.9993 | This concerns 2 male patients who experienced incontinence while taking Drugvenlafaxine . |
| 0.9982 | This concerns 2 male patients who experienced Adverse-Effectincontinence while taking venlafaxine. |
| Score | Text |
|---|---|
| 0.9802 | One patient had severe temporary weakness after an Drugampicillin sodium challenge. |
| 0.9713 | One patient had Adverse-Effectsevere temporary weakness after an ampicillin sodium challenge. |
| Score | Text |
|---|---|
| 0.9992 | Arterial hypertension associated with topical ocular use of Drugphenylephrine in dogs. |
| 0.9919 | Adverse-EffectArterial hypertension associated with topical ocular use of phenylephrine in dogs. |
| Score | Text |
|---|---|
| 0.9996 | DrugTigecycline - induced acute pancreatitis : case report and literature review. |
| 0.9879 | Tigecycline - induced Adverse-Effectacute pancreatitis : case report and literature review. |
| Score | Text |
|---|---|
| 0.9995 | Antineutrophil cytoplasmic antibody - positive crescentic glomerulonephritis associated with Drugpropylthiouracil therapy. |
| 0.9729 | Adverse-EffectAntineutrophil cytoplasmic antibody - positive crescentic glomerulonephritis associated with propylthiouracil therapy. |
| Score | Text |
|---|---|
| 0.9984 | Chronic Drughydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. |
| 0.9822 | Chronic hydroxychloroquine use associated with Adverse-EffectQT prolongation and refractory ventricular arrhythmia. |
| 0.9790 | Chronic hydroxychloroquine use associated with QT prolongation and Adverse-Effectrefractory ventricular arrhythmia . |
| Score | Text |
|---|---|
| 0.9996 | We report here a rare case of pleuropericarditis due to Drugmethotrexate . |
| 0.9963 | We report here a rare case of Adverse-Effectpleuropericarditis due to methotrexate. |
| Score | Text |
|---|---|
| 0.9992 | Inadvertent and accidental Drugepinephrine overdose might result in potentially lethal complications. |
| 0.9799 | Inadvertent and accidental epinephrine overdose might result in potentially Adverse-Effectlethal complications . |
| Score | Text |
|---|---|
| 0.9996 | Reversible heart failure in a patient receiving Drugetanercept for ankylosing spondylitis. |
| 0.9762 | Adverse-EffectReversible heart failure in a patient receiving etanercept for ankylosing spondylitis. |
| Score | Text |
|---|---|
| 0.9995 | Extensive forearm deep venous thrombosis following a severe Druginfliximab infusion reaction. |
| 0.9711 | Adverse-EffectExtensive forearm deep venous thrombosis following a severe infliximab infusion reaction. |
| Score | Text |
|---|---|
| 0.9996 | We report the first case of tuberculous uveitis due to Drugetanercept . |
| 0.9875 | We report the first case of Adverse-Effecttuberculous uveitis due to etanercept. |
| Score | Text |
|---|---|
| 0.9995 | Five months after initiating Drugmirtazapine therapy, she developed symptomatic hyponatremia. |
| 0.9874 | Five months after initiating mirtazapine therapy, she developed Adverse-Effectsymptomatic hyponatremia . |
| Score | Text |
|---|---|
| 0.9995 | PURPOSE : A case of Drugcarbamazepine - induced hyperammonemia is presented. |
| 0.9976 | PURPOSE : A case of carbamazepine - induced Adverse-Effecthyperammonemia is presented. |
| Score | Text |
|---|---|
| 0.9997 | Pneumonitis with pleural and pericardial effusion and neuropathy during Drugamiodarone therapy. |
| 0.9968 | Adverse-EffectPneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy. |
| 0.9955 | Pneumonitis with pleural and pericardial effusion and Adverse-Effectneuropathy during amiodarone therapy. |
| 0.9429 | Pneumonitis with Adverse-Effectpleural and pericardial effusion and neuropathy during amiodarone therapy. |
| Score | Text |
|---|---|
| 0.9995 | Fatal hepatitis after long - term pulse Drugitraconazole treatment for onychomycosis. |
| 0.9900 | Adverse-EffectFatal hepatitis after long - term pulse itraconazole treatment for onychomycosis. |
| Score | Text |
|---|---|
| 0.9994 | This is a rare case of ARDS associated with Druglithium intoxication. |
| 0.9977 | This is a rare case of Adverse-EffectARDS associated with lithium intoxication. |
| Score | Text |
|---|---|
| 0.9993 | Hypersensitivity reactions due to Drugchloramphenicol are rarely reported in the literature. |
| 0.9887 | Adverse-EffectHypersensitivity reactions due to chloramphenicol are rarely reported in the literature. |
| Score | Text |
|---|---|
| 0.9992 | Ischaemia following selfadministered intra - arterial injection of Drugmethylphenidate and diamorphine. |
| 0.9992 | Ischaemia following selfadministered intra - arterial injection of methylphenidate and Drugdiamorphine . |
| 0.9991 | Adverse-EffectIschaemia following selfadministered intra - arterial injection of methylphenidate and diamorphine. |
| Score | Text |
|---|---|
| 0.9986 | Unaccountable severe hypercalcemia in a patient treated for hypoparathyroidism with Drugdihydrotachysterol . |
| 0.9667 | Unaccountable severe Adverse-Effecthypercalcemia in a patient treated for hypoparathyroidism with dihydrotachysterol. |
| Score | Text |
|---|---|
| 0.9995 | DrugAllopurinol - associated hand and foot deformities in chronic tophaceous gout. |
| 0.9822 | Allopurinol - associated Adverse-Effecthand and foot deformities in chronic tophaceous gout. |
| Score | Text |
|---|---|
| 0.9997 | We report a case of DrugRitalin - associated cataract and glaucoma. |
| 0.9990 | We report a case of Ritalin - associated cataract and Adverse-Effectglaucoma . |
| 0.9987 | We report a case of Ritalin - associated Adverse-Effectcataract and glaucoma. |
| Score | Text |
|---|---|
| 0.9996 | Nephrogenic diabetes insipidus and renal tubular acidosis secondary to Drugfoscarnet therapy. |
| 0.9777 | Adverse-EffectNephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. |
| 0.9766 | Nephrogenic diabetes insipidus and Adverse-Effectrenal tubular acidosis secondary to foscarnet therapy. |
| Score | Text |
|---|---|
| 0.9995 | We report here a case of TEN after administration of Drugciprofloxacin . |
| 0.9987 | We report here a case of Adverse-EffectTEN after administration of ciprofloxacin. |
| Score | Text |
|---|---|
| 0.9991 | DISCUSSION : Anaphylactoid reactions have been described previously with Drugcisplatin administration. |
| 0.9908 | DISCUSSION : Adverse-EffectAnaphylactoid reactions have been described previously with cisplatin administration. |
| Score | Text |
|---|---|
| 0.9994 | Central nervous system toxicity associated with Drugmeperidine use in hepatic disease. |
| 0.9841 | Adverse-EffectCentral nervous system toxicity associated with meperidine use in hepatic disease. |
| Score | Text |
|---|---|
| 0.9994 | Drug - induced agranulocytosis during treatment with Druginfliximab in enteropathic spondyloarthropathy. |
| 0.9976 | Drug - induced Adverse-Effectagranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy. |
| Score | Text |
|---|---|
| 0.9991 | One other patient on Drugdigoxin stopped taking it and developed cardiomyopathy. |
| 0.9975 | One other patient on digoxin stopped taking it and developed Adverse-Effectcardiomyopathy . |
| Score | Text |
|---|---|
| 0.9962 | DrugAdrenaline dacryolith : detection by ultrasound examination of the nasolacrimal duct. |
| 0.8982 | Adrenaline Adverse-Effectdacryolith : detection by ultrasound examination of the nasolacrimal duct. |
| Score | Text |
|---|---|
| 0.9993 | DrugGabapentin toxicity in renal failure : the importance of dose adjustment. |
| 0.9805 | Gabapentin toxicity in Adverse-Effectrenal failure : the importance of dose adjustment. |
| Score | Text |
|---|---|
| 0.9983 | Severe steroid - induced Adverse-Effectglaucoma following intravitreal injection of triamcinolone acetonide. |
| 0.9392 | Severe steroid - induced glaucoma following intravitreal injection of Drugtriamcinolone acetonide . |
| 0.9075 | Severe Drugsteroid - induced glaucoma following intravitreal injection of triamcinolone acetonide. |
| Score | Text |
|---|---|
| 0.9996 | A short review on Drugimatinib - related hepatotoxicity is also presented. |
| 0.9969 | A short review on imatinib - related Adverse-Effecthepatotoxicity is also presented. |
| Score | Text |
|---|---|
| 0.9989 | Interaction between tacrolimus and Drugnefazodone in a stable renal transplant recipient. |
| 0.9989 | Interaction between Drugtacrolimus and nefazodone in a stable renal transplant recipient. |
| 0.9899 | Adverse-EffectInteraction between tacrolimus and nefazodone in a stable renal transplant recipient. |
| Score | Text |
|---|---|
| 0.9992 | Severe apnea in an infant exposed to Druglamotrigine in breast milk. |
| 0.9812 | Adverse-EffectSevere apnea in an infant exposed to lamotrigine in breast milk. |
| Score | Text |
|---|---|
| 0.9968 | DrugHalothane hepatitis and prompt resolution with methionine therapy : case report. |
| 0.9319 | Halothane Adverse-Effecthepatitis and prompt resolution with methionine therapy : case report. |
| Score | Text |
|---|---|
| 0.9994 | The elicitation of a movement disorder by Drugtrazodone : case report. |
| 0.9839 | The elicitation of a Adverse-Effectmovement disorder by trazodone : case report. |
| Score | Text |
|---|---|
| 0.9995 | Primary central nervous system lymphoma in a patient treated with Drugnatalizumab . |
| 0.9800 | Adverse-EffectPrimary central nervous system lymphoma in a patient treated with natalizumab. |
| Score | Text |
|---|---|
| 0.9994 | We report three cases of Drugamiodarone - induced torsades de pointe. |
| 0.9752 | We report three cases of amiodarone - induced Adverse-Effecttorsades de pointe . |
| Score | Text |
|---|---|
| 0.9993 | Prominent positive U waves appearing with high - dose intravenous Drugphenylephrine . |
| 0.9577 | Prominent Adverse-Effectpositive U waves appearing with high - dose intravenous phenylephrine. |
| Score | Text |
|---|---|
| 0.9994 | Central nervous system manifestations of an Drugibuprofen overdose reversed by naloxone. |
| 0.9826 | Adverse-EffectCentral nervous system manifestations of an ibuprofen overdose reversed by naloxone. |
| Score | Text |
|---|---|
| 0.9995 | Development of Peyronie's disease during long - term Drugcolchicine treatment. |
| 0.9841 | Development of Adverse-EffectPeyronie's disease during long - term colchicine treatment. |
| Score | Text |
|---|---|
| 0.9993 | Acne provoked by Druggold seems not to have been described elsewhere. |
| 0.9983 | Adverse-EffectAcne provoked by gold seems not to have been described elsewhere. |
| Score | Text |
|---|---|
| 0.9991 | Severe Drugsulfadiazine hypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitis. |
| 0.8716 | Severe sulfadiazine Adverse-Effecthypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitis. |
| Score | Text |
|---|---|
| 0.9995 | Sustained - release Drugprocainamide - induced reversible granulocytopenia after myocardial infarction. |
| 0.9656 | Sustained - release procainamide - induced Adverse-Effectreversible granulocytopenia after myocardial infarction. |
| Score | Text |
|---|---|
| 0.9939 | Carbamyl phosphate synthetase - 1 deficiency discovered after valproic acid - induced Adverse-Effectcoma . |
| 0.9850 | Carbamyl phosphate synthetase - 1 deficiency discovered after Drugvalproic acid - induced coma. |
| Score | Text |
|---|---|
| 0.9994 | Hepatobiliary disorders associated with orally administered Drugterbinafine have rarely been reported. |
| 0.9934 | Adverse-EffectHepatobiliary disorders associated with orally administered terbinafine have rarely been reported. |
| Score | Text |
|---|---|
| 0.9993 | Diffusion - weighted MRI correlates of subacute Drugmethotrexate - related neurotoxicity. |
| 0.9944 | Diffusion - weighted MRI correlates of subacute methotrexate - related Adverse-Effectneurotoxicity . |
| Score | Text |
|---|---|
| 0.9994 | Withdrawal emergent syndrome in an infant associated with maternal Drughaloperidol therapy. |
| 0.9839 | Adverse-EffectWithdrawal emergent syndrome in an infant associated with maternal haloperidol therapy. |
| Score | Text |
|---|---|
| 0.9994 | The patient suffered a life - threatening anaphylactoid reaction to Drugamifostine . |
| 0.9508 | The patient suffered a Adverse-Effectlife - threatening anaphylactoid reaction to amifostine. |
| Score | Text |
|---|---|
| 0.9864 | Three senile patients developed fatal acute encephalopathy while receiving Drugcalcium hopantenate . |
| 0.9775 | Three senile patients developed Adverse-Effectfatal acute encephalopathy while receiving calcium hopantenate. |
| Score | Text |
|---|---|
| 0.9909 | Adverse-EffectHepatocellular damage following therapeutic intravenous iron sucrose infusion in a child. |
| 0.9863 | Hepatocellular damage following therapeutic intravenous Drugiron sucrose infusion in a child. |
| Score | Text |
|---|---|
| 0.9770 | This paper reports a case of fatal Drugperhexiline maleate liver injury. |
| 0.7778 | This paper reports a case of Adverse-Effectfatal perhexiline maleate liver injury . |
| 0.8681 | This paper reports a case of fatal perhexiline Drugmaleate liver injury. |
| 0.6049 | This paper reports a case of fatal Adverse-Effectperhexiline maleate liver injury . |
| Score | Text |
|---|---|
| 0.9995 | Proton MRS examination demonstrated a persistent lactate elevation during Drugmetronidazole treatment. |
| 0.9711 | Proton MRS examination demonstrated a persistent Adverse-Effectlactate elevation during metronidazole treatment. |
| Score | Text |
|---|---|
| 0.9984 | A typical case of Drugdextran - 40 associated acute renal failure is presented. |
| 0.9673 | A typical case of dextran - 40 associated Adverse-Effectacute renal failure is presented. |
| Score | Text |
|---|---|
| 0.9990 | Mycobacterium marinum infection complicating Crohn's disease, treated with Druginfliximab . |
| 0.9842 | Adverse-EffectMycobacterium marinum infection complicating Crohn's disease, treated with infliximab. |
| Score | Text |
|---|---|
| 0.9894 | CONCLUSION : Acetic acid is corrosive and may cause Adverse-Effectvagina bleeding . |
| 0.9778 | CONCLUSION : DrugAcetic acid is corrosive and may cause vagina bleeding. |
| Score | Text |
|---|---|
| 0.9941 | We describe a patient who became Adverse-Effecthypothyroid while taking ferrous sulfate. |
| 0.9799 | We describe a patient who became hypothyroid while taking Drugferrous sulfate . |
| Score | Text |
|---|---|
| 0.9996 | DrugCaptopril - induced lichen planus pemphigoides with pemphigus - like features. |
| 0.9785 | Captopril - induced Adverse-Effectlichen planus pemphigoides with pemphigus - like features. |
| Score | Text |
|---|---|
| 0.9996 | Thrombocytosis associated with Drugenoxaparin : A very rare cause in newborns. |
| 0.9980 | Adverse-EffectThrombocytosis associated with enoxaparin : A very rare cause in newborns. |
| Score | Text |
|---|---|
| 0.9992 | Hypersensitivity reaction following Drugchloramphenicol administration in a patient with typhoid fever. |
| 0.9871 | Adverse-EffectHypersensitivity reaction following chloramphenicol administration in a patient with typhoid fever. |
| Score | Text |
|---|---|
| 0.9886 | Adverse-EffectAnaphylactic reaction to recombinant insulin - like growth factor - I. |
| 0.9045 | Anaphylactic reaction to Drugrecombinant insulin - like growth factor - I . |
| Score | Text |
|---|---|
| 0.9993 | Two reports of spindle coma are noted with alcohol and Drugimipramine . |
| 0.9913 | Two reports of Adverse-Effectspindle coma are noted with alcohol and imipramine. |
| Score | Text |
|---|---|
| 0.9993 | This therapy was also complicated by DrugWarfarin - induced skin necrosis. |
| 0.9917 | This therapy was also complicated by Warfarin - induced Adverse-Effectskin necrosis . |
| Score | Text |
|---|---|
| 0.9990 | DrugMetipranolol associated granulomatous anterior uveitis : not so uncommon as thought. |
| 0.9825 | Metipranolol associated Adverse-Effectgranulomatous anterior uveitis : not so uncommon as thought. |
| Score | Text |
|---|---|
| 0.9992 | Choanal atresia and athelia : Drugmethimazole teratogenicity or a new syndrome? |
| 0.9958 | Choanal atresia and Adverse-Effectathelia : methimazole teratogenicity or a new syndrome? |
| 0.9785 | Adverse-EffectChoanal atresia and athelia : methimazole teratogenicity or a new syndrome? |
| 0.9274 | Choanal atresia and athelia : methimazole Adverse-Effectteratogenicity or a new syndrome? |
| Score | Text |
|---|---|
| 0.9991 | Erythropoietin is beneficial in Drugmitomycin - induced hemolytic - uremic syndrome. |
| 0.9873 | Erythropoietin is beneficial in mitomycin - induced Adverse-Effecthemolytic - uremic syndrome . |
| Score | Text |
|---|---|
| 0.9994 | We report four cases of severe corneal ulceration in Drugmethamphetamine abusers. |
| 0.9804 | We report four cases of Adverse-Effectsevere corneal ulceration in methamphetamine abusers. |
| Score | Text |
|---|---|
| 0.9995 | Pneumocystis carinii pneumonia as a complication of Drugmethotrexate treatment of asthma. |
| 0.9820 | Adverse-EffectPneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma. |
| Score | Text |
|---|---|
| 0.9989 | DrugClofazimine enteropathy caused by crystal deposition can be life - threatening. |
| 0.9569 | Clofazimine enteropathy caused by crystal deposition can be Adverse-Effectlife - threatening . |
| 0.8181 | Clofazimine Adverse-Effectenteropathy caused by crystal deposition can be life - threatening. |
| Score | Text |
|---|---|
| 0.9996 | Interference with the cortisol axis by the microtubule antagonist, DrugCPH82 . |
| 0.9623 | Adverse-EffectInterference with the cortisol axis by the microtubule antagonist, CPH82. |
| Score | Text |
|---|---|
| 0.9995 | DrugDisulfiram - induced fulminant hepatic failure in an active duty soldier. |
| 0.9870 | Disulfiram - induced Adverse-Effectfulminant hepatic failure in an active duty soldier. |
| Score | Text |
|---|---|
| 0.9979 | High - dose phosphate treatment leads to Adverse-Effecthypokalemia in hypophosphatemic osteomalacia. |
| 0.9935 | High - dose Drugphosphate treatment leads to hypokalemia in hypophosphatemic osteomalacia. |
| Score | Text |
|---|---|
| 0.9980 | Possible mechanisms for damage to the urothelium by Drugketamine are suggested. |
| 0.9605 | Possible mechanisms for Adverse-Effectdamage to the urothelium by ketamine are suggested. |
| Score | Text |
|---|---|
| 0.9976 | Adverse-EffectHepatotoxicity induced by cyproterone acetate : a report of three cases. |
| 0.9742 | Hepatotoxicity induced by Drugcyproterone acetate : a report of three cases. |
| Score | Text |
|---|---|
| 0.9873 | Caution with use of Drugcimetidine in tolazoline induced upper gastrointestinal bleeding. |
| 0.9857 | Caution with use of cimetidine in tolazoline induced Adverse-Effectupper gastrointestinal bleeding . |
| 0.9807 | Caution with use of cimetidine in Drugtolazoline induced upper gastrointestinal bleeding. |
| Score | Text |
|---|---|
| 0.9993 | Hypersensitivity pneumonitis - like syndrome associated with the use of Druglenalidomide . |
| 0.9755 | Adverse-EffectHypersensitivity pneumonitis - like syndrome associated with the use of lenalidomide. |
| Score | Text |
|---|---|
| 0.9996 | The medical examiner's report indicated death caused by Drugfluoxetine toxicity. |
| 0.9837 | The medical examiner's report indicated Adverse-Effectdeath caused by fluoxetine toxicity. |
| 0.6587 | The medical examiner's report indicated death caused by Adverse-Effectfluoxetine toxicity . |
| Score | Text |
|---|---|
| 0.9995 | In all the patients, pellagra symptoms appeared during Drugisoniazid therapy. |
| In all the patients, Adverse-Effectpellagra symptoms appeared during isoniazid therapy. | |
| Score | Text |
|---|---|
| 0.9994 | We hypothesize that Drugcapecitabine - induced headache is vascular in nature. |
| 0.9988 | We hypothesize that capecitabine - induced Adverse-Effectheadache is vascular in nature. |
| Score | Text |
|---|---|
| 0.9994 | DrugDesipramine - associated SIADH in an elderly woman : case report. |
| 0.9983 | Desipramine - associated Adverse-EffectSIADH in an elderly woman : case report. |
| Score | Text |
|---|---|
| 0.9858 | Mitomycin - C induced Adverse-Effecthemolytic uremic syndrome : a case report. |
| 0.9635 | DrugMitomycin - C induced hemolytic uremic syndrome : a case report. |
| Score | Text |
|---|---|
| 0.9996 | Esophageal candidiasis following Drugomeprazole therapy : a report of two cases. |
| 0.9895 | Adverse-EffectEsophageal candidiasis following omeprazole therapy : a report of two cases. |
| Score | Text |
|---|---|
| 0.9988 | The syndrome of irreversible Druglithium - effectuated neurotoxicity ( SILENT ). |
| 0.9957 | The syndrome of irreversible lithium - effectuated Adverse-Effectneurotoxicity ( SILENT ). |
| Score | Text |
|---|---|
| 0.9995 | Thrombotic microangiopathy with renal failure in two patients undergoing Druggemcitabine chemotherapy. |
| 0.9877 | Thrombotic microangiopathy with Adverse-Effectrenal failure in two patients undergoing gemcitabine chemotherapy. |
| 0.9869 | Adverse-EffectThrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy. |
| Score | Text |
|---|---|
| 0.9970 | Severe heparin associated Adverse-Effectthrombocytopenia is a rare complication of heparin therapy. |
| 0.9961 | Severe heparin associated thrombocytopenia is a rare complication of Drugheparin therapy. |
| 0.9938 | Severe Drugheparin associated thrombocytopenia is a rare complication of heparin therapy. |
| Score | Text |
|---|---|
| 0.9914 | Adverse-EffectMammary gigantism is a rare complication of D - penicillamine treatment. |
| 0.9639 | Mammary gigantism is a rare complication of DrugD - penicillamine treatment. |
| Score | Text |
|---|---|
| 0.9970 | Zolpidem tissue concentrations in a multiple drug related death involving DrugAmbien . |
| 0.9877 | Zolpidem tissue concentrations in a multiple drug related Adverse-Effectdeath involving Ambien. |
| DrugZolpidem tissue concentrations in a multiple drug related death involving Ambien. | |
| Score | Text |
|---|---|
| 0.9991 | Patient 1 presented bilateral ballism 1 week after intravenous Drugheroin injection. |
| 0.9929 | Patient 1 presented Adverse-Effectbilateral ballism 1 week after intravenous heroin injection. |
| Score | Text |
|---|---|
| 0.9994 | It occasionally accompanies the Drugheparin - associated thrombocytopenia and thrombosis syndrome. |
| 0.9950 | It occasionally accompanies the heparin - associated Adverse-Effectthrombocytopenia and thrombosis syndrome. |
| 0.9934 | It occasionally accompanies the heparin - associated thrombocytopenia and Adverse-Effectthrombosis syndrome . |
| Score | Text |
|---|---|
| 0.9988 | Selective estrogen receptor modulator Drugraloxifene - associated aggravation of nonalcoholic steatohepatitis. |
| 0.9574 | Selective estrogen receptor modulator raloxifene - associated Adverse-Effectaggravation of nonalcoholic steatohepatitis . |
| Score | Text |
|---|---|
| 0.9991 | Hemolytic uremic syndrome following the infusion of Drugoxaliplatin : case report. |
| 0.9871 | Adverse-EffectHemolytic uremic syndrome following the infusion of oxaliplatin : case report. |
| Score | Text |
|---|---|
| 0.9995 | Dose - dependent Drugolanzapine - associated leukopenia : three case reports. |
| 0.9982 | Dose - dependent olanzapine - associated Adverse-Effectleukopenia : three case reports. |
| Score | Text |
|---|---|
| 0.9995 | Pellagra encephalopathy among tuberculous patients : its relation to Drugisoniazid therapy. |
| 0.9695 | Adverse-EffectPellagra encephalopathy among tuberculous patients : its relation to isoniazid therapy. |
| Score | Text |
|---|---|
| 0.9996 | We report the first case of IHA associated with Drugcefuroxime administration. |
| 0.9985 | We report the first case of Adverse-EffectIHA associated with cefuroxime administration. |
| Score | Text |
|---|---|
| 0.9993 | The HIV protease inhibitor Drugindinavir may cause nephrolithiasis and interstitial nephritis. |
| 0.9977 | The HIV protease inhibitor indinavir may cause Adverse-Effectnephrolithiasis and interstitial nephritis. |
| 0.9870 | The HIV protease inhibitor indinavir may cause nephrolithiasis and Adverse-Effectinterstitial nephritis . |
| Score | Text |
|---|---|
| 0.9993 | Physicians should be aware that Drugindinavir nephrolithiasis may cause papillary necrosis. |
| 0.9847 | Physicians should be aware that indinavir nephrolithiasis may cause Adverse-Effectpapillary necrosis . |
| 0.8685 | Physicians should be aware that indinavir Adverse-Effectnephrolithiasis may cause papillary necrosis. |
| Score | Text |
|---|---|
| 0.9994 | DrugTenofovir - associated nephrotoxicity in two HIV - infected adolescent males. |
| 0.9911 | Tenofovir - associated Adverse-Effectnephrotoxicity in two HIV - infected adolescent males. |
| Score | Text |
|---|---|
| 0.9974 | DrugCarbamazepine toxicity following Oxybutynin and Dantrolene administration : a case report. |
| 0.9971 | Carbamazepine toxicity following Oxybutynin and DrugDantrolene administration : a case report. |
| 0.9964 | Carbamazepine toxicity following DrugOxybutynin and Dantrolene administration : a case report. |
| 0.8584 | Adverse-EffectCarbamazepine toxicity following Oxybutynin and Dantrolene administration : a case report. |
| Score | Text |
|---|---|
| 0.9816 | When co - trimoxazole was stopped the Adverse-Effectred cell aplasia resolved. |
| 0.9576 | When Drugco - trimoxazole was stopped the red cell aplasia resolved. |
| Score | Text |
|---|---|
| 0.9996 | DrugGemcitabine - induced pericardial effusion and tamponade after unblocked cardiac irradiation. |
| 0.9947 | Gemcitabine - induced pericardial effusion and Adverse-Effecttamponade after unblocked cardiac irradiation. |
| 0.9875 | Gemcitabine - induced Adverse-Effectpericardial effusion and tamponade after unblocked cardiac irradiation. |
| Score | Text |
|---|---|
| 0.9995 | DrugCytarabine - induced cerebellar syndrome : case report and literature review. |
| 0.9931 | Cytarabine - induced Adverse-Effectcerebellar syndrome : case report and literature review. |
| Score | Text |
|---|---|
| 0.9996 | DrugGemcitabine - related radiation recall preferentially involves internal tissue and organs. |
| 0.9917 | Gemcitabine - related Adverse-Effectradiation recall preferentially involves internal tissue and organs. |
| Score | Text |
|---|---|
| 0.9988 | Can Drugroxithromycin and betamethasone induce acute pancreatitis? A case report. |
| 0.9987 | Can roxithromycin and Drugbetamethasone induce acute pancreatitis? A case report. |
| 0.9871 | Can roxithromycin and betamethasone induce Adverse-Effectacute pancreatitis ? A case report. |
| Score | Text |
|---|---|
| 0.9996 | We report a patient who developed acute pancreatitis during Drugamiodarone therapy. |
| 0.9798 | We report a patient who developed Adverse-Effectacute pancreatitis during amiodarone therapy. |
| Score | Text |
|---|---|
| 0.9996 | This report describes a case of bilateral ptosis induced by Drugchloroquine . |
| 0.9926 | This report describes a case of Adverse-Effectbilateral ptosis induced by chloroquine. |
| Score | Text |
|---|---|
| 0.9995 | DrugSorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. |
| 0.9849 | Sorafenib induced Adverse-Effecttumor lysis syndrome in an advanced hepatocellular carcinoma patient. |
| Score | Text |
|---|---|
| 0.9995 | Toxic optic neuropathy associated with Drugethambutol : implications for current therapy. |
| 0.9784 | Adverse-EffectToxic optic neuropathy associated with ethambutol : implications for current therapy. |
| Score | Text |
|---|---|
| 0.9855 | Adverse-EffectLeukaemoid monocytosis in M4 AML following chemotherapy and G - CSF. |
| 0.9637 | Leukaemoid monocytosis in M4 AML following chemotherapy and DrugG - CSF . |
| Score | Text |
|---|---|
| 0.9987 | Heparin - dependent antibodies and thrombosis without Drugheparin - induced thrombocytopenia. |
| 0.9972 | Heparin - dependent antibodies and thrombosis without heparin - induced Adverse-Effectthrombocytopenia . |
| Score | Text |
|---|---|
| 0.9994 | However, an association of DrugRitalin with glaucoma has been reported. |
| 0.9941 | However, an association of Ritalin with Adverse-Effectglaucoma has been reported. |
| Score | Text |
|---|---|
| 0.9994 | Nonconvulsive status epilepticus : the role of Drugmorphine and its antagonist. |
| 0.9779 | Adverse-EffectNonconvulsive status epilepticus : the role of morphine and its antagonist. |
| Score | Text |
|---|---|
| 0.9994 | A patient with severe cholestatic jaundice induced by Drugcaptopril is presented. |
| 0.8981 | A patient with Adverse-Effectsevere cholestatic jaundice induced by captopril is presented. |
| Score | Text |
|---|---|
| 0.9996 | Interstitial pneumonitis associated with Drugsirolimus : a dilemma for lung transplantation. |
| 0.9859 | Adverse-EffectInterstitial pneumonitis associated with sirolimus : a dilemma for lung transplantation. |
| Score | Text |
|---|---|
| 0.9993 | Complete remission of the nephrosis occurred after discontinuation of Drughydroxychloroquine therapy. |
| 0.9965 | Complete remission of the Adverse-Effectnephrosis occurred after discontinuation of hydroxychloroquine therapy. |
| Score | Text |
|---|---|
| 0.9980 | DrugGold nephropathy : tissue analysis by X - ray fluorescent spectroscopy. |
| 0.8440 | Gold Adverse-Effectnephropathy : tissue analysis by X - ray fluorescent spectroscopy. |
| Score | Text |
|---|---|
| 0.9992 | The role of DrugAdriamycin in the production of cardiotoxicity is reviewed. |
| 0.9935 | The role of Adriamycin in the production of Adverse-Effectcardiotoxicity is reviewed. |
| Score | Text |
|---|---|
| 0.9996 | Hyponatremia in patients treated with Druglorcainide , a new antiarrhythmic drug. |
| 0.9983 | Adverse-EffectHyponatremia in patients treated with lorcainide, a new antiarrhythmic drug. |
| Score | Text |
|---|---|
| 0.9992 | Spontaneous hemothorax following anticoagulation with low - molecular - weight Drugheparin . |
| 0.9902 | Adverse-EffectSpontaneous hemothorax following anticoagulation with low - molecular - weight heparin. |
| Score | Text |
|---|---|
| 0.9993 | The psychotic behavior resolved completely soon after the discontinuation of Druglevetiracetam . |
| 0.9901 | The Adverse-Effectpsychotic behavior resolved completely soon after the discontinuation of levetiracetam. |
| Score | Text |
|---|---|
| 0.9779 | DrugRetinoic acid may increase the risk of bone marrow transplant nephropathy. |
| 0.9696 | Retinoic acid may increase the risk of Adverse-Effectbone marrow transplant nephropathy . |
| Score | Text |
|---|---|
| 0.9993 | The relationship between Druginfliximab treatment and lymphoma in Crohn's disease. |
| 0.9960 | The relationship between infliximab treatment and Adverse-Effectlymphoma in Crohn's disease. |
| Score | Text |
|---|---|
| 0.9992 | Therefore, Drugamantadine was permanently discontinued and the cornea cleared again. |
| 0.9978 | Therefore, amantadine was permanently discontinued and the Adverse-Effectcornea cleared again. |
| Score | Text |
|---|---|
| 0.9996 | This is the first reported case of hepatolithiasis during Drugoctreotide therapy. |
| 0.9980 | This is the first reported case of Adverse-Effecthepatolithiasis during octreotide therapy. |
| Score | Text |
|---|---|
| 0.9993 | The literature search revealed 22 cases of hypersensitivity reaction to Drugcyclosporine . |
| 0.9798 | The literature search revealed 22 cases of Adverse-Effecthypersensitivity reaction to cyclosporine. |
| Score | Text |
|---|---|
| 0.9996 | Seizure with hyponatremia in a child prescribed Drugdesmopressin for nocturnal enuresis. |
| 0.9982 | Adverse-EffectSeizure with hyponatremia in a child prescribed desmopressin for nocturnal enuresis. |
| 0.9969 | Seizure with Adverse-Effecthyponatremia in a child prescribed desmopressin for nocturnal enuresis. |
| Score | Text |
|---|---|
| 0.9959 | Rebound hyperglycemia following overdosing of Druginsulin in cats with diabetes mellitus. |
| 0.8976 | Rebound Adverse-Effecthyperglycemia following overdosing of insulin in cats with diabetes mellitus. |
| Score | Text |
|---|---|
| 0.9994 | Vocal cord paralysis as a consequence of peritonsillar infiltration with Drugbupivacaine . |
| 0.9828 | Adverse-EffectVocal cord paralysis as a consequence of peritonsillar infiltration with bupivacaine. |
| Score | Text |
|---|---|
| 0.9996 | DrugGemcitabine - related radiation recall in a patient with pancreatic cancer. |
| 0.9918 | Gemcitabine - related Adverse-Effectradiation recall in a patient with pancreatic cancer. |
| Score | Text |
|---|---|
| 0.9993 | DrugPropylthiouracil - induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies. |
| 0.9867 | Propylthiouracil - induced Adverse-Effectsensorineural hearing loss associated with antineutrophil cytoplasmic antibodies. |
| 0.9822 | Propylthiouracil - induced sensorineural hearing loss associated with Adverse-Effectantineutrophil cytoplasmic antibodies . |
| Score | Text |
|---|---|
| 0.9981 | Adverse-EffectHepatotoxicity associated with use of D - penicillamine in rheumatoid arthritis. |
| 0.9623 | Hepatotoxicity associated with use of DrugD - penicillamine in rheumatoid arthritis. |
| Score | Text |
|---|---|
| 0.9993 | DrugMesalamine may cause hypersensitivity pneumonitis in patients with Crohn's disease. |
| 0.9830 | Mesalamine may cause Adverse-Effecthypersensitivity pneumonitis in patients with Crohn's disease. |
| Score | Text |
|---|---|
| 0.9991 | However, Drugcyclosporine dependency is associated with the risk of nephrotoxicity. |
| 0.9915 | However, cyclosporine dependency is associated with the risk of Adverse-Effectnephrotoxicity . |
| Score | Text |
|---|---|
| 0.9996 | DrugCapecitabine - induced multifocal leukoencephalopathy : a report of five cases. |
| 0.9840 | Capecitabine - induced Adverse-Effectmultifocal leukoencephalopathy : a report of five cases. |
| Score | Text |
|---|---|
| 0.9996 | In the third child, the tics ceased after DrugCBZ discontinuation. |
| 0.9983 | In the third child, the Adverse-Effecttics ceased after CBZ discontinuation. |
| Score | Text |
|---|---|
| 0.9988 | Can Drugketamine prescribed for pain cause damage to the urinary tract? |
| 0.9651 | Can ketamine prescribed for pain cause Adverse-Effectdamage to the urinary tract ? |
| Score | Text |
|---|---|
| 0.9996 | There have been only two reports of Drugcimetidine - induced hepatitis. |
| 0.9989 | There have been only two reports of cimetidine - induced Adverse-Effecthepatitis . |
| Score | Text |
|---|---|
| 0.9816 | Lower extremity arterial insufficiency after long - term Drugmethysergide maleate therapy. |
| Lower extremity Adverse-Effectarterial insufficiency after long - term methysergide maleate therapy. | |
| Score | Text |
|---|---|
| 0.9926 | Elevated serum triglycerides with Drugclozapine resolved with risperidone in four patients. |
| 0.9643 | Adverse-EffectElevated serum triglycerides with clozapine resolved with risperidone in four patients. |
| Score | Text |
|---|---|
| 0.9991 | Ulcer became worse after Drugtobramycin and gentamycin treatment for 2 days. |
| 0.9991 | Ulcer became worse after tobramycin and Druggentamycin treatment for 2 days. |
| 0.9794 | Adverse-EffectUlcer became worse after tobramycin and gentamycin treatment for 2 days. |
| Score | Text |
|---|---|
| 0.9993 | In some cases this seems to happen because Drugspironolactone causes diarrhoea. |
| 0.9979 | In some cases this seems to happen because spironolactone causes Adverse-Effectdiarrhoea . |
| Score | Text |
|---|---|
| 0.9985 | Secondary hyperparathyroidism in certain patients with Druglithium nephrotoxicity is also possible. |
| 0.8866 | Secondary hyperparathyroidism in certain patients with lithium Adverse-Effectnephrotoxicity is also possible. |
| 0.7906 | Adverse-EffectSecondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible. |
| Score | Text |
|---|---|
| 0.9996 | There have been several reported cases of Drugomeprazole - induced AIN. |
| 0.9976 | There have been several reported cases of omeprazole - induced Adverse-EffectAIN . |
| Score | Text |
|---|---|
| 0.9816 | Stroke - like syndrome after gold sodium thiomalate induced Adverse-Effectvasomotor reaction . |
| 0.9798 | Adverse-EffectStroke - like syndrome after gold sodium thiomalate induced vasomotor reaction. |
| 0.9636 | Stroke - like syndrome after Druggold sodium thiomalate induced vasomotor reaction. |
| Score | Text |
|---|---|
| 0.9993 | Torsade de pointes represents a potential complication of chronic Drugamiodarone therapy. |
| 0.9866 | Adverse-EffectTorsade de pointes represents a potential complication of chronic amiodarone therapy. |
| Score | Text |
|---|---|
| 0.9995 | Intraventricular Drugvancomycin - induced cerebrospinal fluid eosinophilia : report of two patients. |
| 0.9819 | Intraventricular vancomycin - induced Adverse-Effectcerebrospinal fluid eosinophilia : report of two patients. |
| Score | Text |
|---|---|
| 0.9983 | The Drugampicillin rash occurring in cases of infectious mononucleosis is well documented. |
| 0.9764 | The Adverse-Effectampicillin rash occurring in cases of infectious mononucleosis is well documented. |
| Score | Text |
|---|---|
| 0.9989 | We report an unusual pattern of supravenous hyperpigmentation occurring after DrugCHOP chemotherapy. |
| 0.9854 | We report an unusual pattern of Adverse-Effectsupravenous hyperpigmentation occurring after CHOP chemotherapy. |
| Score | Text |
|---|---|
| 0.9990 | DrugHydroxyurea - induced acute interstitial pneumonitis in a patient with essential thrombocythemia. |
| 0.9824 | Hydroxyurea - induced Adverse-Effectacute interstitial pneumonitis in a patient with essential thrombocythemia. |
| Score | Text |
|---|---|
| 0.9995 | Graft versus host - like illness in a child with Drugphenobarbital hypersensitivity. |
| 0.9725 | Adverse-EffectGraft versus host - like illness in a child with phenobarbital hypersensitivity. |
| 0.8109 | Graft versus host - like illness in a child with phenobarbital Adverse-Effecthypersensitivity . |
| Score | Text |
|---|---|
| 0.9988 | Neutropenia and agranulocytosis are risks known to occur with Drugphenothiazines and clozapine. |
| 0.9987 | Neutropenia and agranulocytosis are risks known to occur with phenothiazines and Drugclozapine . |
| 0.9975 | Neutropenia and Adverse-Effectagranulocytosis are risks known to occur with phenothiazines and clozapine. |
| 0.9971 | Adverse-EffectNeutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine. |
| Score | Text |
|---|---|
| 0.9857 | Adverse-EffectMilk - alkali syndrome induced by 1, 25 ( OH ) 2D in a patient with hypoparathyroidism. |
| 0.9750 | Milk - alkali syndrome induced by Drug1, 25 ( OH ) 2D in a patient with hypoparathyroidism. |
| Score | Text |
|---|---|
| 0.9996 | DrugPregabalin - induced cortical negative myoclonus in a patient with neuropathic pain. |
| 0.9841 | Pregabalin - induced Adverse-Effectcortical negative myoclonus in a patient with neuropathic pain. |
| Score | Text |
|---|---|
| 0.9977 | Arthritis and Adverse-Effectbursitis in multiple sclerosis patients treated with interferon - beta. |
| 0.9923 | Adverse-EffectArthritis and bursitis in multiple sclerosis patients treated with interferon - beta. |
| 0.9682 | Arthritis and bursitis in multiple sclerosis patients treated with Druginterferon - beta . |
| Score | Text |
|---|---|
| 0.9995 | A 53 - year - old man developed NMS without rigidity while taking Drugolanzapine . |
| 0.9981 | A 53 - year - old man developed Adverse-EffectNMS without rigidity while taking olanzapine. |
| Score | Text |
|---|---|
| 0.9995 | Accordingly, camptocormia is a dose - dependent side effect of Drugvalproate . |
| 0.9982 | Accordingly, Adverse-Effectcamptocormia is a dose - dependent side effect of valproate. |
| Score | Text |
|---|---|
| 0.9995 | We report a patient who experienced LABD shortly after starting Drugcarbamazepine therapy. |
| 0.9982 | We report a patient who experienced Adverse-EffectLABD shortly after starting carbamazepine therapy. |
| Score | Text |
|---|---|
| 0.9995 | DrugTiclopidine - induced aplastic anemia ( TIAA ) is considered very uncommon. |
| 0.9918 | Ticlopidine - induced Adverse-Effectaplastic anemia ( TIAA ) is considered very uncommon. |
| 0.9889 | Ticlopidine - induced aplastic anemia ( Adverse-EffectTIAA ) is considered very uncommon. |
| Score | Text |
|---|---|
| 0.9996 | Dystonia associated with Drugcarbamazepine administration : experience in brain - damaged children. |
| 0.9991 | Adverse-EffectDystonia associated with carbamazepine administration : experience in brain - damaged children. |
| Score | Text |
|---|---|
| 0.9994 | We report on a patient who developed acute rhabdomyolysis after taking Drugcerivastatin . |
| 0.9745 | We report on a patient who developed Adverse-Effectacute rhabdomyolysis after taking cerivastatin. |
| Score | Text |
|---|---|
| 0.9995 | One patient with systemic lupus erythematosus developed erythema multiforme after taking Druggriseofulvin . |
| 0.9920 | One patient with systemic lupus erythematosus developed Adverse-Effecterythema multiforme after taking griseofulvin. |
| Score | Text |
|---|---|
| 0.9997 | Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after Drugtemozolomide . |
| 0.9836 | Listeria brain abscess, Adverse-EffectPneumocystis pneumonia and Kaposi's sarcoma after temozolomide. |
| 0.9797 | Adverse-EffectListeria brain abscess , Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide. |
| 0.9777 | Listeria brain abscess, Pneumocystis pneumonia and Adverse-EffectKaposi's sarcoma after temozolomide. |
| Score | Text |
|---|---|
| 0.9994 | In these patients, long - acting Drugoctreotide may trigger serious hypoglycemia. |
| 0.9868 | In these patients, long - acting octreotide may trigger Adverse-Effectserious hypoglycemia . |
| Score | Text |
|---|---|
| 0.9994 | DrugAlbuterol - induced hypokalemia and its potential cardiac toxicity are discussed briefly. |
| 0.9978 | Albuterol - induced Adverse-Effecthypokalemia and its potential cardiac toxicity are discussed briefly. |
| 0.9842 | Albuterol - induced hypokalemia and its potential Adverse-Effectcardiac toxicity are discussed briefly. |
| Score | Text |
|---|---|
| 0.9993 | CONCLUSIONS : Infectious endophthalmitis is a potential complication of intravitreal Drugbevacizumab injection. |
| 0.9784 | CONCLUSIONS : Adverse-EffectInfectious endophthalmitis is a potential complication of intravitreal bevacizumab injection. |
| Score | Text |
|---|---|
| 0.9995 | Heat stroke in schizophrenia during Drugclozapine treatment : rapid recognition and management. |
| 0.9936 | Adverse-EffectHeat stroke in schizophrenia during clozapine treatment : rapid recognition and management. |
| Score | Text |
|---|---|
| 0.9979 | Cutaneous reactions to propylthiouracil and Drugmethimazole occur in 3 % - 5 % of adults. |
| 0.9974 | Cutaneous reactions to Drugpropylthiouracil and methimazole occur in 3 % - 5 % of adults. |
| 0.9919 | Adverse-EffectCutaneous reactions to propylthiouracil and methimazole occur in 3 % - 5 % of adults. |
| Score | Text |
|---|---|
| 0.9995 | This report describes a probable case of Druginfliximab - induced membranous nephropathy. |
| 0.9867 | This report describes a probable case of infliximab - induced Adverse-Effectmembranous nephropathy . |
| Score | Text |
|---|---|
| 0.9995 | DrugTemozolomide - induced desquamative skin rash in a patient with metastatic melanoma. |
| 0.9873 | Temozolomide - induced Adverse-Effectdesquamative skin rash in a patient with metastatic melanoma. |
| Score | Text |
|---|---|
| 0.9997 | This represents the first report of nonconvulsive status epilepticus induced by Drugifosfamide . |
| 0.9810 | This represents the first report of Adverse-Effectnonconvulsive status epilepticus induced by ifosfamide. |
| Score | Text |
|---|---|
| 0.9996 | We present a case of Drugsotalol - induced bradycardia reversed by glucagon. |
| 0.9986 | We present a case of sotalol - induced Adverse-Effectbradycardia reversed by glucagon. |
| Score | Text |
|---|---|
| 0.9993 | Eye movement disorders in bone marrow transplant patients on cyclosporin and Drugganciclovir . |
| 0.9992 | Eye movement disorders in bone marrow transplant patients on Drugcyclosporin and ganciclovir. |
| 0.9916 | Adverse-EffectEye movement disorders in bone marrow transplant patients on cyclosporin and ganciclovir. |
| Score | Text |
|---|---|
| 0.9991 | The photosensitivity is still present 3 years after the withdrawal of Drugquinine . |
| 0.9969 | The Adverse-Effectphotosensitivity is still present 3 years after the withdrawal of quinine. |
| Score | Text |
|---|---|
| 0.9960 | The clinical picture was identical to that of Drugchloroquine and hydroxychloroquine maculopathy. |
| 0.9959 | The clinical picture was identical to that of chloroquine and Drughydroxychloroquine maculopathy. |
| 0.9339 | The clinical picture was identical to that of chloroquine and hydroxychloroquine Adverse-Effectmaculopathy . |
| Score | Text |
|---|---|
| 0.9994 | Life - threatening interstitial lung disease associated with Drugtrastuzumab : case report. |
| 0.9818 | Life - threatening Adverse-Effectinterstitial lung disease associated with trastuzumab : case report. |
| Score | Text |
|---|---|
| 0.9992 | Combining Drugmethylephedrine and Chinese herbal drugs might carry a risk of stroke. |
| 0.9967 | Combining methylephedrine and Chinese herbal drugs might carry a risk of Adverse-Effectstroke . |
| Score | Text |
|---|---|
| 0.9994 | Physicians should be aware of the potentially lethal side effects of Drugdapsone . |
| 0.9447 | Physicians should be aware of the potentially Adverse-Effectlethal side effects of dapsone. |
| Score | Text |
|---|---|
| 0.9890 | The use of pamidronate for hypercalcemia secondary to acute Drugvitamin D intoxication. |
| 0.9001 | The use of pamidronate for hypercalcemia secondary to acute Adverse-Effectvitamin D intoxication . |
| 0.7411 | The use of Drugpamidronate for hypercalcemia secondary to acute vitamin D intoxication. |
| 0.6067 | The use of pamidronate for Adverse-Effecthypercalcemia secondary to acute vitamin D intoxication. |
| Score | Text |
|---|---|
| 0.9986 | Both patients suddenly became hypotensive after injection of Drugchymopapain into a disk. |
| 0.9962 | Both patients suddenly became Adverse-Effecthypotensive after injection of chymopapain into a disk. |
| Score | Text |
|---|---|
| 0.9995 | PURPOSE : A case of probable Drugenoxaparin - induced hepatotoxicity is described. |
| 0.9972 | PURPOSE : A case of probable enoxaparin - induced Adverse-Effecthepatotoxicity is described. |
| Score | Text |
|---|---|
| 0.9994 | DrugLithium - associated transient thyrotoxicosis in 4 Chinese women with autoimmune thyroiditis. |
| 0.9711 | Lithium - associated Adverse-Effecttransient thyrotoxicosis in 4 Chinese women with autoimmune thyroiditis. |
| Score | Text |
|---|---|
| 0.9995 | The literature search found 12 cases of radiation recall caused by Druggemcitabine . |
| 0.9910 | The literature search found 12 cases of Adverse-Effectradiation recall caused by gemcitabine. |
| Score | Text |
|---|---|
| 0.9992 | Two patients on long - term Druglithium therapy developed the nephrotic syndrome. |
| 0.9946 | Two patients on long - term lithium therapy developed the Adverse-Effectnephrotic syndrome . |
| Score | Text |
|---|---|
| 0.9994 | Fulminant hepatic failure is a rare complication of Drugdisulfiram treatment for alcoholism. |
| 0.9857 | Adverse-EffectFulminant hepatic failure is a rare complication of disulfiram treatment for alcoholism. |
| Score | Text |
|---|---|
| 0.9992 | Incidence of seizures in pediatric cancer patients treated with imipenem / Drugcilastatin . |
| 0.9992 | Incidence of seizures in pediatric cancer patients treated with Drugimipenem / cilastatin. |
| 0.9986 | Incidence of Adverse-Effectseizures in pediatric cancer patients treated with imipenem / cilastatin. |
| Score | Text |
|---|---|
| 0.9995 | Incomplete posterior hyaloid detachment after intravitreal Drugpegaptanib injection in diabetic macular edema. |
| 0.9669 | Adverse-EffectIncomplete posterior hyaloid detachment after intravitreal pegaptanib injection in diabetic macular edema. |
| Score | Text |
|---|---|
| 0.9993 | Severe corneal toxicity after topical Drugfluoroquinolone therapy : report of two cases. |
| 0.9748 | Adverse-EffectSevere corneal toxicity after topical fluoroquinolone therapy : report of two cases. |
| Score | Text |
|---|---|
| 0.9993 | Tardive oculogyric crisis during treatment with Drugclozapine : report of three cases. |
| 0.9869 | Adverse-EffectTardive oculogyric crisis during treatment with clozapine : report of three cases. |
| Score | Text |
|---|---|
| 0.9990 | Intravenous Drugvalproate associated with significant hypotension in the treatment of status epilepticus. |
| 0.9978 | Intravenous valproate associated with significant Adverse-Effecthypotension in the treatment of status epilepticus. |
| Score | Text |
|---|---|
| 0.9995 | Anterior spinal artery syndrome - - a complication of cervical intrathecal Drugphenol injection. |
| 0.9859 | Adverse-EffectAnterior spinal artery syndrome - - a complication of cervical intrathecal phenol injection. |
| Score | Text |
|---|---|
| 0.9863 | Adverse-EffectPericardial hemorrhage due to acetylsalicylic acid in a patient with essential thrombocythemia. |
| 0.9811 | Pericardial hemorrhage due to Drugacetylsalicylic acid in a patient with essential thrombocythemia. |
| Score | Text |
|---|---|
| 0.9994 | He developed a late secondary infection in some sites treated with Drugimiquimod . |
| 0.9837 | He developed a late Adverse-Effectsecondary infection in some sites treated with imiquimod. |
| Score | Text |
|---|---|
| 0.9875 | PURPOSE : To report a case of Adverse-Effectnodular scleritis following alendronate sodium. |
| 0.9862 | PURPOSE : To report a case of nodular scleritis following Drugalendronate sodium . |
| Score | Text |
|---|---|
| 0.9990 | Toxic hepatitis due to combination therapy with methotrexate and Drugetretinate in psoriasis. |
| 0.9989 | Toxic hepatitis due to combination therapy with Drugmethotrexate and etretinate in psoriasis. |
| 0.9899 | Adverse-EffectToxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis. |
| Score | Text |
|---|---|
| 0.9994 | DrugSuccinylcholine - induced hyperkalemia in a patient with mucositis secondary to chemotherapy. |
| 0.9978 | Succinylcholine - induced Adverse-Effecthyperkalemia in a patient with mucositis secondary to chemotherapy. |
| Score | Text |
|---|---|
| 0.9996 | Nonsustained polymorphous ventricular tachycardia during Drugamiodarone therapy for atrial fibrillation complicating cardiomyopathy. |
| 0.9637 | Adverse-EffectNonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy. |
| Score | Text |
|---|---|
| 0.9870 | CONCLUSIONS : Amphotericin B overdose can be Adverse-Effectfatal in children and infants. |
| 0.9828 | CONCLUSIONS : DrugAmphotericin B overdose can be fatal in children and infants. |
| Score | Text |
|---|---|
| 0.9993 | Stupor and fast activity on electroencephalography in a child treated with Drugvalproate . |
| 0.9990 | Adverse-EffectStupor and fast activity on electroencephalography in a child treated with valproate. |
| Score | Text |
|---|---|
| 0.9991 | Neurological side effects in two patients receiving Druggold injections for rheumatoid arthritis. |
| 0.9784 | Adverse-EffectNeurological side effects in two patients receiving gold injections for rheumatoid arthritis. |
| Score | Text |
|---|---|
| 0.9993 | Increased libido in a woman treated with Drugfluvoxamine : a case report. |
| 0.9887 | Adverse-EffectIncreased libido in a woman treated with fluvoxamine : a case report. |
| Score | Text |
|---|---|
| 0.9994 | Marked sinus tachycardia resulting from the synergistic effects of marijuana and Drugnortriptyline . |
| 0.9818 | Marked Adverse-Effectsinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline. |
| Score | Text |
|---|---|
| 0.9987 | The exophthalmos improved dramatically within 72 hours of the withdrawal of Druglithium . |
| 0.9948 | The Adverse-Effectexophthalmos improved dramatically within 72 hours of the withdrawal of lithium. |
| Score | Text |
|---|---|
| 0.9993 | Hyperglycemia and diabetic coma : possible relationship to diuretic - Drugpropranolol therapy. |
| 0.9970 | Adverse-EffectHyperglycemia and diabetic coma : possible relationship to diuretic - propranolol therapy. |
| 0.9882 | Hyperglycemia and Adverse-Effectdiabetic coma : possible relationship to diuretic - propranolol therapy. |
| Score | Text |
|---|---|
| 0.9995 | Disseminated cellulitic cryptococcosis in the setting of Drugprednisone monotherapy for pemphigus vulgaris. |
| 0.9809 | Adverse-EffectDisseminated cellulitic cryptococcosis in the setting of prednisone monotherapy for pemphigus vulgaris. |
| Score | Text |
|---|---|
| 0.9994 | We describe a case of prolonged Drugterbinafine - induced cholestatic liver disease. |
| 0.9877 | We describe a case of prolonged terbinafine - induced Adverse-Effectcholestatic liver disease . |
| Score | Text |
|---|---|
| 0.9994 | However, 1 eye had vitreous hemorrhage after repeated injections of DrugtPA . |
| 0.9858 | However, 1 eye had Adverse-Effectvitreous hemorrhage after repeated injections of tPA. |
| Score | Text |
|---|---|
| 0.9993 | Stuttering priapism complicating Drugwarfarin therapy in a patient with protein C deficiency. |
| 0.9897 | Adverse-EffectStuttering priapism complicating warfarin therapy in a patient with protein C deficiency. |
| Score | Text |
|---|---|
| 0.9770 | Delayed bowel injury is an infrequently observed complication of Drugchromic phosphate administration. |
| 0.8997 | Delayed Adverse-Effectbowel injury is an infrequently observed complication of chromic phosphate administration. |
| Score | Text |
|---|---|
| 0.9994 | Malignant mixed mullerian tumor of the uterus in a patient taking Drugraloxifene . |
| 0.9640 | Adverse-EffectMalignant mixed mullerian tumor of the uterus in a patient taking raloxifene. |
| Score | Text |
|---|---|
| 0.9982 | Drug5 - Fluorouracil cardiotoxicity complicating treatment of stage IIB cervical cancer - - case report. |
| 0.9274 | 5 - Fluorouracil Adverse-Effectcardiotoxicity complicating treatment of stage IIB cervical cancer - - case report. |
| Score | Text |
|---|---|
| 0.9994 | Physicians should be aware that PLP can occur after initiation of Drugpaclitaxel . |
| 0.9975 | Physicians should be aware that Adverse-EffectPLP can occur after initiation of paclitaxel. |
| Score | Text |
|---|---|
| 0.9996 | Gynaecomastia is a rarely reported adverse drug reaction due to Drugisoniazid therapy. |
| 0.9979 | Adverse-EffectGynaecomastia is a rarely reported adverse drug reaction due to isoniazid therapy. |
| Score | Text |
|---|---|
| 0.9944 | Autopsy findings were consistent with Drugbleomycin and oxygen - induced pulmonary damage. |
| 0.9930 | Autopsy findings were consistent with bleomycin and oxygen - induced Adverse-Effectpulmonary damage . |
| 0.9535 | Autopsy findings were consistent with bleomycin and Drugoxygen - induced pulmonary damage. |
| Score | Text |
|---|---|
| 0.9838 | Adverse-EffectPolymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia. |
| 0.9789 | Polymyoclonus seizure resulting from accidental injection of Drugtranexamic acid in spinal anesthesia. |
| Score | Text |
|---|---|
| 0.9993 | Pediatric Drugheparin - induced thrombocytopenia : management with Danaparoid ( orgaran ). |
| 0.9967 | Pediatric heparin - induced Adverse-Effectthrombocytopenia : management with Danaparoid ( orgaran ). |
| Score | Text |
|---|---|
| 0.9996 | We report a case of sustained hypotension after administration of parenteral Drugverapamil . |
| 0.9818 | We report a case of Adverse-Effectsustained hypotension after administration of parenteral verapamil. |
| Score | Text |
|---|---|
| 0.9996 | The clinical course suggests that the interstitial pneumonitis was induced by Drughydroxyurea . |
| 0.9874 | The clinical course suggests that the Adverse-Effectinterstitial pneumonitis was induced by hydroxyurea. |
| Score | Text |
|---|---|
| 0.9980 | Drug5 - fluorouracil ( 5 - FU ) - associated peripheral neuropathy is an uncommon event. |
| 0.9977 | 5 - fluorouracil ( Drug5 - FU ) - associated peripheral neuropathy is an uncommon event. |
| 0.9893 | 5 - fluorouracil ( 5 - FU ) - associated Adverse-Effectperipheral neuropathy is an uncommon event. |
| Score | Text |
|---|---|
| 0.9965 | Abdominal wall ulceration and Adverse-Effectmucinosis secondary to recombinant human interferon - beta - 1b. |
| 0.9790 | Adverse-EffectAbdominal wall ulceration and mucinosis secondary to recombinant human interferon - beta - 1b. |
| 0.9426 | Abdominal wall ulceration and mucinosis secondary to Drugrecombinant human interferon - beta - 1b . |
| Score | Text |
|---|---|
| 0.9847 | Adverse-EffectToxic epidermal necrolysis after the use of high - dose cytosine arabinoside. |
| 0.9708 | Toxic epidermal necrolysis after the use of high - dose Drugcytosine arabinoside . |
| Score | Text |
|---|---|
| 0.9952 | Symptomatic hypoglycemia secondary to a glipizide - trimethoprim / Drugsulfamethoxazole drug interaction. |
| 0.9947 | Symptomatic hypoglycemia secondary to a glipizide - Drugtrimethoprim / sulfamethoxazole drug interaction. |
| 0.9944 | Symptomatic hypoglycemia secondary to a Drugglipizide - trimethoprim / sulfamethoxazole drug interaction. |
| 0.9795 | Adverse-EffectSymptomatic hypoglycemia secondary to a glipizide - trimethoprim / sulfamethoxazole drug interaction. |
| Score | Text |
|---|---|
| 0.9995 | Angio - oedema as an unusual tolerable side effect of Drugvoriconazole therapy. |
| 0.9900 | Adverse-EffectAngio - oedema as an unusual tolerable side effect of voriconazole therapy. |
| Score | Text |
|---|---|
| 0.9989 | Life - threatening acute hyponatraemia induced by low dose cyclophosphamide and Drugindomethacin . |
| 0.9988 | Life - threatening acute hyponatraemia induced by low dose Drugcyclophosphamide and indomethacin. |
| 0.9858 | Life - threatening Adverse-Effectacute hyponatraemia induced by low dose cyclophosphamide and indomethacin. |
| Score | Text |
|---|---|
| 0.9995 | The authors report five additional cases of Drugcapecitabine - induced multifocal leukoencephalopathy. |
| 0.9860 | The authors report five additional cases of capecitabine - induced Adverse-Effectmultifocal leukoencephalopathy . |
| Score | Text |
|---|---|
| 0.9663 | Chlormadinone acetate Adverse-Effectwithdrawal syndrome under combined androgen blockade for advanced prostate cancer. |
| 0.8715 | DrugChlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer. |
| Score | Text |
|---|---|
| 0.9996 | Pulmonary fibrosis subsequent to high doses of DrugCCNU for chronic myeloid leukemia. |
| 0.9913 | Adverse-EffectPulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia. |
| Score | Text |
|---|---|
| 0.9996 | Three distinct types of Drugminocycline - induced cutaneous pigmentation have been described. |
| 0.9916 | Three distinct types of minocycline - induced Adverse-Effectcutaneous pigmentation have been described. |
| Score | Text |
|---|---|
| 0.9996 | DrugDocetaxel - induced Meibomian duct inflammation and blockage leading to chalazion formation. |
| 0.9954 | Docetaxel - induced Meibomian duct inflammation and blockage leading to Adverse-Effectchalazion formation. |
| 0.9589 | Docetaxel - induced Adverse-EffectMeibomian duct inflammation and blockage leading to chalazion formation. |
| Score | Text |
|---|---|
| 0.9996 | DrugAmikacin - induced type 5 Bartter - like syndrome with severe hypocalcemia. |
| 0.9685 | Amikacin - induced type 5 Bartter - like syndrome with Adverse-Effectsevere hypocalcemia . |
| 0.9535 | Amikacin - induced Adverse-Effecttype 5 Bartter - like syndrome with severe hypocalcemia. |
| Score | Text |
|---|---|
| 0.9992 | Fatal outcome of intravesical Drugformalin instillation, with changes mimicking renal tuberculosis. |
| 0.9784 | Adverse-EffectFatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis. |
| Score | Text |
|---|---|
| 0.9991 | The use of Drugrituximab has been uncommonly associated with delayed pulmonary toxicity. |
| 0.9724 | The use of rituximab has been uncommonly associated with Adverse-Effectdelayed pulmonary toxicity . |
| Score | Text |
|---|---|
| 0.9975 | Neuroleptic malignant syndrome in an adolescent receiving Drugolanzapine - lithium combination therapy. |
| 0.9961 | Neuroleptic malignant syndrome in an adolescent receiving olanzapine - Druglithium combination therapy. |
| 0.9865 | Adverse-EffectNeuroleptic malignant syndrome in an adolescent receiving olanzapine - lithium combination therapy. |
| Score | Text |
|---|---|
| 0.9995 | CONCLUSION : Therapy with Drugindapamide may induce diabetes in essential hypertension patients. |
| 0.9944 | CONCLUSION : Therapy with indapamide may induce Adverse-Effectdiabetes in essential hypertension patients. |
| Score | Text |
|---|---|
| 0.9962 | Adriamycin - induced Adverse-Effectcardiomyopathy aggravated by cis - platinum nephrotoxicity requiring dialysis. |
| 0.8813 | DrugAdriamycin - induced cardiomyopathy aggravated by cis - platinum nephrotoxicity requiring dialysis. |
| Adriamycin - induced cardiomyopathy aggravated by Drugcis - platinum nephrotoxicity requiring dialysis. | |
| Adriamycin - induced cardiomyopathy aggravated by cis - platinum Adverse-Effectnephrotoxicity requiring dialysis. | |
| Score | Text |
|---|---|
| 0.9994 | Reversible MR imaging and MR spectroscopy abnormalities in association with Drugmetronidazole therapy. |
| 0.9564 | Adverse-EffectReversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy. |
| Score | Text |
|---|---|
| 0.9993 | CONCLUSIONS : DrugCefazolin was a probable cause of this patient's leukopenia. |
| 0.9977 | CONCLUSIONS : Cefazolin was a probable cause of this patient's Adverse-Effectleukopenia . |
| Score | Text |
|---|---|
| 0.9988 | Evaluation revealed elevated serum DrugLTG levels and no other etiology for encephalopathy. |
| 0.7162 | Evaluation revealed Adverse-Effectelevated serum LTG levels and no other etiology for encephalopathy. |
| Score | Text |
|---|---|
| 0.9994 | Three diabetic cases of acute dizziness due to initial administration of Drugvoglibose . |
| 0.9865 | Three diabetic cases of Adverse-Effectacute dizziness due to initial administration of voglibose. |
| Score | Text |
|---|---|
| 0.9992 | Hemodialysis should be performed for rapid reversal of Drugmannitol - induced ARF. |
| 0.9983 | Hemodialysis should be performed for rapid reversal of mannitol - induced Adverse-EffectARF . |
| Score | Text |
|---|---|
| 0.9978 | A 54 - year - old man, treated with Drugamiodarone , developed thyrotoxicosis. |
| 0.9976 | A 54 - year - old man, treated with amiodarone, developed Adverse-Effectthyrotoxicosis . |
| Score | Text |
|---|---|
| 0.9993 | CONCLUSIONS : DrugMetoclopramide may cause reversible nonthrombocytopenic vascular - type palpable purpura. |
| 0.9593 | CONCLUSIONS : Metoclopramide may cause reversible Adverse-Effectnonthrombocytopenic vascular - type palpable purpura . |
| Score | Text |
|---|---|
| 0.9944 | Fatal pulmonary fibrosis following 1, 3 - bis ( 2 - chloroethyl ) - 1 - nitrosourea ( DrugBCNU ) therapy. |
| 0.9869 | Adverse-EffectFatal pulmonary fibrosis following 1, 3 - bis ( 2 - chloroethyl ) - 1 - nitrosourea ( BCNU ) therapy. |
| Fatal pulmonary fibrosis following Drug1, 3 - bis ( 2 - chloroethyl ) - 1 - nitrosourea ( BCNU ) therapy. | |
| Score | Text |
|---|---|
| 0.9995 | This report presents a potential case of Drugrisperidone - induced tardive dyskinesia. |
| 0.9907 | This report presents a potential case of risperidone - induced Adverse-Effecttardive dyskinesia . |
| Score | Text |
|---|---|
| 0.9996 | OBJECTIVE : To report a case of angioedema associated with Druglosartan administration. |
| 0.9983 | OBJECTIVE : To report a case of Adverse-Effectangioedema associated with losartan administration. |
| Score | Text |
|---|---|
| 0.9990 | A patient developed optic neuropathy while being treated with isoniazid and Drugethambutol . |
| 0.9989 | A patient developed optic neuropathy while being treated with Drugisoniazid and ethambutol. |
| 0.9898 | A patient developed Adverse-Effectoptic neuropathy while being treated with isoniazid and ethambutol. |
| Score | Text |
|---|---|
| 0.9803 | Adverse-EffectPeripheral nervous system disturbances caused by cytosine arabinoside have rarely been reported. |
| 0.9779 | Peripheral nervous system disturbances caused by Drugcytosine arabinoside have rarely been reported. |
| Score | Text |
|---|---|
| 0.9994 | These cases demonstrate that DrugCBZ can induce simple motor tics in children. |
| 0.9761 | These cases demonstrate that CBZ can induce simple Adverse-Effectmotor tics in children. |
| Score | Text |
|---|---|
| 0.9824 | CONCLUSION : Anterior ischemic optic neuropathy may complicate treatment with Druginterferon alfa . |
| 0.9772 | CONCLUSION : Adverse-EffectAnterior ischemic optic neuropathy may complicate treatment with interferon alfa. |
| Score | Text |
|---|---|
| 0.9995 | Optic neuropathy associated with Drugpenicillamine therapy in a patient with rheumatoid arthritis. |
| 0.9887 | Adverse-EffectOptic neuropathy associated with penicillamine therapy in a patient with rheumatoid arthritis. |
| Score | Text |
|---|---|
| 0.9996 | Diffuse alveolar hemorrhage after Drugleflunomide therapy in a patient with rheumatoid arthritis. |
| 0.9820 | Adverse-EffectDiffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis. |
| Score | Text |
|---|---|
| 0.9995 | This is the first reported case of suspected DIAN due to Drugcefuroxime . |
| 0.9961 | This is the first reported case of suspected Adverse-EffectDIAN due to cefuroxime. |
| Score | Text |
|---|---|
| 0.9824 | Generalized lichen nitidus with involvement of the palms following Druginterferon alpha treatment. |
| 0.9820 | Adverse-EffectGeneralized lichen nitidus with involvement of the palms following interferon alpha treatment. |
| Score | Text |
|---|---|
| 0.9996 | High - grade endometrial stromal sarcoma after Drugtamoxifen therapy for breast cancer. |
| 0.9635 | Adverse-EffectHigh - grade endometrial stromal sarcoma after tamoxifen therapy for breast cancer. |
| Score | Text |
|---|---|
| 0.9812 | Correction of serum electrolyte imbalance prevents cardiac arrhythmia during Drugamphotericin B administration. |
| 0.9809 | Correction of serum electrolyte imbalance prevents Adverse-Effectcardiac arrhythmia during amphotericin B administration. |
| Score | Text |
|---|---|
| 0.9991 | Ophthalmologic and neurologic findings in two children exposed to Drugvigabatrin in utero. |
| 0.9698 | Adverse-EffectOphthalmologic and neurologic findings in two children exposed to vigabatrin in utero. |
| Score | Text |
|---|---|
| 0.9992 | The exact mechanism of DrugIVIG - associated acute renal failure remains unclear. |
| 0.9845 | The exact mechanism of IVIG - associated Adverse-Effectacute renal failure remains unclear. |
| Score | Text |
|---|---|
| 0.9994 | Due to the severity of the rash, Drugtemozolomide was permanently discontinued. |
| 0.9967 | Due to the severity of the Adverse-Effectrash , temozolomide was permanently discontinued. |
| Score | Text |
|---|---|
| 0.9956 | Possible interaction between lopinavir / Drugritonavir and valproic Acid exacerbates bipolar disorder. |
| 0.9923 | Possible interaction between Druglopinavir / ritonavir and valproic Acid exacerbates bipolar disorder. |
| 0.9823 | Possible interaction between lopinavir / ritonavir and valproic Acid exacerbates Adverse-Effectbipolar disorder . |
| 0.9792 | Possible interaction between lopinavir / ritonavir and Drugvalproic Acid exacerbates bipolar disorder. |
| Score | Text |
|---|---|
| 0.9995 | Retinal dysfunction and anterior segment deposits in a patient treated with Drugrifabutin . |
| 0.9870 | Adverse-EffectRetinal dysfunction and anterior segment deposits in a patient treated with rifabutin. |
| 0.9821 | Retinal dysfunction and Adverse-Effectanterior segment deposits in a patient treated with rifabutin. |
| Score | Text |
|---|---|
| 0.9995 | We describe a case of EGE manifested as an allergy to Druggemfibrozil . |
| 0.9978 | We describe a case of Adverse-EffectEGE manifested as an allergy to gemfibrozil. |
| Score | Text |
|---|---|
| 0.9995 | Myasthenic patients receiving Drugampicillin should be closely monitored for possible acute exacerbations. |
| 0.9773 | Myasthenic patients receiving ampicillin should be closely monitored for possible Adverse-Effectacute exacerbations . |
| Score | Text |
|---|---|
| 0.9971 | Adverse-EffectHyperpigmentation during interferon - alpha therapy for chronic hepatitis C virus infection. |
| 0.9692 | Hyperpigmentation during Druginterferon - alpha therapy for chronic hepatitis C virus infection. |
| Score | Text |
|---|---|
| 0.9995 | Primary cutaneous coccidioidomycosis and subsequent drug eruption to Drugitraconazole in a dog. |
| 0.9883 | Primary cutaneous coccidioidomycosis and subsequent Adverse-Effectdrug eruption to itraconazole in a dog. |
| 0.9749 | Adverse-EffectPrimary cutaneous coccidioidomycosis and subsequent drug eruption to itraconazole in a dog. |
| Score | Text |
|---|---|
| 0.9973 | Adverse-EffectOtotoxicity as a result of cis - platinum administration is well documented. |
| 0.9726 | Ototoxicity as a result of Drugcis - platinum administration is well documented. |
| Score | Text |
|---|---|
| 0.9993 | We report a case of pediatric Drugbupropion ingestion resulting in multiple seizures. |
| 0.9872 | We report a case of pediatric bupropion ingestion resulting in Adverse-Effectmultiple seizures . |
| Score | Text |
|---|---|
| 0.9929 | Adverse-EffectNephrotic syndrome in a multiple sclerosis patient treated with interferon beta 1a. |
| 0.9674 | Nephrotic syndrome in a multiple sclerosis patient treated with Druginterferon beta 1a . |
| Score | Text |
|---|---|
| 0.9996 | DrugAmifostine - induced fever : case report and review of the literature. |
| 0.9958 | Amifostine - induced Adverse-Effectfever : case report and review of the literature. |
| Score | Text |
|---|---|
| 0.9996 | Fatal intravascular autoimmune hemolytic anemia after Drugfludarabine treatment for chronic lymphocytic leukemia. |
| 0.9806 | Adverse-EffectFatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia. |
| Score | Text |
|---|---|
| 0.9996 | We report three cases of patients who developed leukopenia during Drugolanzapine treatment. |
| 0.9982 | We report three cases of patients who developed Adverse-Effectleukopenia during olanzapine treatment. |
| Score | Text |
|---|---|
| 0.9982 | He became hyperkalemic on rechallenge with Drugtimolol and normokalemic following its withdrawal. |
| 0.9947 | He became Adverse-Effecthyperkalemic on rechallenge with timolol and normokalemic following its withdrawal. |
| Score | Text |
|---|---|
| 0.9993 | Serious adverse events experienced by patients with chronic heart failure taking Drugspironolactone . |
| 0.9737 | Adverse-EffectSerious adverse events experienced by patients with chronic heart failure taking spironolactone. |
| Score | Text |
|---|---|
| 0.9990 | DrugAminoglutethimide was discontinued until completion of radiotherapy, and the rash resolved. |
| 0.9961 | Aminoglutethimide was discontinued until completion of radiotherapy, and the Adverse-Effectrash resolved. |
| Score | Text |
|---|---|
| 0.9995 | DrugLeflunomide - induced toxic epidermal necrolysis in a patient with rheumatoid arthritis. |
| 0.9860 | Leflunomide - induced Adverse-Effecttoxic epidermal necrolysis in a patient with rheumatoid arthritis. |
| Score | Text |
|---|---|
| 0.9994 | Abnormalities of the pupil and visual - evoked potential in Drugquinine amblyopia. |
| 0.9622 | Adverse-EffectAbnormalities of the pupil and visual - evoked potential in quinine amblyopia. |
| 0.8662 | Abnormalities of the pupil and visual - evoked potential in quinine Adverse-Effectamblyopia . |
| Score | Text |
|---|---|
| 0.9985 | Acute myocardial ischemia following accidental intravenous administration of Drugepinephrine in high concentration. |
| 0.9792 | Adverse-EffectAcute myocardial ischemia following accidental intravenous administration of epinephrine in high concentration. |
| Score | Text |
|---|---|
| 0.9984 | Hepato - biliary abnormalities secondary to Drugceftriaxone use : a case report. |
| 0.9830 | Adverse-EffectHepato - biliary abnormalities secondary to ceftriaxone use : a case report. |
| Score | Text |
|---|---|
| 0.9949 | Metabolic acidosis induced by Drugcetrimide - chlorhexidine solution in hydatid cyst surgery. |
| 0.9925 | Metabolic acidosis induced by cetrimide - Drugchlorhexidine solution in hydatid cyst surgery. |
| 0.9912 | Adverse-EffectMetabolic acidosis induced by cetrimide - chlorhexidine solution in hydatid cyst surgery. |
| Score | Text |
|---|---|
| 0.9864 | Adverse-EffectBone formation induced in an infant by systemic prostaglandin - E2 administration. |
| 0.9588 | Bone formation induced in an infant by systemic Drugprostaglandin - E2 administration. |
| Score | Text |
|---|---|
| 0.9996 | DrugInfliximab - induced lupus in Crohn's disease : a case report. |
| 0.9986 | Infliximab - induced Adverse-Effectlupus in Crohn's disease : a case report. |
| Score | Text |
|---|---|
| 0.9980 | Protamine allergy as a complication of Druginsulin hypersensitivity : A case report. |
| 0.9916 | Adverse-EffectProtamine allergy as a complication of insulin hypersensitivity : A case report. |
| Score | Text |
|---|---|
| 0.9992 | Additionally, Drugdanazol produces hepatocellular damage in approximately 10 % of women. |
| 0.9906 | Additionally, danazol produces Adverse-Effecthepatocellular damage in approximately 10 % of women. |
| Score | Text |
|---|---|
| 0.9996 | Thymic enlargement in a patient with juvenile idiopathic arthritis during Drugetanercept therapy. |
| 0.9907 | Adverse-EffectThymic enlargement in a patient with juvenile idiopathic arthritis during etanercept therapy. |
| Score | Text |
|---|---|
| 0.9996 | Esophageal candidiasis was diagnosed at endoscopy in two patients receiving Drugomeprazole therapy. |
| 0.9871 | Adverse-EffectEsophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy. |
| Score | Text |
|---|---|
| 0.9995 | Symptoms and endoscopic lesions quickly regressed within 1 week of Drugmeloxicam withdrawal. |
| 0.9918 | Symptoms and Adverse-Effectendoscopic lesions quickly regressed within 1 week of meloxicam withdrawal. |
| Score | Text |
|---|---|
| 0.9996 | A 61 year - old male patient developed gynecomastia after starting Drugtheophylline . |
| 0.9984 | A 61 year - old male patient developed Adverse-Effectgynecomastia after starting theophylline. |
| Score | Text |
|---|---|
| 0.9972 | Adverse-EffectPapilloedema and hepatic dysfunction apparently induced by perhexiline maleate ( Pexid ). |
| 0.9963 | Papilloedema and hepatic dysfunction apparently induced by perhexiline maleate ( DrugPexid ). |
| 0.9888 | Papilloedema and Adverse-Effecthepatic dysfunction apparently induced by perhexiline maleate ( Pexid ). |
| 0.9852 | Papilloedema and hepatic dysfunction apparently induced by Drugperhexiline maleate ( Pexid ). |
| Score | Text |
|---|---|
| 0.9994 | Managing cardiovascular collapse in severe Drugflecainide overdose without recourse to extracorporeal therapy. |
| 0.9861 | Managing Adverse-Effectcardiovascular collapse in severe flecainide overdose without recourse to extracorporeal therapy. |
| Score | Text |
|---|---|
| 0.9990 | These nail changes gradually disappeared when the dose of Drugclofazimine was reduced. |
| 0.9882 | These Adverse-Effectnail changes gradually disappeared when the dose of clofazimine was reduced. |
| Score | Text |
|---|---|
| 0.9995 | Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with Drugtacrolimus . |
| 0.9811 | Adverse-EffectReflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus. |
| Score | Text |
|---|---|
| 0.9995 | CONCLUSION : Severe and sustained ocular hypertension may occur after intravitreal Drugranibizumab . |
| 0.9706 | CONCLUSION : Severe and Adverse-Effectsustained ocular hypertension may occur after intravitreal ranibizumab. |
| Score | Text |
|---|---|
| 0.9992 | DrugOxcarbazepine - induced Drug Reaction with Eosinophilia and Systemic Symptoms ( DRESS ). |
| 0.9904 | Oxcarbazepine - induced Drug Reaction with Eosinophilia and Systemic Symptoms ( Adverse-EffectDRESS ). |
| 0.8632 | Oxcarbazepine - induced Adverse-EffectDrug Reaction with Eosinophilia and Systemic Symptoms ( DRESS ). |
| Oxcarbazepine - induced Adverse-EffectDrug Reaction with Eosinophilia and Systemic Symptoms ( DRESS ). | |
| Score | Text |
|---|---|
| 0.9979 | Serotonin syndrome induced by transitioning from Drugphenelzine to venlafaxine : four patient reports. |
| 0.9979 | Serotonin syndrome induced by transitioning from phenelzine to Drugvenlafaxine : four patient reports. |
| 0.9943 | Adverse-EffectSerotonin syndrome induced by transitioning from phenelzine to venlafaxine : four patient reports. |
| Score | Text |
|---|---|
| 0.9995 | Radiation recall related to Druggemcitabine has been reported in lung and breast cancer. |
| 0.9908 | Adverse-EffectRadiation recall related to gemcitabine has been reported in lung and breast cancer. |
| Score | Text |
|---|---|
| 0.9993 | DrugHeparin - induced thrombocytopenia is a rare and serious complication of anticoagulation therapy. |
| 0.9968 | Heparin - induced Adverse-Effectthrombocytopenia is a rare and serious complication of anticoagulation therapy. |
| Score | Text |
|---|---|
| 0.9974 | A patient developed Adverse-Effectpapilloedema and hepatic dysfunction while being treated with perhexiline maleate. |
| 0.9883 | A patient developed papilloedema and Adverse-Effecthepatic dysfunction while being treated with perhexiline maleate. |
| 0.9815 | A patient developed papilloedema and hepatic dysfunction while being treated with Drugperhexiline maleate . |
| Score | Text |
|---|---|
| 0.9866 | Adverse-EffectRestless legs syndrome may thus be an adverse effect of IFN alpha treatment. |
| 0.9825 | Restless legs syndrome may thus be an adverse effect of DrugIFN alpha treatment. |
| Score | Text |
|---|---|
| 0.9991 | The responsibility of DrugCCNU in the pathogenesis of pulmonary fibrosis seems very likely. |
| 0.9539 | The responsibility of CCNU in the pathogenesis of Adverse-Effectpulmonary fibrosis seems very likely. |
| Score | Text |
|---|---|
| 0.9705 | Indolent aspergillus arthritis complicating Drugfludarabine - based non - myeloablative stem cell transplantation. |
| 0.8868 | Indolent Adverse-Effectaspergillus arthritis complicating fludarabine - based non - myeloablative stem cell transplantation. |
| Score | Text |
|---|---|
| 0.9990 | This report suggests that Drugbleomycin lung toxicity may be reversible if treated aggressively. |
| 0.9037 | This report suggests that bleomycin Adverse-Effectlung toxicity may be reversible if treated aggressively. |
| Score | Text |
|---|---|
| 0.9988 | Three days after intravitreal injection of Drugbevacizumab , acute ocular ischemic syndrome occurred. |
| 0.9856 | Three days after intravitreal injection of bevacizumab, Adverse-Effectacute ocular ischemic syndrome occurred. |
| Score | Text |
|---|---|
| 0.9995 | PURPOSE : To report two cases of acute endophthalmitis following intravitreal Drugbevacizumab injection. |
| 0.9798 | PURPOSE : To report two cases of Adverse-Effectacute endophthalmitis following intravitreal bevacizumab injection. |
| Score | Text |
|---|---|
| 0.9984 | CONCLUSIONS : Amphotericin B seems to be the probable cause of the Adverse-Effectseizures . |
| 0.9789 | CONCLUSIONS : DrugAmphotericin B seems to be the probable cause of the seizures. |
| Score | Text |
|---|---|
| 0.9810 | Adverse-EffectAcute myocardial infarction due to coronary spasm associated with L - thyroxine therapy. |
| 0.9728 | Acute myocardial infarction due to Adverse-Effectcoronary spasm associated with L - thyroxine therapy. |
| 0.9665 | Acute myocardial infarction due to coronary spasm associated with DrugL - thyroxine therapy. |
| Score | Text |
|---|---|
| 0.9962 | Adverse-EffectHepatotoxicity of paracetamol enhanced by ingestion of alcohol : report of two cases. |
| 0.9957 | Hepatotoxicity of Drugparacetamol enhanced by ingestion of alcohol : report of two cases. |
| Score | Text |
|---|---|
| 0.9976 | Early overanticoagulation with Drugacenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9. |
| 0.9695 | Early Adverse-Effectoveranticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9. |
| Score | Text |
|---|---|
| 0.9994 | Acute pancreatitis is a known, although rare, complication of Drugmesalamine treatment. |
| 0.9247 | Adverse-EffectAcute pancreatitis is a known, although rare, complication of mesalamine treatment. |
| Score | Text |
|---|---|
| 0.9996 | DISCUSSION : The occurrence of priapism in our patient was related to Drugzuclopenthixol . |
| 0.9978 | DISCUSSION : The occurrence of Adverse-Effectpriapism in our patient was related to zuclopenthixol. |
| Score | Text |
|---|---|
| 0.9824 | Neurointensive care management of raised intracranial pressure caused by severe Drugvalproic acid intoxication. |
| 0.9816 | Neurointensive care management of Adverse-Effectraised intracranial pressure caused by severe valproic acid intoxication. |
| Score | Text |
|---|---|
| 0.9992 | A case of normotensive scleroderma renal crisis after high - dose Drugmethylprednisolone treatment. |
| 0.9752 | A case of Adverse-Effectnormotensive scleroderma renal crisis after high - dose methylprednisolone treatment. |
| Score | Text |
|---|---|
| 0.9976 | Adverse-EffectRhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride. |
| 0.9769 | Rhabdomyolysis has been recognized as a complication of tocolytic therapy with Drugritodrine hydrochloride . |
| Score | Text |
|---|---|
| 0.9995 | DrugIbuprofen - induced meningitis : detection of intrathecal IgG synthesis and immune complexes. |
| 0.9989 | Ibuprofen - induced Adverse-Effectmeningitis : detection of intrathecal IgG synthesis and immune complexes. |
| Score | Text |
|---|---|
| 0.9995 | Transtentorial herniation caused by an intracranial mass lesion following high - dose Drugmethotrexate . |
| 0.9864 | Adverse-EffectTranstentorial herniation caused by an intracranial mass lesion following high - dose methotrexate. |
| 0.9818 | Transtentorial herniation caused by an Adverse-Effectintracranial mass lesion following high - dose methotrexate. |
| Score | Text |
|---|---|
| 0.9993 | Neuroleptic malignant syndrome due to Drugrisperidone treatment in a child with Joubert syndrome. |
| 0.9856 | Adverse-EffectNeuroleptic malignant syndrome due to risperidone treatment in a child with Joubert syndrome. |
| Score | Text |
|---|---|
| 0.9900 | Adverse-EffectSkin necrosis after extravasation of low - dose vasopressin administered for septic shock. |
| 0.8688 | Skin necrosis after extravasation of low - dose Drugvasopressin administered for septic shock. |
| Score | Text |
|---|---|
| 0.9993 | Histological examination of the dacryolith suggested its derivation from breakdown products of Drugadrenaline . |
| 0.9945 | Histological examination of the Adverse-Effectdacryolith suggested its derivation from breakdown products of adrenaline. |
| Score | Text |
|---|---|
| 0.9626 | DrugItraconazole - related increased vincristine neurotoxicity : case report and review of literature. |
| 0.8687 | Itraconazole - related increased Drugvincristine neurotoxicity : case report and review of literature. |
| 0.8702 | Itraconazole - related increased vincristine Adverse-Effectneurotoxicity : case report and review of literature. |
| Itraconazole - related increased Adverse-Effectvincristine neurotoxicity : case report and review of literature. | |
| Score | Text |
|---|---|
| 0.9979 | Para - aminosalicylic acid - induced Adverse-Effecthypoglycaemia in a patient with diabetic nephropathy. |
| 0.9576 | DrugPara - aminosalicylic acid - induced hypoglycaemia in a patient with diabetic nephropathy. |
| Score | Text |
|---|---|
| 0.9979 | Prolonged severe Drug5 - fluorouracil - associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency. |
| 0.9963 | Prolonged severe 5 - fluorouracil - associated Adverse-Effectneurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency. |
| Score | Text |
|---|---|
| 0.9995 | BACKGROUND : reports on delated cutaneous reactions to Drugcaptopril have been seldom reported. |
| 0.9817 | BACKGROUND : reports on Adverse-Effectdelated cutaneous reactions to captopril have been seldom reported. |
| Score | Text |
|---|---|
| 0.9993 | Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with Drugnevirapine . |
| 0.9527 | Severe leukopenia associated with Adverse-Effectmild hepatotoxicity in an HIV carrier treated with nevirapine. |
| 0.9097 | Adverse-EffectSevere leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine. |
| Score | Text |
|---|---|
| 0.9986 | Adverse reaction in a patient with Drugaspirin - induced asthma treated with zafirlukast. |
| 0.9953 | Adverse reaction in a patient with aspirin - induced Adverse-Effectasthma treated with zafirlukast. |
| Score | Text |
|---|---|
| 0.9992 | Fatal complication of intravesical Drugformalin during control of intractable hemorrhage from radiation cystitis. |
| 0.9836 | Adverse-EffectFatal complication of intravesical formalin during control of intractable hemorrhage from radiation cystitis. |
| Score | Text |
|---|---|
| 0.9993 | Cerebral infarcts in a pediatric patient secondary to Drugphenylpropanolamine , a recalled medication. |
| 0.9908 | Adverse-EffectCerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication. |
| Score | Text |
|---|---|
| 0.9995 | A 45 - year - old woman with thyrotoxicosis developed agranulocytosis after treatment with Drugpropylthiouracil . |
| 0.9984 | A 45 - year - old woman with thyrotoxicosis developed Adverse-Effectagranulocytosis after treatment with propylthiouracil. |
| Score | Text |
|---|---|
| 0.9995 | Fatal interstitial lung disease after Drugerlotinib administration in a patient with radiation fibrosis. |
| 0.9839 | Adverse-EffectFatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis. |
| Score | Text |
|---|---|
| 0.9941 | Acute renal failure following intravenous Drugimmunoglobulin therapy in a HIV - infected patient. |
| 0.9768 | Adverse-EffectAcute renal failure following intravenous immunoglobulin therapy in a HIV - infected patient. |
| Score | Text |
|---|---|
| 0.9995 | Restless legs syndrome and periodic limb movements during sleep probably associated with Drugolanzapine . |
| 0.9892 | Adverse-EffectRestless legs syndrome and periodic limb movements during sleep probably associated with olanzapine. |
| 0.9815 | Restless legs syndrome and Adverse-Effectperiodic limb movements during sleep probably associated with olanzapine. |
| Score | Text |
|---|---|
| 0.9983 | Adverse-EffectPancytopenia associated with 5 - aminosalicylic acid use in a patient with Crohn's disease. |
| 0.9754 | Pancytopenia associated with Drug5 - aminosalicylic acid use in a patient with Crohn's disease. |
| Score | Text |
|---|---|
| 0.9995 | The authors report the first case of Drugbucillamine - induced giant mammary hyperplasia. |
| 0.9832 | The authors report the first case of bucillamine - induced Adverse-Effectgiant mammary hyperplasia . |
| Score | Text |
|---|---|
| 0.9995 | Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with Drughydroxyurea . |
| 0.9790 | Adverse-EffectAcute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea. |
| Score | Text |
|---|---|
| 0.9995 | There is no consensus on the treatment of Drugticlopidine - induced marrow aplasia. |
| 0.9942 | There is no consensus on the treatment of ticlopidine - induced Adverse-Effectmarrow aplasia . |
| Score | Text |
|---|---|
| 0.9996 | DrugRisperidone - induced psychosis and depression in a child with a mitochondrial disorder. |
| 0.9989 | Risperidone - induced Adverse-Effectpsychosis and depression in a child with a mitochondrial disorder. |
| 0.9819 | Risperidone - induced psychosis and Adverse-Effectdepression in a child with a mitochondrial disorder. |
| Score | Text |
|---|---|
| 0.9996 | Stevens - Johnson syndrome in a boy with nephrotic syndrome during Drugprednisolone therapy. |
| 0.9855 | Adverse-EffectStevens - Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy. |
| Score | Text |
|---|---|
| 0.9961 | Acyclovir - induced Adverse-Effectneurotoxicity : concentration - side effect relationship in acyclovir overdose. |
| 0.9915 | DrugAcyclovir - induced neurotoxicity : concentration - side effect relationship in acyclovir overdose. |
| Score | Text |
|---|---|
| 0.9992 | CONCLUSION : DrugAlendronate led to nodular scleritis and rechallenge caused recurrence of scleritis. |
| 0.9935 | CONCLUSION : Alendronate led to nodular scleritis and rechallenge caused recurrence of Adverse-Effectscleritis . |
| 0.9839 | CONCLUSION : Alendronate led to Adverse-Effectnodular scleritis and rechallenge caused recurrence of scleritis. |
| Score | Text |
|---|---|
| 0.9990 | Deposits of plasma proteins in the skin during treatment with Drugcarbamazepine and diphenylhydantoin. |
| 0.9989 | Deposits of plasma proteins in the skin during treatment with carbamazepine and Drugdiphenylhydantoin . |
| 0.9728 | Adverse-EffectDeposits of plasma proteins in the skin during treatment with carbamazepine and diphenylhydantoin. |
| Score | Text |
|---|---|
| 0.9968 | L - asparaginase - provoked Adverse-Effectseizures as singular expression of central nervous toxicity. |
| 0.9772 | L - asparaginase - provoked seizures as singular expression of Adverse-Effectcentral nervous toxicity . |
| 0.9667 | DrugL - asparaginase - provoked seizures as singular expression of central nervous toxicity. |
| Score | Text |
|---|---|
| 0.9994 | Provocation of non - convulsive status epilepticus by Drugtiagabine in three adolescent patients. |
| 0.9728 | Provocation of Adverse-Effectnon - convulsive status epilepticus by tiagabine in three adolescent patients. |
| Score | Text |
|---|---|
| 0.9995 | Nineteen cases of allergic contact dermatitis to compound tincture of Drugbenzoin are described. |
| 0.9797 | Nineteen cases of Adverse-Effectallergic contact dermatitis to compound tincture of benzoin are described. |
| Score | Text |
|---|---|
| 0.9993 | This case extends the spectrum of Drugfludarabine pulmonary toxicity to include pulmonary nodules. |
| 0.9856 | This case extends the spectrum of fludarabine pulmonary toxicity to include Adverse-Effectpulmonary nodules . |
| 0.6529 | This case extends the spectrum of fludarabine Adverse-Effectpulmonary toxicity to include pulmonary nodules. |
| Score | Text |
|---|---|
| 0.9995 | A case of oculogyric crisis induced by Drugmetoclopramide is described in this paper. |
| 0.9915 | A case of Adverse-Effectoculogyric crisis induced by metoclopramide is described in this paper. |
| Score | Text |
|---|---|
| 0.9736 | Clostridium difficile toxin - induced colitis after use of Drugclindamycin phosphate vaginal cream. |
| 0.5032 | Adverse-EffectClostridium difficile toxin - induced colitis after use of clindamycin phosphate vaginal cream. |
| 0.6029 | Clostridium difficile toxin - induced Adverse-Effectcolitis after use of clindamycin phosphate vaginal cream. |
| Score | Text |
|---|---|
| 0.9994 | CASE SUMMARIES : Two patients who received Drugifosfamide - containing chemotherapy developed NCSE. |
| 0.9987 | CASE SUMMARIES : Two patients who received ifosfamide - containing chemotherapy developed Adverse-EffectNCSE . |
| Score | Text |
|---|---|
| 0.9996 | The authors describe a case of the catatonia syndrome associated with Drugdisulfiram therapy. |
| 0.9944 | The authors describe a case of the Adverse-Effectcatatonia syndrome associated with disulfiram therapy. |
| Score | Text |
|---|---|
| 0.9992 | Prolonged prostate - specific antigen response in Drugflutamide withdrawal syndrome despite disease progression. |
| 0.9072 | Adverse-EffectProlonged prostate - specific antigen response in flutamide withdrawal syndrome despite disease progression. |
| Prolonged prostate - specific antigen response in Adverse-Effectflutamide withdrawal syndrome despite disease progression. | |
| Score | Text |
|---|---|
| 0.9859 | Anticonvulsant hypersensitivity syndrome associated with DrugBellamine S , a therapy for menopausal symptoms. |
| 0.9813 | Adverse-EffectAnticonvulsant hypersensitivity syndrome associated with Bellamine S, a therapy for menopausal symptoms. |
| Score | Text |
|---|---|
| 0.9964 | Two weeks following rechallenge with alendronate sodium resulted in recurrence of his Adverse-Effectscleritis . |
| 0.9857 | Two weeks following rechallenge with Drugalendronate sodium resulted in recurrence of his scleritis. |
| Score | Text |
|---|---|
| 0.9995 | One patient developed large intramural esophageal hematoma as a complication of Drugheparin therapy. |
| 0.9790 | One patient developed Adverse-Effectlarge intramural esophageal hematoma as a complication of heparin therapy. |
| Score | Text |
|---|---|
| 0.9987 | The patient was diagnosed with Drugcarbamazepine toxicity related to the introduction of ritonavir. |
| 0.9987 | The patient was diagnosed with carbamazepine toxicity related to the introduction of Drugritonavir . |
| 0.8788 | The patient was diagnosed with Adverse-Effectcarbamazepine toxicity related to the introduction of ritonavir. |
| Score | Text |
|---|---|
| 0.9833 | L - asparaginase - induced Adverse-Effectsevere necrotizing pancreatitis successfully treated with percutaneous drainage. |
| 0.9687 | DrugL - asparaginase - induced severe necrotizing pancreatitis successfully treated with percutaneous drainage. |
| Score | Text |
|---|---|
| 0.9995 | We present a case of a sustained monomorphic ventricular tachycardia following Drugadenosine infusion. |
| 0.9826 | We present a case of a Adverse-Effectsustained monomorphic ventricular tachycardia following adenosine infusion. |
| Score | Text |
|---|---|
| 0.9996 | Tremor : a newly described adverse event with long - term Drugitraconazole therapy. |
| 0.9991 | Adverse-EffectTremor : a newly described adverse event with long - term itraconazole therapy. |
| Score | Text |
|---|---|
| 0.9899 | We report 2 patients who developed Adverse-Effectpolyarteritis nodosa following vaccination against hepatitis B. |
| 0.9580 | We report 2 patients who developed polyarteritis nodosa following Drugvaccination against hepatitis B . |
| Score | Text |
|---|---|
| 0.9985 | Three patients receiving Druggold salt treatment for rheumatoid arthritis developed severe aplastic anemia. |
| 0.9692 | Three patients receiving gold salt treatment for rheumatoid arthritis developed severe Adverse-Effectaplastic anemia . |
| Score | Text |
|---|---|
| 0.9993 | Hemorrhage from a falx meningioma after internal use of low - dose Drugaspirin . |
| 0.9985 | Adverse-EffectHemorrhage from a falx meningioma after internal use of low - dose aspirin. |
| Score | Text |
|---|---|
| 0.9994 | DrugTemozolomide was restarted 2 months later ; the patient again developed a fever. |
| 0.9979 | Temozolomide was restarted 2 months later ; the patient again developed a Adverse-Effectfever . |
| Score | Text |
|---|---|
| 0.9994 | Renal injury due to Druganastrozole has not been published in the English literature. |
| 0.9938 | Adverse-EffectRenal injury due to anastrozole has not been published in the English literature. |
| Score | Text |
|---|---|
| 0.9996 | Mechanism of Drugtopiramate - induced acute - onset myopia and angle closure glaucoma. |
| 0.9799 | Mechanism of topiramate - induced acute - onset myopia and Adverse-Effectangle closure glaucoma . |
| 0.9686 | Mechanism of topiramate - induced Adverse-Effectacute - onset myopia and angle closure glaucoma. |
| Score | Text |
|---|---|
| 0.9991 | There is a putative role of Drugliothyronine administration in precipitating or activating hyperthyroidism. |
| 0.9928 | There is a putative role of liothyronine administration in precipitating or activating Adverse-Effecthyperthyroidism . |
| Score | Text |
|---|---|
| 0.9991 | She was treated with Drugacyclovir and subsequently developed VZV antigen - positive zoster. |
| 0.9838 | She was treated with acyclovir and subsequently developed Adverse-EffectVZV antigen - positive zoster . |
| Score | Text |
|---|---|
| 0.9993 | Clostridium difficile colitis associated with Drugcisplatin - based chemotherapy in ovarian cancer patients. |
| 0.9839 | Adverse-EffectClostridium difficile colitis associated with cisplatin - based chemotherapy in ovarian cancer patients. |
| Score | Text |
|---|---|
| 0.9995 | Polysomnographic and pharmacokinetic findings in Druglevodopa - induced augmentation of restless legs syndrome. |
| 0.9077 | Polysomnographic and pharmacokinetic findings in levodopa - induced augmentation of Adverse-Effectrestless legs syndrome . |
| Score | Text |
|---|---|
| 0.9995 | Pemphigus foliaceus was seen in a patient with pulmonary tuberculosis during Drugrifampicin therapy. |
| 0.9849 | Adverse-EffectPemphigus foliaceus was seen in a patient with pulmonary tuberculosis during rifampicin therapy. |
| Score | Text |
|---|---|
| 0.9988 | CONCLUSIONS : Intrathecal Drugbaclofen can impair sexual function and ejaculation in some patients. |
| 0.9588 | CONCLUSIONS : Intrathecal baclofen can Adverse-Effectimpair sexual function and ejaculation in some patients. |
| Score | Text |
|---|---|
| 0.9994 | Acute renal failure should be recognized as a potential complication of Drugsuramin treatment. |
| 0.9517 | Acute Adverse-Effectrenal failure should be recognized as a potential complication of suramin treatment. |
| Score | Text |
|---|---|
| 0.9996 | Lower extremity arterial thrombosis following sonographically guided Drugthrombin injection of a femoral pseudoaneurysm. |
| Lower extremity Adverse-Effectarterial thrombosis following sonographically guided thrombin injection of a femoral pseudoaneurysm. | |
| Score | Text |
|---|---|
| 0.9995 | EEG abnormalities were observed in two of the nine children during Drugchlorambucil therapy. |
| 0.9901 | Adverse-EffectEEG abnormalities were observed in two of the nine children during chlorambucil therapy. |
| Score | Text |
|---|---|
| 0.9993 | Schneiderian first - rank symptoms associated with Drugfluvoxamine treatment : a case report. |
| 0.9782 | Adverse-EffectSchneiderian first - rank symptoms associated with fluvoxamine treatment : a case report. |
| Score | Text |
|---|---|
| 0.9813 | Progression of chronic myeloid leukemia to Adverse-Effectblast crisis during treatment with imatinib mesylate. |
| 0.9654 | Progression of chronic myeloid leukemia to blast crisis during treatment with Drugimatinib mesylate . |
| Score | Text |
|---|---|
| 0.9996 | Anaphylaxis from Drugisoniazid is a possible side effect to this commonly prescribed antibiotic. |
| 0.9987 | Adverse-EffectAnaphylaxis from isoniazid is a possible side effect to this commonly prescribed antibiotic. |
| Score | Text |
|---|---|
| 0.9985 | Differential diagnoses included ocular rosacea with cicatrizing conjunctivitis and Drug5 - FU - induced ectropion. |
| 0.9980 | Differential diagnoses included ocular rosacea with cicatrizing conjunctivitis and 5 - FU - induced Adverse-Effectectropion . |
| Score | Text |
|---|---|
| 0.9956 | We report a case of Drugbaclofen withdrawal syndrome resulting from oral baclofen underdosing. |
| 0.9930 | We report a case of baclofen withdrawal syndrome resulting from oral Drugbaclofen underdosing. |
| 0.9734 | We report a case of baclofen Adverse-Effectwithdrawal syndrome resulting from oral baclofen underdosing. |
| Score | Text |
|---|---|
| 0.9994 | Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with Drugcyclosporine . |
| 0.9727 | Adverse-EffectReversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine. |
| Score | Text |
|---|---|
| 0.9992 | A MEDLINE search identified all the reported cases of hypersensitivity reactions to Drugcyclosporine . |
| 0.9809 | A MEDLINE search identified all the reported cases of Adverse-Effecthypersensitivity reactions to cyclosporine. |
| Score | Text |
|---|---|
| 0.9995 | The mechanism of RTA induced by DrugFK506 has not yet been clearly elucidated. |
| 0.9951 | The mechanism of Adverse-EffectRTA induced by FK506 has not yet been clearly elucidated. |
| Score | Text |
|---|---|
| 0.9995 | DrugMethysergide - induced retroperitoneal fibrosis : successful outcome and two new laboratory features. |
| 0.9888 | Methysergide - induced Adverse-Effectretroperitoneal fibrosis : successful outcome and two new laboratory features. |
| Score | Text |
|---|---|
| 0.9995 | Two renal transplant patients developed anemia during treatment of hypertension with Drugenalapril medication. |
| 0.9976 | Two renal transplant patients developed Adverse-Effectanemia during treatment of hypertension with enalapril medication. |
| Score | Text |
|---|---|
| 0.9994 | Thus, the eosinophilia myalgia syndrome can be associated with parenteral Drugtryptophan administration. |
| 0.9868 | Thus, the Adverse-Effecteosinophilia myalgia syndrome can be associated with parenteral tryptophan administration. |
| Score | Text |
|---|---|
| 0.9923 | When measured, the serum lithium level had increased 4 - fold during Drugacyclovir therapy. |
| 0.8116 | When measured, the serum Druglithium level had increased 4 - fold during acyclovir therapy. |
| When measured, the Adverse-Effectserum lithium level had increased 4 - fold during acyclovir therapy. | |
| Score | Text |
|---|---|
| 0.9996 | We report a case of papillary necrosis in a patient treated with Drugindinavir . |
| 0.9905 | We report a case of Adverse-Effectpapillary necrosis in a patient treated with indinavir. |
| Score | Text |
|---|---|
| 0.9995 | DrugFluoxetine - related death in a child with cytochrome P - 450 2D6 genetic deficiency. |
| 0.9897 | Fluoxetine - related Adverse-Effectdeath in a child with cytochrome P - 450 2D6 genetic deficiency. |
| Score | Text |
|---|---|
| 0.9995 | Visual loss after a single small dose of Drugvincristine has never been reported. |
| 0.9953 | Adverse-EffectVisual loss after a single small dose of vincristine has never been reported. |
| Score | Text |
|---|---|
| 0.9989 | Laryngeal dyspnea in relation to an interaction between Drugacenocoumarol and topical econazole lotion. |
| 0.9988 | Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical Drugeconazole lotion. |
| 0.9901 | Adverse-EffectLaryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion. |
| Score | Text |
|---|---|
| 0.9992 | PURPOSE : To report that acute Druglamotrigine poisoning may result in severe encephalopathy. |
| 0.6888 | PURPOSE : To report that acute lamotrigine poisoning may result in severe Adverse-Effectencephalopathy . |
| Score | Text |
|---|---|
| 0.9995 | RESULTS : Extensive squamous metaplasia was found in endometrial glands following Drugprogestin therapy. |
| 0.9392 | RESULTS : Extensive Adverse-Effectsquamous metaplasia was found in endometrial glands following progestin therapy. |
| Score | Text |
|---|---|
| 0.9967 | They continued to rise for five more days before Drugsalicylate hepatotoxicity was suspected. |
| 0.9201 | They continued to rise for five more days before salicylate Adverse-Effecthepatotoxicity was suspected. |
| Score | Text |
|---|---|
| 0.9996 | OBJECTIVE : To describe a patient with Drugifosfamide - induced nonconvulsive status epilepticus. |
| 0.9861 | OBJECTIVE : To describe a patient with ifosfamide - induced Adverse-Effectnonconvulsive status epilepticus . |
| Score | Text |
|---|---|
| 0.9986 | After four months, while receiving DrugRH , he developed painful bilateral gynaecomastia. |
| 0.9737 | After four months, while receiving RH, he developed painful Adverse-Effectbilateral gynaecomastia . |
| Score | Text |
|---|---|
| 0.9995 | Five cases of Drugclindamycin - associated pseudomembranous colitis in leukaemic patients are reported. |
| 0.9915 | Five cases of clindamycin - associated Adverse-Effectpseudomembranous colitis in leukaemic patients are reported. |
| Score | Text |
|---|---|
| 0.9909 | Trimethoprim - sulfamethoxazole - induced Adverse-Effecthypersensitivity syndrome associated with reactivation of human herpesvirus - 6. |
| 0.8872 | DrugTrimethoprim - sulfamethoxazole - induced hypersensitivity syndrome associated with reactivation of human herpesvirus - 6. |
| Score | Text |
|---|---|
| 0.9994 | However, several case reports have suggested that Drugclozapine could also cause TD. |
| 0.9962 | However, several case reports have suggested that clozapine could also cause Adverse-EffectTD . |
| Score | Text |
|---|---|
| 0.9974 | Atrial fibrillation occurring in a patient taking etanercept plus Drugmethotrexate for rheumatoid arthritis. |
| 0.9965 | Atrial fibrillation occurring in a patient taking Drugetanercept plus methotrexate for rheumatoid arthritis. |
| 0.9923 | Adverse-EffectAtrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis. |
| Score | Text |
|---|---|
| 0.9994 | RESULTS : All cases developed corneal endothelial deposits after previous use of Drugrifabutin . |
| 0.9873 | RESULTS : All cases developed Adverse-Effectcorneal endothelial deposits after previous use of rifabutin. |
| Score | Text |
|---|---|
| 0.9995 | We report a case of RTA secondary to DrugFK506 administration in liver transplantation. |
| 0.9982 | We report a case of Adverse-EffectRTA secondary to FK506 administration in liver transplantation. |
| Score | Text |
|---|---|
| 0.9986 | An adverse reaction to IFN was strongly suspected as the cause of Adverse-EffectCHF . |
| 0.9947 | An adverse reaction to DrugIFN was strongly suspected as the cause of CHF. |
| Score | Text |
|---|---|
| 0.9973 | Both PAN and Drugmethotrexate have been independently demonstrated to cause sensorineural hearing loss. |
| 0.9904 | Both PAN and methotrexate have been independently demonstrated to cause Adverse-Effectsensorineural hearing loss . |
| 0.9758 | Both DrugPAN and methotrexate have been independently demonstrated to cause sensorineural hearing loss. |
| Score | Text |
|---|---|
| 0.9994 | CONCLUSIONS : DrugAnastrozole may be the causative factor in patients with sclerosing glomerulonephritis. |
| 0.8516 | CONCLUSIONS : Anastrozole may be the causative factor in patients with Adverse-Effectsclerosing glomerulonephritis . |
| Score | Text |
|---|---|
| 0.9824 | Adverse-EffectThrombotic thrombocytopenic purpura induced by trimethoprim - sulfamethoxazole in a Jehovah's Witness. |
| 0.9625 | Thrombotic thrombocytopenic purpura induced by Drugtrimethoprim - sulfamethoxazole in a Jehovah's Witness. |
| 0.9102 | Thrombotic thrombocytopenic purpura induced by trimethoprim - Drugsulfamethoxazole in a Jehovah's Witness. |
| Score | Text |
|---|---|
| 0.9995 | Subacute cholestatic hepatitis likely related to the use of Drugsenna for chronic constipation. |
| 0.9728 | Adverse-EffectSubacute cholestatic hepatitis likely related to the use of senna for chronic constipation. |
| Score | Text |
|---|---|
| 0.9995 | Acute myocardial infarction during high - dose Drugmethylprednisolone therapy for Graves'ophthalmopathy. |
| 0.9830 | Adverse-EffectAcute myocardial infarction during high - dose methylprednisolone therapy for Graves'ophthalmopathy. |
| Score | Text |
|---|---|
| 0.9996 | Only 3 cases of Drugimatinib - induced tumor lysis syndrome have been reported. |
| 0.9866 | Only 3 cases of imatinib - induced Adverse-Effecttumor lysis syndrome have been reported. |
| Score | Text |
|---|---|
| 0.9992 | DrugCiprofloxacin - induced toxic epidermal necrolysis in a patient with systemic lupus erythematosus. |
| 0.9847 | Ciprofloxacin - induced Adverse-Effecttoxic epidermal necrolysis in a patient with systemic lupus erythematosus. |
| Score | Text |
|---|---|
| 0.9995 | OBJECTIVE : To report two cases of fixed drug eruption induced by Drugmethylphenidate . |
| 0.9535 | OBJECTIVE : To report two cases of Adverse-Effectfixed drug eruption induced by methylphenidate. |
| Score | Text |
|---|---|
| 0.9971 | Concomitant administration of lithium with olanzapine may place patients at risk for Adverse-EffectNMS . |
| 0.9846 | Concomitant administration of lithium with Drugolanzapine may place patients at risk for NMS. |
| 0.9774 | Concomitant administration of Druglithium with olanzapine may place patients at risk for NMS. |
| Score | Text |
|---|---|
| 0.9993 | METHODS : Three patients with apparent Drugitraconazole - induced liver injury were studied. |
| 0.9939 | METHODS : Three patients with apparent itraconazole - induced Adverse-Effectliver injury were studied. |
| Score | Text |
|---|---|
| 0.9995 | Clinical profile of Drugoxcarbazepine - related angioneurotic edema : case report and review. |
| 0.9922 | Clinical profile of oxcarbazepine - related Adverse-Effectangioneurotic edema : case report and review. |
| Score | Text |
|---|---|
| 0.9994 | Our series of 3 patients supports a causal connection between Drugbleomycin and scleroderma. |
| 0.9944 | Our series of 3 patients supports a causal connection between bleomycin and Adverse-Effectscleroderma . |
| Score | Text |
|---|---|
| 0.9995 | It is concluded that SIADH is an important side effect of Druglorcainide therapy. |
| 0.9978 | It is concluded that Adverse-EffectSIADH is an important side effect of lorcainide therapy. |
| Score | Text |
|---|---|
| 0.9994 | Treatment - related myelodysplastic syndrome after Drugtemozolomide for recurrent high - grade glioma. |
| 0.9903 | Treatment - related Adverse-Effectmyelodysplastic syndrome after temozolomide for recurrent high - grade glioma. |
| Score | Text |
|---|---|
| 0.9806 | Adverse-EffectSustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C. |
| 0.9626 | Sustained hypothyroidism induced by Drugrecombinant alpha interferon in patients with chronic hepatitis C. |
| Score | Text |
|---|---|
| 0.9995 | Leukopenia due to parvovirus B19 in a Crohn's disease patient using Drugazathioprine . |
| 0.9988 | Adverse-EffectLeukopenia due to parvovirus B19 in a Crohn's disease patient using azathioprine. |
| Score | Text |
|---|---|
| 0.9988 | DrugBleomycin and cyclophosphamide toxicity simulating metastatic nodules to the lungs in childhood cancer. |
| 0.9986 | Bleomycin and Drugcyclophosphamide toxicity simulating metastatic nodules to the lungs in childhood cancer. |
| 0.9760 | Bleomycin and cyclophosphamide toxicity simulating Adverse-Effectmetastatic nodules to the lungs in childhood cancer. |
| Score | Text |
|---|---|
| 0.9994 | DrugVerapamil in effort - induced angina pectoris in patients with normal coronary arteries. |
| 0.9914 | Verapamil in effort - induced Adverse-Effectangina pectoris in patients with normal coronary arteries. |
| Score | Text |
|---|---|
| 0.9959 | This is the first report of DrugUFT - induced scleroderma - like reaction. |
| 0.9812 | This is the first report of UFT - induced Adverse-Effectscleroderma - like reaction . |
| This is the first report of Adverse-EffectUFT - induced scleroderma - like reaction . | |
| Score | Text |
|---|---|
| 0.9989 | Self - limited edema is a well - recognized complication of Druginsulin therapy. |
| 0.9831 | Adverse-EffectSelf - limited edema is a well - recognized complication of insulin therapy. |
| Score | Text |
|---|---|
| 0.9953 | Celiac disease onset after pegylated interferon and Drugribavirin treatment of chronic hepatitis C. |
| 0.9932 | Adverse-EffectCeliac disease onset after pegylated interferon and ribavirin treatment of chronic hepatitis C. |
| 0.9777 | Celiac disease onset after Drugpegylated interferon and ribavirin treatment of chronic hepatitis C. |
| Score | Text |
|---|---|
| 0.9996 | Sexual dysfunction associated with intrathecal Drugbaclofen use : a report of two cases. |
| 0.9899 | Adverse-EffectSexual dysfunction associated with intrathecal baclofen use : a report of two cases. |
| Score | Text |
|---|---|
| 0.9972 | Adverse-EffectScleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta - 1a. |
| 0.9755 | Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on Druginterferon beta - 1a . |
| Score | Text |
|---|---|
| 0.9996 | The cases of DrugCBZ - induced SLE reported in the literature were reviewed. |
| 0.9988 | The cases of CBZ - induced Adverse-EffectSLE reported in the literature were reviewed. |
| Score | Text |
|---|---|
| 0.9995 | Treatment of Drugcarbimazole - induced agranulocytosis and sepsis with granulocyte colony stimulating factor. |
| 0.9976 | Treatment of carbimazole - induced Adverse-Effectagranulocytosis and sepsis with granulocyte colony stimulating factor. |
| 0.9962 | Treatment of carbimazole - induced agranulocytosis and Adverse-Effectsepsis with granulocyte colony stimulating factor. |
| Score | Text |
|---|---|
| 0.9989 | Early peritoneal dialysis has not previously been reported for Druglisinopril induced multiorgan failure. |
| 0.9910 | Early peritoneal dialysis has not previously been reported for lisinopril induced Adverse-Effectmultiorgan failure . |
| Score | Text |
|---|---|
| 0.9995 | DrugCyclosporine - induced pain syndrome in a child undergoing hematopoietic stem cell transplant. |
| 0.9923 | Cyclosporine - induced Adverse-Effectpain syndrome in a child undergoing hematopoietic stem cell transplant. |
| Score | Text |
|---|---|
| 0.9994 | DrugBaclofen withdrawal : a cause of prolonged fever in the intensive care unit. |
| 0.9891 | Baclofen withdrawal : a cause of prolonged Adverse-Effectfever in the intensive care unit. |
| Score | Text |
|---|---|
| 0.9996 | Generalised cutaneous rash associated with Drugganciclovir therapy has rarely been reported in literature. |
| 0.9843 | Adverse-EffectGeneralised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature. |
| Score | Text |
|---|---|
| 0.9994 | DrugValproate embryopathy in three sets of siblings : further proof of hereditary susceptibility. |
| 0.8735 | Valproate Adverse-Effectembryopathy in three sets of siblings : further proof of hereditary susceptibility. |
| Adverse-EffectValproate embryopathy in three sets of siblings : further proof of hereditary susceptibility. | |
| Score | Text |
|---|---|
| 0.9996 | Granulocytopenia and agranulocytosis are considered among the most dangerous adverse effects of Drugclozapine . |
| 0.9979 | Granulocytopenia and Adverse-Effectagranulocytosis are considered among the most dangerous adverse effects of clozapine. |
| 0.9977 | Adverse-EffectGranulocytopenia and agranulocytosis are considered among the most dangerous adverse effects of clozapine. |
| Score | Text |
|---|---|
| 0.9995 | The observations suggest that testicular swelling and pain are side effects of Drugdesipramine . |
| 0.9899 | The observations suggest that Adverse-Effecttesticular swelling and pain are side effects of desipramine. |
| 0.9877 | The observations suggest that testicular swelling and Adverse-Effectpain are side effects of desipramine. |
| Score | Text |
|---|---|
| 0.9896 | Adverse-EffectNeurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency. |
| 0.9895 | Neurologic degeneration associated with Drugnitrous oxide anesthesia in patients with vitamin B12 deficiency. |
| Score | Text |
|---|---|
| 0.9994 | This is the first report of a disulfiram - like reaction with Drugcefmenoxime . |
| 0.9820 | This is the first report of a Adverse-Effectdisulfiram - like reaction with cefmenoxime. |
| Score | Text |
|---|---|
| 0.9995 | METHODS : We report two cases of pseudoporphyria caused by Drugnaproxen and oxaprozin. |
| 0.9994 | METHODS : We report two cases of pseudoporphyria caused by naproxen and Drugoxaprozin . |
| 0.9978 | METHODS : We report two cases of Adverse-Effectpseudoporphyria caused by naproxen and oxaprozin. |
| Score | Text |
|---|---|
| 0.9885 | A case of Adverse-Effectcontact dermatitis due to sodium bisulfite in an ophthalmic solution. |
| 0.9870 | A case of contact dermatitis due to Drugsodium bisulfite in an ophthalmic solution. |
| Score | Text |
|---|---|
| 0.9920 | The authors report 2 cases of Adverse-Effectrenal damage associated with lithium carbonate treatment. |
| 0.9847 | The authors report 2 cases of renal damage associated with Druglithium carbonate treatment. |
| Score | Text |
|---|---|
| 0.9993 | Cutaneous rashes and eruptions can be caused by many medications, including Drugcarbamazepine . |
| 0.9979 | Cutaneous rashes and Adverse-Effecteruptions can be caused by many medications, including carbamazepine. |
| 0.9925 | Adverse-EffectCutaneous rashes and eruptions can be caused by many medications, including carbamazepine. |
| Score | Text |
|---|---|
| 0.9991 | Acute generalized exanthematous pustulosis induced by Drugsalazosulfapyridine in a patient with ulcerative colitis. |
| 0.9722 | Adverse-EffectAcute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis. |
| Score | Text |
|---|---|
| 0.9993 | Possible linkage of Drugamprenavir with intracranial bleeding in an HIV - infected hemophiliac. |
| 0.9783 | Possible linkage of amprenavir with Adverse-Effectintracranial bleeding in an HIV - infected hemophiliac. |
| Score | Text |
|---|---|
| 0.9995 | DrugTamoxifen is suggested to be carcinogenic both through direct genotoxic and epigenetic mechanisms. |
| 0.9955 | Tamoxifen is suggested to be Adverse-Effectcarcinogenic both through direct genotoxic and epigenetic mechanisms. |
| Score | Text |
|---|---|
| 0.9976 | Clearance rates of cerivastatin metabolites in a patient with cerivastatin - induced Adverse-Effectrhabdomyolysis . |
| 0.9794 | Clearance rates of cerivastatin metabolites in a patient with Drugcerivastatin - induced rhabdomyolysis. |
| Score | Text |
|---|---|
| 0.9996 | Two cases of Drugsirolimus - associated pneumonitis have been reported after cardiac transplantation. |
| 0.9982 | Two cases of sirolimus - associated Adverse-Effectpneumonitis have been reported after cardiac transplantation. |
| Score | Text |
|---|---|
| 0.9995 | Seizures and transient blindness following intravenous pulse Drugmethylprednisolone in children with primary glomerulonephritis. |
| 0.9983 | Adverse-EffectSeizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis. |
| 0.9906 | Seizures and Adverse-Effecttransient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis. |
| Score | Text |
|---|---|
| 0.9993 | We conclude that MB is an effective treatment for Drugifosfamide - induced encephalopathy. |
| 0.9968 | We conclude that MB is an effective treatment for ifosfamide - induced Adverse-Effectencephalopathy . |
| We conclude that MB is an effective treatment for Adverse-Effectifosfamide - induced encephalopathy . | |
| Score | Text |
|---|---|
| 0.9995 | Possible heart failure exacerbation associated with Drugrosiglitazone : case report and literature review. |
| 0.9810 | Possible Adverse-Effectheart failure exacerbation associated with rosiglitazone : case report and literature review. |
| Score | Text |
|---|---|
| 0.9962 | Acute interstitial pneumonia induced by ONO - 1078 ( Drugpranlukast ), a leukotriene receptor antagonist. |
| 0.9812 | Acute interstitial pneumonia induced by DrugONO - 1078 ( pranlukast ), a leukotriene receptor antagonist. |
| 0.9551 | Adverse-EffectAcute interstitial pneumonia induced by ONO - 1078 ( pranlukast ), a leukotriene receptor antagonist. |
| Acute Adverse-Effectinterstitial pneumonia induced by ONO - 1078 ( pranlukast ), a leukotriene receptor antagonist. | |
| Score | Text |
|---|---|
| 0.9994 | A 48 - year - old woman who was treated for thyrotoxicosis with Drugmethimazole developed agranulocytosis. |
| 0.9980 | A 48 - year - old woman who was treated for thyrotoxicosis with methimazole developed Adverse-Effectagranulocytosis . |
| Score | Text |
|---|---|
| 0.9978 | Rapid resolution of topiramate - induced angle - closure glaucoma with Drugmethylprednisolone and mannitol. |
| 0.9977 | Rapid resolution of topiramate - induced angle - closure glaucoma with methylprednisolone and Drugmannitol . |
| 0.9964 | Rapid resolution of Drugtopiramate - induced angle - closure glaucoma with methylprednisolone and mannitol. |
| 0.9840 | Rapid resolution of topiramate - induced Adverse-Effectangle - closure glaucoma with methylprednisolone and mannitol. |
| Score | Text |
|---|---|
| 0.9974 | Adverse-EffectRetinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin. |
| 0.9934 | Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and Drugribavirin . |
| 0.9782 | Retinopathy in hepatitis C patients due to combination therapy with Drugpegylated interferon and ribavirin. |
| Score | Text |
|---|---|
| 0.9985 | However, DrugEO - induced noncardiogenic pulmonary edema has not been reported in human. |
| 0.9868 | However, EO - induced Adverse-Effectnoncardiogenic pulmonary edema has not been reported in human. |
| Score | Text |
|---|---|
| 0.9995 | A case is reported of a child with fatal pulmonary fibrosis following DrugBCNU therapy. |
| 0.9795 | A case is reported of a child with Adverse-Effectfatal pulmonary fibrosis following BCNU therapy. |
| Score | Text |
|---|---|
| 0.9996 | Fatal interstitial pneumonitis following high - dose intermittent Drugchlorambucil therapy for chronic lymphocyte leukemia. |
| 0.9845 | Adverse-EffectFatal interstitial pneumonitis following high - dose intermittent chlorambucil therapy for chronic lymphocyte leukemia. |
| Score | Text |
|---|---|
| 0.9993 | Anaphylactic reaction to oral Drugprednisone : a case report and review of the literature. |
| 0.9899 | Adverse-EffectAnaphylactic reaction to oral prednisone : a case report and review of the literature. |
| Score | Text |
|---|---|
| 0.9995 | The following is a report of 2 cases of Drugrifampicin - induced renal insufficiency. |
| 0.9912 | The following is a report of 2 cases of rifampicin - induced Adverse-Effectrenal insufficiency . |
| Score | Text |
|---|---|
| 0.9991 | High - dose Drugmethotrexate - associated acute renal failure may be an avoidable complication. |
| 0.9846 | High - dose methotrexate - associated Adverse-Effectacute renal failure may be an avoidable complication. |
| Score | Text |
|---|---|
| 0.9993 | CONCLUSIONS : Fixed drug rash induced by Drugmethylphenidate is a possible but rare phenomenon. |
| 0.9638 | CONCLUSIONS : Adverse-EffectFixed drug rash induced by methylphenidate is a possible but rare phenomenon. |
| Score | Text |
|---|---|
| 0.9996 | Here, we report a case of angio - oedema associated with DrugVRC therapy. |
| 0.9870 | Here, we report a case of Adverse-Effectangio - oedema associated with VRC therapy. |
| Score | Text |
|---|---|
| 0.9995 | DrugMethotrexate - induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis. |
| 0.9920 | Methotrexate - induced Adverse-Effecthepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis. |
| Score | Text |
|---|---|
| 0.9995 | Scleroderma in association with the use of Drugbleomycin : a report of 3 cases. |
| 0.9980 | Adverse-EffectScleroderma in association with the use of bleomycin : a report of 3 cases. |
| Score | Text |
|---|---|
| 0.9989 | DrugVoriconazole ( VRC ) has not previously been reported to cause angio - oedema. |
| 0.9984 | Voriconazole ( DrugVRC ) has not previously been reported to cause angio - oedema. |
| 0.9867 | Voriconazole ( VRC ) has not previously been reported to cause Adverse-Effectangio - oedema . |
| Score | Text |
|---|---|
| 0.9994 | Five days after the fourth dose of Drugvincristine , she presented with bilateral ptosis. |
| 0.9947 | Five days after the fourth dose of vincristine, she presented with Adverse-Effectbilateral ptosis . |
| Score | Text |
|---|---|
| 0.9986 | However, repeated intracameral DrugtPA injections may cause unwanted complications such as vitreous hemorrhage. |
| 0.9910 | However, repeated intracameral tPA injections may cause unwanted complications such as Adverse-Effectvitreous hemorrhage . |
| Score | Text |
|---|---|
| 0.9815 | Oral 25 - hydroxyvitain D3 in treatment of osteomalacia associated with Adverse-Effectileal resection and cholestyramine therapy. |
| 0.9635 | Oral Drug25 - hydroxyvitain D3 in treatment of osteomalacia associated with ileal resection and cholestyramine therapy. |
| Score | Text |
|---|---|
| 0.9987 | Sideroblastic anemia due to Druglinezolid in a patient with a left ventricular assist device. |
| 0.9914 | Adverse-EffectSideroblastic anemia due to linezolid in a patient with a left ventricular assist device. |
| Score | Text |
|---|---|
| 0.9993 | Idiosyncratic pulmonary reactions to Drugnitrofurantoin are not unusual, often presenting as eosinophilic pneumonia. |
| 0.9796 | Adverse-EffectIdiosyncratic pulmonary reactions to nitrofurantoin are not unusual, often presenting as eosinophilic pneumonia. |
| 0.9693 | Idiosyncratic pulmonary reactions to nitrofurantoin are not unusual, often presenting as Adverse-Effecteosinophilic pneumonia . |
| Score | Text |
|---|---|
| 0.9994 | Hepatotoxicity resolved once Drugerlotinib was discontinued and serum transaminases returned to baseline normal values. |
| 0.9975 | Adverse-EffectHepatotoxicity resolved once erlotinib was discontinued and serum transaminases returned to baseline normal values. |
| Score | Text |
|---|---|
| 0.9995 | A patient with acute changes suggesting acute hepatitis after parenteral Drugamiodarone administration is described. |
| 0.9881 | A patient with acute changes suggesting Adverse-Effectacute hepatitis after parenteral amiodarone administration is described. |
| Score | Text |
|---|---|
| 0.9977 | Adverse-EffectCardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin - D and mithramycin. |
| 0.9518 | Cardiomyopathy after widely separated courses of Drugadriamycin exacerbated by actinomycin - D and mithramycin. |
| 0.9309 | Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin - D and Drugmithramycin . |
| 0.9296 | Cardiomyopathy after widely separated courses of adriamycin exacerbated by Drugactinomycin - D and mithramycin. |
| Score | Text |
|---|---|
| 0.9904 | Because Adverse-Effectnephrotic syndrome may be induced by IFN therapy, the IFN was stopped. |
| 0.9561 | Because nephrotic syndrome may be induced by IFN therapy, the DrugIFN was stopped. |
| 0.9559 | Because nephrotic syndrome may be induced by DrugIFN therapy, the IFN was stopped. |
| Score | Text |
|---|---|
| 0.9995 | Decreased plasma cortisol level during Drugalprazolam treatment of panic disorder : a case report. |
| 0.9715 | Adverse-EffectDecreased plasma cortisol level during alprazolam treatment of panic disorder : a case report. |
| Score | Text |
|---|---|
| 0.9992 | Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of Drugdoxorubicin . |
| 0.9825 | Neurological improvement and rehabilitation potential following Adverse-Effecttoxic myelopathy due to intrathecal injection of doxorubicin. |
| Score | Text |
|---|---|
| 0.9994 | Persistent hypoglycemia in a patient with diabetes taking Drugetanercept for the treatment of psoriasis. |
| 0.9807 | Adverse-EffectPersistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis. |
| Score | Text |
|---|---|
| 0.9986 | An unusual cause of burn injury : unsupervised use of drugs that contain Adverse-Effectpsoralens . |
| 0.8276 | An unusual cause of Adverse-Effectburn injury : unsupervised use of drugs that contain psoralens. |
| An unusual cause of Drugburn injury : unsupervised use of drugs that contain psoralens. | |
| Score | Text |
|---|---|
| 0.9990 | Intravenous Drughaloperidol is generally well tolerated, but multiform ventricular tachycardia has been reported. |
| 0.9661 | Intravenous haloperidol is generally well tolerated, but Adverse-Effectmultiform ventricular tachycardia has been reported. |
| Score | Text |
|---|---|
| 0.9992 | When DrugDSCG was withdrawn, urticaria vanished and the child remained symptom - free. |
| 0.9975 | When DSCG was withdrawn, Adverse-Effecturticaria vanished and the child remained symptom - free. |
| Score | Text |
|---|---|
| 0.9700 | Growth and adrenal suppression in asthmatic children treated with high - dose Drugfluticasone propionate . |
| 0.9397 | Adverse-EffectGrowth and adrenal suppression in asthmatic children treated with high - dose fluticasone propionate. |
| Score | Text |
|---|---|
| 0.9991 | Development of Crohn's disease in a patient with multiple sclerosis treated with Drugcopaxone . |
| 0.9826 | Development of Adverse-EffectCrohn's disease in a patient with multiple sclerosis treated with copaxone. |
| Score | Text |
|---|---|
| 0.9985 | A young woman developed Adverse-Effectgalactorrhea during treatment with a new dibenzoxazepine antidepressant, amoxapine. |
| 0.9941 | A young woman developed galactorrhea during treatment with a new dibenzoxazepine antidepressant, Drugamoxapine . |
| 0.9679 | A young woman developed galactorrhea during treatment with a new Drugdibenzoxazepine antidepressant, amoxapine. |
| Score | Text |
|---|---|
| 0.9991 | Central pontine myelinolysis manifested by temporary blindness : a possible complication of Druglithium toxicity. |
| 0.9853 | Central pontine myelinolysis manifested by Adverse-Effecttemporary blindness : a possible complication of lithium toxicity. |
| Adverse-EffectCentral pontine myelinolysis manifested by temporary blindness : a possible complication of lithium toxicity. | |
| Score | Text |
|---|---|
| 0.9995 | Skin manifestations of a case of Drugphenylbutazone - induced serum sickness - like reactions. |
| 0.9821 | Adverse-EffectSkin manifestations of a case of phenylbutazone - induced serum sickness - like reactions. |
| 0.9785 | Skin manifestations of a case of phenylbutazone - induced Adverse-Effectserum sickness - like reactions . |
| Score | Text |
|---|---|
| 0.9996 | Cardiac arrest after Drugesmolol administration : a review of acute beta - blocker toxicity. |
| 0.9946 | Adverse-EffectCardiac arrest after esmolol administration : a review of acute beta - blocker toxicity. |
| Score | Text |
|---|---|
| 0.9985 | The nephrotic syndrome developed in a patient receiving therapy with Druggold for rheumatoid arthritis. |
| 0.9949 | The Adverse-Effectnephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis. |
| Score | Text |
|---|---|
| 0.9989 | Adverse-EffectVitiligo associated with alpha - interferon in a patient with chronic active hepatitis C. |
| 0.9533 | Vitiligo associated with Drugalpha - interferon in a patient with chronic active hepatitis C. |
| Score | Text |
|---|---|
| 0.9982 | All - trans retinoic acid - induced focal myositis, synovitis, and Adverse-Effectmononeuritis . |
| 0.9973 | All - trans retinoic acid - induced focal myositis, Adverse-Effectsynovitis , and mononeuritis. |
| 0.9898 | All - trans retinoic acid - induced Adverse-Effectfocal myositis , synovitis, and mononeuritis. |
| 0.9563 | DrugAll - trans retinoic acid - induced focal myositis, synovitis, and mononeuritis. |
| Score | Text |
|---|---|
| 0.9866 | Subcutaneous DrugIL - 2 is safe and well tolerated, with a mortality rate < 3 %. |
| Subcutaneous IL - 2 is safe and well tolerated, with a Adverse-Effectmortality rate < 3 %. | |
| Score | Text |
|---|---|
| 0.9995 | We report a case of IDDM which occurred during Druginterferon therapy for chronic hepatitis. |
| 0.9988 | We report a case of Adverse-EffectIDDM which occurred during interferon therapy for chronic hepatitis. |
| Score | Text |
|---|---|
| 0.9996 | Severe autoimmune hemolytic anemia following Drugrituximab therapy in a patient with a lymphoproliferative disorder. |
| 0.8827 | Adverse-EffectSevere autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder. |
| Severe Adverse-Effectautoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder. | |
| Score | Text |
|---|---|
| 0.9988 | CCBs should be considered in the treatment of 5 - FU or capecitabine - induced Adverse-Effectheadaches . |
| 0.9951 | CCBs should be considered in the treatment of 5 - FU or Drugcapecitabine - induced headaches. |
| 0.9899 | CCBs should be considered in the treatment of Drug5 - FU or capecitabine - induced headaches. |
| Score | Text |
|---|---|
| 0.9995 | She developed a severe urticarial rash 3 weeks following initiation of therapy with DrugEnoxaparin . |
| 0.9855 | She developed a Adverse-Effectsevere urticarial rash 3 weeks following initiation of therapy with Enoxaparin. |
| Score | Text |
|---|---|
| 0.9995 | Three months after starting Drugcitalopram , she experienced episodes of chest tightness and dizziness. |
| 0.9980 | Three months after starting citalopram, she experienced episodes of chest tightness and Adverse-Effectdizziness . |
| 0.9936 | Three months after starting citalopram, she experienced episodes of Adverse-Effectchest tightness and dizziness. |
| Score | Text |
|---|---|
| 0.9996 | Interstitial pneumonia probably associated with Drugsorafenib treatment : An alert of an adverse event. |
| 0.9880 | Adverse-EffectInterstitial pneumonia probably associated with sorafenib treatment : An alert of an adverse event. |
| Score | Text |
|---|---|
| 0.9991 | Detection of activated eosinophils in nasal polyps of an Drugaspirin - induced asthma patient. |
| 0.9976 | Detection of activated eosinophils in nasal polyps of an aspirin - induced Adverse-Effectasthma patient. |
| Score | Text |
|---|---|
| 0.9885 | Toxic epidermal necrolysis resulted after 19 days of treatment with Drug5 - fluorocytosine and amphotericin B. |
| 0.9863 | Adverse-EffectToxic epidermal necrolysis resulted after 19 days of treatment with 5 - fluorocytosine and amphotericin B. |
| 0.9826 | Toxic epidermal necrolysis resulted after 19 days of treatment with 5 - fluorocytosine and Drugamphotericin B . |
| Score | Text |
|---|---|
| 0.9995 | A case of severe aplastic anemia secondary to treatment with Druglenalidomide for multiple myeloma. |
| 0.9766 | A case of Adverse-Effectsevere aplastic anemia secondary to treatment with lenalidomide for multiple myeloma. |
| Score | Text |
|---|---|
| 0.9996 | Hepatic angiosarcoma occurring after Drugcyclophosphamide therapy : case report and review of the literature. |
| 0.9867 | Adverse-EffectHepatic angiosarcoma occurring after cyclophosphamide therapy : case report and review of the literature. |
| Score | Text |
|---|---|
| 0.9994 | We report three cases of severe hepatotoxicity related to Drugbenzarone , a benzofuran derivative. |
| 0.9520 | We report three cases of Adverse-Effectsevere hepatotoxicity related to benzarone, a benzofuran derivative. |
| Score | Text |
|---|---|
| 0.9990 | Two infants developed hyperkalemia shortly after cessation of prolonged DrugACTH therapy for infantile spasms. |
| 0.9986 | Two infants developed Adverse-Effecthyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms. |
| Score | Text |
|---|---|
| 0.9995 | However, acute cardiomyopathy and pericarditis secondary to Drugmethylphenidate use has been rarely reported. |
| 0.9975 | However, acute cardiomyopathy and Adverse-Effectpericarditis secondary to methylphenidate use has been rarely reported. |
| 0.9859 | However, Adverse-Effectacute cardiomyopathy and pericarditis secondary to methylphenidate use has been rarely reported. |
| Score | Text |
|---|---|
| 0.9995 | We now present four cases of RSDS in kidney transplant recipients treated with Drugtacrolimus . |
| 0.9980 | We now present four cases of Adverse-EffectRSDS in kidney transplant recipients treated with tacrolimus. |
| Score | Text |
|---|---|
| 0.9991 | This sulfonamide like nephropathy should be differentiated from Drugacetazolamide - related calcium phosphate nephrolithiasis. |
| 0.9475 | This sulfonamide like nephropathy should be differentiated from acetazolamide - related Adverse-Effectcalcium phosphate nephrolithiasis . |
| Score | Text |
|---|---|
| 0.9992 | Alveolar - interstitial pneumopathy after Druggold - salts compounds administration, requiring mechanical ventilation. |
| 0.9684 | Adverse-EffectAlveolar - interstitial pneumopathy after gold - salts compounds administration, requiring mechanical ventilation. |
| Score | Text |
|---|---|
| 0.9990 | The epivodes of NMS occured under treatment with clozapine, risperidone, and Drugamisulpride . |
| 0.9987 | The epivodes of NMS occured under treatment with clozapine, Drugrisperidone , and amisulpride. |
| 0.9987 | The epivodes of NMS occured under treatment with Drugclozapine , risperidone, and amisulpride. |
| 0.9944 | The epivodes of Adverse-EffectNMS occured under treatment with clozapine, risperidone, and amisulpride. |
| Score | Text |
|---|---|
| 0.9993 | Cardiac hypersensitivity and myopericarditis have been reported during long - term treatment with Drugmesalazine . |
| 0.9966 | Cardiac hypersensitivity and Adverse-Effectmyopericarditis have been reported during long - term treatment with mesalazine. |
| 0.9872 | Adverse-EffectCardiac hypersensitivity and myopericarditis have been reported during long - term treatment with mesalazine. |
| Score | Text |
|---|---|
| 0.9995 | Interstitial fibrosis of the lung is a potential complication of Drugmethotrexate therapy for psoriasis. |
| 0.9807 | Adverse-EffectInterstitial fibrosis of the lung is a potential complication of methotrexate therapy for psoriasis. |
| Score | Text |
|---|---|
| 0.9994 | The events of non - convulsive status epilepticus subsided following reduction in Drugtiagabine dosages. |
| 0.9760 | The events of Adverse-Effectnon - convulsive status epilepticus subsided following reduction in tiagabine dosages. |
| Score | Text |
|---|---|
| 0.9992 | CONCLUSION : This case illustrates a potential link between dermatologic and ocular Drug5 - FU toxicities. |
| 0.6309 | CONCLUSION : This case illustrates a potential link between Adverse-Effectdermatologic and ocular 5 - FU toxicities . |
| Score | Text |
|---|---|
| 0.9974 | Visual hallucinations after intravitreal injection of Drugbevacizumab in vascular age - related macular degeneration. |
| 0.9877 | Adverse-EffectVisual hallucinations after intravitreal injection of bevacizumab in vascular age - related macular degeneration. |
| Score | Text |
|---|---|
| 0.9990 | CONCLUSIONS : Symptoms and pathologic changes of colitis are associated with exposure to Drugrofecoxib . |
| 0.9920 | CONCLUSIONS : Symptoms and pathologic changes of Adverse-Effectcolitis are associated with exposure to rofecoxib. |
| Score | Text |
|---|---|
| 0.9850 | Adverse-EffectReye - like syndrome following treatment with the pantothenic acid antagonist, calcium hopantenate. |
| 0.9833 | Reye - like syndrome following treatment with the pantothenic acid antagonist, Drugcalcium hopantenate . |
| Score | Text |
|---|---|
| 0.9994 | Presented is a case of acute renal failure induced by Drugacetazolamide therapy for glaucoma. |
| 0.9799 | Presented is a case of Adverse-Effectacute renal failure induced by acetazolamide therapy for glaucoma. |
| Score | Text |
|---|---|
| 0.9994 | Such anagen effluvium with lichenoid eruption following DrugINH therapy has not been observed previously. |
| 0.9911 | Such anagen effluvium with Adverse-Effectlichenoid eruption following INH therapy has not been observed previously. |
| 0.9841 | Such Adverse-Effectanagen effluvium with lichenoid eruption following INH therapy has not been observed previously. |
| Score | Text |
|---|---|
| 0.9989 | The mean time from starting DrugMMF to the development of neutropenia was 4 months. |
| 0.9970 | The mean time from starting MMF to the development of Adverse-Effectneutropenia was 4 months. |
| Score | Text |
|---|---|
| 0.9995 | Psoriasis - like skin reaction in a patient with rheumatoid arthritis after Drugsulphasalazine therapy. |
| 0.9817 | Adverse-EffectPsoriasis - like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy. |
| Score | Text |
|---|---|
| 0.9596 | Severe rhabdomyolysis following massive ingestion of Drugoolong tea : caffeine intoxication with coexisting hyponatremia. |
| 0.9505 | Severe rhabdomyolysis following massive ingestion of oolong tea : Drugcaffeine intoxication with coexisting hyponatremia. |
| 0.5731 | Severe rhabdomyolysis following massive ingestion of oolong tea : Adverse-Effectcaffeine intoxication with coexisting hyponatremia. |
| 0.6836 | Adverse-EffectSevere rhabdomyolysis following massive ingestion of oolong tea : caffeine intoxication with coexisting hyponatremia. |
| Severe Adverse-Effectrhabdomyolysis following massive ingestion of oolong tea : caffeine intoxication with coexisting hyponatremia. | |
| Score | Text |
|---|---|
| 0.9993 | DrugIbuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation. |
| 0.9916 | Ibuprofen overdose is usually characterized by Adverse-EffectGI upset , dizziness, and mild sedation. |
| 0.9913 | Ibuprofen overdose is usually characterized by GI upset, Adverse-Effectdizziness , and mild sedation. |
| 0.9864 | Ibuprofen overdose is usually characterized by GI upset, dizziness, and Adverse-Effectmild sedation . |
| Score | Text |
|---|---|
| 0.9288 | Administration of cisplatin in three patients with Drugcarboplatin hypersensitivity : is skin testing useful? |
| 0.9113 | Administration of cisplatin in three patients with carboplatin Adverse-Effecthypersensitivity : is skin testing useful? |
| Score | Text |
|---|---|
| 0.9992 | Severe hepatotoxicity related to Drugbenzarone : a report of three cases with two fatalities. |
| 0.9508 | Adverse-EffectSevere hepatotoxicity related to benzarone : a report of three cases with two fatalities. |
| Score | Text |
|---|---|
| 0.9996 | OBJECTIVE : To report a case of reversible nonthrombocytopenic palpable purpura associated with Drugmetoclopramide . |
| 0.9468 | OBJECTIVE : To report a case of reversible Adverse-Effectnonthrombocytopenic palpable purpura associated with metoclopramide. |
| Score | Text |
|---|---|
| 0.9814 | DrugActinomycin D associated hepatic veno - occlusive disease - - a report of 2 cases. |
| 0.9736 | Actinomycin D associated Adverse-Effecthepatic veno - occlusive disease - - a report of 2 cases. |
| Score | Text |
|---|---|
| 0.9897 | A patient developed typical Adverse-EffectECM after subcutaneous selfinjection of glatiramer acetate for multiple sclerosis. |
| 0.9815 | A patient developed typical ECM after subcutaneous selfinjection of Drugglatiramer acetate for multiple sclerosis. |
| Score | Text |
|---|---|
| 0.9995 | Two patients are described who developed testicular swelling and pain during treatment with Drugdesipramine . |
| 0.9930 | Two patients are described who developed Adverse-Effecttesticular swelling and pain during treatment with desipramine. |
| 0.9873 | Two patients are described who developed testicular swelling and Adverse-Effectpain during treatment with desipramine. |
| Score | Text |
|---|---|
| 0.9908 | Putaminal infarct in Drugmethanol intoxication : case report and role of brain imaging studies. |
| 0.9314 | Adverse-EffectPutaminal infarct in methanol intoxication : case report and role of brain imaging studies. |
| 0.7082 | Putaminal infarct in Adverse-Effectmethanol intoxication : case report and role of brain imaging studies. |
| Score | Text |
|---|---|
| 0.9994 | Worsening of neurologic syndrome in patients with Wilson's disease with initial Drugpenicillamine therapy. |
| 0.9699 | Adverse-EffectWorsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. |
| Score | Text |
|---|---|
| 0.9989 | This is the first histologically confirmed case of NASH that was aggravated by Drugraloxifene . |
| 0.9983 | This is the first histologically confirmed case of Adverse-EffectNASH that was aggravated by raloxifene. |
| Score | Text |
|---|---|
| 0.9991 | This was accepted as evidence for Drugpropranolol being the cause of this conduction disorder. |
| 0.9614 | This was accepted as evidence for propranolol being the cause of this Adverse-Effectconduction disorder . |
| Score | Text |
|---|---|
| 0.9844 | Adverse-EffectPeripheral nerve dysfunction is a potentially serious complication of high - dose cytosine arabinoside. |
| 0.9706 | Peripheral nerve dysfunction is a potentially serious complication of high - dose Drugcytosine arabinoside . |
| Score | Text |
|---|---|
| 0.9994 | Torsade de pointes associated with Drugmoxifloxacin : a rare but potentially fatal adverse event. |
| 0.9879 | Adverse-EffectTorsade de pointes associated with moxifloxacin : a rare but potentially fatal adverse event. |
| Score | Text |
|---|---|
| 0.9973 | Hyperammonemia secondary to valproic acid as a cause of Adverse-Effectlethargy in a postictal patient. |
| 0.9972 | Adverse-EffectHyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient. |
| 0.9801 | Hyperammonemia secondary to Drugvalproic acid as a cause of lethargy in a postictal patient. |
| Score | Text |
|---|---|
| 0.9994 | A small number of Drugoxaliplatin - related hemolytic and / or thrombocytopenic reactions have been reported. |
| 0.9810 | A small number of oxaliplatin - related Adverse-Effecthemolytic and / or thrombocytopenic reactions have been reported. |
| Score | Text |
|---|---|
| 0.9964 | Clinical signs of Adverse-Effecthypermagnesemia are an uncommon complication following oral administration of magnesium sulfate. |
| 0.9761 | Clinical signs of hypermagnesemia are an uncommon complication following oral administration of Drugmagnesium sulfate . |
| Score | Text |
|---|---|
| 0.9996 | Acute hemorrhagic gastritis associated with Drugacetazolamide intoxication in a patient with chronic renal failure. |
| 0.9832 | Adverse-EffectAcute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure. |
| Acute hemorrhagic gastritis associated with Adverse-Effectacetazolamide intoxication in a patient with chronic renal failure. | |
| Score | Text |
|---|---|
| 0.9938 | Adverse-EffectMyasthenia gravis during low - dose IFN - alpha therapy for chronic hepatitis C. |
| 0.9716 | Myasthenia gravis during low - dose DrugIFN - alpha therapy for chronic hepatitis C. |
| Score | Text |
|---|---|
| 0.9990 | His fever resolved, but he developed symptoms consistent with those of Drugchloroquine toxicity. |
| 0.9497 | His fever resolved, but he developed symptoms consistent with those of Adverse-Effectchloroquine toxicity . |
| Score | Text |
|---|---|
| 0.9866 | Adverse-EffectLupus - like syndrome caused by 5 - aminosalicylic acid in patients with inflammatory bowel disease. |
| 0.9748 | Lupus - like syndrome caused by Drug5 - aminosalicylic acid in patients with inflammatory bowel disease. |
| Score | Text |
|---|---|
| 0.9996 | Intensive high - flux hemodiafiltration is often used in the management of Drugvancomycin toxicity. |
| 0.8261 | Intensive high - flux hemodiafiltration is often used in the management of Adverse-Effectvancomycin toxicity . |
| Score | Text |
|---|---|
| 0.9995 | She developed neurotoxicity with an adjustment dosage of Drugvalacyclovir for a cutaneous zoster infection. |
| 0.9972 | She developed Adverse-Effectneurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection. |
| Score | Text |
|---|---|
| 0.9991 | DrugThalidomide was withdrawn from world markets in 1961 following recognition of its teratogenic effects. |
| 0.9723 | Thalidomide was withdrawn from world markets in 1961 following recognition of its Adverse-Effectteratogenic effects . |
| Score | Text |
|---|---|
| 0.9993 | Itch and skin rash from chocolate during Drugfluoxetine and sertraline treatment : case report. |
| 0.9993 | Itch and skin rash from chocolate during fluoxetine and Drugsertraline treatment : case report. |
| 0.9979 | Adverse-EffectItch and skin rash from chocolate during fluoxetine and sertraline treatment : case report. |
| 0.9938 | Itch and Adverse-Effectskin rash from chocolate during fluoxetine and sertraline treatment : case report. |
| Score | Text |
|---|---|
| 0.9994 | OBJECTIVE : To describe a case of thrombocytopenia associated with the administration of Druglansoprazole . |
| 0.9959 | OBJECTIVE : To describe a case of Adverse-Effectthrombocytopenia associated with the administration of lansoprazole. |
| Score | Text |
|---|---|
| 0.9994 | Special care should be taken when pulmonary symptoms appear in association with Drugticlopidine treatment. |
| 0.9832 | Special care should be taken when Adverse-Effectpulmonary symptoms appear in association with ticlopidine treatment. |
| Score | Text |
|---|---|
| 0.9990 | It is well - recognized that Drugflucloxacillin may occasionally result in fatal hepatic injury. |
| 0.9850 | It is well - recognized that flucloxacillin may occasionally result in Adverse-Effectfatal hepatic injury . |
| Score | Text |
|---|---|
| 0.9994 | It is the first case of Drugciprofloxacin - induced VBDS successfully treated with tacrolimus. |
| 0.9986 | It is the first case of ciprofloxacin - induced Adverse-EffectVBDS successfully treated with tacrolimus. |
| Score | Text |
|---|---|
| 0.9995 | We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal Drugmethotrexate . |
| 0.9916 | We attribute the clinical and radiographic findings to Adverse-Effectcytotoxic edema secondary to intrathecal methotrexate. |
| Score | Text |
|---|---|
| 0.9996 | DrugBenzocaine - induced methemoglobinemia has been reported in man, dogs, and cats. |
| 0.9976 | Benzocaine - induced Adverse-Effectmethemoglobinemia has been reported in man, dogs, and cats. |
| Score | Text |
|---|---|
| 0.9992 | Squamous - cell carcinoma arising in a basal - cell epithelioma treated with Drug5 - fluorouracil . |
| 0.9758 | Adverse-EffectSquamous - cell carcinoma arising in a basal - cell epithelioma treated with 5 - fluorouracil. |
| Score | Text |
|---|---|
| 0.9995 | DrugRisperidone withdrawal - related respiratory dyskinesia : a case diagnosed by spirography and fibroscopy. |
| 0.9911 | Risperidone withdrawal - related Adverse-Effectrespiratory dyskinesia : a case diagnosed by spirography and fibroscopy. |
| Score | Text |
|---|---|
| 0.9840 | Induction of Adverse-Effectrapid mood cycling during L - dopa treatment in a bipolar patient. |
| 0.9673 | Induction of rapid mood cycling during DrugL - dopa treatment in a bipolar patient. |
| Score | Text |
|---|---|
| 0.9985 | Drug induced Adverse-Effectpolymyositis secondary to leuprolide acetate ( Lupron ) therapy for prostate carcinoma. |
| 0.9969 | Drug induced polymyositis secondary to leuprolide acetate ( DrugLupron ) therapy for prostate carcinoma. |
| 0.9830 | Drug induced polymyositis secondary to Drugleuprolide acetate ( Lupron ) therapy for prostate carcinoma. |
| Score | Text |
|---|---|
| 0.9984 | Adverse-EffectAnaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine : case report and review. |
| 0.9746 | Anaphylaxis to intravenous Drugcyclosporine and tolerance to oral cyclosporine : case report and review. |
| Score | Text |
|---|---|
| 0.9977 | Acute renal failure in a patient treated by continuous Drugpovidone - iodine mediastinal irrigation. |
| 0.9968 | Acute renal failure in a patient treated by continuous povidone - Drugiodine mediastinal irrigation. |
| 0.9643 | Adverse-EffectAcute renal failure in a patient treated by continuous povidone - iodine mediastinal irrigation. |
| Score | Text |
|---|---|
| 0.9995 | We describe the first case of disseminated salmonellosis in a patient treated with Drugtemozolomide . |
| 0.9876 | We describe the first case of Adverse-Effectdisseminated salmonellosis in a patient treated with temozolomide. |
| Score | Text |
|---|---|
| 0.9994 | New onset of Crohn's disease during treatment of active ankylosing spondylitis with Drugetanercept . |
| 0.9645 | New onset of Adverse-EffectCrohn's disease during treatment of active ankylosing spondylitis with etanercept. |
| Score | Text |
|---|---|
| 0.9992 | CONCLUSIONS : Topical Drugbrimonidine may be associated with central nervous system depression in infants. |
| 0.9867 | CONCLUSIONS : Topical brimonidine may be associated with Adverse-Effectcentral nervous system depression in infants. |
| Score | Text |
|---|---|
| 0.9957 | Pseudomembranous colitis readily occurs in at least certain population groups receiving trimethoprim - Drugsulfamethoxazole . |
| 0.9933 | Pseudomembranous colitis readily occurs in at least certain population groups receiving Drugtrimethoprim - sulfamethoxazole. |
| 0.9902 | Adverse-EffectPseudomembranous colitis readily occurs in at least certain population groups receiving trimethoprim - sulfamethoxazole. |
| Score | Text |
|---|---|
| 0.9995 | We believe that the acute renal failure in our patient was associated with Druganastrozole . |
| 0.9828 | We believe that the Adverse-Effectacute renal failure in our patient was associated with anastrozole. |
| Score | Text |
|---|---|
| 0.9978 | Adverse-EffectMyoclonus was induced and enhanced by L - dopa, developing into generalized seizures. |
| 0.9772 | Myoclonus was induced and enhanced by L - dopa, developing into Adverse-Effectgeneralized seizures . |
| 0.9669 | Myoclonus was induced and enhanced by DrugL - dopa , developing into generalized seizures. |
| Score | Text |
|---|---|
| 0.9589 | Intravenous administration of levodopa ameliorated a refractory akathisia case induced by Druginterferon - alpha . |
| 0.9556 | Intravenous administration of levodopa ameliorated a refractory Adverse-Effectakathisia case induced by interferon - alpha. |
| Score | Text |
|---|---|
| 0.9907 | Adverse-EffectCutaneous seeding after ultrasound - guided percutaneous ethanol injection for treatment of hepatocellular carcinoma. |
| 0.9730 | Cutaneous seeding after ultrasound - guided percutaneous Drugethanol injection for treatment of hepatocellular carcinoma. |
| Cutaneous seeding after ultrasound - guided percutaneous Drugethanol injection for treatment of hepatocellular carcinoma. | |
| Score | Text |
|---|---|
| 0.9990 | A patient presented with dilated cardiomyopathy after many years of overusing an Drugadrenaline inhaler. |
| 0.9865 | A patient presented with Adverse-Effectdilated cardiomyopathy after many years of overusing an adrenaline inhaler. |
| Score | Text |
|---|---|
| 0.9995 | Are nasal decongestants safer than rhinitis? A case of Drugoxymetazoline - induced syncope. |
| 0.9986 | Are nasal decongestants safer than rhinitis? A case of oxymetazoline - induced Adverse-Effectsyncope . |
| Score | Text |
|---|---|
| 0.9996 | Sixteen of 33 patients developed significant hyponatremia and hypoosmolality during oral treatment with Druglorcainide . |
| 0.9982 | Sixteen of 33 patients developed significant Adverse-Effecthyponatremia and hypoosmolality during oral treatment with lorcainide. |
| 0.9979 | Sixteen of 33 patients developed significant hyponatremia and Adverse-Effecthypoosmolality during oral treatment with lorcainide. |
| Score | Text |
|---|---|
| 0.9990 | Serious Drugphenytoin hypersensitivity reactions may appear as dermatologic, lymphoid, or hepatic syndromes. |
| 0.9426 | Serious phenytoin hypersensitivity reactions may appear as Adverse-Effectdermatologic, lymphoid, or hepatic syndromes . |
| 0.8640 | Serious phenytoin Adverse-Effecthypersensitivity reactions may appear as dermatologic, lymphoid, or hepatic syndromes. |
| Score | Text |
|---|---|
| 0.9992 | DrugGemcitabine should be added to the list of drugs known to cause radiation recall. |
| 0.9930 | Gemcitabine should be added to the list of drugs known to cause Adverse-Effectradiation recall . |
| Score | Text |
|---|---|
| 0.9993 | Symptomatic hypocalcaemia and renal impairment associated with Drugbisphosphonate treatment in patients with multiple myeloma. |
| 0.9875 | Symptomatic hypocalcaemia and Adverse-Effectrenal impairment associated with bisphosphonate treatment in patients with multiple myeloma. |
| 0.9842 | Adverse-EffectSymptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma. |
| Score | Text |
|---|---|
| 0.9994 | In one case, Drugdisulfiram was the only potential teratogen exposed to the fetus. |
| 0.9976 | In one case, disulfiram was the only potential Adverse-Effectteratogen exposed to the fetus. |
| Score | Text |
|---|---|
| 0.9991 | Conventional and diffusion - weighted MRI findings of Drugmethotrexate related sub - acute neurotoxicity. |
| 0.9627 | Conventional and diffusion - weighted MRI findings of methotrexate related Adverse-Effectsub - acute neurotoxicity . |
| Score | Text |
|---|---|
| 0.9993 | METHOD : We describe three case - reports concerning haematological adverse effects of Drugquetiapine . |
| 0.9671 | METHOD : We describe three case - reports concerning Adverse-Effecthaematological adverse effects of quetiapine. |
| Score | Text |
|---|---|
| 0.9993 | Oral intake and Drugacarbose were withheld and the ileus spontaneously resolved after 2 days. |
| 0.9960 | Oral intake and acarbose were withheld and the Adverse-Effectileus spontaneously resolved after 2 days. |
| Score | Text |
|---|---|
| 0.9839 | Adverse-EffectKaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia. |
| 0.9805 | Kaposi's sarcoma in a patient treated with Drugimatinib mesylate for chronic myeloid leukemia. |
| Score | Text |
|---|---|
| 0.9975 | Drug2 - CdA induces lymphocytopenia, which may explain the improvement in this patient's psoriasis. |
| 0.9962 | 2 - CdA induces Adverse-Effectlymphocytopenia , which may explain the improvement in this patient's psoriasis. |
| Score | Text |
|---|---|
| 0.9996 | Development of tics in a thirteen - year - old male following Drugatomoxetine use. |
| 0.9987 | Development of Adverse-Effecttics in a thirteen - year - old male following atomoxetine use. |
| Score | Text |
|---|---|
| 0.9986 | Gynecomastia in epileptics treated with Drugphenobarbital , phenytoin and fluoresone : two case reports. |
| 0.9985 | Gynecomastia in epileptics treated with phenobarbital, phenytoin and Drugfluoresone : two case reports. |
| 0.9985 | Gynecomastia in epileptics treated with phenobarbital, Drugphenytoin and fluoresone : two case reports. |
| 0.9984 | Adverse-EffectGynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone : two case reports. |
| Score | Text |
|---|---|
| 0.9992 | The two middle aged women presented with respiratory symptoms after prolonged treatment with Drugnitrofurantoin . |
| 0.9901 | The two middle aged women presented with Adverse-Effectrespiratory symptoms after prolonged treatment with nitrofurantoin. |
| Score | Text |
|---|---|
| 0.9797 | Visual system side effects caused by Adverse-Effectparasympathetic dysfunction after botulinum toxin type B injections. |
| 0.9661 | Adverse-EffectVisual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections. |
| 0.9609 | Visual system side effects caused by parasympathetic dysfunction after Drugbotulinum toxin type B injections. |
| Score | Text |
|---|---|
| 0.9994 | Neutropenic colitis during standard dose combination chemotherapy with Drugnedaplatin and irinotecan for testicular cancer. |
| 0.9993 | Neutropenic colitis during standard dose combination chemotherapy with nedaplatin and Drugirinotecan for testicular cancer. |
| 0.9922 | Adverse-EffectNeutropenic colitis during standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer. |
| Score | Text |
|---|---|
| 0.9984 | Pharmacokinetic determinants of Drug6 - mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia. |
| 0.9299 | Pharmacokinetic determinants of 6 - mercaptopurine Adverse-Effectmyelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia. |
| Score | Text |
|---|---|
| 0.9992 | This supports the well - reported potential of Drugbleomycin to trigger acral vascular toxicity. |
| 0.9853 | This supports the well - reported potential of bleomycin to trigger Adverse-Effectacral vascular toxicity . |
| Score | Text |
|---|---|
| 0.9995 | We discuss a variety of bronchopulmonary complications of IBD and their association with Drugsulfasalazine . |
| 0.9695 | We discuss a variety of bronchopulmonary complications of Adverse-EffectIBD and their association with sulfasalazine. |
| Score | Text |
|---|---|
| 0.9996 | DrugMethotrexate - induced papular eruption following treatment of psoriasis has not been previously reported. |
| 0.9918 | Methotrexate - induced Adverse-Effectpapular eruption following treatment of psoriasis has not been previously reported. |
| Score | Text |
|---|---|
| 0.9996 | Acute erythroid leukemia after Drugcyclophosphamide therapy for multiple myeloma : report of two cases. |
| 0.9689 | Adverse-EffectAcute erythroid leukemia after cyclophosphamide therapy for multiple myeloma : report of two cases. |
| Score | Text |
|---|---|
| 0.9995 | We report a case of Drugibuprofen - induced meningitis in an otherwise healthy individual. |
| 0.9989 | We report a case of ibuprofen - induced Adverse-Effectmeningitis in an otherwise healthy individual. |
| Score | Text |
|---|---|
| 0.9953 | Fatal Drugdigoxin poisoning : an unsuccessful resuscitation with use of digoxin - immune Fab. |
| 0.8115 | Adverse-EffectFatal digoxin poisoning : an unsuccessful resuscitation with use of digoxin - immune Fab. |
| Score | Text |
|---|---|
| 0.9994 | BACKGROUND : Headaches have been reported as a potential side effect of Drugcapecitabine therapy. |
| 0.9975 | BACKGROUND : Adverse-EffectHeadaches have been reported as a potential side effect of capecitabine therapy. |
| Score | Text |
|---|---|
| 0.9993 | Transient cardiac arrhythmias related to Druglopinavir / ritonavir in two patients with HIV infection. |
| 0.9992 | Transient cardiac arrhythmias related to lopinavir / Drugritonavir in two patients with HIV infection. |
| 0.9640 | Adverse-EffectTransient cardiac arrhythmias related to lopinavir / ritonavir in two patients with HIV infection. |
| Score | Text |
|---|---|
| 0.9995 | DrugChlorambucil - induced chromosome damage to human lymphocytes is dose - dependent and cumulative. |
| 0.9918 | Chlorambucil - induced Adverse-Effectchromosome damage to human lymphocytes is dose - dependent and cumulative. |
| Score | Text |
|---|---|
| 0.9996 | A complex pattern of melanonychia and onycholysis after treatment with Drugpemetrexed for lung cancer. |
| 0.9979 | A complex pattern of Adverse-Effectmelanonychia and onycholysis after treatment with pemetrexed for lung cancer. |
| 0.9962 | A complex pattern of melanonychia and Adverse-Effectonycholysis after treatment with pemetrexed for lung cancer. |
| Score | Text |
|---|---|
| 0.9879 | Niflumic acid - induced Adverse-Effectskeletal fluorosis : iatrogenic disease or therapeutic perspective for osteoporosis? |
| 0.9752 | DrugNiflumic acid - induced skeletal fluorosis : iatrogenic disease or therapeutic perspective for osteoporosis? |
| Score | Text |
|---|---|
| 0.9996 | Bone marrow aplasia and severe skin rash after a single low dose of Drugmethotrexate . |
| 0.9882 | Bone marrow aplasia and Adverse-Effectsevere skin rash after a single low dose of methotrexate. |
| 0.9821 | Adverse-EffectBone marrow aplasia and severe skin rash after a single low dose of methotrexate. |
| Score | Text |
|---|---|
| 0.9638 | Delayed pseudocyst of the pancreas can be a complication of intramuscular DrugL - asparaginase . |
| 0.8995 | Adverse-EffectDelayed pseudocyst of the pancreas can be a complication of intramuscular L - asparaginase. |
| Score | Text |
|---|---|
| 0.9993 | Drug rash with eosinophilia and systemic symptoms after Drugchlorambucil treatment in chronic lymphocytic leukaemia. |
| Adverse-EffectDrug rash with eosinophilia and systemic symptoms after chlorambucil treatment in chronic lymphocytic leukaemia. | |
| Score | Text |
|---|---|
| 0.9979 | The patient was initially treated with hydration and Drugfurosemide but developed congestive heart failure. |
| 0.9876 | The patient was initially treated with hydration and furosemide but developed Adverse-Effectcongestive heart failure . |
| Score | Text |
|---|---|
| 0.9987 | There are now reports of liver failure following treatment of childhood cancers with DrugAMD . |
| 0.9944 | There are now reports of Adverse-Effectliver failure following treatment of childhood cancers with AMD. |
| Score | Text |
|---|---|
| 0.9962 | Adverse-EffectCalcification and ossification of the spinal arachnoid after intrathecal administration of Depo - Medrol. |
| 0.9777 | Calcification and Adverse-Effectossification of the spinal arachnoid after intrathecal administration of Depo - Medrol. |
| 0.9650 | Calcification and ossification of the spinal arachnoid after intrathecal administration of DrugDepo - Medrol . |
| Score | Text |
|---|---|
| 0.9992 | The association of central diabetes insipidus ( CDI ) with Druglithium use is rare. |
| 0.9921 | The association of central diabetes insipidus ( Adverse-EffectCDI ) with lithium use is rare. |
| 0.9816 | The association of Adverse-Effectcentral diabetes insipidus ( CDI ) with lithium use is rare. |
| Score | Text |
|---|---|
| 0.9996 | DrugProcainamide - induced incessant supraventricular tachycardia in the Wolff - Parkinson - White syndrome. |
| 0.9709 | Procainamide - induced Adverse-Effectincessant supraventricular tachycardia in the Wolff - Parkinson - White syndrome. |
| Score | Text |
|---|---|
| 0.9995 | Upper tract urothelial malignancy after Drugcyclophosphamide therapy : a case report and literature review. |
| 0.9741 | Adverse-EffectUpper tract urothelial malignancy after cyclophosphamide therapy : a case report and literature review. |
| Score | Text |
|---|---|
| 0.9995 | A case of severe visual loss following a single dose of Drugvincristine is described. |
| 0.9828 | A case of Adverse-Effectsevere visual loss following a single dose of vincristine is described. |
| Score | Text |
|---|---|
| 0.9995 | Graves'hyperthyroidism following transient thyrotoxicosis during Druginterferon therapy for chronic hepatitis type C. |
| 0.9755 | Adverse-EffectGraves'hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C. |
| 0.9537 | Graves'hyperthyroidism following Adverse-Effecttransient thyrotoxicosis during interferon therapy for chronic hepatitis type C. |
| Score | Text |
|---|---|
| 0.9982 | After 5 weeks of therapy, she stopped taking Drugpantoprazole due to general malaise. |
| 0.9571 | After 5 weeks of therapy, she stopped taking pantoprazole due to Adverse-Effectgeneral malaise . |
| Score | Text |
|---|---|
| 0.9995 | Acute severe intoxication with Drugcarbamazepine is associated with seizures, coma and respiratory depression. |
| 0.9985 | Acute severe intoxication with carbamazepine is associated with Adverse-Effectseizures , coma and respiratory depression. |
| 0.9940 | Acute severe intoxication with carbamazepine is associated with seizures, coma and Adverse-Effectrespiratory depression . |
| 0.9876 | Acute severe intoxication with carbamazepine is associated with seizures, Adverse-Effectcoma and respiratory depression. |
| Score | Text |
|---|---|
| 0.9996 | OBJECTIVE : To describe a probable case of transient global amnesia caused by Drugpropafenone . |
| 0.9795 | OBJECTIVE : To describe a probable case of Adverse-Effecttransient global amnesia caused by propafenone. |
| Score | Text |
|---|---|
| 0.9994 | This clinical course suggests that the sensorimotor polyneuropathy may have been caused by Drug5 - ASA . |
| 0.9887 | This clinical course suggests that the Adverse-Effectsensorimotor polyneuropathy may have been caused by 5 - ASA. |
| Score | Text |
|---|---|
| 0.9990 | Vanishing bile duct and Stevens - Johnson syndrome associated with Drugciprofloxacin treated with tacrolimus. |
| 0.9806 | Adverse-EffectVanishing bile duct and Stevens - Johnson syndrome associated with ciprofloxacin treated with tacrolimus. |
| 0.9802 | Vanishing bile duct and Adverse-EffectStevens - Johnson syndrome associated with ciprofloxacin treated with tacrolimus. |
| Score | Text |
|---|---|
| 0.9914 | Paradoxical precipitation of tonic seizures by Druglorazepam in a child with atypical absence seizures. |
| 0.8368 | Adverse-EffectParadoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures. |
| Score | Text |
|---|---|
| 0.9996 | DrugCaptopril - induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease. |
| 0.8863 | Captopril - induced Adverse-Effectpulmonary infiltrates with eosinophilia in an infant with congenital heart disease. |
| Score | Text |
|---|---|
| 0.9990 | Reduction of Drugmethylprednisolone dosage rather than insulin therapy resulted in better control of glycemia. |
| 0.9950 | Reduction of methylprednisolone dosage rather than insulin therapy resulted in better control of Adverse-Effectglycemia . |
| Score | Text |
|---|---|
| 0.9837 | We report a case of chronic use of HCQ associated with Adverse-Effecttorsade de pointes . |
| 0.9771 | We report a case of chronic use of DrugHCQ associated with torsade de pointes. |
| Score | Text |
|---|---|
| 0.9997 | Hepatolithiasis ( intrahepatic stone ) during Drugoctreotide therapy for acromegaly : a case report. |
| 0.9981 | Adverse-EffectHepatolithiasis ( intrahepatic stone ) during octreotide therapy for acromegaly : a case report. |
| Score | Text |
|---|---|
| 0.9996 | We report a case of glaucoma induced by Drugdoxetaxel therapy for metastatic breast cancer. |
| 0.9984 | We report a case of Adverse-Effectglaucoma induced by doxetaxel therapy for metastatic breast cancer. |
| Score | Text |
|---|---|
| 0.9988 | DrugLithium therapy was discontinued because of poor compliance to the medication and intolerable polyuria. |
| 0.9237 | Lithium therapy was discontinued because of poor compliance to the medication and intolerable Adverse-Effectpolyuria . |
| Score | Text |
|---|---|
| 0.9863 | Horner's syndrome and Adverse-Effectdemyelinating peripheral neuropathy caused by high - dose cytosine arabinoside. |
| 0.9818 | Adverse-EffectHorner's syndrome and demyelinating peripheral neuropathy caused by high - dose cytosine arabinoside. |
| 0.9716 | Horner's syndrome and demyelinating peripheral neuropathy caused by high - dose Drugcytosine arabinoside . |
| Score | Text |
|---|---|
| 0.9996 | Leiomyosarcoma in urinary bladder after Drugcyclophosphamide therapy for retinoblastoma and review of bladder sarcomas. |
| 0.9965 | Adverse-EffectLeiomyosarcoma in urinary bladder after cyclophosphamide therapy for retinoblastoma and review of bladder sarcomas. |
| Score | Text |
|---|---|
| 0.9990 | The authors caution that treatment with Drugalprazolam may be complicated by the induction of mania. |
| 0.9963 | The authors caution that treatment with alprazolam may be complicated by the induction of Adverse-Effectmania . |
| Score | Text |
|---|---|
| 0.9867 | To treat hepatitis B, Druginterferon alpha was administered until the proximal muscle weakness developed. |
| 0.9380 | To treat hepatitis B, interferon alpha was administered until the proximal Adverse-Effectmuscle weakness developed. |
| Score | Text |
|---|---|
| 0.9995 | Aggressive endometrial carcinoma in a breast cancer patient treated with Drugtamoxifen with normal transvaginal ultrasonography. |
| 0.9794 | Adverse-EffectAggressive endometrial carcinoma in a breast cancer patient treated with tamoxifen with normal transvaginal ultrasonography. |
| Score | Text |
|---|---|
| 0.9993 | Two children with rheumatic fever developed anicteric hepatitis while on high - dose Drugaspirin therapy. |
| 0.9923 | Two children with rheumatic fever developed Adverse-Effectanicteric hepatitis while on high - dose aspirin therapy. |
| Score | Text |
|---|---|
| 0.9996 | Myoclonus associated with continuous Drugdobutamine infusion in a patient with end - stage renal disease. |
| 0.9990 | Adverse-EffectMyoclonus associated with continuous dobutamine infusion in a patient with end - stage renal disease. |
| Score | Text |
|---|---|
| 0.9803 | Induction of Adverse-Effectsystemic lupus erythematosus by interferon - gamma in a patient with rheumatoid arthritis. |
| 0.9638 | Induction of systemic lupus erythematosus by Druginterferon - gamma in a patient with rheumatoid arthritis. |
| Score | Text |
|---|---|
| 0.9971 | We describe the case of acute hepatitis induced by Druggliclazide , a second generation sulfonylurea. |
| 0.9840 | We describe the case of Adverse-Effectacute hepatitis induced by gliclazide, a second generation sulfonylurea. |
| Score | Text |
|---|---|
| 0.9994 | DrugAcyclovir produces neurologic symptoms that resemble extension of viral infection into the central nervous system. |
| 0.9892 | Acyclovir produces Adverse-Effectneurologic symptoms that resemble extension of viral infection into the central nervous system. |
| Score | Text |
|---|---|
| 0.9981 | OBJECTIVE : To report the occurrence of anaphylactoid reactions to intraperitoneal Drugcisplatin in 3 patients. |
| 0.9904 | OBJECTIVE : To report the occurrence of Adverse-Effectanaphylactoid reactions to intraperitoneal cisplatin in 3 patients. |
| Score | Text |
|---|---|
| 0.9965 | A case of Adverse-Effectpolymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B. |
| 0.9850 | A case of polymyositis with dilated cardiomyopathy associated with Druginterferon alpha treatment for hepatitis B. |
| 0.9803 | A case of polymyositis with Adverse-Effectdilated cardiomyopathy associated with interferon alpha treatment for hepatitis B. |
| Score | Text |
|---|---|
| 0.9995 | Focal glomerulonephritis and interstitial nephritis in Drugmethicillin - treated, heroin - related infective endocarditis. |
| 0.9793 | Adverse-EffectFocal glomerulonephritis and interstitial nephritis in methicillin - treated, heroin - related infective endocarditis. |
| 0.9793 | Focal glomerulonephritis and Adverse-Effectinterstitial nephritis in methicillin - treated, heroin - related infective endocarditis. |
| Score | Text |
|---|---|
| 0.9996 | We describe two women who developed HUS after DrugMMC therapy and presented massive pulmonary bleeding. |
| 0.9984 | We describe two women who developed Adverse-EffectHUS after MMC therapy and presented massive pulmonary bleeding. |
| 0.9829 | We describe two women who developed HUS after MMC therapy and presented Adverse-Effectmassive pulmonary bleeding . |
| Score | Text |
|---|---|
| 0.9996 | Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to Drugphenytoin . |
| 0.9877 | Adverse-EffectBasilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin. |
| 0.9745 | Basilar invagination and Adverse-Effectmid - line skeletal abnormalities due to in utero exposure to phenytoin. |
| Score | Text |
|---|---|
| 0.9996 | CONCLUSIONS : There is very little published information regarding Drugofloxacin - induced toxic epidermal necrolysis. |
| 0.9853 | CONCLUSIONS : There is very little published information regarding ofloxacin - induced Adverse-Effecttoxic epidermal necrolysis . |
| Score | Text |
|---|---|
| 0.9991 | While undergoing treatment with Drugalbendazole , he developed worsening diarrhea with abdominal pain and fever. |
| 0.9889 | While undergoing treatment with albendazole, he developed worsening diarrhea with Adverse-Effectabdominal pain and fever. |
| 0.9815 | While undergoing treatment with albendazole, he developed worsening diarrhea with abdominal pain and Adverse-Effectfever . |
| 0.9757 | While undergoing treatment with albendazole, he developed Adverse-Effectworsening diarrhea with abdominal pain and fever. |
| Score | Text |
|---|---|
| 0.9994 | This is the first report of pulmonary hypertension in an adult patient during Druglithium therapy. |
| 0.9881 | This is the first report of Adverse-Effectpulmonary hypertension in an adult patient during lithium therapy. |
| Score | Text |
|---|---|
| 0.9977 | Cystoid macular edema in a low - risk patient after switching from Druglatanoprost to bimatoprost. |
| 0.9974 | Cystoid macular edema in a low - risk patient after switching from latanoprost to Drugbimatoprost . |
| 0.9864 | Adverse-EffectCystoid macular edema in a low - risk patient after switching from latanoprost to bimatoprost. |
| Score | Text |
|---|---|
| 0.9993 | The patient's arthritis flared after the second infusion of Druginfliximab , which was discontinued. |
| 0.9857 | The patient's Adverse-Effectarthritis flared after the second infusion of infliximab, which was discontinued. |
| Score | Text |
|---|---|
| 0.9993 | Therefore, parenteral Drugamiodarone was implicated as the cause of acute hepatitis in this patient. |
| 0.9864 | Therefore, parenteral amiodarone was implicated as the cause of Adverse-Effectacute hepatitis in this patient. |
| Score | Text |
|---|---|
| 0.9991 | The other patient developed transient intraoperative hypertension immediately after inadvertent submucosal injection of concentrated Drugepinephrine . |
| 0.9773 | The other patient developed Adverse-Effecttransient intraoperative hypertension immediately after inadvertent submucosal injection of concentrated epinephrine. |
| Score | Text |
|---|---|
| 0.9995 | Sustained ventricular tachycardia in a Drugthalidomide - treated patient with primary plasma - cell leukemia. |
| 0.9747 | Adverse-EffectSustained ventricular tachycardia in a thalidomide - treated patient with primary plasma - cell leukemia. |
| Score | Text |
|---|---|
| 0.9839 | Vogt - Koyanagi - Harada disease occurring during Druginterferon alpha therapy for chronic hepatitis C. |
| 0.9770 | Adverse-EffectVogt - Koyanagi - Harada disease occurring during interferon alpha therapy for chronic hepatitis C. |
| Score | Text |
|---|---|
| 0.9990 | Following discontinuation of Drugclozapine , she was rechallenged and again was observed to have seizures. |
| 0.9989 | Following discontinuation of clozapine, she was rechallenged and again was observed to have Adverse-Effectseizures . |
| Score | Text |
|---|---|
| 0.9985 | Discontinuation of simvastatin and Drugcyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function. |
| 0.9983 | Discontinuation of Drugsimvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function. |
| 0.9976 | Discontinuation of simvastatin and cyclosporine resulted in resolution of Adverse-Effectrhabdomyolysis and normalization of renal function. |
| Score | Text |
|---|---|
| 0.9994 | DrugClozapine is speculated to cause rhabdomyolysis in patients with defective calcium - activated K + channels. |
| 0.9974 | Clozapine is speculated to cause Adverse-Effectrhabdomyolysis in patients with defective calcium - activated K + channels. |
| Score | Text |
|---|---|
| 0.9994 | Recurrent palmar - plantar erythrodysaesthesia following high - dose Drugcytarabine treatment for acute lymphoblastic leukemia. |
| 0.9052 | Adverse-EffectRecurrent palmar - plantar erythrodysaesthesia following high - dose cytarabine treatment for acute lymphoblastic leukemia. |
| Recurrent Adverse-Effectpalmar - plantar erythrodysaesthesia following high - dose cytarabine treatment for acute lymphoblastic leukemia. | |
| Score | Text |
|---|---|
| 0.9994 | Renal tubular acidosis secondary to DrugFK506 in living donor liver transplantation : a case report. |
| 0.9861 | Adverse-EffectRenal tubular acidosis secondary to FK506 in living donor liver transplantation : a case report. |
| Score | Text |
|---|---|
| 0.9986 | A 58 - year - old man with rheumatoid arthritis developed lichen planus during treatment with Druggold . |
| 0.9934 | A 58 - year - old man with rheumatoid arthritis developed Adverse-Effectlichen planus during treatment with gold. |
| Score | Text |
|---|---|
| 0.9988 | We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and Druglamivudine . |
| 0.9987 | We present an AIDS patient with severe and prolonged lactic acidosis on Drugstavudine and lamivudine. |
| 0.9600 | We present an AIDS patient with severe and prolonged Adverse-Effectlactic acidosis on stavudine and lamivudine. |
| Score | Text |
|---|---|
| 0.9988 | DrugDiphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria. |
| 0.9773 | Diphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the Adverse-Effectacute intermittent porphyria . |
| Score | Text |
|---|---|
| 0.9994 | Two patients who were receiving DrugTolazoline by infusion developed duodenal ulceration and subsequent intestinal perforation. |
| 0.9909 | Two patients who were receiving Tolazoline by infusion developed Adverse-Effectduodenal ulceration and subsequent intestinal perforation. |
| 0.9894 | Two patients who were receiving Tolazoline by infusion developed duodenal ulceration and subsequent Adverse-Effectintestinal perforation . |
| Score | Text |
|---|---|
| 0.9992 | Here, we report a case of DrugRFP - induced hypothyroidism without underlying thyroid disease. |
| 0.9971 | Here, we report a case of RFP - induced Adverse-Effecthypothyroidism without underlying thyroid disease. |
| Score | Text |
|---|---|
| 0.9996 | Generalized maculopapular and papular purpuric eruptions are perhaps the most common Drugthionamide - induced reactions. |
| 0.9323 | Adverse-EffectGeneralized maculopapular and papular purpuric eruptions are perhaps the most common thionamide - induced reactions. |
| Score | Text |
|---|---|
| 0.9995 | This case illustrates the potential decoupling of PSA response from disease status in Drugflutamide withdrawal. |
| 0.9770 | This case illustrates the potential Adverse-Effectdecoupling of PSA response from disease status in flutamide withdrawal. |
| Score | Text |
|---|---|
| 0.9993 | Intracranial haemorrhage from a meningioma in a patient receiving Drugaspirin prophylaxis : a case report. |
| 0.9884 | Adverse-EffectIntracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis : a case report. |
| Score | Text |
|---|---|
| 0.9988 | It is likely that DrugRA contributed to the deterioration in renal function in these patients. |
| 0.9645 | It is likely that RA contributed to the Adverse-Effectdeterioration in renal function in these patients. |
| Score | Text |
|---|---|
| 0.9990 | We report the case of a 21 - year - old female patient with Drugdapsone hypersensitivity syndrome. |
| 0.9269 | We report the case of a 21 - year - old female patient with dapsone Adverse-Effecthypersensitivity syndrome . |
| Score | Text |
|---|---|
| 0.9993 | DrugNitrofurantoin - induced lung disease : two cases demonstrating resolution of apparently irreversible CT abnormalities. |
| 0.9920 | Nitrofurantoin - induced Adverse-Effectlung disease : two cases demonstrating resolution of apparently irreversible CT abnormalities. |
| Score | Text |
|---|---|
| 0.9984 | Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and Druggemcitabine . |
| 0.9981 | Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with Drugcarboplatin and gemcitabine. |
| 0.9562 | Adverse-EffectSevere hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine. |
| Score | Text |
|---|---|
| 0.9987 | Adverse-EffectPolyarthritis , hepatitis and anti - native DNA antibodies after treatment with ethambutol and rifampicin. |
| 0.9986 | Polyarthritis, hepatitis and anti - native DNA antibodies after treatment with ethambutol and Drugrifampicin . |
| 0.9984 | Polyarthritis, hepatitis and anti - native DNA antibodies after treatment with Drugethambutol and rifampicin. |
| 0.9981 | Polyarthritis, Adverse-Effecthepatitis and anti - native DNA antibodies after treatment with ethambutol and rifampicin. |
| 0.9686 | Polyarthritis, hepatitis and Adverse-Effectanti - native DNA antibodies after treatment with ethambutol and rifampicin. |
| Score | Text |
|---|---|
| 0.9987 | There was a clear relationship between restarting the DrugAccutane and recurrence of the transient myopia. |
| 0.9865 | There was a clear relationship between restarting the Accutane and recurrence of the Adverse-Effecttransient myopia . |
| Score | Text |
|---|---|
| 0.9873 | To our knowledge, this is the first Adverse-Effectgranulomatous reaction described after calcium hydroxylapatite injection. |
| 0.9873 | To our knowledge, this is the first granulomatous reaction described after Drugcalcium hydroxylapatite injection. |
| Score | Text |
|---|---|
| 0.9976 | Myelodysplasia terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with Drug2 - deoxycoformycin . |
| 0.9966 | Adverse-EffectMyelodysplasia terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with 2 - deoxycoformycin. |
| 0.9580 | Myelodysplasia terminating in Adverse-Effectacute myeloid leukemia in a hairy cell leukemia patient treated with 2 - deoxycoformycin. |
| Score | Text |
|---|---|
| 0.9979 | Proconvulsive tendency of Drugimipenem / cilastatin is one of its well - known side effects. |
| 0.9978 | Proconvulsive tendency of imipenem / Drugcilastatin is one of its well - known side effects. |
| Adverse-EffectProconvulsive tendency of imipenem / cilastatin is one of its well - known side effects. | |
| Score | Text |
|---|---|
| 0.9975 | Thoracoscopic biopsy to confirm metastasis revealed instead fibrotic lesions apparently attributable to bleomycin or Drugcyclophosphamide . |
| 0.9974 | Thoracoscopic biopsy to confirm metastasis revealed instead fibrotic lesions apparently attributable to Drugbleomycin or cyclophosphamide. |
| 0.9883 | Thoracoscopic biopsy to confirm metastasis revealed instead Adverse-Effectfibrotic lesions apparently attributable to bleomycin or cyclophosphamide. |
| Score | Text |
|---|---|
| 0.9996 | DrugFlecainide - associated pneumonitis with acute respiratory failure in a patient with the LEOPARD syndrome. |
| 0.9979 | Flecainide - associated Adverse-Effectpneumonitis with acute respiratory failure in a patient with the LEOPARD syndrome. |
| 0.9854 | Flecainide - associated pneumonitis with Adverse-Effectacute respiratory failure in a patient with the LEOPARD syndrome. |
| Score | Text |
|---|---|
| 0.9879 | We report a case of contact dermatitis due to Drugsodium bisulfite in Tathion eye drops. |
| 0.9844 | We report a case of Adverse-Effectcontact dermatitis due to sodium bisulfite in Tathion eye drops. |
| Score | Text |
|---|---|
| 0.9992 | Neutrophilic eccrine hidradenitis mimicking cutaneous vasculitis in a lupus patient : a complication of Drugcyclophosphamide . |
| 0.9763 | Adverse-EffectNeutrophilic eccrine hidradenitis mimicking cutaneous vasculitis in a lupus patient : a complication of cyclophosphamide. |
| Score | Text |
|---|---|
| 0.9807 | Epsilon - aminocaproic acid and Adverse-Effectrenal complications : case report and review of the literature. |
| 0.9390 | DrugEpsilon - aminocaproic acid and renal complications : case report and review of the literature. |
| Score | Text |
|---|---|
| 0.9842 | The use of beclomethasone diproprionate inhaler complicated by the development of an Adverse-Effecteosinophilic pneumonia reaction . |
| 0.9629 | The use of Drugbeclomethasone diproprionate inhaler complicated by the development of an eosinophilic pneumonia reaction. |
| Score | Text |
|---|---|
| 0.9990 | De novo absence status of late onset following withdrawal of Druglorazepam : a case report. |
| 0.9511 | Adverse-EffectDe novo absence status of late onset following withdrawal of lorazepam : a case report. |
| Score | Text |
|---|---|
| 0.9816 | Two elderly women suffered an acute deterioration of renal function after treatment with Drugcefoxitin sodium . |
| 0.9739 | Two elderly women suffered an Adverse-Effectacute deterioration of renal function after treatment with cefoxitin sodium. |
| Score | Text |
|---|---|
| 0.9970 | Case study : a modified topical treatment regimen for sodium Drugwarfarin - induced necrotizing fasciitis. |
| 0.9900 | Case study : a modified topical treatment regimen for sodium warfarin - induced Adverse-Effectnecrotizing fasciitis . |
| Score | Text |
|---|---|
| 0.9902 | Adverse-EffectThyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon. |
| 0.9518 | Thyroid dysfunction has been reported in patients with malignant disease treated with Drugrecombinant alpha interferon . |
| Score | Text |
|---|---|
| 0.9947 | BACKGROUND : DrugAccutane a teratogenic prescription drug licensed to treat severe, recalcitrant nodular acne. |
| 0.9707 | BACKGROUND : Accutane a Adverse-Effectteratogenic prescription drug licensed to treat severe, recalcitrant nodular acne. |
| Score | Text |
|---|---|
| 0.9994 | The use of Drugcyclosporin has been associated with the development of cholelithiasis in transplant recipients. |
| 0.9985 | The use of cyclosporin has been associated with the development of Adverse-Effectcholelithiasis in transplant recipients. |
| Score | Text |
|---|---|
| 0.9990 | CONCLUSION : These cases suggest that Drugmoxifloxacin may interfere with the healing of corneal ulcers. |
| 0.9724 | CONCLUSION : These cases suggest that moxifloxacin may interfere with the healing of Adverse-Effectcorneal ulcers . |
| Score | Text |
|---|---|
| 0.9995 | The literature on Drugthiabendazole - induced cholestasis and its association with sicca complex is reviewed. |
| 0.9972 | The literature on thiabendazole - induced Adverse-Effectcholestasis and its association with sicca complex is reviewed. |
| 0.9935 | The literature on thiabendazole - induced cholestasis and its association with Adverse-Effectsicca complex is reviewed. |
| Score | Text |
|---|---|
| 0.9882 | Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following Drugnitrous oxide anesthesia. |
| 0.9721 | Patients with vitamin B12 deficiency are exceedingly sensitive to Adverse-Effectneurologic deterioration following nitrous oxide anesthesia. |
| Score | Text |
|---|---|
| 0.9993 | Clinicians should include Drugphenolphthalein in their list of possible causes of drug - induced TEN. |
| 0.9989 | Clinicians should include phenolphthalein in their list of possible causes of drug - induced Adverse-EffectTEN . |
| Score | Text |
|---|---|
| 0.9992 | DrugStatin - associated myasthenia gravis : report of 4 cases and review of the literature. |
| 0.9911 | Statin - associated Adverse-Effectmyasthenia gravis : report of 4 cases and review of the literature. |
| Score | Text |
|---|---|
| 0.9996 | Fever, pulmonary infiltrates, and pleural effusion following Drugacyclovir therapy for herpes zoster ophthalmicus. |
| 0.9872 | Fever, pulmonary infiltrates, and Adverse-Effectpleural effusion following acyclovir therapy for herpes zoster ophthalmicus. |
| 0.9860 | Adverse-EffectFever , pulmonary infiltrates, and pleural effusion following acyclovir therapy for herpes zoster ophthalmicus. |
| 0.9771 | Fever, Adverse-Effectpulmonary infiltrates , and pleural effusion following acyclovir therapy for herpes zoster ophthalmicus. |
| Score | Text |
|---|---|
| 0.9980 | However, other factors or drugs ( e. g. Drugcresol ) are thought to induce MH. |
| 0.9961 | However, other factors or drugs ( e. g. cresol ) are thought to induce Adverse-EffectMH . |
| Score | Text |
|---|---|
| 0.9989 | We report two cases of neutropenia following Drugcaptopril use in cardiac patients with trisomy 21. |
| 0.9972 | We report two cases of Adverse-Effectneutropenia following captopril use in cardiac patients with trisomy 21. |
| Score | Text |
|---|---|
| 0.9991 | Life - threatening alterations in heart rate after the use of Drugadenosine in atrial flutter. |
| 0.9775 | Life - threatening Adverse-Effectalterations in heart rate after the use of adenosine in atrial flutter. |
| Score | Text |
|---|---|
| 0.9993 | A case of liver damage following treatment with DrugDanazol for fibrocystic breast disease is reported. |
| 0.9932 | A case of Adverse-Effectliver damage following treatment with Danazol for fibrocystic breast disease is reported. |
| Score | Text |
|---|---|
| 0.9993 | Alopecia, nausea, and vomiting were attributed to the Drugcyclophosphamide component of the therapy. |
| 0.9990 | Adverse-EffectAlopecia , nausea, and vomiting were attributed to the cyclophosphamide component of the therapy. |
| 0.9989 | Alopecia, nausea, and Adverse-Effectvomiting were attributed to the cyclophosphamide component of the therapy. |
| 0.9988 | Alopecia, Adverse-Effectnausea , and vomiting were attributed to the cyclophosphamide component of the therapy. |
| Score | Text |
|---|---|
| 0.9978 | In one case, the readministration of riluzole was followed by the relapse of Adverse-Effecthepatitis . |
| 0.9952 | In one case, the readministration of Drugriluzole was followed by the relapse of hepatitis. |
| Score | Text |
|---|---|
| 0.9993 | Subfulminant hepatitis B after Druginfliximab in Crohn's disease : need for HBV - screening? |
| 0.9516 | Adverse-EffectSubfulminant hepatitis B after infliximab in Crohn's disease : need for HBV - screening? |
| Score | Text |
|---|---|
| 0.9809 | Adverse-EffectSystemic capillary leak syndrome after granulocyte colony - stimulating factor ( G - CSF ). |
| 0.9559 | Systemic capillary leak syndrome after Druggranulocyte colony - stimulating factor ( G - CSF ). |
| 0.9443 | Systemic capillary leak syndrome after granulocyte colony - stimulating factor ( DrugG - CSF ). |
| Score | Text |
|---|---|
| 0.9990 | Markedly increased pigmementation of skin immediately overlying veins used for multiple Drug5 - fluorouracil infusions was noted. |
| 0.9745 | Markedly Adverse-Effectincreased pigmementation of skin immediately overlying veins used for multiple 5 - fluorouracil infusions was noted. |
| Score | Text |
|---|---|
| 0.9993 | Severe hyperkalemia as a complication of Drugtimolol , a topically applied beta - adrenergic antagonist. |
| 0.9419 | Adverse-EffectSevere hyperkalemia as a complication of timolol, a topically applied beta - adrenergic antagonist. |
| Score | Text |
|---|---|
| 0.9991 | This is the second report of lactic acidosis in a patient on stavudine and Druglamivudine . |
| 0.9990 | This is the second report of lactic acidosis in a patient on Drugstavudine and lamivudine. |
| 0.9918 | This is the second report of Adverse-Effectlactic acidosis in a patient on stavudine and lamivudine. |
| Score | Text |
|---|---|
| 0.9995 | Drug - induced eosinophilia is a non - dose - dependent side effect of Drugclozapine . |
| 0.9984 | Drug - induced Adverse-Effecteosinophilia is a non - dose - dependent side effect of clozapine. |
| Score | Text |
|---|---|
| 0.9991 | A review of the literature showed no previous description of this pattern in Drugbenzodiazepine coma. |
| 0.9896 | A review of the literature showed no previous description of this pattern in benzodiazepine Adverse-Effectcoma . |
| 0.4425 | A review of the literature showed no previous description of this pattern in Adverse-Effectbenzodiazepine coma . |
| Score | Text |
|---|---|
| 0.9993 | We report a case of intrathecal Drugmethotrexate neurotoxicity manifesting as left arm weakness and aphasia. |
| 0.9962 | We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and Adverse-Effectaphasia . |
| 0.9739 | We report a case of intrathecal methotrexate neurotoxicity manifesting as Adverse-Effectleft arm weakness and aphasia. |
| 0.9493 | We report a case of intrathecal methotrexate Adverse-Effectneurotoxicity manifesting as left arm weakness and aphasia. |
| Score | Text |
|---|---|
| 0.9985 | Prior neurologic illness and the syndrome of irreversible Druglithium - effectuated neurotoxicity ( SILENT ). |
| 0.9949 | Prior neurologic illness and the syndrome of irreversible lithium - effectuated Adverse-Effectneurotoxicity ( SILENT ). |
| Score | Text |
|---|---|
| 0.9995 | Herein we report four patients who underwent liver transplantation and developed neutropenia while receiving DrugMMF . |
| 0.9681 | Herein we report four patients who underwent liver transplantation and developed Adverse-Effectneutropenia while receiving MMF. |
| Score | Text |
|---|---|
| 0.9736 | Multiple myeloma complicated by Adverse-Effectcongestive heart failure following first administration of recombinant alpha - interferon. |
| 0.9142 | Multiple myeloma complicated by congestive heart failure following first administration of Drugrecombinant alpha - interferon . |
| Score | Text |
|---|---|
| 0.9997 | Thus, Drugtacrolimus - induced HUS is a rare cause of ARF in nephrotic syndrome. |
| 0.9981 | Thus, tacrolimus - induced Adverse-EffectHUS is a rare cause of ARF in nephrotic syndrome. |
| 0.9965 | Thus, tacrolimus - induced HUS is a rare cause of Adverse-EffectARF in nephrotic syndrome. |
| Score | Text |
|---|---|
| 0.9996 | According to the Naranjo probability scale, the papular eruption was probably caused by Drugmethotrexate . |
| 0.9924 | According to the Naranjo probability scale, the Adverse-Effectpapular eruption was probably caused by methotrexate. |
| Score | Text |
|---|---|
| 0.9995 | Cerebral demyelinating disease developed in a patient during adjuvant therapy with Druglevamisole for malignant melanoma. |
| 0.9838 | Adverse-EffectCerebral demyelinating disease developed in a patient during adjuvant therapy with levamisole for malignant melanoma. |
| Score | Text |
|---|---|
| 0.9990 | However, re - initiation of Drugsunitinib treatment was followed by bilateral breast enlargement again. |
| 0.9818 | However, re - initiation of sunitinib treatment was followed by Adverse-Effectbilateral breast enlargement again. |
| Score | Text |
|---|---|
| 0.9975 | Two patients developed diabetic coma when taking a combination of a Drugthiazide diuretic and propranolol. |
| 0.9965 | Two patients developed diabetic coma when taking a combination of a thiazide diuretic and Drugpropranolol . |
| 0.9937 | Two patients developed Adverse-Effectdiabetic coma when taking a combination of a thiazide diuretic and propranolol. |
| Score | Text |
|---|---|
| 0.9994 | Surprisingly, we found that three patients appeared to develop tardive OGC while taking Drugclozapine . |
| 0.9931 | Surprisingly, we found that three patients appeared to develop Adverse-Effecttardive OGC while taking clozapine. |
| Score | Text |
|---|---|
| 0.9995 | So far, few cases of pulmonary side effects caused by Drugticlopidine have been reported. |
| 0.9844 | So far, few cases of Adverse-Effectpulmonary side effects caused by ticlopidine have been reported. |
| Score | Text |
|---|---|
| 0.9988 | CONCLUSION : The present findings suggest that Drugfluvoxamine can cause increased libido in some patients. |
| 0.9907 | CONCLUSION : The present findings suggest that fluvoxamine can cause Adverse-Effectincreased libido in some patients. |
| Score | Text |
|---|---|
| 0.9991 | Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g Drugdoxycycline . |
| 0.9865 | Adverse-EffectRenal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline. |
| Score | Text |
|---|---|
| 0.9997 | Fatal pulmonary fibrosis induced by Drugpaclitaxel : a case report and review of the literature. |
| 0.9856 | Adverse-EffectFatal pulmonary fibrosis induced by paclitaxel : a case report and review of the literature. |
| Score | Text |
|---|---|
| 0.9992 | Adrenal suppression in a fetus due to administration of Drugmethylprednisolone has hitherto been rarely published. |
| 0.9792 | Adverse-EffectAdrenal suppression in a fetus due to administration of methylprednisolone has hitherto been rarely published. |
| Score | Text |
|---|---|
| 0.9985 | Cis - retinoic acid ( RA ) may further increase the risk of developing Adverse-EffectBMTN . |
| 0.9658 | DrugCis - retinoic acid ( RA ) may further increase the risk of developing BMTN. |
| 0.9597 | Cis - retinoic acid ( DrugRA ) may further increase the risk of developing BMTN. |
| Score | Text |
|---|---|
| 0.9991 | We describe 3 cases of Drugdiphenhydramine - induced cardiac toxicity that were responsive to bicarbonate. |
| 0.9915 | We describe 3 cases of diphenhydramine - induced Adverse-Effectcardiac toxicity that were responsive to bicarbonate. |
| Score | Text |
|---|---|
| 0.9991 | DrugPropoxyphene - induced wide QRS complex dysrhythmia responsive to sodium bicarbonate - - a case report. |
| 0.9788 | Propoxyphene - induced Adverse-Effectwide QRS complex dysrhythmia responsive to sodium bicarbonate - - a case report. |
| Score | Text |
|---|---|
| 0.9993 | Pleuropulmonary fibrosis after long - term treatment with the dopamine agonist Drugpergolide for Parkinson Disease. |
| 0.9894 | Adverse-EffectPleuropulmonary fibrosis after long - term treatment with the dopamine agonist pergolide for Parkinson Disease. |
| Score | Text |
|---|---|
| 0.9853 | Acute onset of Adverse-Effectnephrotic syndrome during interferon - alpha retreatment for chronic active hepatitis C. |
| 0.9682 | Acute onset of nephrotic syndrome during Druginterferon - alpha retreatment for chronic active hepatitis C. |
| Score | Text |
|---|---|
| 0.9991 | Sweet's syndrome associated with Drugsargramostim ( granulocyte - macrophage colony stimulating factor ) treatment. |
| 0.9822 | Adverse-EffectSweet's syndrome associated with sargramostim ( granulocyte - macrophage colony stimulating factor ) treatment. |
| Score | Text |
|---|---|
| 0.9995 | We report the first case of Drugdoxycycline - induced hypoglycemia in a young nondiabetic man. |
| 0.9980 | We report the first case of doxycycline - induced Adverse-Effecthypoglycemia in a young nondiabetic man. |
| Score | Text |
|---|---|
| 0.9862 | Under the suspicion of amiodarone - induced Adverse-Effectacute pancreatitis , amiodarone was substituted by propafenone. |
| 0.9327 | Under the suspicion of Drugamiodarone - induced acute pancreatitis, amiodarone was substituted by propafenone. |
| Score | Text |
|---|---|
| 0.9995 | A diagnosis of Druginfliximab - induced lupus was made and the drug treatment was withdrawn. |
| 0.9982 | A diagnosis of infliximab - induced Adverse-Effectlupus was made and the drug treatment was withdrawn. |
| Score | Text |
|---|---|
| 0.9966 | Aggressive management of doxorubicin - induced Adverse-Effectcardiomyopathy associated with'low'doses of doxorubicin. |
| 0.9422 | Aggressive management of Drugdoxorubicin - induced cardiomyopathy associated with'low'doses of doxorubicin. |
| 0.8350 | Aggressive management of doxorubicin - induced cardiomyopathy associated with'low'doses of Drugdoxorubicin . |
| Score | Text |
|---|---|
| 0.9994 | Hypertension develops in most patients after transplantation when immunosuppression is based on cyclosporine and Drugprednisone . |
| 0.9993 | Hypertension develops in most patients after transplantation when immunosuppression is based on Drugcyclosporine and prednisone. |
| 0.9983 | Adverse-EffectHypertension develops in most patients after transplantation when immunosuppression is based on cyclosporine and prednisone. |
| Score | Text |
|---|---|
| 0.9995 | However, each infant demonstrated hemodynamic decompensation shortly after Drugverapamil administration and required cardiopulmonary resuscitation. |
| 0.9876 | However, each infant demonstrated Adverse-Effecthemodynamic decompensation shortly after verapamil administration and required cardiopulmonary resuscitation. |
| Score | Text |
|---|---|
| 0.9995 | A case of aseptic pleuropericarditis in a patient with chronic plaque psoriasis under Drugmethotrexate therapy. |
| 0.9804 | A case of Adverse-Effectaseptic pleuropericarditis in a patient with chronic plaque psoriasis under methotrexate therapy. |
| Score | Text |
|---|---|
| 0.9995 | We report a case of a bullous lichenoid eruption due to the intake of Drugcaptopril . |
| 0.9870 | We report a case of a Adverse-Effectbullous lichenoid eruption due to the intake of captopril. |
| Score | Text |
|---|---|
| 0.9934 | Therapy with IFN - beta has rarely been associated with the development of Adverse-Effectautoimmune disorders . |
| 0.9692 | Therapy with DrugIFN - beta has rarely been associated with the development of autoimmune disorders. |
| Score | Text |
|---|---|
| 0.9990 | The side effects of DrugMMF , such as bone marrow toxicity, have been reported. |
| 0.9857 | The side effects of MMF, such as Adverse-Effectbone marrow toxicity , have been reported. |
| Score | Text |
|---|---|
| 0.9985 | Adverse-EffectHypoglycemia induced by long - acting somatostatin analogues in a patient with nonfunctional neuroendocrine tumor. |
| 0.9973 | Hypoglycemia induced by long - acting Drugsomatostatin analogues in a patient with nonfunctional neuroendocrine tumor. |
| Score | Text |
|---|---|
| 0.9996 | PURPOSE : Symptomatic visual field constriction thought to be associated with Drugvigabatrin has been reported. |
| 0.9639 | PURPOSE : Symptomatic Adverse-Effectvisual field constriction thought to be associated with vigabatrin has been reported. |
| Score | Text |
|---|---|
| 0.9993 | An 11 - day - old infant became lethargic and apneic after a single drop of Drugbrimonidine . |
| 0.9972 | An 11 - day - old infant became Adverse-Effectlethargic and apneic after a single drop of brimonidine. |
| 0.9956 | An 11 - day - old infant became lethargic and Adverse-Effectapneic after a single drop of brimonidine. |
| Score | Text |
|---|---|
| 0.9993 | Ballistic movements due to ischemic infarcts after intravenous Drugheroin overdose : report of two cases. |
| 0.9838 | Adverse-EffectBallistic movements due to ischemic infarcts after intravenous heroin overdose : report of two cases. |
| 0.9766 | Ballistic movements due to Adverse-Effectischemic infarcts after intravenous heroin overdose : report of two cases. |
| Score | Text |
|---|---|
| 0.9989 | Although myelosuppression is mild, immunosuppression and superinfection are potential hazards of treatment with DrugDCF . |
| 0.9745 | Although myelosuppression is mild, immunosuppression and Adverse-Effectsuperinfection are potential hazards of treatment with DCF. |
| 0.9418 | Although myelosuppression is mild, Adverse-Effectimmunosuppression and superinfection are potential hazards of treatment with DCF. |
| Score | Text |
|---|---|
| 0.9984 | To our knowledge, this recurrence of Drugamiodarone pulmonary toxicity has not been reported previously. |
| 0.8608 | To our knowledge, this recurrence of amiodarone Adverse-Effectpulmonary toxicity has not been reported previously. |
| Score | Text |
|---|---|
| 0.9994 | CONCLUSION : Squamous metaplasia in these cases appears to be a consequence of Drugprogestin therapy. |
| 0.9793 | CONCLUSION : Adverse-EffectSquamous metaplasia in these cases appears to be a consequence of progestin therapy. |
| Score | Text |
|---|---|
| 0.9989 | We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of Drugmonooctanoin . |
| 0.9843 | We describe a patient in whom Adverse-Effectnoncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin. |
| Score | Text |
|---|---|
| 0.9993 | Occurrence of withdrawal dyskinesia indicates that the neuroleptic effects of Drugamoxapine may be clinically significant. |
| 0.9953 | Occurrence of withdrawal Adverse-Effectdyskinesia indicates that the neuroleptic effects of amoxapine may be clinically significant. |
| Score | Text |
|---|---|
| 0.9942 | Pulmonary fibrosis is a severe complication associated with bis - chloronitrosourea ( DrugBCNU ) therapy. |
| 0.9893 | Adverse-EffectPulmonary fibrosis is a severe complication associated with bis - chloronitrosourea ( BCNU ) therapy. |
| 0.9662 | Pulmonary fibrosis is a severe complication associated with Drugbis - chloronitrosourea ( BCNU ) therapy. |
| Score | Text |
|---|---|
| 0.9996 | Clinicians should be aware of the possibility that Drugvinorelbine may cause SIADH and possibly hypokalemia. |
| 0.9981 | Clinicians should be aware of the possibility that vinorelbine may cause SIADH and possibly Adverse-Effecthypokalemia . |
| 0.9979 | Clinicians should be aware of the possibility that vinorelbine may cause Adverse-EffectSIADH and possibly hypokalemia. |
| Score | Text |
|---|---|
| 0.9993 | Early recognition of renal toxicity of high - dose Drugmethotrexate therapy : a case report. |
| 0.9885 | Early recognition of Adverse-Effectrenal toxicity of high - dose methotrexate therapy : a case report. |
| Score | Text |
|---|---|
| 0.9981 | Reactivation of cytomegalovirus probably followed the treatment of Wegener's granulomatosis with corticosteroids and Drugazathioprine . |
| 0.9504 | Adverse-EffectReactivation of cytomegalovirus probably followed the treatment of Wegener's granulomatosis with corticosteroids and azathioprine. |
| Score | Text |
|---|---|
| 0.9948 | Adverse-EffectInfections are a major adverse effect during the treatment with anti - TNF - alpha. |
| 0.9483 | Infections are a major adverse effect during the treatment with Druganti - TNF - alpha . |
| Score | Text |
|---|---|
| 0.9994 | A 15 - kg weight gain developed in a patient during the third week of Drugibuprofen therapy. |
| 0.9824 | A Adverse-Effect15 - kg weight gain developed in a patient during the third week of ibuprofen therapy. |
| Score | Text |
|---|---|
| 0.9995 | Nephrogenic diabetes insipidus ( NDI ) is a well - documented complication of Druglithium use. |
| 0.9965 | Nephrogenic diabetes insipidus ( Adverse-EffectNDI ) is a well - documented complication of lithium use. |
| 0.9820 | Adverse-EffectNephrogenic diabetes insipidus ( NDI ) is a well - documented complication of lithium use. |
| Score | Text |
|---|---|
| 0.9987 | Introduction of Drugetanercept was also clinically effective but followed by development of severe heart failure. |
| 0.9915 | Introduction of etanercept was also clinically effective but followed by development of Adverse-Effectsevere heart failure . |
| Score | Text |
|---|---|
| 0.9698 | Nineteen cases of unusual enhanced Drugvincristine neurotoxicity related to itraconazole have been reported in children. |
| 0.9315 | Nineteen cases of unusual enhanced vincristine neurotoxicity related to Drugitraconazole have been reported in children. |
| 0.8451 | Nineteen cases of unusual enhanced vincristine Adverse-Effectneurotoxicity related to itraconazole have been reported in children. |
| Score | Text |
|---|---|
| 0.9990 | DrugPropranolol : an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass. |
| 0.9804 | Propranolol : an unrecognized cause of Adverse-Effectcentral nervous system dysfunction in patients undergoing cardiopulmonary bypass. |
| Score | Text |
|---|---|
| 0.9984 | Severe acidosis in patients taking Drugmetformin - - rapid reversal and survival despite high APACHE score. |
| 0.9888 | Adverse-EffectSevere acidosis in patients taking metformin - - rapid reversal and survival despite high APACHE score. |
| Score | Text |
|---|---|
| 0.9994 | We report on a child with fatal Drugvalproate - related hepatotoxic effects despite this supplementation. |
| 0.9736 | We report on a child with fatal valproate - related Adverse-Effecthepatotoxic effects despite this supplementation. |
| We report on a child with Adverse-Effectfatal valproate - related hepatotoxic effects despite this supplementation. | |
| Score | Text |
|---|---|
| 0.9994 | Hypogammaglobulinemia associated with Druggold therapy : evidence for a partial maturation blockade of B cells. |
| 0.9966 | Adverse-EffectHypogammaglobulinemia associated with gold therapy : evidence for a partial maturation blockade of B cells. |
| Score | Text |
|---|---|
| 0.9973 | DrugErythromycin is a macrolide antibiotic that may increase the risk of lovastatin - induced rhabdomyolysis. |
| 0.9965 | Erythromycin is a macrolide antibiotic that may increase the risk of lovastatin - induced Adverse-Effectrhabdomyolysis . |
| 0.9961 | Erythromycin is a macrolide antibiotic that may increase the risk of Druglovastatin - induced rhabdomyolysis. |
| Score | Text |
|---|---|
| 0.9992 | The mechanism of anaphylactoid reaction to Drugzomepirac in this case, therefore, remains unclear. |
| 0.9864 | The mechanism of Adverse-Effectanaphylactoid reaction to zomepirac in this case, therefore, remains unclear. |
| Score | Text |
|---|---|
| 0.9993 | However, the occurrence and management of akathisia induced by Drugfluvoxamine have not been described. |
| 0.9964 | However, the occurrence and management of Adverse-Effectakathisia induced by fluvoxamine have not been described. |
| Score | Text |
|---|---|
| 0.9970 | Upon discontinuation of DrugMTX , her ascites resolved, and her arthritis became more active. |
| 0.9944 | Upon discontinuation of MTX, her Adverse-Effectascites resolved, and her arthritis became more active. |
| Score | Text |
|---|---|
| 0.9996 | Pulmonary fibrosis is a complication of Drugpaclitaxel therapy that may occur despite treatments with corticosteroids. |
| 0.9916 | Adverse-EffectPulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids. |
| Score | Text |
|---|---|
| 0.9994 | Onset of male gynaecomastia in a patient treated with Drugsunitinib for metastatic renal cell carcinoma. |
| 0.9703 | Onset of male Adverse-Effectgynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma. |
| Score | Text |
|---|---|
| 0.9980 | Adverse-EffectMethemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field. |
| 0.9976 | Methemoglobinemia after axillary block with Drugbupivacaine and additional injection of lidocaine in the operative field. |
| 0.9968 | Methemoglobinemia after axillary block with bupivacaine and additional injection of Druglidocaine in the operative field. |
| Score | Text |
|---|---|
| 0.9994 | Acute dystonia with thalamic and brainstem lesions after initial Drugpenicillamine treatment in Wilson's disease. |
| 0.9850 | Adverse-EffectAcute dystonia with thalamic and brainstem lesions after initial penicillamine treatment in Wilson's disease. |
| 0.9714 | Acute dystonia with Adverse-Effectthalamic and brainstem lesions after initial penicillamine treatment in Wilson's disease. |
| Score | Text |
|---|---|
| 0.9868 | In two patients Drugclozapine was reinstated after risperidone was discontinued ; serum triglyceride levels increased. |
| 0.9740 | In two patients clozapine was reinstated after risperidone was discontinued ; Adverse-Effectserum triglyceride levels increased . |
| Score | Text |
|---|---|
| 0.9993 | DrugNifedipine may induce, or aggravate, pre - existing, gastro - oesophageal reflux. |
| 0.9587 | Nifedipine may induce, or aggravate, pre - existing, Adverse-Effectgastro - oesophageal reflux . |
| Score | Text |
|---|---|
| 0.9943 | A major limitation in the use of amphotericin B is its potential to cause Adverse-Effectnephrotoxicity . |
| 0.9778 | A major limitation in the use of Drugamphotericin B is its potential to cause nephrotoxicity. |
| Score | Text |
|---|---|
| 0.9991 | After receiving 3 doses of Drugifosfamide / mesna, she was found to be unresponsive. |
| 0.9988 | After receiving 3 doses of ifosfamide / Drugmesna , she was found to be unresponsive. |
| 0.9920 | After receiving 3 doses of ifosfamide / mesna, she was found to be Adverse-Effectunresponsive . |
| Score | Text |
|---|---|
| 0.9984 | Adverse-EffectRhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy. |
| 0.9844 | Rhabdomyolysis caused by tocolysis with oral Drugritodrine hydrochloride in a pregnant patient with myotonic dystrophy. |
| Score | Text |
|---|---|
| 0.9996 | A case of SIADH associated with Drugdesipramine treatment in an elderly depressed woman is described. |
| 0.9980 | A case of Adverse-EffectSIADH associated with desipramine treatment in an elderly depressed woman is described. |
| Score | Text |
|---|---|
| 0.9983 | We assume that rIFN - gamma induced the de novo development of Adverse-EffectSLE in our patient. |
| 0.9742 | We assume that DrugrIFN - gamma induced the de novo development of SLE in our patient. |
| Score | Text |
|---|---|
| 0.9986 | Adverse-EffectHypernatraemia induced by sodium polystyrene sulphonate ( Kayexalate ) in two extremely low birth weight newborns. |
| 0.9947 | Hypernatraemia induced by sodium polystyrene sulphonate ( DrugKayexalate ) in two extremely low birth weight newborns. |
| 0.9712 | Hypernatraemia induced by Drugsodium polystyrene sulphonate ( Kayexalate ) in two extremely low birth weight newborns. |
| Score | Text |
|---|---|
| 0.9995 | DrugRifampicin - induced adrenal insufficiency in the acquired immunodeficiency syndrome : difficulties in diagnosis and treatment. |
| 0.9897 | Rifampicin - induced Adverse-Effectadrenal insufficiency in the acquired immunodeficiency syndrome : difficulties in diagnosis and treatment. |
| Score | Text |
|---|---|
| 0.9859 | Rituximab - CHOP induced Adverse-Effectinterstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma. |
| 0.9578 | DrugRituximab - CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma. |
| Score | Text |
|---|---|
| 0.9705 | Early - onset acute transverse myelitis following Drughepatitis B vaccination and respiratory infection : case report. |
| 0.9689 | Early - onset Adverse-Effectacute transverse myelitis following hepatitis B vaccination and respiratory infection : case report. |
| Score | Text |
|---|---|
| 0.9992 | A case is presented which illustrates a probably fatal interaction between Drugminoxidil and a coagulation disorder. |
| 0.9527 | A case is presented which illustrates a probably Adverse-Effectfatal interaction between minoxidil and a coagulation disorder. |
| Score | Text |
|---|---|
| 0.9988 | A patient developed transient, acute myopia while on Drugisotretinoin ( Accutane ) therapy for acne. |
| 0.9987 | A patient developed transient, acute myopia while on isotretinoin ( DrugAccutane ) therapy for acne. |
| 0.9835 | A patient developed transient, Adverse-Effectacute myopia while on isotretinoin ( Accutane ) therapy for acne. |
| Score | Text |
|---|---|
| 0.9994 | A patient that received Drugmethadone for cancer - associated pain developed myoclonus as a side effect. |
| 0.9987 | A patient that received methadone for cancer - associated pain developed Adverse-Effectmyoclonus as a side effect. |
| Score | Text |
|---|---|
| 0.9995 | Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, DrugAmikacin . |
| 0.9904 | Recovery of the Adverse-Effecttubular dysfunction took 15 days following cessation of the offending drug, Amikacin. |
| Score | Text |
|---|---|
| 0.9994 | Renal toxicities have been reported in less than one percent of the patients receiving Drugciprofloxacin therapy. |
| 0.9916 | Adverse-EffectRenal toxicities have been reported in less than one percent of the patients receiving ciprofloxacin therapy. |
| Score | Text |
|---|---|
| 0.9997 | Myoglobinuria and acute renal failure were observed in two patients with Drugvasopressin - treated gastrointestinal hemorrhage. |
| 0.9970 | Adverse-EffectMyoglobinuria and acute renal failure were observed in two patients with vasopressin - treated gastrointestinal hemorrhage. |
| 0.9873 | Myoglobinuria and Adverse-Effectacute renal failure were observed in two patients with vasopressin - treated gastrointestinal hemorrhage. |
| Score | Text |
|---|---|
| 0.9954 | Valproic acid induced Adverse-Effectcoma is presented in an adult patient without a history of metabolic disease. |
| 0.9867 | DrugValproic acid induced coma is presented in an adult patient without a history of metabolic disease. |
| Score | Text |
|---|---|
| 0.9986 | We report two patients with infectious mononucleosis - like syndrome induced by Drugsalazosulfapyridine ( SASP ). |
| 0.9978 | We report two patients with infectious mononucleosis - like syndrome induced by salazosulfapyridine ( DrugSASP ). |
| 0.9724 | We report two patients with Adverse-Effectinfectious mononucleosis - like syndrome induced by salazosulfapyridine ( SASP ). |
| Score | Text |
|---|---|
| 0.9996 | over the past 3 years there have been several reports of uveitis associated with Drugrifabutin therapy. |
| 0.9980 | over the past 3 years there have been several reports of Adverse-Effectuveitis associated with rifabutin therapy. |
| Score | Text |
|---|---|
| 0.9978 | Posterior leukoencephalopathy following cisplatin, Drugbleomycin and vinblastine therapy for germ cell tumor of the ovary. |
| 0.9976 | Posterior leukoencephalopathy following Drugcisplatin , bleomycin and vinblastine therapy for germ cell tumor of the ovary. |
| 0.9970 | Posterior leukoencephalopathy following cisplatin, bleomycin and Drugvinblastine therapy for germ cell tumor of the ovary. |
| 0.9767 | Adverse-EffectPosterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary. |
| Score | Text |
|---|---|
| 0.9977 | Colonic mucosal necrosis following administration of calcium polystryrene sulfonate ( DrugKalimate ) in a uremic patient. |
| 0.9868 | Adverse-EffectColonic mucosal necrosis following administration of calcium polystryrene sulfonate ( Kalimate ) in a uremic patient. |
| 0.9677 | Colonic mucosal necrosis following administration of Drugcalcium polystryrene sulfonate ( Kalimate ) in a uremic patient. |
| Score | Text |
|---|---|
| 0.9994 | Two patients are described in whom subtle cognitive impairments are associated with therapeutic doses of Drugamoxapine . |
| 0.9838 | Two patients are described in whom subtle Adverse-Effectcognitive impairments are associated with therapeutic doses of amoxapine. |
| Score | Text |
|---|---|
| 0.9995 | Thus, tardive seizures in our cases are thought to be related to piperacillin and Drugcefotiam . |
| 0.9995 | Thus, tardive seizures in our cases are thought to be related to Drugpiperacillin and cefotiam. |
| 0.9897 | Thus, Adverse-Effecttardive seizures in our cases are thought to be related to piperacillin and cefotiam. |
| Score | Text |
|---|---|
| 0.9995 | Secondary leukemia in a child with neuroblastoma while on oral Drugetoposide : what is the cause? |
| 0.8589 | Adverse-EffectSecondary leukemia in a child with neuroblastoma while on oral etoposide : what is the cause? |
| Score | Text |
|---|---|
| 0.9995 | The incidence of angioedema secondary to Druglosartan , an angiotensin II receptor antagonist, is unknown. |
| 0.9979 | The incidence of Adverse-Effectangioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown. |
| Score | Text |
|---|---|
| 0.9988 | A case report of a patient with probable cisplatin and bleomycin - induced Adverse-EffectTMA is presented. |
| 0.9972 | A case report of a patient with probable cisplatin and Drugbleomycin - induced TMA is presented. |
| 0.9954 | A case report of a patient with probable Drugcisplatin and bleomycin - induced TMA is presented. |
| Score | Text |
|---|---|
| 0.9876 | Adverse-EffectSkin necrosis secondary to low - molecular weight heparin in a patient with antiphospholipid antibody syndrome. |
| 0.9601 | Skin necrosis secondary to Druglow - molecular weight heparin in a patient with antiphospholipid antibody syndrome. |
| Score | Text |
|---|---|
| 0.9892 | These case reports provide evidence that 5 - aminosalicylic acid may induce Adverse-Effectacute pancreatitis after long term treatment. |
| 0.9777 | These case reports provide evidence that Drug5 - aminosalicylic acid may induce acute pancreatitis after long term treatment. |
| Score | Text |
|---|---|
| 0.9995 | The fifth patient exhibited paraesthesia and agitation caused by Drugolanzapine that was misdiagnosed as psychotic agitation. |
| 0.9978 | The fifth patient exhibited Adverse-Effectparaesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation. |
| 0.9964 | The fifth patient exhibited paraesthesia and Adverse-Effectagitation caused by olanzapine that was misdiagnosed as psychotic agitation. |
| Score | Text |
|---|---|
| 0.9994 | Severe respiratory syncytial virus pulmonary infection in a patient treated with Drugfludarabine for chronic lymphocytic leukemia. |
| 0.9459 | Adverse-EffectSevere respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia. |
| Score | Text |
|---|---|
| 0.9978 | We report here a case of cardiovascular and neurological depression induced by Drugoxymetalzoline in a toddler. |
| 0.9510 | We report here a case of cardiovascular and Adverse-Effectneurological depression induced by oxymetalzoline in a toddler. |
| Score | Text |
|---|---|
| 0.9920 | Dihydropyrimidine dehydrogenase deficiency : a pharmacogenetic defect causing severe adverse reactions to Drug5 - fluorouracil - based chemotherapy. |
| 0.9649 | Dihydropyrimidine dehydrogenase deficiency : a pharmacogenetic defect causing Adverse-Effectsevere adverse reactions to 5 - fluorouracil - based chemotherapy. |
| Score | Text |
|---|---|
| 0.9921 | Adverse-EffectThrombotic stroke associated with the use of porcine factor VIII in a patient with acquired haemophilia. |
| 0.9714 | Thrombotic stroke associated with the use of Drugporcine factor VIII in a patient with acquired haemophilia. |
| Score | Text |
|---|---|
| 0.9996 | We describe four patients who had seizures while receiving Drugofloxacin ; no other causes were evident. |
| 0.9987 | We describe four patients who had Adverse-Effectseizures while receiving ofloxacin ; no other causes were evident. |
| Score | Text |
|---|---|
| 0.9981 | We report two adults who received Druggabapentin ( GBP ) and subsequently developed behavioural side effects. |
| 0.9956 | We report two adults who received gabapentin ( DrugGBP ) and subsequently developed behavioural side effects. |
| 0.9827 | We report two adults who received gabapentin ( GBP ) and subsequently developed Adverse-Effectbehavioural side effects . |
| Score | Text |
|---|---|
| 0.9991 | When tuberculosis patients on Drugisoniazid eat certain varieties of fish they may develop a histamine reaction. |
| 0.9896 | When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a Adverse-Effecthistamine reaction . |
| Score | Text |
|---|---|
| 0.9995 | We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of Drugtobramycin . |
| 0.9878 | We report a case of Adverse-Effectexfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin. |
| Score | Text |
|---|---|
| 0.9991 | Within 24 hours of fluid restriction and cessation of Drugdesmopressin , her symptoms and hyponatremia resolved. |
| 0.9977 | Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and Adverse-Effecthyponatremia resolved. |
| Score | Text |
|---|---|
| 0.9996 | Hepatitis with bridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking Drugmethotrexate . |
| 0.9985 | Adverse-EffectHepatitis with bridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking methotrexate. |
| 0.9852 | Hepatitis with Adverse-Effectbridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking methotrexate. |
| 0.9766 | Hepatitis with bridging fibrosis and Adverse-Effectreversible hepatic insufficiency in a woman with rheumatoid arthritis taking methotrexate. |
| Score | Text |
|---|---|
| 0.9993 | A 64 - year - old man with schizophrenia developed myoclonic jerks when given higher doses of Drugquetiapine . |
| 0.9931 | A 64 - year - old man with schizophrenia developed Adverse-Effectmyoclonic jerks when given higher doses of quetiapine. |
| Score | Text |
|---|---|
| 0.9595 | Acute renal failure is a rare complication following the administration of intravenous Drugimmunoglobulin ( IVIG ). |
| 0.7604 | Adverse-EffectAcute renal failure is a rare complication following the administration of intravenous immunoglobulin ( IVIG ). |
| 0.5427 | Acute Adverse-Effectrenal failure is a rare complication following the administration of intravenous immunoglobulin ( IVIG ). |
| Score | Text |
|---|---|
| 0.9982 | It is concluded that simultaneous administration of Drugciprofloxacin and tazobactam / piperacillin may cause marked thrombocytosis. |
| 0.9979 | It is concluded that simultaneous administration of ciprofloxacin and Drugtazobactam / piperacillin may cause marked thrombocytosis. |
| 0.9975 | It is concluded that simultaneous administration of ciprofloxacin and tazobactam / Drugpiperacillin may cause marked thrombocytosis. |
| 0.9951 | It is concluded that simultaneous administration of ciprofloxacin and tazobactam / piperacillin may cause marked Adverse-Effectthrombocytosis . |
| Score | Text |
|---|---|
| 0.9994 | The present report describes the first case of acute pancreatitis associated with Drugdanazol treatment of endometriosis. |
| 0.9855 | The present report describes the first case of Adverse-Effectacute pancreatitis associated with danazol treatment of endometriosis. |
| Score | Text |
|---|---|
| 0.9993 | Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with Drughydroxyurea for Philadelphia negative essential thrombocythaemia. |
| 0.9631 | Emergence of Adverse-EffectPhiladelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Philadelphia negative essential thrombocythaemia. |
| Score | Text |
|---|---|
| 0.9996 | The patient experienced muscle twitches, tremulousness, and anxiety on day 17 of Drugfoscarnet therapy. |
| 0.9977 | The patient experienced muscle twitches, tremulousness, and Adverse-Effectanxiety on day 17 of foscarnet therapy. |
| 0.9970 | The patient experienced muscle twitches, Adverse-Effecttremulousness , and anxiety on day 17 of foscarnet therapy. |
| 0.9885 | The patient experienced Adverse-Effectmuscle twitches , tremulousness, and anxiety on day 17 of foscarnet therapy. |
| Score | Text |
|---|---|
| 0.9921 | Adverse-EffectScrotal ulceration induced by all - trans retinoic acid in a patient with acute promyelocytic leukemia. |
| 0.9525 | Scrotal ulceration induced by Drugall - trans retinoic acid in a patient with acute promyelocytic leukemia. |
| Scrotal ulceration induced by all - trans Drugretinoic acid in a patient with acute promyelocytic leukemia. | |
| Score | Text |
|---|---|
| 0.9994 | Acute Drugesmolol toxicity may be self - limiting because of its extremely short half - life. |
| 0.6531 | Acute Adverse-Effectesmolol toxicity may be self - limiting because of its extremely short half - life. |
| Score | Text |
|---|---|
| 0.9961 | We present a surprising case of a woman schizophrenic patient treated with Drugclozapine suffering from EPS. |
| 0.9951 | We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from Adverse-EffectEPS . |
| Score | Text |
|---|---|
| 0.9996 | This is the first description, to our knowledge, of ductopenia apparently caused by Drugclindamycin . |
| 0.9983 | This is the first description, to our knowledge, of Adverse-Effectductopenia apparently caused by clindamycin. |
| Score | Text |
|---|---|
| 0.9995 | To our knowledge, this case is the first published report of Druglevofloxacin - induced TEN. |
| 0.9992 | To our knowledge, this case is the first published report of levofloxacin - induced Adverse-EffectTEN . |
| Score | Text |
|---|---|
| 0.9959 | Cutaneous sarcoidosis during interferon alfa and Drugribavirin treatment of hepatitis C virus infection : two cases. |
| 0.9899 | Adverse-EffectCutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection : two cases. |
| 0.9879 | Cutaneous sarcoidosis during Druginterferon alfa and ribavirin treatment of hepatitis C virus infection : two cases. |
| Score | Text |
|---|---|
| 0.9890 | Adverse-EffectLichen planus induced by hepatitis B vaccination : a new case and review of the literature. |
| 0.9666 | Lichen planus induced by Drughepatitis B vaccination : a new case and review of the literature. |
| Score | Text |
|---|---|
| 0.9996 | Contact dermatitis due to Drugbudesonide : report of five cases and review of the Japanese literature. |
| 0.9897 | Adverse-EffectContact dermatitis due to budesonide : report of five cases and review of the Japanese literature. |
| Score | Text |
|---|---|
| 0.9995 | Potential mechanisms involved in the occurrence of ischemic colitis in patients receiving Drugtegaserod are also discussed. |
| 0.9927 | Potential mechanisms involved in the occurrence of Adverse-Effectischemic colitis in patients receiving tegaserod are also discussed. |
| Score | Text |
|---|---|
| 0.9994 | In four patients, spasm occurred spontaneous and in one patient after 0. 05 mg of Drugergonovine . |
| 0.9975 | In four patients, Adverse-Effectspasm occurred spontaneous and in one patient after 0. 05 mg of ergonovine. |
| Score | Text |
|---|---|
| 0.9983 | There is a dose - effect relationship between Drugdoxorubicin and the incidence of symptomatic cardiac failure. |
| 0.9832 | There is a dose - effect relationship between doxorubicin and the incidence of Adverse-Effectsymptomatic cardiac failure . |
| Score | Text |
|---|---|
| 0.9996 | A rechallenge, performed in both patients, confirmed the diagnosis of Drugmesalamine - induced pancreatitis. |
| 0.9985 | A rechallenge, performed in both patients, confirmed the diagnosis of mesalamine - induced Adverse-Effectpancreatitis . |
| Score | Text |
|---|---|
| 0.9994 | CONCLUSION : The findings in these two patients suggest that Drugcolchicine may delay corneal wound healing. |
| 0.9394 | CONCLUSION : The findings in these two patients suggest that colchicine may Adverse-Effectdelay corneal wound healing . |
| Score | Text |
|---|---|
| 0.9994 | A 69 - year - old man developed pure red cell aplasia after taking Drugfenoprofen for ten months. |
| 0.9780 | A 69 - year - old man developed Adverse-Effectpure red cell aplasia after taking fenoprofen for ten months. |
| Score | Text |
|---|---|
| 0.9994 | New onset of CD may be considered as an immune - mediated injury induced by Drugetanercept . |
| 0.9717 | New onset of CD may be considered as an Adverse-Effectimmune - mediated injury induced by etanercept. |
| 0.9674 | New onset of Adverse-EffectCD may be considered as an immune - mediated injury induced by etanercept. |
| Score | Text |
|---|---|
| 0.9992 | Three patients with no history of asthma or allergy developed bronchospasm while taking Drugpropranolol for hypertension. |
| 0.9987 | Three patients with no history of asthma or allergy developed Adverse-Effectbronchospasm while taking propranolol for hypertension. |
| Score | Text |
|---|---|
| 0.9956 | OBJECTIVE : To report a case of DrugCarbamazepine toxicity following the administration of Oxybutynin and Dantrolene. |
| 0.9922 | OBJECTIVE : To report a case of Carbamazepine toxicity following the administration of Oxybutynin and DrugDantrolene . |
| 0.9887 | OBJECTIVE : To report a case of Carbamazepine toxicity following the administration of DrugOxybutynin and Dantrolene. |
| 0.9079 | OBJECTIVE : To report a case of Adverse-EffectCarbamazepine toxicity following the administration of Oxybutynin and Dantrolene. |
| Score | Text |
|---|---|
| 0.9996 | The delayed encephalopathy developed 9 and 22 months respectively after the first dose of intrathecal Drugmethotrexate . |
| 0.9950 | The delayed Adverse-Effectencephalopathy developed 9 and 22 months respectively after the first dose of intrathecal methotrexate. |
| Score | Text |
|---|---|
| 0.9896 | Adverse-EffectHepatotoxicity associated with choline magnesium trisalicylate : case report and review of salicylate - induced hepatotoxicity. |
| 0.9708 | Hepatotoxicity associated with choline magnesium trisalicylate : case report and review of salicylate - induced Adverse-Effecthepatotoxicity . |
| 0.7307 | Hepatotoxicity associated with choline magnesium trisalicylate : case report and review of Drugsalicylate - induced hepatotoxicity. |
| Hepatotoxicity associated with Drugcholine magnesium trisalicylate : case report and review of salicylate - induced hepatotoxicity. | |
| Score | Text |
|---|---|
| 0.9992 | DrugSulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease ( IBD ) in adults. |
| 0.9861 | Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease ( Adverse-EffectIBD ) in adults. |
| 0.9663 | Sulfasalazine has been associated with Adverse-Effectbronchopulmonary complications of inflammatory bowel disease ( IBD ) in adults. |
| Score | Text |
|---|---|
| 0.9751 | DrugZoledronic acid - induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases. |
| 0.9722 | Zoledronic acid - induced Adverse-Effectsevere hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases. |
| Score | Text |
|---|---|
| 0.9994 | DrugInfliximab therapy may cause a lupus - like syndrome that is reversible upon discontinuing this agent. |
| 0.9831 | Infliximab therapy may cause a Adverse-Effectlupus - like syndrome that is reversible upon discontinuing this agent. |
| Score | Text |
|---|---|
| 0.9990 | DISCUSSION : This case shows that switching to Drugzidovudine potentially can lead to a hyperlactatemia relapse. |
| 0.9761 | DISCUSSION : This case shows that switching to zidovudine potentially can lead to a Adverse-Effecthyperlactatemia relapse . |
| Score | Text |
|---|---|
| 0.9995 | A 15 - year follow - up of Drugphenytoin - induced unilateral gingival hyperplasia : a case report. |
| 0.9840 | A 15 - year follow - up of phenytoin - induced Adverse-Effectunilateral gingival hyperplasia : a case report. |
| Score | Text |
|---|---|
| 0.9990 | This finding suggests that Drugfluvoxamine can precipitate Schneiderian first - rank symptoms in some susceptible patients. |
| 0.9783 | This finding suggests that fluvoxamine can precipitate Adverse-EffectSchneiderian first - rank symptoms in some susceptible patients. |
| Score | Text |
|---|---|
| 0.9988 | The hearing impairment and Adverse-Effecttinnitus were gradually reduced after PTU withdrawal and corticosteroid and azathioprine treatment. |
| 0.9935 | The hearing impairment and tinnitus were gradually reduced after DrugPTU withdrawal and corticosteroid and azathioprine treatment. |
| 0.9820 | The Adverse-Effecthearing impairment and tinnitus were gradually reduced after PTU withdrawal and corticosteroid and azathioprine treatment. |
| Score | Text |
|---|---|
| 0.9980 | The changes were progressive regardless of discontinuation of Drugcyclophosphamide and led to severe restrictive ventilatory defect. |
| 0.9737 | The changes were progressive regardless of discontinuation of cyclophosphamide and led to Adverse-Effectsevere restrictive ventilatory defect . |
| Score | Text |
|---|---|
| 0.9996 | Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning Drugprednisone therapy. |
| 0.7859 | Adverse-EffectSevere hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy. |
| Score | Text |
|---|---|
| 0.9994 | Glomerulonephritis in Drugprocainamide induced lupus erythematosus : report of a case and review of the literature. |
| 0.9855 | Adverse-EffectGlomerulonephritis in procainamide induced lupus erythematosus : report of a case and review of the literature. |
| 0.9837 | Glomerulonephritis in procainamide induced Adverse-Effectlupus erythematosus : report of a case and review of the literature. |
| Score | Text |
|---|---|
| 0.9957 | Atrial fibrillation was induced by diltiazem in two patients and verapamil induced Adverse-Effectsyncope in one patient. |
| 0.9619 | Atrial fibrillation was induced by diltiazem in two patients and Drugverapamil induced syncope in one patient. |
| 0.9431 | Adverse-EffectAtrial fibrillation was induced by diltiazem in two patients and verapamil induced syncope in one patient. |
| 0.8201 | Atrial fibrillation was induced by Drugdiltiazem in two patients and verapamil induced syncope in one patient. |
| Score | Text |
|---|---|
| 0.9995 | OBJECTIVE : To present a single case of Drugzuclopenthixol - induced priapism and a literature review. |
| 0.9984 | OBJECTIVE : To present a single case of zuclopenthixol - induced Adverse-Effectpriapism and a literature review. |
| Score | Text |
|---|---|
| 0.9990 | A case of Drugallopurinol hypersensitivity, possibly the first in a black African, is reported. |
| 0.8979 | A case of allopurinol Adverse-Effecthypersensitivity , possibly the first in a black African, is reported. |
| Score | Text |
|---|---|
| 0.9956 | Prolonged used of Drughydroxyurea in patients with ET may lead to therapy - associated acute leukemia. |
| 0.9908 | Prolonged used of hydroxyurea in patients with ET may lead to therapy - associated Adverse-Effectacute leukemia . |
| Score | Text |
|---|---|
| 0.9995 | DrugSulfasalazine - induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein - Barr virus. |
| 0.9937 | Sulfasalazine - induced hypersensitivity syndrome and Adverse-Effecthemophagocytic syndrome associated with reactivation of Epstein - Barr virus. |
| 0.9923 | Sulfasalazine - induced Adverse-Effecthypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein - Barr virus. |
| Score | Text |
|---|---|
| 0.9993 | In one child, a second course of Drugcarbamazepine resulted in a return of the dystonia. |
| 0.9975 | In one child, a second course of carbamazepine resulted in a return of the Adverse-Effectdystonia . |
| Score | Text |
|---|---|
| 0.9995 | RESULTS : Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after DrugIVTA injection. |
| 0.9861 | RESULTS : Two patients with ocular inflammation of unknown origin developed Adverse-Effectsevere chorioretinitis after IVTA injection. |
| Score | Text |
|---|---|
| 0.9994 | Flumazenil reversal of Drugbenzodiazepine - induced sedation for a patient with severe pre - ECT anxiety. |
| 0.9969 | Flumazenil reversal of benzodiazepine - induced Adverse-Effectsedation for a patient with severe pre - ECT anxiety. |
| Score | Text |
|---|---|
| 0.9996 | These multiple overlapping factors probably lead to rhabdomyolysis in a minority of patients receiving Drugvasopressin infusion. |
| 0.9967 | These multiple overlapping factors probably lead to Adverse-Effectrhabdomyolysis in a minority of patients receiving vasopressin infusion. |
| Score | Text |
|---|---|
| 0.9993 | Six patients with rheumatoid arthritis developed a syndrome resembling lupus erythematosus while being treated with Drugpenicillamine . |
| 0.9884 | Six patients with rheumatoid arthritis developed a syndrome resembling Adverse-Effectlupus erythematosus while being treated with penicillamine. |
| Score | Text |
|---|---|
| 0.9752 | Adverse-EffectAcute neutrophilic dermatosis induced by all - trans - retinoic acid treatment for acute promyelocytic leukemia. |
| 0.9478 | Acute neutrophilic dermatosis induced by Drugall - trans - retinoic acid treatment for acute promyelocytic leukemia. |
| Score | Text |
|---|---|
| 0.9987 | A second episode of jaundice followed the intravaginal administration of a mixture of furazolidone and Drugnifuroxime . |
| 0.9986 | A second episode of jaundice followed the intravaginal administration of a mixture of Drugfurazolidone and nifuroxime. |
| 0.9983 | A second episode of Adverse-Effectjaundice followed the intravaginal administration of a mixture of furazolidone and nifuroxime. |
| Score | Text |
|---|---|
| 0.9993 | In addition, the tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after Drugprocainamide . |
| 0.9972 | In addition, the Adverse-Effecttachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after procainamide. |
| Score | Text |
|---|---|
| 0.9994 | Within 6 months of Drugpranlukast withdrawal, anemia resolved and urinary sediment and renal function normalized. |
| 0.9962 | Within 6 months of pranlukast withdrawal, Adverse-Effectanemia resolved and urinary sediment and renal function normalized. |
| Score | Text |
|---|---|
| 0.9841 | Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil - induced Adverse-Effectacute hepatic failure . |
| 0.9713 | Successful treatment of hyperthyroidism with amiodarone in a patient with Drugpropylthiouracil - induced acute hepatic failure. |
| Score | Text |
|---|---|
| 0.9995 | An objective causality assessment suggests that the JHR in our patient was probably related to Drugpenicillin . |
| 0.9977 | An objective causality assessment suggests that the Adverse-EffectJHR in our patient was probably related to penicillin. |
| Score | Text |
|---|---|
| 0.9867 | Adverse-EffectAcute pancreatitis in a child with idiopathic ulcerative colitis on long - term 5 - aminosalicylic acid therapy. |
| 0.9779 | Acute pancreatitis in a child with idiopathic ulcerative colitis on long - term Drug5 - aminosalicylic acid therapy. |
| Score | Text |
|---|---|
| 0.9991 | Systemic disease, most commonly renal dysfunction, preceded all 30 reported cases of Drugacyclovir neurotoxicity. |
| 0.9249 | Systemic disease, most commonly renal dysfunction, preceded all 30 reported cases of acyclovir Adverse-Effectneurotoxicity . |
| Score | Text |
|---|---|
| 0.9995 | Two cases of polymorphic ventricular tachycardia induced by the administration of Drugverapamil against paroxysmal supraventricular tachycardia. |
| 0.9848 | Two cases of Adverse-Effectpolymorphic ventricular tachycardia induced by the administration of verapamil against paroxysmal supraventricular tachycardia. |
| Score | Text |
|---|---|
| 0.9995 | This is the first case of Drughydroxyurea - induced acute interstitial pneumonitis reported in the literature. |
| 0.9860 | This is the first case of hydroxyurea - induced Adverse-Effectacute interstitial pneumonitis reported in the literature. |
| Score | Text |
|---|---|
| 0.9995 | The sub - conjunctival haematoma in a patient receiving Drugwarfarin can pose a significant management challenge. |
| 0.9827 | The Adverse-Effectsub - conjunctival haematoma in a patient receiving warfarin can pose a significant management challenge. |
| Score | Text |
|---|---|
| 0.9992 | DrugGemcitabine therapy has been associated with radiation recall reactions when used in the treatment of carcinoma. |
| 0.9880 | Gemcitabine therapy has been associated with Adverse-Effectradiation recall reactions when used in the treatment of carcinoma. |
| Score | Text |
|---|---|
| 0.9994 | Skin necrosis is a rare complication of subcutaneous Drugheparin therapy that usually occurs at injection sites. |
| 0.9924 | Adverse-EffectSkin necrosis is a rare complication of subcutaneous heparin therapy that usually occurs at injection sites. |
| Score | Text |
|---|---|
| 0.9990 | It may cause a severe adverse drug reaction with multiorgan involvement known as Drugdapsone hypersensitivity syndrome. |
| 0.9257 | It may cause a severe adverse drug reaction with multiorgan involvement known as dapsone Adverse-Effecthypersensitivity syndrome . |
| Score | Text |
|---|---|
| 0.9995 | Reversible sclerotic changes of lumbar spine and femur due to long - term oral Drugisotretinoin therapy. |
| 0.9359 | Adverse-EffectReversible sclerotic changes of lumbar spine and femur due to long - term oral isotretinoin therapy. |
| Reversible Adverse-Effectsclerotic changes of lumbar spine and femur due to long - term oral isotretinoin therapy. | |
| Score | Text |
|---|---|
| 0.9990 | We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to DrugVGB . |
| 0.9798 | We explored Adverse-Effectophthalmic and neurologic findings in two children who have been exposed prenatally to VGB. |
| Score | Text |
|---|---|
| 0.9818 | The possible role of Druginterferon beta in the pathogenesis of sarcoidosis in this patient is discussed. |
| 0.9677 | The possible role of interferon beta in the pathogenesis of Adverse-Effectsarcoidosis in this patient is discussed. |
| Score | Text |
|---|---|
| 0.9980 | We observed transient panhypogammaglobulinaemia in a patient with neuropsychiatric SLE after treatment with prednisolone and Drugcyclophosphamide . |
| 0.9980 | We observed transient panhypogammaglobulinaemia in a patient with neuropsychiatric SLE after treatment with Drugprednisolone and cyclophosphamide. |
| 0.7591 | We observed transient Adverse-Effectpanhypogammaglobulinaemia in a patient with neuropsychiatric SLE after treatment with prednisolone and cyclophosphamide. |
| Score | Text |
|---|---|
| 0.9811 | Massive prolapse of the urethral mucosa following periurethral injection of Drugcalcium hydroxylapatite for stress urinary incontinence. |
| 0.8187 | Massive prolapse of the Adverse-Effecturethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence. |
| 0.7621 | Adverse-EffectMassive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence. |
| Massive Adverse-Effectprolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence. | |
| Score | Text |
|---|---|
| 0.9996 | This is the second report of acute lung injury and diffuse alveolar damage caused by Drugmefloquine . |
| 0.9883 | This is the second report of acute lung injury and Adverse-Effectdiffuse alveolar damage caused by mefloquine. |
| 0.9880 | This is the second report of Adverse-Effectacute lung injury and diffuse alveolar damage caused by mefloquine. |
| Score | Text |
|---|---|
| 0.9808 | Adverse-EffectSudden death in an infant from methemoglobinemia after administration of " sweet spirits of nitre ". |
| 0.9478 | Sudden death in an infant from methemoglobinemia after administration of " Drugsweet spirits of nitre ". |
| Score | Text |
|---|---|
| 0.9859 | A patient with rheumatoid arthritis developed an acute intrahepatic cholestasis after 100 mg of Drugsodium aurothiomalate . |
| 0.9846 | A patient with rheumatoid arthritis developed an Adverse-Effectacute intrahepatic cholestasis after 100 mg of sodium aurothiomalate. |
| A patient with rheumatoid arthritis developed an acute Adverse-Effectintrahepatic cholestasis after 100 mg of sodium aurothiomalate. | |
| Score | Text |
|---|---|
| 0.9984 | Acute myopathy with selective degeneration of myosin filaments following status asthmaticus treated with methylprednisolone and Drugvecuronium . |
| 0.9984 | Acute myopathy with selective degeneration of myosin filaments following status asthmaticus treated with Drugmethylprednisolone and vecuronium. |
| 0.9838 | Adverse-EffectAcute myopathy with selective degeneration of myosin filaments following status asthmaticus treated with methylprednisolone and vecuronium. |
| 0.9750 | Acute myopathy with selective Adverse-Effectdegeneration of myosin filaments following status asthmaticus treated with methylprednisolone and vecuronium. |
| Score | Text |
|---|---|
| 0.9994 | We discuss the association between Drugcarbamazepine and hyponatremia and the causes of hyponatremia after cardiopulmonary bypass. |
| 0.9880 | We discuss the association between carbamazepine and Adverse-Effecthyponatremia and the causes of hyponatremia after cardiopulmonary bypass. |
| 0.9928 | We discuss the association between carbamazepine and hyponatremia and the causes of Adverse-Effecthyponatremia after cardiopulmonary bypass. |
| Score | Text |
|---|---|
| 0.9994 | A case of Drugbarbiturate - induced submassive hepatic necrosis is presented and the literature is reviewed. |
| 0.9862 | A case of barbiturate - induced Adverse-Effectsubmassive hepatic necrosis is presented and the literature is reviewed. |
| Score | Text |
|---|---|
| 0.9994 | A reversible toxic liver damage was observed in a non - alcoholic woman treated with Drugdisulfiram . |
| 0.9862 | A Adverse-Effectreversible toxic liver damage was observed in a non - alcoholic woman treated with disulfiram. |
| Score | Text |
|---|---|
| 0.9958 | Haemolytic - uraemic syndrome complicating long - term mitomycin C and Drug5 - fluorouracil therapy for gastric carcinoma. |
| 0.9858 | Haemolytic - uraemic syndrome complicating long - term Drugmitomycin C and 5 - fluorouracil therapy for gastric carcinoma. |
| 0.9850 | Adverse-EffectHaemolytic - uraemic syndrome complicating long - term mitomycin C and 5 - fluorouracil therapy for gastric carcinoma. |
| Score | Text |
|---|---|
| 0.9991 | DrugZidovudine use in pregnancy : a report on 104 cases and the occurrence of birth defects. |
| 0.9891 | Zidovudine use in pregnancy : a report on 104 cases and the occurrence of Adverse-Effectbirth defects . |
| Score | Text |
|---|---|
| 0.9987 | Coagulopathy associated with the use of cephalosporin or Drugmoxalactam antibiotics in acute and chronic renal failure. |
| 0.9985 | Adverse-EffectCoagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure. |
| 0.9985 | Coagulopathy associated with the use of Drugcephalosporin or moxalactam antibiotics in acute and chronic renal failure. |
| Score | Text |
|---|---|
| 0.9858 | Pulmonary hemorrhage as a clinical manifestation of hemolytic - uremic syndrome associated with Drugmitomycin C therapy. |
| 0.9840 | Adverse-EffectPulmonary hemorrhage as a clinical manifestation of hemolytic - uremic syndrome associated with mitomycin C therapy. |
| 0.9775 | Pulmonary hemorrhage as a clinical manifestation of Adverse-Effecthemolytic - uremic syndrome associated with mitomycin C therapy. |
| Score | Text |
|---|---|
| 0.9992 | Syringotropic hypersensitivity reaction associated with Druginfliximab and leflunomide combination therapy in a child with psoriatic arthritis. |
| 0.9992 | Syringotropic hypersensitivity reaction associated with infliximab and Drugleflunomide combination therapy in a child with psoriatic arthritis. |
| 0.9855 | Adverse-EffectSyringotropic hypersensitivity reaction associated with infliximab and leflunomide combination therapy in a child with psoriatic arthritis. |
| Score | Text |
|---|---|
| 0.9995 | This is the first report of a catatonic syndrome occurring in a patient receiving Drugdisulfiram treatment. |
| 0.9946 | This is the first report of a Adverse-Effectcatatonic syndrome occurring in a patient receiving disulfiram treatment. |
| Score | Text |
|---|---|
| 0.9990 | DLST is a good diagnostic tool for DrugAZA allergy, especially for severe drug allergy cases. |
| 0.9662 | DLST is a good diagnostic tool for AZA Adverse-Effectallergy , especially for severe drug allergy cases. |
| Score | Text |
|---|---|
| 0.9993 | A case of Drugtimolol - associated heart failure in a 73 - year old white man is reported. |
| 0.9938 | A case of timolol - associated Adverse-Effectheart failure in a 73 - year old white man is reported. |
| Score | Text |
|---|---|
| 0.9986 | We describe a renal transplant recipient maintained on cyclosporine and Drugprednisone developing Nocardia Asteroides brain abscess. |
| 0.9984 | We describe a renal transplant recipient maintained on Drugcyclosporine and prednisone developing Nocardia Asteroides brain abscess. |
| 0.9823 | We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Adverse-EffectNocardia Asteroides brain abscess . |
| Score | Text |
|---|---|
| 0.9995 | Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with Drugadalimumab . |
| 0.9842 | Visceral leishmaniasis and Adverse-Effectmacrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab. |
| 0.9794 | Adverse-EffectVisceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab. |
| Score | Text |
|---|---|
| 0.9826 | Cholesterol crystal embolization - associated Adverse-Effectrenal failure after therapy with recombinant tissue - type plasminogen activator. |
| 0.9435 | Adverse-EffectCholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator. |
| 0.8778 | Cholesterol crystal embolization - associated renal failure after therapy with recombinant Drugtissue - type plasminogen activator . |
| 0.8588 | Cholesterol crystal embolization - associated renal failure after therapy with Drugrecombinant tissue - type plasminogen activator . |
| Score | Text |
|---|---|
| 0.9995 | DrugHeparin - induced thrombocytopenia complicated with massive thrombosis of the inferior vena cava after filter placement. |
| 0.9958 | Heparin - induced Adverse-Effectthrombocytopenia complicated with massive thrombosis of the inferior vena cava after filter placement. |
| 0.9642 | Heparin - induced thrombocytopenia complicated with Adverse-Effectmassive thrombosis of the inferior vena cava after filter placement. |
| Score | Text |
|---|---|
| 0.9995 | Cholelithiasis and thrombosis of the central retinal vein in a renal transplant recipient treated with Drugcyclosporin . |
| 0.9980 | Adverse-EffectCholelithiasis and thrombosis of the central retinal vein in a renal transplant recipient treated with cyclosporin. |
| 0.9792 | Cholelithiasis and Adverse-Effectthrombosis of the central retinal vein in a renal transplant recipient treated with cyclosporin. |
| Score | Text |
|---|---|
| 0.9991 | Young children undergoing Drugcisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss. |
| 0.9705 | Young children undergoing cisplatin chemotherapy are known to be at risk for Adverse-Effectprogressive sensorineural hearing loss . |
| Score | Text |
|---|---|
| 0.9995 | Prolongation of the QT interval and ventricular tachyarrhymias have been described in patients on Drugamiodarone therapy. |
| 0.9870 | Prolongation of the QT interval and Adverse-Effectventricular tachyarrhymias have been described in patients on amiodarone therapy. |
| 0.9752 | Adverse-EffectProlongation of the QT interval and ventricular tachyarrhymias have been described in patients on amiodarone therapy. |
| Score | Text |
|---|---|
| 0.9947 | Diarrhea - associated over - anticoagulation in a patient taking Drugwarfarin : therapeutic role of cholestyramine. |
| 0.9377 | Adverse-EffectDiarrhea - associated over - anticoagulation in a patient taking warfarin : therapeutic role of cholestyramine. |
| Score | Text |
|---|---|
| 0.9994 | The patient whose case is reviewed had migraine headaches and received Drugmethysergide maleate for 13 years. |
| 0.9891 | The patient whose case is reviewed had Adverse-Effectmigraine headaches and received methysergide maleate for 13 years. |
| Score | Text |
|---|---|
| 0.9987 | CONCLUSIONS : Acute severe hepatitis though rare is occasionally observed with EGFR inhibitors gefitinib or Drugerlotinib . |
| 0.9985 | CONCLUSIONS : Acute severe hepatitis though rare is occasionally observed with EGFR inhibitors Druggefitinib or erlotinib. |
| 0.9309 | CONCLUSIONS : Adverse-EffectAcute severe hepatitis though rare is occasionally observed with EGFR inhibitors gefitinib or erlotinib. |
| Score | Text |
|---|---|
| 0.9994 | Hypoxia is a predisposing factor for premature ductal closure and often occurs after maternal Drugindomethacin therapy. |
| 0.9950 | Adverse-EffectHypoxia is a predisposing factor for premature ductal closure and often occurs after maternal indomethacin therapy. |
| 0.9801 | Hypoxia is a predisposing factor for Adverse-Effectpremature ductal closure and often occurs after maternal indomethacin therapy. |
| Score | Text |
|---|---|
| 0.9987 | Patients should be informed about the risk of osteonecrosis when taking Drugdexamethasone as an antiemetic drug. |
| 0.9928 | Patients should be informed about the risk of Adverse-Effectosteonecrosis when taking dexamethasone as an antiemetic drug. |
| Score | Text |
|---|---|
| 0.9995 | Rapid onset of Drugquetiapine - induced diabetic ketoacidosis in an elderly patient : a case report. |
| 0.9874 | Rapid onset of quetiapine - induced Adverse-Effectdiabetic ketoacidosis in an elderly patient : a case report. |
| Score | Text |
|---|---|
| 0.9993 | On the other hand, Drugaspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma. |
| 0.9762 | On the other hand, aspirin may have promoted the Adverse-Effectenlargement of spontaneous hemorrhage from meningioma. |
| Score | Text |
|---|---|
| 0.9994 | Renal failure after high - dose Drugmethotrexate in a child homozygous for MTHFR C677 T polymorphism. |
| 0.9939 | Adverse-EffectRenal failure after high - dose methotrexate in a child homozygous for MTHFR C677 T polymorphism. |
| Score | Text |
|---|---|
| 0.9996 | Fatal interstitial pneumonitis associated with Drugdocetaxel administration in a patient with hormone - refractory prostate cancer. |
| 0.9846 | Adverse-EffectFatal interstitial pneumonitis associated with docetaxel administration in a patient with hormone - refractory prostate cancer. |
| Score | Text |
|---|---|
| 0.9574 | In vitro inhibition of hematopoiesis in a patient with systemic sclerosis treated with DrugD - penicillamine . |
| 0.9555 | In vitro Adverse-Effectinhibition of hematopoiesis in a patient with systemic sclerosis treated with D - penicillamine. |
| Score | Text |
|---|---|
| 0.9995 | Severe adenovirus pneumonia ( AVP ) following Druginfliximab infusion for the treatment of Crohn's disease. |
| 0.9912 | Severe adenovirus pneumonia ( Adverse-EffectAVP ) following infliximab infusion for the treatment of Crohn's disease. |
| 0.7624 | Adverse-EffectSevere adenovirus pneumonia ( AVP ) following infliximab infusion for the treatment of Crohn's disease. |
| Score | Text |
|---|---|
| 0.9937 | Capecitabine was discontinued and the Adverse-Effectallergic reactions resolved after the woman took diphenhydramine for 1 week. |
| 0.9883 | DrugCapecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week. |
| Score | Text |
|---|---|
| 0.9995 | We present a unique case of GTBM in a patient with myeloma following treatment with DrugMelphalan . |
| 0.9983 | We present a unique case of Adverse-EffectGTBM in a patient with myeloma following treatment with Melphalan. |
| Score | Text |
|---|---|
| 0.9992 | Based on our findings, it is thus concluded that Drugcisplatin may cause C. difficile colitis. |
| 0.9829 | Based on our findings, it is thus concluded that cisplatin may cause Adverse-EffectC. difficile colitis . |
| Score | Text |
|---|---|
| 0.9974 | Administration of excessive Druginsulin induced hypoglycemia within 4 to 8 hours, followed by rebound hyperglycemia. |
| 0.9964 | Administration of excessive insulin induced Adverse-Effecthypoglycemia within 4 to 8 hours, followed by rebound hyperglycemia. |
| 0.9355 | Administration of excessive insulin induced hypoglycemia within 4 to 8 hours, followed by Adverse-Effectrebound hyperglycemia . |
| Score | Text |
|---|---|
| 0.9995 | A case of Drugfluoxetine induced seizures, in a person with Down syndrome, is described. |
| 0.9988 | A case of fluoxetine induced Adverse-Effectseizures , in a person with Down syndrome, is described. |
| Score | Text |
|---|---|
| 0.9925 | Adverse-EffectPulmonary edema occurred 24 hours after intravenous ritodrine therapy and 10 hours after subcutaneous terbutaline therapy. |
| 0.9896 | Pulmonary edema occurred 24 hours after intravenous Drugritodrine therapy and 10 hours after subcutaneous terbutaline therapy. |
| 0.9645 | Pulmonary edema occurred 24 hours after intravenous ritodrine therapy and 10 hours after subcutaneous Drugterbutaline therapy. |
| Score | Text |
|---|---|
| 0.9988 | After treatment with a beta - sympathomimetic drug ( DrugPartusisten ) one fetus developed supraventricular tachycardia. |
| 0.9855 | After treatment with a beta - sympathomimetic drug ( Partusisten ) one fetus developed Adverse-Effectsupraventricular tachycardia . |
| Score | Text |
|---|---|
| 0.9913 | DrugChlorambucil central nervous toxicity : a significant side effect of chlorambucil therapy in childhood nephrotic syndrome. |
| 0.9294 | Chlorambucil Adverse-Effectcentral nervous toxicity : a significant side effect of chlorambucil therapy in childhood nephrotic syndrome. |
| 0.9870 | Chlorambucil central nervous toxicity : a significant side effect of Drugchlorambucil therapy in childhood nephrotic syndrome. |
| Score | Text |
|---|---|
| 0.9987 | The pulmonary toxicity of Druggold salts is an uncommon cause of life - threatening respiratory failure. |
| 0.9672 | The Adverse-Effectpulmonary toxicity of gold salts is an uncommon cause of life - threatening respiratory failure. |
| 0.8891 | The pulmonary toxicity of gold salts is an uncommon cause of life - threatening Adverse-Effectrespiratory failure . |
| Score | Text |
|---|---|
| 0.9897 | Antacid and Drugsucralfate - induced hypophosphatemic osteomalacia : a case report and review of the literature. |
| 0.9864 | Antacid and sucralfate - induced Adverse-Effecthypophosphatemic osteomalacia : a case report and review of the literature. |
| Score | Text |
|---|---|
| 0.9995 | Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of DrugGliadel wafers. |
| 0.9898 | Following are two clinical case reports demonstrating profound Adverse-Effectcerebral edema associated with implantation of Gliadel wafers. |
| Score | Text |
|---|---|
| 0.9995 | Severe visual loss after a single dose of Drugvincristine in a patient with spinal cord astrocytoma. |
| 0.9770 | Adverse-EffectSevere visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma. |
| Score | Text |
|---|---|
| 0.9995 | Thus any case of severe neutropenia occurring in a patient receiving Drugolanzapine is alarming to clinicians. |
| 0.9505 | Thus any case of Adverse-Effectsevere neutropenia occurring in a patient receiving olanzapine is alarming to clinicians. |
| Score | Text |
|---|---|
| 0.9685 | The 9 other reported cases of DrugD - penicillamine induced rapidly progressive glomerulonephritis have been reviewed. |
| 0.9659 | The 9 other reported cases of D - penicillamine induced Adverse-Effectrapidly progressive glomerulonephritis have been reviewed. |
| Score | Text |
|---|---|
| 0.9989 | Pigmentary disorders are recognized adverse effects of the semi - synthetic tetracycline derivative antibiotic, Drugminocycline . |
| 0.9910 | Adverse-EffectPigmentary disorders are recognized adverse effects of the semi - synthetic tetracycline derivative antibiotic, minocycline. |
| Score | Text |
|---|---|
| 0.9858 | Adverse-EffectHerpes simplex esophagitis in a renal transplant patient treated with cyclosporine A : a case report. |
| 0.9818 | Herpes simplex esophagitis in a renal transplant patient treated with Drugcyclosporine A : a case report. |
| Score | Text |
|---|---|
| 0.9995 | We describe a patient with idiopathic RLS who developed augmentation after 8 months of Druglevodopa treatment. |
| 0.9958 | We describe a patient with idiopathic RLS who developed Adverse-Effectaugmentation after 8 months of levodopa treatment. |
| Score | Text |
|---|---|
| 0.9990 | Two patients with osteomyelitis who developed reversible cholestatic jaundice during treatment with Drugoxacillin derivatives are described. |
| 0.8738 | Two patients with osteomyelitis who developed Adverse-Effectreversible cholestatic jaundice during treatment with oxacillin derivatives are described. |
| Score | Text |
|---|---|
| 0.9988 | Only one report links Drugphenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM. |
| 0.9544 | Only one report links phenylpropanolamine consumption to an Adverse-Effectintracerebral hemorrhage in a patient with an AVM. |
| Score | Text |
|---|---|
| 0.9996 | DrugOlanzapine - induced hyperglycaemic coma and neuroleptic malignant syndrome : case report and review of literature. |
| 0.9894 | Olanzapine - induced Adverse-Effecthyperglycaemic coma and neuroleptic malignant syndrome : case report and review of literature. |
| 0.9884 | Olanzapine - induced hyperglycaemic coma and Adverse-Effectneuroleptic malignant syndrome : case report and review of literature. |
| Score | Text |
|---|---|
| 0.9993 | In all cases, seizures were controlled by withdrawal of Drugphenytoin and reduction of drug levels. |
| 0.9968 | In all cases, Adverse-Effectseizures were controlled by withdrawal of phenytoin and reduction of drug levels. |
| Score | Text |
|---|---|
| 0.9994 | A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of Drugnortriptyline . |
| 0.9877 | A young patient experienced marked Adverse-Effectsinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline. |
| Score | Text |
|---|---|
| 0.9995 | A severe form of exophthalmos resulting from Druglithium therapy has not been described in the literature. |
| 0.9953 | A severe form of Adverse-Effectexophthalmos resulting from lithium therapy has not been described in the literature. |
| Score | Text |
|---|---|
| 0.9986 | Adverse-EffectBulbar and pseudobulbar palsy complicating therapy with high - dose cytosine arabinoside in children with leukemia. |
| 0.9915 | Bulbar and Adverse-Effectpseudobulbar palsy complicating therapy with high - dose cytosine arabinoside in children with leukemia. |
| 0.9785 | Bulbar and pseudobulbar palsy complicating therapy with high - dose Drugcytosine arabinoside in children with leukemia. |
| Score | Text |
|---|---|
| 0.9992 | The cause of his bleeding was a severe thrombocytopoaenia, induced by chronic ingestion of Drugquinine . |
| 0.9029 | The cause of his bleeding was a Adverse-Effectsevere thrombocytopoaenia , induced by chronic ingestion of quinine. |
| Score | Text |
|---|---|
| 0.9709 | DrugL - asparaginase - induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children. |
| 0.9871 | L - asparaginase - induced Adverse-Effectposterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children. |
| L - asparaginase - induced Adverse-Effectposterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children. | |
| Score | Text |
|---|---|
| 0.9994 | Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the Drugcephalosporin . |
| 0.9980 | Nevertheless, the Adverse-Effectcoagulopathy seemed to be most closely associated with the administration of the cephalosporin. |
| Score | Text |
|---|---|
| 0.9979 | Favorable outcome of de novo hepatitis B infection after liver transplantation with lamivudine and Drugadefovir therapy. |
| 0.9973 | Favorable outcome of de novo hepatitis B infection after liver transplantation with Druglamivudine and adefovir therapy. |
| 0.9740 | Favorable outcome of de novo Adverse-Effecthepatitis B infection after liver transplantation with lamivudine and adefovir therapy. |
| Score | Text |
|---|---|
| 0.9995 | Thrombocytosis induced by Drugenoxaparin has been reported as a rare adverse effect of this medication in adults. |
| 0.9973 | Adverse-EffectThrombocytosis induced by enoxaparin has been reported as a rare adverse effect of this medication in adults. |
| Score | Text |
|---|---|
| 0.9991 | This is the first report of non - convulsive status epilepticus provoked by Drugtiagabine in adolescent patients. |
| 0.9755 | This is the first report of Adverse-Effectnon - convulsive status epilepticus provoked by tiagabine in adolescent patients. |
| Score | Text |
|---|---|
| 0.9986 | L - asparaginase - induced Adverse-Effectpancreatitis has been reported during or closely following administration of the drug. |
| 0.9699 | DrugL - asparaginase - induced pancreatitis has been reported during or closely following administration of the drug. |
| Score | Text |
|---|---|
| 0.9994 | The majority of radiation recall reactions attributed to Druggemcitabine are reported to affect internal tissue or organs. |
| 0.9881 | The majority of Adverse-Effectradiation recall reactions attributed to gemcitabine are reported to affect internal tissue or organs. |
| Score | Text |
|---|---|
| 0.9883 | Adverse-EffectMinimal change disease in a patient receiving IFN - alpha therapy for chronic hepatitis C virus infection. |
| 0.9731 | Minimal change disease in a patient receiving DrugIFN - alpha therapy for chronic hepatitis C virus infection. |
| Score | Text |
|---|---|
| 0.9985 | DrugClozapine - induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies. |
| 0.9976 | Clozapine - induced Adverse-Effecteosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies. |
| Score | Text |
|---|---|
| 0.9910 | In association with this tocolysis, Adverse-Effecturinary calculus of magnesium ammonium phosphate occurred at 34 weeks gestation. |
| 0.9670 | In association with this tocolysis, urinary calculus of Drugmagnesium ammonium phosphate occurred at 34 weeks gestation. |
| Score | Text |
|---|---|
| 0.9977 | Cessation of D - Pen and the start of corticosteroid therapy were followed by recovery from Adverse-Effectbicytopenia . |
| 0.9679 | Cessation of DrugD - Pen and the start of corticosteroid therapy were followed by recovery from bicytopenia. |
| Score | Text |
|---|---|
| 0.9995 | We report on a 37 - year - old female who complained of moderate hair loss during Drugparoxetine treatment. |
| 0.9667 | We report on a 37 - year - old female who complained of moderate Adverse-Effecthair loss during paroxetine treatment. |
| Score | Text |
|---|---|
| 0.9996 | These novel findings may offer specific therapeutic targets in the treatment of DrugBCNU - associated pulmonary fibrosis. |
| 0.9911 | These novel findings may offer specific therapeutic targets in the treatment of BCNU - associated Adverse-Effectpulmonary fibrosis . |
| Score | Text |
|---|---|
| 0.9994 | An insulin - dependent diabetic patient with nephropathy developed severe acidosis after treatment with Drugacetazolamide for glaucoma. |
| 0.9822 | An insulin - dependent diabetic patient with nephropathy developed Adverse-Effectsevere acidosis after treatment with acetazolamide for glaucoma. |
| Score | Text |
|---|---|
| 0.9993 | Interstitial lung disease ( ILD ) related to therapy with the drug Druggefitinib has been well reported. |
| 0.9927 | Interstitial lung disease ( Adverse-EffectILD ) related to therapy with the drug gefitinib has been well reported. |
| 0.9865 | Adverse-EffectInterstitial lung disease ( ILD ) related to therapy with the drug gefitinib has been well reported. |
| Score | Text |
|---|---|
| 0.9994 | CONCLUSIONS : This study confirmed that in most patients DrugMTX - induced liver cirrhosis is not aggressive. |
| 0.9901 | CONCLUSIONS : This study confirmed that in most patients MTX - induced Adverse-Effectliver cirrhosis is not aggressive. |
| Score | Text |
|---|---|
| 0.9908 | Since tamoxifen therapy can induce Adverse-Effectendometrial disorders , surveillance schemes of women taking tamoxifen have been recommended. |
| 0.9876 | Since Drugtamoxifen therapy can induce endometrial disorders, surveillance schemes of women taking tamoxifen have been recommended. |
| 0.9703 | Since tamoxifen therapy can induce endometrial disorders, surveillance schemes of women taking Drugtamoxifen have been recommended. |
| Score | Text |
|---|---|
| 0.9985 | Intravenous cytarabine and Drugmethotrexate appear to act synergistically to enhance the potential for central nervous system toxicity. |
| 0.9984 | Intravenous Drugcytarabine and methotrexate appear to act synergistically to enhance the potential for central nervous system toxicity. |
| 0.9796 | Intravenous cytarabine and methotrexate appear to act synergistically to enhance the potential for Adverse-Effectcentral nervous system toxicity . |
| Score | Text |
|---|---|
| 0.9996 | CONCLUSIONS : The fundus picture shown in these cases may be typical of ASPPC after DrugIVTA injection. |
| 0.9942 | CONCLUSIONS : The fundus picture shown in these cases may be typical of Adverse-EffectASPPC after IVTA injection. |
| Score | Text |
|---|---|
| 0.9979 | CONCLUSIONS : DrugLTG overdose may result in a severe but reversible encephalopathy, a previously undescribed phenomenon. |
| 0.7497 | CONCLUSIONS : LTG overdose may result in a severe but reversible Adverse-Effectencephalopathy , a previously undescribed phenomenon. |
| Score | Text |
|---|---|
| 0.9993 | Several such HBV reactivations were reported after combined Drugrituximab and multiagent chemotherapy for B - cell lymphomas. |
| 0.9813 | Several such Adverse-EffectHBV reactivations were reported after combined rituximab and multiagent chemotherapy for B - cell lymphomas. |
| Score | Text |
|---|---|
| 0.9992 | Acute renal insufficiency is known to occur in patients who are taking Drugciprofloxacin , particularly the elderly. |
| 0.9650 | Adverse-EffectAcute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly. |
| Score | Text |
|---|---|
| 0.9991 | Soon after its introduction in 1952, Drugchlorpromazine was noted to induce symptoms resembling Parkinson's disease. |
| 0.6055 | Soon after its introduction in 1952, chlorpromazine was noted to induce Adverse-Effectsymptoms resembling Parkinson's disease . |
| Score | Text |
|---|---|
| 0.9984 | A young woman with epilepsy had tonic - clonic seizures during antineoplastic therapy with Drugadriamycin and cisplatin. |
| 0.9982 | A young woman with epilepsy had tonic - clonic seizures during antineoplastic therapy with adriamycin and Drugcisplatin . |
| 0.9698 | A young woman with epilepsy had Adverse-Effecttonic - clonic seizures during antineoplastic therapy with adriamycin and cisplatin. |
| Score | Text |
|---|---|
| 0.9993 | We describe six patients who developed tardive dyskinesia after treatment with Drugsulpiride for depression or gastrointestinal symptoms. |
| 0.9909 | We describe six patients who developed Adverse-Effecttardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms. |
| Score | Text |
|---|---|
| 0.9984 | Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous Drugheroin overdose. |
| 0.9936 | Two heroin addicts, aged 34 and 19 years, developed Adverse-Effectballistic movements after intravenous heroin overdose. |
| Score | Text |
|---|---|
| 0.9856 | Generalised pustular psoriasis induced by Drugcyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. |
| 0.9855 | Adverse-EffectGeneralised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. |
| Score | Text |
|---|---|
| 0.9889 | Clozapine - induced Adverse-Effecttardive dyskinesia in schizophrenic patients taking clozapine as a first - line antipsychotic drug. |
| 0.9677 | DrugClozapine - induced tardive dyskinesia in schizophrenic patients taking clozapine as a first - line antipsychotic drug. |
| Score | Text |
|---|---|
| 0.9995 | Interstitial pneumonitis and alveolar hemorrhage complicating use of Drugrituximab : case report and review of the literature. |
| 0.9874 | Adverse-EffectInterstitial pneumonitis and alveolar hemorrhage complicating use of rituximab : case report and review of the literature. |
| 0.9871 | Interstitial pneumonitis and Adverse-Effectalveolar hemorrhage complicating use of rituximab : case report and review of the literature. |
| Score | Text |
|---|---|
| 0.9994 | Use of the Naranjo probability scale determined the association between Drugcephalosporin use and leukopenia to be probable. |
| 0.9963 | Use of the Naranjo probability scale determined the association between cephalosporin use and Adverse-Effectleukopenia to be probable. |
| Score | Text |
|---|---|
| 0.9993 | CONCLUSIONS : DrugAmantadine can cause reversible corneal edema but can irreversibly reduce the density of endothelial cells. |
| 0.9765 | CONCLUSIONS : Amantadine can cause Adverse-Effectreversible corneal edema but can irreversibly reduce the density of endothelial cells. |
| Score | Text |
|---|---|
| 0.9981 | Failure of plasmapheresis, corticosteroids and thionamides to ameliorate a case of protracted Drugamiodarone - induced thyroiditis. |
| 0.9978 | Failure of plasmapheresis, corticosteroids and thionamides to ameliorate a case of protracted amiodarone - induced Adverse-Effectthyroiditis . |
| Score | Text |
|---|---|
| 0.9991 | An asymptomatic HIV - infected woman experienced right - sided renal colicky pain during treatment with Drugindinavir . |
| 0.9837 | An asymptomatic HIV - infected woman experienced right - sided Adverse-Effectrenal colicky pain during treatment with indinavir. |
| Score | Text |
|---|---|
| 0.9993 | The temporal relationship suggests that the spinal cord infarction may be related to the use of Drugzolmitriptan . |
| 0.9879 | The temporal relationship suggests that the Adverse-Effectspinal cord infarction may be related to the use of zolmitriptan. |
| Score | Text |
|---|---|
| 0.9881 | To date, there have been few reports of Adverse-Effectvisual disturbances associated with BTX - B use. |
| 0.9774 | To date, there have been few reports of visual disturbances associated with DrugBTX - B use. |
| Score | Text |
|---|---|
| 0.9996 | We describe two cases of acute pancreatitis that occurred after long term Drugmesalamine therapy for ulcerative colitis. |
| 0.9775 | We describe two cases of Adverse-Effectacute pancreatitis that occurred after long term mesalamine therapy for ulcerative colitis. |
| Score | Text |
|---|---|
| 0.9981 | Despite administration of phenytoin and lorazepam, the Adverse-Effectseizures persisted and occurred only during amphotercin B administration. |
| 0.9806 | Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during Drugamphotercin B administration. |
| Score | Text |
|---|---|
| 0.9480 | In both patients the Adverse-Effectrippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine. |
| 0.9220 | In both patients the rippling phenomena worsened with Drugpyridostigmine treatment but markedly improved after immunosuppression with azathioprine. |
| 0.7934 | In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with Drugazathioprine . |
| Score | Text |
|---|---|
| 0.9359 | Acute hyperphosphatemia caused by Drugsodium phosphate enema in a patient with liver dysfunction and chronic renal failure. |
| Acute Adverse-Effecthyperphosphatemia caused by sodium phosphate enema in a patient with liver dysfunction and chronic renal failure. | |
| Score | Text |
|---|---|
| 0.9833 | A new case of Adverse-EffectCreutzfeldt - Jakob disease associated with human growth hormone therapy in New Zealand. |
| 0.9700 | A new case of Creutzfeldt - Jakob disease associated with Drughuman growth hormone therapy in New Zealand. |
| Score | Text |
|---|---|
| 0.9994 | The Naranjo probability scale suggests a highly probable relationship between AIN and Drugpantoprazole therapy in this patient. |
| 0.9963 | The Naranjo probability scale suggests a highly probable relationship between Adverse-EffectAIN and pantoprazole therapy in this patient. |
| Score | Text |
|---|---|
| 0.9988 | Inadvertent subsequent rechallenge with celiprolol led to recurrence of the Adverse-Effectpneumonitis , 10 weeks after drug readministration. |
| 0.9968 | Inadvertent subsequent rechallenge with Drugceliprolol led to recurrence of the pneumonitis, 10 weeks after drug readministration. |
| Score | Text |
|---|---|
| 0.9997 | This is the first report of acute kidney injury due to Drugzonisamide - induced DRESS / DIHS. |
| 0.9977 | This is the first report of acute kidney injury due to zonisamide - induced Adverse-EffectDRESS / DIHS. |
| 0.9974 | This is the first report of acute kidney injury due to zonisamide - induced DRESS / Adverse-EffectDIHS . |
| 0.9692 | This is the first report of Adverse-Effectacute kidney injury due to zonisamide - induced DRESS / DIHS. |
| Score | Text |
|---|---|
| 0.9974 | Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life - threatening Drugvincristine neurotoxicity. |
| 0.7719 | Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life - threatening vincristine Adverse-Effectneurotoxicity . |
| Early recognition of hereditary motor and sensory neuropathy type 1 can avoid Adverse-Effectlife - threatening vincristine neurotoxicity . | |
| Score | Text |
|---|---|
| 0.9814 | It is tempting to speculate that interferon alpha may be involved in the pathogenesis of Adverse-Effectlichen nitidus . |
| 0.9802 | It is tempting to speculate that Druginterferon alpha may be involved in the pathogenesis of lichen nitidus. |
| Score | Text |
|---|---|
| 0.9993 | These data indicated that Druginfliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis. |
| 0.9867 | These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant Adverse-Effectautoimmune agranulocytosis . |
| 0.9026 | These data indicated that infliximab possibly triggered Adverse-Effectproduction of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis. |
| Score | Text |
|---|---|
| 0.9994 | Clinicians should be aware of fasting hypoglycemia as an unusual but potentially serious complication of Drugdisopyramide therapy. |
| 0.9725 | Clinicians should be aware of Adverse-Effectfasting hypoglycemia as an unusual but potentially serious complication of disopyramide therapy. |
| Score | Text |
|---|---|
| 0.9993 | DrugIFNalpha - induced recurrence of Graves'disease ten years after thyroidectomy in chronic viral hepatitis C. |
| 0.9858 | IFNalpha - induced recurrence of Adverse-EffectGraves'disease ten years after thyroidectomy in chronic viral hepatitis C. |
| Score | Text |
|---|---|
| 0.9995 | Following 7 days of Drugtigecycline she developed severe abdominal pain and elevated pancreatic enzymes suggesting acute pancreatitis. |
| 0.9818 | Following 7 days of tigecycline she developed severe abdominal pain and elevated pancreatic enzymes suggesting Adverse-Effectacute pancreatitis . |
| 0.9760 | Following 7 days of tigecycline she developed Adverse-Effectsevere abdominal pain and elevated pancreatic enzymes suggesting acute pancreatitis. |
| 0.9750 | Following 7 days of tigecycline she developed severe abdominal pain and Adverse-Effectelevated pancreatic enzymes suggesting acute pancreatitis. |
| Score | Text |
|---|---|
| 0.9997 | Since its FDA approval in 2002, there are no known citations of Drugezetimibe - induced pancreatitis. |
| 0.9984 | Since its FDA approval in 2002, there are no known citations of ezetimibe - induced Adverse-Effectpancreatitis . |
| Score | Text |
|---|---|
| 0.9989 | We describe a case of life - threatening hyponatremia associated with Drugsibutramine use in an obese woman. |
| 0.9713 | We describe a case of life - threatening Adverse-Effecthyponatremia associated with sibutramine use in an obese woman. |
| Score | Text |
|---|---|
| 0.9994 | A 14 - year - old girl with newly diagnosed SLE developed a pruritic bullous eruption while on Drugprednisone . |
| 0.9901 | A 14 - year - old girl with newly diagnosed SLE developed a Adverse-Effectpruritic bullous eruption while on prednisone. |
| Score | Text |
|---|---|
| 0.9994 | CONCLUSION : DrugTamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state. |
| 0.9669 | CONCLUSION : Tamoxifen may cause Adverse-Effectmalignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state. |
| Score | Text |
|---|---|
| 0.9992 | Administration of Drugpyridoxine to an infant after a long period of convulsions was followed by acute hypotonia. |
| 0.9911 | Administration of pyridoxine to an infant after a long period of convulsions was followed by Adverse-Effectacute hypotonia . |
| Score | Text |
|---|---|
| 0.9993 | A case report of fatal Drugdapsone - induced agranulocytosis in an Indian mid - borderline leprosy patient. |
| 0.9979 | A case report of fatal dapsone - induced Adverse-Effectagranulocytosis in an Indian mid - borderline leprosy patient. |
| Score | Text |
|---|---|
| 0.9929 | Warfarin - induced skin necrosis and heparin - induced Adverse-Effectthrombocytopenia following mitral valve replacement for marantic endocarditis. |
| 0.7253 | DrugWarfarin - induced skin necrosis and heparin - induced thrombocytopenia following mitral valve replacement for marantic endocarditis. |
| 0.7013 | Warfarin - induced skin necrosis and Drugheparin - induced thrombocytopenia following mitral valve replacement for marantic endocarditis. |
| 0.5326 | Warfarin - induced Adverse-Effectskin necrosis and heparin - induced thrombocytopenia following mitral valve replacement for marantic endocarditis. |
| 0.5174 | Warfarin - induced skin necrosis and heparin - induced thrombocytopenia following Drugmitral valve replacement for marantic endocarditis. |
| Score | Text |
|---|---|
| 0.9976 | Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving Drugpentamidine throughout the duration of therapy. |
| 0.9923 | Clinicians should be vigilant when monitoring for Adverse-Effectcardiotoxicity in patients receiving pentamidine throughout the duration of therapy. |
| Score | Text |
|---|---|
| 0.9995 | We present a depressive patient who developed mild parkinsonian signs and camptocormia after the introduction of Drugolanzapine . |
| 0.9962 | We present a depressive patient who developed mild parkinsonian signs and Adverse-Effectcamptocormia after the introduction of olanzapine. |
| 0.9867 | We present a depressive patient who developed Adverse-Effectmild parkinsonian signs and camptocormia after the introduction of olanzapine. |
| Score | Text |
|---|---|
| 0.9995 | Despite the underlying hepatitis C, this case represents renal abnormalities consistent with DrugIFNalpha therapy for CML. |
| 0.9892 | Despite the underlying hepatitis C, this case represents Adverse-Effectrenal abnormalities consistent with IFNalpha therapy for CML. |
| Score | Text |
|---|---|
| 0.9987 | The ocular motor disturbances are probably an expression of regional Drug5 - FU neurotoxicity primarily affecting the brain stem. |
| 0.9727 | The Adverse-Effectocular motor disturbances are probably an expression of regional 5 - FU neurotoxicity primarily affecting the brain stem. |
| 0.9357 | The ocular motor disturbances are probably an expression of regional 5 - FU Adverse-Effectneurotoxicity primarily affecting the brain stem. |
| Score | Text |
|---|---|
| 0.9995 | RESULTS : DrugQuetiapine was associated with leucopenia in two patients and clinically apparent agranulocytosis in one patient. |
| 0.9969 | RESULTS : Quetiapine was associated with leucopenia in two patients and clinically apparent Adverse-Effectagranulocytosis in one patient. |
| 0.9968 | RESULTS : Quetiapine was associated with Adverse-Effectleucopenia in two patients and clinically apparent agranulocytosis in one patient. |
| Score | Text |
|---|---|
| 0.9963 | In a 61 - year - old man receiving chronic low - dosage Drugamiodarone an interstitial pneumopathy was observed. |
| 0.9866 | In a 61 - year - old man receiving chronic low - dosage amiodarone an Adverse-Effectinterstitial pneumopathy was observed. |
| Score | Text |
|---|---|
| 0.9982 | Cerebrovascular complications of L - asparaginase therapy in children with leukemia : Adverse-Effectaphasia and other neuropsychological deficits. |
| 0.9902 | Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other Adverse-Effectneuropsychological deficits . |
| 0.9680 | Cerebrovascular complications of DrugL - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits. |
| 0.8472 | Adverse-EffectCerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits. |
| Score | Text |
|---|---|
| 0.9995 | A case of Drugmetoclopramide - induced oculogyric crisis in a 16 - year - old girl with cystic fibrosis. |
| 0.9935 | A case of metoclopramide - induced Adverse-Effectoculogyric crisis in a 16 - year - old girl with cystic fibrosis. |
| Score | Text |
|---|---|
| 0.9994 | We describe a case of severe aplastic anemia ( AA ) that was probably induced by Druglenalidomide . |
| 0.9702 | We describe a case of Adverse-Effectsevere aplastic anemia ( AA ) that was probably induced by lenalidomide. |
| 0.9608 | We describe a case of severe aplastic anemia ( Adverse-EffectAA ) that was probably induced by lenalidomide. |
| Score | Text |
|---|---|
| 0.9983 | Case report : Drugdapsone hypersensitivity syndrome associated with treatment of the bite of a brown recluse spider. |
| 0.9270 | Case report : dapsone Adverse-Effecthypersensitivity syndrome associated with treatment of the bite of a brown recluse spider. |
| Score | Text |
|---|---|
| 0.9774 | Experience with five patients in whom impaired renal function developed early during Drugamphotericin B therapy is reported. |
| 0.9652 | Experience with five patients in whom Adverse-Effectimpaired renal function developed early during amphotericin B therapy is reported. |
| Score | Text |
|---|---|
| 0.9988 | METHODS : We report a patient who had an anaphylactic reaction during the intravenous infusion of Drugcyclosporine . |
| 0.9900 | METHODS : We report a patient who had an Adverse-Effectanaphylactic reaction during the intravenous infusion of cyclosporine. |
| Score | Text |
|---|---|
| 0.9993 | CONCLUSION : There may be an association between Drugraloxifene and the development of malignant mixed mesodermal tumor. |
| 0.9825 | CONCLUSION : There may be an association between raloxifene and the development of Adverse-Effectmalignant mixed mesodermal tumor . |
| Score | Text |
|---|---|
| 0.9993 | BACKGROUND : To describe the occurrence of ocular hypertension in four patients following injection of Drugranibizumab intravitreally. |
| 0.9918 | BACKGROUND : To describe the occurrence of Adverse-Effectocular hypertension in four patients following injection of ranibizumab intravitreally. |
| Score | Text |
|---|---|
| 0.9993 | DrugVancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD. |
| 0.9987 | Vancomycin is the most frequently implicated drug, but other agents have been reported to cause Adverse-EffectLABD . |
| Score | Text |
|---|---|
| 0.9995 | Two of our patients developed TD after 23 months and 34 months of Drugziprasidone monotherapy, respectively. |
| 0.9970 | Two of our patients developed Adverse-EffectTD after 23 months and 34 months of ziprasidone monotherapy, respectively. |
| Score | Text |
|---|---|
| 0.9986 | While both Drugamiodarone and digoxin can cause permanent visual changes, the ocular effects are often reversible. |
| 0.9985 | While both amiodarone and Drugdigoxin can cause permanent visual changes, the ocular effects are often reversible. |
| 0.9781 | While both amiodarone and digoxin can cause permanent visual changes, the Adverse-Effectocular effects are often reversible. |
| 0.9676 | While both amiodarone and digoxin can cause permanent Adverse-Effectvisual changes , the ocular effects are often reversible. |
| Score | Text |
|---|---|
| 0.9995 | A fatal massive pulmonary embolus developed in a patient treated with Drugstreptokinase for acute deep vein thrombosis. |
| 0.9821 | A Adverse-Effectfatal massive pulmonary embolus developed in a patient treated with streptokinase for acute deep vein thrombosis. |
| Score | Text |
|---|---|
| 0.9804 | L - Carnitine supplementation has been recommended to prevent the Adverse-Effectfatal hepatotoxic effects associated with valproic acid. |
| 0.9788 | L - Carnitine supplementation has been recommended to prevent the fatal hepatotoxic effects associated with Drugvalproic acid . |
| Score | Text |
|---|---|
| 0.9952 | Biopsy - proven acute interstitial nephritis associated with the tyrosine kinase inhibitor Drugsunitinib : a class effect? |
| 0.9768 | Biopsy - proven Adverse-Effectacute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib : a class effect? |
| Score | Text |
|---|---|
| 0.9993 | Four patients receiving high - dose Drugtamoxifen for greater than 1 year have demonstrated similar retinal changes. |
| 0.9855 | Four patients receiving high - dose tamoxifen for greater than 1 year have demonstrated similar Adverse-Effectretinal changes . |
| Score | Text |
|---|---|
| 0.9989 | After five and six weeks of continuous oral administration of Drugmethylprednisolone , the boys developed steroid diabetes. |
| 0.9939 | After five and six weeks of continuous oral administration of methylprednisolone, the boys developed Adverse-Effectsteroid diabetes . |
| Score | Text |
|---|---|
| 0.9994 | Multiple complications of Drugpropylthiouracil treatment : granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization. |
| 0.9974 | Multiple complications of propylthiouracil treatment : granulocytopenia, eosinophilia, skin reaction and Adverse-Effecthepatitis with lymphocyte sensitization. |
| 0.9973 | Multiple complications of propylthiouracil treatment : Adverse-Effectgranulocytopenia , eosinophilia, skin reaction and hepatitis with lymphocyte sensitization. |
| 0.9968 | Multiple complications of propylthiouracil treatment : granulocytopenia, Adverse-Effecteosinophilia , skin reaction and hepatitis with lymphocyte sensitization. |
| 0.9880 | Multiple complications of propylthiouracil treatment : granulocytopenia, eosinophilia, Adverse-Effectskin reaction and hepatitis with lymphocyte sensitization. |
| 0.9536 | Multiple complications of propylthiouracil treatment : granulocytopenia, eosinophilia, skin reaction and hepatitis with Adverse-Effectlymphocyte sensitization . |
| Score | Text |
|---|---|
| 0.9990 | Myoclonus and seizures in a patient with parkinsonism : induction by Druglevodopa and its confirmation on SEPs. |
| 0.9990 | Adverse-EffectMyoclonus and seizures in a patient with parkinsonism : induction by levodopa and its confirmation on SEPs. |
| 0.9986 | Myoclonus and Adverse-Effectseizures in a patient with parkinsonism : induction by levodopa and its confirmation on SEPs. |
| Score | Text |
|---|---|
| 0.9995 | We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic Drugaripiprazole . |
| 0.9983 | We report a patient of organic bipolar affective disorder who developed Adverse-Effecthiccups with the atypical antipsychotic aripiprazole. |
| Score | Text |
|---|---|
| 0.9988 | Based on the history and clinical features, a diagnosis of Druginsulin - induced lipohypertrophy was made. |
| 0.9970 | Based on the history and clinical features, a diagnosis of insulin - induced Adverse-Effectlipohypertrophy was made. |
| Score | Text |
|---|---|
| 0.9995 | We present a neonate with a seizure disorder who acutely developed pupillary mydriasis secondary to Druglidocaine overdose. |
| 0.9895 | We present a neonate with a seizure disorder who acutely developed Adverse-Effectpupillary mydriasis secondary to lidocaine overdose. |
| Score | Text |
|---|---|
| 0.9994 | There are, however, case studies describing patients experiencing recurrences of tics following treatment with Drugatomoxetine . |
| 0.9961 | There are, however, case studies describing patients experiencing recurrences of Adverse-Effecttics following treatment with atomoxetine. |
| Score | Text |
|---|---|
| 0.9780 | We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic Drugvitamin D poisoning. |
| 0.8507 | We report the use of pamidronate for acute, Adverse-Effectsevere hypercalcemia secondary to iatrogenic vitamin D poisoning. |
| 0.7589 | We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic Adverse-Effectvitamin D poisoning . |
| 0.6314 | We report the use of Drugpamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning. |
| Score | Text |
|---|---|
| 0.9993 | We present a case of photo - onycholysis in a patient treated with Drugdoxycycline for acne vulgaris. |
| 0.9781 | We present a case of Adverse-Effectphoto - onycholysis in a patient treated with doxycycline for acne vulgaris. |
| Score | Text |
|---|---|
| 0.9873 | We herein report this rare case of acute onset of Adverse-Effectnephrotic syndrome during interferon - alpha retreatment. |
| 0.9631 | We herein report this rare case of acute onset of nephrotic syndrome during Druginterferon - alpha retreatment. |
| Score | Text |
|---|---|
| 0.9995 | The occurrence of severe AIHA in CLL patients treated with Drugfludarabine has been reported by several authors. |
| 0.9938 | The occurrence of severe Adverse-EffectAIHA in CLL patients treated with fludarabine has been reported by several authors. |
| Score | Text |
|---|---|
| 0.9833 | We present the first case of a patient with priapism after oral intake of the phenothiazine Drugprothipendylhydrochloride . |
| 0.9826 | We present the first case of a patient with Adverse-Effectpriapism after oral intake of the phenothiazine prothipendylhydrochloride. |
| Score | Text |
|---|---|
| 0.9990 | Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of Drugamodiaquine and artesunate. |
| 0.9989 | Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and Drugartesunate . |
| 0.9656 | Adverse-EffectAcute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate. |
| Acute Adverse-Effectasymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate. | |
| Score | Text |
|---|---|
| 0.9995 | This case highlights the possible development of acute coronary syndrome as a side effect of DrugCapecitabine therapy. |
| 0.9869 | This case highlights the possible development of Adverse-Effectacute coronary syndrome as a side effect of Capecitabine therapy. |
| Score | Text |
|---|---|
| 0.9714 | Adverse-EffectAvascular necrosis of the femoral head in patients with prostate cancer treated with cyproterone acetate and radiotherapy. |
| 0.9680 | Avascular necrosis of the femoral head in patients with prostate cancer treated with Drugcyproterone acetate and radiotherapy. |
| Score | Text |
|---|---|
| 0.9995 | DrugTorsemide appears to also be a part of a long list of agents that can cause pancreatitis. |
| 0.9986 | Torsemide appears to also be a part of a long list of agents that can cause Adverse-Effectpancreatitis . |
| Score | Text |
|---|---|
| 0.9994 | Acute renal failure most likely was secondary to the nephrotoxic effect of Drugcaptopril on chronically hypoperfused kidneys. |
| 0.9401 | Adverse-EffectAcute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys. |
| Score | Text |
|---|---|
| 0.9992 | The patient was given Drugmethimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred. |
| 0.9973 | The patient was given methimazole instead of propylthiouracil but, 10 weeks later, Adverse-Effectagranulocytosis again occurred. |
| Score | Text |
|---|---|
| 0.9974 | The present case is the first report of Adverse-Effecthypercalcemia induced by vitamin D3 ointment and thiazide simultaneously. |
| 0.9953 | The present case is the first report of hypercalcemia induced by vitamin D3 ointment and Drugthiazide simultaneously. |
| 0.9898 | The present case is the first report of hypercalcemia induced by Drugvitamin D3 ointment and thiazide simultaneously. |
| Score | Text |
|---|---|
| 0.9996 | We describe a case of Drugclozapine - induced seizures in a patient with treatment - resistant schizophrenia. |
| 0.9988 | We describe a case of clozapine - induced Adverse-Effectseizures in a patient with treatment - resistant schizophrenia. |
| Score | Text |
|---|---|
| 0.9992 | Pleuropulmonary changes during treatment of Parkinson's disease with a long - acting ergot derivative, Drugcabergoline . |
| 0.9918 | Adverse-EffectPleuropulmonary changes during treatment of Parkinson's disease with a long - acting ergot derivative, cabergoline. |
| Score | Text |
|---|---|
| 0.9972 | However, because Drugdiphenhydramine also exhibits type IA sodium channel blockade, cardiac toxicity is also possible. |
| 0.9872 | However, because diphenhydramine also exhibits type IA sodium channel blockade, Adverse-Effectcardiac toxicity is also possible. |
| Score | Text |
|---|---|
| 0.9992 | While 40 mg / day of Drugprednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously. |
| 0.9417 | While 40 mg / day of prednisolone improved hepatic dysfunction dramatically, her Adverse-Effectdiabetic milieu deteriorated seriously. |
| Score | Text |
|---|---|
| 0.9965 | Two cases of Adverse-Effecthypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported. |
| 0.9623 | Two cases of hypothyroidism in patients with chronic hepatitis C treated with Drugrecombinant alpha interferon are reported. |
| Score | Text |
|---|---|
| 0.9996 | We report DrugAZA - induced drug eruption that developed in two cases of systemic scleroderma with polymyositis. |
| 0.9880 | We report AZA - induced Adverse-Effectdrug eruption that developed in two cases of systemic scleroderma with polymyositis. |
| Score | Text |
|---|---|
| 0.9996 | The condition should be suspected in patients who develop unexplained abdominal pain or collapse following Drugvasopressin treatment. |
| 0.9912 | The condition should be suspected in patients who develop unexplained Adverse-Effectabdominal pain or collapse following vasopressin treatment. |
| 0.9772 | The condition should be suspected in patients who develop unexplained abdominal pain or Adverse-Effectcollapse following vasopressin treatment. |
| Score | Text |
|---|---|
| 0.9991 | Reversal of Druggold - induced neutropenia with granulocyte colony - stimulating factor ( G - CSF ). |
| 0.9978 | Reversal of gold - induced Adverse-Effectneutropenia with granulocyte colony - stimulating factor ( G - CSF ). |
| Score | Text |
|---|---|
| 0.9996 | Psychosis in a 12 - year - old HIV - positive girl with an increased serum concentration of Drugefavirenz . |
| 0.9987 | Adverse-EffectPsychosis in a 12 - year - old HIV - positive girl with an increased serum concentration of efavirenz. |
| Score | Text |
|---|---|
| 0.9993 | A 35 - year - old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with Drugfenclofenac . |
| 0.9899 | A 35 - year - old man with seropositive rheumatoid arthritis developed selective Adverse-EffectIgA deficiency during treatment with fenclofenac. |
| Score | Text |
|---|---|
| 0.9979 | We report a case of recurrent torsades de pointes following treatment with pentavalent antimonial drugs and Drugamiodarone . |
| 0.9742 | We report a case of recurrent Adverse-Effecttorsades de pointes following treatment with pentavalent antimonial drugs and amiodarone. |
| Score | Text |
|---|---|
| 0.9991 | SUBSEQUENT COURSE : The nephrosis resolved almost completely once the Druginterferon was stopped and after immunosuppressive treatment. |
| 0.9955 | SUBSEQUENT COURSE : The Adverse-Effectnephrosis resolved almost completely once the interferon was stopped and after immunosuppressive treatment. |
| Score | Text |
|---|---|
| 0.9995 | Asthenozoospermia : possible association with long - term exposure to an anti - epileptic drug of Drugcarbamazepine . |
| 0.9964 | Adverse-EffectAsthenozoospermia : possible association with long - term exposure to an anti - epileptic drug of carbamazepine. |
| Score | Text |
|---|---|
| 0.9994 | PURPOSE : We studied a case of vortex keratopathy that was associated with the use of Drugatovaquone . |
| 0.9868 | PURPOSE : We studied a case of Adverse-Effectvortex keratopathy that was associated with the use of atovaquone. |
| Score | Text |
|---|---|
| 0.9995 | OBJECTIVE : To report 2 cases of nonconvulsive status epilepticus ( NCSE ) following infusion of Drugifosfamide . |
| 0.9913 | OBJECTIVE : To report 2 cases of nonconvulsive status epilepticus ( Adverse-EffectNCSE ) following infusion of ifosfamide. |
| 0.9800 | OBJECTIVE : To report 2 cases of Adverse-Effectnonconvulsive status epilepticus ( NCSE ) following infusion of ifosfamide. |
| Score | Text |
|---|---|
| 0.9991 | The cause is presumed to be secondary to hypercoagulability due to Drugasparaginase - induced antithrombin III deficiency. |
| 0.9836 | The cause is presumed to be secondary to hypercoagulability due to asparaginase - induced Adverse-Effectantithrombin III deficiency . |
| Score | Text |
|---|---|
| 0.9995 | OBJECTIVE : To describe the development of Drugvalproate - related reproductive endocrine disorders in women with epilepsy. |
| 0.9868 | OBJECTIVE : To describe the development of valproate - related Adverse-Effectreproductive endocrine disorders in women with epilepsy. |
| Score | Text |
|---|---|
| 0.9992 | Physicians treating patients with Drugmethotrexate for juvenile rheumatoid arthritis must be aware of this extraarticular side effect. |
| 0.9103 | Physicians treating patients with methotrexate for juvenile rheumatoid arthritis must be aware of this Adverse-Effectextraarticular side effect . |
| Score | Text |
|---|---|
| 0.9949 | Slow acetylator genotypes as a possible risk factor for infectious mononucleosis - like syndrome induced by Drugsalazosulfapyridine . |
| 0.9769 | Slow acetylator genotypes as a possible risk factor for Adverse-Effectinfectious mononucleosis - like syndrome induced by salazosulfapyridine. |
| Score | Text |
|---|---|
| 0.9997 | We report the first case, to our knowledge, of Drugrituximab - related autoimmune hemolytic anemia. |
| 0.9865 | We report the first case, to our knowledge, of rituximab - related Adverse-Effectautoimmune hemolytic anemia . |
| Score | Text |
|---|---|
| 0.9995 | A depressed woman with no history of bipolar illness developed a manic episode during treatment with Drugfluoxetine . |
| 0.9925 | A depressed woman with no history of bipolar illness developed a Adverse-Effectmanic episode during treatment with fluoxetine. |
| Score | Text |
|---|---|
| 0.9988 | With Drugitraconazole , hepatotoxic reactions have only very rarely been reported, and histologic data are lacking. |
| 0.6515 | With itraconazole, Adverse-Effecthepatotoxic reactions have only very rarely been reported, and histologic data are lacking. |
| 0.9858 | With itraconazole, Adverse-Effecthepatotoxic reactions have only very rarely been reported, and histologic data are lacking. |
| Score | Text |
|---|---|
| 0.9987 | The other woman had rheumatoid arthritis and developed acute tubular necrosis after treatment with Druggentamicin and cefoxitin. |
| 0.9980 | The other woman had rheumatoid arthritis and developed acute tubular necrosis after treatment with gentamicin and Drugcefoxitin . |
| 0.9893 | The other woman had rheumatoid arthritis and developed Adverse-Effectacute tubular necrosis after treatment with gentamicin and cefoxitin. |
| Score | Text |
|---|---|
| 0.9996 | OBJECTIVE : To report a case of possible Drugfoscarnet - induced severe hypomagnesemia and other electrolyte disorders. |
| 0.9927 | OBJECTIVE : To report a case of possible foscarnet - induced severe hypomagnesemia and other Adverse-Effectelectrolyte disorders . |
| 0.9872 | OBJECTIVE : To report a case of possible foscarnet - induced Adverse-Effectsevere hypomagnesemia and other electrolyte disorders. |
| Score | Text |
|---|---|
| 0.9921 | CONCLUSION : Lipoid pneumonia as a result of Drugmineral oil aspiration still occurs in the pediatric population. |
| 0.9887 | CONCLUSION : Adverse-EffectLipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population. |
| Score | Text |
|---|---|
| 0.9995 | Secretory endometrial adenocarcinoma in a patient on Drugtamoxifen for breast cancer : a report of a case. |
| 0.9717 | Adverse-EffectSecretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer : a report of a case. |
| Score | Text |
|---|---|
| 0.9996 | METHODS : Five cases of contact dermatitis due to Drugbudesonide , a nonhalogenated steroid, are described. |
| 0.9875 | METHODS : Five cases of Adverse-Effectcontact dermatitis due to budesonide, a nonhalogenated steroid, are described. |
| Score | Text |
|---|---|
| 0.9922 | We describe 2 children with cerebral palsy who suffered significant Adverse-Effectmorbidity immediately after treatment with hyperbaric oxygen. |
| 0.9843 | We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with Drughyperbaric oxygen . |
| Score | Text |
|---|---|
| 0.9975 | Cyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin - induced Adverse-Effectrhabdomyolysis . |
| 0.9937 | DrugCyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin - induced rhabdomyolysis. |
| 0.9759 | Cyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate Drugsimvastatin - induced rhabdomyolysis. |
| Score | Text |
|---|---|
| 0.9991 | To our knowledge, no prior cases of Drugpenicillamine - induced TTP in RA have been reported. |
| 0.9953 | To our knowledge, no prior cases of penicillamine - induced Adverse-EffectTTP in RA have been reported. |
| Score | Text |
|---|---|
| 0.9996 | We report two patients with acne vulgaris with a fourth type of Drugminocycline - induced cutaneous pigmentation. |
| 0.9936 | We report two patients with acne vulgaris with a fourth type of minocycline - induced Adverse-Effectcutaneous pigmentation . |
| Score | Text |
|---|---|
| 0.9984 | Tumor lysis syndrome after transcatheter arterial infusion of Drugcisplatin and embolization therapy for liver metastases of melanoma. |
| 0.9868 | Adverse-EffectTumor lysis syndrome after transcatheter arterial infusion of cisplatin and embolization therapy for liver metastases of melanoma. |
| Score | Text |
|---|---|
| 0.9993 | Severe cardiomyopathy following treatment with the tumour necrosis factor - alpha inhibitor Drugadalimumab for Crohn's disease. |
| 0.9394 | Adverse-EffectSevere cardiomyopathy following treatment with the tumour necrosis factor - alpha inhibitor adalimumab for Crohn's disease. |
| Score | Text |
|---|---|
| 0.9827 | Detection of antineutrophil cytoplasmic antibody in a patient with L - tryptophan induced Adverse-Effecteosinophilia - myalgia syndrome . |
| 0.9654 | Detection of antineutrophil cytoplasmic antibody in a patient with DrugL - tryptophan induced eosinophilia - myalgia syndrome. |
| Score | Text |
|---|---|
| 0.9993 | A patient with seropositive rheumatoid arthritis developed ascites while taking weekly doses of Drugmethotrexate ( MTX ). |
| 0.9988 | A patient with seropositive rheumatoid arthritis developed ascites while taking weekly doses of methotrexate ( DrugMTX ). |
| 0.9986 | A patient with seropositive rheumatoid arthritis developed Adverse-Effectascites while taking weekly doses of methotrexate ( MTX ). |
| Score | Text |
|---|---|
| 0.9996 | We describe 3 elderly patients with moderate to severe ataxia that occurred while they were taking Drugpropafenone . |
| 0.9666 | We describe 3 elderly patients with moderate to severe Adverse-Effectataxia that occurred while they were taking propafenone. |
| Score | Text |
|---|---|
| 0.9976 | DrugAluminum intoxication, along with other factors, was considered to be the cause of TC development. |
| 0.9895 | Aluminum intoxication, along with other factors, was considered to be the cause of Adverse-EffectTC development. |
| 0.8917 | Adverse-EffectAluminum intoxication , along with other factors, was considered to be the cause of TC development. |
| Score | Text |
|---|---|
| 0.9994 | Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with Druglithium use. |
| 0.9641 | Adverse-EffectTransient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use. |
| Score | Text |
|---|---|
| 0.9991 | Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with Drughalofantrine . |
| 0.9725 | Adverse-EffectProlongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine. |
| Score | Text |
|---|---|
| 0.9995 | We report the first histopathologically documented case of oral mucosa pigmentation after OLP treatment with topical Drugtacrolimus . |
| 0.9857 | We report the first histopathologically documented case of Adverse-Effectoral mucosa pigmentation after OLP treatment with topical tacrolimus. |
| Score | Text |
|---|---|
| 0.9994 | After cessation of Drugamantadine , the edema resolved, and the endothelial cell densities were < or = 600 / mm. |
| 0.9972 | After cessation of amantadine, the Adverse-Effectedema resolved, and the endothelial cell densities were < or = 600 / mm. |
| Score | Text |
|---|---|
| 0.9995 | A possible mechanism for focal neurological deficit in brain - damaged patients on Drugphenytoin therapy is discussed. |
| 0.9780 | A possible mechanism for Adverse-Effectfocal neurological deficit in brain - damaged patients on phenytoin therapy is discussed. |
| Score | Text |
|---|---|
| 0.9995 | Acute generalized exanthematous pustulosis caused by Drugmorphine , confirmed by positive patch test and lymphocyte transformation test. |
| 0.9678 | Adverse-EffectAcute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test. |
| Score | Text |
|---|---|
| 0.9992 | OBJECTIVE : To report a patient developing fulminant liver failure while being treated with Drugclarithromycin for pneumonia. |
| 0.9878 | OBJECTIVE : To report a patient developing Adverse-Effectfulminant liver failure while being treated with clarithromycin for pneumonia. |
| Score | Text |
|---|---|
| 0.9993 | One patient suffered coronary artery vasospasm, attributed to the use of topical 1 : 1000 Drugepinephrine during surgery. |
| 0.9850 | One patient suffered Adverse-Effectcoronary artery vasospasm , attributed to the use of topical 1 : 1000 epinephrine during surgery. |
| Score | Text |
|---|---|
| 0.9993 | DrugAcetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion. |
| 0.9979 | Acetazolamide may have accelerated the development of Adverse-Effectosteomalacia by several mechanisms, including increased renal calcium excretion. |
| Score | Text |
|---|---|
| 0.9970 | The incidence of 5 - fluorouracil ( Drug5 - FU ) - related cardiotoxicity seems to be dosage and schedule dependent. |
| 0.9965 | The incidence of 5 - fluorouracil ( 5 - FU ) - related Adverse-Effectcardiotoxicity seems to be dosage and schedule dependent. |
| 0.9962 | The incidence of Drug5 - fluorouracil ( 5 - FU ) - related cardiotoxicity seems to be dosage and schedule dependent. |
| Score | Text |
|---|---|
| 0.9995 | A case of acute respiratory failure due to diaphragmatic weakness following Drugadalimumab therapy for psoriasis is described. |
| 0.9852 | A case of Adverse-Effectacute respiratory failure due to diaphragmatic weakness following adalimumab therapy for psoriasis is described. |
| 0.5635 | A case of acute respiratory failure due to Adverse-Effectdiaphragmatic weakness following adalimumab therapy for psoriasis is described. |
| Score | Text |
|---|---|
| 0.9988 | DrugIndinavir - associated nephrolithiasis and chronic interstitial nephritis were the only possible causes identified in this patient. |
| 0.9931 | Indinavir - associated Adverse-Effectnephrolithiasis and chronic interstitial nephritis were the only possible causes identified in this patient. |
| 0.9400 | Indinavir - associated nephrolithiasis and chronic Adverse-Effectinterstitial nephritis were the only possible causes identified in this patient. |
| Score | Text |
|---|---|
| 0.9897 | Diagnosis of Adverse-Effecthypothyroidism during treatment can be difficult because of the common side effects of alpha interferon. |
| 0.9451 | Diagnosis of hypothyroidism during treatment can be difficult because of the common side effects of Drugalpha interferon . |
| Score | Text |
|---|---|
| 0.9835 | OBJECTIVE : To report a case of Adverse-Effectcutaneous and hematologic toxicity in a patient treated with IL - 2. |
| 0.9705 | OBJECTIVE : To report a case of cutaneous and hematologic toxicity in a patient treated with DrugIL - 2 . |
| Score | Text |
|---|---|
| 0.9989 | Improved awareness of and further investigation into the neurotoxic effects of Drugofloxacin may enhance its safe use. |
| 0.9821 | Improved awareness of and further investigation into the Adverse-Effectneurotoxic effects of ofloxacin may enhance its safe use. |
| Score | Text |
|---|---|
| 0.9954 | Several possible explanations of the mechanism of renal failure associated with the use of Drugdextran - 40 are discussed. |
| 0.9923 | Several possible explanations of the mechanism of Adverse-Effectrenal failure associated with the use of dextran - 40 are discussed. |
| Score | Text |
|---|---|
| 0.9990 | We postulate that the bolus of Drugsulprostone resulted in possible coronary spasm that resulted in cardiac arrest. |
| 0.9910 | We postulate that the bolus of sulprostone resulted in possible coronary spasm that resulted in Adverse-Effectcardiac arrest . |
| 0.9866 | We postulate that the bolus of sulprostone resulted in possible Adverse-Effectcoronary spasm that resulted in cardiac arrest. |
| Score | Text |
|---|---|
| 0.9989 | Neurophysiological mechanisms which aid in elucidating the role of Drugdisulfiram in the etiology of catatonia are discussed. |
| 0.9968 | Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of Adverse-Effectcatatonia are discussed. |
| Score | Text |
|---|---|
| 0.9982 | There is documentation of ocular toxicity with Drugethambutol when administered at dosages generally pronounced as being safe. |
| 0.9854 | There is documentation of Adverse-Effectocular toxicity with ethambutol when administered at dosages generally pronounced as being safe. |
| Score | Text |
|---|---|
| 0.9833 | Hydrocortisone may decrease the incidence of mortality associated with Adverse-Effectcardiac arrhythmias in children receiving amphotericin B overdoses. |
| 0.9794 | Hydrocortisone may decrease the incidence of Adverse-Effectmortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses. |
| 0.9784 | Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving Drugamphotericin B overdoses. |
| Score | Text |
|---|---|
| 0.9995 | There are no previous reports in the literature about the emergence of CML during treatment with Drughydroxyurea . |
| 0.9974 | There are no previous reports in the literature about the emergence of Adverse-EffectCML during treatment with hydroxyurea. |
| Score | Text |
|---|---|
| 0.9993 | An infertile patient with amenorrhea - galactorrhea syndrome lost vision during a pregnancy occurring after DrugBromocryptine treatment. |
| 0.9631 | An infertile patient with amenorrhea - galactorrhea syndrome Adverse-Effectlost vision during a pregnancy occurring after Bromocryptine treatment. |
| Score | Text |
|---|---|
| 0.9994 | Herein, we present a patient with severe and prolonged hypoglycemia after long - acting Drugoctreotide treatment. |
| 0.8601 | Herein, we present a patient with severe and prolonged Adverse-Effecthypoglycemia after long - acting octreotide treatment. |
| Herein, we present a patient with severe and Adverse-Effectprolonged hypoglycemia after long - acting octreotide treatment. | |
| Score | Text |
|---|---|
| 0.9995 | We describe a case of pneumonitis following local administration of Drugmethotrexate for nonsurgical termination of an ectopic pregnancy. |
| 0.9986 | We describe a case of Adverse-Effectpneumonitis following local administration of methotrexate for nonsurgical termination of an ectopic pregnancy. |
| Score | Text |
|---|---|
| 0.9996 | Progressive hypoxemia mandated endotracheal intubation 1 week after Drugrituximab administration and led to death 4 weeks after admission. |
| 0.9888 | Adverse-EffectProgressive hypoxemia mandated endotracheal intubation 1 week after rituximab administration and led to death 4 weeks after admission. |
| Score | Text |
|---|---|
| 0.9984 | Adverse-EffectHUS has been reported after several anticancer chemotherapies and most often after mitomycin C - based chemotherapy regimens. |
| 0.9880 | HUS has been reported after several anticancer chemotherapies and most often after Drugmitomycin C - based chemotherapy regimens. |
| Score | Text |
|---|---|
| 0.9987 | RESULTS : Evidence of neurological improvement and rehabilitation potential after severe myelopathy due to intrathecal injection of Drugdoxorubicin . |
| 0.9692 | RESULTS : Evidence of neurological improvement and rehabilitation potential after Adverse-Effectsevere myelopathy due to intrathecal injection of doxorubicin. |
| Score | Text |
|---|---|
| 0.9968 | Adverse-EffectHyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy. |
| 0.9854 | Hyperkalaemia with Adverse-Effectrenal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy. |
| 0.7867 | Hyperkalaemia with renal tubular dysfunction by Drugsulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy. |
| Score | Text |
|---|---|
| 0.9992 | CONCLUSION : DrugAtovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium. |
| 0.9879 | CONCLUSION : Atovaquone should be added to the list of agents causing Adverse-Effectvortex keratopathy involving the corneal epithelium. |
| Score | Text |
|---|---|
| 0.9992 | Posterior reversible encephalopathy syndrome associated with Drugmethotrexate neurotoxicity : conventional magnetic resonance and diffusion - weighted imaging findings. |
| 0.9175 | Adverse-EffectPosterior reversible encephalopathy syndrome associated with methotrexate neurotoxicity : conventional magnetic resonance and diffusion - weighted imaging findings. |
| Score | Text |
|---|---|
| 0.9993 | A 23 - year - old woman with systemic lupus erythematosus had a severe hypersensitivity reaction to the drug Drugibuprofen . |
| 0.9485 | A 23 - year - old woman with systemic lupus erythematosus had a Adverse-Effectsevere hypersensitivity reaction to the drug ibuprofen. |
| Score | Text |
|---|---|
| 0.9982 | We report a case of Graves'hyperthyroidism induced by long - term Druginterferon ( IFN ) therapy. |
| 0.9973 | We report a case of Graves'hyperthyroidism induced by long - term interferon ( DrugIFN ) therapy. |
| 0.9806 | We report a case of Adverse-EffectGraves'hyperthyroidism induced by long - term interferon ( IFN ) therapy. |
| Score | Text |
|---|---|
| 0.9995 | We describe a case of ulcerative proctitis after Drugibuprofen treatment in a girl with juvenile systemic lupus erythematosus. |
| 0.9878 | We describe a case of Adverse-Effectulcerative proctitis after ibuprofen treatment in a girl with juvenile systemic lupus erythematosus. |
| Score | Text |
|---|---|
| 0.9992 | These cases indicate that Drugsulpiride can cause tardive dyskinesia and that this drug should be administered with caution. |
| 0.9910 | These cases indicate that sulpiride can cause Adverse-Effecttardive dyskinesia and that this drug should be administered with caution. |
| Score | Text |
|---|---|
| 0.9988 | Premature closure of the ductus arteriosus : variable response among monozygotic twins after in utero exposure to Drugindomethacin . |
| 0.9687 | Adverse-EffectPremature closure of the ductus arteriosus : variable response among monozygotic twins after in utero exposure to indomethacin. |
| Score | Text |
|---|---|
| 0.9994 | When vague symptoms develop during Drugdesmopressin therapy, hyponatremia must be considered as part of the differential diagnosis. |
| 0.9954 | When vague symptoms develop during desmopressin therapy, Adverse-Effecthyponatremia must be considered as part of the differential diagnosis. |
| 0.9797 | When Adverse-Effectvague symptoms develop during desmopressin therapy, hyponatremia must be considered as part of the differential diagnosis. |
| Score | Text |
|---|---|
| 0.9995 | A 78 - year - old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral Drugprocainamide therapy. |
| 0.9878 | A 78 - year - old man with a transvenous cardioverter defibrillator system developed frequent Adverse-Effectshocks during oral procainamide therapy. |
| Score | Text |
|---|---|
| 0.9989 | Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and Drugbleomycin . |
| 0.9988 | Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, Drugvinblastine , and bleomycin. |
| 0.9986 | Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with Drugcisplatinum , vinblastine, and bleomycin. |
| 0.9943 | Transient left homonymous hemianopsia and Adverse-Effectencephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin. |
| 0.8590 | Adverse-EffectTransient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin. |
| Score | Text |
|---|---|
| 0.9879 | Pirmenol hydrochloride - induced Adverse-EffectQT prolongation and T wave inversion on electrocardiogram during treatment for symptomatic atrial fibrillation. |
| 0.9839 | Pirmenol hydrochloride - induced QT prolongation and Adverse-EffectT wave inversion on electrocardiogram during treatment for symptomatic atrial fibrillation. |
| 0.9751 | DrugPirmenol hydrochloride - induced QT prolongation and T wave inversion on electrocardiogram during treatment for symptomatic atrial fibrillation. |
| Score | Text |
|---|---|
| 0.9994 | Reported are three children who developed progressive paraparesis after intrathecal Drugmethotrexate administration followed by complete or partial recovery. |
| 0.9796 | Reported are three children who developed Adverse-Effectprogressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery. |
| Score | Text |
|---|---|
| 0.9975 | Dexamethasone treatment of amiodarone - induced Adverse-Effectthyrotoxicosis ( AIT ) with or without persistent administration of the drug. |
| 0.9918 | Dexamethasone treatment of Drugamiodarone - induced thyrotoxicosis ( AIT ) with or without persistent administration of the drug. |
| Score | Text |
|---|---|
| 0.9995 | Gallstones and bile sludge are common side effects of Drugoctreotide therapy but rarely become symptomatic or require treatment. |
| 0.9971 | Adverse-EffectGallstones and bile sludge are common side effects of octreotide therapy but rarely become symptomatic or require treatment. |
| 0.9905 | Gallstones and Adverse-Effectbile sludge are common side effects of octreotide therapy but rarely become symptomatic or require treatment. |
| Score | Text |
|---|---|
| 0.9974 | DrugIsoniazid inhibits the conversion of tryptophan to niacin and may induce pellagra, particularly in poorly nourished patients. |
| 0.9942 | Isoniazid inhibits the conversion of tryptophan to niacin and may induce Adverse-Effectpellagra , particularly in poorly nourished patients. |
| Score | Text |
|---|---|
| 0.9995 | DISCUSSION : A review of the cases of SS with implication of Drugmirtazapine as the cause was performed. |
| 0.9938 | DISCUSSION : A review of the cases of Adverse-EffectSS with implication of mirtazapine as the cause was performed. |
| Score | Text |
|---|---|
| 0.9972 | Both 6 - MP and DrugAZA are widely used and are known to cause hepatotoxicity in a proportion of patients. |
| 0.9969 | Both 6 - MP and AZA are widely used and are known to cause Adverse-Effecthepatotoxicity in a proportion of patients. |
| 0.9950 | Both Drug6 - MP and AZA are widely used and are known to cause hepatotoxicity in a proportion of patients. |
| Score | Text |
|---|---|
| 0.9976 | We report a case of radiotherapy - enhanced Drugaminoglutethimide skin toxicity in a patient with metastatic breast cancer. |
| 0.9091 | We report a case of radiotherapy - enhanced aminoglutethimide Adverse-Effectskin toxicity in a patient with metastatic breast cancer. |
| Score | Text |
|---|---|
| 0.9987 | It is increasingly recognized that dose adjustment of oral Drugvalacyclovir in renal failure is necessary to avoid neurotoxicity. |
| 0.9960 | It is increasingly recognized that dose adjustment of oral valacyclovir in renal failure is necessary to avoid Adverse-Effectneurotoxicity . |
| Score | Text |
|---|---|
| 0.9861 | Long - term follow - up after Adverse-Effectneoplastic seeding complicating percutaneous ethanol injection for treatment of hepatocellular carcinoma. |
| 0.9857 | Long - term follow - up after neoplastic seeding complicating percutaneous Drugethanol injection for treatment of hepatocellular carcinoma. |
| Score | Text |
|---|---|
| 0.9990 | Administration of lamotrigine, especially in combination with valproic acid, may lead to the development of Adverse-EffectTEN . |
| 0.9893 | Administration of Druglamotrigine , especially in combination with valproic acid, may lead to the development of TEN. |
| 0.9779 | Administration of lamotrigine, especially in combination with Drugvalproic acid , may lead to the development of TEN. |
| Score | Text |
|---|---|
| 0.9996 | We believe that this is the first report of secretory carcinoma of the endometrium associated with Drugtamoxifen use. |
| 0.9731 | We believe that this is the first report of Adverse-Effectsecretory carcinoma of the endometrium associated with tamoxifen use. |
| Score | Text |
|---|---|
| 0.9996 | To our knowledge, four cases of interstitial pneumonitis associated with Drugfludarabine have been reported in medical literature. |
| 0.9875 | To our knowledge, four cases of Adverse-Effectinterstitial pneumonitis associated with fludarabine have been reported in medical literature. |
| Score | Text |
|---|---|
| 0.9992 | Two cases of widespread cutaneous vasculitis are described in association with Drugdiltiazem , a recently introduced calcium antagonist. |
| 0.9834 | Two cases of widespread Adverse-Effectcutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist. |
| Score | Text |
|---|---|
| 0.9925 | To our knowledge, this is the first reported case of Adverse-Effectbromide intoxication due to pyridostigmine bromide administration. |
| 0.9765 | To our knowledge, this is the first reported case of bromide intoxication due to Drugpyridostigmine bromide administration. |
| Score | Text |
|---|---|
| 0.9993 | DrugVerapamil is widely used for the termination of paroxysmal supraventricular tachycardia ( PSVT ) with little proarrhythmic effect. |
| 0.9748 | Verapamil is widely used for the termination of paroxysmal supraventricular tachycardia ( PSVT ) with little Adverse-Effectproarrhythmic effect . |
| Score | Text |
|---|---|
| 0.9992 | However, the amount of Drugprednisone required to maintain normotension resulted in Cushingoid features and has been discontinued. |
| 0.9881 | However, the amount of prednisone required to maintain normotension resulted in Adverse-EffectCushingoid features and has been discontinued. |
| Score | Text |
|---|---|
| 0.9995 | This is a case of Drugpseudoephedrine - induced intracerebral hemorrhage in a patient with an underlying vascular malformation. |
| 0.9905 | This is a case of pseudoephedrine - induced Adverse-Effectintracerebral hemorrhage in a patient with an underlying vascular malformation. |
| Score | Text |
|---|---|
| 0.9993 | DrugNitrofurantoin - induced pulmonary toxicity during pregnancy : a report of a case and review of the literature. |
| 0.9897 | Nitrofurantoin - induced Adverse-Effectpulmonary toxicity during pregnancy : a report of a case and review of the literature. |
| Score | Text |
|---|---|
| 0.9982 | Knowledge regarding potential adverse effects of DrugCAP is paramount and dose modification is indicated with development of neurotoxicity. |
| 0.9969 | Knowledge regarding potential adverse effects of CAP is paramount and dose modification is indicated with development of Adverse-Effectneurotoxicity . |
| Score | Text |
|---|---|
| 0.9854 | A 75 - year - old man developed Adverse-Effectbilateral lower leg edema 6 months after switching from troglitazone to pioglitazone. |
| 0.9180 | A 75 - year - old man developed bilateral lower leg edema 6 months after switching from troglitazone to Drugpioglitazone . |
| 0.9155 | A 75 - year - old man developed bilateral lower leg edema 6 months after switching from Drugtroglitazone to pioglitazone. |
| Score | Text |
|---|---|
| 0.9994 | A patient with an allergy to a macrolide antibiotic was given Drugtacrolimus and developed a sudden cutaneous reaction. |
| 0.9910 | A patient with an allergy to a macrolide antibiotic was given tacrolimus and developed a Adverse-Effectsudden cutaneous reaction . |
| Score | Text |
|---|---|
| 0.9994 | However, there are few reports in the literature of Drugampicillin as a cause of acute interstitial nephritis. |
| 0.9795 | However, there are few reports in the literature of ampicillin as a cause of Adverse-Effectacute interstitial nephritis . |
| Score | Text |
|---|---|
| 0.9995 | Pulmonary eosinophilia or granulomas, classically seen in previously reported cases of Drugmethotrexate pneumonitis, were not observed. |
| 0.9955 | Pulmonary eosinophilia or Adverse-Effectgranulomas , classically seen in previously reported cases of methotrexate pneumonitis, were not observed. |
| 0.9796 | Adverse-EffectPulmonary eosinophilia or granulomas, classically seen in previously reported cases of methotrexate pneumonitis, were not observed. |
| 0.8327 | Pulmonary eosinophilia or granulomas, classically seen in previously reported cases of methotrexate Adverse-Effectpneumonitis , were not observed. |
| Score | Text |
|---|---|
| 0.9991 | Acute myelogenous leukemia in patients receiving Drugchlorambucil as long - term adjuvant chemotherapy for stage II breast cancer. |
| 0.9790 | Adverse-EffectAcute myelogenous leukemia in patients receiving chlorambucil as long - term adjuvant chemotherapy for stage II breast cancer. |
| Score | Text |
|---|---|
| 0.9987 | Adverse-EffectHepatoxicity is a rare complication of SRL therapy and may be connected with some diagnostic and / or therapeutic problems. |
| 0.9952 | Hepatoxicity is a rare complication of DrugSRL therapy and may be connected with some diagnostic and / or therapeutic problems. |
| Score | Text |
|---|---|
| 0.9688 | RESULTS : Replacing Drugvalproate with lamotrigine resulted in a decrease in serum testosterone concentrations in all 3 women. |
| 0.9711 | RESULTS : Replacing valproate with lamotrigine resulted in a Adverse-Effectdecrease in serum testosterone concentrations in all 3 women. |
| RESULTS : Replacing valproate with lamotrigine resulted in a decrease in Adverse-Effectserum testosterone concentrations in all 3 women. | |
| Score | Text |
|---|---|
| 0.9989 | DrugTacrolimus ( FK506 ), an immunosuppressant, has been associated with mutism in adults after liver transplant. |
| 0.9983 | Tacrolimus ( DrugFK506 ), an immunosuppressant, has been associated with mutism in adults after liver transplant. |
| 0.9950 | Tacrolimus ( FK506 ), an immunosuppressant, has been associated with Adverse-Effectmutism in adults after liver transplant. |
| Score | Text |
|---|---|
| 0.9995 | Both the longitudinal melanonychia and the multiple skin cancers first appeared after approximately 6 months of Drughydroxyurea treatment. |
| 0.9878 | Both the Adverse-Effectlongitudinal melanonychia and the multiple skin cancers first appeared after approximately 6 months of hydroxyurea treatment. |
| 0.9876 | Both the longitudinal melanonychia and the Adverse-Effectmultiple skin cancers first appeared after approximately 6 months of hydroxyurea treatment. |
| Score | Text |
|---|---|
| 0.9995 | The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking Drugleflunomide . |
| 0.9787 | The NZ Pharmacovigilance Centre has received 7 additional reports of Adverse-Effectsevere infections in patients with RA taking leflunomide. |
| Score | Text |
|---|---|
| 0.9984 | DrugINH , which is a leading cause of drug eruptions in the above group of drugs was withdrawn. |
| 0.9366 | INH, which is a leading cause of Adverse-Effectdrug eruptions in the above group of drugs was withdrawn. |
| Score | Text |
|---|---|
| 0.9994 | We report two cases of cerebrospinal fluid eosinophilia ( CSFE ) secondary to the intraventricular administration of Drugvancomycin . |
| 0.9810 | We report two cases of Adverse-Effectcerebrospinal fluid eosinophilia ( CSFE ) secondary to the intraventricular administration of vancomycin. |
| 0.9794 | We report two cases of cerebrospinal fluid eosinophilia ( Adverse-EffectCSFE ) secondary to the intraventricular administration of vancomycin. |
| Score | Text |
|---|---|
| 0.9994 | DISCUSSION : The Naranjo probability scale indicated a probable relationship between Drugsertraline treatment and the onset of rhabdomyolysis. |
| 0.9972 | DISCUSSION : The Naranjo probability scale indicated a probable relationship between sertraline treatment and the onset of Adverse-Effectrhabdomyolysis . |
| Score | Text |
|---|---|
| 0.9974 | CONCLUSION : We have introduced a case of Adverse-Effectanaphylaxis by calcitonin that suggest an IgE mediated hypersensitivity reaction. |
| 0.9919 | CONCLUSION : We have introduced a case of anaphylaxis by Drugcalcitonin that suggest an IgE mediated hypersensitivity reaction. |
| Score | Text |
|---|---|
| 0.9841 | No explanation for this delay was found, other than the possibility that Drugmagnesium sulfate treatment impeded lactogenesis. |
| 0.9627 | No explanation for this delay was found, other than the possibility that magnesium sulfate treatment Adverse-Effectimpeded lactogenesis . |
| Score | Text |
|---|---|
| 0.9994 | Here we report Drugramipril - induced cutaneous vasculitis in a patient who required steroid therapy to control it. |
| 0.9817 | Here we report ramipril - induced Adverse-Effectcutaneous vasculitis in a patient who required steroid therapy to control it. |
| Score | Text |
|---|---|
| 0.9971 | DrugHydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject. |
| 0.9854 | Hydroxyurea associated with concomitant occurrence of Adverse-Effectdiffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject. |
| 0.9815 | Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and Adverse-Effectmultiple squamous cell carcinomas in an elderly subject. |
| Score | Text |
|---|---|
| 0.9992 | This case suggests the importance of careful observation for extramedullary relapse in patients who are treated with DrugATRA . |
| 0.9860 | This case suggests the importance of careful observation for Adverse-Effectextramedullary relapse in patients who are treated with ATRA. |
| Score | Text |
|---|---|
| 0.9836 | With the increasing use of Cyclosporine A in transplant patients, the incidence of Adverse-Effectherpes esophagitis may increase. |
| 0.9798 | With the increasing use of DrugCyclosporine A in transplant patients, the incidence of herpes esophagitis may increase. |
| Score | Text |
|---|---|
| 0.9991 | DrugIsotretinoin , a drug used for the treatment of acne, has been shown to have teratogenic effects. |
| 0.9882 | Isotretinoin, a drug used for the treatment of acne, has been shown to have Adverse-Effectteratogenic effects . |
| Score | Text |
|---|---|
| 0.9992 | The Drugazathioprine dose was low ( 1 mg / kg ) and pancytopenia occurred after 56 days therapy. |
| 0.9965 | The azathioprine dose was low ( 1 mg / kg ) and Adverse-Effectpancytopenia occurred after 56 days therapy. |
| Score | Text |
|---|---|
| 0.9995 | We report 3 patients with severe hepatocellular damage due to DrugCPA therapy, 2 with fatal fulminant hepatitis. |
| 0.9855 | We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with Adverse-Effectfatal fulminant hepatitis . |
| 0.9759 | We report 3 patients with Adverse-Effectsevere hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis. |
| Score | Text |
|---|---|
| 0.9977 | This case study describes an atypical case of refractory, sodium warfarin - induced necrotizing fasciitis and Adverse-Effectmyonecrosis . |
| 0.9910 | This case study describes an atypical case of refractory, sodium warfarin - induced Adverse-Effectnecrotizing fasciitis and myonecrosis. |
| 0.9861 | This case study describes an atypical case of refractory, Drugsodium warfarin - induced necrotizing fasciitis and myonecrosis. |
| Score | Text |
|---|---|
| 0.9993 | A 77 - year - old man developed ankle, hand, and facial swelling 2 weeks after starting Drugrosiglitazone . |
| 0.9788 | A 77 - year - old man developed Adverse-Effectankle, hand, and facial swelling 2 weeks after starting rosiglitazone. |
| Score | Text |
|---|---|
| 0.9986 | It has been reported that Drugfluoroquinolone antimicrobials prolong the corrected QT interval but rarely cause torsade de pointes. |
| 0.9767 | It has been reported that fluoroquinolone antimicrobials prolong the corrected QT interval but rarely cause Adverse-Effecttorsade de pointes . |
| Score | Text |
|---|---|
| 0.9986 | Beneficial effect of low - dose mianserin on fluvoxamine - induced Adverse-Effectakathisia in an obsessive - compulsive patient. |
| 0.9938 | Beneficial effect of low - dose mianserin on Drugfluvoxamine - induced akathisia in an obsessive - compulsive patient. |
| Score | Text |
|---|---|
| 0.9995 | DrugLinezolid - associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms ( DRESS ) syndrome. |
| 0.9855 | Linezolid - associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms ( Adverse-EffectDRESS ) syndrome. |
| 0.9812 | Linezolid - associated Adverse-Effectacute interstitial nephritis and drug rash with eosinophilia and systemic symptoms ( DRESS ) syndrome. |
| 0.9425 | Linezolid - associated acute interstitial nephritis and Adverse-Effectdrug rash with eosinophilia and systemic symptoms ( DRESS ) syndrome. |
| Score | Text |
|---|---|
| 0.9987 | Immunosuppression elicited by the extensive administration of Drugprednisolone was suspected for the initiation of the generalized mite infestation. |
| 0.9331 | Immunosuppression elicited by the extensive administration of prednisolone was suspected for the initiation of the generalized Adverse-Effectmite infestation . |
| Score | Text |
|---|---|
| 0.9995 | BACKGROUND : Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of Drugsirolimus therapy. |
| 0.9899 | BACKGROUND : Adverse-EffectAphthous stomatitis , a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy. |
| Score | Text |
|---|---|
| 0.9995 | The authors report two cases of acute dystonic reactions ( ADRs ) as a side effect of Druglamivudine . |
| 0.9908 | The authors report two cases of acute dystonic reactions ( Adverse-EffectADRs ) as a side effect of lamivudine. |
| 0.9882 | The authors report two cases of Adverse-Effectacute dystonic reactions ( ADRs ) as a side effect of lamivudine. |
| Score | Text |
|---|---|
| 0.9990 | A 52 - year - old woman developed symmetric sensorimotor polyneuropathy and cerebellar syndrome after 24 months of Drugamiodarone treatment. |
| 0.9908 | A 52 - year - old woman developed symmetric sensorimotor polyneuropathy and Adverse-Effectcerebellar syndrome after 24 months of amiodarone treatment. |
| 0.9849 | A 52 - year - old woman developed Adverse-Effectsymmetric sensorimotor polyneuropathy and cerebellar syndrome after 24 months of amiodarone treatment. |
| Score | Text |
|---|---|
| 0.9995 | It is hoped that this case report creates awareness that Drugofloxacin - induced toxic epidermal necrolysis is possible. |
| 0.9864 | It is hoped that this case report creates awareness that ofloxacin - induced Adverse-Effecttoxic epidermal necrolysis is possible. |
| Score | Text |
|---|---|
| 0.9862 | A second possibility is an interaction between Drugclarithromycin and isradipine, potentially increasing the hepatic toxicity of isradipine. |
| 0.9821 | A second possibility is an interaction between clarithromycin and Drugisradipine , potentially increasing the hepatic toxicity of isradipine. |
| 0.9550 | A second possibility is an interaction between clarithromycin and isradipine, potentially Adverse-Effectincreasing the hepatic toxicity of isradipine. |
| 0.9538 | A second possibility is an interaction between clarithromycin and isradipine, potentially increasing the hepatic toxicity of Drugisradipine . |
| Score | Text |
|---|---|
| 0.9907 | These cases highlight the occurrence of Adverse-Effectlivedo reticularis as an uncommon side - effect of interferon alpha treatment. |
| 0.9821 | These cases highlight the occurrence of livedo reticularis as an uncommon side - effect of Druginterferon alpha treatment. |
| Score | Text |
|---|---|
| 0.9994 | CONCLUSION : Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with Drugleflunomide . |
| 0.9924 | CONCLUSION : Significant Adverse-Effectweight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide. |
| Score | Text |
|---|---|
| 0.9886 | We report a case of Adverse-Effectacne fulminans occurring during treatment with 13 - cis - retinoic acid for cystic acne. |
| 0.9506 | We report a case of acne fulminans occurring during treatment with Drug13 - cis - retinoic acid for cystic acne. |
| Score | Text |
|---|---|
| 0.9996 | Fever and maculopapular rashes appeared at 10 days after Drugphenytoin initiation, and then the drug was discontinued. |
| 0.9940 | Fever and Adverse-Effectmaculopapular rashes appeared at 10 days after phenytoin initiation, and then the drug was discontinued. |
| 0.9833 | Adverse-EffectFever and maculopapular rashes appeared at 10 days after phenytoin initiation, and then the drug was discontinued. |
| Score | Text |
|---|---|
| 0.9990 | This case and other published evidence should alert physicians to the possibility of fatal Drugerlotinib - induced ILD. |
| 0.9986 | This case and other published evidence should alert physicians to the possibility of fatal erlotinib - induced Adverse-EffectILD . |
| Score | Text |
|---|---|
| 0.9990 | The ototoxicity of Drugquinine can accurately be studied with ultrahigh frequency audiometry ( up to 20 kHz ). |
| 0.9928 | The Adverse-Effectototoxicity of quinine can accurately be studied with ultrahigh frequency audiometry ( up to 20 kHz ). |
| Score | Text |
|---|---|
| 0.9996 | One case of priapism occurred during Drugheparin therapy for a previous surgical operation to the knee is reported. |
| 0.9986 | One case of Adverse-Effectpriapism occurred during heparin therapy for a previous surgical operation to the knee is reported. |
| Score | Text |
|---|---|
| 0.9993 | This prompted us to suspect that DrugddI might be responsible for fulminant hepatitis in all three AIDS patients. |
| 0.9893 | This prompted us to suspect that ddI might be responsible for Adverse-Effectfulminant hepatitis in all three AIDS patients. |
| Score | Text |
|---|---|
| 0.9995 | Drug eruption caused by Drugazathioprine : value of using the drug - induced lymphocytes stimulation test for diagnosis. |
| 0.9876 | Adverse-EffectDrug eruption caused by azathioprine : value of using the drug - induced lymphocytes stimulation test for diagnosis. |
| Score | Text |
|---|---|
| 0.9994 | Reye syndrome ( RS ) is believed to occur infrequently among children receiving long - term Drugaspirin therapy. |
| 0.9940 | Adverse-EffectReye syndrome ( RS ) is believed to occur infrequently among children receiving long - term aspirin therapy. |
| 0.9642 | Reye syndrome ( Adverse-EffectRS ) is believed to occur infrequently among children receiving long - term aspirin therapy. |
| Score | Text |
|---|---|
| 0.9994 | A retrospective study was conducted of 40 Drugloperamide poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires. |
| 0.9197 | A retrospective study was conducted of 40 Adverse-Effectloperamide poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires. |
| Score | Text |
|---|---|
| 0.9992 | The case of a bipolar patient who developed thyrotoxicosis with severe exophthalmos while on Druglithium therapy is described. |
| 0.9958 | The case of a bipolar patient who developed Adverse-Effectthyrotoxicosis with severe exophthalmos while on lithium therapy is described. |
| 0.9686 | The case of a bipolar patient who developed thyrotoxicosis with Adverse-Effectsevere exophthalmos while on lithium therapy is described. |
| Score | Text |
|---|---|
| 0.9929 | Reports of colonic perforation as a result of the administration of calcium polystyrene sulfonate and Drugsorbitol are rare. |
| 0.9904 | Reports of Adverse-Effectcolonic perforation as a result of the administration of calcium polystyrene sulfonate and sorbitol are rare. |
| 0.9625 | Reports of colonic perforation as a result of the administration of Drugcalcium polystyrene sulfonate and sorbitol are rare. |
| Score | Text |
|---|---|
| 0.9995 | BACKGROUND : Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under Drugtamoxifen therapy is rare. |
| 0.9924 | BACKGROUND : Adverse-EffectOvarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare. |
| Score | Text |
|---|---|
| 0.9991 | Administration of steroid and decreasing the dose of DrugPTU produced a good clinical response and the ANCA disappeared. |
| 0.9973 | Administration of steroid and decreasing the dose of PTU produced a good clinical response and the Adverse-EffectANCA disappeared. |
| Score | Text |
|---|---|
| 0.9992 | Prior reports have emphasized the tubular and interstitial lesions associated with intermittent or discontinuous Drugrifampin therapy for tuberculosis. |
| 0.9647 | Prior reports have emphasized the Adverse-Effecttubular and interstitial lesions associated with intermittent or discontinuous rifampin therapy for tuberculosis. |
| Score | Text |
|---|---|
| 0.9993 | We report a case of a scleroderma - like reaction induced by long - term administration of DrugUFT . |
| 0.9865 | We report a case of a Adverse-Effectscleroderma - like reaction induced by long - term administration of UFT. |
| Score | Text |
|---|---|
| 0.9895 | DrugFludarabine induced lung toxicity must be considered in all patients who develop unexplained lung disease while receiving fludarabine. |
| 0.9845 | Fludarabine induced lung toxicity must be considered in all patients who develop unexplained Adverse-Effectlung disease while receiving fludarabine. |
| 0.9570 | Fludarabine induced Adverse-Effectlung toxicity must be considered in all patients who develop unexplained lung disease while receiving fludarabine. |
| Fludarabine induced lung toxicity must be considered in all patients who develop unexplained lung disease while receiving Drugfludarabine . | |
| Score | Text |
|---|---|
| 0.9983 | DrugPhenylpropanolamine ( PPA ) recently has been publicly implicated as a cause of stroke and other neurologic events. |
| 0.9977 | Phenylpropanolamine ( DrugPPA ) recently has been publicly implicated as a cause of stroke and other neurologic events. |
| 0.9874 | Phenylpropanolamine ( PPA ) recently has been publicly implicated as a cause of Adverse-Effectstroke and other neurologic events. |
| 0.9873 | Phenylpropanolamine ( PPA ) recently has been publicly implicated as a cause of stroke and other Adverse-Effectneurologic events . |
| Score | Text |
|---|---|
| 0.9995 | This is the first case, to our knowledge, of onset of prolonged Druginfliximab - induced lupus. |
| 0.9988 | This is the first case, to our knowledge, of onset of prolonged infliximab - induced Adverse-Effectlupus . |
| Score | Text |
|---|---|
| 0.9987 | DrugRitonavir should be added to the list of drugs that can induce adverse cutaneous reactions in HIV patients. |
| 0.9847 | Ritonavir should be added to the list of drugs that can induce Adverse-Effectadverse cutaneous reactions in HIV patients. |
| Score | Text |
|---|---|
| 0.9991 | High - dose Drugmethylprednisolone in a pregnant woman with Crohn's disease and adrenal suppression in her newborn. |
| 0.9847 | High - dose methylprednisolone in a pregnant woman with Crohn's disease and Adverse-Effectadrenal suppression in her newborn. |
| Score | Text |
|---|---|
| 0.9993 | A 55 - year - old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving Drugmethyldopa for hypertension. |
| 0.9965 | A 55 - year - old woman developed symptoms suggestive of Adverse-Effecthepatitis 12 weeks after first receiving methyldopa for hypertension. |
| Score | Text |
|---|---|
| 0.9954 | Successful recovery from interstitial pneumonitis, induced by Drugbicalutamide and leuprorelin acetate given as treatment for prostate cancer. |
| 0.9851 | Successful recovery from Adverse-Effectinterstitial pneumonitis , induced by bicalutamide and leuprorelin acetate given as treatment for prostate cancer. |
| 0.9783 | Successful recovery from interstitial pneumonitis, induced by bicalutamide and Drugleuprorelin acetate given as treatment for prostate cancer. |
| Score | Text |
|---|---|
| 0.9992 | After the patient discontinued Drugrifampicin , the skin lesions cleared completely within 5 weeks without any systemic medication. |
| 0.9915 | After the patient discontinued rifampicin, the Adverse-Effectskin lesions cleared completely within 5 weeks without any systemic medication. |
| Score | Text |
|---|---|
| 0.9994 | DrugMannitol - induced ARF responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure. |
| 0.9975 | Mannitol - induced Adverse-EffectARF responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure. |
| Score | Text |
|---|---|
| 0.9992 | In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received Drugcaptopril treatment. |
| 0.9804 | In a patient with severe renovascular hypertension, Adverse-Effectnonoliguric acute renal failure developed after she received captopril treatment. |
| Score | Text |
|---|---|
| 0.9841 | We present a case of Adverse-Effectcutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor. |
| 0.9829 | We present a case of cutaneous leucocytoclastic vasculitis in which Drugamphotericin B might presumably be the aetiological factor. |
| Score | Text |
|---|---|
| 0.9987 | This is the first report of an adverse effect of fetal renal circulation by maternal ingestion of Drugnimesulide . |
| 0.8952 | This is the first report of an adverse effect of Adverse-Effectfetal renal circulation by maternal ingestion of nimesulide. |
| This is the first report of an Adverse-Effectadverse effect of fetal renal circulation by maternal ingestion of nimesulide. | |
| Score | Text |
|---|---|
| 0.9990 | We report on a patient who developed hypersensitivity pneumonitis during treatment with the beta - blocker, Drugceliprolol . |
| 0.9766 | We report on a patient who developed Adverse-Effecthypersensitivity pneumonitis during treatment with the beta - blocker, celiprolol. |
| Score | Text |
|---|---|
| 0.9995 | He developed recurrent skin rash, fever, hypereosinophilia, and acute renal failure after rechallenge with Drugchlorambucil . |
| 0.9952 | He developed recurrent skin rash, fever, Adverse-Effecthypereosinophilia , and acute renal failure after rechallenge with chlorambucil. |
| 0.9878 | He developed recurrent skin rash, fever, hypereosinophilia, and Adverse-Effectacute renal failure after rechallenge with chlorambucil. |
| 0.9866 | He developed recurrent skin rash, Adverse-Effectfever , hypereosinophilia, and acute renal failure after rechallenge with chlorambucil. |
| 0.9849 | He developed recurrent Adverse-Effectskin rash , fever, hypereosinophilia, and acute renal failure after rechallenge with chlorambucil. |
| Score | Text |
|---|---|
| 0.9994 | We report a male patient with advanced AIDS who developed hypercalcemia 2 weeks after institution of DrugrhGH therapy. |
| 0.9978 | We report a male patient with advanced AIDS who developed Adverse-Effecthypercalcemia 2 weeks after institution of rhGH therapy. |
| Score | Text |
|---|---|
| 0.9994 | A rare case of advanced ovarian carcinoma who developed difficulty walking 25 days after treatment with weekly Drugpaclitaxel . |
| 0.9908 | A rare case of advanced ovarian carcinoma who developed Adverse-Effectdifficulty walking 25 days after treatment with weekly paclitaxel. |
| Score | Text |
|---|---|
| 0.9996 | We report two cases that developed acute myeloid leukaemia ( AML ) during Drugtamoxifen therapy for breast cancer. |
| 0.9903 | We report two cases that developed acute myeloid leukaemia ( Adverse-EffectAML ) during tamoxifen therapy for breast cancer. |
| 0.9852 | We report two cases that developed Adverse-Effectacute myeloid leukaemia ( AML ) during tamoxifen therapy for breast cancer. |
| Score | Text |
|---|---|
| 0.9983 | We report three cases of severe hypocalcaemia associated with i. v. Drugbisphosphonate treatment in patients with multiple myeloma. |
| 0.9344 | We report three cases of Adverse-Effectsevere hypocalcaemia associated with i. v. bisphosphonate treatment in patients with multiple myeloma. |
| Score | Text |
|---|---|
| 0.9660 | The authors report two cases of delayed elimination of methotrexate in patients receiving Drugciprofloxacin , with severe toxicity. |
| 0.6428 | The authors report two cases of delayed elimination of Drugmethotrexate in patients receiving ciprofloxacin, with severe toxicity. |
| 0.5697 | The authors report two cases of Adverse-Effectdelayed elimination of methotrexate in patients receiving ciprofloxacin, with severe toxicity. |
| 0.9239 | The authors report two cases of delayed elimination of methotrexate in patients receiving ciprofloxacin, with Adverse-Effectsevere toxicity . |
| The authors report two cases of delayed elimination of methotrexate in patients receiving ciprofloxacin, with severe Adverse-Effecttoxicity . | |
| Score | Text |
|---|---|
| 0.9987 | Administration of Drugamantadine was associated with psychotic decompensations in two schizophrenic patients being maintained on concomitant neuroleptic medication. |
| 0.9846 | Administration of amantadine was associated with Adverse-Effectpsychotic decompensations in two schizophrenic patients being maintained on concomitant neuroleptic medication. |
| Score | Text |
|---|---|
| 0.9988 | Two patients are described who developed sensory neuropathy after the ingestion of 30. 6 and 114 g Drugmetronidazole respectively. |
| 0.9894 | Two patients are described who developed Adverse-Effectsensory neuropathy after the ingestion of 30. 6 and 114 g metronidazole respectively. |
| Score | Text |
|---|---|
| 0.9870 | Adverse-EffectFatal ventricular fibrillation after treatment with digoxin in a 27 - year - old man with mitral leaflet prolapse syndrome. |
| 0.9805 | Fatal ventricular fibrillation after treatment with Drugdigoxin in a 27 - year - old man with mitral leaflet prolapse syndrome. |
| Score | Text |
|---|---|
| 0.9994 | We report a case of interstitial pulmonary disease that occurred together with lymphocytic colitis during treatment with Drugticlopidine . |
| 0.9900 | We report a case of interstitial pulmonary disease that occurred together with Adverse-Effectlymphocytic colitis during treatment with ticlopidine. |
| 0.9842 | We report a case of Adverse-Effectinterstitial pulmonary disease that occurred together with lymphocytic colitis during treatment with ticlopidine. |
| Score | Text |
|---|---|
| 0.9956 | These skin lesions may be induced or worsened during antiviral therapy with interferon - alpha ( DrugIFN ). |
| 0.9790 | These Adverse-Effectskin lesions may be induced or worsened during antiviral therapy with interferon - alpha ( IFN ). |
| 0.9676 | These skin lesions may be induced or worsened during antiviral therapy with Druginterferon - alpha ( IFN ). |
| Score | Text |
|---|---|
| 0.9986 | After treatment with Drugcimetidine , there was a rapid deterioration with decreased oxygen saturation and arterial PO2 values. |
| 0.5623 | After treatment with cimetidine, there was a rapid deterioration with Adverse-Effectdecreased oxygen saturation and arterial PO2 values. |
| 0.7231 | After treatment with cimetidine, there was a rapid Adverse-Effectdeterioration with decreased oxygen saturation and arterial PO2 values. |
| Score | Text |
|---|---|
| 0.9992 | DrugFlecainide overdose can rapidly result in profound cardiovascular collapse, and is associated with a relatively high mortality. |
| 0.9816 | Flecainide overdose can rapidly result in profound Adverse-Effectcardiovascular collapse , and is associated with a relatively high mortality. |
| Score | Text |
|---|---|
| 0.9983 | The three reported cases demonstrate that Drugtroglitazone is an idiosyncratic hepatotoxin that can lead to irreversible liver injury. |
| 0.9780 | The three reported cases demonstrate that troglitazone is an idiosyncratic hepatotoxin that can lead to Adverse-Effectirreversible liver injury . |
| Score | Text |
|---|---|
| 0.9995 | OBJECTIVE : The aim of this paper is to describe a case of increased libido during Drugfluvoxamine therapy. |
| 0.9903 | OBJECTIVE : The aim of this paper is to describe a case of Adverse-Effectincreased libido during fluvoxamine therapy. |
| Score | Text |
|---|---|
| 0.9993 | The development of erythroid leukemia plus carcinoma in these two men suggests mutagenic change secondary to Drugcyclophosphamide therapy. |
| 0.9862 | The development of erythroid leukemia plus Adverse-Effectcarcinoma in these two men suggests mutagenic change secondary to cyclophosphamide therapy. |
| Score | Text |
|---|---|
| 0.9992 | Acute renal failure with severe tubulointerstitial changes in a patient with minimal change nephrotic syndrome treated with Drugenalapril . |
| 0.9740 | Acute renal failure with Adverse-Effectsevere tubulointerstitial changes in a patient with minimal change nephrotic syndrome treated with enalapril. |
| 0.8912 | Adverse-EffectAcute renal failure with severe tubulointerstitial changes in a patient with minimal change nephrotic syndrome treated with enalapril. |
| Score | Text |
|---|---|
| 0.9994 | DISCUSSION : To our knowledge this is the first reported case of tuberculous uveitis following treatment with Drugetanercept . |
| 0.9887 | DISCUSSION : To our knowledge this is the first reported case of Adverse-Effecttuberculous uveitis following treatment with etanercept. |
| Score | Text |
|---|---|
| 0.9959 | L - asparaginase - induced Adverse-Effectpancreatitis is an uncommon but potential lethal complication of the treatment of leukemia. |
| 0.9856 | L - asparaginase - induced pancreatitis is an uncommon but potential Adverse-Effectlethal complication of the treatment of leukemia. |
| 0.9692 | DrugL - asparaginase - induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia. |
| Score | Text |
|---|---|
| 0.9991 | The cases of two asthmatic patients who became hypokalemic after inhalation of normal doses of Drugalbuterol are presented. |
| 0.9939 | The cases of two asthmatic patients who became Adverse-Effecthypokalemic after inhalation of normal doses of albuterol are presented. |
| Score | Text |
|---|---|
| 0.9875 | How low can you go? Use of very low dosage of Druggold in patients with mucocutaneous reactions. |
| 0.9678 | How low can you go? Use of very low dosage of gold in patients with Adverse-Effectmucocutaneous reactions . |
| Score | Text |
|---|---|
| 0.9994 | Rhabdomyolysis associated with Drugclozapine treatment in a patient with decreased calcium - dependent potassium permeability of cell membranes. |
| 0.9984 | Adverse-EffectRhabdomyolysis associated with clozapine treatment in a patient with decreased calcium - dependent potassium permeability of cell membranes. |
| Score | Text |
|---|---|
| 0.9666 | Adverse-EffectPosterior reversible encephalopathy syndrome ( PRES ) induced by cyclosporine use in a patient with collapsing focal glomeruloesclerosis. |
| 0.9091 | Posterior reversible encephalopathy syndrome ( PRES ) induced by Drugcyclosporine use in a patient with collapsing focal glomeruloesclerosis. |
| Posterior reversible encephalopathy syndrome ( DrugPRES ) induced by cyclosporine use in a patient with collapsing focal glomeruloesclerosis. | |
| Posterior reversible encephalopathy syndrome ( PRES ) induced by Adverse-Effectcyclosporine use in a patient with collapsing focal glomeruloesclerosis. | |
| Score | Text |
|---|---|
| 0.9992 | The association of Drugvenlafaxine treatment with ischaemic events could be explained by its unique pharmacological and haemodynamic properties. |
| 0.9141 | The association of venlafaxine treatment with Adverse-Effectischaemic events could be explained by its unique pharmacological and haemodynamic properties. |
| Score | Text |
|---|---|
| 0.9995 | OBJECTIVE : To report a case of a diffuse papular eruption following treatment of psoriasis with Drugmethotrexate injections. |
| 0.9836 | OBJECTIVE : To report a case of a Adverse-Effectdiffuse papular eruption following treatment of psoriasis with methotrexate injections. |
| Score | Text |
|---|---|
| 0.9984 | Attenuation of Drugasparaginase - induced hyperglycemia after substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation. |
| 0.9978 | Attenuation of asparaginase - induced Adverse-Effecthyperglycemia after substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation. |
| Score | Text |
|---|---|
| 0.9981 | Posthypoglycemic hyperglycemia ( rebound hyperglycemia ) after overdosing of Druginsulin was diagnosed in 6 cats with diabetes mellitus. |
| 0.9859 | Adverse-EffectPosthypoglycemic hyperglycemia ( rebound hyperglycemia ) after overdosing of insulin was diagnosed in 6 cats with diabetes mellitus. |
| 0.9437 | Posthypoglycemic hyperglycemia ( Adverse-Effectrebound hyperglycemia ) after overdosing of insulin was diagnosed in 6 cats with diabetes mellitus. |
| Score | Text |
|---|---|
| 0.9956 | A case of Drugclozapine - induced tonic - clonic seizures managed with valproate : implications for clinical care. |
| 0.9850 | A case of clozapine - induced Adverse-Effecttonic - clonic seizures managed with valproate : implications for clinical care. |
| Score | Text |
|---|---|
| 0.9993 | This report describes a case of neuroleptic malignant syndrome due to Drugrisperidone in a child with Joubert syndrome. |
| 0.9864 | This report describes a case of Adverse-Effectneuroleptic malignant syndrome due to risperidone in a child with Joubert syndrome. |
| Score | Text |
|---|---|
| 0.9966 | It has been suggested that Adverse-EffectPPE caused by cytarabine does not recur with subsequent cytarabine re - challenge. |
| 0.9324 | It has been suggested that PPE caused by Drugcytarabine does not recur with subsequent cytarabine re - challenge. |
| 0.5246 | It has been suggested that PPE caused by cytarabine does not recur with subsequent Drugcytarabine re - challenge. |
| Score | Text |
|---|---|
| 0.9972 | Treatment of amiodarone - induced Adverse-Effectthyrotoxicosis ( AIT ) with thionamide, lithium or radioactive iodine is ineffective. |
| 0.9936 | Treatment of Drugamiodarone - induced thyrotoxicosis ( AIT ) with thionamide, lithium or radioactive iodine is ineffective. |
| Score | Text |
|---|---|
| 0.9976 | A 68 - year - old female patient with advanced ovarian carcinoma collapsed whilst receiving a carboplatin and Drugcyclophosphamide infusion. |
| 0.9973 | A 68 - year - old female patient with advanced ovarian carcinoma collapsed whilst receiving a Drugcarboplatin and cyclophosphamide infusion. |
| 0.9912 | A 68 - year - old female patient with advanced ovarian carcinoma Adverse-Effectcollapsed whilst receiving a carboplatin and cyclophosphamide infusion. |
| Score | Text |
|---|---|
| 0.9995 | DrugImidazoline intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children. |
| 0.8765 | Adverse-EffectImidazoline intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children. |
| Score | Text |
|---|---|
| 0.9989 | The occurrence of Adverse-EffectBMTN in two children treated with RA in our unit is unlikely to be coincidental. |
| 0.9986 | The occurrence of BMTN in two children treated with DrugRA in our unit is unlikely to be coincidental. |
| Score | Text |
|---|---|
| 0.9995 | Multiple pulmonary nodules : an unusual presentation of Drugfludarabine pulmonary toxicity : case report and review of literature. |
| 0.9751 | Adverse-EffectMultiple pulmonary nodules : an unusual presentation of fludarabine pulmonary toxicity : case report and review of literature. |
| 0.6834 | Multiple pulmonary nodules : an unusual presentation of fludarabine Adverse-Effectpulmonary toxicity : case report and review of literature. |
| Score | Text |
|---|---|
| 0.9991 | Extrapyramidal symptoms are well - documented complications of therapy with Drughaloperidol , even when small doses are used. |
| 0.9909 | Adverse-EffectExtrapyramidal symptoms are well - documented complications of therapy with haloperidol, even when small doses are used. |
| Score | Text |
|---|---|
| 0.8168 | Case report : Adverse-Effectlife - threatening hypoglycaemia associated with sulfadoxine - pyrimethamine, a commonly used antimalarial drug. |
| 0.7266 | Case report : life - threatening hypoglycaemia associated with Drugsulfadoxine - pyrimethamine , a commonly used antimalarial drug. |
| Score | Text |
|---|---|
| 0.9995 | DrugBenzocaine , an ester - type local anesthetic, was believed responsible for apparent methemoglobinemia in a cat. |
| 0.9964 | Benzocaine, an ester - type local anesthetic, was believed responsible for apparent Adverse-Effectmethemoglobinemia in a cat. |
| Score | Text |
|---|---|
| 0.9987 | We report a case of NEH masquerading as cutaneous vasculitis in a woman receiving Drugcyclophosphamide for lupus nephritis. |
| 0.9949 | We report a case of Adverse-EffectNEH masquerading as cutaneous vasculitis in a woman receiving cyclophosphamide for lupus nephritis. |
| Score | Text |
|---|---|
| 0.9967 | We report two cases of Drugtenofovir ( TDF ) - associated nephrotoxicity in perinatally HIV - infected adolescents. |
| 0.9954 | We report two cases of tenofovir ( DrugTDF ) - associated nephrotoxicity in perinatally HIV - infected adolescents. |
| 0.9953 | We report two cases of tenofovir ( TDF ) - associated Adverse-Effectnephrotoxicity in perinatally HIV - infected adolescents. |
| Score | Text |
|---|---|
| 0.9993 | DrugMethotrexate may rarely provoke serositis, even with low doses and after just a few weeks of therapy. |
| 0.9980 | Methotrexate may rarely provoke Adverse-Effectserositis , even with low doses and after just a few weeks of therapy. |
| Score | Text |
|---|---|
| 0.9992 | In addition, Drugethambutol rarely causes visual loss during the early period or when given at lower doses. |
| 0.9921 | In addition, ethambutol rarely causes Adverse-Effectvisual loss during the early period or when given at lower doses. |
| Score | Text |
|---|---|
| 0.9993 | Cushing's syndrome persisted more than 6 months while DrugTCA concentrations remained detectable for at least 80 days. |
| 0.9831 | Adverse-EffectCushing's syndrome persisted more than 6 months while TCA concentrations remained detectable for at least 80 days. |
| Score | Text |
|---|---|
| 0.9987 | Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced Adverse-Effecttremor during lithium carbonate therapy. |
| 0.9904 | Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during Druglithium carbonate therapy. |
| Score | Text |
|---|---|
| 0.9992 | RESULTS : Both patients experienced a previously unreported side effect - - falling backward - - associated with Drugbupropion use. |
| 0.9908 | RESULTS : Both patients experienced a previously unreported side effect - - Adverse-Effectfalling backward - - associated with bupropion use. |
| Score | Text |
|---|---|
| 0.9992 | Vision declined after treatment with Drugmethylprednisolone , after which fundus examination became consistent with progressive outer retinal necrosis. |
| 0.9954 | Adverse-EffectVision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis. |
| Score | Text |
|---|---|
| 0.9995 | A patient with chronic myelomonocytic leukemia developed drug - induced pulmonary toxicity after using low dose oral Drugetoposide . |
| 0.9900 | A patient with chronic myelomonocytic leukemia developed drug - induced Adverse-Effectpulmonary toxicity after using low dose oral etoposide. |
| Score | Text |
|---|---|
| 0.9991 | Physicians should be aware of the possible association between the use of Drugalteplase and the development of subfascial hemorrhage. |
| 0.9889 | Physicians should be aware of the possible association between the use of alteplase and the development of Adverse-Effectsubfascial hemorrhage . |
| Score | Text |
|---|---|
| 0.9993 | A patient, while on intravenous Drugritodrine therapy for preterm labor, experienced an episode of acute chest pain. |
| 0.9904 | A patient, while on intravenous ritodrine therapy for preterm labor, experienced an episode of Adverse-Effectacute chest pain . |
| Score | Text |
|---|---|
| 0.9998 | Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis : a severe adverse reaction to Drugminocycline . |
| 0.9981 | Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and Adverse-Effectdermatitis : a severe adverse reaction to minocycline. |
| 0.9981 | Fever, lymphadenopathy, eosinophilia, lymphocytosis, Adverse-Effecthepatitis , and dermatitis : a severe adverse reaction to minocycline. |
| 0.9972 | Fever, lymphadenopathy, Adverse-Effecteosinophilia , lymphocytosis, hepatitis, and dermatitis : a severe adverse reaction to minocycline. |
| 0.9961 | Fever, lymphadenopathy, eosinophilia, Adverse-Effectlymphocytosis , hepatitis, and dermatitis : a severe adverse reaction to minocycline. |
| 0.9957 | Fever, Adverse-Effectlymphadenopathy , eosinophilia, lymphocytosis, hepatitis, and dermatitis : a severe adverse reaction to minocycline. |
| 0.9878 | Adverse-EffectFever , lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis : a severe adverse reaction to minocycline. |
| Score | Text |
|---|---|
| 0.9994 | A case of Erythema Multiforme Bullosum in patient of lepromatous leprosy with pulmonary tuberculosis due to DrugRifampicin is described. |
| 0.9802 | A case of Adverse-EffectErythema Multiforme Bullosum in patient of lepromatous leprosy with pulmonary tuberculosis due to Rifampicin is described. |
| Score | Text |
|---|---|
| 0.9995 | CONCLUSIONS : DrugColchicine - induced myopathy should be excluded in patients with FMF who present with generalized muscle weakness. |
| 0.9977 | CONCLUSIONS : Colchicine - induced Adverse-Effectmyopathy should be excluded in patients with FMF who present with generalized muscle weakness. |
| 0.8260 | CONCLUSIONS : Colchicine - induced myopathy should be excluded in patients with FMF who present with Adverse-Effectgeneralized muscle weakness . |
| Score | Text |
|---|---|
| 0.9814 | Because of a Adverse-Effecthypersensitivity reaction , initial therapy with penicillin G and gentamicin was stopped and substituted with cefazolin. |
| 0.9707 | Because of a hypersensitivity reaction, initial therapy with Drugpenicillin G and gentamicin was stopped and substituted with cefazolin. |
| 0.9431 | Because of a hypersensitivity reaction, initial therapy with penicillin G and Druggentamicin was stopped and substituted with cefazolin. |
| Score | Text |
|---|---|
| 0.9964 | The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on Drugamitriptyline and lithium carbonate. |
| 0.9901 | The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and Druglithium carbonate . |
| 0.9875 | The authors describe a case of Adverse-Effectneuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate. |
| Score | Text |
|---|---|
| 0.9991 | Typically, drug - induced neutropenia occurs in a patient receiving a semisynthetic Drugpenicillin for two weeks or more. |
| 0.9983 | Typically, drug - induced Adverse-Effectneutropenia occurs in a patient receiving a semisynthetic penicillin for two weeks or more. |
| Score | Text |
|---|---|
| 0.9993 | DrugMethimazole - induced aplastic anemia in third exposure : successful treatment with recombinant human granulocyte colony - stimulating factor. |
| 0.9925 | Methimazole - induced Adverse-Effectaplastic anemia in third exposure : successful treatment with recombinant human granulocyte colony - stimulating factor. |
| Score | Text |
|---|---|
| 0.9966 | The newborn manifested a four day course of Adverse-Effectlethargy with unexplained high lithium levels in the adult toxic range. |
| 0.9945 | The newborn manifested a four day course of lethargy with unexplained high Druglithium levels in the adult toxic range. |
| Score | Text |
|---|---|
| 0.9936 | We experienced 2 cases of mequitazine - induced Adverse-Effectphotosensitivity reaction in patients who took mequitazine for their dermatologic problems. |
| 0.9768 | We experienced 2 cases of Drugmequitazine - induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems. |
| 0.8451 | We experienced 2 cases of mequitazine - induced photosensitivity reaction in patients who took Drugmequitazine for their dermatologic problems. |
| Score | Text |
|---|---|
| 0.9982 | CONCLUSION : Fixed drug eruption is associated with many drugs but this is the first such report with Drugomeprazole . |
| 0.9932 | CONCLUSION : Fixed drug Adverse-Effecteruption is associated with many drugs but this is the first such report with omeprazole. |
| Score | Text |
|---|---|
| 0.9992 | FSGS induced by DrugAdriamycin ( Pharmacia & Upjohn, Columbus, OH ) has been observed experimentally in rats. |
| 0.9985 | Adverse-EffectFSGS induced by Adriamycin ( Pharmacia & Upjohn, Columbus, OH ) has been observed experimentally in rats. |
| Score | Text |
|---|---|
| 0.9864 | Adverse-EffectPulmonary leukostasis secondary to all - trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse. |
| 0.9534 | Pulmonary leukostasis secondary to Drugall - trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse. |
| Score | Text |
|---|---|
| 0.9996 | An objective causality assessment by use of the Naranjo probability scale revealed that NCSE due to Drugifosfamide was probable. |
| 0.9976 | An objective causality assessment by use of the Naranjo probability scale revealed that Adverse-EffectNCSE due to ifosfamide was probable. |
| Score | Text |
|---|---|
| 0.9994 | A patient with acute esophageal variceal bleeding developed fatal rhabdomyolysis during treatment with a continuous intravenous infusion of Drugvasopressin . |
| 0.9886 | A patient with acute esophageal variceal bleeding developed Adverse-Effectfatal rhabdomyolysis during treatment with a continuous intravenous infusion of vasopressin. |
| Score | Text |
|---|---|
| 0.9809 | Electrocardiographic findings and laboratory data indicated a diagnosis of Adverse-Effectacute myocardial infarction due to the L - thyroxine therapy. |
| 0.9689 | Electrocardiographic findings and laboratory data indicated a diagnosis of acute myocardial infarction due to the DrugL - thyroxine therapy. |
| Score | Text |
|---|---|
| 0.9958 | Establishment of diuresis with fluids and IV administration of calcium may provide successful treatment of Drugmagnesium toxicosis in horses. |
| 0.8562 | Establishment of diuresis with fluids and IV administration of calcium may provide successful treatment of Adverse-Effectmagnesium toxicosis in horses. |
| Score | Text |
|---|---|
| 0.9994 | We describe a patient who presented with bloody diarrhoea after 15 mg Drugmeloxicam daily for 10 days for osteoarthritis. |
| 0.9887 | We describe a patient who presented with Adverse-Effectbloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis. |
| Score | Text |
|---|---|
| 0.9933 | Four cases of Adverse-Effectoesophageal damage associated with ingestion of the urinary anti - spasmodic agent emepronium bromide are described. |
| 0.9772 | Four cases of oesophageal damage associated with ingestion of the urinary anti - spasmodic agent Drugemepronium bromide are described. |
| Score | Text |
|---|---|
| 0.9992 | A case of heatstroke is reported in a 32 - year - old man diagnosed with schizophrenia and on Drugclozapine monotherapy. |
| 0.9964 | A case of Adverse-Effectheatstroke is reported in a 32 - year - old man diagnosed with schizophrenia and on clozapine monotherapy. |
| Score | Text |
|---|---|
| 0.9995 | Due to discomfort, diplopia and lagophthalmos, the haematoma necessitated suspension of Drugwarfarin therapy and a surgical evacuation. |
| 0.9936 | Due to discomfort, diplopia and lagophthalmos, the Adverse-Effecthaematoma necessitated suspension of warfarin therapy and a surgical evacuation. |
| 0.9903 | Due to discomfort, Adverse-Effectdiplopia and lagophthalmos, the haematoma necessitated suspension of warfarin therapy and a surgical evacuation. |
| 0.9884 | Due to Adverse-Effectdiscomfort , diplopia and lagophthalmos, the haematoma necessitated suspension of warfarin therapy and a surgical evacuation. |
| 0.9820 | Due to discomfort, diplopia and Adverse-Effectlagophthalmos , the haematoma necessitated suspension of warfarin therapy and a surgical evacuation. |
| Score | Text |
|---|---|
| 0.9764 | Adverse-EffectAtypical ventricular tachycardia ( torsade de pointes ) induced by amiodarone : arrhythmia previously induced by quinidine and disopyramide. |
| 0.9756 | Atypical ventricular tachycardia ( Adverse-Effecttorsade de pointes ) induced by amiodarone : arrhythmia previously induced by quinidine and disopyramide. |
| 0.9404 | Atypical ventricular tachycardia ( torsade de pointes ) induced by amiodarone : Adverse-Effectarrhythmia previously induced by quinidine and disopyramide. |
| 0.9219 | Atypical ventricular tachycardia ( torsade de pointes ) induced by Drugamiodarone : arrhythmia previously induced by quinidine and disopyramide. |
| 0.6185 | Atypical ventricular tachycardia ( torsade de pointes ) induced by amiodarone : arrhythmia previously induced by quinidine and Drugdisopyramide . |
| 0.5836 | Atypical ventricular tachycardia ( torsade de pointes ) induced by amiodarone : arrhythmia previously induced by Drugquinidine and disopyramide. |
| Score | Text |
|---|---|
| 0.9994 | OBJECTIVE : To describe a case of Drugsertraline - induced rhabdomyolysis in an elderly patient with dementia and comorbidities. |
| 0.9974 | OBJECTIVE : To describe a case of sertraline - induced Adverse-Effectrhabdomyolysis in an elderly patient with dementia and comorbidities. |
| Score | Text |
|---|---|
| 0.9991 | Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing Drugtryptophan . |
| 0.9835 | Adverse-EffectFatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan. |
| Score | Text |
|---|---|
| 0.9994 | We report the first case of a patient in a Drugpromethazine - induced coma responding to treatment with flumazenil. |
| 0.9941 | We report the first case of a patient in a promethazine - induced Adverse-Effectcoma responding to treatment with flumazenil. |
| Score | Text |
|---|---|
| 0.9911 | DrugMineral oil , a hydrocarbon, may not elicit a normal protective cough reflex and may impair mucociliary transport. |
| 0.9579 | Mineral oil, a hydrocarbon, may not elicit a normal protective cough reflex and may Adverse-Effectimpair mucociliary transport . |
| Score | Text |
|---|---|
| 0.9996 | We report 3 children with epilepsy who developed facial motor tics after initiation of DrugCBZ for complex partial seizures. |
| 0.9911 | We report 3 children with epilepsy who developed Adverse-Effectfacial motor tics after initiation of CBZ for complex partial seizures. |
| Score | Text |
|---|---|
| 0.9995 | A 43 - year - old white man developed a shallow erosion of a psoriatic plaque after chronic administration of Drugmethotrexate . |
| 0.9702 | A 43 - year - old white man developed a shallow Adverse-Effecterosion of a psoriatic plaque after chronic administration of methotrexate. |
| Score | Text |
|---|---|
| 0.9996 | One case of Drugtacrolimus - induced hepatic VOD developing after lung transplantation ( LT ) has been recently reported. |
| 0.9937 | One case of tacrolimus - induced Adverse-Effecthepatic VOD developing after lung transplantation ( LT ) has been recently reported. |
| Score | Text |
|---|---|
| 0.9995 | While the mechanism of Drugdextran - associated renal failure remains unsolved, plasma exchange seems to be effective therapy. |
| 0.9921 | While the mechanism of dextran - associated Adverse-Effectrenal failure remains unsolved, plasma exchange seems to be effective therapy. |
| Score | Text |
|---|---|
| 0.9988 | Adverse-EffectMyoclonus and seizures disappeared after discontinuation of L - dopa and the introduction of valproate sodium ( VPA ). |
| 0.9985 | Myoclonus and Adverse-Effectseizures disappeared after discontinuation of L - dopa and the introduction of valproate sodium ( VPA ). |
| 0.9683 | Myoclonus and seizures disappeared after discontinuation of DrugL - dopa and the introduction of valproate sodium ( VPA ). |
| 0.9902 | Myoclonus and seizures disappeared after discontinuation of L - dopa and the introduction of valproate sodium ( DrugVPA ). |
| 0.9724 | Myoclonus and seizures disappeared after discontinuation of L - dopa and the introduction of Drugvalproate sodium ( VPA ). |
| Score | Text |
|---|---|
| 0.9996 | CASE DESCRIPTION : A 59 - year - old man with known neurocysticercosis developed a large cerebral infarction during Drugpraziquantel therapy. |
| 0.9874 | CASE DESCRIPTION : A 59 - year - old man with known neurocysticercosis developed a Adverse-Effectlarge cerebral infarction during praziquantel therapy. |
| Score | Text |
|---|---|
| 0.9995 | Atypical endometriosis may act as a precancerous lesion in the process of Drugtamoxifen - induced malignant transformation of endometriosis. |
| 0.9794 | Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen - induced Adverse-Effectmalignant transformation of endometriosis . |
| Score | Text |
|---|---|
| 0.9984 | Mechanisms and triggering factors of hypoglycaemia induced by Drugmefloquine and some other anti - malarial quinine analogues are discussed. |
| 0.9937 | Mechanisms and triggering factors of Adverse-Effecthypoglycaemia induced by mefloquine and some other anti - malarial quinine analogues are discussed. |
| Score | Text |
|---|---|
| 0.9874 | a 67 - year - old man with bipolar disorder developed a Adverse-EffectCreutzfeldt - Jakob like syndrome during lithium carbonate treatment. |
| 0.9853 | a 67 - year - old man with bipolar disorder developed a Creutzfeldt - Jakob like syndrome during Druglithium carbonate treatment. |
| Score | Text |
|---|---|
| 0.9993 | DrugTiagabine overdose causes an unusual array of neurological symptoms, many similar to reported adverse effects during therapeutic use. |
| 0.7767 | Tiagabine overdose causes an unusual array of Adverse-Effectneurological symptoms , many similar to reported adverse effects during therapeutic use. |
| Tiagabine overdose causes an Adverse-Effectunusual array of neurological symptoms , many similar to reported adverse effects during therapeutic use. | |
| Score | Text |
|---|---|
| 0.9975 | Increased lash length, thickness, and pigmentation are well - documented side effects of Drugprostaglandin analog glaucoma drops. |
| 0.9853 | Increased lash length, thickness, and Adverse-Effectpigmentation are well - documented side effects of prostaglandin analog glaucoma drops. |
| 0.9637 | Adverse-EffectIncreased lash length , thickness, and pigmentation are well - documented side effects of prostaglandin analog glaucoma drops. |
| Score | Text |
|---|---|
| 0.9997 | We have reported six cases of Drugmetoclopramide - induced parkinsonism seen in consultation over a two - year period. |
| 0.9985 | We have reported six cases of metoclopramide - induced Adverse-Effectparkinsonism seen in consultation over a two - year period. |
| Score | Text |
|---|---|
| 0.9984 | METHOD : We describe two patients who presented with diabetic ketoacidosis after treatment with Drugquetiapine and risperidone, respectively. |
| 0.9983 | METHOD : We describe two patients who presented with diabetic ketoacidosis after treatment with quetiapine and Drugrisperidone , respectively. |
| 0.9839 | METHOD : We describe two patients who presented with Adverse-Effectdiabetic ketoacidosis after treatment with quetiapine and risperidone, respectively. |
| Score | Text |
|---|---|
| 0.9995 | We describe two cases of PSVT that changed to non - sustained polymorphic ventricular tachycardia after administration of Drugverapamil . |
| 0.9362 | We describe two cases of PSVT that changed to Adverse-Effectnon - sustained polymorphic ventricular tachycardia after administration of verapamil. |
| Score | Text |
|---|---|
| 0.9995 | Gastric tumor, endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with Drugtamoxifen for breast cancer. |
| 0.9912 | Adverse-EffectGastric tumor , endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with tamoxifen for breast cancer. |
| 0.9892 | Gastric tumor, endometrial carcinoma and Adverse-Effectcervical adenocarcinoma in situ were detected after treatment with tamoxifen for breast cancer. |
| 0.9882 | Gastric tumor, Adverse-Effectendometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with tamoxifen for breast cancer. |
| Score | Text |
|---|---|
| 0.9860 | Intravenous sodium bicarbonate appears to be indicated prophylactically in combating the associated metabolic acidosis due to absorbed Drugformic acid . |
| 0.9656 | Intravenous sodium bicarbonate appears to be indicated prophylactically in combating the associated Adverse-Effectmetabolic acidosis due to absorbed formic acid. |
| Score | Text |
|---|---|
| 0.9994 | We describe a detailed case of fulminant hepatitis induced by Drugnevirapine ( Viramune ) and treated by liver transplantation. |
| 0.9994 | We describe a detailed case of fulminant hepatitis induced by nevirapine ( DrugViramune ) and treated by liver transplantation. |
| 0.9908 | We describe a detailed case of Adverse-Effectfulminant hepatitis induced by nevirapine ( Viramune ) and treated by liver transplantation. |
| Score | Text |
|---|---|
| 0.9961 | Interferon - alpha - induced Adverse-Effecthyperthyroidism : a three - stage evolution from silent thyroiditis towards Graves'disease. |
| 0.9629 | DrugInterferon - alpha - induced hyperthyroidism : a three - stage evolution from silent thyroiditis towards Graves'disease. |
| Score | Text |
|---|---|
| 0.9992 | A diagnosis of masked Drugtheophylline poisoning should be considered in similar situations involving a rapid decrease of insulin requirements. |
| 0.8430 | A diagnosis of masked Adverse-Effecttheophylline poisoning should be considered in similar situations involving a rapid decrease of insulin requirements. |
| Score | Text |
|---|---|
| 0.9996 | To our knowledge, our report is one of the first on shock and angio - oedema from Drugirbesartan . |
| 0.9896 | To our knowledge, our report is one of the first on shock and Adverse-Effectangio - oedema from irbesartan. |
| 0.9814 | To our knowledge, our report is one of the first on Adverse-Effectshock and angio - oedema from irbesartan. |
| Score | Text |
|---|---|
| 0.9992 | The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal Drugmethotrexate and cytarabine. |
| 0.9992 | The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and Drugcytarabine . |
| 0.9745 | The authors report a case of Adverse-EffectBalint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine. |
| 0.8717 | The authors report a case of Balint syndrome with irreversible Adverse-Effectposterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine. |
| Score | Text |
|---|---|
| 0.9973 | Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim - Drugsulfamethoxazole . |
| 0.9969 | Aseptic meningitis, hemolytic anemia, Adverse-Effecthepatitis , and orthostatic hypotension in a patient treated with trimethoprim - sulfamethoxazole. |
| 0.9937 | Adverse-EffectAseptic meningitis , hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim - sulfamethoxazole. |
| 0.9931 | Aseptic meningitis, Adverse-Effecthemolytic anemia , hepatitis, and orthostatic hypotension in a patient treated with trimethoprim - sulfamethoxazole. |
| 0.9913 | Aseptic meningitis, hemolytic anemia, hepatitis, and Adverse-Effectorthostatic hypotension in a patient treated with trimethoprim - sulfamethoxazole. |
| 0.9902 | Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with Drugtrimethoprim - sulfamethoxazole. |
| Score | Text |
|---|---|
| 0.9952 | Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed Adverse-Effectpancreatitis caused by meglumine antimoniate. |
| 0.9673 | Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by Drugmeglumine antimoniate . |
| 0.5456 | Successful treatment of visceral leishmaniasis with allopurinol plus Drugketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate. |
| Score | Text |
|---|---|
| 0.9811 | CONCLUSIONS : The administration of Drugprostaglandin E1 to neonates can cause gastric - outlet obstruction due to antral hyperplasia. |
| 0.9801 | CONCLUSIONS : The administration of prostaglandin E1 to neonates can cause Adverse-Effectgastric - outlet obstruction due to antral hyperplasia. |
| 0.9392 | CONCLUSIONS : The administration of prostaglandin E1 to neonates can cause gastric - outlet obstruction due to Adverse-Effectantral hyperplasia . |
| Score | Text |
|---|---|
| 0.9995 | We report the first case of rhabdomyolysis related to the administration of Drugclarithromycin without concurrent use of other medications. |
| 0.9979 | We report the first case of Adverse-Effectrhabdomyolysis related to the administration of clarithromycin without concurrent use of other medications. |
| Score | Text |
|---|---|
| 0.9996 | We describe 2 cases of SJS related to Drugnevirapine use and review the literature on this newly recognized association. |
| 0.9981 | We describe 2 cases of Adverse-EffectSJS related to nevirapine use and review the literature on this newly recognized association. |
| Score | Text |
|---|---|
| 0.9944 | Used injudiciously, Drugnaloxone can lead to withdrawal syndrome, return of severe pain, and other adverse effects. |
| 0.9920 | Used injudiciously, naloxone can lead to Adverse-Effectwithdrawal syndrome , return of severe pain, and other adverse effects. |
| 0.9842 | Used injudiciously, naloxone can lead to withdrawal syndrome, return of Adverse-Effectsevere pain , and other adverse effects. |
| Score | Text |
|---|---|
| 0.9994 | The case concerns the sudden death of a 29 - year - old male during Drugclozapine therapy started 2 weeks before. |
| 0.9967 | The case concerns the Adverse-Effectsudden death of a 29 - year - old male during clozapine therapy started 2 weeks before. |
| Score | Text |
|---|---|
| 0.9981 | Prior neurologic illness or CNS insult of any kind is known to increase the vulnerability to neurotoxicity of Druglithium . |
| 0.9903 | Prior neurologic illness or CNS insult of any kind is known to increase the vulnerability to Adverse-Effectneurotoxicity of lithium. |
| Score | Text |
|---|---|
| 0.9996 | The objective of this report is to describe a case of fixed drug eruption that occurred during Drugomeprazole treatment. |
| 0.9813 | The objective of this report is to describe a case of fixed drug Adverse-Effecteruption that occurred during omeprazole treatment. |
| Score | Text |
|---|---|
| 0.9975 | Iatrogenic Cushing syndrome after epidural Drugtriamcinolone injections in an HIV type 1 - infected patient receiving therapy with ritonavir - lopinavir. |
| 0.9855 | Adverse-EffectIatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1 - infected patient receiving therapy with ritonavir - lopinavir. |
| Score | Text |
|---|---|
| 0.9987 | The clinical symptoms of gastric mucosa foveolar hyperplasia due to long - term DrugPGE1 therapy simulate hypertrophic pyloric stenosis. |
| 0.9804 | The clinical symptoms of Adverse-Effectgastric mucosa foveolar hyperplasia due to long - term PGE1 therapy simulate hypertrophic pyloric stenosis. |
| Score | Text |
|---|---|
| 0.9987 | Occasionally, despite good therapeutic response, Drugclozapine must be stopped due to dangerous side effects such as agranulocytosis. |
| 0.9980 | Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as Adverse-Effectagranulocytosis . |
| Score | Text |
|---|---|
| 0.9994 | Findings on discontinuation and rechallenge supported the assumption that the hair loss was a side effect of the Drugparoxetine . |
| 0.9927 | Findings on discontinuation and rechallenge supported the assumption that the Adverse-Effecthair loss was a side effect of the paroxetine. |
| Score | Text |
|---|---|
| 0.9995 | Psoriasis triggered by toll - like receptor 7 agonist Drugimiquimod in the presence of dermal plasmacytoid dendritic cell precursors. |
| 0.9984 | Adverse-EffectPsoriasis triggered by toll - like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. |
| Score | Text |
|---|---|
| 0.9919 | Iatrogenic hypercalcemia due to vitamin D3 ointment ( 1, 24 ( OH ) 2D3 ) combined with Drugthiazide diuretics in a case of psoriasis. |
| 0.9787 | Iatrogenic hypercalcemia due to Drugvitamin D3 ointment ( 1, 24 ( OH ) 2D3 ) combined with thiazide diuretics in a case of psoriasis. |
| 0.9669 | Iatrogenic hypercalcemia due to vitamin D3 ointment ( Drug1, 24 ( OH ) 2D3 ) combined with thiazide diuretics in a case of psoriasis. |
| 0.9713 | Adverse-EffectIatrogenic hypercalcemia due to vitamin D3 ointment ( 1, 24 ( OH ) 2D3 ) combined with thiazide diuretics in a case of psoriasis. |
| Iatrogenic Adverse-Effecthypercalcemia due to vitamin D3 ointment ( 1, 24 ( OH ) 2D3 ) combined with thiazide diuretics in a case of psoriasis. | |
| Score | Text |
|---|---|
| 0.9995 | A patient with ulcerative colitis developed skin pigmentation and diffuse pulmonary shadowing without respiratory symptomatology, while taking Drugsulfasalazine . |
| 0.9887 | A patient with ulcerative colitis developed Adverse-Effectskin pigmentation and diffuse pulmonary shadowing without respiratory symptomatology, while taking sulfasalazine. |
| 0.9844 | A patient with ulcerative colitis developed skin pigmentation and Adverse-Effectdiffuse pulmonary shadowing without respiratory symptomatology, while taking sulfasalazine. |
| Score | Text |
|---|---|
| 0.9994 | In this case, CIPS was considered to be probably associated with Drugcyclosporine according to the Naranjo probability scale. |
| 0.9985 | In this case, Adverse-EffectCIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale. |
| Score | Text |
|---|---|
| 0.9988 | This treatment has the potential to cause severe vision loss as a result of intractable Drugcorticosteroid - induced glaucoma. |
| 0.9965 | This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid - induced Adverse-Effectglaucoma . |
| 0.9541 | This treatment has the potential to cause Adverse-Effectsevere vision loss as a result of intractable corticosteroid - induced glaucoma. |
| Score | Text |
|---|---|
| 0.9973 | DrugLithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis, serial electroencephalograms being the most valuable. |
| 0.9658 | Lithium neurotoxicity should be considered in Adverse-EffectCreutzfeldt - Jakob disease differential diagnosis, serial electroencephalograms being the most valuable. |
| 0.8859 | Lithium Adverse-Effectneurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis, serial electroencephalograms being the most valuable. |
| Adverse-EffectLithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis, serial electroencephalograms being the most valuable. | |
| Score | Text |
|---|---|
| 0.9987 | We report a case of penile fibrosis after intracavernous self - injection of a combination of Drugphentolamine and papaverine. |
| 0.9987 | We report a case of penile fibrosis after intracavernous self - injection of a combination of phentolamine and Drugpapaverine . |
| 0.9900 | We report a case of Adverse-Effectpenile fibrosis after intracavernous self - injection of a combination of phentolamine and papaverine. |
| Score | Text |
|---|---|
| 0.9989 | We report the first case of a 54 - year - old Turkish woman who presented with ceftriaxone - induced Adverse-EffectFDE . |
| 0.9948 | We report the first case of a 54 - year - old Turkish woman who presented with Drugceftriaxone - induced FDE. |
| Score | Text |
|---|---|
| 0.9985 | We report such a series of patients who had transient asymptomatic bradycardia after being treated with continuous infusion Drug5 - FU . |
| 0.9760 | We report such a series of patients who had Adverse-Effecttransient asymptomatic bradycardia after being treated with continuous infusion 5 - FU. |
| Score | Text |
|---|---|
| 0.9964 | Relief by naloxone of Drugmorphine - induced spasm of the sphincter of Oddi in a post - cholecystectomy patient. |
| 0.9960 | Relief by naloxone of morphine - induced Adverse-Effectspasm of the sphincter of Oddi in a post - cholecystectomy patient. |
| Score | Text |
|---|---|
| 0.9912 | The present report suggests that Drugclarithromycin coadministration induces increased plasma carbamazepine concentrations, which may result in carbamazepine toxicity. |
| 0.9877 | The present report suggests that clarithromycin coadministration induces increased plasma carbamazepine concentrations, which may result in Drugcarbamazepine toxicity. |
| 0.9848 | The present report suggests that clarithromycin coadministration induces increased plasma Drugcarbamazepine concentrations, which may result in carbamazepine toxicity. |
| 0.6427 | The present report suggests that clarithromycin coadministration induces increased plasma carbamazepine concentrations, which may result in Adverse-Effectcarbamazepine toxicity . |
| The present report suggests that clarithromycin coadministration induces Adverse-Effectincreased plasma carbamazepine concentrations, which may result in carbamazepine toxicity. | |
| Score | Text |
|---|---|
| 0.9969 | A case of Drugphenobarbital exacerbation of a preexisting maladaptive behavior partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy. |
| 0.9344 | A case of phenobarbital Adverse-Effectexacerbation of a preexisting maladaptive behavior partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy. |
| 0.5273 | A case of Adverse-Effectphenobarbital exacerbation of a preexisting maladaptive behavior partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy. |
| Score | Text |
|---|---|
| 0.9893 | Adverse-EffectIntracranial hemorrhage and focal seizures secondary to use of L - asparaginase during induction therapy of acute lymphocytic leukemia. |
| 0.9864 | Intracranial hemorrhage and Adverse-Effectfocal seizures secondary to use of L - asparaginase during induction therapy of acute lymphocytic leukemia. |
| 0.9683 | Intracranial hemorrhage and focal seizures secondary to use of DrugL - asparaginase during induction therapy of acute lymphocytic leukemia. |
| Score | Text |
|---|---|
| 0.9985 | A case of prolonged Drugsuxamethonium apnoea successfully terminated by the infusion of a commercial preparation of serumcholinesterase is reported. |
| 0.9061 | A case of prolonged suxamethonium Adverse-Effectapnoea successfully terminated by the infusion of a commercial preparation of serumcholinesterase is reported. |
| Score | Text |
|---|---|
| 0.9988 | After the Drugchlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML. |
| 0.9982 | After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical Adverse-EffectAML . |
| Score | Text |
|---|---|
| 0.9995 | We describe 2 patients with prior amputation who experienced phantom limb pain ( PLP ) after receiving Drugpaclitaxel therapy. |
| 0.9948 | We describe 2 patients with prior amputation who experienced phantom limb pain ( Adverse-EffectPLP ) after receiving paclitaxel therapy. |
| 0.9891 | We describe 2 patients with prior amputation who experienced Adverse-Effectphantom limb pain ( PLP ) after receiving paclitaxel therapy. |
| Score | Text |
|---|---|
| 0.9971 | Localized panniculitis and subsequent Adverse-Effectlipoatrophy with subcutaneous glatiramer acetate ( Copaxone ) injection for the treatment of multiple sclerosis. |
| 0.9930 | Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate ( DrugCopaxone ) injection for the treatment of multiple sclerosis. |
| 0.9791 | Localized panniculitis and subsequent lipoatrophy with subcutaneous Drugglatiramer acetate ( Copaxone ) injection for the treatment of multiple sclerosis. |
| 0.9776 | Adverse-EffectLocalized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate ( Copaxone ) injection for the treatment of multiple sclerosis. |
| Score | Text |
|---|---|
| 0.9964 | The aim of our paper was to describe hepatotoxicity of Drugsirolimus ( SRL ) in a kidney graft recipient. |
| 0.9937 | The aim of our paper was to describe Adverse-Effecthepatotoxicity of sirolimus ( SRL ) in a kidney graft recipient. |
| Score | Text |
|---|---|
| 0.9995 | We report a case of drug - induced pemphigus caused by an angiotensin - converting enzyme inhibitor, Drugcaptopril . |
| 0.9984 | We report a case of drug - induced Adverse-Effectpemphigus caused by an angiotensin - converting enzyme inhibitor, captopril. |
| Score | Text |
|---|---|
| 0.9951 | OBJECTIVE : To report teicoplanin - related Adverse-Effectneutropenia that developed after an episode of neutropenia induced by vancomycin therapy. |
| 0.9787 | OBJECTIVE : To report teicoplanin - related neutropenia that developed after an episode of Adverse-Effectneutropenia induced by vancomycin therapy. |
| 0.8851 | OBJECTIVE : To report Drugteicoplanin - related neutropenia that developed after an episode of neutropenia induced by vancomycin therapy. |
| 0.8835 | OBJECTIVE : To report teicoplanin - related neutropenia that developed after an episode of neutropenia induced by Drugvancomycin therapy. |
| Score | Text |
|---|---|
| 0.9996 | Two patients with HLH developed Drugetoposide - related secondary acute myeloid leukemia ( sAML ) following therapy for HLH. |
| 0.9834 | Two patients with HLH developed etoposide - related Adverse-Effectsecondary acute myeloid leukemia ( sAML ) following therapy for HLH. |
| 0.9828 | Two patients with HLH developed etoposide - related secondary acute myeloid leukemia ( Adverse-EffectsAML ) following therapy for HLH. |
| Score | Text |
|---|---|
| 0.9993 | The first patient is undergoing hemodialysis and, though responding to Drugsunitinib , is having significant fatigue and hypertension. |
| 0.9991 | The first patient is undergoing hemodialysis and, though responding to sunitinib, is having significant Adverse-Effectfatigue and hypertension. |
| 0.9991 | The first patient is undergoing hemodialysis and, though responding to sunitinib, is having significant fatigue and Adverse-Effecthypertension . |
| Score | Text |
|---|---|
| 0.9991 | This communication describes a patient who developed Schneiderian first - rank symptoms in the course of treatment with Drugfluvoxamine . |
| 0.9821 | This communication describes a patient who developed Adverse-EffectSchneiderian first - rank symptoms in the course of treatment with fluvoxamine. |
| Score | Text |
|---|---|
| 0.9885 | Initiation of Drugposaconazole led to clinical improvement until the patient's demise from bacteremic vancomycin - resistant enterococcal peritonitis. |
| 0.9279 | Initiation of posaconazole led to clinical improvement until the patient's demise from bacteremic vancomycin - resistant Adverse-Effectenterococcal peritonitis . |
| Score | Text |
|---|---|
| 0.9933 | Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and Drugprednisone . |
| 0.9789 | Adverse-EffectRed blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and prednisone. |
| 0.9675 | Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of Drugmycophenolate mofetil and prednisone. |
| Score | Text |
|---|---|
| 0.9984 | After 3 - to 13 - month period of therapy without Drugindapamide , glucose levels of all patients decreased and diabetes disappeared. |
| 0.9962 | After 3 - to 13 - month period of therapy without indapamide, glucose levels of all patients decreased and Adverse-Effectdiabetes disappeared. |
| Score | Text |
|---|---|
| 0.9994 | OBJECTIVE : To report a case of severe apnea in an infant exposed to Druglamotrigine through breast - feeding. |
| 0.9824 | OBJECTIVE : To report a case of Adverse-Effectsevere apnea in an infant exposed to lamotrigine through breast - feeding. |
| Score | Text |
|---|---|
| 0.9994 | According to the Naranjo adverse drug reaction probability scale, Drugtigecycline was the probable cause of her acute pancreatitis. |
| 0.9750 | According to the Naranjo adverse drug reaction probability scale, tigecycline was the probable cause of her Adverse-Effectacute pancreatitis . |
| Score | Text |
|---|---|
| 0.9983 | The time course of events suggested that amphotericin B was the cause of the Adverse-Effectseizures in this AIDS patient. |
| 0.9819 | The time course of events suggested that Drugamphotericin B was the cause of the seizures in this AIDS patient. |
| Score | Text |
|---|---|
| 0.9991 | The case history and toxicological findings of an infant fatality involving Drugpseudoephedrine , brompheniramine, and dextromethorphan are presented. |
| 0.9990 | The case history and toxicological findings of an infant fatality involving pseudoephedrine, brompheniramine, and Drugdextromethorphan are presented. |
| 0.9990 | The case history and toxicological findings of an infant fatality involving pseudoephedrine, Drugbrompheniramine , and dextromethorphan are presented. |
| 0.9779 | The case history and toxicological findings of an infant Adverse-Effectfatality involving pseudoephedrine, brompheniramine, and dextromethorphan are presented. |
| Score | Text |
|---|---|
| 0.9969 | This regimen could prove useful for other patients who develop hypersensitivity reactions to Drugcarboplatin and allow therapy to continue. |
| 0.8828 | This regimen could prove useful for other patients who develop Adverse-Effecthypersensitivity reactions to carboplatin and allow therapy to continue. |
| 0.9795 | This regimen could prove useful for other patients who develop Adverse-Effecthypersensitivity reactions to carboplatin and allow therapy to continue. |
| Score | Text |
|---|---|
| 0.9996 | The most common side effects associated with Drugamifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions. |
| 0.9983 | The most common side effects associated with amifostine are nausea, vomiting, hypotension, Adverse-Effecthypocalcemia and allergic reactions. |
| 0.9983 | The most common side effects associated with amifostine are nausea, vomiting, Adverse-Effecthypotension , hypocalcemia and allergic reactions. |
| 0.9979 | The most common side effects associated with amifostine are nausea, Adverse-Effectvomiting , hypotension, hypocalcemia and allergic reactions. |
| 0.9969 | The most common side effects associated with amifostine are Adverse-Effectnausea , vomiting, hypotension, hypocalcemia and allergic reactions. |
| 0.9939 | The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and Adverse-Effectallergic reactions . |
| Score | Text |
|---|---|
| 0.9967 | A 51 - year old physically fit woman experienced angio - oedema and hypotensive shock after Drugirbesartan ingestion requiring noradrenaline infusion. |
| 0.9925 | A 51 - year old physically fit woman experienced angio - oedema and Adverse-Effecthypotensive shock after irbesartan ingestion requiring noradrenaline infusion. |
| 0.9868 | A 51 - year old physically fit woman experienced Adverse-Effectangio - oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion. |
| Score | Text |
|---|---|
| 0.9995 | This case supports the assessment that MH and diabetes are associated diseases and that Drugcresol could possibly trigger MH. |
| 0.9937 | This case supports the assessment that MH and diabetes are associated diseases and that cresol could possibly trigger Adverse-EffectMH . |
| Score | Text |
|---|---|
| 0.9973 | This is the third report of reversible hepatic decompensation associated with prolonged DrugMTX therapy in patients with rheumatoid arthritis. |
| 0.9696 | This is the third report of reversible Adverse-Effecthepatic decompensation associated with prolonged MTX therapy in patients with rheumatoid arthritis. |
| Score | Text |
|---|---|
| 0.9995 | A patient is described who developed a poorly differentiated sarcoma after Drugcyclophosphamide was used to treat his rheumatoid arthritis. |
| 0.9832 | A patient is described who developed a poorly differentiated Adverse-Effectsarcoma after cyclophosphamide was used to treat his rheumatoid arthritis. |
| Score | Text |
|---|---|
| 0.9990 | Both Drugcolchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy. |
| 0.9989 | Both colchicine and Drugstatin therapy may be associated with myopathy, which usually occurs after several months of therapy. |
| 0.9986 | Both colchicine and statin therapy may be associated with Adverse-Effectmyopathy , which usually occurs after several months of therapy. |
| Score | Text |
|---|---|
| 0.9993 | We report two patients with anhedonic ejaculation ( ejaculation without orgasm ) associated with initiation of treatment with Drugdesipramine . |
| 0.9830 | We report two patients with Adverse-Effectanhedonic ejaculation ( ejaculation without orgasm ) associated with initiation of treatment with desipramine. |
| 0.9166 | We report two patients with anhedonic ejaculation ( Adverse-Effectejaculation without orgasm ) associated with initiation of treatment with desipramine. |
| Score | Text |
|---|---|
| 0.9996 | RESULTS : Including our own patient, a total of 26 cases of Druggemcitabine - associated HUS were identified. |
| 0.9988 | RESULTS : Including our own patient, a total of 26 cases of gemcitabine - associated Adverse-EffectHUS were identified. |
| Score | Text |
|---|---|
| 0.9948 | We describe a 5 - year - old girl showed recovery of Drugvincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment. |
| 0.9883 | We describe a 5 - year - old girl showed recovery of vincristine induced Adverse-Effectcranial polyneuropathy with pyridoxine and pyridostigmine treatment. |
| Score | Text |
|---|---|
| 0.9960 | She was placed on adjuvant DrugAdriamycin ( doxorubicin ) chemotherapy, but 6 months later died of Adriamycin toxicity. |
| 0.9948 | She was placed on adjuvant Adriamycin ( Drugdoxorubicin ) chemotherapy, but 6 months later died of Adriamycin toxicity. |
| 0.9896 | She was placed on adjuvant Adriamycin ( doxorubicin ) chemotherapy, but 6 months later died of DrugAdriamycin toxicity. |
| 0.9647 | She was placed on adjuvant Adriamycin ( doxorubicin ) chemotherapy, but 6 months later Adverse-Effectdied of Adriamycin toxicity. |
| 0.9153 | She was placed on adjuvant Adriamycin ( doxorubicin ) chemotherapy, but 6 months later died of Adverse-EffectAdriamycin toxicity . |
| Score | Text |
|---|---|
| 0.9959 | DrugQuinine and its isomer quinidine are well - known causes of iatrogenic hypoglycaemia, due to excessive insulin secretion. |
| 0.9930 | Quinine and its isomer Drugquinidine are well - known causes of iatrogenic hypoglycaemia, due to excessive insulin secretion. |
| 0.9868 | Quinine and its isomer quinidine are well - known causes of Adverse-Effectiatrogenic hypoglycaemia , due to excessive insulin secretion. |
| Score | Text |
|---|---|
| 0.9996 | However, he developed acute renal failure, hyperkalemia, and hyperuricemia 30 d after receiving the Drugsorafenib treatment. |
| 0.9976 | However, he developed acute renal failure, hyperkalemia, and Adverse-Effecthyperuricemia 30 d after receiving the sorafenib treatment. |
| 0.9970 | However, he developed acute renal failure, Adverse-Effecthyperkalemia , and hyperuricemia 30 d after receiving the sorafenib treatment. |
| 0.9836 | However, he developed Adverse-Effectacute renal failure , hyperkalemia, and hyperuricemia 30 d after receiving the sorafenib treatment. |
| Score | Text |
|---|---|
| 0.9993 | CONCLUSION : A woman receiving Drugenoxaparin every 12 hours developed signs and symptoms of hepatotoxicity after the second dose. |
| 0.9967 | CONCLUSION : A woman receiving enoxaparin every 12 hours developed signs and symptoms of Adverse-Effecthepatotoxicity after the second dose. |
| Score | Text |
|---|---|
| 0.9981 | She had been on DrugCopaxone 20 mg / day treatment for 2 years when she first exhibited gastrointestinal symptoms. |
| 0.9918 | She had been on Copaxone 20 mg / day treatment for 2 years when she first exhibited Adverse-Effectgastrointestinal symptoms . |
| Score | Text |
|---|---|
| 0.9984 | However, dermatologists should be cautious about a photosensitivity reaction induced by Drugmequitazine or other phenothiazine - derivative drugs. |
| 0.9068 | However, dermatologists should be cautious about a Adverse-Effectphotosensitivity reaction induced by mequitazine or other phenothiazine - derivative drugs. |
| 0.9864 | However, dermatologists should be cautious about a Adverse-Effectphotosensitivity reaction induced by mequitazine or other phenothiazine - derivative drugs. |
| Score | Text |
|---|---|
| 0.9996 | To date, this is the first reported case of what appears to be isolated thrombocytopenia associated with Druglansoprazole . |
| 0.9961 | To date, this is the first reported case of what appears to be isolated Adverse-Effectthrombocytopenia associated with lansoprazole. |
| Score | Text |
|---|---|
| 0.9991 | This report describes the first case of Druginsulin - induced cardiac failure in a patient without underlying heart disease. |
| 0.9938 | This report describes the first case of insulin - induced Adverse-Effectcardiac failure in a patient without underlying heart disease. |
| Score | Text |
|---|---|
| 0.9849 | Patients receiving neutral protamine Hagedorn ( NPH ) insulin are at increased risk for the development of Adverse-Effectprotamine hypersensitivity . |
| 0.9057 | Patients receiving Drugneutral protamine Hagedorn ( NPH ) insulin are at increased risk for the development of protamine hypersensitivity. |
| 0.5008 | Patients receiving neutral Drugprotamine Hagedorn ( NPH ) insulin are at increased risk for the development of protamine hypersensitivity. |
| Score | Text |
|---|---|
| 0.9993 | Radiation recall from Druggemcitabine is rare, but can potentially arise in any site that has been previously irradiated. |
| 0.9901 | Adverse-EffectRadiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated. |
| Score | Text |
|---|---|
| 0.9994 | Neutropenia is an infrequent complication following administration of the angiotensin - converting enzyme ( ACE ) inhibitor, Drugcaptopril . |
| 0.9982 | Adverse-EffectNeutropenia is an infrequent complication following administration of the angiotensin - converting enzyme ( ACE ) inhibitor, captopril. |
| Score | Text |
|---|---|
| 0.9955 | Cholestatic liver disease with Adverse-Effectductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole. |
| 0.9930 | Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of Drugclindamycin and trimethoprim - sulfamethoxazole. |
| 0.9862 | Adverse-EffectCholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole. |
| 0.9817 | Cholestatic liver disease with ductopenia ( Adverse-Effectvanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole. |
| 0.7034 | Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and Drugtrimethoprim - sulfamethoxazole . |
| Score | Text |
|---|---|
| 0.9995 | Physicians should keep in mind that taxanes such as Drugpaclitaxel have the potential to cause pneumonitis and lung fibrosis. |
| 0.9988 | Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause Adverse-Effectpneumonitis and lung fibrosis. |
| 0.9899 | Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and Adverse-Effectlung fibrosis . |
| Score | Text |
|---|---|
| 0.9993 | Hypersensitivity to Drugaspirin can be manifested as acute asthma, urticaria and / or angioedema, or a systemic anaphylactoid reaction. |
| 0.9972 | Hypersensitivity to aspirin can be manifested as acute asthma, Adverse-Effecturticaria and / or angioedema, or a systemic anaphylactoid reaction. |
| 0.9969 | Hypersensitivity to aspirin can be manifested as acute asthma, urticaria and / or Adverse-Effectangioedema , or a systemic anaphylactoid reaction. |
| 0.9830 | Hypersensitivity to aspirin can be manifested as acute asthma, urticaria and / or angioedema, or a Adverse-Effectsystemic anaphylactoid reaction . |
| 0.9904 | Hypersensitivity to aspirin can be manifested as Adverse-Effectacute asthma , urticaria and / or angioedema, or a systemic anaphylactoid reaction. |
| Score | Text |
|---|---|
| 0.9992 | Intravitreal Drugtriamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient. |
| 0.9743 | Intravitreal triamcinolone may have had an influence on the Adverse-Effectexacerbation of retinochoroiditis in the posterior pole of the patient. |
| Score | Text |
|---|---|
| 0.9817 | A 30 - year - old pharmacist suffered from Adverse-Effectacute allergic contact dermatitis due to 4 - chloro - 7 - nitrobenzofurazan ( NBD - Cl ). |
| 0.9615 | A 30 - year - old pharmacist suffered from acute allergic contact dermatitis due to 4 - chloro - 7 - nitrobenzofurazan ( DrugNBD - Cl ). |
| 0.9409 | A 30 - year - old pharmacist suffered from acute allergic contact dermatitis due to Drug4 - chloro - 7 - nitrobenzofurazan ( NBD - Cl ). |
| Score | Text |
|---|---|
| 0.9994 | Pneumonitis is emerging as one of the most unpredictable and potentially serious, adverse effects of treatment with DrugMTX . |
| 0.9974 | Adverse-EffectPneumonitis is emerging as one of the most unpredictable and potentially serious, adverse effects of treatment with MTX. |
| Score | Text |
|---|---|
| 0.9993 | The female patient received Drugclozapine in a daily dose of 400 mg, which induced agranulocytosis after 2 months. |
| 0.9986 | The female patient received clozapine in a daily dose of 400 mg, which induced Adverse-Effectagranulocytosis after 2 months. |
| Score | Text |
|---|---|
| 0.9959 | She continued to receive regular Druginsulin 4 times per day over the following 3 years with only occasional hives. |
| 0.9916 | She continued to receive regular insulin 4 times per day over the following 3 years with only occasional Adverse-Effecthives . |
| Score | Text |
|---|---|
| 0.9992 | DrugPropoxyphene - induced wide complex dysrhythmia responsive to sodium bicarbonate therapy has not been previously reported in the literature. |
| 0.9835 | Propoxyphene - induced Adverse-Effectwide complex dysrhythmia responsive to sodium bicarbonate therapy has not been previously reported in the literature. |
| Score | Text |
|---|---|
| 0.9920 | Adverse-EffectProgressive anemia following combination therapy with interferon - alpha and interleukin - 2 in a patient with metastatic renal cell carcinoma. |
| 0.9753 | Progressive anemia following combination therapy with interferon - alpha and Druginterleukin - 2 in a patient with metastatic renal cell carcinoma. |
| 0.9708 | Progressive anemia following combination therapy with Druginterferon - alpha and interleukin - 2 in a patient with metastatic renal cell carcinoma. |
| Score | Text |
|---|---|
| 0.9976 | Visual changes secondary to initiation of Drugamiodarone : a case report and review involving ocular management in cardiac polypharmacy. |
| 0.9939 | Adverse-EffectVisual changes secondary to initiation of amiodarone : a case report and review involving ocular management in cardiac polypharmacy. |
| Score | Text |
|---|---|
| 0.9978 | Metabolic balance studies and rechallenge with hydrochlorothiazide were undertaken to investigate the mechanism of the thiazide - induced Adverse-Effecthyponatremia . |
| 0.9658 | Metabolic balance studies and rechallenge with Drughydrochlorothiazide were undertaken to investigate the mechanism of the thiazide - induced hyponatremia. |
| 0.9721 | Metabolic balance studies and rechallenge with hydrochlorothiazide were undertaken to investigate the mechanism of the Drugthiazide - induced hyponatremia. |
| Score | Text |
|---|---|
| 0.9978 | Adverse-EffectGoiter and hypothyroidism during re - treatment with amiodarone in a patient who previously experienced amiodarone - induced thyrotoxicosis. |
| 0.9771 | Goiter and Adverse-Effecthypothyroidism during re - treatment with amiodarone in a patient who previously experienced amiodarone - induced thyrotoxicosis. |
| 0.9644 | Goiter and hypothyroidism during re - treatment with amiodarone in a patient who previously experienced amiodarone - induced Adverse-Effectthyrotoxicosis . |
| 0.8658 | Goiter and hypothyroidism during re - treatment with amiodarone in a patient who previously experienced Drugamiodarone - induced thyrotoxicosis. |
| 0.8296 | Goiter and hypothyroidism during re - treatment with Drugamiodarone in a patient who previously experienced amiodarone - induced thyrotoxicosis. |
| Score | Text |
|---|---|
| 0.9970 | Other thiazolidinediones currently in clinical trials may be able to provide the therapeutic benefits of Drugtroglitazone without significant hepatotoxicity. |
| 0.9534 | Other thiazolidinediones currently in clinical trials may be able to provide the therapeutic benefits of troglitazone without significant Adverse-Effecthepatotoxicity . |
| Score | Text |
|---|---|
| 0.9981 | Our case is the second one in which hemorrhage from a meningioma may have been induced by Drugaspirin prophylaxis. |
| 0.9978 | Our case is the second one in which Adverse-Effecthemorrhage from a meningioma may have been induced by aspirin prophylaxis. |
| Score | Text |
|---|---|
| 0.9991 | The authors report one case of incomplete posterior hyaloid detachment ( PHD ) following intravitreal Drugpegaptanib to treat DME. |
| 0.9753 | The authors report one case of Adverse-Effectincomplete posterior hyaloid detachment ( PHD ) following intravitreal pegaptanib to treat DME. |
| 0.9853 | The authors report one case of incomplete posterior hyaloid detachment ( Adverse-EffectPHD ) following intravitreal pegaptanib to treat DME. |
| Score | Text |
|---|---|
| 0.9715 | DrugL - DOPA - induced excessive daytime sleepiness in PD : a placebo - controlled case with MSLT assessment. |
| 0.6509 | L - DOPA - induced excessive Adverse-Effectdaytime sleepiness in PD : a placebo - controlled case with MSLT assessment. |
| 0.8773 | L - DOPA - induced Adverse-Effectexcessive daytime sleepiness in PD : a placebo - controlled case with MSLT assessment. |
| Score | Text |
|---|---|
| 0.9985 | Nine azotemic patients who developed a Adverse-Effectcoagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported. |
| 0.9982 | Nine azotemic patients who developed a coagulopathy associated with the use of either Drugcephalosporin or moxalactam antibiotics are reported. |
| 0.9979 | Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or Drugmoxalactam antibiotics are reported. |
| Score | Text |
|---|---|
| 0.9894 | Two patients treated with Drugalprazolam had histories suggestive of a bipolar disorder and developed lithium - responsive manic episodes. |
| 0.9792 | Two patients treated with alprazolam had histories suggestive of a bipolar disorder and developed lithium - responsive Adverse-Effectmanic episodes . |
| 0.9732 | Two patients treated with alprazolam had histories suggestive of a bipolar disorder and developed Druglithium - responsive manic episodes. |
| Score | Text |
|---|---|
| 0.9985 | A patient with generalized MG was effectively managed with DrugMM but developed CNS lymphoma after 3 years of treatment. |
| 0.9931 | A patient with generalized MG was effectively managed with MM but developed Adverse-EffectCNS lymphoma after 3 years of treatment. |
| Score | Text |
|---|---|
| 0.9987 | High - dose intravenous Drugmannitol infusion in various clinical settings may result in acute renal failure ( ARF ). |
| 0.9957 | High - dose intravenous mannitol infusion in various clinical settings may result in acute renal failure ( Adverse-EffectARF ). |
| 0.9887 | High - dose intravenous mannitol infusion in various clinical settings may result in Adverse-Effectacute renal failure ( ARF ). |
| Score | Text |
|---|---|
| 0.9992 | This progressed to tracheal compression with stridor after he had taken some Drugaspirin for relief of the neck pain. |
| 0.9887 | This progressed to Adverse-Effecttracheal compression with stridor after he had taken some aspirin for relief of the neck pain. |
| Score | Text |
|---|---|
| 0.9994 | CONCLUSIONS : There was a temporal relationship between the onset of nonconvulsive status epilepticus and initiation of Drugifosfamide infusion. |
| 0.9842 | CONCLUSIONS : There was a temporal relationship between the onset of Adverse-Effectnonconvulsive status epilepticus and initiation of ifosfamide infusion. |
| Score | Text |
|---|---|
| 0.9991 | CONCLUSIONS : Clinicians should be aware that Crohn's disease is a potential novel adverse drug effect of DrugCopaxone . |
| 0.9751 | CONCLUSIONS : Clinicians should be aware that Adverse-EffectCrohn's disease is a potential novel adverse drug effect of Copaxone. |
| Score | Text |
|---|---|
| 0.9994 | We report a 45 - year - old psoriasis patient who developed eruptive mollusca contagiosa during an antipsoriatic treatment with Drugefalizumab . |
| 0.9855 | We report a 45 - year - old psoriasis patient who developed Adverse-Effecteruptive mollusca contagiosa during an antipsoriatic treatment with efalizumab. |
| Score | Text |
|---|---|
| 0.9994 | We report a case of Sweet's syndrome in association with Drugsargramostim treatment following chemotherapy for acute myelogenous leukemia. |
| 0.9824 | We report a case of Adverse-EffectSweet's syndrome in association with sargramostim treatment following chemotherapy for acute myelogenous leukemia. |
| Score | Text |
|---|---|
| 0.9900 | Scleroderma - like reaction induced by uracil - tegafur ( DrugUFT ), a second - generation anticancer agent. |
| 0.9850 | Adverse-EffectScleroderma - like reaction induced by uracil - tegafur ( UFT ), a second - generation anticancer agent. |
| 0.9259 | Scleroderma - like reaction induced by Druguracil - tegafur ( UFT ), a second - generation anticancer agent. |
| Score | Text |
|---|---|
| 0.9992 | OBJECTIVE : We report a case of cutaneous KS lesions in a patient affected by CML treated with Drugimatinib . |
| 0.9858 | OBJECTIVE : We report a case of Adverse-Effectcutaneous KS lesions in a patient affected by CML treated with imatinib. |
| Score | Text |
|---|---|
| 0.9964 | A case of a 53 - year - old man who developed acute pneumonitis after Drugbleomycin and moderate oxygen administration is presented. |
| 0.9824 | A case of a 53 - year - old man who developed acute pneumonitis after bleomycin and moderate Drugoxygen administration is presented. |
| 0.9758 | A case of a 53 - year - old man who developed Adverse-Effectacute pneumonitis after bleomycin and moderate oxygen administration is presented. |
| Score | Text |
|---|---|
| 0.9956 | Caution is, therefore, needed to prevent undesired accumulation of DrugTCA that may lead to protracted Cushing's syndrome. |
| 0.9702 | Caution is, therefore, needed to prevent undesired accumulation of TCA that may lead to protracted Adverse-EffectCushing's syndrome . |
| Score | Text |
|---|---|
| 0.9994 | In a postoperative patient with pre - existent myasthenia gravis, oral Drugverapamil caused a marked exacerbation in myasthenic weakness. |
| 0.9635 | In a postoperative patient with pre - existent myasthenia gravis, oral verapamil caused a marked Adverse-Effectexacerbation in myasthenic weakness . |
| Score | Text |
|---|---|
| 0.9978 | The concomitant use, however, of Drugcolchicine and statin has been associated with the rapid onset of muscle weakness. |
| 0.9973 | The concomitant use, however, of colchicine and Drugstatin has been associated with the rapid onset of muscle weakness. |
| 0.9922 | The concomitant use, however, of colchicine and statin has been associated with the rapid onset of Adverse-Effectmuscle weakness . |
| Score | Text |
|---|---|
| 0.9980 | A 64 - year - old man presented with Adverse-Effectproteinuria during postoperative interferon ( IFN ) - beta therapy against malignant melanoma. |
| 0.7965 | A 64 - year - old man presented with proteinuria during postoperative Druginterferon ( IFN ) - beta therapy against malignant melanoma. |
| 0.5163 | A 64 - year - old man presented with proteinuria during postoperative interferon ( DrugIFN ) - beta therapy against malignant melanoma. |
| Score | Text |
|---|---|
| 0.9994 | Recognition of a potential drug - induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with Drugifosfamide . |
| 0.9937 | Recognition of a potential drug - induced Adverse-EffectFanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide. |
| Score | Text |
|---|---|
| 0.9973 | We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with DrugAZ intoxication. |
| 0.9895 | We experienced a case of chronic renal failure in a patient suffering from Adverse-Effectacute hemorrhagic gastritis associated with AZ intoxication. |
| 0.7112 | We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with Adverse-EffectAZ intoxication . |
| 0.5287 | We experienced a case of chronic Adverse-Effectrenal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication. |
| Score | Text |
|---|---|
| 0.9976 | The patient's other comorbidities and medications have not been suggested as possible interactions with sertraline that can cause Adverse-Effectrhabdomyolysis . |
| 0.9915 | The patient's other comorbidities and medications have not been suggested as possible interactions with Drugsertraline that can cause rhabdomyolysis. |
| Score | Text |
|---|---|
| 0.9994 | To the best of the authors'knowledge, this is the first reported case of DrugPropecia - associated cataract. |
| 0.9990 | To the best of the authors'knowledge, this is the first reported case of Propecia - associated Adverse-Effectcataract . |
| Score | Text |
|---|---|
| 0.9993 | RESULTS : Our patient developed Crohn's disease while on DrugCopaxone treatment as a consequence of long - term immunosuppression. |
| 0.9795 | RESULTS : Our patient developed Crohn's disease while on Copaxone treatment as a consequence of Adverse-Effectlong - term immunosuppression . |
| RESULTS : Our patient developed Adverse-EffectCrohn's disease while on Copaxone treatment as a consequence of long - term immunosuppression. | |
| Score | Text |
|---|---|
| 0.9994 | In this report, we describe a fatal Druggemcitabine - induced pulmonary toxicity in a patient with gallbladder metastatic adenocarcinoma. |
| 0.9893 | In this report, we describe a fatal gemcitabine - induced Adverse-Effectpulmonary toxicity in a patient with gallbladder metastatic adenocarcinoma. |
| Score | Text |
|---|---|
| 0.9992 | We suggest that Drugmeloxicam might have intestinal toxic effects when taken in high doses, because of reduced COX - 2 selectivity. |
| 0.9849 | We suggest that meloxicam might have Adverse-Effectintestinal toxic effects when taken in high doses, because of reduced COX - 2 selectivity. |
| Score | Text |
|---|---|
| 0.9992 | A chronic reaction associated with long - term treatment with Drugnitrofurantoin has also been reported and causes irreversible pulmonary fibrosis. |
| 0.9178 | A chronic reaction associated with long - term treatment with nitrofurantoin has also been reported and causes irreversible Adverse-Effectpulmonary fibrosis . |
| Score | Text |
|---|---|
| 0.9979 | One patient developed severe hyponatremia with serum Na + of 108 mEq / L when Drughydrochlorothiazide was given to control hypertension. |
| 0.9800 | One patient developed Adverse-Effectsevere hyponatremia with serum Na + of 108 mEq / L when hydrochlorothiazide was given to control hypertension. |
| Score | Text |
|---|---|
| 0.9995 | We describe a 43 - year - old man who developed signs and symptoms of bilateral optic neuropathy during treatment with Drugethambutol . |
| 0.9825 | We describe a 43 - year - old man who developed signs and symptoms of Adverse-Effectbilateral optic neuropathy during treatment with ethambutol. |
| Score | Text |
|---|---|
| 0.9970 | We report a case of noncardiogenic pulmonary edema developed after therapeutic trial of DrugEO as sclerosing agent for esophageal varix. |
| 0.9870 | We report a case of Adverse-Effectnoncardiogenic pulmonary edema developed after therapeutic trial of EO as sclerosing agent for esophageal varix. |
| Score | Text |
|---|---|
| 0.9966 | CONCLUSION : A patient with CHF and ESRD developed myoclonic muscle spasms after receiving Drugdobutamine by continuous i. v. infusion. |
| 0.9862 | CONCLUSION : A patient with CHF and ESRD developed Adverse-Effectmyoclonic muscle spasms after receiving dobutamine by continuous i. v. infusion. |
| Score | Text |
|---|---|
| 0.9995 | We report a case of an 11 - year - old boy who experienced an anaphylactic reaction after administration of Drugbacitracin ointment. |
| 0.9939 | We report a case of an 11 - year - old boy who experienced an Adverse-Effectanaphylactic reaction after administration of bacitracin ointment. |
| Score | Text |
|---|---|
| 0.9983 | These two cases highlight the importance of considering Druglopinavir / ritonavir induced arrhythmias when dealing with HIV - positive individuals. |
| 0.9980 | These two cases highlight the importance of considering lopinavir / Drugritonavir induced arrhythmias when dealing with HIV - positive individuals. |
| 0.9967 | These two cases highlight the importance of considering lopinavir / ritonavir induced Adverse-Effectarrhythmias when dealing with HIV - positive individuals. |
| Score | Text |
|---|---|
| 0.9996 | On the other hand, DrugMTX - induced pneumonitis seems to be very rare in psoriatic arthritis ( PsA ). |
| 0.9987 | On the other hand, MTX - induced Adverse-Effectpneumonitis seems to be very rare in psoriatic arthritis ( PsA ). |
| Score | Text |
|---|---|
| 0.9783 | Patients treated with captopril who develop " Adverse-Effectatypical cholangitis " should be suspected of having captopril - associated liver damage. |
| 0.9687 | Patients treated with captopril who develop " atypical cholangitis " should be suspected of having captopril - associated Adverse-Effectliver damage . |
| 0.9396 | Patients treated with Drugcaptopril who develop " atypical cholangitis " should be suspected of having captopril - associated liver damage. |
| 0.8816 | Patients treated with captopril who develop " atypical cholangitis " should be suspected of having Drugcaptopril - associated liver damage. |
| 0.5360 | Patients treated with captopril who develop " Adverse-Effectatypical cholangitis " should be suspected of having captopril - associated liver damage. |
| 0.5358 | Patients treated with captopril who develop " Adverse-Effectatypical cholangitis " should be suspected of having captopril - associated liver damage. |
| 0.5184 | Patients treated with captopril who develop " Adverse-Effectatypical cholangitis " should be suspected of having captopril - associated liver damage. |
| Score | Text |
|---|---|
| 0.9997 | He developed fever, nausea, diarrhea, and malaise and stopped taking on the third day after commencing DrugPentasa . |
| 0.9992 | He developed fever, nausea, Adverse-Effectdiarrhea , and malaise and stopped taking on the third day after commencing Pentasa. |
| 0.9984 | He developed fever, nausea, diarrhea, and Adverse-Effectmalaise and stopped taking on the third day after commencing Pentasa. |
| 0.9981 | He developed fever, Adverse-Effectnausea , diarrhea, and malaise and stopped taking on the third day after commencing Pentasa. |
| 0.9940 | He developed Adverse-Effectfever , nausea, diarrhea, and malaise and stopped taking on the third day after commencing Pentasa. |
| Score | Text |
|---|---|
| 0.9871 | The authors'results suggest that L - dopa may cause Adverse-Effectdaytime somnolence in some patients with Parkinson's disease. |
| 0.9731 | The authors'results suggest that DrugL - dopa may cause daytime somnolence in some patients with Parkinson's disease. |
| Score | Text |
|---|---|
| 0.9995 | The aim of this study was to describe the occurrence of acute coronary syndromes in 3 cases of Drugrituximab infusions. |
| 0.9892 | The aim of this study was to describe the occurrence of Adverse-Effectacute coronary syndromes in 3 cases of rituximab infusions. |
| Score | Text |
|---|---|
| 0.9995 | Despite a very low complication rate, several severe arterial thrombotic events have been reported following Drugthrombin injection of pseudoaneurysms. |
| 0.9827 | Despite a very low complication rate, several Adverse-Effectsevere arterial thrombotic events have been reported following thrombin injection of pseudoaneurysms. |
| Score | Text |
|---|---|
| 0.9992 | In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering Drugbretylium . |
| 0.9884 | In the first patient, two episodes of Adverse-Effectventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium. |
| Score | Text |
|---|---|
| 0.9972 | OBJECTIVE : To report a case of multiple episodes of Adverse-Effectseizure activity in an AIDS patent following amphotericin B infusion. |
| 0.9833 | OBJECTIVE : To report a case of multiple episodes of seizure activity in an AIDS patent following Drugamphotericin B infusion. |
| Score | Text |
|---|---|
| 0.9996 | A drug addict with staphylococcal endocarditis treated with Drugmethicillin , who developed massive proteinuria and acute nephritic syndrome is described. |
| 0.9925 | A drug addict with staphylococcal endocarditis treated with methicillin, who developed Adverse-Effectmassive proteinuria and acute nephritic syndrome is described. |
| 0.9894 | A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and Adverse-Effectacute nephritic syndrome is described. |
| Score | Text |
|---|---|
| 0.9992 | CONCLUSIONS : Prolonged exposure to Drugitraconazole , administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events. |
| 0.7655 | CONCLUSIONS : Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate Adverse-Effectsevere and irreversible hepatotoxic events . |
| Score | Text |
|---|---|
| 0.9993 | The patient's defects may be due to Drugmethimazole teratogenicity or could represent a previously undescribed syndrome affecting ectodermal structures. |
| 0.9522 | The patient's defects may be due to methimazole Adverse-Effectteratogenicity or could represent a previously undescribed syndrome affecting ectodermal structures. |
| Score | Text |
|---|---|
| 0.9954 | Gestational diabetes was no less severe ( degree of hyperglycaemia, need for insulin therapy ) when associated with Drugnorethisterone . |
| 0.9900 | Adverse-EffectGestational diabetes was no less severe ( degree of hyperglycaemia, need for insulin therapy ) when associated with norethisterone. |
| Score | Text |
|---|---|
| 0.9988 | Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin, Drugclarithromycin and ethambutol. |
| 0.9986 | Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin, clarithromycin and Drugethambutol . |
| 0.9985 | Adverse-EffectUveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin, clarithromycin and ethambutol. |
| 0.9985 | Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of Drugrifabutin , clarithromycin and ethambutol. |
| Score | Text |
|---|---|
| 0.9992 | Following several of these courses of therapy, respiratory distress occurred 9 to 12 days after the Drugchlorambucil was given. |
| 0.9929 | Following several of these courses of therapy, Adverse-Effectrespiratory distress occurred 9 to 12 days after the chlorambucil was given. |
| Score | Text |
|---|---|
| 0.9958 | Three cases of acute renal toxicity in patients receiving long - term therapy with mitomycin C and Drug5 - fluorouracil are reported. |
| 0.9844 | Three cases of acute renal toxicity in patients receiving long - term therapy with Drugmitomycin C and 5 - fluorouracil are reported. |
| 0.9801 | Three cases of Adverse-Effectacute renal toxicity in patients receiving long - term therapy with mitomycin C and 5 - fluorouracil are reported. |
| Score | Text |
|---|---|
| 0.9967 | DrugRamipril - induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before. |
| 0.9912 | Ramipril - induced Adverse-Effectcutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before. |
| Score | Text |
|---|---|
| 0.9991 | We report on a young adolescent with benign intracranial hypertension which we attribute to the use of Drugminocycline for acne. |
| 0.9769 | We report on a young adolescent with Adverse-Effectbenign intracranial hypertension which we attribute to the use of minocycline for acne. |
| Score | Text |
|---|---|
| 0.9860 | An adolescent male developed Adverse-Effectacute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L - asparaginase. |
| 0.9825 | An adolescent male developed acute pancreatitis and Adverse-Effectpseudocyst of the pancreas 16 weeks after cessation of intramuscular L - asparaginase. |
| 0.9711 | An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular DrugL - asparaginase . |
| Score | Text |
|---|---|
| 0.9839 | Four cases of Adverse-Effectfat embolism are described in infants receiving prolonged intravenous infusion of fat ( Intralipid 20 % ). |
| 0.9737 | Four cases of fat embolism are described in infants receiving prolonged intravenous infusion of fat ( DrugIntralipid 20 % ). |
| Score | Text |
|---|---|
| 0.9990 | According to the Naranjo probability scale, the relationship of Druggemcitabine treatment with cutaneous eruption in our patient is possible. |
| 0.9770 | According to the Naranjo probability scale, the relationship of gemcitabine treatment with Adverse-Effectcutaneous eruption in our patient is possible. |
| Score | Text |
|---|---|
| 0.9854 | A boy with chronic neutropenia and recurrent inflammatory skin lesions developed Adverse-Effectmultiple erythematous nodules following administration of G - CSF. |
| 0.9753 | A boy with chronic neutropenia and recurrent inflammatory skin lesions developed multiple erythematous nodules following administration of DrugG - CSF . |
| Score | Text |
|---|---|
| 0.9986 | Despite the known pulmonary side effects of Drugnitrofurantoin , there is no report of this toxicity occurring in pregnant patients. |
| 0.9829 | Despite the known Adverse-Effectpulmonary side effects of nitrofurantoin, there is no report of this toxicity occurring in pregnant patients. |
| Score | Text |
|---|---|
| 0.9993 | Evidence is shown in this report that Drugadenosine was associated with dangerous worsening of arrhythmia in patients with atrial flutter. |
| 0.9800 | Evidence is shown in this report that adenosine was associated with dangerous worsening of Adverse-Effectarrhythmia in patients with atrial flutter. |
| Score | Text |
|---|---|
| 0.9995 | A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving Drugpaclitaxel . |
| 0.9803 | A third patient experienced Adverse-Effectdisabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel. |
| Score | Text |
|---|---|
| 0.9995 | The authors report a case of urinary incontinence ( UI ) that occurred in a woman after administration of Drugvenlafaxine . |
| 0.9976 | The authors report a case of urinary incontinence ( Adverse-EffectUI ) that occurred in a woman after administration of venlafaxine. |
| 0.9885 | The authors report a case of Adverse-Effecturinary incontinence ( UI ) that occurred in a woman after administration of venlafaxine. |
| Score | Text |
|---|---|
| 0.9970 | Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and Adverse-Effectbronchospasm . |
| 0.9931 | Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of Adverse-Effectcarpopedal spasm and bronchospasm. |
| 0.9729 | Four days after intravenous DrugZoledronic acid , the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm. |
| Score | Text |
|---|---|
| 0.9993 | Four patients who manifested symptoms of the antiepileptic drug ( AED ) hypersensitivity syndrome during therapy with Drugcarbamazepine are reported. |
| 0.9593 | Four patients who manifested symptoms of the antiepileptic drug ( AED ) Adverse-Effecthypersensitivity syndrome during therapy with carbamazepine are reported. |
| Score | Text |
|---|---|
| 0.9985 | A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long - term Drugcyclophosphamide treatment. |
| 0.9895 | A review of the literature revealed two other cases of Adverse-Effecthepatic angiosarcoma in patients after long - term cyclophosphamide treatment. |
| Score | Text |
|---|---|
| 0.9989 | The neurotoxicity seen with DrugHDARAC is dose - related and has occurred in up to 60 percent of treated patients. |
| 0.9976 | The Adverse-Effectneurotoxicity seen with HDARAC is dose - related and has occurred in up to 60 percent of treated patients. |
| Score | Text |
|---|---|
| 0.9968 | Intra - neural ceroid - like pigment following the treatment of lepromatous leprosy with Drugclofazimine ( B663 ; Lamprene ). |
| 0.9965 | Intra - neural ceroid - like pigment following the treatment of lepromatous leprosy with clofazimine ( B663 ; DrugLamprene ). |
| 0.9955 | Intra - neural ceroid - like pigment following the treatment of lepromatous leprosy with clofazimine ( DrugB663 ; Lamprene ). |
| 0.9771 | Adverse-EffectIntra - neural ceroid - like pigment following the treatment of lepromatous leprosy with clofazimine ( B663 ; Lamprene ). |
| Score | Text |
|---|---|
| 0.9986 | This is the first report on the histopathological findings of thyroid tissue from a patient with Drugamiodarone - induced hypothyroidism. |
| 0.9960 | This is the first report on the histopathological findings of thyroid tissue from a patient with amiodarone - induced Adverse-Effecthypothyroidism . |
| Score | Text |
|---|---|
| 0.9980 | Herein, we describe 2 patients who developed unusual CD8 + cutaneous lymphoproliferative disorders after treatment with efalizumab and Druginfliximab . |
| 0.9972 | Herein, we describe 2 patients who developed unusual CD8 + cutaneous lymphoproliferative disorders after treatment with Drugefalizumab and infliximab. |
| 0.9799 | Herein, we describe 2 patients who developed unusual Adverse-EffectCD8 + cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab. |
| Score | Text |
|---|---|
| 0.9993 | After excluding other causes of long QT syndrome, the DrugHCQ was suspected as the cause of her ventricular tachycardia. |
| 0.9824 | After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her Adverse-Effectventricular tachycardia . |
| Score | Text |
|---|---|
| 0.9992 | We conclude that neurosurgeons and neurologists should be aware of calcium antagonist - - related ileus in patients treated with Drugnimodipine . |
| 0.9921 | We conclude that neurosurgeons and neurologists should be aware of calcium antagonist - - related Adverse-Effectileus in patients treated with nimodipine. |
| Score | Text |
|---|---|
| 0.9994 | NMS is a drug - related response to various medications, such as DrugHaloperidol , which the patient was receiving. |
| 0.9980 | Adverse-EffectNMS is a drug - related response to various medications, such as Haloperidol, which the patient was receiving. |
| Score | Text |
|---|---|
| 0.9721 | The noted increase in the theophylline level after Drugzafirlukast administration is in contrast to the original reports by the manufacturer. |
| 0.9653 | The noted increase in the Drugtheophylline level after zafirlukast administration is in contrast to the original reports by the manufacturer. |
| 0.7393 | The noted Adverse-Effectincrease in the theophylline level after zafirlukast administration is in contrast to the original reports by the manufacturer. |
| Score | Text |
|---|---|
| 0.9995 | To our knowledge, this is the first case of Drugivermectin - induced severe liver disease published in the literature. |
| 0.9904 | To our knowledge, this is the first case of ivermectin - induced Adverse-Effectsevere liver disease published in the literature. |
| Score | Text |
|---|---|
| 0.9840 | Adverse-EffectPalpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment. |
| 0.9833 | Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of Drugamphotericin B treatment. |
| Score | Text |
|---|---|
| 0.9994 | Three years later, treatment with Drugampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy. |
| 0.9928 | Three years later, treatment with ampicillin caused another episode of cholestatic hepatitis with Adverse-Effectcholestasis and duct paucity on rebiopsy. |
| 0.9891 | Three years later, treatment with ampicillin caused another episode of Adverse-Effectcholestatic hepatitis with cholestasis and duct paucity on rebiopsy. |
| 0.9877 | Three years later, treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and Adverse-Effectduct paucity on rebiopsy. |
| Score | Text |
|---|---|
| 0.9957 | Teicoplanin - induced agranulocytosis that followed vancomycin - induced Adverse-Effectagranulocytosis suggests a possible cross - reactivity between the 2 drugs. |
| 0.9544 | Teicoplanin - induced agranulocytosis that followed Drugvancomycin - induced agranulocytosis suggests a possible cross - reactivity between the 2 drugs. |
| 0.8805 | Teicoplanin - induced Adverse-Effectagranulocytosis that followed vancomycin - induced agranulocytosis suggests a possible cross - reactivity between the 2 drugs. |
| 0.8686 | DrugTeicoplanin - induced agranulocytosis that followed vancomycin - induced agranulocytosis suggests a possible cross - reactivity between the 2 drugs. |
| Score | Text |
|---|---|
| 0.9996 | This unusual pattern of low - grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with Drugtamoxifen therapy. |
| 0.9874 | This unusual pattern of low - grade endometrial carcinoma adds to the spectrum of Adverse-Effectuterine neoplasia associated with tamoxifen therapy. |
| 0.9179 | This unusual pattern of Adverse-Effectlow - grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy. |
| Score | Text |
|---|---|
| 0.9994 | This is a case report of subtle, mild hypothermia in a 54 - year old female patient receiving Drugrisperidone for schizophrenia. |
| 0.9264 | This is a case report of subtle, mild Adverse-Effecthypothermia in a 54 - year old female patient receiving risperidone for schizophrenia. |
| Score | Text |
|---|---|
| 0.9940 | Infliximab and its serious adverse effects are discussed, and other cases of Adverse-Effectosteomyelitis with infliximab use are also reviewed. |
| 0.9399 | Infliximab and its serious adverse effects are discussed, and other cases of osteomyelitis with Druginfliximab use are also reviewed. |
| 0.9208 | DrugInfliximab and its serious adverse effects are discussed, and other cases of osteomyelitis with infliximab use are also reviewed. |
| Score | Text |
|---|---|
| 0.9985 | This is a unique autopsy case of hepatocellular carcinoma closely related to Drugdiethylstilbestrol ( DES ) therapy for prostatic cancer. |
| 0.9952 | This is a unique autopsy case of hepatocellular carcinoma closely related to diethylstilbestrol ( DrugDES ) therapy for prostatic cancer. |
| 0.9896 | This is a unique autopsy case of Adverse-Effecthepatocellular carcinoma closely related to diethylstilbestrol ( DES ) therapy for prostatic cancer. |
| Score | Text |
|---|---|
| 0.9995 | DrugVigabatrin - induced visual field defects are at present the most important safety issue in the use of the drug. |
| 0.9890 | Vigabatrin - induced Adverse-Effectvisual field defects are at present the most important safety issue in the use of the drug. |
| Score | Text |
|---|---|
| 0.9994 | We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic / anaphylactoid reaction to Drugmethotrexate . |
| 0.9800 | We report the case of a child with metastatic osteosarcoma, who experienced an Adverse-Effectanaphylactic / anaphylactoid reaction to methotrexate. |
| 0.8443 | We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic / Adverse-Effectanaphylactoid reaction to methotrexate. |
| 0.7172 | We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic Adverse-Effect/ anaphylactoid reaction to methotrexate. |
| Score | Text |
|---|---|
| 0.8480 | Complications of chemotherapy for a synovial sarcoma in an eight - year old boy included cisplatinum Adverse-Effectnephrotoxicity and adriamycin cardiotoxicity. |
| 0.8074 | Complications of chemotherapy for a synovial sarcoma in an eight - year old boy included Drugcisplatinum nephrotoxicity and adriamycin cardiotoxicity. |
| 0.9095 | Complications of chemotherapy for a synovial sarcoma in an eight - year old boy included cisplatinum nephrotoxicity and Adverse-Effectadriamycin cardiotoxicity . |
| 0.7480 | Complications of chemotherapy for a synovial sarcoma in an eight - year old boy included Adverse-Effectcisplatinum nephrotoxicity and adriamycin cardiotoxicity. |
| Complications of chemotherapy for a synovial sarcoma in an eight - year old boy included cisplatinum nephrotoxicity and Drugadriamycin cardiotoxicity. | |
| Complications of chemotherapy for a synovial sarcoma in an eight - year old boy included cisplatinum nephrotoxicity and adriamycin Adverse-Effectcardiotoxicity . | |
| Score | Text |
|---|---|
| 0.9994 | RTA is one type of nephrotoxicity induced by DrugFK506 , and it is reversible in mild cases when appropriately treated. |
| 0.9966 | Adverse-EffectRTA is one type of nephrotoxicity induced by FK506, and it is reversible in mild cases when appropriately treated. |
| 0.9808 | RTA is one type of Adverse-Effectnephrotoxicity induced by FK506, and it is reversible in mild cases when appropriately treated. |
| Score | Text |
|---|---|
| 0.9993 | Three male patients aged 78 - 83 years are presented, in whom severe hepatotoxic reactions emerged after DrugCPA administration. |
| 0.8939 | Three male patients aged 78 - 83 years are presented, in whom Adverse-Effectsevere hepatotoxic reactions emerged after CPA administration. |
| Score | Text |
|---|---|
| 0.9806 | Two patients with Adverse-Effectextrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM - SPECT. |
| 0.9685 | Two patients with extrapyramidal side effects after the use of Drugfluphenazine decanoate were evaluated by means of IBZM - SPECT. |
| Score | Text |
|---|---|
| 0.9996 | Muscle biopsy revealed variation in muscle fiber size and few vacuolated fibers which were features of Drugcolchicine - induced myopathy. |
| 0.9929 | Muscle biopsy revealed variation in muscle fiber size and few vacuolated fibers which were features of colchicine - induced Adverse-Effectmyopathy . |
| 0.9834 | Muscle biopsy revealed variation in muscle fiber size and few Adverse-Effectvacuolated fibers which were features of colchicine - induced myopathy. |
| 0.9574 | Muscle biopsy revealed Adverse-Effectvariation in muscle fiber size and few vacuolated fibers which were features of colchicine - induced myopathy. |
| Score | Text |
|---|---|
| 0.9895 | Allergic side effects of DrugAZA are rare, and reported allergic skin eruptions from AZA are very limited in Japan. |
| 0.9872 | Allergic side effects of AZA are rare, and reported Adverse-Effectallergic skin eruptions from AZA are very limited in Japan. |
| 0.9862 | Allergic side effects of AZA are rare, and reported allergic skin eruptions from DrugAZA are very limited in Japan. |
| Score | Text |
|---|---|
| 0.9995 | Adverse effects of Drugamiodarone including pulmonary toxicity, hepatotoxicity, aggravation of arrhythmia, and thyroid diseases are well understood. |
| 0.9945 | Adverse effects of amiodarone including pulmonary toxicity, Adverse-Effecthepatotoxicity , aggravation of arrhythmia, and thyroid diseases are well understood. |
| 0.9910 | Adverse effects of amiodarone including Adverse-Effectpulmonary toxicity , hepatotoxicity, aggravation of arrhythmia, and thyroid diseases are well understood. |
| 0.9905 | Adverse effects of amiodarone including pulmonary toxicity, hepatotoxicity, aggravation of arrhythmia, and Adverse-Effectthyroid diseases are well understood. |
| 0.9795 | Adverse effects of amiodarone including pulmonary toxicity, hepatotoxicity, Adverse-Effectaggravation of arrhythmia , and thyroid diseases are well understood. |
| Score | Text |
|---|---|
| 0.9982 | The patient presented with fulminant microangiopathic hemolytic anemia and thrombocytopenia within 48 hr of initiating therapy with trimethoprim - Drugsulfamethoxazole . |
| 0.9962 | The patient presented with fulminant microangiopathic hemolytic anemia and thrombocytopenia within 48 hr of initiating therapy with Drugtrimethoprim - sulfamethoxazole. |
| 0.9942 | The patient presented with fulminant microangiopathic hemolytic anemia and Adverse-Effectthrombocytopenia within 48 hr of initiating therapy with trimethoprim - sulfamethoxazole. |
| 0.9856 | The patient presented with Adverse-Effectfulminant microangiopathic hemolytic anemia and thrombocytopenia within 48 hr of initiating therapy with trimethoprim - sulfamethoxazole. |
| Score | Text |
|---|---|
| 0.9984 | CONCLUSIONS : For all patients with Drugvancomycin - induced neutropenia, possible cross - reactivity of teicoplanin should be monitored. |
| 0.9982 | CONCLUSIONS : For all patients with vancomycin - induced Adverse-Effectneutropenia , possible cross - reactivity of teicoplanin should be monitored. |
| Score | Text |
|---|---|
| 0.9828 | Reinstitution of penicillamine treatment caused a recurrence thus proving a causal relationship between penicillamine and the described Adverse-Effectnail - changes . |
| 0.8582 | Reinstitution of penicillamine treatment caused a recurrence thus proving a causal relationship between Drugpenicillamine and the described nail - changes. |
| 0.6889 | Reinstitution of Drugpenicillamine treatment caused a recurrence thus proving a causal relationship between penicillamine and the described nail - changes. |
| Score | Text |
|---|---|
| 0.9800 | OBJECTIVE : To investigate the mechanisms involved in Adverse-Effecthypersensitivity reactions to cyclosporine and determine the feasibility of future cyclosporine use. |
| 0.9279 | OBJECTIVE : To investigate the mechanisms involved in hypersensitivity reactions to Drugcyclosporine and determine the feasibility of future cyclosporine use. |
| 0.9183 | OBJECTIVE : To investigate the mechanisms involved in hypersensitivity reactions to cyclosporine and determine the feasibility of future Drugcyclosporine use. |
| Score | Text |
|---|---|
| 0.9992 | A case of tuberculosis in a patient on Efalizumab and DrugEtanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis. |
| 0.9992 | A case of tuberculosis in a patient on DrugEfalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis. |
| 0.9919 | A case of Adverse-Effecttuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis. |
| Score | Text |
|---|---|
| 0.9941 | Development of Adverse-Effectnephrotic syndrome in a patient with acute myeloblastic leukemia after treatment with macrophage - colony - stimulating factor. |
| 0.9557 | Development of nephrotic syndrome in a patient with acute myeloblastic leukemia after treatment with Drugmacrophage - colony - stimulating factor . |
| Score | Text |
|---|---|
| 0.9995 | Typical symptoms of active CD occurred 11, 12, and 26 months after start of Drugetanercept therapy, respectively. |
| 0.9867 | Typical symptoms of active Adverse-EffectCD occurred 11, 12, and 26 months after start of etanercept therapy, respectively. |
| Score | Text |
|---|---|
| 0.9991 | The dermatology literature heretofore has not noted that anemia is a side effect of patients taking DrugMMF to treat pemphigus. |
| 0.9985 | The dermatology literature heretofore has not noted that Adverse-Effectanemia is a side effect of patients taking MMF to treat pemphigus. |
| Score | Text |
|---|---|
| 0.9943 | We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate ( DrugHOPA ). |
| 0.9921 | We report a girl with the Rett syndrome who had acute encephalopathy probably induced by Drugcalcium hopantenate ( HOPA ). |
| 0.9856 | We report a girl with the Rett syndrome who had Adverse-Effectacute encephalopathy probably induced by calcium hopantenate ( HOPA ). |
| Score | Text |
|---|---|
| 0.9992 | Increased awareness is needed on the possible occurrence of LPD resembling gastric cancer in rheumatoid arthritis patients treated with DrugMTX . |
| 0.9969 | Increased awareness is needed on the possible occurrence of Adverse-EffectLPD resembling gastric cancer in rheumatoid arthritis patients treated with MTX. |
| 0.7042 | Increased awareness is needed on the possible occurrence of LPD resembling Adverse-Effectgastric cancer in rheumatoid arthritis patients treated with MTX. |
| Score | Text |
|---|---|
| 0.9901 | Adverse-EffectOptic neuropathy developed in a patient with rheumatoid arthritis who had been receiving D - penicillamine for about 1 year. |
| 0.9722 | Optic neuropathy developed in a patient with rheumatoid arthritis who had been receiving DrugD - penicillamine for about 1 year. |
| Score | Text |
|---|---|
| 0.9993 | Surgeons and physicians should therefore be aware of the potential for RTA to occur with DrugFK506 after any organ transplantation. |
| 0.9948 | Surgeons and physicians should therefore be aware of the potential for Adverse-EffectRTA to occur with FK506 after any organ transplantation. |
| Score | Text |
|---|---|
| 0.9992 | We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a Drugstatin drug. |
| 0.9930 | We report 4 patients who developed symptoms of Adverse-Effectmyasthenia gravis within 2 weeks of starting treatment with a statin drug. |
| Score | Text |
|---|---|
| 0.9973 | She was treated with Pancrease MT 16, but had consistent Adverse-Effectvomiting 1 to 2 hours after administration of enzymes. |
| 0.9770 | She was treated with DrugPancrease MT 16 , but had consistent vomiting 1 to 2 hours after administration of enzymes. |
| Score | Text |
|---|---|
| 0.9975 | We report here a rare case of ritodrine - hydrochloride - induced Adverse-Effectrhabdomyolysis in a pregnant patient with myotonic dystrophy. |
| 0.9778 | We report here a rare case of Drugritodrine - hydrochloride - induced rhabdomyolysis in a pregnant patient with myotonic dystrophy. |
| Score | Text |
|---|---|
| 0.9797 | Our literature review revealed an additional six cases of onset of Adverse-Effectinflammatory arthritis in MS patients receiving IFN - beta. |
| 0.9738 | Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving DrugIFN - beta . |
| Score | Text |
|---|---|
| 0.9818 | Imatinib mesylate - related Adverse-Effectfatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. |
| 0.9647 | DrugImatinib mesylate - related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. |
| Score | Text |
|---|---|
| 0.9851 | PURPOSE : To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural Druginterferon alpha administration. |
| 0.9838 | PURPOSE : To describe Adverse-Effectbilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration. |
| Score | Text |
|---|---|
| 0.9995 | Our findings reveal that even in patients without a history of seizures, Drugpregabalin can cause a cortical negative myoclonus. |
| 0.9854 | Our findings reveal that even in patients without a history of seizures, pregabalin can cause a Adverse-Effectcortical negative myoclonus . |
| Score | Text |
|---|---|
| 0.9952 | Disseminated intravascular coagulation associated with acute hemoglobinemia or Adverse-Effecthemoglobinuria following Rh ( 0 ) ( D ) immune globulin intravenous administration for immune thrombocytopenic purpura. |
| 0.9841 | Disseminated intravascular coagulation associated with Adverse-Effectacute hemoglobinemia or hemoglobinuria following Rh ( 0 ) ( D ) immune globulin intravenous administration for immune thrombocytopenic purpura. |
| 0.9786 | Adverse-EffectDisseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh ( 0 ) ( D ) immune globulin intravenous administration for immune thrombocytopenic purpura. |
| 0.9396 | Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following DrugRh ( 0 ) ( D ) immune globulin intravenous administration for immune thrombocytopenic purpura. |
| Score | Text |
|---|---|
| 0.9996 | Pneumocystis pneumonia should be considered in asthmatic patients taking Drugmethotrexate who present with fever, pulmonary infiltrates, and hypoxia. |
| 0.9985 | Pneumocystis pneumonia should be considered in asthmatic patients taking methotrexate who present with fever, pulmonary infiltrates, and Adverse-Effecthypoxia . |
| 0.9864 | Adverse-EffectPneumocystis pneumonia should be considered in asthmatic patients taking methotrexate who present with fever, pulmonary infiltrates, and hypoxia. |
| 0.9855 | Pneumocystis pneumonia should be considered in asthmatic patients taking methotrexate who present with Adverse-Effectfever , pulmonary infiltrates, and hypoxia. |
| 0.9609 | Pneumocystis pneumonia should be considered in asthmatic patients taking methotrexate who present with fever, Adverse-Effectpulmonary infiltrates , and hypoxia. |
| Score | Text |
|---|---|
| 0.9982 | ADH hypersecretion in relation to plasma osmolality was reversed by Drugmizoribin withdrawal, suggesting that bredinin might adversely induce SIADH. |
| 0.9719 | ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce Adverse-EffectSIADH . |
| 0.8256 | Adverse-EffectADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH. |
| 0.8517 | ADH hypersecretion in relation to Adverse-Effectplasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH. |
| ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that Drugbredinin might adversely induce SIADH. | |
| Score | Text |
|---|---|
| 0.9991 | The known side effects of Drugsibutramine , ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects. |
| 0.9935 | The known side effects of sibutramine, ie, hypertension and Adverse-Effecttachycardia , depend on its adrenergic and serotoninergic effects. |
| 0.9927 | The known side effects of sibutramine, ie, Adverse-Effecthypertension and tachycardia, depend on its adrenergic and serotoninergic effects. |
| Score | Text |
|---|---|
| 0.9995 | During the anti - tuberculous therapy, visual loss can be related to Drugethambutol toxicity or the tuberculosis infection itself. |
| 0.9909 | During the anti - tuberculous therapy, Adverse-Effectvisual loss can be related to ethambutol toxicity or the tuberculosis infection itself. |
| Score | Text |
|---|---|
| 0.9936 | Late development of diabetes mellitus after interferon - alfa and Drugribavirin therapy for chronic hepatitis C : a case report. |
| 0.9932 | Late development of Adverse-Effectdiabetes mellitus after interferon - alfa and ribavirin therapy for chronic hepatitis C : a case report. |
| 0.9771 | Late development of diabetes mellitus after Druginterferon - alfa and ribavirin therapy for chronic hepatitis C : a case report. |
| Score | Text |
|---|---|
| 0.9990 | OBJECTIVES : To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to Drugrofecoxib . |
| 0.9765 | OBJECTIVES : To describe clinical and pathologic findings in patients noted to develop Adverse-Effectlower gastrointestinal symptoms when exposed to rofecoxib. |
| Score | Text |
|---|---|
| 0.9993 | The probability of developing acute leukemia in this study was not significantly correlated to the total cumulative dosage of DrugTreosulfan . |
| 0.9891 | The probability of developing Adverse-Effectacute leukemia in this study was not significantly correlated to the total cumulative dosage of Treosulfan. |
| Score | Text |
|---|---|
| 0.9910 | DrugCarboplatin hypersensitivity induced by low - dose paclitaxel / carboplatin in multiple platinum - treated patients with recurrent ovarian cancer. |
| 0.9843 | Carboplatin hypersensitivity induced by low - dose Drugpaclitaxel / carboplatin in multiple platinum - treated patients with recurrent ovarian cancer. |
| 0.9819 | Carboplatin hypersensitivity induced by low - dose paclitaxel / Drugcarboplatin in multiple platinum - treated patients with recurrent ovarian cancer. |
| 0.8826 | Carboplatin Adverse-Effecthypersensitivity induced by low - dose paclitaxel / carboplatin in multiple platinum - treated patients with recurrent ovarian cancer. |
| Score | Text |
|---|---|
| 0.9983 | Elderly patients for whom Drugnitrate has been prescribed should be warned of the occurrence of hypotension, leading to unconsciousness. |
| 0.9980 | Elderly patients for whom nitrate has been prescribed should be warned of the occurrence of Adverse-Effecthypotension , leading to unconsciousness. |
| 0.9979 | Elderly patients for whom nitrate has been prescribed should be warned of the occurrence of hypotension, leading to Adverse-Effectunconsciousness . |
| Score | Text |
|---|---|
| 0.9994 | DrugQuetiapine and obsessive - compulsive symptoms ( OCS ) : case report and review of atypical antipsychotic - induced OCS. |
| 0.9931 | Quetiapine and obsessive - compulsive symptoms ( Adverse-EffectOCS ) : case report and review of atypical antipsychotic - induced OCS. |
| 0.9817 | Quetiapine and Adverse-Effectobsessive - compulsive symptoms ( OCS ) : case report and review of atypical antipsychotic - induced OCS. |
| 0.9588 | Quetiapine and obsessive - compulsive symptoms ( OCS ) : case report and review of atypical antipsychotic - induced Adverse-EffectOCS . |
| Score | Text |
|---|---|
| 0.9991 | Unintended exposure to Drugacyclovir early in pregnancy, which is not uncommon, may cause excessive maternal and physician anxiety. |
| 0.8427 | Unintended exposure to acyclovir early in pregnancy, which is not uncommon, may cause Adverse-Effectexcessive maternal and physician anxiety . |
| Score | Text |
|---|---|
| 0.9993 | After the second Druginfliximab infusion, he was found to have a severe transient neutropenia ( 0. 5 x 10 ( 9 ) / L ). |
| 0.9462 | After the second infliximab infusion, he was found to have a Adverse-Effectsevere transient neutropenia ( 0. 5 x 10 ( 9 ) / L ). |
| Score | Text |
|---|---|
| 0.9873 | INTERPRETATION : When high doses of fluticasone propionate are used, growth may be retarded and Adverse-Effectadrenal suppression may occur. |
| 0.9787 | INTERPRETATION : When high doses of Drugfluticasone propionate are used, growth may be retarded and adrenal suppression may occur. |
| 0.9607 | INTERPRETATION : When high doses of fluticasone propionate are used, Adverse-Effectgrowth may be retarded and adrenal suppression may occur. |
| Score | Text |
|---|---|
| 0.9809 | OBJECTIVE : To report the first five cases of Drugamphotericin B overdose with secondary cardiac complications in a pediatric population. |
| 0.9584 | OBJECTIVE : To report the first five cases of amphotericin B overdose with secondary Adverse-Effectcardiac complications in a pediatric population. |
| Score | Text |
|---|---|
| 0.9991 | Because Drugpsoralens sensitize skin to ultraviolet A light, phototoxic reactions are the most frequent adverse effect of this treatment. |
| 0.9933 | Because psoralens sensitize skin to ultraviolet A light, Adverse-Effectphototoxic reactions are the most frequent adverse effect of this treatment. |
| Score | Text |
|---|---|
| 0.9993 | A unique case of a transient, nonpigmenting fixed drug eruption caused by the radiopaque contrast medium Drugiothalamate is reported. |
| 0.8677 | A unique case of a transient, nonpigmenting Adverse-Effectfixed drug eruption caused by the radiopaque contrast medium iothalamate is reported. |
| Score | Text |
|---|---|
| 0.9994 | A case of Drughalothane induced hepatitis is reported in a middle aged woman who underwent gastric surgery for morbid obesity. |
| 0.9979 | A case of halothane induced Adverse-Effecthepatitis is reported in a middle aged woman who underwent gastric surgery for morbid obesity. |
| Score | Text |
|---|---|
| 0.9941 | With the first cyclosporine dose, the patient complained of Adverse-Effectleg pain that was most severe during the cyclosporine infusion. |
| 0.9852 | With the first Drugcyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion. |
| 0.9837 | With the first cyclosporine dose, the patient complained of leg pain that was most severe during the Drugcyclosporine infusion. |
| Score | Text |
|---|---|
| 0.9887 | Colonic necrosis is known as a rare complication following the administration of DrugKayexalate ( sodium polystryrene sulfonate ) in sorbitol. |
| 0.9865 | Adverse-EffectColonic necrosis is known as a rare complication following the administration of Kayexalate ( sodium polystryrene sulfonate ) in sorbitol. |
| 0.9527 | Colonic necrosis is known as a rare complication following the administration of Kayexalate ( Drugsodium polystryrene sulfonate ) in sorbitol. |
| Score | Text |
|---|---|
| 0.9991 | It is suggested therefore that Drugmethotrexate be added to the list of agents capable of inducing diffuse interstitial pulmonary fibrosis. |
| 0.9738 | It is suggested therefore that methotrexate be added to the list of agents capable of inducing Adverse-Effectdiffuse interstitial pulmonary fibrosis . |
| Score | Text |
|---|---|
| 0.9970 | The renal insufficiency of three patients and the timing of the seizures implicate accumulation of Drugofloxacin as a contributing factor. |
| 0.9945 | The renal insufficiency of three patients and the timing of the Adverse-Effectseizures implicate accumulation of ofloxacin as a contributing factor. |
| 0.9745 | The Adverse-Effectrenal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor. |
| Score | Text |
|---|---|
| 0.9994 | Although an association between exposure to Drugbleomycin and the development of scleroderma has been suspected, few cases are reported. |
| 0.9975 | Although an association between exposure to bleomycin and the development of Adverse-Effectscleroderma has been suspected, few cases are reported. |
| Score | Text |
|---|---|
| 0.9994 | The cause of death was determined to be acute intoxication by Drugolanzapine , and the manner of death was accidental. |
| 0.9903 | The cause of death was determined to be Adverse-Effectacute intoxication by olanzapine, and the manner of death was accidental. |
| Score | Text |
|---|---|
| 0.9990 | We recommended periodic examination of the serum proteins in patients receiving Drugdiphenylhydantoin in order to detect development of monoclonal gammopathy. |
| 0.9878 | We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of Adverse-Effectmonoclonal gammopathy . |
| Score | Text |
|---|---|
| 0.9967 | Acute non - lymphocytic leukemia in patients with ovarian carcinoma following long - term treatment with DrugTreosulfan ( = dihydroxybusulfan ). |
| 0.9951 | Acute non - lymphocytic leukemia in patients with ovarian carcinoma following long - term treatment with Treosulfan ( = Drugdihydroxybusulfan ). |
| 0.9683 | Adverse-EffectAcute non - lymphocytic leukemia in patients with ovarian carcinoma following long - term treatment with Treosulfan ( = dihydroxybusulfan ). |
| Score | Text |
|---|---|
| 0.9995 | In our patient, DIAN possibly was related to Drugcefuroxime , but the patient did not experience associated allergic symptoms. |
| 0.9944 | In our patient, Adverse-EffectDIAN possibly was related to cefuroxime, but the patient did not experience associated allergic symptoms. |
| Score | Text |
|---|---|
| 0.9995 | CASES : Two postmenopausal women treated with Drugtamoxifen and progestational agents for breast carcinoma developed uterine enlargement and intermittent spotting. |
| 0.9920 | CASES : Two postmenopausal women treated with tamoxifen and progestational agents for breast carcinoma developed Adverse-Effectuterine enlargement and intermittent spotting. |
| 0.9910 | CASES : Two postmenopausal women treated with tamoxifen and progestational agents for breast carcinoma developed uterine enlargement and Adverse-Effectintermittent spotting . |
| Score | Text |
|---|---|
| 0.9984 | As far as we know, this is the first case report of acute hemorrhagic gastritis associated with DrugAZ intoxication. |
| 0.9843 | As far as we know, this is the first case report of Adverse-Effectacute hemorrhagic gastritis associated with AZ intoxication. |
| 0.5770 | As far as we know, this is the first case report of acute hemorrhagic gastritis associated with Adverse-EffectAZ intoxication . |
| Score | Text |
|---|---|
| 0.9994 | DrugRitonavir acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity. |
| 0.9779 | Ritonavir acted as a CYP3A4 inhibitor, Adverse-Effectdiminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity. |
| 0.9769 | Ritonavir acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an Adverse-Effectincrease in serum levels and clinical toxicity. |
| 0.6867 | Ritonavir acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and Adverse-Effectclinical toxicity . |
| Score | Text |
|---|---|
| 0.9781 | Diagnosis of Adverse-Effectsclerosing glomerulonephritis occurred in this patient during anastrozole use, suggesting a newly defined side effect of anastrozole. |
| 0.9345 | Diagnosis of sclerosing glomerulonephritis occurred in this patient during Druganastrozole use, suggesting a newly defined side effect of anastrozole. |
| 0.6437 | Diagnosis of sclerosing glomerulonephritis occurred in this patient during anastrozole use, suggesting a newly defined side effect of Druganastrozole . |
| Score | Text |
|---|---|
| 0.9995 | We report a patient who developed spontaneous splenic infarction after the use of Drugsumatriptan for the treatment of migraine headache. |
| 0.9872 | We report a patient who developed Adverse-Effectspontaneous splenic infarction after the use of sumatriptan for the treatment of migraine headache. |
| Score | Text |
|---|---|
| 0.9989 | A potential role for renal and hepatic impairment in the observed protracted course of Drugamiodarone - induced thyrotoxicosis is suggested. |
| 0.9964 | A potential role for renal and hepatic impairment in the observed protracted course of amiodarone - induced Adverse-Effectthyrotoxicosis is suggested. |
| Score | Text |
|---|---|
| 0.9995 | OBJECTIVE : To report a case of marked elevation of serum creatine kinase ( CK ) associated with Drugolanzapine therapy. |
| 0.9769 | OBJECTIVE : To report a case of marked Adverse-Effectelevation of serum creatine kinase ( CK ) associated with olanzapine therapy. |
| Score | Text |
|---|---|
| 0.9983 | A 21 - year - old patient developed Adverse-Effectrhabdomyolysis during his nineteenth week of treatment with clozapine for drug - resistant schizophrenia. |
| 0.9974 | A 21 - year - old patient developed rhabdomyolysis during his nineteenth week of treatment with Drugclozapine for drug - resistant schizophrenia. |
| Score | Text |
|---|---|
| 0.9994 | We report the first case of acute renal failure with hyperkalemia associated with the recently marketed direct renin inhibitor Drugaliskiren . |
| 0.9935 | We report the first case of acute renal failure with Adverse-Effecthyperkalemia associated with the recently marketed direct renin inhibitor aliskiren. |
| 0.9781 | We report the first case of Adverse-Effectacute renal failure with hyperkalemia associated with the recently marketed direct renin inhibitor aliskiren. |
| Score | Text |
|---|---|
| 0.9760 | A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of Drugviloxazine . |
| 0.9503 | A case is reported of Drugtheophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine. |
| 0.8408 | A case is reported of Adverse-Effecttheophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine. |
| 0.8555 | A case is reported of theophylline intoxication due to a dramatic decrease in Drugtheophylline clearance following concomitant administration of viloxazine. |
| A case is reported of theophylline intoxication due to a dramatic Adverse-Effectdecrease in theophylline clearance following concomitant administration of viloxazine. | |
| Score | Text |
|---|---|
| 0.9852 | Postoperative hypocalcemic tetany caused by fleet phospho - soda preparation in a patient taking Drugalendronate sodium : report of a case. |
| 0.9821 | Postoperative Adverse-Effecthypocalcemic tetany caused by fleet phospho - soda preparation in a patient taking alendronate sodium : report of a case. |
| 0.9598 | Postoperative hypocalcemic tetany caused by Drugfleet phospho - soda preparation in a patient taking alendronate sodium : report of a case. |
| Score | Text |
|---|---|
| 0.9987 | The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of Drugbleomycin . |
| 0.9848 | The patient expired after seven cycles of treatment had been completed because of Adverse-Effectpulmonary fibrosis and the drug toxicity of bleomycin. |
| Score | Text |
|---|---|
| 0.9993 | Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience Drugmethotrexate - induced anaphylaxis. |
| 0.9979 | Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate - induced Adverse-Effectanaphylaxis . |
| Score | Text |
|---|---|
| 0.9990 | A 10 - year - old girl with Lennox - Gastaut syndrome who received intravenous Druglorazepam for atypical absence status seizures is reported. |
| 0.9919 | A 10 - year - old girl with Lennox - Gastaut syndrome who received intravenous lorazepam for atypical absence status Adverse-Effectseizures is reported. |
| Score | Text |
|---|---|
| 0.9944 | The induction of Adverse-Effecthypoglycaemia with PAS in this patient suggests a potential role for PAS in the treatment of diabetes mellitus. |
| 0.9389 | The induction of hypoglycaemia with DrugPAS in this patient suggests a potential role for PAS in the treatment of diabetes mellitus. |
| 0.5010 | The induction of hypoglycaemia with PAS in this patient suggests a potential role for DrugPAS in the treatment of diabetes mellitus. |
| Score | Text |
|---|---|
| 0.9990 | In two patients, Drugapomorphine remained effective in the morning, but increased the intensity of the dyskinesias in the afternoon. |
| 0.9930 | In two patients, apomorphine remained effective in the morning, but increased the intensity of the Adverse-Effectdyskinesias in the afternoon. |
| Score | Text |
|---|---|
| 0.9993 | The visual loss in this patient seems to result from Drugphenol neurotoxicity rather than mechanical compression of the intraorbital optic nerve. |
| 0.9892 | The Adverse-Effectvisual loss in this patient seems to result from phenol neurotoxicity rather than mechanical compression of the intraorbital optic nerve. |
| 0.9045 | The visual loss in this patient seems to result from phenol Adverse-Effectneurotoxicity rather than mechanical compression of the intraorbital optic nerve. |
| Score | Text |
|---|---|
| 0.9996 | Here we describe another case of VOD occurring after LT, but in which the causative role was played by Drugazathioprine . |
| 0.9986 | Here we describe another case of Adverse-EffectVOD occurring after LT, but in which the causative role was played by azathioprine. |
| Score | Text |
|---|---|
| 0.9978 | OBJECTIVE : To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to Drugcapecitabine . |
| 0.9878 | OBJECTIVE : To report the safe use of fluorouracil in a patient with breast cancer who had Adverse-Effectallergic reactions to capecitabine. |
| Score | Text |
|---|---|
| 0.9973 | METHODS : The patient required insulin desensitization for severe urticaria, Adverse-Effectangioedema , and occasional wheezing resulting from her insulin dose. |
| 0.9963 | METHODS : The patient required insulin desensitization for severe urticaria, angioedema, and occasional Adverse-Effectwheezing resulting from her insulin dose. |
| 0.9943 | METHODS : The patient required Druginsulin desensitization for severe urticaria, angioedema, and occasional wheezing resulting from her insulin dose. |
| 0.9941 | METHODS : The patient required insulin desensitization for severe urticaria, angioedema, and occasional wheezing resulting from her Druginsulin dose. |
| 0.9902 | METHODS : The patient required insulin desensitization for Adverse-Effectsevere urticaria , angioedema, and occasional wheezing resulting from her insulin dose. |
| Score | Text |
|---|---|
| 0.9978 | Adverse-EffectArrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them. |
| 0.9945 | Arrhythmias and Adverse-Effectcardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them. |
| 0.9811 | Arrhythmias and cardiac arrest have been reported during Drugamphotericin B administration but no effective technique has been described to prevent them. |
| Score | Text |
|---|---|
| 0.9931 | We describe the first case of de novo asthma following treatment with the angiotensin converting enzyme ( ACE ) inhibitor Drugcaptopril . |
| 0.9873 | We describe the first case of de novo Adverse-Effectasthma following treatment with the angiotensin converting enzyme ( ACE ) inhibitor captopril. |
| Score | Text |
|---|---|
| 0.9968 | We report two new cases of Adverse-Effectsarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin. |
| 0.9956 | We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and Drugribavirin . |
| 0.9891 | We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with Druginterferon alfa and ribavirin. |
| Score | Text |
|---|---|
| 0.9992 | BACKGROUND : DrugMethotrexate ( MTX ) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis. |
| 0.9986 | BACKGROUND : Methotrexate ( DrugMTX ) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis. |
| 0.9985 | BACKGROUND : Methotrexate ( MTX ) may induce liver damage, which in some psoriatics will lead to fibrosis or Adverse-Effectcirrhosis . |
| 0.9983 | BACKGROUND : Methotrexate ( MTX ) may induce liver damage, which in some psoriatics will lead to Adverse-Effectfibrosis or cirrhosis. |
| 0.9900 | BACKGROUND : Methotrexate ( MTX ) may induce Adverse-Effectliver damage , which in some psoriatics will lead to fibrosis or cirrhosis. |
| Score | Text |
|---|---|
| 0.9994 | Inhaled Drugtobramycin solution - associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis : a case report. |
| 0.9836 | Inhaled tobramycin solution - associated recurrent eosinophilia and Adverse-Effectsevere persistent bronchospasm in a patient with cystic fibrosis : a case report. |
| 0.9753 | Inhaled tobramycin solution - associated Adverse-Effectrecurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis : a case report. |
| Score | Text |
|---|---|
| 0.9985 | Within 3 weeks of beginning continuous daily Drugisoniazid and rifampin therapy for pulmonary tuberculosis, a patient developed acute renal failure. |
| 0.9984 | Within 3 weeks of beginning continuous daily isoniazid and Drugrifampin therapy for pulmonary tuberculosis, a patient developed acute renal failure. |
| 0.9886 | Within 3 weeks of beginning continuous daily isoniazid and rifampin therapy for pulmonary tuberculosis, a patient developed Adverse-Effectacute renal failure . |
| Score | Text |
|---|---|
| 0.9907 | Patient B developed perioral and upper extremity paresthesias during the fourth cycle of DrugCAP alone ( 2500 mg / m2 ). |
| 0.9808 | Patient B developed Adverse-Effectperioral and upper extremity paresthesias during the fourth cycle of CAP alone ( 2500 mg / m2 ). |
| Score | Text |
|---|---|
| 0.9995 | Moreover, these findings suggest that the incidence of BOOP following Drugrituximab therapy may be higher than has been previously appreciated. |
| 0.9987 | Moreover, these findings suggest that the incidence of Adverse-EffectBOOP following rituximab therapy may be higher than has been previously appreciated. |
| Score | Text |
|---|---|
| 0.9993 | This compound, used by adults in the child's home, had caused accidental Drugtheophylline poisoning, mimicking diabetic ketoacidosis. |
| 0.8118 | This compound, used by adults in the child's home, had caused accidental Adverse-Effecttheophylline poisoning , mimicking diabetic ketoacidosis. |
| Score | Text |
|---|---|
| 0.9994 | Up to four percent of patients treated with Drugimatinib may develop hepatotoxicity, which usually resolves with discontinuation of the drug. |
| 0.9978 | Up to four percent of patients treated with imatinib may develop Adverse-Effecthepatotoxicity , which usually resolves with discontinuation of the drug. |
| Score | Text |
|---|---|
| 0.9983 | L - Thyroxine - induced Adverse-Effectleukopenia in a patient with Hashimoto's disease : involvement of suppressor - cytotoxic T cells. |
| 0.9739 | DrugL - Thyroxine - induced leukopenia in a patient with Hashimoto's disease : involvement of suppressor - cytotoxic T cells. |
| Score | Text |
|---|---|
| 0.9965 | Methotrexate - induced Adverse-Effectleukoencephalopathy is treatable with high - dose folinic acid : a case report and analysis of the literature. |
| 0.9964 | DrugMethotrexate - induced leukoencephalopathy is treatable with high - dose folinic acid : a case report and analysis of the literature. |
| Score | Text |
|---|---|
| 0.9995 | We report a case of hyperpigmentation due to Drugbleomycin treatment in a patient with acquired immune deficiency syndrome ( AIDS ). |
| 0.9960 | We report a case of Adverse-Effecthyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome ( AIDS ). |
| Score | Text |
|---|---|
| 0.9995 | Although Drugfluoxetine - induced headache occurred in one patient, the other five reported no side effects at the doses used. |
| 0.9989 | Although fluoxetine - induced Adverse-Effectheadache occurred in one patient, the other five reported no side effects at the doses used. |
| Score | Text |
|---|---|
| 0.9994 | DrugRifampin can be associated with severe adverse effects such as hepatitis, acute renal failure, hemolytic anemia, and thrombocytopenia. |
| 0.9983 | Rifampin can be associated with severe adverse effects such as Adverse-Effecthepatitis , acute renal failure, hemolytic anemia, and thrombocytopenia. |
| 0.9975 | Rifampin can be associated with severe adverse effects such as hepatitis, acute renal failure, hemolytic anemia, and Adverse-Effectthrombocytopenia . |
| 0.9921 | Rifampin can be associated with severe adverse effects such as hepatitis, acute renal failure, Adverse-Effecthemolytic anemia , and thrombocytopenia. |
| 0.9858 | Rifampin can be associated with severe adverse effects such as hepatitis, Adverse-Effectacute renal failure , hemolytic anemia, and thrombocytopenia. |
| Score | Text |
|---|---|
| 0.9996 | To date, eight cases of TEN and one of SJS related to Druglamotrigine administration have been reported in the literature. |
| 0.9987 | To date, eight cases of Adverse-EffectTEN and one of SJS related to lamotrigine administration have been reported in the literature. |
| 0.9966 | To date, eight cases of TEN and one of Adverse-EffectSJS related to lamotrigine administration have been reported in the literature. |
| Score | Text |
|---|---|
| 0.9993 | DISCUSSION : Patients with Drug5 - FU - induced ectropion experience tender, red, scaled lids, making contact lens wear difficult. |
| 0.9976 | DISCUSSION : Patients with 5 - FU - induced Adverse-Effectectropion experience tender, red, scaled lids, making contact lens wear difficult. |
| 0.9333 | DISCUSSION : Patients with 5 - FU - induced ectropion experience Adverse-Effecttender, red, scaled lids , making contact lens wear difficult. |
| Score | Text |
|---|---|
| 0.9993 | We present the case of a 5 - year - old girl who developed bilateral vocal cord paralysis following preoperative peritonsillar Drugbupivacaine infiltration. |
| 0.9879 | We present the case of a 5 - year - old girl who developed Adverse-Effectbilateral vocal cord paralysis following preoperative peritonsillar bupivacaine infiltration. |
| Score | Text |
|---|---|
| 0.9968 | It remains to be seen whether the Adverse-Effecthepatotoxicity associated with troglitazone is a drug - class effect or specific to troglitazone. |
| 0.9760 | It remains to be seen whether the hepatotoxicity associated with Drugtroglitazone is a drug - class effect or specific to troglitazone. |
| 0.9500 | It remains to be seen whether the hepatotoxicity associated with troglitazone is a drug - class effect or specific to Drugtroglitazone . |
| Score | Text |
|---|---|
| 0.9993 | Severe hepatotoxicity from Drugphenobarbital occurred in an infant boy who had a complicated illness with chronic bilateral subdural hematomas and sepsis. |
| 0.9583 | Adverse-EffectSevere hepatotoxicity from phenobarbital occurred in an infant boy who had a complicated illness with chronic bilateral subdural hematomas and sepsis. |
| Score | Text |
|---|---|
| 0.9995 | To the best of our knowledge, this is the first case of Druglithium - associated CDI and NDI presenting concurrently. |
| 0.9984 | To the best of our knowledge, this is the first case of lithium - associated Adverse-EffectCDI and NDI presenting concurrently. |
| 0.9976 | To the best of our knowledge, this is the first case of lithium - associated CDI and Adverse-EffectNDI presenting concurrently. |
| Score | Text |
|---|---|
| 0.9992 | OBJECTIVE : To report the finding of squamous metaplasia within endometrial glands occurring as a result of Drugprogestin therapy of hyperplasia. |
| 0.9777 | OBJECTIVE : To report the finding of Adverse-Effectsquamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia. |
| OBJECTIVE : To report the finding of Adverse-Effectsquamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia. | |
| Score | Text |
|---|---|
| 0.9962 | It was concluded that potassium loss occurred by a non - renal ( intestinal ) route in Drugphosphate - induced hypokalemia. |
| 0.9932 | It was concluded that potassium loss occurred by a non - renal ( intestinal ) route in phosphate - induced Adverse-Effecthypokalemia . |
| 0.9851 | It was concluded that Adverse-Effectpotassium loss occurred by a non - renal ( intestinal ) route in phosphate - induced hypokalemia. |
| Score | Text |
|---|---|
| 0.9712 | CONCLUSION : Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with Drugpegylated interferon . |
| 0.9692 | CONCLUSION : Significant Adverse-Effectocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon. |
| 0.5947 | CONCLUSION : Significant ocular complications such as an Adverse-Effectirreversible decrease of visual acuity may develop in patients treated with pegylated interferon. |
| 0.8878 | CONCLUSION : Significant ocular complications such as an irreversible Adverse-Effectdecrease of visual acuity may develop in patients treated with pegylated interferon. |
| Score | Text |
|---|---|
| 0.9822 | CD4 T - lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of Drugfludarabine phosphate therapy. |
| 0.9783 | CD4 T - lymphocyte depletion, Adverse-Effectmyelosuppression , and subsequent severe infections are the major side effects of fludarabine phosphate therapy. |
| 0.9732 | Adverse-EffectCD4 T - lymphocyte depletion , myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy. |
| 0.9681 | CD4 T - lymphocyte depletion, myelosuppression, and subsequent Adverse-Effectsevere infections are the major side effects of fludarabine phosphate therapy. |
| Score | Text |
|---|---|
| 0.9995 | METHODS : Repeated blood samples were drawn in a patient with severe Drugacyclovir overdose who developed coma and nonoliguric renal failure. |
| 0.9910 | METHODS : Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed Adverse-Effectcoma and nonoliguric renal failure. |
| 0.9904 | METHODS : Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and Adverse-Effectnonoliguric renal failure . |
| Score | Text |
|---|---|
| 0.9989 | CONCLUSION : This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of Drugdoxorubicin . |
| 0.9821 | CONCLUSION : This is, to our knowledge, the first report of Adverse-Effectsevere myelopathy following accidental intrathecal administration of doxorubicin. |
| Score | Text |
|---|---|
| 0.9993 | We report the case of a man, treated with Drugmesalazine for Crohn's disease who developed drug - induced pericarditis. |
| 0.9984 | We report the case of a man, treated with mesalazine for Crohn's disease who developed drug - induced Adverse-Effectpericarditis . |
| Score | Text |
|---|---|
| 0.9891 | The authors presented a case of Adverse-Effectpulmonary hypertension during lithium therapy, while she has been on lithium for 6 years. |
| 0.9685 | The authors presented a case of pulmonary hypertension during Druglithium therapy, while she has been on lithium for 6 years. |
| 0.6043 | The authors presented a case of pulmonary hypertension during lithium therapy, while she has been on Druglithium for 6 years. |
| Score | Text |
|---|---|
| 0.9991 | Following the institution of intravenous therapy with Drugacyclovir , the patient developed fever, hemoptysis, and a pleural friction rub. |
| 0.9987 | Following the institution of intravenous therapy with acyclovir, the patient developed fever, Adverse-Effecthemoptysis , and a pleural friction rub. |
| 0.9908 | Following the institution of intravenous therapy with acyclovir, the patient developed Adverse-Effectfever , hemoptysis, and a pleural friction rub. |
| 0.9898 | Following the institution of intravenous therapy with acyclovir, the patient developed fever, hemoptysis, and a Adverse-Effectpleural friction rub . |
| Score | Text |
|---|---|
| 0.9987 | We report 3 cases of children with acute lymphoblastic leukemia who developed Adverse-Effectseizures and altered sensorium after L - asparaginase therapy. |
| 0.9917 | We report 3 cases of children with acute lymphoblastic leukemia who developed seizures and Adverse-Effectaltered sensorium after L - asparaginase therapy. |
| 0.9770 | We report 3 cases of children with acute lymphoblastic leukemia who developed seizures and altered sensorium after DrugL - asparaginase therapy. |
| Score | Text |
|---|---|
| 0.9996 | CONCLUSION : There are only a few confirmed cases of Druggemcitabine - associated HUS despite the widespread use of the drug. |
| 0.9982 | CONCLUSION : There are only a few confirmed cases of gemcitabine - associated Adverse-EffectHUS despite the widespread use of the drug. |
| Score | Text |
|---|---|
| 0.9989 | We report a case of acute generalized exanthematous pustulosis ( AGEP ) induced by Drugsalazosulfapyridine in a patient with ulcerative colitis. |
| 0.9799 | We report a case of Adverse-Effectacute generalized exanthematous pustulosis ( AGEP ) induced by salazosulfapyridine in a patient with ulcerative colitis. |
| 0.9879 | We report a case of acute generalized exanthematous pustulosis ( Adverse-EffectAGEP ) induced by salazosulfapyridine in a patient with ulcerative colitis. |
| Score | Text |
|---|---|
| 0.9991 | We presented a patient with status asthmaticus treated with a combination of Drugtheophylline and prednisone who developed a perforated gastric ulcer. |
| 0.9990 | We presented a patient with status asthmaticus treated with a combination of theophylline and Drugprednisone who developed a perforated gastric ulcer. |
| 0.9800 | We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a Adverse-Effectperforated gastric ulcer . |
| Score | Text |
|---|---|
| 0.9993 | The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of Drugpenicillin . |
| 0.9971 | The patient described feeling cold with worsening headache and Adverse-Effectchills approximately one hour after infusion of the first dose of penicillin. |
| 0.9935 | The patient described Adverse-Effectfeeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin. |
| 0.9850 | The patient described feeling cold with Adverse-Effectworsening headache and chills approximately one hour after infusion of the first dose of penicillin. |
| Score | Text |
|---|---|
| 0.9989 | The capacity of Drugzuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha - adrenergic receptors. |
| 0.9976 | The capacity of zuclopenthixol to induce Adverse-Effectpriapism is thought to be due to its antagonist activity on alpha - adrenergic receptors. |
| Score | Text |
|---|---|
| 0.9993 | After discontinuing Drugcaptopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved. |
| 0.9923 | After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her Adverse-Effecteosinophilia and radiographic abnormalities both resolved. |
| 0.9644 | After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and Adverse-Effectradiographic abnormalities both resolved. |
| Score | Text |
|---|---|
| 0.9995 | We report a 13 year - old male who developed life - threatening anaphylaxis early in the course of DrugIncrelex therapy. |
| 0.9931 | We report a 13 year - old male who developed life - threatening Adverse-Effectanaphylaxis early in the course of Increlex therapy. |
| Score | Text |
|---|---|
| 0.9994 | PURPOSE : To report patients who presented to the oculoplastics department for repair of cicatrical entropion after topical use of Drugdipivefrin . |
| 0.9902 | PURPOSE : To report patients who presented to the oculoplastics department for repair of Adverse-Effectcicatrical entropion after topical use of dipivefrin. |
| Score | Text |
|---|---|
| 0.9984 | CONCLUSION : Long - term treatment with Drugrifabutin may have a reversible and previously undescribed side - effect on retinal function. |
| CONCLUSION : Long - term treatment with rifabutin may have a reversible and previously undescribed Adverse-Effectside - effect on retinal function . | |
| Score | Text |
|---|---|
| 0.9992 | OBJECTIVE : DrugClozapine causes few extrapyramidal symptoms and is recommended as a treatment drug for severe tardive dyskinesia ( TD ). |
| 0.9886 | OBJECTIVE : Clozapine causes few Adverse-Effectextrapyramidal symptoms and is recommended as a treatment drug for severe tardive dyskinesia ( TD ). |
| Score | Text |
|---|---|
| 0.9995 | We report the case of a 27 - year - old Indian woman who developed maculopapular rash and angioedema secondary to Drugcarbamazepine administration. |
| 0.9970 | We report the case of a 27 - year - old Indian woman who developed maculopapular rash and Adverse-Effectangioedema secondary to carbamazepine administration. |
| 0.9929 | We report the case of a 27 - year - old Indian woman who developed Adverse-Effectmaculopapular rash and angioedema secondary to carbamazepine administration. |
| Score | Text |
|---|---|
| 0.9987 | The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and Drugaripiprazole . |
| 0.9980 | The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as Drugmianserin and aripiprazole. |
| 0.9847 | The present study describes a patient who had Adverse-Effectunusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole. |
| Score | Text |
|---|---|
| 0.9988 | We report a patient who developed Drugheparin associated thrombocytopenia during continuous arteriovenous haemofiltration and discuss its implications and alternative anticoagulant treatment. |
| 0.9972 | We report a patient who developed heparin associated Adverse-Effectthrombocytopenia during continuous arteriovenous haemofiltration and discuss its implications and alternative anticoagulant treatment. |
| Score | Text |
|---|---|
| 0.9994 | The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to Drugcimetidine is discussed. |
| 0.9853 | The case of an adult who developed both Adverse-Effecthepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed. |
| 0.9725 | The case of an adult who developed both hepatic dysfunction and an Adverse-Effectimpaired macrophage migration after exposure to cimetidine is discussed. |
| Score | Text |
|---|---|
| 0.9992 | DrugIbuprofen rarely causes lower gastrointestinal adverse reactions but has been implicated in systemic and local side effects in patients with lupus. |
| 0.7419 | Ibuprofen rarely causes lower Adverse-Effectgastrointestinal adverse reactions but has been implicated in systemic and local side effects in patients with lupus. |
| 0.8398 | Ibuprofen rarely causes Adverse-Effectlower gastrointestinal adverse reactions but has been implicated in systemic and local side effects in patients with lupus. |
| Score | Text |
|---|---|
| 0.9996 | Presently, treatment of acute Drugibuprofen intoxication with complications requires supportive therapy until the symptoms resolve over 24 to 48 hours. |
| 0.8918 | Presently, treatment of acute Adverse-Effectibuprofen intoxication with complications requires supportive therapy until the symptoms resolve over 24 to 48 hours. |
| Score | Text |
|---|---|
| 0.9994 | The international literature regarding opportunistic infections after immunosuppressive therapy with Drugalemtuzumab with particular attention on fungal infections has also been reviewed. |
| 0.9907 | The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on Adverse-Effectfungal infections has also been reviewed. |
| 0.8817 | The international literature regarding Adverse-Effectopportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed. |
| Score | Text |
|---|---|
| 0.9995 | Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of Drugcolchicine resulted in resolution of clinical and biochemical features of rhabdomylysis. |
| 0.9946 | Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of Adverse-Effectrhabdomylysis . |
| Score | Text |
|---|---|
| 0.9994 | We describe a 15 - year - old female patient diagnosed with acute lymphoblastic leukemia presenting with status epilepticus after receiving intrathecal Drugmethotrexate . |
| 0.9477 | We describe a 15 - year - old female patient diagnosed with Adverse-Effectacute lymphoblastic leukemia presenting with status epilepticus after receiving intrathecal methotrexate. |
| Score | Text |
|---|---|
| 0.9994 | The mechanism by which Drugsunitinib induces gynaecomastia is thought to be associated with an unknown direct action on breast hormonal receptors. |
| 0.9975 | The mechanism by which sunitinib induces Adverse-Effectgynaecomastia is thought to be associated with an unknown direct action on breast hormonal receptors. |
| Score | Text |
|---|---|
| 0.9996 | In the following case report, a patient developed acute interstitial nephritis with renal failure and exfoliative dermatitis following Drugampicillin therapy. |
| 0.9899 | In the following case report, a patient developed acute interstitial nephritis with renal failure and Adverse-Effectexfoliative dermatitis following ampicillin therapy. |
| 0.9890 | In the following case report, a patient developed acute interstitial nephritis with Adverse-Effectrenal failure and exfoliative dermatitis following ampicillin therapy. |
| 0.9862 | In the following case report, a patient developed Adverse-Effectacute interstitial nephritis with renal failure and exfoliative dermatitis following ampicillin therapy. |
| Score | Text |
|---|---|
| 0.9990 | We describe two dark - skinned patients who developed hyperpigmented skin and tongue lesions during combination therapy with IFN and Drugribavirin . |
| 0.9986 | We describe two dark - skinned patients who developed hyperpigmented skin and tongue lesions during combination therapy with DrugIFN and ribavirin. |
| 0.9903 | We describe two dark - skinned patients who developed Adverse-Effecthyperpigmented skin and tongue lesions during combination therapy with IFN and ribavirin. |
| 0.9893 | We describe two dark - skinned patients who developed hyperpigmented skin and Adverse-Effecttongue lesions during combination therapy with IFN and ribavirin. |
| Score | Text |
|---|---|
| 0.9996 | OBJECTIVE : To report a case of Drugcolchicine - induced myopathy in a teenager with familial Mediterranean fever ( FMF ). |
| 0.9985 | OBJECTIVE : To report a case of colchicine - induced Adverse-Effectmyopathy in a teenager with familial Mediterranean fever ( FMF ). |
| Score | Text |
|---|---|
| 0.9993 | A case of basilar invagination which is thought to have arisen from the patient's intrauterine exposure to Drugphenytoin is presented. |
| 0.9908 | A case of Adverse-Effectbasilar invagination which is thought to have arisen from the patient's intrauterine exposure to phenytoin is presented. |
| Score | Text |
|---|---|
| 0.9824 | Interferon - alpha - induced Adverse-Effectfocal segmental glomerulosclerosis in chronic myelogenous leukemia : a case report and review of the literature. |
| 0.9665 | DrugInterferon - alpha - induced focal segmental glomerulosclerosis in chronic myelogenous leukemia : a case report and review of the literature. |
| Score | Text |
|---|---|
| 0.9992 | We describe rupture of a cerebral arterial aneurysm in a 32 year old hypertensive woman following the introduction of Drugnifedipine treatment. |
| 0.9785 | We describe Adverse-Effectrupture of a cerebral arterial aneurysm in a 32 year old hypertensive woman following the introduction of nifedipine treatment. |
| Score | Text |
|---|---|
| 0.9988 | Presentation of three palliative care patients who were given Drugketamine as an analgesic and subsequently developed significant and debilitating urological symptoms. |
| 0.9918 | Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating Adverse-Effecturological symptoms . |
| Score | Text |
|---|---|
| 0.9994 | A patient with the Wolff - Parkinson - White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of Drugprocainamide therapy. |
| 0.9612 | A patient with the Wolff - Parkinson - White syndrome presented with Adverse-Effectincessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy. |
| Score | Text |
|---|---|
| 0.9995 | OBJECTIVE : To report a case of linear immunoglobulin ( Ig ) A bullous dermatosis ( LABD ) induced by Druggemcitabine . |
| 0.9879 | OBJECTIVE : To report a case of linear immunoglobulin ( Ig ) A bullous dermatosis ( Adverse-EffectLABD ) induced by gemcitabine. |
| 0.9448 | OBJECTIVE : To report a case of Adverse-Effectlinear immunoglobulin ( Ig ) A bullous dermatosis ( LABD ) induced by gemcitabine. |
| Score | Text |
|---|---|
| 0.9991 | The Naranjo probability scale indicated a probable relationship between apnea and exposure to Druglamotrigine through breast - feeding in this infant. |
| 0.9973 | The Naranjo probability scale indicated a probable relationship between Adverse-Effectapnea and exposure to lamotrigine through breast - feeding in this infant. |
| Score | Text |
|---|---|
| 0.9995 | In patients with Drugmethotrexate - induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression. |
| 0.9983 | In patients with methotrexate - induced Adverse-Effectanaphylaxis , discontinuation of treatment may increase the risk of death due to cancer progression. |
| 0.6594 | In patients with methotrexate - induced anaphylaxis, discontinuation of treatment may increase the risk of Adverse-Effectdeath due to cancer progression. |
| Score | Text |
|---|---|
| 0.9956 | On the fifth day of tocolysis with magnesium sulfate, Drugnifedipine , terbutaline and betamethasone, edema developed in both labia. |
| 0.9941 | On the fifth day of tocolysis with magnesium sulfate, nifedipine, terbutaline and betamethasone, Adverse-Effectedema developed in both labia. |
| 0.9937 | On the fifth day of tocolysis with magnesium sulfate, nifedipine, Drugterbutaline and betamethasone, edema developed in both labia. |
| 0.9920 | On the fifth day of tocolysis with magnesium sulfate, nifedipine, terbutaline and Drugbetamethasone , edema developed in both labia. |
| 0.9865 | On the fifth day of tocolysis with Drugmagnesium sulfate , nifedipine, terbutaline and betamethasone, edema developed in both labia. |
| Score | Text |
|---|---|
| 0.9985 | We report a case of Adverse-Effectseizure associated with L - asparaginase therapy but no evidence of hemorrhagic or thrombotic cerebrovascular events. |
| 0.9732 | We report a case of seizure associated with DrugL - asparaginase therapy but no evidence of hemorrhagic or thrombotic cerebrovascular events. |
| Score | Text |
|---|---|
| 0.9992 | A 28 year old white schizophrenic male has been under Drugrisperidone monotherapy for about one year when he developed dyskinetic movements. |
| 0.9925 | A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed Adverse-Effectdyskinetic movements . |
| Score | Text |
|---|---|
| 0.9889 | The second patient, who developed cholestasis after receiving trimethoprim - sulfamethoxazole, had marked Adverse-Effectduct paucity in the liver biopsy. |
| 0.9859 | The second patient, who developed Adverse-Effectcholestasis after receiving trimethoprim - sulfamethoxazole, had marked duct paucity in the liver biopsy. |
| The second patient, who developed cholestasis after receiving Drugtrimethoprim - sulfamethoxazole , had marked duct paucity in the liver biopsy. | |
| Score | Text |
|---|---|
| 0.9995 | DrugTiclopidine - induced aplastic anemia : two new case reports, review, and meta - analysis of 55 additional cases. |
| 0.9931 | Ticlopidine - induced Adverse-Effectaplastic anemia : two new case reports, review, and meta - analysis of 55 additional cases. |
| Score | Text |
|---|---|
| 0.9982 | Fulminant hepatic failure developed in a 24 - year - old black woman who had been treated with Drugpropylthiouracil and propranolol for hyperthyroidism. |
| 0.9975 | Fulminant hepatic failure developed in a 24 - year - old black woman who had been treated with propylthiouracil and Drugpropranolol for hyperthyroidism. |
| 0.9872 | Adverse-EffectFulminant hepatic failure developed in a 24 - year - old black woman who had been treated with propylthiouracil and propranolol for hyperthyroidism. |
| Score | Text |
|---|---|
| 0.9994 | Children receiving Drugzonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature. |
| 0.9952 | Children receiving zonisamide should be monitored for Adverse-Effectoligohidrosis and the development of neurological symptoms associated with an elevation of body temperature. |
| 0.9865 | Children receiving zonisamide should be monitored for oligohidrosis and the development of Adverse-Effectneurological symptoms associated with an elevation of body temperature. |
| Score | Text |
|---|---|
| 0.9995 | A 72 - year - old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting Drugcarbimazole . |
| 0.9913 | A 72 - year - old woman with a history of thyrotoxicosis presented with Adverse-Effectsore throat and fever two weeks after starting carbimazole. |
| 0.9885 | A 72 - year - old woman with a history of thyrotoxicosis presented with sore throat and Adverse-Effectfever two weeks after starting carbimazole. |
| Score | Text |
|---|---|
| 0.9989 | Soon after introduction of Druginsulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion. |
| 0.9969 | Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, Adverse-Effectascites and pleural effusion. |
| 0.9909 | Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and Adverse-Effectpleural effusion . |
| 0.9892 | Soon after introduction of insulin therapy, she developed severe anasarca, including marked Adverse-Effectperipheral oedema , ascites and pleural effusion. |
| 0.9831 | Soon after introduction of insulin therapy, she developed Adverse-Effectsevere anasarca , including marked peripheral oedema, ascites and pleural effusion. |
| Score | Text |
|---|---|
| 0.9992 | DrugNiacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0. 67 % of patients taking high doses of the drug. |
| 0.9728 | Niacin causes a Adverse-Effectreversible toxic cystoid maculopathy that occurs in approximately 0. 67 % of patients taking high doses of the drug. |
| Score | Text |
|---|---|
| 0.9987 | After the addition of Drugcitalopram , a desmethylclomipramine plasma level increase and an 8 - hydroacy - desmethylclomipramine plasma level decrease were observed. |
| 0.9852 | After the addition of citalopram, a Adverse-Effectdesmethylclomipramine plasma level increase and an 8 - hydroacy - desmethylclomipramine plasma level decrease were observed. |
| 0.9752 | After the addition of citalopram, a desmethylclomipramine plasma level increase and an Adverse-Effect8 - hydroacy - desmethylclomipramine plasma level decrease were observed. |
| Score | Text |
|---|---|
| 0.9995 | An 8 - year - old child with familial Mediterranean fever exhibited signs of Drugcolchicine intoxication while receiving prophylactic doses of the drug. |
| 0.9266 | An 8 - year - old child with familial Mediterranean fever exhibited signs of Adverse-Effectcolchicine intoxication while receiving prophylactic doses of the drug. |
| Score | Text |
|---|---|
| 0.9971 | Two patients treated with 5 - fluorouracil ( 5 - FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of Drug5 - FU neurotoxicity. |
| 0.9969 | Two patients treated with Drug5 - fluorouracil ( 5 - FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5 - FU neurotoxicity. |
| 0.9965 | Two patients treated with 5 - fluorouracil ( Drug5 - FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5 - FU neurotoxicity. |
| 0.9891 | Two patients treated with 5 - fluorouracil ( 5 - FU ) for disseminated adenocarcinoma of the colon developed Adverse-Effectcerebellar dysfunction typical of 5 - FU neurotoxicity. |
| 0.9544 | Two patients treated with 5 - fluorouracil ( 5 - FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5 - FU Adverse-Effectneurotoxicity . |
| Score | Text |
|---|---|
| 0.9985 | We describe the first documented case of Drugazathioprine - induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease. |
| 0.5549 | We describe the first documented case of azathioprine - induced severe Adverse-Effectmyelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease. |
| 0.9742 | We describe the first documented case of azathioprine - induced Adverse-Effectsevere myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease. |
| Score | Text |
|---|---|
| 0.9995 | We recommend that clinicians monitor patients for signs and symptoms of pancreatitis, including abdominal pain, during treatment with Drugtigecycline . |
| 0.9958 | We recommend that clinicians monitor patients for signs and symptoms of pancreatitis, including Adverse-Effectabdominal pain , during treatment with tigecycline. |
| 0.9953 | We recommend that clinicians monitor patients for signs and symptoms of Adverse-Effectpancreatitis , including abdominal pain, during treatment with tigecycline. |
| Score | Text |
|---|---|
| 0.9995 | DrugBortezomib - induced paralytic ileus is a potential gastrointestinal side effect of this first - in - class anticancer proteasome inhibitor. |
| 0.9910 | Bortezomib - induced Adverse-Effectparalytic ileus is a potential gastrointestinal side effect of this first - in - class anticancer proteasome inhibitor. |
| 0.9697 | Bortezomib - induced paralytic ileus is a potential Adverse-Effectgastrointestinal side effect of this first - in - class anticancer proteasome inhibitor. |
| Score | Text |
|---|---|
| 0.9974 | The male patient was treated with 225 - mg / day Drugclozapine and the time to the diagnosis of agranulocytosis was 6 weeks. |
| 0.9962 | The male patient was treated with 225 - mg / day clozapine and the time to the diagnosis of Adverse-Effectagranulocytosis was 6 weeks. |
| Score | Text |
|---|---|
| 0.9994 | BACKGROUND : How to best treat psychotic patients who have had past Drugclozapine - induced agranulocytosis or granulocytopenia remains a problem. |
| 0.9975 | BACKGROUND : How to best treat psychotic patients who have had past clozapine - induced agranulocytosis or Adverse-Effectgranulocytopenia remains a problem. |
| 0.9974 | BACKGROUND : How to best treat psychotic patients who have had past clozapine - induced Adverse-Effectagranulocytosis or granulocytopenia remains a problem. |
| Score | Text |
|---|---|
| 0.9995 | We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with Drugcarbamazepine use. |
| 0.9980 | We have cared for three children in whom four episodes of dystonia proceeding to Adverse-Effectopisthotonus occurred in association with carbamazepine use. |
| 0.9952 | We have cared for three children in whom four episodes of Adverse-Effectdystonia proceeding to opisthotonus occurred in association with carbamazepine use. |
| Score | Text |
|---|---|
| 0.9995 | Ten hours after the second Drugmethotrexate injection, the patient experienced a diffuse pruritic papular eruption located mainly on the limbs. |
| 0.9866 | Ten hours after the second methotrexate injection, the patient experienced a Adverse-Effectdiffuse pruritic papular eruption located mainly on the limbs. |
| Score | Text |
|---|---|
| 0.9993 | Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with Drugalemtuzumab : case report and review of the literature. |
| 0.9841 | Adverse-EffectCryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab : case report and review of the literature. |
| Score | Text |
|---|---|
| 0.9993 | CONCLUSIONS : The pathogenesis of Drugmethotrexate - induced papular eruption in collagen vascular diseases may suggest cutaneous small - vessel vasculitis. |
| 0.9843 | CONCLUSIONS : The pathogenesis of methotrexate - induced Adverse-Effectpapular eruption in collagen vascular diseases may suggest cutaneous small - vessel vasculitis. |
| 0.6170 | CONCLUSIONS : The pathogenesis of methotrexate - induced papular eruption in collagen vascular diseases may suggest Adverse-Effectcutaneous small - vessel vasculitis . |
| Score | Text |
|---|---|
| 0.9866 | The patient developed Adverse-Effectoccipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid. |
| The patient developed occipital infarcts and was found to have extremely elevated levels of DrugPPA in his blood and dialysis fluid. | |
| The patient developed occipital infarcts and was found to have Adverse-Effectextremely elevated levels of PPA in his blood and dialysis fluid. | |
| Score | Text |
|---|---|
| 0.9988 | Two cases of childhood - onset schizophrenia associated with Drugclozapine - induced akathisia responsive to beta - blocker treatment are described. |
| 0.9978 | Two cases of childhood - onset schizophrenia associated with clozapine - induced Adverse-Effectakathisia responsive to beta - blocker treatment are described. |
| Score | Text |
|---|---|
| 0.9988 | Adverse-EffectPolymyositis is a rare complication of interferon alpha treatment as a result of immune - modulating role of the drug itself. |
| 0.9840 | Polymyositis is a rare complication of Druginterferon alpha treatment as a result of immune - modulating role of the drug itself. |
| Score | Text |
|---|---|
| 0.9991 | On the next day, after a total dose of only 600 mg of Drugdanazol , gingival bleeding and purpura occurred. |
| 0.9987 | On the next day, after a total dose of only 600 mg of danazol, gingival bleeding and Adverse-Effectpurpura occurred. |
| 0.9922 | On the next day, after a total dose of only 600 mg of danazol, Adverse-Effectgingival bleeding and purpura occurred. |
| Score | Text |
|---|---|
| 0.9994 | We describe two patients with aspergillus arthritis of the knee joint following Drugfludarabine - based non - myeloablative stem cell transplantation. |
| 0.9737 | We describe two patients with Adverse-Effectaspergillus arthritis of the knee joint following fludarabine - based non - myeloablative stem cell transplantation. |
| Score | Text |
|---|---|
| 0.9988 | Concurrent acute megaloblastic anaemia and pneumonitis : a severe side - effect of low - dose Drugmethotrexate therapy during rheumatoid arthritis. |
| 0.9967 | Concurrent acute megaloblastic anaemia and Adverse-Effectpneumonitis : a severe side - effect of low - dose methotrexate therapy during rheumatoid arthritis. |
| 0.7416 | Concurrent Adverse-Effectacute megaloblastic anaemia and pneumonitis : a severe side - effect of low - dose methotrexate therapy during rheumatoid arthritis. |
| Adverse-EffectConcurrent acute megaloblastic anaemia and pneumonitis : a severe side - effect of low - dose methotrexate therapy during rheumatoid arthritis. | |
| Score | Text |
|---|---|
| 0.9958 | We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and Drugcarbamazepine . |
| 0.9930 | We present findings from three patients who experienced a Adverse-Effectpsoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine. |
| 0.9553 | We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents Drugsodium valproate and carbamazepine. |
| Score | Text |
|---|---|
| 0.9742 | A case of a 21 - year - old woman who had developed mild hepatotoxicity while receiving Drugcholine magnesium trisalicylate therapy is described. |
| 0.6535 | A case of a 21 - year - old woman who had developed mild Adverse-Effecthepatotoxicity while receiving choline magnesium trisalicylate therapy is described. |
| 0.8785 | A case of a 21 - year - old woman who had developed Adverse-Effectmild hepatotoxicity while receiving choline magnesium trisalicylate therapy is described. |
| Score | Text |
|---|---|
| 0.9982 | PURPOSE : DrugTopiramate - induced angle - closure glaucoma ( TiACG ) is believed to be related to its sulfonamide moiety. |
| 0.9859 | PURPOSE : Topiramate - induced Adverse-Effectangle - closure glaucoma ( TiACG ) is believed to be related to its sulfonamide moiety. |
| Score | Text |
|---|---|
| 0.9993 | CONCLUSIONS : We report this case of the concomitant appearance of multiple skin cancers and nail changes associated with Drughydroxyurea use. |
| 0.9894 | CONCLUSIONS : We report this case of the concomitant appearance of multiple skin cancers and Adverse-Effectnail changes associated with hydroxyurea use. |
| 0.9834 | CONCLUSIONS : We report this case of the concomitant appearance of Adverse-Effectmultiple skin cancers and nail changes associated with hydroxyurea use. |
| Score | Text |
|---|---|
| 0.9993 | The authors report on two patients with corneal ulcers refractory to conventional treatment while the patients were undergoing oral Drugcolchicine therapy. |
| 0.7547 | The authors report on two patients with Adverse-Effectcorneal ulcers refractory to conventional treatment while the patients were undergoing oral colchicine therapy. |
| 0.7430 | The authors report on two patients with Adverse-Effectcorneal ulcers refractory to conventional treatment while the patients were undergoing oral colchicine therapy. |
| 0.5529 | The authors report on two patients with Adverse-Effectcorneal ulcers refractory to conventional treatment while the patients were undergoing oral colchicine therapy. |
| 0.5324 | The authors report on two patients with Adverse-Effectcorneal ulcers refractory to conventional treatment while the patients were undergoing oral colchicine therapy. |
| Score | Text |
|---|---|
| 0.9899 | OBJECTIVE : To report a case of fatal hyperkalemia owing to Drugsuccinylcholine administration in a patient with mucositis secondary to chemotherapy. |
| 0.9871 | OBJECTIVE : To report a case of Adverse-Effectfatal hyperkalemia owing to succinylcholine administration in a patient with mucositis secondary to chemotherapy. |
| Score | Text |
|---|---|
| 0.9993 | A 52 - year - old Black woman on Drugphenytoin therapy for post - traumatic epilepsy developed transient hemiparesis contralateral to the injury. |
| 0.9699 | A 52 - year - old Black woman on phenytoin therapy for post - traumatic epilepsy developed Adverse-Effecttransient hemiparesis contralateral to the injury. |
| Score | Text |
|---|---|
| 0.9917 | The pharmacology and toxicology of chloral hydrate are discussed with particular reference to the Adverse-Effectcardiac arrhythmias that are seen with overdosage. |
| 0.9804 | The pharmacology and toxicology of Drugchloral hydrate are discussed with particular reference to the cardiac arrhythmias that are seen with overdosage. |
| Score | Text |
|---|---|
| 0.9995 | To our knowledge, this is the first case of Druggriseofulvin - exacerbated lupus in which nephrotic syndrome has been observed. |
| 0.9845 | To our knowledge, this is the first case of griseofulvin - exacerbated Adverse-Effectlupus in which nephrotic syndrome has been observed. |
| 0.9630 | To our knowledge, this is the first case of griseofulvin - exacerbated lupus in which Adverse-Effectnephrotic syndrome has been observed. |
| Score | Text |
|---|---|
| 0.9987 | We report in detail an unusual adverse reaction to Druginfliximab therapy, a drug - induced lupus - like clinical syndrome. |
| 0.9810 | We report in detail an unusual adverse reaction to infliximab therapy, a drug - induced Adverse-Effectlupus - like clinical syndrome . |
| Score | Text |
|---|---|
| 0.9856 | When the disease recurred conventional Drugamphotericin B was used again, but had to be stopped because of severe side effects. |
| 0.8919 | When the disease recurred conventional amphotericin B was used again, but had to be stopped because of Adverse-Effectsevere side effects . |
| Score | Text |
|---|---|
| 0.9870 | We report a case of acute hyperphosphatemia secondary to rectal administration of Drugsodium phosphate and sodium biphosphate ( Fleet enema ). |
| 0.9822 | We report a case of acute hyperphosphatemia secondary to rectal administration of sodium phosphate and Drugsodium biphosphate ( Fleet enema ). |
| 0.5684 | We report a case of acute Adverse-Effecthyperphosphatemia secondary to rectal administration of sodium phosphate and sodium biphosphate ( Fleet enema ). |
| Score | Text |
|---|---|
| 0.9981 | A case of phenytoin - induced Adverse-Effecthepatitis with mononucleosis is reported, and syndromes associated with phenytoin hypersensitivity reactions are discussed. |
| 0.9654 | A case of Drugphenytoin - induced hepatitis with mononucleosis is reported, and syndromes associated with phenytoin hypersensitivity reactions are discussed. |
| 0.9328 | A case of phenytoin - induced hepatitis with Adverse-Effectmononucleosis is reported, and syndromes associated with phenytoin hypersensitivity reactions are discussed. |
| 0.8485 | A case of phenytoin - induced hepatitis with mononucleosis is reported, and syndromes associated with Drugphenytoin hypersensitivity reactions are discussed. |
| 0.6192 | A case of phenytoin - induced hepatitis with mononucleosis is reported, and syndromes associated with Adverse-Effectphenytoin hypersensitivity reactions are discussed. |
| A case of phenytoin - induced hepatitis with mononucleosis is reported, and syndromes associated with phenytoin Adverse-Effecthypersensitivity reactions are discussed. | |
| Score | Text |
|---|---|
| 0.9992 | CONCLUSIONS : DrugClarithromycin may be a cause of fulminant liver failure either alone or by inhibiting the metabolism of other drugs. |
| 0.9881 | CONCLUSIONS : Clarithromycin may be a cause of Adverse-Effectfulminant liver failure either alone or by inhibiting the metabolism of other drugs. |
| Score | Text |
|---|---|
| 0.9991 | We describe a patient who developed NEH on three separate occasions provoked by two different chemotherapeutic agents - - cytarabine and Drugmitoxantrone . |
| 0.9991 | We describe a patient who developed NEH on three separate occasions provoked by two different chemotherapeutic agents - - Drugcytarabine and mitoxantrone. |
| 0.9953 | We describe a patient who developed Adverse-EffectNEH on three separate occasions provoked by two different chemotherapeutic agents - - cytarabine and mitoxantrone. |
| Score | Text |
|---|---|
| 0.9991 | OBJECTIVES : A delayed stroke - like leukoencephalopathy has been observed in patients receiving Drugmethotrexate ( MTX ) for childhood leukemia. |
| 0.9987 | OBJECTIVES : A delayed stroke - like leukoencephalopathy has been observed in patients receiving methotrexate ( DrugMTX ) for childhood leukemia. |
| 0.9707 | OBJECTIVES : A delayed Adverse-Effectstroke - like leukoencephalopathy has been observed in patients receiving methotrexate ( MTX ) for childhood leukemia. |
| Score | Text |
|---|---|
| 0.9984 | A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic Drugaspirin therapy is presented. |
| 0.9796 | A case of Adverse-Effectacute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented. |
| Score | Text |
|---|---|
| 0.9991 | We describe a 41 yr old leprosy patient treated for 10 yrs with Drugclofazimine who underwent laparotomy for severe abdominal pain. |
| 0.9450 | We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe Adverse-Effectabdominal pain . |
| 0.5764 | We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent Adverse-Effectlaparotomy for severe abdominal pain. |
| Score | Text |
|---|---|
| 0.9949 | Brugada type electrocardiographic changes induced by concomitant use of lithium and Drugpropafenone in patient with Wolff - Parkinson - White syndrome. |
| 0.9902 | Brugada type electrocardiographic changes induced by concomitant use of Druglithium and propafenone in patient with Wolff - Parkinson - White syndrome. |
| 0.9773 | Adverse-EffectBrugada type electrocardiographic changes induced by concomitant use of lithium and propafenone in patient with Wolff - Parkinson - White syndrome. |
| Score | Text |
|---|---|
| 0.9986 | We evaluated a patient who developed a psychotic disorder after 4 months of Drugisoniazid prophylaxis for a positive tuberculosis tine test. |
| 0.9909 | We evaluated a patient who developed a Adverse-Effectpsychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test. |
| Score | Text |
|---|---|
| 0.9974 | To our knowledge, these cases are the first published reports of lovastatin - induced Adverse-Effectrhabdomyolysis associated with azithromycin and clarithromycin. |
| 0.9971 | To our knowledge, these cases are the first published reports of lovastatin - induced rhabdomyolysis associated with azithromycin and Drugclarithromycin . |
| 0.9969 | To our knowledge, these cases are the first published reports of Druglovastatin - induced rhabdomyolysis associated with azithromycin and clarithromycin. |
| 0.9963 | To our knowledge, these cases are the first published reports of lovastatin - induced rhabdomyolysis associated with Drugazithromycin and clarithromycin. |
| Score | Text |
|---|---|
| 0.9991 | A 60 year - old woman with chronic renal failure developed acute proximal muscle weakness after receiving a regular dosage of Drugcolchicine . |
| 0.9841 | A 60 year - old woman with chronic renal failure developed Adverse-Effectacute proximal muscle weakness after receiving a regular dosage of colchicine. |
| A 60 year - old woman with chronic renal failure developed acute Adverse-Effectproximal muscle weakness after receiving a regular dosage of colchicine. | |
| Score | Text |
|---|---|
| 0.9995 | OBJECTIVE : To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral Drugofloxacin for epididymitis. |
| 0.9582 | OBJECTIVE : To report a fatal case of Adverse-Effecttoxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis. |
| Score | Text |
|---|---|
| 0.9944 | Dural sinus thrombosis developed in two children with acute lymphoblastic leukemia during induction treatment with vincristine sulfate, Drugprednisone , and asparaginase. |
| 0.9930 | Dural sinus thrombosis developed in two children with acute lymphoblastic leukemia during induction treatment with vincristine sulfate, prednisone, and Drugasparaginase . |
| 0.9842 | Adverse-EffectDural sinus thrombosis developed in two children with acute lymphoblastic leukemia during induction treatment with vincristine sulfate, prednisone, and asparaginase. |
| 0.9822 | Dural sinus thrombosis developed in two children with acute lymphoblastic leukemia during induction treatment with Drugvincristine sulfate , prednisone, and asparaginase. |
| Score | Text |
|---|---|
| 0.9991 | We present the first case ( to our knowledge ) of a potentially serious drug - drug interaction between zafirlukast and Drugtheophylline . |
| 0.9991 | We present the first case ( to our knowledge ) of a potentially serious drug - drug interaction between Drugzafirlukast and theophylline. |
| 0.9657 | We present the first case ( to our knowledge ) of a potentially serious Adverse-Effectdrug - drug interaction between zafirlukast and theophylline. |
| Score | Text |
|---|---|
| 0.9994 | The fetal Drugvalproate syndrome ( FVS ) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay. |
| 0.9962 | The fetal valproate syndrome ( Adverse-EffectFVS ) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay. |
| 0.9878 | The fetal valproate syndrome ( FVS ) is characterized by distinctive facial appearance, major and minor malformations, and Adverse-Effectdevelopmental delay . |
| 0.9812 | The fetal valproate syndrome ( FVS ) is characterized by Adverse-Effectdistinctive facial appearance , major and minor malformations, and developmental delay. |
| 0.9673 | The fetal valproate syndrome ( FVS ) is characterized by distinctive facial appearance, Adverse-Effectmajor and minor malformations , and developmental delay. |
| 0.6023 | The Adverse-Effectfetal valproate syndrome ( FVS ) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay. |
| Score | Text |
|---|---|
| 0.9986 | This patient rapidly progressed from mild neurotoxicity to fatal encephalopathy after one dose of intrathecal Drugmethotrexate during his third cycle of chemotherapy. |
| 0.9876 | This patient rapidly progressed from mild neurotoxicity to Adverse-Effectfatal encephalopathy after one dose of intrathecal methotrexate during his third cycle of chemotherapy. |
| 0.9801 | This patient rapidly progressed from Adverse-Effectmild neurotoxicity to fatal encephalopathy after one dose of intrathecal methotrexate during his third cycle of chemotherapy. |
| Score | Text |
|---|---|
| 0.9990 | She died within six weeks of developing congestive heart failure coupled with liver failure due to haemosiderosis despite regular use of Drugdesferrioxamine . |
| 0.9942 | She died within six weeks of developing congestive heart failure coupled with Adverse-Effectliver failure due to haemosiderosis despite regular use of desferrioxamine. |
| 0.9914 | She died within six weeks of developing congestive heart failure coupled with liver failure due to Adverse-Effecthaemosiderosis despite regular use of desferrioxamine. |
| 0.9873 | She died within six weeks of developing Adverse-Effectcongestive heart failure coupled with liver failure due to haemosiderosis despite regular use of desferrioxamine. |
| Score | Text |
|---|---|
| 0.9891 | A second patient with a similar glucose tolerance test result showed Adverse-Effectpostprandial hyperglycemia when treated similarly with betamethasone valerate cream 0. 1 %. |
| 0.9682 | A second patient with a similar glucose tolerance test result showed postprandial hyperglycemia when treated similarly with Drugbetamethasone valerate cream 0. 1 %. |
| Score | Text |
|---|---|
| 0.9996 | We describe the clinical and liver biopsy morphologic features for 4 patients with Drugminocycline - induced autoimmune hepatitis ( group 1 ). |
| 0.9918 | We describe the clinical and liver biopsy morphologic features for 4 patients with minocycline - induced Adverse-Effectautoimmune hepatitis ( group 1 ). |
| Score | Text |
|---|---|
| 0.9995 | Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by Drugdesmopressin . |
| 0.9672 | Without other causes for the Adverse-Effecthyponatremia , she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin. |
| 0.9544 | Without other causes for the hyponatremia, she was diagnosed with the Adverse-Effectsyndrome of inappropriate antidiuretic hormone , presumably caused by desmopressin. |
| Score | Text |
|---|---|
| 0.9783 | In contrast to chronic or subacute thyroiditis, Graves'disease rarely complicates DrugIFN - alpha therapy for chronic viral C hepatitis. |
| 0.7993 | In contrast to chronic or subacute thyroiditis, Adverse-EffectGraves'disease rarely complicates IFN - alpha therapy for chronic viral C hepatitis. |
| 0.6416 | In contrast to chronic or Adverse-Effectsubacute thyroiditis , Graves'disease rarely complicates IFN - alpha therapy for chronic viral C hepatitis. |
| Score | Text |
|---|---|
| 0.9975 | We report the case of a female acromegalic patient in whom multiple hepatic adenomas appeared soon after Drugdanazol treatment for uterine fibromatosis. |
| 0.9758 | We report the case of a female acromegalic patient in whom multiple Adverse-Effecthepatic adenomas appeared soon after danazol treatment for uterine fibromatosis. |
| Score | Text |
|---|---|
| 0.9904 | CONCLUSIONS : We have seen an increased incidence of acute DrugINH neurotoxicity because of the resurgence of TB in New York City. |
| 0.9141 | CONCLUSIONS : We have seen an increased incidence of acute INH Adverse-Effectneurotoxicity because of the resurgence of TB in New York City. |
| Score | Text |
|---|---|
| 0.9915 | Adverse-EffectParalytic ileus in patients undergoing bortezomib treatment has been reported, although a definite attribution to bortezomib administration has not been established. |
| 0.9581 | Paralytic ileus in patients undergoing Drugbortezomib treatment has been reported, although a definite attribution to bortezomib administration has not been established. |
| 0.8984 | Paralytic ileus in patients undergoing bortezomib treatment has been reported, although a definite attribution to Drugbortezomib administration has not been established. |
| Score | Text |
|---|---|
| 0.9988 | STUDY DESIGN : Case report of a 31 - year - old woman who presented with toxic myelopathy due to intrathecal administration of Drugdoxorubicin . |
| 0.9901 | STUDY DESIGN : Case report of a 31 - year - old woman who presented with Adverse-Effecttoxic myelopathy due to intrathecal administration of doxorubicin. |
| Score | Text |
|---|---|
| 0.9997 | DrugColchicine - induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed. |
| 0.9981 | Colchicine - induced Adverse-Effectrhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed. |
| Score | Text |
|---|---|
| 0.9984 | Telescoped digits of the hands and feet developed in a 69 - year - old male with severe chronic tophaceous gout during Drugallopurinol treatment. |
| 0.9701 | Adverse-EffectTelescoped digits of the hands and feet developed in a 69 - year - old male with severe chronic tophaceous gout during allopurinol treatment. |
| Score | Text |
|---|---|
| 0.9921 | Although other nitrites induce methemoglobinemia, exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational Adverse-Effectmethemoglobinemia . |
| 0.9822 | Although other nitrites induce methemoglobinemia, exposure to Drugmethyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia. |
| 0.9735 | Although other nitrites induce Adverse-Effectmethemoglobinemia , exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia. |
| Score | Text |
|---|---|
| 0.9814 | FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have Adverse-Effectadrenal suppression . |
| 0.9761 | FINDINGS : Six children with Adverse-Effectgrowth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression. |
| 0.9726 | FINDINGS : Six children with growth retardation noted after treatment with high - dose Drugfluticasone propionate were found to have adrenal suppression. |
| Score | Text |
|---|---|
| 0.9968 | Thus, the possible in vivo effects of insulin on adipocytes were clearly observed in this case of insulin - induced Adverse-Effectlipohypertrophy . |
| 0.7648 | Thus, the possible in vivo effects of insulin on adipocytes were clearly observed in this case of Druginsulin - induced lipohypertrophy. |
| 0.9265 | Thus, the possible in vivo effects of Druginsulin on adipocytes were clearly observed in this case of insulin - induced lipohypertrophy. |
| Score | Text |
|---|---|
| 0.9995 | DrugNaproxen is a commonly used nonsteroidal anti - inflammatory drug ( NSAID ) whose side effects include tinnitus and transient hearing loss. |
| 0.9986 | Naproxen is a commonly used nonsteroidal anti - inflammatory drug ( NSAID ) whose side effects include Adverse-Effecttinnitus and transient hearing loss. |
| 0.9903 | Naproxen is a commonly used nonsteroidal anti - inflammatory drug ( NSAID ) whose side effects include tinnitus and Adverse-Effecttransient hearing loss . |
| Score | Text |
|---|---|
| 0.9993 | We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of Drugrituximab . |
| 0.9916 | We reviewed the records of 3 patients with lymphoproliferative disorders who experienced Adverse-Effectacute coronary syndromes associated with their initial infusion of rituximab. |
| Score | Text |
|---|---|
| 0.9994 | The patient, a 28 - year - old man suffering from panic disorder, developed several first - rank symptoms during Drugfluvoxamine administration. |
| 0.9870 | The patient, a 28 - year - old man suffering from panic disorder, developed several Adverse-Effectfirst - rank symptoms during fluvoxamine administration. |
| Score | Text |
|---|---|
| 0.9968 | Although this G - CSF - driven Adverse-Effectleucocytosis was alarming it did not appear to have adversely affected the patient's prognosis. |
| 0.9711 | Although this DrugG - CSF - driven leucocytosis was alarming it did not appear to have adversely affected the patient's prognosis. |
| Score | Text |
|---|---|
| 0.9985 | We also describe a new, noninvasive method to assess Drugmagnesium - induced neuromuscular block when curariform muscle relaxant was given simultaneously. |
| 0.9932 | We also describe a new, noninvasive method to assess magnesium - induced Adverse-Effectneuromuscular block when curariform muscle relaxant was given simultaneously. |
| Score | Text |
|---|---|
| 0.9986 | Acute non - lymphocytic leukemia occurred in eight women following long - term treatment with DrugTreosulfan ( = dihydroxybusulfan ) for ovarian carcinoma. |
| 0.9975 | Acute non - lymphocytic leukemia occurred in eight women following long - term treatment with Treosulfan ( = Drugdihydroxybusulfan ) for ovarian carcinoma. |
| 0.9658 | Adverse-EffectAcute non - lymphocytic leukemia occurred in eight women following long - term treatment with Treosulfan ( = dihydroxybusulfan ) for ovarian carcinoma. |
| Score | Text |
|---|---|
| 0.9945 | We concluded that the colonic ulcer and the sigmoidovesical fistula had been caused by the administration of calcium polystyrene sulfonate and Drugsorbitol . |
| 0.9931 | We concluded that the Adverse-Effectcolonic ulcer and the sigmoidovesical fistula had been caused by the administration of calcium polystyrene sulfonate and sorbitol. |
| 0.9850 | We concluded that the colonic ulcer and the Adverse-Effectsigmoidovesical fistula had been caused by the administration of calcium polystyrene sulfonate and sorbitol. |
| 0.9503 | We concluded that the colonic ulcer and the sigmoidovesical fistula had been caused by the administration of Drugcalcium polystyrene sulfonate and sorbitol. |
| Score | Text |
|---|---|
| 0.9861 | This case suggests that Drugacyclovir when given intravenously in doses of 10 mg / kg may result in increased serum lithium concentrations. |
| 0.9525 | This case suggests that acyclovir when given intravenously in doses of 10 mg / kg may result in increased serum Druglithium concentrations. |
| This case suggests that acyclovir when given intravenously in doses of 10 mg / kg may result in Adverse-Effectincreased serum lithium concentrations. | |
| Score | Text |
|---|---|
| 0.9995 | Acute delirium resulting from Druglevofloxacin therapy is an exceedingly rare complication that has been thought to occur more commonly in elderly patients. |
| 0.9864 | Adverse-EffectAcute delirium resulting from levofloxacin therapy is an exceedingly rare complication that has been thought to occur more commonly in elderly patients. |
| Score | Text |
|---|---|
| 0.9919 | Sixteen hours after the first administration of IFN, IFN was suspended by the symptoms of congestive heart failure ( Adverse-EffectCHF ). |
| 0.9855 | Sixteen hours after the first administration of IFN, IFN was suspended by the symptoms of Adverse-Effectcongestive heart failure ( CHF ). |
| 0.9269 | Sixteen hours after the first administration of IFN, DrugIFN was suspended by the symptoms of congestive heart failure ( CHF ). |
| Score | Text |
|---|---|
| 0.9991 | The case of a 4 - year - old girl with Drugvalproate - induced stupor and electroencephalographic pattern of increased fast activity is reported. |
| 0.9990 | The case of a 4 - year - old girl with valproate - induced Adverse-Effectstupor and electroencephalographic pattern of increased fast activity is reported. |
| Score | Text |
|---|---|
| 0.9975 | We report a case of biopsy proven Adverse-Effectmyositis whose symptoms began within 10 days of receiving leuprolide acetate therapy for prostate cancer. |
| 0.9808 | We report a case of biopsy proven myositis whose symptoms began within 10 days of receiving Drugleuprolide acetate therapy for prostate cancer. |
| Score | Text |
|---|---|
| 0.9985 | Adverse-EffectOsteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines. |
| 0.9974 | Osteonecrosis is a serious side effect of antiemetic treatment with Drugdexamethasone and this serious complication should be incorporated in the current guidelines. |
| Score | Text |
|---|---|
| 0.9990 | Case report : lack of control of diabetes and weight gain in a patient on initiation and rechallenge of therapy with Drugolanzapine . |
| 0.9963 | Case report : lack of control of diabetes and Adverse-Effectweight gain in a patient on initiation and rechallenge of therapy with olanzapine. |
| 0.9866 | Case report : lack of control of Adverse-Effectdiabetes and weight gain in a patient on initiation and rechallenge of therapy with olanzapine. |
| Score | Text |
|---|---|
| 0.9996 | She developed a generalized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of Drugcapecitabine . |
| 0.9976 | She developed a generalized rash and Adverse-Effectitching , sore throat, and dizziness approximately 4 hours after the first dose of capecitabine. |
| 0.9967 | She developed a generalized rash and itching, sore throat, and Adverse-Effectdizziness approximately 4 hours after the first dose of capecitabine. |
| 0.9935 | She developed a Adverse-Effectgeneralized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of capecitabine. |
| 0.9917 | She developed a generalized rash and itching, Adverse-Effectsore throat , and dizziness approximately 4 hours after the first dose of capecitabine. |
| Score | Text |
|---|---|
| 0.9989 | We described the occurrence of L - dopa - induced Adverse-Effectmyoclonus and seizures in a case of parkinsonism with its SEPs findings. |
| 0.9977 | We described the occurrence of L - dopa - induced myoclonus and Adverse-Effectseizures in a case of parkinsonism with its SEPs findings. |
| 0.9787 | We described the occurrence of DrugL - dopa - induced myoclonus and seizures in a case of parkinsonism with its SEPs findings. |
| Score | Text |
|---|---|
| 0.9905 | A patient developed Adverse-Effectrestless legs symptoms paralleling the course of interferon - alpha ( IFN alpha ) therapy for chronic hepatitis C. |
| 0.9814 | A patient developed restless legs symptoms paralleling the course of interferon - alpha ( DrugIFN alpha ) therapy for chronic hepatitis C. |
| 0.9723 | A patient developed restless legs symptoms paralleling the course of Druginterferon - alpha ( IFN alpha ) therapy for chronic hepatitis C. |
| Score | Text |
|---|---|
| 0.9854 | In the other patient, a 78 - year - old woman, Neisseria mucosa knee arthritis occurred after a single Drugsodium hyaluronate injection. |
| 0.9773 | In the other patient, a 78 - year - old woman, Adverse-EffectNeisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection. |
| Score | Text |
|---|---|
| 0.9996 | Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with Drugfluoxetine treatment of depression and obsessive - compulsive disorder. |
| 0.9814 | Prominent eye movements during NREM sleep and Adverse-EffectREM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive - compulsive disorder. |
| 0.9600 | Adverse-EffectProminent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive - compulsive disorder. |
| Score | Text |
|---|---|
| 0.9988 | In patients with chronic heart failure, Drugspironolactone added to conventional treatment may lead to serious and, occasionally, fatal hyperkalaemia. |
| 0.9525 | In patients with chronic heart failure, spironolactone added to conventional treatment may lead to serious and, occasionally, Adverse-Effectfatal hyperkalaemia . |
| In patients with chronic heart failure, spironolactone added to conventional treatment may lead to Adverse-Effectserious and, occasionally, fatal hyperkalaemia . | |
| Score | Text |
|---|---|
| 0.9990 | We report a case of Adverse-Effectvitiligo that occurred during the second month of interferon alpha 2a therapy for chronic active hepatitis C. |
| 0.9794 | We report a case of vitiligo that occurred during the second month of Druginterferon alpha 2a therapy for chronic active hepatitis C. |
| Score | Text |
|---|---|
| 0.9992 | Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and Drugthiazide . |
| 0.9992 | Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving Drugolanzapine and thiazide. |
| 0.9980 | Second, we report a case of Adverse-Effectneutropenia , which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide. |
| Score | Text |
|---|---|
| 0.9974 | The results of the ultrasound examination combined with clinical anamnesis allowed diagnosis of gastric mucosa foveolar hyperplasia due to prolonged DrugPGE1 therapy. |
| 0.9758 | The results of the ultrasound examination combined with clinical anamnesis allowed diagnosis of Adverse-Effectgastric mucosa foveolar hyperplasia due to prolonged PGE1 therapy. |
| Score | Text |
|---|---|
| 0.9991 | The potential role of Drugpropranolol in inducing central nervous system disturbances is emphasized, and the literature on the subject is reviewed. |
| 0.9833 | The potential role of propranolol in inducing Adverse-Effectcentral nervous system disturbances is emphasized, and the literature on the subject is reviewed. |
| Score | Text |
|---|---|
| 0.9902 | Therefore, we concluded that this patient's pulmonary disease was caused by Drugcalcium stearate , an additive for an antihistaminic drug. |
| 0.9748 | Therefore, we concluded that this patient's Adverse-Effectpulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug. |
| Score | Text |
|---|---|
| 0.9989 | DATA SYNTHESIS : A 49 - year - old man developed symptoms of severe psychosis concomitant with Drugciprofloxacin ( 250 mg bid ) treatment. |
| 0.9727 | DATA SYNTHESIS : A 49 - year - old man developed symptoms of Adverse-Effectsevere psychosis concomitant with ciprofloxacin ( 250 mg bid ) treatment. |
| Score | Text |
|---|---|
| 0.9997 | We present a patient with human immunodeficiency virus infection under treatment with Drugfoscarnet for CMV retinitis who complained of thirst and polyuria. |
| 0.9993 | We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and Adverse-Effectpolyuria . |
| 0.9984 | We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of Adverse-Effectthirst and polyuria. |
| Score | Text |
|---|---|
| 0.9991 | We report a fatal case of acute interstitial pneumonitis in a patient treated with Drugcarmustine ( BCNU ) for a brain tumor. |
| 0.9988 | We report a fatal case of acute interstitial pneumonitis in a patient treated with carmustine ( DrugBCNU ) for a brain tumor. |
| 0.9604 | We report a fatal case of Adverse-Effectacute interstitial pneumonitis in a patient treated with carmustine ( BCNU ) for a brain tumor. |
| 0.5407 | We report a Adverse-Effectfatal case of acute interstitial pneumonitis in a patient treated with carmustine ( BCNU ) for a brain tumor. |
| We report a Adverse-Effectfatal case of acute interstitial pneumonitis in a patient treated with carmustine ( BCNU ) for a brain tumor. | |
| Score | Text |
|---|---|
| 0.9903 | CASE SUMMARY : A 10 - year - old white girl with bilateral optic glioma developed a hypersensitivity reaction to Drugcarboplatin after nine courses. |
| 0.8115 | CASE SUMMARY : A 10 - year - old white girl with bilateral optic glioma developed a Adverse-Effecthypersensitivity reaction to carboplatin after nine courses. |
| 0.9802 | CASE SUMMARY : A 10 - year - old white girl with bilateral optic glioma developed a Adverse-Effecthypersensitivity reaction to carboplatin after nine courses. |
| Score | Text |
|---|---|
| 0.9983 | We report the case of a young healthy woman who presented an early overanticoagulation when receiving Drugacenocoumarol for a first thromboembolic episode. |
| 0.9889 | We report the case of a young healthy woman who presented an early Adverse-Effectoveranticoagulation when receiving acenocoumarol for a first thromboembolic episode. |
| Score | Text |
|---|---|
| 0.9994 | Beginning ductopenia was present in two, suggesting that Drugitraconazole might be responsible for the occurrence of prolonged drug - induced cholangiopathy. |
| 0.9983 | Beginning Adverse-Effectductopenia was present in two, suggesting that itraconazole might be responsible for the occurrence of prolonged drug - induced cholangiopathy. |
| 0.9950 | Beginning ductopenia was present in two, suggesting that itraconazole might be responsible for the occurrence of prolonged drug - induced Adverse-Effectcholangiopathy . |
| Score | Text |
|---|---|
| 0.9995 | Early - onset Drugpentamidine - associated second - degree heart block and sinus bradycardia : case report and review of the literature. |
| 0.9919 | Early - onset pentamidine - associated second - degree heart block and Adverse-Effectsinus bradycardia : case report and review of the literature. |
| 0.9763 | Early - onset pentamidine - associated Adverse-Effectsecond - degree heart block and sinus bradycardia : case report and review of the literature. |
| Score | Text |
|---|---|
| 0.9972 | CONCLUSION : We believe this to be the first reported case of rhGH - induced Adverse-Effecthypercalcemia in an HIV - infected patient. |
| 0.9972 | CONCLUSION : We believe this to be the first reported case of DrugrhGH - induced hypercalcemia in an HIV - infected patient. |
| Score | Text |
|---|---|
| 0.9997 | We reported a case of Drugdisulfiram - induced hepatitis with unique clinical features and compared our case with others in the literature. |
| 0.9989 | We reported a case of disulfiram - induced Adverse-Effecthepatitis with unique clinical features and compared our case with others in the literature. |
| Score | Text |
|---|---|
| 0.9966 | We report a case of severe hypotension associated with intravenous Drugvalproate used to treat status epilepticus in an 11 - year - old girl. |
| 0.5539 | We report a case of severe Adverse-Effecthypotension associated with intravenous valproate used to treat status epilepticus in an 11 - year - old girl. |
| 0.8276 | We report a case of Adverse-Effectsevere hypotension associated with intravenous valproate used to treat status epilepticus in an 11 - year - old girl. |
| Score | Text |
|---|---|
| 0.9988 | AIM : To report three cases of extensive skin necrosis in cirrhotic patients treated with the vasoconstrictor agent Drugterlipressin ( Glypressin ). |
| 0.9988 | AIM : To report three cases of extensive skin necrosis in cirrhotic patients treated with the vasoconstrictor agent terlipressin ( DrugGlypressin ). |
| 0.9904 | AIM : To report three cases of extensive Adverse-Effectskin necrosis in cirrhotic patients treated with the vasoconstrictor agent terlipressin ( Glypressin ). |
| Score | Text |
|---|---|
| 0.9941 | The occurrence of neuromuscular blockade and the resulting potentiation of muscle relaxants during magnesium sulfate ( DrugMgSO4 ) administration is well known. |
| 0.9886 | The occurrence of Adverse-Effectneuromuscular blockade and the resulting potentiation of muscle relaxants during magnesium sulfate ( MgSO4 ) administration is well known. |
| 0.9872 | The occurrence of neuromuscular blockade and the resulting potentiation of muscle relaxants during Drugmagnesium sulfate ( MgSO4 ) administration is well known. |
| 0.9850 | The occurrence of neuromuscular blockade and the resulting Adverse-Effectpotentiation of muscle relaxants during magnesium sulfate ( MgSO4 ) administration is well known. |
| Score | Text |
|---|---|
| 0.9992 | Thirty patients with hepatic reactions to Drugcyclofenil , a non - steroidal drug with a stimulating effect on ovulation, are reviewed. |
| 0.9813 | Thirty patients with Adverse-Effecthepatic reactions to cyclofenil, a non - steroidal drug with a stimulating effect on ovulation, are reviewed. |
| Score | Text |
|---|---|
| 0.9990 | His symptoms of brain stem compression were alleviated and the role of Drugphenytoin in the production of his craniocervical abnormality is discussed. |
| 0.9667 | His symptoms of brain stem compression were alleviated and the role of phenytoin in the production of his Adverse-Effectcraniocervical abnormality is discussed. |
| 0.9254 | His symptoms of Adverse-Effectbrain stem compression were alleviated and the role of phenytoin in the production of his craniocervical abnormality is discussed. |
| Score | Text |
|---|---|
| 0.9989 | The second had acute cystitis and was treated by sulphonamide and the third developed Adverse-Effectmyopia coincident with metronidazole treatment for trichomonas vaginalis. |
| 0.9763 | The second had acute cystitis and was treated by Drugsulphonamide and the third developed myopia coincident with metronidazole treatment for trichomonas vaginalis. |
| 0.8458 | The second had acute cystitis and was treated by sulphonamide and the third developed myopia coincident with Drugmetronidazole treatment for trichomonas vaginalis. |
| Score | Text |
|---|---|
| 0.9995 | The renal biopsy showed focal segmental glomerulosclerosis, which has only been previously reported in two cases of CML treated with DrugIFNalpha . |
| 0.9833 | The renal biopsy showed Adverse-Effectfocal segmental glomerulosclerosis , which has only been previously reported in two cases of CML treated with IFNalpha. |
| Score | Text |
|---|---|
| 0.9991 | The most commonly recognized toxic effect of Drugethambutol is optic neuropathy, which generally is considered uncommon and reversible in medical literature. |
| 0.9805 | The most commonly recognized toxic effect of ethambutol is Adverse-Effectoptic neuropathy , which generally is considered uncommon and reversible in medical literature. |
| Score | Text |
|---|---|
| 0.9980 | Based on the clinical status of the patient, it was suspected that several conditions contributed to the abnormal hypersensitivity to Drugwarfarin . |
| 0.9885 | Based on the clinical status of the patient, it was suspected that several conditions contributed to the Adverse-Effectabnormal hypersensitivity to warfarin. |
| Score | Text |
|---|---|
| 0.9988 | A case is presented in which a 68 - year - old man became delirious after being withdrawn from a low dosage of Drugalprazolam . |
| 0.9957 | A case is presented in which a 68 - year - old man became Adverse-Effectdelirious after being withdrawn from a low dosage of alprazolam. |
| Score | Text |
|---|---|
| 0.9992 | However, Drugadenosine shortens the antegrade refractoriness of accessory atrioventricular connections and may cause acceleration of the ventricular rate during atrial fibrillation. |
| 0.9803 | However, adenosine shortens the antegrade refractoriness of accessory atrioventricular connections and may cause Adverse-Effectacceleration of the ventricular rate during atrial fibrillation. |
| Score | Text |
|---|---|
| 0.9984 | Nonspecific but significant abnormalities have been described in the infants of women treated with Drugdisulfiram in the first trimester of their pregnancies. |
| 0.9329 | Nonspecific but Adverse-Effectsignificant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies. |
| 0.9908 | Nonspecific but significant Adverse-Effectabnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies. |
| Score | Text |
|---|---|
| 0.9989 | Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of Drugifosfamide and metabolites in an anephric pediatric patient with Wilms'tumor. |
| 0.9968 | Adverse-EffectToxicity , pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms'tumor. |
| Score | Text |
|---|---|
| 0.9992 | The case resembles two previously reported cases of optic neuropathy which occurred in patients with Wilson's disease who were receiving Drugpenicillamine . |
| 0.9899 | The case resembles two previously reported cases of Adverse-Effectoptic neuropathy which occurred in patients with Wilson's disease who were receiving penicillamine. |
| Score | Text |
|---|---|
| 0.9974 | In the present paper, we discuss the first Japanese vivax malaria patient whose QT interval was prolonged after treatment with Drughalofantrine . |
| 0.9185 | In the present paper, we discuss the first Japanese vivax malaria patient whose Adverse-EffectQT interval was prolonged after treatment with halofantrine. |
| Score | Text |
|---|---|
| 0.9934 | Adverse-EffectAnaphylactoid shock , disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache. |
| 0.9860 | Anaphylactoid shock, disseminated intravascular coagulation, and Adverse-Effectanuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache. |
| 0.9824 | Anaphylactoid shock, Adverse-Effectdisseminated intravascular coagulation , and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache. |
| 0.9702 | Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving Drugzomepirac sodium for toothache. |
| Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving Drugzomepirac sodium for toothache. | |
| Score | Text |
|---|---|
| 0.9983 | High - resolution computed tomography scan findings were consistent with ILD, which was sufficient to diagnose as Drugerlotinib - induced ILD. |
| 0.9962 | High - resolution computed tomography scan findings were consistent with ILD, which was sufficient to diagnose as erlotinib - induced Adverse-EffectILD . |
| Score | Text |
|---|---|
| 0.9990 | She had been taking Drugnabumetone for 6 months, but had discontinued the agent 2 weeks before admission due to progressive edema. |
| 0.9726 | She had been taking nabumetone for 6 months, but had discontinued the agent 2 weeks before admission due to progressive Adverse-Effectedema . |
| Score | Text |
|---|---|
| 0.9934 | The reversal of heparin by protamine may cause severe hemodynamic deterioration, characterized by systemic hypotension, pulmonary hypertension, and Adverse-Effectbronchoconstriction . |
| 0.9923 | The reversal of heparin by protamine may cause severe hemodynamic deterioration, characterized by systemic hypotension, Adverse-Effectpulmonary hypertension , and bronchoconstriction. |
| 0.9881 | The reversal of heparin by protamine may cause severe hemodynamic deterioration, characterized by Adverse-Effectsystemic hypotension , pulmonary hypertension, and bronchoconstriction. |
| 0.9773 | The reversal of heparin by protamine may cause Adverse-Effectsevere hemodynamic deterioration , characterized by systemic hypotension, pulmonary hypertension, and bronchoconstriction. |
| The reversal of heparin by Drugprotamine may cause severe hemodynamic deterioration, characterized by systemic hypotension, pulmonary hypertension, and bronchoconstriction. | |
| Score | Text |
|---|---|
| 0.9984 | PURPOSE : To report a case of angiographically documented cystoid macula edema occurring after switching a pseudophakic patient from Druglatanoprost to bimatoprost. |
| 0.9980 | PURPOSE : To report a case of angiographically documented cystoid macula edema occurring after switching a pseudophakic patient from latanoprost to Drugbimatoprost . |
| 0.9862 | PURPOSE : To report a case of angiographically documented Adverse-Effectcystoid macula edema occurring after switching a pseudophakic patient from latanoprost to bimatoprost. |
| Score | Text |
|---|---|
| 0.9970 | The Adverse-Effectnodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other. |
| 0.9836 | The nodules regressed after withdrawal of Drugmethotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other. |
| Score | Text |
|---|---|
| 0.9995 | CONCLUSIONS : Clinicians should be aware of the possible association of thrombocytopenia with Druglansoprazole and discontinue the drug if thrombocytopenia becomes apparent. |
| 0.9930 | CONCLUSIONS : Clinicians should be aware of the possible association of Adverse-Effectthrombocytopenia with lansoprazole and discontinue the drug if thrombocytopenia becomes apparent. |
| Score | Text |
|---|---|
| 0.9992 | To our knowledge, these cases represent the first reports of DrugTDF - associated irreversible renal failure and rickets in pediatric patients. |
| 0.9982 | To our knowledge, these cases represent the first reports of TDF - associated irreversible renal failure and Adverse-Effectrickets in pediatric patients. |
| 0.9696 | To our knowledge, these cases represent the first reports of TDF - associated Adverse-Effectirreversible renal failure and rickets in pediatric patients. |
| Score | Text |
|---|---|
| 0.9992 | DrugCyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests. |
| 0.9981 | Cyclosporin side effects included hirsutism, Adverse-Effecthypertension , increased blood levels of urea and creatinine, and abnormalities in liver function tests. |
| 0.9973 | Cyclosporin side effects included Adverse-Effecthirsutism , hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests. |
| 0.9596 | Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and Adverse-Effectabnormalities in liver function tests . |
| 0.9187 | Cyclosporin side effects included hirsutism, hypertension, Adverse-Effectincreased blood levels of urea and creatinine , and abnormalities in liver function tests. |
| 0.9191 | Cyclosporin side effects included hirsutism, hypertension, Adverse-Effectincreased blood levels of urea and creatinine, and abnormalities in liver function tests. |
| 0.8538 | Cyclosporin side effects included hirsutism, hypertension, Adverse-Effectincreased blood levels of urea and creatinine, and abnormalities in liver function tests. |
| Score | Text |
|---|---|
| 0.9993 | Atrioventricular block complicating Drugamiodarone - induced hypothyroidism in a patient with pre - excitation and rate - dependent bilateral bundle branch block. |
| 0.9902 | Adverse-EffectAtrioventricular block complicating amiodarone - induced hypothyroidism in a patient with pre - excitation and rate - dependent bilateral bundle branch block. |
| 0.9855 | Atrioventricular block complicating amiodarone - induced Adverse-Effecthypothyroidism in a patient with pre - excitation and rate - dependent bilateral bundle branch block. |
| Score | Text |
|---|---|
| 0.9996 | Behavioral side effects associated with Drugclonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums. |
| 0.9981 | Behavioral side effects associated with clonazepam may include agitation, Adverse-Effectaggression , hyperactivity, irritability, property destruction, and temper tantrums. |
| 0.9981 | Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, Adverse-Effectirritability , property destruction, and temper tantrums. |
| 0.9972 | Behavioral side effects associated with clonazepam may include Adverse-Effectagitation , aggression, hyperactivity, irritability, property destruction, and temper tantrums. |
| 0.9958 | Behavioral side effects associated with clonazepam may include agitation, aggression, Adverse-Effecthyperactivity , irritability, property destruction, and temper tantrums. |
| 0.9945 | Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, Adverse-Effectproperty destruction , and temper tantrums. |
| 0.9921 | Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and Adverse-Effecttemper tantrums . |
| Score | Text |
|---|---|
| 0.9995 | OBJECTIVE : To determine the frequency of weight loss in patients treated with Drugleflunomide for rheumatoid arthritis at an arthritis referral center. |
| 0.9882 | OBJECTIVE : To determine the frequency of Adverse-Effectweight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center. |
| Score | Text |
|---|---|
| 0.9685 | A well - recognized complication of Drugethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked. |
| 0.9621 | A well - recognized complication of ethambutol use is Adverse-Effectoptic neuropathy , but the potential ocular toxicity of isoniazid is often overlooked. |
| 0.8415 | A well - recognized complication of ethambutol use is optic neuropathy, but the potential Adverse-Effectocular toxicity of isoniazid is often overlooked. |
| 0.8264 | A well - recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of Drugisoniazid is often overlooked. |
| Score | Text |
|---|---|
| 0.9992 | CONCLUSIONS : The increasing prevalence of Type 2 diabetes and its treatment with Drugmetformin might result in more cases of lactic acidosis. |
| 0.9919 | CONCLUSIONS : The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of Adverse-Effectlactic acidosis . |
| Score | Text |
|---|---|
| 0.9850 | Treatment of APL in pregnancy is controversial as the use of DrugATRA has been questioned due to the teratogenic effect of retinoids. |
| 0.9675 | Treatment of APL in pregnancy is controversial as the use of ATRA has been questioned due to the Adverse-Effectteratogenic effect of retinoids. |
| Score | Text |
|---|---|
| 0.9982 | RESULTS : One case of recurrent primary peritoneal carcinoma previously treated with a Drugcarboplatin - based regimen, developed a platinum hypersensitivity. |
| 0.9913 | RESULTS : One case of recurrent primary peritoneal carcinoma previously treated with a carboplatin - based regimen, developed a Adverse-Effectplatinum hypersensitivity . |
| Score | Text |
|---|---|
| 0.9690 | Controversy concerning the nephrotoxicity of Druglithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided. |
| 0.9672 | Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of Adverse-Effectrenal failure during lithium therapy are provided. |
| 0.9476 | Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during Druglithium therapy are provided. |
| 0.8845 | Controversy concerning the Adverse-Effectnephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided. |
| Score | Text |
|---|---|
| 0.9994 | PURPOSE : To describe bilateral corneal endothelial dysfunction in a patient with Parkinson disease who was treated with long - term Drugamantadine . |
| 0.9837 | PURPOSE : To describe Adverse-Effectbilateral corneal endothelial dysfunction in a patient with Parkinson disease who was treated with long - term amantadine. |
| Score | Text |
|---|---|
| 0.9996 | DrugMethotrexate - induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis : report of five cases and review of the literature. |
| 0.9985 | Methotrexate - induced Adverse-Effectpneumonitis in patients with rheumatoid arthritis and psoriatic arthritis : report of five cases and review of the literature. |
| Score | Text |
|---|---|
| 0.9996 | Type I second - degree AV block ( Mobitz type I, Wenckebach AV block ) during Drugritodrine therapy for preterm labor. |
| 0.9875 | Type I second - degree AV block ( Mobitz type I, Adverse-EffectWenckebach AV block ) during ritodrine therapy for preterm labor. |
| 0.9850 | Type I second - degree AV block ( Adverse-EffectMobitz type I , Wenckebach AV block ) during ritodrine therapy for preterm labor. |
| 0.9746 | Adverse-EffectType I second - degree AV block ( Mobitz type I, Wenckebach AV block ) during ritodrine therapy for preterm labor. |
| Score | Text |
|---|---|
| 0.9981 | We present the case of a 58 - year - old woman who ingested more than 35 g of Drugcaffeine in a suicide attempt. |
| 0.9542 | We present the case of a 58 - year - old woman who ingested more than 35 g of caffeine in a Adverse-Effectsuicide attempt . |
| Score | Text |
|---|---|
| 0.9986 | Insulin - dependent diabetes mellitus developed in a young woman 8 weeks after the initiation of Drugdanazol for treatment of pelvic endometriosis. |
| 0.9698 | Adverse-EffectInsulin - dependent diabetes mellitus developed in a young woman 8 weeks after the initiation of danazol for treatment of pelvic endometriosis. |
| Score | Text |
|---|---|
| 0.9878 | A patient with coccidioidal meningitis was treated with intrathecally administered amphotericin B, and an Adverse-Effectacute toxic delirium with EEG abnormalities developed. |
| 0.9844 | A patient with coccidioidal meningitis was treated with intrathecally administered Drugamphotericin B , and an acute toxic delirium with EEG abnormalities developed. |
| 0.9728 | A patient with coccidioidal meningitis was treated with intrathecally administered amphotericin B, and an acute toxic delirium with Adverse-EffectEEG abnormalities developed. |
| Score | Text |
|---|---|
| 0.9973 | We report a 46 - yr - old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and Drugcyclophosphamide . |
| 0.9969 | We report a 46 - yr - old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with Drugcisplatin and cyclophosphamide. |
| 0.9885 | We report a 46 - yr - old woman with ovarian carcinoma who developed Adverse-Effectporphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide. |
| Score | Text |
|---|---|
| 0.9970 | Based on these findings, the patient was diagnosed with diabetes insipidus secondary to Druglithium therapy and was treated successfully with amiloride. |
| 0.9792 | Based on these findings, the patient was diagnosed with Adverse-Effectdiabetes insipidus secondary to lithium therapy and was treated successfully with amiloride. |
| Score | Text |
|---|---|
| 0.9996 | Thus, the patient's clinical course and workup strongly support a diagnosis of Druglenalidomide - induced hypersensitivity pneumonitis - like syndrome. |
| 0.9834 | Thus, the patient's clinical course and workup strongly support a diagnosis of lenalidomide - induced Adverse-Effecthypersensitivity pneumonitis - like syndrome . |
| Score | Text |
|---|---|
| 0.9991 | Severe C. difficile colitis occurred in 2 patients ( 6. 1 % ) after receiving Drugcisplatin - based combination chemotherapy for ovarian malignancies. |
| 0.8962 | Severe Adverse-EffectC. difficile colitis occurred in 2 patients ( 6. 1 % ) after receiving cisplatin - based combination chemotherapy for ovarian malignancies. |
| Score | Text |
|---|---|
| 0.9995 | Physicians should be aware of the potential for developing a Druggemcitabine - induced radiation recall reaction resulting in hemodynamically significant pericardial effusion. |
| 0.9880 | Physicians should be aware of the potential for developing a gemcitabine - induced radiation recall reaction resulting in hemodynamically significant Adverse-Effectpericardial effusion . |
| 0.9855 | Physicians should be aware of the potential for developing a gemcitabine - induced Adverse-Effectradiation recall reaction resulting in hemodynamically significant pericardial effusion. |
| Score | Text |
|---|---|
| 0.9972 | A cause - effect relationship to capecitabine was suggested due to resolution of Adverse-Effectheadache with capecitabine withdrawal and reappearance with capecitabine rechallenge. |
| 0.8569 | A cause - effect relationship to capecitabine was suggested due to resolution of headache with Drugcapecitabine withdrawal and reappearance with capecitabine rechallenge. |
| 0.7759 | A cause - effect relationship to Drugcapecitabine was suggested due to resolution of headache with capecitabine withdrawal and reappearance with capecitabine rechallenge. |
| Score | Text |
|---|---|
| 0.9995 | This report highlights a case of drug - induced dysphagia in a patient receiving Drughaloperidol for obsessive nocturnal thoughts and auditory disturbances. |
| 0.9979 | This report highlights a case of drug - induced Adverse-Effectdysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances. |
| Score | Text |
|---|---|
| 0.9973 | Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i. e. cause insulin Adverse-Effectoedema ? |
| 0.9808 | Does the use of Druginsulin in a patient with liver dysfunction increase water retention in the body, i. e. cause insulin oedema? |
| 0.8657 | Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i. e. cause Adverse-Effectinsulin oedema ? |
| Score | Text |
|---|---|
| 0.9985 | This article describes the case of a 25 - year - old man found dead at home who had been prescribed Drugolanzapine for schizophrenia. |
| 0.9914 | This article describes the case of a 25 - year - old man found Adverse-Effectdead at home who had been prescribed olanzapine for schizophrenia. |
| Score | Text |
|---|---|
| 0.9990 | It is very likely that the Drugdexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients. |
| 0.9974 | It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of Adverse-Effectosteonecrosis in these patients. |
| Score | Text |
|---|---|
| 0.9979 | Adverse-EffectAngioedema , a rare side effect of carbamazepine, involves vascular leakage in dermis and subcutis mediated by immunoglobulin E and / or bradykinins. |
| 0.9971 | Angioedema, a rare side effect of Drugcarbamazepine , involves vascular leakage in dermis and subcutis mediated by immunoglobulin E and / or bradykinins. |
| Score | Text |
|---|---|
| 0.9991 | Like other atypical neuroleptics Drugolanzapine is considered to show a reduced prevalence of extrapyramidal side effects when compared to classical neuroleptic drugs. |
| 0.9791 | Like other atypical neuroleptics olanzapine is considered to show a reduced prevalence of Adverse-Effectextrapyramidal side effects when compared to classical neuroleptic drugs. |
| Score | Text |
|---|---|
| 0.9994 | The favourable outcome in these two patients contrasts with the fatal outcome of the two other reported cases of Drugnitrofurantoin induced BOOP. |
| 0.9592 | The favourable outcome in these two patients contrasts with the Adverse-Effectfatal outcome of the two other reported cases of nitrofurantoin induced BOOP. |
| 0.9973 | The favourable outcome in these two patients contrasts with the fatal outcome of the two other reported cases of nitrofurantoin induced Adverse-EffectBOOP . |
| The favourable outcome in these two patients contrasts with the fatal outcome of the two other reported cases of Adverse-Effectnitrofurantoin induced BOOP . | |
| Score | Text |
|---|---|
| 0.9986 | RESULTS : A clinical diagnosis of fixed drug eruption owing to use of the PDE5 inhibitor Drugtadalafil ( Cialis ) was made. |
| 0.9972 | RESULTS : A clinical diagnosis of fixed drug eruption owing to use of the PDE5 inhibitor tadalafil ( DrugCialis ) was made. |
| 0.8867 | RESULTS : A clinical diagnosis of Adverse-Effectfixed drug eruption owing to use of the PDE5 inhibitor tadalafil ( Cialis ) was made. |
| Score | Text |
|---|---|
| 0.9994 | Protease inhibitors ( ritonavir and saquinavir ) were added to the treatment and the patient developed progressive ataxia related to Drugcarbamazepine toxicity. |
| 0.9991 | Protease inhibitors ( Drugritonavir and saquinavir ) were added to the treatment and the patient developed progressive ataxia related to carbamazepine toxicity. |
| 0.9989 | Protease inhibitors ( ritonavir and Drugsaquinavir ) were added to the treatment and the patient developed progressive ataxia related to carbamazepine toxicity. |
| 0.8999 | Protease inhibitors ( ritonavir and saquinavir ) were added to the treatment and the patient developed Adverse-Effectprogressive ataxia related to carbamazepine toxicity. |
| 0.7616 | Protease inhibitors ( ritonavir and saquinavir ) were added to the treatment and the patient developed progressive ataxia related to Adverse-Effectcarbamazepine toxicity . |
| Score | Text |
|---|---|
| 0.9992 | A 56 - year - old male parkinsonian patient developed a unique behavioral change following the oral administration of Drugcinepazide , a cerebral vasodilator. |
| 0.9835 | A 56 - year - old male parkinsonian patient developed a unique Adverse-Effectbehavioral change following the oral administration of cinepazide, a cerebral vasodilator. |
| Score | Text |
|---|---|
| 0.9996 | Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under Drugtamoxifen therapy for breast cancer : a case report. |
| 0.9802 | Adverse-EffectOvarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer : a case report. |
| Score | Text |
|---|---|
| 0.9916 | This is the first case of TMP - SMX - induced Adverse-Effecthypersensitivity syndrome associated with the reactivation of a latent viral infection. |
| 0.9702 | This is the first case of DrugTMP - SMX - induced hypersensitivity syndrome associated with the reactivation of a latent viral infection. |
| Score | Text |
|---|---|
| 0.9987 | We report a case of 48 - year - old woman with seizure disorder on divalproex sodium ( Depakote ) who presented with Adverse-Effectdyspnea . |
| 0.9957 | We report a case of 48 - year - old woman with seizure disorder on divalproex sodium ( DrugDepakote ) who presented with dyspnea. |
| 0.9862 | We report a case of 48 - year - old woman with seizure disorder on Drugdivalproex sodium ( Depakote ) who presented with dyspnea. |
| Score | Text |
|---|---|
| 0.9995 | Skin rash began after 2 weeks of treatment, and signs of hepatocellular failure developed 3 weeks after Drugphenobarbital had been started. |
| 0.9923 | Adverse-EffectSkin rash began after 2 weeks of treatment, and signs of hepatocellular failure developed 3 weeks after phenobarbital had been started. |
| 0.9912 | Skin rash began after 2 weeks of treatment, and signs of Adverse-Effecthepatocellular failure developed 3 weeks after phenobarbital had been started. |
| Score | Text |
|---|---|
| 0.9853 | OBJECTIVE : To report a case of severe Drugchloroquine toxicity in the presence of high - grade chloroquine - resistant Plasmodium vivax. |
| 0.8007 | OBJECTIVE : To report a case of Adverse-Effectsevere chloroquine toxicity in the presence of high - grade chloroquine - resistant Plasmodium vivax. |
| 0.5136 | OBJECTIVE : To report a case of severe Adverse-Effectchloroquine toxicity in the presence of high - grade chloroquine - resistant Plasmodium vivax. |
| Score | Text |
|---|---|
| 0.9984 | RESULTS : DrugEthambutol , and to a lesser extent isoniazid, are both implicated in the development of visually related side effects. |
| 0.9971 | RESULTS : Ethambutol, and to a lesser extent Drugisoniazid , are both implicated in the development of visually related side effects. |
| 0.8924 | RESULTS : Ethambutol, and to a lesser extent isoniazid, are both implicated in the Adverse-Effectdevelopment of visually related side effects . |
| Score | Text |
|---|---|
| 0.9993 | Our objective is to present a retrospective analysis of the DWI findings in four patients who suffered subacute neurotoxicity after intrathecal DrugMTX . |
| 0.9729 | Our objective is to present a retrospective analysis of the DWI findings in four patients who suffered Adverse-Effectsubacute neurotoxicity after intrathecal MTX. |
| Score | Text |
|---|---|
| 0.9990 | Rituximab - based therapy for Druggemcitabine - induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma : a case report. |
| 0.9864 | Rituximab - based therapy for gemcitabine - induced Adverse-Effecthemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma : a case report. |
| Score | Text |
|---|---|
| 0.9975 | We report a patient receiving chronic Druglithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI. |
| 0.9810 | We report a patient receiving chronic lithium therapy who presented with a transient Adverse-EffectCDI occurring in the setting of underlying chronic NDI. |
| Score | Text |
|---|---|
| 0.9988 | Syndrome of inappropriate secretion of ADH ( SIADH ) following Drugcisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion. |
| 0.9924 | Syndrome of inappropriate secretion of ADH ( Adverse-EffectSIADH ) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion. |
| 0.9634 | Adverse-EffectSyndrome of inappropriate secretion of ADH ( SIADH ) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion. |
| Score | Text |
|---|---|
| 0.9947 | In this paper, we report a patient with primary anti - phospholipid syndrome treated by Drugcorticosteroid , who developed disseminated nocardiosis. |
| 0.9899 | In this paper, we report a patient with primary anti - phospholipid syndrome treated by corticosteroid, who developed Adverse-Effectdisseminated nocardiosis . |
| Score | Text |
|---|---|
| 0.9995 | A wide variety of adverse central nervous system effects have been reported in association with Drugpropafenone ; dizziness is the most common. |
| 0.9848 | A wide variety of adverse central nervous system effects have been reported in association with propafenone ; Adverse-Effectdizziness is the most common. |
| 0.9765 | A wide variety of Adverse-Effectadverse central nervous system effects have been reported in association with propafenone ; dizziness is the most common. |
| Score | Text |
|---|---|
| 0.9996 | Pulmonary hemorrhage is an uncommon feature in the HUS, and seems to appear especially in the HUS associated with DrugMMC therapy. |
| 0.9970 | Pulmonary hemorrhage is an uncommon feature in the HUS, and seems to appear especially in the Adverse-EffectHUS associated with MMC therapy. |
| 0.9961 | Pulmonary hemorrhage is an uncommon feature in the Adverse-EffectHUS , and seems to appear especially in the HUS associated with MMC therapy. |
| 0.9871 | Adverse-EffectPulmonary hemorrhage is an uncommon feature in the HUS, and seems to appear especially in the HUS associated with MMC therapy. |
| Score | Text |
|---|---|
| 0.9857 | The Center for Disease Control has received numerous reports of an Adverse-Effecteosinophilia - myalgia syndrome related to products containing L - tryptophan. |
| 0.9645 | The Center for Disease Control has received numerous reports of an eosinophilia - myalgia syndrome related to products containing DrugL - tryptophan . |
| Score | Text |
|---|---|
| 0.9994 | We report a case of fatal pulmonary toxicity in a patient with advanced non - small cell lung cancer who received Drugerlotinib . |
| 0.9833 | We report a case of Adverse-Effectfatal pulmonary toxicity in a patient with advanced non - small cell lung cancer who received erlotinib. |
| Score | Text |
|---|---|
| 0.9985 | We report a 76 - year - old man who developed an acute blistering eruption following high - dose Drugpenicillin treatment for pneumococcal septicaemia. |
| 0.9872 | We report a 76 - year - old man who developed an Adverse-Effectacute blistering eruption following high - dose penicillin treatment for pneumococcal septicaemia. |
| Score | Text |
|---|---|
| 0.9989 | The spectrum of renal lesions occurring during antituberculous therapy, particularly in association with Drugrifampin , may be wider than previously suspected. |
| 0.9917 | The spectrum of Adverse-Effectrenal lesions occurring during antituberculous therapy, particularly in association with rifampin, may be wider than previously suspected. |
| Score | Text |
|---|---|
| 0.9800 | Complications associated with primary and secondary perforation of the bladder following immediate instillations of Drugepirubicin after transurethral resection of superficial urothelial tumours. |
| 0.9752 | Complications associated with Adverse-Effectprimary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours. |
| Score | Text |
|---|---|
| 0.9807 | 2 - Chloro - deoxyadenosine induces durable complete remission in Castleman's disease but may accelerate its transformation to Adverse-Effectnon - Hodgkin's lymphoma . |
| 0.8421 | Drug2 - Chloro - deoxyadenosine induces durable complete remission in Castleman's disease but may accelerate its transformation to non - Hodgkin's lymphoma. |
| Score | Text |
|---|---|
| 0.9994 | A 42 year old man, treated for testicular carcinoma with combination chemotherapy that included Drugbleomycin , developed life threatening interstitial pneumonitis. |
| 0.9873 | A 42 year old man, treated for testicular carcinoma with combination chemotherapy that included bleomycin, developed life threatening Adverse-Effectinterstitial pneumonitis . |
| Score | Text |
|---|---|
| 0.9941 | Severe histological osteomalacia developed in a woman with Crohn's disease 2 years after ileal resection and the start of Drugcholestyramine therapy. |
| 0.8602 | Severe histological Adverse-Effectosteomalacia developed in a woman with Crohn's disease 2 years after ileal resection and the start of cholestyramine therapy. |
| Score | Text |
|---|---|
| 0.9871 | We report the first case of herpes esophagitis in a renal transplant patient treated with DrugCyclosporine A while on chronic steroid therapy. |
| 0.9851 | We report the first case of Adverse-Effectherpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy. |
| Score | Text |
|---|---|
| 0.9929 | A case is reported of a 40 year old woman treated with intraventricular DrugIL - 2 for leptomeningeal disease who developed progressive cognitive dysfunction. |
| 0.9386 | A case is reported of a 40 year old woman treated with intraventricular IL - 2 for leptomeningeal disease who developed progressive Adverse-Effectcognitive dysfunction . |
| Score | Text |
|---|---|
| 0.9982 | Although the essential cause of PV is unclear, its onset has occasionally been associated with drug therapy, in particular Drugpenicillamine . |
| 0.9912 | Although the essential cause of Adverse-EffectPV is unclear, its onset has occasionally been associated with drug therapy, in particular penicillamine. |
| Score | Text |
|---|---|
| 0.9985 | A case history of a 15 - year - old boy who developed incapacitating tardive dyskinesia that resolved during treatment with Drugdeanol is presented. |
| 0.9791 | A case history of a 15 - year - old boy who developed incapacitating Adverse-Effecttardive dyskinesia that resolved during treatment with deanol is presented. |
| Score | Text |
|---|---|
| 0.9995 | These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during Drugolanzapine treatment might be dose - related. |
| 0.9980 | These cases suggest the possibility that, in some patients, Adverse-Effectleukopenia or agranulocytosis during olanzapine treatment might be dose - related. |
| 0.9977 | These cases suggest the possibility that, in some patients, leukopenia or Adverse-Effectagranulocytosis during olanzapine treatment might be dose - related. |
| Score | Text |
|---|---|
| 0.9986 | Interferon - induced Adverse-Effectpsychosis as a " psychiatric contraindication " to hepatitis C treatment : a review and case - based discussion. |
| 0.9971 | DrugInterferon - induced psychosis as a " psychiatric contraindication " to hepatitis C treatment : a review and case - based discussion. |
| Score | Text |
|---|---|
| 0.9914 | CONCLUSIONS : The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to Drugcapecitabine . |
| 0.9069 | CONCLUSIONS : The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild Adverse-Effectallergic reactions to capecitabine. |
| Score | Text |
|---|---|
| 0.9980 | In patients with a known access to INH, Adverse-Effectseizures should be considered to be caused by INH toxicity unless proved otherwise. |
| 0.9965 | In patients with a known access to INH, seizures should be considered to be caused by DrugINH toxicity unless proved otherwise. |
| Score | Text |
|---|---|
| 0.9996 | During the first treatment, dysarthria and ataxia were seen after completion of the patient's eighth and final dose of DrugHDARAC . |
| 0.9988 | During the first treatment, Adverse-Effectdysarthria and ataxia were seen after completion of the patient's eighth and final dose of HDARAC. |
| 0.9988 | During the first treatment, dysarthria and Adverse-Effectataxia were seen after completion of the patient's eighth and final dose of HDARAC. |
| Score | Text |
|---|---|
| 0.9996 | OBJECTIVE : To describe onset of syndrome of inappropriate antidiuretic hormone ( SIADH ) associated with Drugvinorelbine therapy for advanced breast cancer. |
| 0.9951 | OBJECTIVE : To describe onset of syndrome of inappropriate antidiuretic hormone ( Adverse-EffectSIADH ) associated with vinorelbine therapy for advanced breast cancer. |
| 0.9781 | OBJECTIVE : To describe onset of Adverse-Effectsyndrome of inappropriate antidiuretic hormone ( SIADH ) associated with vinorelbine therapy for advanced breast cancer. |
| Score | Text |
|---|---|
| 0.9929 | Pancreatitis has been associated with the tetracycline class of antibiotics and concerns about Drugtigecycline - induced acute pancreatitis have recently been raised. |
| 0.9865 | Pancreatitis has been associated with the tetracycline class of antibiotics and concerns about tigecycline - induced Adverse-Effectacute pancreatitis have recently been raised. |
| Score | Text |
|---|---|
| 0.9994 | Only one case of severe symptomatic hepatitis occurring after pulse therapy with Drugitraconazole for onychomycosis and requiring transplantation has been reported previously. |
| 0.9832 | Only one case of Adverse-Effectsevere symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously. |
| Score | Text |
|---|---|
| 0.9995 | OBJECTIVE : To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with Drugolanzapine . |
| 0.9977 | OBJECTIVE : To report a case of rapidly occurring Adverse-Effecthyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine. |
| Score | Text |
|---|---|
| 0.9986 | While on a maximal dose of Drugphenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug. |
| 0.9847 | While on a maximal dose of phenylephrine she developed prominent Adverse-Effectpositive U waves , which disappeared with the cessation of the drug. |
| Score | Text |
|---|---|
| 0.9995 | It is suggested that the fatal stroke may have resulted from arterial spasm caused by Drugergotamine overdosage and possibly complicated by thrombosis. |
| 0.9885 | It is suggested that the fatal stroke may have resulted from Adverse-Effectarterial spasm caused by ergotamine overdosage and possibly complicated by thrombosis. |
| 0.9844 | It is suggested that the Adverse-Effectfatal stroke may have resulted from arterial spasm caused by ergotamine overdosage and possibly complicated by thrombosis. |
| Score | Text |
|---|---|
| 0.9994 | Electro - oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with Drugvigabatrin - attributed visual field constriction. |
| 0.9866 | Electro - oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin - attributed Adverse-Effectvisual field constriction . |
| Score | Text |
|---|---|
| 0.9892 | Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate - related Adverse-Effectmyocardial infarction in patients with haemophilia and inhibitors. |
| 0.9687 | Recombinant VIIa concentrate in the management of bleeding following Drugprothrombin complex concentrate - related myocardial infarction in patients with haemophilia and inhibitors. |
| Score | Text |
|---|---|
| 0.9993 | We report a case of fatal fulminant hepatitis caused by the use of Drugdisulfiram in a man with previously normal hepatocellular function. |
| 0.9823 | We report a case of Adverse-Effectfatal fulminant hepatitis caused by the use of disulfiram in a man with previously normal hepatocellular function. |
| Score | Text |
|---|---|
| 0.9996 | We describe a 73 - year - old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with Drugcladribine . |
| 0.9983 | We describe a 73 - year - old woman who developed serious systemic vasculitis with associated Adverse-Effectthrombocytopenia in the course of treatment with cladribine. |
| 0.7229 | We describe a 73 - year - old woman who developed serious Adverse-Effectsystemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine. |
| Score | Text |
|---|---|
| 0.9994 | A combination of behavioural and cognitive adverse effects is illustrated in this case report of a recurrent Drugtriazolam - induced eating disorder. |
| 0.9955 | A combination of behavioural and cognitive adverse effects is illustrated in this case report of a recurrent triazolam - induced Adverse-Effecteating disorder . |
| Score | Text |
|---|---|
| 0.9974 | Extra caution should be taken in using Drugoctreotide or its long - acting analog in patients otherwise predisposed to intrahepatic bile stasis. |
| 0.9729 | Extra caution should be taken in using octreotide or its long - acting analog in patients otherwise predisposed to Adverse-Effectintrahepatic bile stasis . |
| Score | Text |
|---|---|
| 0.9992 | We report 3 cases of HIV - 1 infected patients who experienced symptomatic angiolipomas shortly after starting antiretroviral therapy including the protease inhibitor Drugindinavir . |
| 0.5069 | We report 3 cases of HIV - 1 infected patients who experienced symptomatic Adverse-Effectangiolipomas shortly after starting antiretroviral therapy including the protease inhibitor indinavir. |
| 0.9573 | We report 3 cases of HIV - 1 infected patients who experienced Adverse-Effectsymptomatic angiolipomas shortly after starting antiretroviral therapy including the protease inhibitor indinavir. |
| Score | Text |
|---|---|
| 0.9989 | In this case Drugsenna was likely the cause of a subacute cholestatic hepatitis exemplifying again the potential role of herbal related liver injury. |
| 0.9684 | In this case senna was likely the cause of a Adverse-Effectsubacute cholestatic hepatitis exemplifying again the potential role of herbal related liver injury. |
| 0.9380 | In this case senna was likely the cause of a subacute cholestatic hepatitis exemplifying again the potential role of herbal related Adverse-Effectliver injury . |
| Score | Text |
|---|---|
| 0.9969 | Chronic myelogenous leukemia ( CML ), hepatitis C, and interferon alpha ( DrugIFNalpha ) have all been associated with renal dysfunction. |
| 0.9910 | Chronic myelogenous leukemia ( CML ), hepatitis C, and interferon alpha ( IFNalpha ) have all been associated with Adverse-Effectrenal dysfunction . |
| 0.9885 | Chronic myelogenous leukemia ( CML ), hepatitis C, and Druginterferon alpha ( IFNalpha ) have all been associated with renal dysfunction. |
| Score | Text |
|---|---|
| 0.9948 | The authors conclude that among patients taking high doses of oral Drugniacin only those who experience visual symptoms need to be ophthalmologically evaluated. |
| 0.9900 | The authors conclude that among patients taking high doses of oral niacin only those who experience Adverse-Effectvisual symptoms need to be ophthalmologically evaluated. |
| Score | Text |
|---|---|
| 0.9985 | A 37 - year - old woman with relapsing invasive vertebral aspergillosis received intravenous DrugVRC and developed angio - oedema 10 days after starting therapy. |
| 0.9900 | A 37 - year - old woman with relapsing invasive vertebral aspergillosis received intravenous VRC and developed Adverse-Effectangio - oedema 10 days after starting therapy. |
| Score | Text |
|---|---|
| 0.9979 | This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and Drugsulphasalazine . |
| 0.9978 | This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by Drugfenclofenac as well as aurothiomalate and sulphasalazine. |
| 0.9978 | This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as Drugaurothiomalate and sulphasalazine. |
| 0.9872 | This case demonstrates the association of selective Adverse-EffectIgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine. |
| Score | Text |
|---|---|
| 0.9973 | METHODS : A 55 - year - old woman became stuporous after overdose with Druglamotrigine ( LTG ) and valproic acid ( VPA ) tablets. |
| 0.9964 | METHODS : A 55 - year - old woman became Adverse-Effectstuporous after overdose with lamotrigine ( LTG ) and valproic acid ( VPA ) tablets. |
| 0.9958 | METHODS : A 55 - year - old woman became stuporous after overdose with lamotrigine ( LTG ) and valproic acid ( DrugVPA ) tablets. |
| 0.9953 | METHODS : A 55 - year - old woman became stuporous after overdose with lamotrigine ( DrugLTG ) and valproic acid ( VPA ) tablets. |
| 0.9894 | METHODS : A 55 - year - old woman became stuporous after overdose with lamotrigine ( LTG ) and Drugvalproic acid ( VPA ) tablets. |
| Score | Text |
|---|---|
| 0.9993 | She received an accidental 450 - mg bolus injection of Drugmorphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure. |
| 0.9981 | She received an accidental 450 - mg bolus injection of morphine intrathecally and developed Adverse-Effecthypertension , status epilepticus, intracerebral hemorrhage, and respiratory failure. |
| 0.9957 | She received an accidental 450 - mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and Adverse-Effectrespiratory failure . |
| 0.9914 | She received an accidental 450 - mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, Adverse-Effectintracerebral hemorrhage , and respiratory failure. |
| 0.9865 | She received an accidental 450 - mg bolus injection of morphine intrathecally and developed hypertension, Adverse-Effectstatus epilepticus , intracerebral hemorrhage, and respiratory failure. |
| Score | Text |
|---|---|
| 0.9959 | A 49 - year - old man with Crohn's disease treated with Drugprednisone and mesalamine ( 5 - ASA ) developed worsening respiratory distress and fever. |
| 0.9956 | A 49 - year - old man with Crohn's disease treated with prednisone and Drugmesalamine ( 5 - ASA ) developed worsening respiratory distress and fever. |
| 0.9838 | A 49 - year - old man with Crohn's disease treated with prednisone and mesalamine ( 5 - ASA ) developed worsening respiratory distress and Adverse-Effectfever . |
| 0.9771 | A 49 - year - old man with Crohn's disease treated with prednisone and mesalamine ( 5 - ASA ) developed Adverse-Effectworsening respiratory distress and fever. |
| 0.9642 | A 49 - year - old man with Crohn's disease treated with prednisone and mesalamine ( Drug5 - ASA ) developed worsening respiratory distress and fever. |
| Score | Text |
|---|---|
| 0.9950 | Massive pulmonary embolism due to late - onset heparin - induced Adverse-Effectthrombocytopenia following coronary artery bypass graft surgery : successful treatment with lepirudin. |
| 0.9937 | Massive pulmonary embolism due to late - onset Drugheparin - induced thrombocytopenia following coronary artery bypass graft surgery : successful treatment with lepirudin. |
| 0.9490 | Adverse-EffectMassive pulmonary embolism due to late - onset heparin - induced thrombocytopenia following coronary artery bypass graft surgery : successful treatment with lepirudin. |
| Score | Text |
|---|---|
| 0.9996 | Methemoglobinemia is another common finding among patients receiving Drugdapsone therapy, but rarely does it result in prominent symptoms other than transient pallor. |
| 0.9978 | Adverse-EffectMethemoglobinemia is another common finding among patients receiving dapsone therapy, but rarely does it result in prominent symptoms other than transient pallor. |
| Score | Text |
|---|---|
| 0.9996 | Physicians using this " new " drug must be aware of the potential danger of Drugsulfonamide - induced injury to the urinary tract. |
| 0.9525 | Physicians using this " new " drug must be aware of the potential danger of sulfonamide - induced Adverse-Effectinjury to the urinary tract . |
| Score | Text |
|---|---|
| 0.9714 | Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the Adverse-Effectbronchospasm was believed to be caused by propranolol. |
| 0.9302 | Since the bronchospasm was relieved with discontinuation of Drugpropranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol. |
| 0.9004 | Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by Drugpropranolol . |
| 0.8952 | Since the Adverse-Effectbronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol. |
| Score | Text |
|---|---|
| 0.9786 | Destructive thyrotoxicosis appeared 4 - 6 months after starting IFN - alpha, followed by Adverse-EffectGraves'hyperthyroidism within 8 to 11 months. |
| 0.9763 | Destructive thyrotoxicosis appeared 4 - 6 months after starting DrugIFN - alpha , followed by Graves'hyperthyroidism within 8 to 11 months. |
| 0.9269 | Destructive Adverse-Effectthyrotoxicosis appeared 4 - 6 months after starting IFN - alpha, followed by Graves'hyperthyroidism within 8 to 11 months. |
| Score | Text |
|---|---|
| 0.9810 | Adverse-EffectSagittal sinus thrombosis associated with transient free protein S deficiency after L - asparaginase treatment : case report and review of the literature. |
| 0.9667 | Sagittal sinus thrombosis associated with transient free protein S deficiency after DrugL - asparaginase treatment : case report and review of the literature. |
| 0.9649 | Sagittal sinus thrombosis associated with Adverse-Effecttransient free protein S deficiency after L - asparaginase treatment : case report and review of the literature. |
| Score | Text |
|---|---|
| 0.9990 | Reversible leukopenia was documented in an 81 - year - old woman treated with adjunctive Drugibopamine 100 mg t. i. d. for chronic congestive heart failure. |
| 0.8100 | Adverse-EffectReversible leukopenia was documented in an 81 - year - old woman treated with adjunctive ibopamine 100 mg t. i. d. for chronic congestive heart failure. |
| Score | Text |
|---|---|
| 0.9966 | The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of Drugcaffeine - containing beverages. |
| 0.9483 | The possibility of severe rhabdomyolysis should be considered in a patient with Adverse-Effectwater intoxication due to massive ingestion of caffeine - containing beverages. |
| 0.8624 | The possibility of severe Adverse-Effectrhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine - containing beverages. |
| 0.5865 | The possibility of Adverse-Effectsevere rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine - containing beverages. |
| Score | Text |
|---|---|
| 0.9789 | The second patient developed both autoimmune thyroid disease and a refractory pre - patellar bursitis after 50 months of DrugIFN - beta therapy. |
| 0.9748 | The second patient developed both autoimmune thyroid disease and a Adverse-Effectrefractory pre - patellar bursitis after 50 months of IFN - beta therapy. |
| 0.9718 | The second patient developed both Adverse-Effectautoimmune thyroid disease and a refractory pre - patellar bursitis after 50 months of IFN - beta therapy. |
| Score | Text |
|---|---|
| 0.9986 | Amiodarone hydrochloride, a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by Adverse-Effectcough , dyspnea and diffuse pulmonary infiltrates. |
| 0.9984 | Amiodarone hydrochloride, a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by cough, Adverse-Effectdyspnea and diffuse pulmonary infiltrates. |
| 0.9896 | Amiodarone hydrochloride, a new antiarrhythmic agent, has been associated with Adverse-Effectpulmonary toxicity characterized by cough, dyspnea and diffuse pulmonary infiltrates. |
| 0.9874 | Amiodarone hydrochloride, a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by cough, dyspnea and Adverse-Effectdiffuse pulmonary infiltrates . |
| 0.9788 | DrugAmiodarone hydrochloride , a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by cough, dyspnea and diffuse pulmonary infiltrates. |
| Score | Text |
|---|---|
| 0.9481 | The biochemistry of paracetamol Adverse-Effecthepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon. |
| 0.9409 | The biochemistry of Drugparacetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon. |
| 0.8755 | The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of Drugparacetamol is remarked upon. |
| 0.6493 | The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the Adverse-Effecthepatotoxic effects of paracetamol is remarked upon. |
| 0.7184 | The biochemistry of Adverse-Effectparacetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon. |
| Score | Text |
|---|---|
| 0.9993 | We report the development of squamous - cell carcinoma within a basal - cell epithelioma that was treated with intralesional injections of Drug5 - FU . |
| 0.9763 | We report the development of Adverse-Effectsquamous - cell carcinoma within a basal - cell epithelioma that was treated with intralesional injections of 5 - FU. |
| Score | Text |
|---|---|
| 0.9980 | A patient presented with a painful, oedematous, cyanosed hand having injected a solution of diamorphine and Drugmethylphenidate into his radial artery. |
| 0.9979 | A patient presented with a painful, oedematous, cyanosed hand having injected a solution of Drugdiamorphine and methylphenidate into his radial artery. |
| 0.5163 | A patient presented with a Adverse-Effectpainful , oedematous, cyanosed hand having injected a solution of diamorphine and methylphenidate into his radial artery. |
| A patient presented with a Adverse-Effectpainful, oedematous, cyanosed hand having injected a solution of diamorphine and methylphenidate into his radial artery. | |
| Score | Text |
|---|---|
| 0.9995 | We report on three patients who developed acute liver damage during therapy with Drugitraconazole , and in whom liver biopsy specimens were obtained. |
| 0.9838 | We report on three patients who developed Adverse-Effectacute liver damage during therapy with itraconazole, and in whom liver biopsy specimens were obtained. |
| We report on three patients who developed acute Adverse-Effectliver damage during therapy with itraconazole, and in whom liver biopsy specimens were obtained. | |
| Score | Text |
|---|---|
| 0.9971 | Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of Drugazathioprine . |
| 0.9840 | Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound Adverse-Effectmyelosuppression after a short course of azathioprine. |
| Score | Text |
|---|---|
| 0.9994 | AIM : To report a patient with diabetic rubeosis who suffered from acute retinal ischemic change and stroke after intravitreal injection of Drugbevacizumab . |
| 0.9928 | AIM : To report a patient with diabetic rubeosis who suffered from acute retinal ischemic change and Adverse-Effectstroke after intravitreal injection of bevacizumab. |
| 0.9849 | AIM : To report a patient with diabetic rubeosis who suffered from Adverse-Effectacute retinal ischemic change and stroke after intravitreal injection of bevacizumab. |
| Score | Text |
|---|---|
| 0.9992 | This is a case report of possible association of Drugmethylphenidate and enuresis in an 11 - year - old boy with attention deficit hyperactivity disorder. |
| 0.9924 | This is a case report of possible association of methylphenidate and Adverse-Effectenuresis in an 11 - year - old boy with attention deficit hyperactivity disorder. |
| Score | Text |
|---|---|
| 0.9940 | Methylene blue in the treatment and prevention of Drugifosfamide - induced encephalopathy : report of 12 cases and a review of the literature. |
| 0.9972 | Methylene blue in the treatment and prevention of ifosfamide - induced Adverse-Effectencephalopathy : report of 12 cases and a review of the literature. |
| Methylene blue in the treatment and prevention of Adverse-Effectifosfamide - induced encephalopathy : report of 12 cases and a review of the literature. | |
| Score | Text |
|---|---|
| 0.9996 | NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving Drugifosfamide . |
| 0.9989 | Adverse-EffectNCSE , an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide. |
| Score | Text |
|---|---|
| 0.9996 | This is the first case of HBV reactivation occurring during the year following Drugrituximab monotherapy in the absence of any other immunosuppressive factor. |
| 0.9910 | This is the first case of Adverse-EffectHBV reactivation occurring during the year following rituximab monotherapy in the absence of any other immunosuppressive factor. |
| Score | Text |
|---|---|
| 0.9850 | We describe a case of subcutaneous metastasis along the needle track after percutaneous Drugethanol injection ( PEI ) for treatment of hepatocellular carcinoma. |
| 0.9655 | We describe a case of Adverse-Effectsubcutaneous metastasis along the needle track after percutaneous ethanol injection ( PEI ) for treatment of hepatocellular carcinoma. |
| 0.9501 | We describe a case of subcutaneous metastasis along the needle track after percutaneous ethanol injection ( DrugPEI ) for treatment of hepatocellular carcinoma. |
| 0.8603 | We describe a case of subcutaneous metastasis along the needle track after percutaneous Drugethanol injection ( PEI ) for treatment of hepatocellular carcinoma. |
| Score | Text |
|---|---|
| 0.9988 | This report describes an unexpected drug - induced Adverse-Effecthepatitis in a previously healthy young woman exposed to 2 doses of amodiaquine and artesunate. |
| 0.9987 | This report describes an unexpected drug - induced hepatitis in a previously healthy young woman exposed to 2 doses of amodiaquine and Drugartesunate . |
| 0.9985 | This report describes an unexpected drug - induced hepatitis in a previously healthy young woman exposed to 2 doses of Drugamodiaquine and artesunate. |
| Score | Text |
|---|---|
| 0.9831 | Adverse-EffectTumor - volume increase at beginning of primary treatment with topical interferon alpha 2 - beta in a case of conjunctiva - cornea intraepithelial neoplasia. |
| 0.9563 | Tumor - volume increase at beginning of primary treatment with topical Druginterferon alpha 2 - beta in a case of conjunctiva - cornea intraepithelial neoplasia. |
| Score | Text |
|---|---|
| 0.9950 | This entity is probably related to a combination of high doses of corticosteroids, Drugvecuronium administration and metabolic abnormalities associated with respiratory failure. |
| 0.9923 | This entity is probably related to a combination of high doses of corticosteroids, vecuronium administration and metabolic abnormalities associated with Adverse-Effectrespiratory failure . |
| Score | Text |
|---|---|
| 0.9993 | We describe a patient who, after receiving his first dose of Drugpregabalin to relieve neuropathic pain, presented with a negative myoclonus. |
| 0.9876 | We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a Adverse-Effectnegative myoclonus . |
| Score | Text |
|---|---|
| 0.9830 | We describe a patient who had a systemic allergic contact dermatitis to Drug8 - MOP develop during her second course of PUVA treatment for psoriasis. |
| 0.9785 | We describe a patient who had a Adverse-Effectsystemic allergic contact dermatitis to 8 - MOP develop during her second course of PUVA treatment for psoriasis. |
| Score | Text |
|---|---|
| 0.9994 | In two of these cases akathisia resolved after withdrawal of Drugolanzapine and substitution by a classical or an atypical neuroleptic agent, respectively. |
| 0.9978 | In two of these cases Adverse-Effectakathisia resolved after withdrawal of olanzapine and substitution by a classical or an atypical neuroleptic agent, respectively. |
| Score | Text |
|---|---|
| 0.9989 | Although the movement disorder could not with certainty be attributed to Drugtrazodone alone, the drug at least acted as an eliciting agent. |
| 0.9862 | Although the Adverse-Effectmovement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent. |
| Score | Text |
|---|---|
| 0.9995 | DISCUSSION : Central nervous system ( CNS ) toxicity has been described with Drugifosfamide , with most cases reported in the pediatric population. |
| 0.8372 | DISCUSSION : Adverse-EffectCentral nervous system ( CNS ) toxicity has been described with ifosfamide, with most cases reported in the pediatric population. |
| Score | Text |
|---|---|
| 0.9991 | Albeit rare among Western patients, such Druglithium - associated thyroid dysfunctions appeared to be more likely to occur in Hong Kong Chinese. |
| 0.9882 | Albeit rare among Western patients, such lithium - associated Adverse-Effectthyroid dysfunctions appeared to be more likely to occur in Hong Kong Chinese. |
| Score | Text |
|---|---|
| 0.9994 | Fever caused by the use of Drugfurosemide was proved ; the fever resolved after discontinuation of this medication and recurred after its reintroduction. |
| 0.9942 | Adverse-EffectFever caused by the use of furosemide was proved ; the fever resolved after discontinuation of this medication and recurred after its reintroduction. |
| Score | Text |
|---|---|
| 0.9914 | We describe a 10 - year - old boy with ulcerative colitis who developed Adverse-Effectacute pancreatitis while on long - term treatment with 5 - aminosalicylic acid. |
| 0.9785 | We describe a 10 - year - old boy with ulcerative colitis who developed acute pancreatitis while on long - term treatment with Drug5 - aminosalicylic acid . |
| Score | Text |
|---|---|
| 0.9996 | This case represents the third example of erythroid aplasia associated with an anti - inflammatory agent and the first instance due to Drugfenoprofen . |
| 0.9905 | This case represents the third example of Adverse-Effecterythroid aplasia associated with an anti - inflammatory agent and the first instance due to fenoprofen. |
| Score | Text |
|---|---|
| 0.9993 | After approximately two weeks of Drugsertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake. |
| 0.9828 | After approximately two weeks of sertraline treatment he noted an Adverse-Effectintense itching sensation in his scalp after eating a piece of chocolate cake. |
| Score | Text |
|---|---|
| 0.9995 | Eosinophilia has been encountered from 0. 2 to 61. 7 % in Drugclozapine - treated patients, mostly with a transient course and spontaneous remission. |
| 0.9980 | Adverse-EffectEosinophilia has been encountered from 0. 2 to 61. 7 % in clozapine - treated patients, mostly with a transient course and spontaneous remission. |
| Score | Text |
|---|---|
| 0.9875 | Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, Drugchlorpropamide . |
| 0.9840 | Acute intravascular hemolysis developed when a diabetic patient, previously treated with Drugglyburide , was started on another oral sulfonylurea drug, chlorpropamide. |
| 0.9780 | Adverse-EffectAcute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide. |
| Score | Text |
|---|---|
| 0.9994 | Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with Druginfliximab . |
| 0.9799 | Thus, clinical recognition of Adverse-Effectsleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab. |
| Score | Text |
|---|---|
| 0.9779 | A patient with disseminated herpes zoster developed a syndrome of inappropriate antidiuretic hormone and profound hyponatremia secondary to the administration of Drugadenine arabinoside . |
| 0.9702 | A patient with disseminated herpes zoster developed a Adverse-Effectsyndrome of inappropriate antidiuretic hormone and profound hyponatremia secondary to the administration of adenine arabinoside. |
| 0.9511 | A patient with disseminated herpes zoster developed a syndrome of inappropriate antidiuretic hormone and profound Adverse-Effecthyponatremia secondary to the administration of adenine arabinoside. |
| Score | Text |
|---|---|
| 0.9996 | CASE REPORT : We report a case of acute severe hepatitis resulting from Drugerlotinib monotherapy in a patient with locally advanced pancreatic cancer. |
| 0.9610 | CASE REPORT : We report a case of Adverse-Effectacute severe hepatitis resulting from erlotinib monotherapy in a patient with locally advanced pancreatic cancer. |
| Score | Text |
|---|---|
| 0.9994 | Described here are 2 patients who developed thrombotic microangiopathy of the kidneys after receiving high cumulative doses of the new anticancer drug Druggemcitabine . |
| 0.9860 | Described here are 2 patients who developed Adverse-Effectthrombotic microangiopathy of the kidneys after receiving high cumulative doses of the new anticancer drug gemcitabine. |
| Score | Text |
|---|---|
| 0.9995 | We report the first case of Drugchlorambucil - induced DRESS syndrome in a 70 - year - old man recently diagnosed with chronic lymphocytic leukaemia. |
| 0.9927 | We report the first case of chlorambucil - induced Adverse-EffectDRESS syndrome in a 70 - year - old man recently diagnosed with chronic lymphocytic leukaemia. |
| Score | Text |
|---|---|
| 0.9996 | In this report, we describe a patient receiving Druglenalidomide in whom dyspnea, fever, hypoxia, and diffuse pulmonary infiltrates developed. |
| 0.9982 | In this report, we describe a patient receiving lenalidomide in whom Adverse-Effectdyspnea , fever, hypoxia, and diffuse pulmonary infiltrates developed. |
| 0.9982 | In this report, we describe a patient receiving lenalidomide in whom dyspnea, fever, Adverse-Effecthypoxia , and diffuse pulmonary infiltrates developed. |
| 0.9896 | In this report, we describe a patient receiving lenalidomide in whom dyspnea, Adverse-Effectfever , hypoxia, and diffuse pulmonary infiltrates developed. |
| 0.9813 | In this report, we describe a patient receiving lenalidomide in whom dyspnea, fever, hypoxia, and Adverse-Effectdiffuse pulmonary infiltrates developed. |
| Score | Text |
|---|---|
| 0.9989 | Based on the Naranjo probability scale, serotonin syndrome was a probable adverse reaction associated with co - administration of Drugcitalopram and fentanyl. |
| 0.9988 | Based on the Naranjo probability scale, serotonin syndrome was a probable adverse reaction associated with co - administration of citalopram and Drugfentanyl . |
| 0.9890 | Based on the Naranjo probability scale, Adverse-Effectserotonin syndrome was a probable adverse reaction associated with co - administration of citalopram and fentanyl. |
| Score | Text |
|---|---|
| 0.9990 | METHOD : The authors followed a patient with chronic HCV who received Druginterferon and ribavirin and who developed hallucinations ultimately requiring psychiatric hospitalization. |
| 0.9990 | METHOD : The authors followed a patient with chronic HCV who received interferon and Drugribavirin and who developed hallucinations ultimately requiring psychiatric hospitalization. |
| 0.9987 | METHOD : The authors followed a patient with chronic HCV who received interferon and ribavirin and who developed Adverse-Effecthallucinations ultimately requiring psychiatric hospitalization. |
| Score | Text |
|---|---|
| 0.9990 | Case 2 : A 43 - year - old male alcoholic remained completely abstinent with Drugcyanamide treatment for 5 years and complained of general fatigue. |
| 0.9931 | Case 2 : A 43 - year - old male alcoholic remained completely abstinent with cyanamide treatment for 5 years and complained of Adverse-Effectgeneral fatigue . |
| Score | Text |
|---|---|
| 0.9991 | A healthy, 30 - year - old man, exposed to Drugsulindac on two separate occasions, had an incapacitating isolated idential sensory neuropathy. |
| 0.9674 | A healthy, 30 - year - old man, exposed to sulindac on two separate occasions, had an incapacitating Adverse-Effectisolated idential sensory neuropathy . |
| Score | Text |
|---|---|
| 0.9994 | According to the Naranjo et al. adverse - reaction probability scale, Drugenoxaparin was the probable cause of hepatotoxicity in this patient. |
| 0.9968 | According to the Naranjo et al. adverse - reaction probability scale, enoxaparin was the probable cause of Adverse-Effecthepatotoxicity in this patient. |
| Score | Text |
|---|---|
| 0.9995 | CONCLUSIONS : Clinicians treating elderly patients with Drugolanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly. |
| 0.9976 | CONCLUSIONS : Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing Adverse-Effecthyperglycemia and monitor such patients accordingly. |
| Score | Text |
|---|---|
| 0.9992 | We describe a patient with extranodal non - Hodgkin lymphoma who developed systemic candidiasis after treatment with a Drugcyclophosphamide - based chemotherapy regimen. |
| 0.9933 | We describe a patient with extranodal non - Hodgkin lymphoma who developed Adverse-Effectsystemic candidiasis after treatment with a cyclophosphamide - based chemotherapy regimen. |
| Score | Text |
|---|---|
| 0.9975 | Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( Adverse-EffectHUS ). |
| 0.9944 | Mitomycin C ( DrugMMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ). |
| 0.9876 | DrugMitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ). |
| 0.9867 | Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the Adverse-Effecthemolytic - uremic syndrome ( HUS ). |
| Score | Text |
|---|---|
| 0.9994 | DISCUSSION : DrugOlanzapine , like other atypical antipsychotic drugs, may cause muscle injury with concomitant elevations of serum CK of muscle origin. |
| 0.9621 | DISCUSSION : Olanzapine, like other atypical antipsychotic drugs, may cause Adverse-Effectmuscle injury with concomitant elevations of serum CK of muscle origin. |
| DISCUSSION : Olanzapine, like other atypical antipsychotic drugs, may cause Adverse-Effectmuscle injury with concomitant elevations of serum CK of muscle origin. | |
| Score | Text |
|---|---|
| 0.9994 | CASE SUMMARY : Two children with attention deficit disorder treated with Drugmethylphenidate as a simple drug developed fixed drug eruption of the scrotum. |
| 0.9433 | CASE SUMMARY : Two children with attention deficit disorder treated with methylphenidate as a simple drug developed Adverse-Effectfixed drug eruption of the scrotum . |
| Score | Text |
|---|---|
| 0.9974 | CONCLUSIONS : Jet - injection devices might constitute a helpful method to treat those patients affected by severe human insulin - induced Adverse-Effectlipoatrophy . |
| 0.9907 | CONCLUSIONS : Jet - injection devices might constitute a helpful method to treat those patients affected by severe Drughuman insulin - induced lipoatrophy. |
| Score | Text |
|---|---|
| 0.9992 | Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly Drugclozapine , and is easily misdiagnosed in children. |
| 0.9986 | Adverse-EffectAkathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children. |
| Score | Text |
|---|---|
| 0.9995 | METHODS / RESULTS : This paper presents a new case of Drugrifabutin uveitis and a review of the various published reports to date. |
| 0.8683 | METHODS / RESULTS : This paper presents a new case of rifabutin Adverse-Effectuveitis and a review of the various published reports to date. |
| Score | Text |
|---|---|
| 0.9993 | Effect of beta - blockade on symptomatic Drugdexamethasone - induced hypertrophic obstructive cardiomyopathy in premature infants : three case reports and literature review. |
| 0.9841 | Effect of beta - blockade on symptomatic dexamethasone - induced Adverse-Effecthypertrophic obstructive cardiomyopathy in premature infants : three case reports and literature review. |
| Score | Text |
|---|---|
| 0.9935 | OBJECTIVES : To describe the presentation and treatment of acute Drugisoniazid ( INH ) neurotoxicity appearing at an inner - city municipal hospital. |
| 0.9880 | OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( DrugINH ) neurotoxicity appearing at an inner - city municipal hospital. |
| 0.9641 | OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( INH ) Adverse-Effectneurotoxicity appearing at an inner - city municipal hospital. |
| Score | Text |
|---|---|
| 0.9992 | An 11 - year - old boy developed a severe enteropathy 2 years after initiation of Drugclofazimine treatment for graft - versus - host disease. |
| 0.9756 | An 11 - year - old boy developed a Adverse-Effectsevere enteropathy 2 years after initiation of clofazimine treatment for graft - versus - host disease. |
| Score | Text |
|---|---|
| 0.9976 | Because the cerebellar toxicity may be worsened by continuation of therapy after initial onset of symptoms, prompt termination of DrugHDARAC is recommended. |
| 0.9870 | Because the Adverse-Effectcerebellar toxicity may be worsened by continuation of therapy after initial onset of symptoms, prompt termination of HDARAC is recommended. |
| Score | Text |
|---|---|
| 0.9918 | To our knowledge, this is the first case of spontaneous remission of MTX - associated Adverse-Effectgastric LPD after discontinuation of MTX therapy. |
| 0.9561 | To our knowledge, this is the first case of spontaneous remission of DrugMTX - associated gastric LPD after discontinuation of MTX therapy. |
| 0.7789 | To our knowledge, this is the first case of spontaneous remission of MTX - associated gastric LPD after discontinuation of DrugMTX therapy. |
| Score | Text |
|---|---|
| 0.9851 | CONCLUSION : Under certain circumstances topical Drugbrimonidine can cause paradoxical raised IOP necessitating vigilance in follow - up of patients on topical brimonidine. |
| 0.9714 | CONCLUSION : Under certain circumstances topical brimonidine can cause Adverse-Effectparadoxical raised IOP necessitating vigilance in follow - up of patients on topical brimonidine. |
| 0.9298 | CONCLUSION : Under certain circumstances topical brimonidine can cause Adverse-Effectparadoxical raised IOP necessitating vigilance in follow - up of patients on topical brimonidine. |
| Score | Text |
|---|---|
| 0.9988 | A case of Drugpropranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented. |
| 0.9768 | A case of propranolol overdose complicated by Adverse-Effectesophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented. |
| Score | Text |
|---|---|
| 0.9995 | We present the first case of ovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with Drugtamoxifen for breast cancer. |
| 0.9939 | We present the first case of ovarian endometrioid carcinoma and Adverse-Effectendometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer. |
| 0.9830 | We present the first case of Adverse-Effectovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer. |
| Score | Text |
|---|---|
| 0.9992 | Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving Drugheparin therapy. |
| 0.8735 | Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing Adverse-Effectthrombosis who are receiving heparin therapy. |
| 0.8767 | Clinicians should be cognizant of this possibility and consider a diagnosis of Adverse-EffectHDAs in patients with ongoing thrombosis who are receiving heparin therapy. |
| Score | Text |
|---|---|
| 0.9851 | Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or Druginterferon alfa . |
| 0.9641 | Adverse-EffectSecond cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa. |
| 0.9513 | Second cancers including various types of Adverse-Effecthematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa. |
| Score | Text |
|---|---|
| 0.9961 | The abnormal rhythm disappeared with the withdrawal of Drugpropranolol and when the drug was restarted a 2 / 1 S - A block was seen. |
| 0.9850 | The Adverse-Effectabnormal rhythm disappeared with the withdrawal of propranolol and when the drug was restarted a 2 / 1 S - A block was seen. |
| Score | Text |
|---|---|
| 0.9995 | In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with DrugSASP . |
| 0.9946 | In both cases, Adverse-Effecthigh fever , skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP. |
| 0.9936 | In both cases, high fever, Adverse-Effectskin rash , liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP. |
| 0.9834 | In both cases, high fever, skin rash, liver dysfunction and Adverse-Effectatypical lymphocytosis developed 3 weeks after initiating treatment with SASP. |
| 0.9794 | In both cases, high fever, skin rash, Adverse-Effectliver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP. |
| Score | Text |
|---|---|
| 0.9956 | We report the specifics of 12 cases of severe hypertension after the intraoperative use of topical Drugphenylephrine , submucosal epinephrine, or both. |
| 0.9926 | We report the specifics of 12 cases of severe hypertension after the intraoperative use of topical phenylephrine, submucosal Drugepinephrine , or both. |
| 0.9851 | We report the specifics of 12 cases of Adverse-Effectsevere hypertension after the intraoperative use of topical phenylephrine, submucosal epinephrine, or both. |
| Score | Text |
|---|---|
| 0.9996 | RESULTS : Three patients who developed symptoms of inflammatory bowel disease ( IBD ) during Drugrofecoxib exposure are described along with pathology findings. |
| 0.9924 | RESULTS : Three patients who developed symptoms of inflammatory bowel disease ( Adverse-EffectIBD ) during rofecoxib exposure are described along with pathology findings. |
| 0.9812 | RESULTS : Three patients who developed symptoms of Adverse-Effectinflammatory bowel disease ( IBD ) during rofecoxib exposure are described along with pathology findings. |
| Score | Text |
|---|---|
| 0.9991 | We report a case of secondary glaucoma caused by epithelial downgrowth in which filtration surgery was performed with adjunctive use of subconjunctival Drug5 - fluorouracil . |
| 0.9906 | We report a case of secondary Adverse-Effectglaucoma caused by epithelial downgrowth in which filtration surgery was performed with adjunctive use of subconjunctival 5 - fluorouracil. |
| Score | Text |
|---|---|
| 0.9990 | We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and Drugcidofovir . |
| 0.9990 | We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with Drugganciclovir , foscarnet, and cidofovir. |
| 0.9989 | We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, Drugfoscarnet , and cidofovir. |
| 0.9941 | We report an allogeneic bone marrow transplant recipient who developed Adverse-EffectCMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir. |
| Score | Text |
|---|---|
| 0.9977 | Adverse-EffectPtosis occurring 24 h after chloroquine therapy, with full recovery 48 h after cessation of chloroquine, has not been described previously. |
| 0.9925 | Ptosis occurring 24 h after Drugchloroquine therapy, with full recovery 48 h after cessation of chloroquine, has not been described previously. |
| 0.9884 | Ptosis occurring 24 h after chloroquine therapy, with full recovery 48 h after cessation of Drugchloroquine , has not been described previously. |
| Score | Text |
|---|---|
| 0.9996 | Dyspnea, hypoxemia, and pleuritic chest pain occurred within 24 hours of Drugrituximab administration, and there was no other apparent explanation. |
| 0.9982 | Adverse-EffectDyspnea , hypoxemia, and pleuritic chest pain occurred within 24 hours of rituximab administration, and there was no other apparent explanation. |
| 0.9975 | Dyspnea, Adverse-Effecthypoxemia , and pleuritic chest pain occurred within 24 hours of rituximab administration, and there was no other apparent explanation. |
| 0.9898 | Dyspnea, hypoxemia, and Adverse-Effectpleuritic chest pain occurred within 24 hours of rituximab administration, and there was no other apparent explanation. |
| Score | Text |
|---|---|
| 0.9987 | Emphasis is given to the differentiation of Drugdiphenylhydantoin induced gingival hyperplasia from the angiomatous enlargement of the gingiva before any treatment is planned. |
| 0.9927 | Emphasis is given to the differentiation of diphenylhydantoin induced Adverse-Effectgingival hyperplasia from the angiomatous enlargement of the gingiva before any treatment is planned. |
| Score | Text |
|---|---|
| 0.9979 | Most cases of Adverse-Effectpancreatitis associated with L - asparaginase toxicity are self - limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation. |
| 0.9681 | Most cases of pancreatitis associated with DrugL - asparaginase toxicity are self - limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation. |
| 0.4759 | Most cases of pancreatitis associated with Adverse-EffectL - asparaginase toxicity are self - limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation. |
| Score | Text |
|---|---|
| 0.9994 | We present a case of significant over - anticoagulation temporally associated with a bout of protracted diarrhea in a patient on Drugwarfarin therapy. |
| 0.9713 | We present a case of significant Adverse-Effectover - anticoagulation temporally associated with a bout of protracted diarrhea in a patient on warfarin therapy. |
| 0.8912 | We present a case of significant over - anticoagulation temporally associated with a bout of protracted Adverse-Effectdiarrhea in a patient on warfarin therapy. |
| Score | Text |
|---|---|
| 0.9993 | Regardless of a negative history of asthma, therefore, life - threatening bronchospasm must be considered a possible complication of Drugpropranolol therapy. |
| 0.9778 | Regardless of a negative history of asthma, therefore, life - threatening Adverse-Effectbronchospasm must be considered a possible complication of propranolol therapy. |
| Score | Text |
|---|---|
| 0.9994 | After three weeks of Drugcarbamazepine therapy, the patient arrived at the emergency department ( ED ) with severe agitation and aggressive behavior. |
| 0.9936 | After three weeks of carbamazepine therapy, the patient arrived at the emergency department ( ED ) with severe agitation and Adverse-Effectaggressive behavior . |
| 0.9916 | After three weeks of carbamazepine therapy, the patient arrived at the emergency department ( ED ) with Adverse-Effectsevere agitation and aggressive behavior. |
| Score | Text |
|---|---|
| 0.9970 | We report the case of intoxication of a 41 - year - old female patient suffering from major depression with Drugmirtazapine complicated by severe hypothermia. |
| 0.9859 | We report the case of Adverse-Effectintoxication of a 41 - year - old female patient suffering from major depression with mirtazapine complicated by severe hypothermia. |
| 0.7986 | We report the case of intoxication of a 41 - year - old female patient suffering from major depression with mirtazapine complicated by Adverse-Effectsevere hypothermia . |
| Score | Text |
|---|---|
| 0.9898 | A 57 - year - old woman developed Adverse-Effectpulmonary sarcoidosis during therapy with interferon beta for advanced renal cell carcinoma metastatic to mediastinal lymph nodes. |
| 0.9865 | A 57 - year - old woman developed pulmonary sarcoidosis during therapy with Druginterferon beta for advanced renal cell carcinoma metastatic to mediastinal lymph nodes. |
| Score | Text |
|---|---|
| 0.9945 | In addition to the recognized arrhythmic complications, the authors emphasize myocardial necrosis as a possible further manifestation of Drugamsacrine - related cardiotoxicity. |
| 0.9926 | In addition to the recognized arrhythmic complications, the authors emphasize myocardial necrosis as a possible further manifestation of amsacrine - related Adverse-Effectcardiotoxicity . |
| 0.8592 | In addition to the recognized arrhythmic complications, the authors emphasize Adverse-Effectmyocardial necrosis as a possible further manifestation of amsacrine - related cardiotoxicity. |
| Score | Text |
|---|---|
| 0.9996 | This article presents a case of an atypical localized cutaneous eruption with an unusual course and protracted resolution time associated with Drugsorafenib therapy. |
| 0.9511 | This article presents a case of an Adverse-Effectatypical localized cutaneous eruption with an unusual course and protracted resolution time associated with sorafenib therapy. |
| Score | Text |
|---|---|
| 0.9917 | Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of Drugbenzalkonium ( Zephiran ) chloride prescribed for treatment of candidiasis. |
| 0.9915 | Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium ( DrugZephiran ) chloride prescribed for treatment of candidiasis. |
| 0.8723 | Infant twins sustained Adverse-Effectsevere circumoral and pharyngeal burns from a concentrated solution of benzalkonium ( Zephiran ) chloride prescribed for treatment of candidiasis. |
| Infant twins sustained severe Adverse-Effectcircumoral and pharyngeal burns from a concentrated solution of benzalkonium ( Zephiran ) chloride prescribed for treatment of candidiasis. | |
| Score | Text |
|---|---|
| 0.9979 | Epstein - Barr virus - associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and Drugrofecoxib : idiosyncratic reaction or pharmacogenetics? |
| 0.9976 | Epstein - Barr virus - associated lymphoproliferative disorder in a patient with rheumatoid arthritis on Drugmethotrexate and rofecoxib : idiosyncratic reaction or pharmacogenetics? |
| 0.9600 | Adverse-EffectEpstein - Barr virus - associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib : idiosyncratic reaction or pharmacogenetics? |
| Score | Text |
|---|---|
| 0.9988 | DrugNorethisterone in these 69 pregnancies accounted for 33. 3 % ( 5 of 15 ) cases of clitoral hypertrophy diagnosed in 100, 756 consecutive births. |
| 0.9916 | Norethisterone in these 69 pregnancies accounted for 33. 3 % ( 5 of 15 ) cases of Adverse-Effectclitoral hypertrophy diagnosed in 100, 756 consecutive births. |
| Score | Text |
|---|---|
| 0.9989 | The ocular toxicity of DrugDCF , previously described as conjunctivitis, appears to be a keratitis of moderate severity which requires further study. |
| 0.9947 | The ocular toxicity of DCF, previously described as conjunctivitis, appears to be a Adverse-Effectkeratitis of moderate severity which requires further study. |
| 0.9897 | The ocular toxicity of DCF, previously described as Adverse-Effectconjunctivitis , appears to be a keratitis of moderate severity which requires further study. |
| 0.9536 | The Adverse-Effectocular toxicity of DCF, previously described as conjunctivitis, appears to be a keratitis of moderate severity which requires further study. |
| Score | Text |
|---|---|
| 0.9995 | We report a rare case of recurrent ( stuttering ) priapism in a patient with protein C deficiency while maintained on DrugWarfarin therapy. |
| 0.9696 | We report a rare case of recurrent ( Adverse-Effectstuttering ) priapism in a patient with protein C deficiency while maintained on Warfarin therapy. |
| 0.9147 | We report a rare case of recurrent ( stuttering ) Adverse-Effectpriapism in a patient with protein C deficiency while maintained on Warfarin therapy. |
| Score | Text |
|---|---|
| 0.9978 | We report a case of severe respiratory failure due to Druggold salt toxicity in a patient suffering from rheumatoid arthritis requiring mechanical ventilation. |
| 0.7047 | We report a case of severe Adverse-Effectrespiratory failure due to gold salt toxicity in a patient suffering from rheumatoid arthritis requiring mechanical ventilation. |
| 0.8865 | We report a case of Adverse-Effectsevere respiratory failure due to gold salt toxicity in a patient suffering from rheumatoid arthritis requiring mechanical ventilation. |
| Score | Text |
|---|---|
| 0.9921 | He was diagnosed with possible Adverse-Effectserotonin syndrome ; his symptoms resolved after clomipramine was stopped but before clozapine was restarted eight days later. |
| 0.9585 | He was diagnosed with possible serotonin syndrome ; his symptoms resolved after Drugclomipramine was stopped but before clozapine was restarted eight days later. |
| 0.7189 | He was diagnosed with possible serotonin syndrome ; his symptoms resolved after clomipramine was stopped but before Drugclozapine was restarted eight days later. |
| Score | Text |
|---|---|
| 0.9973 | Since amiodarone was first marketed in 1992 in Japan, the incidence of amiodarone - induced Adverse-Effectthyrotoxicosis ( AIT ) has been increasing. |
| 0.9414 | Since amiodarone was first marketed in 1992 in Japan, the incidence of Drugamiodarone - induced thyrotoxicosis ( AIT ) has been increasing. |
| 0.8776 | Since amiodarone was first marketed in 1992 in Japan, the incidence of amiodarone - induced thyrotoxicosis ( Adverse-EffectAIT ) has been increasing. |
| 0.5573 | Since Drugamiodarone was first marketed in 1992 in Japan, the incidence of amiodarone - induced thyrotoxicosis ( AIT ) has been increasing. |
| Score | Text |
|---|---|
| 0.9993 | A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of Drughaloperidol . |
| 0.9889 | A patient suffering from a rare enzyme deficiency developed a Adverse-Effectmalignant neuroleptic syndrome after having been treated with one single dose of haloperidol. |
| Score | Text |
|---|---|
| 0.9934 | One of the subjects who was using extemporaneous topical minoxidil had Adverse-Effecthypertension and arteriosclerotic disease and the other died of a myocardial infarction. |
| 0.9915 | One of the subjects who was using extemporaneous topical Drugminoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction. |
| 0.9885 | One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a Adverse-Effectmyocardial infarction . |
| 0.9765 | One of the subjects who was using extemporaneous topical minoxidil had hypertension and Adverse-Effectarteriosclerotic disease and the other died of a myocardial infarction. |
| Score | Text |
|---|---|
| 0.9849 | Adverse-EffectAutoimmune thyroid disease is a common side - effect of interferon - alpha ( IFN - alpha ) treatment of viral hepatitis C. |
| 0.9667 | Autoimmune thyroid disease is a common side - effect of Druginterferon - alpha ( IFN - alpha ) treatment of viral hepatitis C. |
| 0.9537 | Autoimmune thyroid disease is a common side - effect of interferon - alpha ( DrugIFN - alpha ) treatment of viral hepatitis C. |
| Score | Text |
|---|---|
| 0.9964 | A noninvasive method in the differential diagnosis of vecuronium - induced and Drugmagnesium - induced protracted neuromuscular block in a severely preeclamptic patient. |
| 0.9898 | A noninvasive method in the differential diagnosis of Drugvecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient. |
| 0.9708 | A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced Adverse-Effectprotracted neuromuscular block in a severely preeclamptic patient. |
| Score | Text |
|---|---|
| 0.9991 | The patient received only the ophthalmic Drugsulfonamide , and it was used for one day, but he developed Stevens - Johnson syndrome. |
| 0.9829 | The patient received only the ophthalmic sulfonamide, and it was used for one day, but he developed Adverse-EffectStevens - Johnson syndrome . |
| Score | Text |
|---|---|
| 0.9930 | This review presents the first case series of DIC associated with acute hemoglobinemia or Adverse-Effecthemoglobinuria following anti - D IGIV administration for ITP. |
| 0.9927 | This review presents the first case series of Adverse-EffectDIC associated with acute hemoglobinemia or hemoglobinuria following anti - D IGIV administration for ITP. |
| 0.9891 | This review presents the first case series of DIC associated with Adverse-Effectacute hemoglobinemia or hemoglobinuria following anti - D IGIV administration for ITP. |
| 0.9750 | This review presents the first case series of DIC associated with acute hemoglobinemia or hemoglobinuria following Druganti - D IGIV administration for ITP. |
| Score | Text |
|---|---|
| 0.9889 | Patient A reported Adverse-Effectright leg weakness ( foot drop ) during week 4 of CAP - XRT ( 1600 mg / m2 ). |
| 0.9872 | Patient A reported right leg weakness ( Adverse-Effectfoot drop ) during week 4 of CAP - XRT ( 1600 mg / m2 ). |
| 0.9733 | Patient A reported right leg weakness ( foot drop ) during week 4 of DrugCAP - XRT ( 1600 mg / m2 ). |
| Score | Text |
|---|---|
| 0.9984 | Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with Drugmetripranolol 0. 6 % eye drops. |
| 0.9841 | Two case reports of Adverse-Effectbilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0. 6 % eye drops. |
| Score | Text |
|---|---|
| 0.9994 | CASE SUMMARY : A 58 - year - old white woman developed fulminant liver failure while being treated with the macrolide antibiotic Drugclarithromycin for pneumonia. |
| 0.9896 | CASE SUMMARY : A 58 - year - old white woman developed Adverse-Effectfulminant liver failure while being treated with the macrolide antibiotic clarithromycin for pneumonia. |
| Score | Text |
|---|---|
| 0.9991 | DrugMethamphetamine ' s extensive physiologic effects, inconsistent street purity, and multiple routes of administration offer many possibilities for injury to the cornea. |
| 0.9742 | Methamphetamine's extensive physiologic effects, inconsistent street purity, and multiple routes of administration offer many possibilities for Adverse-Effectinjury to the cornea . |
| Score | Text |
|---|---|
| 0.9977 | TREATMENT / OUTCOME : Standard anti - tuberculosis therapy was administered but was complicated by interaction with cyclosporine and drug - induced Adverse-Effectcholestasis . |
| 0.9972 | TREATMENT / OUTCOME : Standard anti - tuberculosis therapy was administered but was complicated by interaction with Drugcyclosporine and drug - induced cholestasis. |
| Score | Text |
|---|---|
| 0.9990 | We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with visual disturbance during treatment with Drugrifabutin . |
| 0.9776 | We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with Adverse-Effectvisual disturbance during treatment with rifabutin. |
| Score | Text |
|---|---|
| 0.9989 | After reviewing the literature we suggest the CPM was a complication of Druglithium toxicity which affected the lateral geniculate nucleus which produced blindness. |
| 0.9960 | After reviewing the literature we suggest the CPM was a complication of lithium toxicity which affected the lateral geniculate nucleus which produced Adverse-Effectblindness . |
| 0.9935 | After reviewing the literature we suggest the Adverse-EffectCPM was a complication of lithium toxicity which affected the lateral geniculate nucleus which produced blindness. |
| Score | Text |
|---|---|
| 0.9993 | The pathophysiological mechanisms remain unknown, although the drug could act through massive cytokines liberation after destruction of CD20 positive cells by Drugrituximab . |
| 0.9659 | The pathophysiological mechanisms remain unknown, although the drug could act through Adverse-Effectmassive cytokines liberation after destruction of CD20 positive cells by rituximab. |
| 0.9564 | The pathophysiological mechanisms remain unknown, although the drug could act through massive cytokines liberation after Adverse-Effectdestruction of CD20 positive cells by rituximab. |
| Score | Text |
|---|---|
| 0.9995 | We report a case of a patient with Drugciprofloxacin - induced SJS and acute onset of VBDS, and reviewed the related literature. |
| 0.9973 | We report a case of a patient with ciprofloxacin - induced Adverse-EffectSJS and acute onset of VBDS, and reviewed the related literature. |
| 0.9973 | We report a case of a patient with ciprofloxacin - induced SJS and acute onset of Adverse-EffectVBDS , and reviewed the related literature. |
| Score | Text |
|---|---|
| 0.9994 | CONCLUSION : DrugZidovudine is well a known cause of anaemia and thus should be used with caution in the initiation of antiretroviral therapy. |
| 0.9977 | CONCLUSION : Zidovudine is well a known cause of Adverse-Effectanaemia and thus should be used with caution in the initiation of antiretroviral therapy. |
| Score | Text |
|---|---|
| 0.9993 | Motor fluctuations appear after 2 - 3 years of Druglevodopa treatment, and affect at least 50 % of patients after five years. |
| 0.9927 | Adverse-EffectMotor fluctuations appear after 2 - 3 years of levodopa treatment, and affect at least 50 % of patients after five years. |
| Score | Text |
|---|---|
| 0.9988 | The second patient experienced mild nitritoid symptoms following several DrugGSTM injections prior experiencing a cerebrovascular accident within several hours of her next injection. |
| 0.9890 | The second patient experienced Adverse-Effectmild nitritoid symptoms following several GSTM injections prior experiencing a cerebrovascular accident within several hours of her next injection. |
| 0.7810 | The second patient experienced mild nitritoid symptoms following several GSTM injections prior experiencing a Adverse-Effectcerebrovascular accident within several hours of her next injection. |
| Score | Text |
|---|---|
| 0.9958 | We describe a case of fibrosing alveolitis, diagnosed by lung biopsy, in a patient receiving Drugamiodarone which responded to corticosteroid therapy. |
| 0.9866 | We describe a case of Adverse-Effectfibrosing alveolitis , diagnosed by lung biopsy, in a patient receiving amiodarone which responded to corticosteroid therapy. |
| Score | Text |
|---|---|
| 0.9991 | One type of SMON is associated with acrodermatitis enteropathica which has a very high frequency of occurrence in association with administration of Drugclioquinol . |
| 0.9925 | One type of Adverse-EffectSMON is associated with acrodermatitis enteropathica which has a very high frequency of occurrence in association with administration of clioquinol. |
| 0.9796 | One type of SMON is associated with Adverse-Effectacrodermatitis enteropathica which has a very high frequency of occurrence in association with administration of clioquinol. |
| Score | Text |
|---|---|
| 0.9995 | Intrahepatic cholestasis and cutaneous bullae associated with Drugglibenclamide therapy are described in a 61 - year - old diabetic patient who presented wit hypoglycaemic coma. |
| 0.9914 | Intrahepatic cholestasis and Adverse-Effectcutaneous bullae associated with glibenclamide therapy are described in a 61 - year - old diabetic patient who presented wit hypoglycaemic coma. |
| 0.9901 | Adverse-EffectIntrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61 - year - old diabetic patient who presented wit hypoglycaemic coma. |
| Score | Text |
|---|---|
| 0.9791 | We present a case of severe unilateral posterior scleritis associated with Drugzoledronic acid administration that was recognized and treated in a timely manner. |
| 0.9761 | We present a case of Adverse-Effectsevere unilateral posterior scleritis associated with zoledronic acid administration that was recognized and treated in a timely manner. |
| Score | Text |
|---|---|
| 0.9993 | Both had impaired lung function and abnormal computed tomographic scans, and their condition improved when Drugnitrofurantoin was withdrawn and corticosteroid treatment commenced. |
| 0.9469 | Both had impaired lung function and Adverse-Effectabnormal computed tomographic scans , and their condition improved when nitrofurantoin was withdrawn and corticosteroid treatment commenced. |
| 0.9386 | Both had Adverse-Effectimpaired lung function and abnormal computed tomographic scans, and their condition improved when nitrofurantoin was withdrawn and corticosteroid treatment commenced. |
| Score | Text |
|---|---|
| 0.9988 | We report the first biopsy confirmed occurrence of acute interstitial nephritis in a patient receiving treatment with DrugSunitinib for metastatic renal cell cancer. |
| 0.9795 | We report the first biopsy confirmed occurrence of Adverse-Effectacute interstitial nephritis in a patient receiving treatment with Sunitinib for metastatic renal cell cancer. |
| Score | Text |
|---|---|
| 0.9974 | DrugMeperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine. |
| 0.7770 | Meperidine - associated Adverse-Effectcentral nervous system ( CNS ) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine. |
| 0.5135 | Meperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by Adverse-Effectaccumulation of the active metabolite normeperidine . |
| 0.9671 | Meperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by Adverse-Effectaccumulation of the active metabolite normeperidine. |
| Score | Text |
|---|---|
| 0.9877 | Amiodarone is well recognized as an anti - arrhythmic drug containing a high dose of iodine with considerable potential to cause Adverse-Effectthyroid dysfunction . |
| 0.9856 | DrugAmiodarone is well recognized as an anti - arrhythmic drug containing a high dose of iodine with considerable potential to cause thyroid dysfunction. |
| 0.5127 | Amiodarone is well recognized as an anti - arrhythmic drug containing a high dose of Drugiodine with considerable potential to cause thyroid dysfunction. |
| Score | Text |
|---|---|
| 0.9995 | A case report of the hypersensitivity syndrome occurring in a patient being treated with Drugdapsone for a brown recluse spider bite is presented. |
| 0.9911 | A case report of the Adverse-Effecthypersensitivity syndrome occurring in a patient being treated with dapsone for a brown recluse spider bite is presented. |
| Score | Text |
|---|---|
| 0.9953 | Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine - induced Adverse-Effectlupus syndrome . |
| 0.9775 | Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of Drugsulfasalazine - induced lupus syndrome. |
| 0.8945 | Physicians who use Drugsulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine - induced lupus syndrome. |
| Score | Text |
|---|---|
| 0.9995 | In this article, we describe a Japanese patient with severe interstitial pneumonia probably caused by Drugsorafenib treatment for metastatic renal cell carcinoma. |
| 0.8152 | In this article, we describe a Japanese patient with Adverse-Effectsevere interstitial pneumonia probably caused by sorafenib treatment for metastatic renal cell carcinoma. |
| 0.8862 | In this article, we describe a Japanese patient with severe Adverse-Effectinterstitial pneumonia probably caused by sorafenib treatment for metastatic renal cell carcinoma. |
| Score | Text |
|---|---|
| 0.9994 | Recognizing early signs of HMSN, such as areflexia and pes cavus deformity, can prevent severe neurotoxicity of polychemotherapy by avoiding Drugvincristine . |
| 0.8656 | Recognizing early signs of HMSN, such as areflexia and pes cavus deformity, can prevent Adverse-Effectsevere neurotoxicity of polychemotherapy by avoiding vincristine. |
| Score | Text |
|---|---|
| 0.9994 | She was diagnosed with Epstein - Barr virus - associated polymorphic lymphoproliferative disorder ( LPD ) due to immunodeficiency caused by DrugMTX administration. |
| 0.9807 | She was diagnosed with Epstein - Barr virus - associated polymorphic lymphoproliferative disorder ( Adverse-EffectLPD ) due to immunodeficiency caused by MTX administration. |
| 0.9705 | She was diagnosed with Epstein - Barr virus - associated polymorphic lymphoproliferative disorder ( LPD ) due to Adverse-Effectimmunodeficiency caused by MTX administration. |
| 0.8888 | She was diagnosed with Adverse-EffectEpstein - Barr virus - associated polymorphic lymphoproliferative disorder ( LPD ) due to immunodeficiency caused by MTX administration. |
| Score | Text |
|---|---|
| 0.9994 | We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with Drugquetiapine . |
| 0.9715 | We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which Adverse-Effectsuicidal overdose deaths were associated with quetiapine. |
| Score | Text |
|---|---|
| 0.9991 | Although Drugtaxol has shown significant activity in advanced ovarian cancer, peripheral neuropathy is likely to become the major dose - limiting toxicity. |
| 0.9773 | Although taxol has shown significant activity in advanced ovarian cancer, Adverse-Effectperipheral neuropathy is likely to become the major dose - limiting toxicity. |
| Score | Text |
|---|---|
| 0.9986 | It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with DrugPTU appeared to induce ANCA. |
| 0.9970 | It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce Adverse-EffectANCA . |
| 0.9946 | It was concluded that Adverse-EffectANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA. |
| Score | Text |
|---|---|
| 0.9971 | We recommend the cautious use of ketorolac in patients with underlying illnesses where NSAID - induced Adverse-Effectototoxicity could result in adverse otologic consequences. |
| 0.9863 | We recommend the cautious use of Drugketorolac in patients with underlying illnesses where NSAID - induced ototoxicity could result in adverse otologic consequences. |
| Score | Text |
|---|---|
| 0.9980 | Adverse-EffectAnaphylaxis to cisplatin is an infrequent life - threatening complication which may occur even in patients who have received prior treatment with cisplatin. |
| 0.9474 | Anaphylaxis to Drugcisplatin is an infrequent life - threatening complication which may occur even in patients who have received prior treatment with cisplatin. |
| Score | Text |
|---|---|
| 0.9987 | We describe a case of significant elevation of serum transaminases in a patient treated with Drug6 - TG for a flare of Crohn's disease. |
| 0.9805 | We describe a case of significant Adverse-Effectelevation of serum transaminases in a patient treated with 6 - TG for a flare of Crohn's disease. |
| Score | Text |
|---|---|
| 0.9784 | RESULTS : Similar to previous findings of drug - induced Adverse-Effectvortex keratopathy , atovaquone vortex keratopathy is presumably caused by its lipophilic properties. |
| 0.9135 | RESULTS : Similar to previous findings of drug - induced vortex keratopathy, atovaquone Adverse-Effectvortex keratopathy is presumably caused by its lipophilic properties. |
| 0.8975 | RESULTS : Similar to previous findings of drug - induced vortex keratopathy, Drugatovaquone vortex keratopathy is presumably caused by its lipophilic properties. |
| Score | Text |
|---|---|
| 0.9995 | CONCLUSION : Although a definite association has not been proven, clinicians should be aware of the possibility of agranulocytosis while using Drugquetiapine . |
| 0.9971 | CONCLUSION : Although a definite association has not been proven, clinicians should be aware of the possibility of Adverse-Effectagranulocytosis while using quetiapine. |
| Score | Text |
|---|---|
| 0.9995 | A 54 - year - old man developed TEN 4 weeks after beginning Druglamotrigine for complex partial seizures related to a glioblastoma multiforme brain tumor. |
| 0.9989 | A 54 - year - old man developed Adverse-EffectTEN 4 weeks after beginning lamotrigine for complex partial seizures related to a glioblastoma multiforme brain tumor. |
| Score | Text |
|---|---|
| 0.9740 | We have safely used recombinant factor VIIa to treat bleeding in the immediate and long - term period following PCC - related Adverse-EffectMI . |
| 0.9485 | We have safely used recombinant factor VIIa to treat bleeding in the immediate and long - term period following DrugPCC - related MI. |
| 0.6563 | We have safely used Drugrecombinant factor VIIa to treat bleeding in the immediate and long - term period following PCC - related MI. |
| Score | Text |
|---|---|
| 0.9995 | We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation - recall related to Druggemcitabine and review literature. |
| 0.9909 | We report a patient with inoperable pancreatic cancer who developed Adverse-Effectgastrointestinal bleeding secondary to radiation - recall related to gemcitabine and review literature. |
| 0.9819 | We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to Adverse-Effectradiation - recall related to gemcitabine and review literature. |
| Score | Text |
|---|---|
| 0.9883 | METHODS : Adverse-EffectGrowth retardation was observed in six severely asthmatic children after introduction of high - dose fluticasone propionate treatment ( dry powder ). |
| 0.9786 | METHODS : Growth retardation was observed in six severely asthmatic children after introduction of high - dose Drugfluticasone propionate treatment ( dry powder ). |
| Score | Text |
|---|---|
| 0.9994 | We report the case of a 40 - year - old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral Drugflucloxacillin . |
| 0.9915 | We report the case of a 40 - year - old woman who developed fulminant hepatic failure and Adverse-Effectaplastic anaemia following a course of oral flucloxacillin. |
| 0.9876 | We report the case of a 40 - year - old woman who developed Adverse-Effectfulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin. |
| Score | Text |
|---|---|
| 0.9988 | The hospital course of the acute renal failure is presented with a review of the literature on cases of acute renal failure after DrugIVIG . |
| 0.9711 | The hospital course of the acute renal failure is presented with a review of the literature on cases of Adverse-Effectacute renal failure after IVIG. |
| Score | Text |
|---|---|
| 0.9931 | Use of the Naranjo probability scale indicated a highly probable relationship between the observed Adverse-Effectcardiac toxicity and amphotericin B deoxycholate therapy in this patient. |
| 0.9741 | Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and Drugamphotericin B deoxycholate therapy in this patient. |
| Score | Text |
|---|---|
| 0.9931 | We describe 2 patients with cutaneous lupus erythematosus who developed severe Drugdapsone reaction after low dose therapy, with a fatal outcome in one. |
| 0.7561 | We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy, with a Adverse-Effectfatal outcome in one. |
| 0.6010 | We describe 2 patients with cutaneous lupus erythematosus who developed severe Adverse-Effectdapsone reaction after low dose therapy, with a fatal outcome in one. |
| 0.8940 | We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy, with a Adverse-Effectfatal outcome in one. |
| Score | Text |
|---|---|
| 0.9995 | CONCLUSIONS : Because of its structural similarity to the other vinca alkaloids, Drugvinorelbine is believed to be responsible for SIADH in our patient. |
| 0.9976 | CONCLUSIONS : Because of its structural similarity to the other vinca alkaloids, vinorelbine is believed to be responsible for Adverse-EffectSIADH in our patient. |
| Score | Text |
|---|---|
| 0.9923 | Interferon - based treatments have the potential to decrease the burden of disease, but are complicated by side effects, including Adverse-Effectneuropsychiatric symptoms . |
| 0.9894 | DrugInterferon - based treatments have the potential to decrease the burden of disease, but are complicated by side effects, including neuropsychiatric symptoms. |
| Score | Text |
|---|---|
| 0.9988 | Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin, phenobarbital, and Drugacetazolamide . |
| 0.9987 | Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin, Drugphenobarbital , and acetazolamide. |
| 0.9985 | Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of Drugphenytoin , phenobarbital, and acetazolamide. |
| 0.6728 | Adverse-EffectSevere osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin, phenobarbital, and acetazolamide. |
| Score | Text |
|---|---|
| 0.9991 | Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with Drugfludarabine and autologous peripheral blood stem - cell transplantation. |
| 0.9905 | Acute myeloid leukemia and Adverse-Effectlung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem - cell transplantation. |
| 0.9796 | Adverse-EffectAcute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem - cell transplantation. |
| Score | Text |
|---|---|
| 0.9998 | OBJECTIVE : 1 ) To describe a patient with rheumatoid arthritis receiving Drugadalimumab who developed fever, pancytopenia, splenomegaly, and extreme hyperferritinemia. |
| 0.9977 | OBJECTIVE : 1 ) To describe a patient with rheumatoid arthritis receiving adalimumab who developed fever, Adverse-Effectpancytopenia , splenomegaly, and extreme hyperferritinemia. |
| 0.9975 | OBJECTIVE : 1 ) To describe a patient with rheumatoid arthritis receiving adalimumab who developed fever, pancytopenia, Adverse-Effectsplenomegaly , and extreme hyperferritinemia. |
| 0.9903 | OBJECTIVE : 1 ) To describe a patient with rheumatoid arthritis receiving adalimumab who developed fever, pancytopenia, splenomegaly, and Adverse-Effectextreme hyperferritinemia . |
| 0.9888 | OBJECTIVE : 1 ) To describe a patient with rheumatoid arthritis receiving adalimumab who developed Adverse-Effectfever , pancytopenia, splenomegaly, and extreme hyperferritinemia. |
| Score | Text |
|---|---|
| 0.9995 | The hyperpigmentation was diffuse scattered, flagellate like and linear streaking which was thought to be mainly related to the skin toxicity of Drugbleomycin . |
| 0.9808 | The hyperpigmentation was diffuse scattered, flagellate like and linear streaking which was thought to be mainly related to the Adverse-Effectskin toxicity of bleomycin. |
| Score | Text |
|---|---|
| 0.9917 | OBJECTIVE : This case report outlines a significant type of morbidity due to continued use of Druggabapentin during an episode of acute renal failure. |
| 0.9503 | OBJECTIVE : This case report outlines a significant type of morbidity due to continued use of gabapentin during an episode of Adverse-Effectacute renal failure . |
| Score | Text |
|---|---|
| 0.9993 | The findings were judged to be consistent with soft - tissue injury associated with intravenous administration of Drugphenytoin , also termed purple glove syndrome. |
| 0.9849 | The findings were judged to be consistent with Adverse-Effectsoft - tissue injury associated with intravenous administration of phenytoin, also termed purple glove syndrome. |
| 0.9845 | The findings were judged to be consistent with soft - tissue injury associated with intravenous administration of phenytoin, also termed Adverse-Effectpurple glove syndrome . |
| Score | Text |
|---|---|
| 0.9937 | Several case reports of Adverse-Effectaplastic anemia with use of acetazolamide, and two cases with use of methazolamide, have appeared in the literature. |
| 0.9842 | Several case reports of aplastic anemia with use of Drugacetazolamide , and two cases with use of methazolamide, have appeared in the literature. |
| 0.9773 | Several case reports of aplastic anemia with use of acetazolamide, and two cases with use of Drugmethazolamide , have appeared in the literature. |
| Score | Text |
|---|---|
| 0.9993 | A 2 - year - old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of Drugzonisamide . |
| 0.9923 | A 2 - year - old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled Adverse-Effectheat stroke during the administration of zonisamide. |
| Score | Text |
|---|---|
| 0.9973 | Fracture of the femoral neck occurred in one patient during DrugPSL therapy, although the relationship between the fracture and PSL therapy was uncertain. |
| 0.9817 | Adverse-EffectFracture of the femoral neck occurred in one patient during PSL therapy, although the relationship between the fracture and PSL therapy was uncertain. |
| Score | Text |
|---|---|
| 0.9962 | Despite a postulated dopaminergic mechanism, there seems to have been only one previous report of Drugamantadine ' s precipitating psychosis in a schizophrenic patient. |
| 0.9734 | Despite a postulated dopaminergic mechanism, there seems to have been only one previous report of amantadine's Adverse-Effectprecipitating psychosis in a schizophrenic patient. |
| Score | Text |
|---|---|
| 0.9992 | We report a 78 - year - old man who had acute unilateral total visual loss after retrogasserian Drugphenol injection for the treatment of trigeminal neuralgia. |
| 0.9886 | We report a 78 - year - old man who had Adverse-Effectacute unilateral total visual loss after retrogasserian phenol injection for the treatment of trigeminal neuralgia. |
| Score | Text |
|---|---|
| 0.9994 | In addition to its known effect on gallbladder stasis, Drugoctreotide alters bile acid composition and may thus hasten intrahepatic sludge and stone formation. |
| 0.9679 | In addition to its known effect on gallbladder stasis, octreotide alters bile acid composition and may thus Adverse-Effecthasten intrahepatic sludge and stone formation. |
| 0.9593 | In addition to its known effect on gallbladder stasis, octreotide alters bile acid composition and may thus hasten intrahepatic sludge and Adverse-Effectstone formation . |
| 0.9169 | In addition to its known effect on Adverse-Effectgallbladder stasis , octreotide alters bile acid composition and may thus hasten intrahepatic sludge and stone formation. |
| 0.8598 | In addition to its known effect on gallbladder stasis, octreotide Adverse-Effectalters bile acid composition and may thus hasten intrahepatic sludge and stone formation. |
| Score | Text |
|---|---|
| 0.9993 | To our knowledge, this is the first case reported in the English literature of a generalized exanthem due to subcutaneous injection of Drugenoxaparin . |
| 0.9885 | To our knowledge, this is the first case reported in the English literature of a Adverse-Effectgeneralized exanthem due to subcutaneous injection of enoxaparin. |
| Score | Text |
|---|---|
| 0.9987 | In keeping with findings in the literature, the aortic wall in this case was damaged by secondary changes following irradiation and DrugBleomycin treatment. |
| 0.8952 | In keeping with findings in the literature, the Adverse-Effectaortic wall in this case was damaged by secondary changes following irradiation and Bleomycin treatment. |
| Score | Text |
|---|---|
| 0.9991 | We report the case of a patient with increased cerebral cortical excitability following intoxication with Drugflupirtine , a centrally acting analgesic and antispastic drug. |
| 0.9791 | We report the case of a patient with Adverse-Effectincreased cerebral cortical excitability following intoxication with flupirtine, a centrally acting analgesic and antispastic drug. |
| Score | Text |
|---|---|
| 0.9929 | A 10 - year - old asthmatic boy began to suffer from Adverse-Effecturticarial rash and moderately severe bronchospasm after 8 weeks'treatment with disodium cromoglycate. |
| 0.9724 | A 10 - year - old asthmatic boy began to suffer from urticarial rash and moderately severe bronchospasm after 8 weeks'treatment with Drugdisodium cromoglycate . |
| 0.9526 | A 10 - year - old asthmatic boy began to suffer from urticarial rash and Adverse-Effectmoderately severe bronchospasm after 8 weeks'treatment with disodium cromoglycate. |
| Score | Text |
|---|---|
| 0.9989 | We report a case of long lasting respiratory depression after intravenous administration of Drugmorphine to a 7 year old girl with haemolytic uraemic syndrome. |
| 0.9884 | We report a case of long lasting Adverse-Effectrespiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome. |
| Score | Text |
|---|---|
| 0.9860 | We believe that these skin eruptions belong to a spectrum of Adverse-Effectneutrophilic dermatoses that can be induced or aggravated by G - CSF therapy. |
| 0.9860 | We believe that these Adverse-Effectskin eruptions belong to a spectrum of neutrophilic dermatoses that can be induced or aggravated by G - CSF therapy. |
| 0.9752 | We believe that these skin eruptions belong to a spectrum of neutrophilic dermatoses that can be induced or aggravated by DrugG - CSF therapy. |
| Score | Text |
|---|---|
| 0.9994 | We describe the clinical course of 2 patients with Crohn's disease ( CD ) in whom lymphoma was diagnosed after treatment with Druginfliximab . |
| 0.9966 | We describe the clinical course of 2 patients with Crohn's disease ( CD ) in whom Adverse-Effectlymphoma was diagnosed after treatment with infliximab. |
| Score | Text |
|---|---|
| 0.9996 | Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during Drugtamoxifen therapy : a case report and review of the literature. |
| 0.9969 | Ovarian endometrioid carcinoma and Adverse-Effectendometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy : a case report and review of the literature. |
| 0.9833 | Adverse-EffectOvarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy : a case report and review of the literature. |
| Score | Text |
|---|---|
| 0.9866 | We report here two cases of Adverse-Effectdyserythropoietic anaemia associated with long - term linezolid use that share striking similarities to chloramphenicol - associated myelotoxicity. |
| 0.9718 | We report here two cases of dyserythropoietic anaemia associated with long - term Druglinezolid use that share striking similarities to chloramphenicol - associated myelotoxicity. |
| 0.9633 | We report here two cases of dyserythropoietic anaemia associated with long - term linezolid use that share striking similarities to chloramphenicol - associated Adverse-Effectmyelotoxicity . |
| 0.9125 | We report here two cases of dyserythropoietic anaemia associated with long - term linezolid use that share striking similarities to Drugchloramphenicol - associated myelotoxicity. |
| Score | Text |
|---|---|
| 0.9995 | With the negative viral serologies, the clinical picture was most consistent with an infectious mononucleosis - like syndrome produced by the Drugminocycline ingestion. |
| 0.7272 | With the negative viral serologies, the clinical picture was most consistent with an infectious Adverse-Effectmononucleosis - like syndrome produced by the minocycline ingestion. |
| Score | Text |
|---|---|
| 0.9992 | The association between Drugheparin and priapism is often recognized ; abnormal platelet aggregation could play a role in the pathogenesis of this side effect. |
| 0.9946 | The association between heparin and Adverse-Effectpriapism is often recognized ; abnormal platelet aggregation could play a role in the pathogenesis of this side effect. |
| 0.9676 | The association between heparin and priapism is often recognized ; Adverse-Effectabnormal platelet aggregation could play a role in the pathogenesis of this side effect. |
| Score | Text |
|---|---|
| 0.9993 | We describe a premenopausal woman who, while having Drugtamoxifen due to a diagnosis of in situ ductal carcinoma, developed endometriosis requiring surgery. |
| 0.9983 | We describe a premenopausal woman who, while having tamoxifen due to a diagnosis of in situ ductal carcinoma, developed Adverse-Effectendometriosis requiring surgery. |
| Score | Text |
|---|---|
| 0.9994 | This case describes fulminant hepatic failure in a patient taking Drugdisulfiram with no previous liver disease and report of being compliant with alcohol abstinence. |
| 0.9862 | This case describes Adverse-Effectfulminant hepatic failure in a patient taking disulfiram with no previous liver disease and report of being compliant with alcohol abstinence. |
| Score | Text |
|---|---|
| 0.9990 | Ophthalmologists should be aware of the ocular side effects of DrugIFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia. |
| 0.9966 | Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of Adverse-Effecthypoalbuminemia and thrombocytopenia. |
| 0.9958 | Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and Adverse-Effectthrombocytopenia . |
| 0.9641 | Ophthalmologists should be aware of the Adverse-Effectocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia. |
| Score | Text |
|---|---|
| 0.9884 | The authors describe Adverse-Effectpericardial hemorrhage , which is related to the use of low - dose acetylsalicylic acid in a patient with essential thrombocythemia. |
| 0.9841 | The authors describe pericardial hemorrhage, which is related to the use of low - dose Drugacetylsalicylic acid in a patient with essential thrombocythemia. |
| Score | Text |
|---|---|
| 0.9992 | The case of a 29 - year - old man suffering from falciparum malaria disease who got a reversible hearing loss from Drugquinine therapy is presented. |
| 0.9890 | The case of a 29 - year - old man suffering from falciparum malaria disease who got a Adverse-Effectreversible hearing loss from quinine therapy is presented. |
| Score | Text |
|---|---|
| 0.9996 | We describe a case of interstitial hypoxaemiant pneumonitis probably related to Drugflecainide in a patient with the LEOPARD syndrome, a rare congenital disorder. |
| 0.9828 | We describe a case of Adverse-Effectinterstitial hypoxaemiant pneumonitis probably related to flecainide in a patient with the LEOPARD syndrome, a rare congenital disorder. |
| Score | Text |
|---|---|
| 0.9995 | To our knowledge, the syndrome of fever, pulmonary infiltrates, and pleural effusion following use of Drugacyclovir has not been previously reported. |
| 0.9897 | To our knowledge, the syndrome of Adverse-Effectfever , pulmonary infiltrates, and pleural effusion following use of acyclovir has not been previously reported. |
| 0.9850 | To our knowledge, the syndrome of fever, pulmonary infiltrates, and Adverse-Effectpleural effusion following use of acyclovir has not been previously reported. |
| 0.9773 | To our knowledge, the syndrome of fever, Adverse-Effectpulmonary infiltrates , and pleural effusion following use of acyclovir has not been previously reported. |
| Score | Text |
|---|---|
| 0.9855 | We report two patients who developed intense Adverse-Effectlivedo reticularis clearly related to the administration of interferon alpha 2b as an adjuvant therapy for melanoma. |
| 0.9702 | We report two patients who developed intense livedo reticularis clearly related to the administration of Druginterferon alpha 2b as an adjuvant therapy for melanoma. |
| Score | Text |
|---|---|
| 0.9983 | This profile should trigger a " red flag " as to the possibility of Drugphenobarbital behavioral side effects or exacerbation of preexisting maladaptive behaviors. |
| 0.9712 | This profile should trigger a " red flag " as to the possibility of phenobarbital behavioral side effects or Adverse-Effectexacerbation of preexisting maladaptive behaviors . |
| 0.9579 | This profile should trigger a " red flag " as to the possibility of phenobarbital Adverse-Effectbehavioral side effects or exacerbation of preexisting maladaptive behaviors. |
| 0.5645 | This profile should trigger a " red flag " as to the possibility of Adverse-Effectphenobarbital behavioral side effects or exacerbation of preexisting maladaptive behaviors. |
| Score | Text |
|---|---|
| 0.9959 | A 70 - year - old man was admitted to our hospital because of Adverse-Effectdyspnea after taking an antihistaminic agent ( homochlorcyclizine hydrochloride ) for itching. |
| 0.9784 | A 70 - year - old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent ( Drughomochlorcyclizine hydrochloride ) for itching. |
| Score | Text |
|---|---|
| 0.9994 | Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking Drugdofetilide for atrial fibrillation : a cautionary tale. |
| 0.9865 | Marked QT prolongation and Adverse-Effecttorsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation : a cautionary tale. |
| 0.9815 | Adverse-EffectMarked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation : a cautionary tale. |
| 0.9702 | Marked QT prolongation and torsades de pointes secondary to Adverse-Effectacute ischemia in an elderly man taking dofetilide for atrial fibrillation : a cautionary tale. |
| Score | Text |
|---|---|
| 0.9991 | A case is described of severe splenic hemorrhage and rupture which developed 3 h after completion of DrugtPA infusion for suspected acute myocardial infarction. |
| 0.9834 | A case is described of Adverse-Effectsevere splenic hemorrhage and rupture which developed 3 h after completion of tPA infusion for suspected acute myocardial infarction. |
| Score | Text |
|---|---|
| 0.9908 | The authors present a case report of a Adverse-Effectgranulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite. |
| 0.9860 | The authors present a case report of a granulomatous reaction leading to Adverse-Effecturethral prolapse , 3 months after the transurethral injection of calcium hydroxylapatite. |
| 0.9786 | The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of Drugcalcium hydroxylapatite . |
| Score | Text |
|---|---|
| 0.9988 | After only the third dose of Drugpentamidine , it was noted that the patient's heart rate had decreased to 48 beats / minute. |
| 0.9653 | After only the third dose of pentamidine, it was noted that the patient's Adverse-Effectheart rate had decreased to 48 beats / minute. |
| Score | Text |
|---|---|
| 0.9947 | However, prolongation of 5 - FU half - life and an increase in INR have been reported with the concurrent use of 5 - FU and Drugwarfarin . |
| 0.9929 | However, prolongation of 5 - FU half - life and an increase in INR have been reported with the concurrent use of Drug5 - FU and warfarin. |
| 0.9807 | However, prolongation of 5 - FU half - life and an Adverse-Effectincrease in INR have been reported with the concurrent use of 5 - FU and warfarin. |
| Score | Text |
|---|---|
| 0.9995 | The association with prolonged unopposed estrogen - like stimulation with Drugtamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed. |
| 0.9791 | The association with prolonged unopposed estrogen - like stimulation with tamoxifen as a possible factor in the development of Adverse-Effectovarian endometrioid carcinoma is discussed. |
| Score | Text |
|---|---|
| 0.9996 | OBJECTIVE : To describe a patient with asymptomatic bronchial asthma and hypertension who developed an acute asthma attack after receiving sustained - release Drugverapamil . |
| 0.9079 | OBJECTIVE : To describe a patient with asymptomatic bronchial asthma and hypertension who developed an Adverse-Effectacute asthma attack after receiving sustained - release verapamil. |
| 0.9926 | OBJECTIVE : To describe a patient with asymptomatic bronchial asthma and hypertension who developed an Adverse-Effectacute asthma attack after receiving sustained - release verapamil. |
| Score | Text |
|---|---|
| 0.9994 | We report a 53 - year - old - man who developed rippling muscle disease ( RMD ) 2 months after starting Drugsimvastatin therapy for hypercholesterolemia. |
| 0.9930 | We report a 53 - year - old - man who developed rippling muscle disease ( Adverse-EffectRMD ) 2 months after starting simvastatin therapy for hypercholesterolemia. |
| 0.9859 | We report a 53 - year - old - man who developed Adverse-Effectrippling muscle disease ( RMD ) 2 months after starting simvastatin therapy for hypercholesterolemia. |
| Score | Text |
|---|---|
| 0.9986 | This case report describes a 38 - year - old male in whom SIADH was strongly suspected secondary to DrugTegretol therapy to control a seizure disorder. |
| 0.9928 | This case report describes a 38 - year - old male in whom Adverse-EffectSIADH was strongly suspected secondary to Tegretol therapy to control a seizure disorder. |
| Score | Text |
|---|---|
| 0.9993 | PURPOSE : The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of Drugrifabutin . |
| 0.9893 | PURPOSE : The aim of this study was to report on the possible development of Adverse-Effectcorneal endothelial deposits resulting from the use of rifabutin. |
| Score | Text |
|---|---|
| 0.9996 | METHODS : In an institutional practice setting, two women, aged 25 and 45, developed acute myopia after starting Drugtopiramate for epilepsy. |
| 0.9947 | METHODS : In an institutional practice setting, two women, aged 25 and 45, developed Adverse-Effectacute myopia after starting topiramate for epilepsy. |
| Score | Text |
|---|---|
| 0.9934 | Our case points to the need for increased awareness by the general pediatricians of the potential hazards of Drugmineral oil use for chronic constipation. |
| 0.9220 | Our case points to the need for increased awareness by the general pediatricians of the Adverse-Effectpotential hazards of mineral oil use for chronic constipation. |
| Score | Text |
|---|---|
| 0.9990 | Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of DrugCCNU may be dose - related. |
| 0.9897 | Although lung specimens were lacking from these three patients, it is suggested that the Adverse-Effectpulmonary toxicity of CCNU may be dose - related. |
| Score | Text |
|---|---|
| 0.9980 | DrugBaclofen withdrawal syndrome resulting from underdosing of oral baclofen should be considered as a potential source of prolonged fever in the intensive care unit. |
| 0.9975 | Baclofen withdrawal syndrome resulting from underdosing of oral Drugbaclofen should be considered as a potential source of prolonged fever in the intensive care unit. |
| 0.9576 | Baclofen Adverse-Effectwithdrawal syndrome resulting from underdosing of oral baclofen should be considered as a potential source of prolonged fever in the intensive care unit. |
| 0.6245 | Baclofen withdrawal syndrome resulting from underdosing of oral baclofen should be considered as a potential source of prolonged Adverse-Effectfever in the intensive care unit. |
| Score | Text |
|---|---|
| 0.9240 | PURPOSE : We evaluated the in vitro hemodialysis ratio and subsequent toxicity and pharmacokinetics of Drugifosfamide in an anephric patient with Wilms'tumor. |
| 0.8246 | PURPOSE : We evaluated the in vitro hemodialysis ratio and subsequent Adverse-Effecttoxicity and pharmacokinetics of ifosfamide in an anephric patient with Wilms'tumor. |
| PURPOSE : We evaluated the in vitro hemodialysis ratio and subsequent toxicity and pharmacokinetics of Adverse-Effectifosfamide in an anephric patient with Wilms'tumor. | |
| PURPOSE : We evaluated the in vitro hemodialysis ratio and subsequent Drugtoxicity and pharmacokinetics of ifosfamide in an anephric patient with Wilms'tumor. | |
| Score | Text |
|---|---|
| 0.9994 | RESULTS : Five of 70 patients who had begun Drugleflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies. |
| 0.9966 | RESULTS : Five of 70 patients who had begun leflunomide therapy had significant Adverse-Effectweight loss that could not be linked to other identifiable etiologies. |
| Score | Text |
|---|---|
| 0.9983 | Eleven days after initiation of therapy with Drugamiodarone , the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia. |
| 0.9976 | Eleven days after initiation of therapy with amiodarone, the patient experienced Adverse-Effectsyncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia. |
| 0.9867 | Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of Adverse-Effectpolymorphous ventricular tachycardia . |
| Score | Text |
|---|---|
| 0.9995 | Severe loss of vision after removal of cataract caused by intravitreal Drugtriamcinolone in combination with photodynamic therapy for exudative age - related macular degeneration. |
| 0.9935 | Severe loss of vision after removal of Adverse-Effectcataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age - related macular degeneration. |
| 0.9475 | Adverse-EffectSevere loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age - related macular degeneration. |
| Score | Text |
|---|---|
| 0.9989 | BACKGROUND : The risk / benefit ratio of Drugwarfarin therapy changes in the over 75s, when haemorrhagic side - effects become more common. |
| 0.9759 | BACKGROUND : The risk / benefit ratio of warfarin therapy changes in the over 75s, when Adverse-Effecthaemorrhagic side - effects become more common. |
| Score | Text |
|---|---|
| 0.9994 | We present a case report of a patient who developed a prolonged QT while being treated with oral Drugmethadone for a chronic pain syndrome. |
| 0.9885 | We present a case report of a patient who developed a Adverse-Effectprolonged QT while being treated with oral methadone for a chronic pain syndrome. |
| Score | Text |
|---|---|
| 0.9929 | DISCUSSION : Methotrexate - induced Adverse-Effectpapular eruption is rarely reported shortly after beginning methotrexate therapy in patients with acute exacerbation of collagen vascular diseases. |
| 0.9844 | DISCUSSION : DrugMethotrexate - induced papular eruption is rarely reported shortly after beginning methotrexate therapy in patients with acute exacerbation of collagen vascular diseases. |
| 0.6666 | DISCUSSION : Methotrexate - induced papular eruption is rarely reported shortly after beginning Drugmethotrexate therapy in patients with acute exacerbation of collagen vascular diseases. |
| Score | Text |
|---|---|
| 0.9992 | RESULTS : Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with Drugmoxifloxacin . |
| 0.9896 | RESULTS : Both cases presented here describe Adverse-Effectcorneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin. |
| Score | Text |
|---|---|
| 0.9985 | We present a case of hemolytic - uremic syndrome that developed during the 4th cycle of combination chemotherapy with oxaliplatin, 5 - fluorouracil and Drugleucovorin . |
| 0.9985 | We present a case of hemolytic - uremic syndrome that developed during the 4th cycle of combination chemotherapy with oxaliplatin, Drug5 - fluorouracil and leucovorin. |
| 0.9985 | We present a case of hemolytic - uremic syndrome that developed during the 4th cycle of combination chemotherapy with Drugoxaliplatin , 5 - fluorouracil and leucovorin. |
| 0.9848 | We present a case of Adverse-Effecthemolytic - uremic syndrome that developed during the 4th cycle of combination chemotherapy with oxaliplatin, 5 - fluorouracil and leucovorin. |
| Score | Text |
|---|---|
| 0.9990 | The authors think that although Druglamivudine is widely used and well tolerated, it can cause ADRs, which are reversible after drug withdrawal. |
| 0.9984 | The authors think that although lamivudine is widely used and well tolerated, it can cause Adverse-EffectADRs , which are reversible after drug withdrawal. |
| Score | Text |
|---|---|
| 0.9996 | The case of a patient with infectious mononucleosis treated with Drugcephalexin who later showed a rash is presented and the previous literature is reviewed. |
| 0.9974 | The case of a patient with infectious mononucleosis treated with cephalexin who later showed a Adverse-Effectrash is presented and the previous literature is reviewed. |
| Score | Text |
|---|---|
| 0.9992 | Twenty - four hours after the administration of Druggemcitabine , a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs. |
| 0.9407 | Twenty - four hours after the administration of gemcitabine, a Adverse-Effectsymmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs. |
| Score | Text |
|---|---|
| 0.9969 | We report 4 patients, 2 on Drugmethylphenidate and 2 on dextroamphetamine who presented with acral cyanosis, livedo reticularis, or Raynaud phenomenon. |
| 0.9951 | We report 4 patients, 2 on methylphenidate and 2 on Drugdextroamphetamine who presented with acral cyanosis, livedo reticularis, or Raynaud phenomenon. |
| 0.9913 | We report 4 patients, 2 on methylphenidate and 2 on dextroamphetamine who presented with Adverse-Effectacral cyanosis , livedo reticularis, or Raynaud phenomenon. |
| 0.9911 | We report 4 patients, 2 on methylphenidate and 2 on dextroamphetamine who presented with acral cyanosis, livedo reticularis, or Adverse-EffectRaynaud phenomenon . |
| 0.9906 | We report 4 patients, 2 on methylphenidate and 2 on dextroamphetamine who presented with acral cyanosis, Adverse-Effectlivedo reticularis , or Raynaud phenomenon. |
| Score | Text |
|---|---|
| 0.9831 | From these data, Adverse-Effectacute generalized dystonia with brainstem and thalamic lesions may occur in WD patients after an initial d - penicillamine therapy. |
| 0.9738 | From these data, acute generalized dystonia with Adverse-Effectbrainstem and thalamic lesions may occur in WD patients after an initial d - penicillamine therapy. |
| 0.9718 | From these data, acute generalized dystonia with brainstem and thalamic lesions may occur in WD patients after an initial Drugd - penicillamine therapy. |
| Score | Text |
|---|---|
| 0.9886 | We present a case report of a patient with typhoid fever who experienced a Adverse-Effecthypersensitivity reaction subsequent to the infusion of chloramphenicol sodium succinate. |
| 0.9711 | We present a case report of a patient with typhoid fever who experienced a hypersensitivity reaction subsequent to the infusion of Drugchloramphenicol sodium succinate . |
| Score | Text |
|---|---|
| 0.9841 | A patient who had been treated with large doses of thyroid hormone for several years developed features of secondary Adverse-Effecthypothyroidism after thyroid hormone withdrawal. |
| 0.9831 | A patient who had been treated with large doses of Drugthyroid hormone for several years developed features of secondary hypothyroidism after thyroid hormone withdrawal. |
| Score | Text |
|---|---|
| 0.9989 | Seizures occurred in two patients with probable Alzheimer's disease who were receiving long - term treatment with Drugmetrifonate , an irreversible acetylcholinesterase inhibitor. |
| 0.9988 | Adverse-EffectSeizures occurred in two patients with probable Alzheimer's disease who were receiving long - term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor. |
| Score | Text |
|---|---|
| 0.9992 | RESULTS : A previously healthy 42 - year - old woman presented with acute - onset delirium with psychotic features as a consequence of Druglevofloxacin therapy. |
| RESULTS : A previously healthy 42 - year - old woman presented with Adverse-Effectacute - onset delirium with psychotic features as a consequence of levofloxacin therapy. | |
| Score | Text |
|---|---|
| 0.9994 | The exacerbation of psoriasis was accompanied by a massive induction of lesional type I interferon activity, detected by MxA expression after Drugimiquimod therapy. |
| 0.9840 | The Adverse-Effectexacerbation of psoriasis was accompanied by a massive induction of lesional type I interferon activity, detected by MxA expression after imiquimod therapy. |
| Score | Text |
|---|---|
| 0.9986 | Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with Drugquetiapine treatment that required its discontinuation. |
| 0.9972 | Although adverse effects are usually mild, the author reports here a case of Adverse-Effectleucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation. |
| 0.9961 | Although adverse effects are usually mild, the author reports here a case of leucocytopenia and Adverse-Effectthrombocytopenia with quetiapine treatment that required its discontinuation. |
| Score | Text |
|---|---|
| 0.9969 | DrugMethanol toxicity can cause severe central nervous system insult in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies. |
| 0.9676 | Methanol toxicity can cause severe central nervous system insult in which a characteristic pattern of Adverse-Effectbilateral putaminal injury is noted on brain imaging studies. |
| 0.9377 | Methanol toxicity can cause Adverse-Effectsevere central nervous system insult in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies. |
| Adverse-EffectMethanol toxicity can cause severe central nervous system insult in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies. | |
| Score | Text |
|---|---|
| 0.9904 | We report on a 14 - year - old boy with severe haemophilia A who developed a Adverse-Effectportal vein thrombosis during continuous infusion of F VIII. |
| 0.9792 | We report on a 14 - year - old boy with severe haemophilia A who developed a portal vein thrombosis during continuous infusion of DrugF VIII . |
| Score | Text |
|---|---|
| 0.9991 | CONCLUSIONS : The 3 cases presented here illustrate the development of reproductive endocrine disorders after the initiation of Drugvalproate therapy in women with epilepsy. |
| 0.9874 | CONCLUSIONS : The 3 cases presented here illustrate the development of Adverse-Effectreproductive endocrine disorders after the initiation of valproate therapy in women with epilepsy. |
| Score | Text |
|---|---|
| 0.9995 | We report a case of severe AVP three weeks following the administration of Druginfliximab for the treatment of Crohn's disease ( CD ). |
| 0.9874 | We report a case of Adverse-Effectsevere AVP three weeks following the administration of infliximab for the treatment of Crohn's disease ( CD ). |
| Score | Text |
|---|---|
| 0.9978 | CONCLUSION : During and after DrugIFN therapy, OCT is a useful examination technique for revealing macular edema in patients who have decreased vision. |
| 0.9810 | CONCLUSION : During and after IFN therapy, OCT is a useful examination technique for revealing Adverse-Effectmacular edema in patients who have decreased vision. |
| 0.9326 | CONCLUSION : During and after IFN therapy, OCT is a useful examination technique for revealing macular edema in patients who have Adverse-Effectdecreased vision . |
| Score | Text |
|---|---|
| 0.9969 | The increasing prevalence of methamphetamine abuse and the severity of the associated ulcers should alert ophthalmologists to the problem of methamphetamine - related Adverse-Effectkeratitis . |
| 0.9955 | The increasing prevalence of methamphetamine abuse and the severity of the associated Adverse-Effectulcers should alert ophthalmologists to the problem of methamphetamine - related keratitis. |
| 0.9559 | The increasing prevalence of Drugmethamphetamine abuse and the severity of the associated ulcers should alert ophthalmologists to the problem of methamphetamine - related keratitis. |
| 0.9172 | The increasing prevalence of methamphetamine abuse and the severity of the associated ulcers should alert ophthalmologists to the problem of Drugmethamphetamine - related keratitis. |
| Score | Text |
|---|---|
| 0.9974 | A patient with Parkinson's disease, initially treated with Drugbromocriptine and subsequently with cabergoline, developed progressive pleuropulmonary abnormalities during the latter therapy. |
| 0.9968 | A patient with Parkinson's disease, initially treated with bromocriptine and subsequently with Drugcabergoline , developed progressive pleuropulmonary abnormalities during the latter therapy. |
| 0.9707 | A patient with Parkinson's disease, initially treated with bromocriptine and subsequently with cabergoline, developed progressive Adverse-Effectpleuropulmonary abnormalities during the latter therapy. |
| Score | Text |
|---|---|
| 0.9997 | It is believed that this is the first reported case of reversible Drugazathioprine - induced cholestasis associated with histological evidence of bile duct injury. |
| 0.9983 | It is believed that this is the first reported case of reversible azathioprine - induced Adverse-Effectcholestasis associated with histological evidence of bile duct injury. |
| Score | Text |
|---|---|
| 0.9992 | The pathogenic mechanisms involved in the development of Drugadriamycin cardiomyopathy are reviewed, and the possible synergistic effect of other antitumor antibiotics is discussed. |
| 0.8933 | The pathogenic mechanisms involved in the development of adriamycin Adverse-Effectcardiomyopathy are reviewed, and the possible synergistic effect of other antitumor antibiotics is discussed. |
| Score | Text |
|---|---|
| 0.9990 | One should therefore be aware of possible extrapyramidal side effects with Drugolanzapine that are reduced compared to classical neuroleptic drugs but not completely eliminated. |
| 0.9789 | One should therefore be aware of possible Adverse-Effectextrapyramidal side effects with olanzapine that are reduced compared to classical neuroleptic drugs but not completely eliminated. |
| Score | Text |
|---|---|
| 0.9978 | Development of Adverse-Effectsarcoidosis during interferon alpha 2b and ribavirin combination therapy for chronic hepatitis C - - a case report and review of the literature. |
| 0.9965 | Development of sarcoidosis during interferon alpha 2b and Drugribavirin combination therapy for chronic hepatitis C - - a case report and review of the literature. |
| 0.9834 | Development of sarcoidosis during Druginterferon alpha 2b and ribavirin combination therapy for chronic hepatitis C - - a case report and review of the literature. |
| 0.5607 | Development of sarcoidosis during Druginterferon alpha 2b and ribavirin combination therapy for chronic hepatitis C - - a case report and review of the literature. |
| Score | Text |
|---|---|
| 0.9986 | Exacerbation of Druganthracycline - induced early chronic cardiomyopathy with ATRA : role of B - type natriuretic peptide as an indicator of cardiac dysfunction. |
| 0.9821 | Exacerbation of anthracycline - induced Adverse-Effectearly chronic cardiomyopathy with ATRA : role of B - type natriuretic peptide as an indicator of cardiac dysfunction. |
| 0.5246 | Exacerbation of anthracycline - induced early chronic cardiomyopathy with ATRA : role of B - type natriuretic peptide as an indicator of Adverse-Effectcardiac dysfunction . |
| Score | Text |
|---|---|
| 0.9995 | RESULTS : A male and a female patient with spasticity treated with intrathecal Drugbaclofen were recognized to have sexual dysfunction side effects from treatment. |
| 0.9795 | RESULTS : A male and a female patient with spasticity treated with intrathecal baclofen were recognized to have Adverse-Effectsexual dysfunction side effects from treatment. |
| Score | Text |
|---|---|
| 0.9926 | The diagnosis of Adverse-Effecthypothermia was delayed until it was apparent for several days but resolved with the discontinuation of risperidone and continuation of clozapine. |
| 0.9816 | The diagnosis of hypothermia was delayed until it was apparent for several days but resolved with the discontinuation of Drugrisperidone and continuation of clozapine. |
| 0.9808 | The diagnosis of hypothermia was delayed until it was apparent for several days but resolved with the discontinuation of risperidone and continuation of Drugclozapine . |
| Score | Text |
|---|---|
| 0.9991 | Other potential causes of renal failure were not present in our patient and his renal function gradually recovered with the cessation of Drugsuramin treatment. |
| 0.9922 | Other potential causes of Adverse-Effectrenal failure were not present in our patient and his renal function gradually recovered with the cessation of suramin treatment. |
| Score | Text |
|---|---|
| 0.9992 | In this paper we report a case of Drugnimodipine overdosage resulting in prolonged hypotension and hypoxemia, which was successfully treated with calcium gluconate. |
| 0.9981 | In this paper we report a case of nimodipine overdosage resulting in prolonged hypotension and Adverse-Effecthypoxemia , which was successfully treated with calcium gluconate. |
| 0.9715 | In this paper we report a case of nimodipine overdosage resulting in Adverse-Effectprolonged hypotension and hypoxemia, which was successfully treated with calcium gluconate. |
| Score | Text |
|---|---|
| 0.9988 | The first case concerns a 70 - year - old man who developed severe aplastic anemia 7 weeks after treatment with 500 mg of Drugticlopidine daily. |
| 0.7078 | The first case concerns a 70 - year - old man who developed severe Adverse-Effectaplastic anemia 7 weeks after treatment with 500 mg of ticlopidine daily. |
| 0.9564 | The first case concerns a 70 - year - old man who developed Adverse-Effectsevere aplastic anemia 7 weeks after treatment with 500 mg of ticlopidine daily. |
| Score | Text |
|---|---|
| 0.9995 | Thus, an immunological mechanism might be involved in the mechanism of Drugpirmenol - induced QT prolongation and T wave inversion on the electrocardiogram. |
| 0.9901 | Thus, an immunological mechanism might be involved in the mechanism of pirmenol - induced Adverse-EffectQT prolongation and T wave inversion on the electrocardiogram. |
| 0.9824 | Thus, an immunological mechanism might be involved in the mechanism of pirmenol - induced QT prolongation and Adverse-EffectT wave inversion on the electrocardiogram. |
| Score | Text |
|---|---|
| 0.9994 | DISCUSSION : DrugColchicine , the most important drug in treatment of FMF, can cause myopathy in patients with impaired renal and hepatic function. |
| 0.9984 | DISCUSSION : Colchicine, the most important drug in treatment of FMF, can cause Adverse-Effectmyopathy in patients with impaired renal and hepatic function. |
| Score | Text |
|---|---|
| 0.9724 | After other potential causes of liver toxicity were excluded, DrugTMP - SMX was determined to be the cause of his acute liver toxicity. |
| 0.9546 | After other potential causes of liver toxicity were excluded, TMP - SMX was determined to be the cause of his Adverse-Effectacute liver toxicity . |
| 0.9322 | After other potential causes of Adverse-Effectliver toxicity were excluded, TMP - SMX was determined to be the cause of his acute liver toxicity. |
| Score | Text |
|---|---|
| 0.9993 | The autopsy findings and a detailed medical history supported the conclusion that Drugclozapine - induced hypersensitivity myocarditis was the most likely cause of death. |
| 0.9874 | The autopsy findings and a detailed medical history supported the conclusion that clozapine - induced Adverse-Effecthypersensitivity myocarditis was the most likely cause of death. |
| Score | Text |
|---|---|
| 0.9982 | Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon - alpha can induce a condition resembling Adverse-EffectRPLS . |
| 0.9976 | Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, Drugtacrolimus , and interferon - alpha can induce a condition resembling RPLS. |
| 0.9970 | Moreover, treatment with immunosuppressive drugs such as Drugcyclosporine , cisplatin, tacrolimus, and interferon - alpha can induce a condition resembling RPLS. |
| 0.9969 | Moreover, treatment with immunosuppressive drugs such as cyclosporine, Drugcisplatin , tacrolimus, and interferon - alpha can induce a condition resembling RPLS. |
| 0.9705 | Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and Druginterferon - alpha can induce a condition resembling RPLS. |
| Score | Text |
|---|---|
| 0.9906 | We have recently encountered a patient with acquired haemophilia who developed a Adverse-Effectthrombotic left middle cerebral artery distribution stroke while being treated with pFVIII. |
| 0.8679 | We have recently encountered a patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke while being treated with DrugpFVIII . |
| Score | Text |
|---|---|
| 0.9899 | We believe this is the first report of Adverse-Effectmyocardial infarction due to coronary spasm, demonstrated by angiography associated with L - thyroxine therapy. |
| 0.9706 | We believe this is the first report of myocardial infarction due to coronary spasm, demonstrated by angiography associated with DrugL - thyroxine therapy. |
| 0.8920 | We believe this is the first report of myocardial infarction due to Adverse-Effectcoronary spasm , demonstrated by angiography associated with L - thyroxine therapy. |
| Score | Text |
|---|---|
| 0.9996 | We present the case of an adult Crohn's disease patient with a parvovirus B19 infection and leukopenia during long - term DrugAZA therapy. |
| 0.9973 | We present the case of an adult Crohn's disease patient with a parvovirus B19 infection and Adverse-Effectleukopenia during long - term AZA therapy. |
| Score | Text |
|---|---|
| 0.9993 | DrugThalidomide neuropathy is often associated with proximal weakness and may progress even after discontinuation of treatment, in the phenomenon of'coasting '. |
| 0.9636 | Thalidomide neuropathy is often associated with Adverse-Effectproximal weakness and may progress even after discontinuation of treatment, in the phenomenon of'coasting '. |
| 0.9247 | Thalidomide Adverse-Effectneuropathy is often associated with proximal weakness and may progress even after discontinuation of treatment, in the phenomenon of'coasting '. |
| Score | Text |
|---|---|
| 0.9971 | The possibility of phenytoin hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, rash, and Adverse-Effectlymphadenopathy . |
| 0.9950 | The possibility of phenytoin hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, Adverse-Effectrash , and lymphadenopathy. |
| 0.9872 | The possibility of Drugphenytoin hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, rash, and lymphadenopathy. |
| 0.9856 | The possibility of phenytoin hypersensitivity reactions should be considered when patients receiving Drugphenytoin have unusual symptoms, particularly fever, rash, and lymphadenopathy. |
| 0.9840 | The possibility of phenytoin hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly Adverse-Effectfever , rash, and lymphadenopathy. |
| 0.9359 | The possibility of phenytoin Adverse-Effecthypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, rash, and lymphadenopathy. |
| 0.5432 | The possibility of Adverse-Effectphenytoin hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, rash, and lymphadenopathy. |
| Score | Text |
|---|---|
| 0.9995 | She was administered Drugmetoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a movement disorder. |
| 0.9986 | She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, Adverse-Effectdiaphoresis , and a movement disorder. |
| 0.9984 | She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, Adverse-Effectdysarthria , diaphoresis, and a movement disorder. |
| 0.9981 | She was administered metoclopramide because of nausea and, within 2 hours, developed Adverse-Effectagitation , dysarthria, diaphoresis, and a movement disorder. |
| 0.9977 | She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a Adverse-Effectmovement disorder . |
| Score | Text |
|---|---|
| 0.9992 | Four Chinese female patients who suffered from manic - depressive disorder and underlying autoimmune thyroiditis developed transient episodes of thyrotoxicosis during maintenance Druglithium therapy. |
| 0.9965 | Four Chinese female patients who suffered from manic - depressive disorder and underlying autoimmune thyroiditis developed transient episodes of Adverse-Effectthyrotoxicosis during maintenance lithium therapy. |
| Score | Text |
|---|---|
| 0.9995 | The patient described in this paper was a 78 - year - old diabetic man who developed oral lesions of PV following institution of Drugglibenclamide therapy. |
| 0.9857 | The patient described in this paper was a 78 - year - old diabetic man who developed Adverse-Effectoral lesions of PV following institution of glibenclamide therapy. |
| Score | Text |
|---|---|
| 0.9954 | OBJECTIVE : To report on the possible development of Adverse-Effectserotonin syndrome in a patient receiving clomipramine after clozapine was withdrawn from the treatment regimen. |
| 0.9513 | OBJECTIVE : To report on the possible development of serotonin syndrome in a patient receiving Drugclomipramine after clozapine was withdrawn from the treatment regimen. |
| 0.9276 | OBJECTIVE : To report on the possible development of serotonin syndrome in a patient receiving clomipramine after Drugclozapine was withdrawn from the treatment regimen. |
| Score | Text |
|---|---|
| 0.9996 | We describe two patients with rheumatoid factor - positive, polyarticular - onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during Drugmethotrexate therapy. |
| 0.9875 | We describe two patients with rheumatoid factor - positive, polyarticular - onset juvenile rheumatoid arthritis in whom Adverse-Effectaccelerated nodulosis developed during methotrexate therapy. |
| Score | Text |
|---|---|
| 0.9993 | Development of an extensive skin rash following a single dose of DrugMTX may be an early warning sign for life - threatening bone marrow aplasia. |
| 0.9866 | Development of an Adverse-Effectextensive skin rash following a single dose of MTX may be an early warning sign for life - threatening bone marrow aplasia. |
| Score | Text |
|---|---|
| 0.9995 | However, follow - up revealed that gestational diabetes when associated with Drugnorethisterone had a lesser risk of emerging diabetes mellitus and impaired glucose tolerance. |
| 0.9801 | However, follow - up revealed that Adverse-Effectgestational diabetes when associated with norethisterone had a lesser risk of emerging diabetes mellitus and impaired glucose tolerance. |
| 0.9665 | However, follow - up revealed that gestational diabetes when associated with norethisterone had a lesser risk of emerging diabetes mellitus and Adverse-Effectimpaired glucose tolerance . |
| 0.9616 | However, follow - up revealed that gestational diabetes when associated with norethisterone had a lesser risk of emerging Adverse-Effectdiabetes mellitus and impaired glucose tolerance. |
| Score | Text |
|---|---|
| 0.9933 | After administration of Oxybutynin concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of DrugCarbamazepine intoxication. |
| 0.9385 | After administration of Oxybutynin concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of Adverse-EffectCarbamazepine intoxication . |
| 0.9083 | After administration of DrugOxybutynin concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of Carbamazepine intoxication. |
| 0.7613 | After administration of Oxybutynin concomitantly with an increase in the dose of DrugDantrolene , she presented the clinical symptoms and laboratory finding of Carbamazepine intoxication. |
| Score | Text |
|---|---|
| 0.9993 | We report a case of Drugcodeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit. |
| 0.8589 | We report a case of Adverse-Effectcodeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit. |
| Score | Text |
|---|---|
| 0.9991 | We report 5 cases of acute reversible renal failure coinciding with the onset of treatment with Drugcaptopril in patients with severe drug - resistant hypertension. |
| 0.9839 | We report 5 cases of Adverse-Effectacute reversible renal failure coinciding with the onset of treatment with captopril in patients with severe drug - resistant hypertension. |
| Score | Text |
|---|---|
| 0.9992 | We present a fatal case of subacute Drugmethanol toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression. |
| 0.9894 | We present a fatal case of subacute methanol toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and Adverse-Effectcerebral edema with ventricular compression. |
| 0.9881 | We present a fatal case of subacute methanol toxicity with associated Adverse-Effectdiffuse brain involvement , including bilateral putaminal necrosis and cerebral edema with ventricular compression. |
| 0.9879 | We present a fatal case of subacute methanol toxicity with associated diffuse brain involvement, including Adverse-Effectbilateral putaminal necrosis and cerebral edema with ventricular compression. |
| 0.9844 | We present a fatal case of subacute methanol toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with Adverse-Effectventricular compression . |
| 0.8690 | We present a Adverse-Effectfatal case of subacute methanol toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression. |
| We present a fatal case of subacute Adverse-Effectmethanol toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression. | |
| Score | Text |
|---|---|
| 0.9984 | Abrupt, accidental withdrawal of Drugtrihexyphenidyl triggered severe exacerbation of the cranial dystonia associated with inspiratory stridor and acute respiratory difficulties, prompting emergency admission. |
| 0.9889 | Abrupt, accidental withdrawal of trihexyphenidyl triggered severe exacerbation of the cranial dystonia associated with Adverse-Effectinspiratory stridor and acute respiratory difficulties, prompting emergency admission. |
| 0.9863 | Abrupt, accidental withdrawal of trihexyphenidyl triggered severe exacerbation of the cranial dystonia associated with inspiratory stridor and Adverse-Effectacute respiratory difficulties , prompting emergency admission. |
| 0.8852 | Abrupt, accidental withdrawal of trihexyphenidyl triggered severe exacerbation of the Adverse-Effectcranial dystonia associated with inspiratory stridor and acute respiratory difficulties, prompting emergency admission. |
| Score | Text |
|---|---|
| 0.9941 | Such a case induced by Adverse-Effecthypothyroidism complicating long - term therapy with amiodarone in a 45 year old woman with pre - excitation is presented. |
| 0.9647 | Such a case induced by hypothyroidism complicating long - term therapy with Drugamiodarone in a 45 year old woman with pre - excitation is presented. |
| Score | Text |
|---|---|
| 0.9994 | After having received Druggemcitabine on day 1 of the second course, the patient developed dry cough, subfebrile temperatures and dyspnea within 48 h. |
| 0.9987 | After having received gemcitabine on day 1 of the second course, the patient developed dry cough, subfebrile temperatures and Adverse-Effectdyspnea within 48 h. |
| 0.9937 | After having received gemcitabine on day 1 of the second course, the patient developed dry cough, Adverse-Effectsubfebrile temperatures and dyspnea within 48 h. |
| 0.9936 | After having received gemcitabine on day 1 of the second course, the patient developed Adverse-Effectdry cough , subfebrile temperatures and dyspnea within 48 h. |
| Score | Text |
|---|---|
| 0.9997 | We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving Drugcyclosporine . |
| 0.9989 | We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, Adverse-Effectheadache , and seizure after receiving cyclosporine. |
| 0.9986 | We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and Adverse-Effectseizure after receiving cyclosporine. |
| 0.9918 | We report a case of a young woman with SLE and thrombocytopenia, who developed Adverse-Effectsevere perspiration , headache, and seizure after receiving cyclosporine. |
| Score | Text |
|---|---|
| 0.9996 | The more common grade 3 or 4 adverse effects of Drugsunitinib include hypertension, fatigue, hand - foot syndrome, elevated lipase and lymphopenia. |
| 0.9989 | The more common grade 3 or 4 adverse effects of sunitinib include Adverse-Effecthypertension , fatigue, hand - foot syndrome, elevated lipase and lymphopenia. |
| 0.9989 | The more common grade 3 or 4 adverse effects of sunitinib include hypertension, Adverse-Effectfatigue , hand - foot syndrome, elevated lipase and lymphopenia. |
| 0.9982 | The more common grade 3 or 4 adverse effects of sunitinib include hypertension, fatigue, hand - foot syndrome, elevated lipase and Adverse-Effectlymphopenia . |
| 0.9925 | The more common grade 3 or 4 adverse effects of sunitinib include hypertension, fatigue, hand - foot syndrome, Adverse-Effectelevated lipase and lymphopenia. |
| 0.9784 | The more common grade 3 or 4 adverse effects of sunitinib include hypertension, fatigue, Adverse-Effecthand - foot syndrome , elevated lipase and lymphopenia. |
| Score | Text |
|---|---|
| 0.9994 | Four patients in whom pulmonary oedema developed during tocolysis with Drughexoprenaline are described and the aetiological factors and pathogenesis of this potentially lethal complication discussed. |
| 0.9893 | Four patients in whom Adverse-Effectpulmonary oedema developed during tocolysis with hexoprenaline are described and the aetiological factors and pathogenesis of this potentially lethal complication discussed. |
| Score | Text |
|---|---|
| 0.9897 | We present a case of a diabetic patient taking glyburide who was prescribed Drugciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours. |
| 0.9881 | We present a case of a diabetic patient taking Drugglyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours. |
| 0.9869 | We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed Adverse-Effectprolonged hypoglycemia , which persisted for over 24 hours. |
| Score | Text |
|---|---|
| 0.9994 | DrugZiprasidone is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including tardive dyskinesia ( TD ). |
| 0.9921 | Ziprasidone is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including Adverse-Effecttardive dyskinesia ( TD ). |
| 0.9889 | Ziprasidone is an atypical antipsychotic drug that is believed to have a low propensity for inducing Adverse-Effectextrapyramidal symptoms , including tardive dyskinesia ( TD ). |
| 0.9770 | Ziprasidone is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including tardive dyskinesia ( Adverse-EffectTD ). |
| Score | Text |
|---|---|
| 0.9978 | Drug - induced Adverse-Effecthepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long - acting repeatable attributed to the use of pegvisomant. |
| 0.9889 | Drug - induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and Drugoctreotide long - acting repeatable attributed to the use of pegvisomant. |
| 0.9844 | Drug - induced hepatitis in an acromegalic patient during combined treatment with Drugpegvisomant and octreotide long - acting repeatable attributed to the use of pegvisomant. |
| 0.9804 | Drug - induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long - acting repeatable attributed to the use of Drugpegvisomant . |
| Score | Text |
|---|---|
| 0.9986 | MATERIALS AND METHODS : We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of Drugepirubicin . |
| 0.9735 | MATERIALS AND METHODS : We present two cases of significant morbidity related to Adverse-Effectprimary and secondary perforation of the bladder following two instillations of epirubicin. |
| Score | Text |
|---|---|
| 0.9994 | Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between Drugfoscarnet therapy and these abnormalities. |
| 0.9846 | Our patient developed both nephrogenic diabetes insipidus and Adverse-Effectrenal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities. |
| 0.9786 | Our patient developed both Adverse-Effectnephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities. |
| Score | Text |
|---|---|
| 0.9995 | There have been numerous case reports of hyperglycemia with Drugolanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication. |
| 0.9932 | There have been numerous case reports of Adverse-Effecthyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication. |
| 0.9866 | There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported Adverse-Effecthyperglycemia within days of initiation of the medication. |
| Score | Text |
|---|---|
| 0.9964 | To our knowledge, drug - induced Adverse-Effectfever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker. |
| 0.9864 | To our knowledge, drug - induced fever has not been reported with the use of Drugdiltiazem hydrochloride , a commonly prescribed calcium channel blocker. |
| Score | Text |
|---|---|
| 0.9959 | We present the case of a postictal patient with Adverse-Effectlethargy , hyperammonemia, otherwise normal liver function tests, and a therapeutic valproic acid level. |
| 0.9879 | We present the case of a postictal patient with lethargy, hyperammonemia, otherwise normal liver function tests, and a therapeutic Drugvalproic acid level. |
| 0.9858 | We present the case of a postictal patient with lethargy, Adverse-Effecthyperammonemia , otherwise normal liver function tests, and a therapeutic valproic acid level. |
| Score | Text |
|---|---|
| 0.9981 | In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with Drugpsoralens plus long - wave ultraviolet radiation ( PUVA ). |
| 0.9823 | In two patients with mycosis fungoides, a Adverse-Effectsquamous cell carcinoma developed during therapy with psoralens plus long - wave ultraviolet radiation ( PUVA ). |
| Score | Text |
|---|---|
| 0.9988 | Sunburn may sometimes be a major injury in Drugpsoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive. |
| 0.9943 | Adverse-EffectSunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive. |
| 0.9752 | Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the Adverse-Effectskin extremely sensitive . |
| Score | Text |
|---|---|
| 0.9990 | A 35 - year - old nephrotic man developed acute renal failure with serum creatinine to 1543 micromol / l after a month of therapy with Drugenalapril . |
| 0.9875 | A 35 - year - old nephrotic man developed Adverse-Effectacute renal failure with serum creatinine to 1543 micromol / l after a month of therapy with enalapril. |
| Score | Text |
|---|---|
| 0.9993 | A 33 - year - old man with a history of recreational Drugbenztropine abuse presented to the emergency department with confusion, abdominal pain, and distention. |
| 0.9986 | A 33 - year - old man with a history of recreational benztropine abuse presented to the emergency department with confusion, abdominal pain, and Adverse-Effectdistention . |
| 0.9976 | A 33 - year - old man with a history of recreational benztropine abuse presented to the emergency department with confusion, Adverse-Effectabdominal pain , and distention. |
| 0.9908 | A 33 - year - old man with a history of recreational benztropine abuse presented to the emergency department with Adverse-Effectconfusion , abdominal pain, and distention. |
| Score | Text |
|---|---|
| 0.9952 | We report a fatal case of toxic epidermal necrolysis ( Adverse-EffectTEN ) resulting from a high dose of cytosine arabinoside ( ARA - C ). |
| 0.9749 | We report a fatal case of toxic epidermal necrolysis ( TEN ) resulting from a high dose of Drugcytosine arabinoside ( ARA - C ). |
| 0.9698 | We report a fatal case of toxic epidermal necrolysis ( TEN ) resulting from a high dose of cytosine arabinoside ( DrugARA - C ). |
| 0.9664 | We report a fatal case of Adverse-Effecttoxic epidermal necrolysis ( TEN ) resulting from a high dose of cytosine arabinoside ( ARA - C ). |
| Score | Text |
|---|---|
| 0.9996 | We report a third case of a 6 - week - old infant with Escherichia coli sepsis who received Drugampicillin and other antibiotics and subsequently developed TEN. |
| 0.9990 | We report a third case of a 6 - week - old infant with Escherichia coli sepsis who received ampicillin and other antibiotics and subsequently developed Adverse-EffectTEN . |
| Score | Text |
|---|---|
| 0.9992 | A 58 - year old patient is reported who developed an ischaemic cerebrovascular accident 22 hours after successful thrombolysis with Drugstreptokinase for life - threatening pulmonary emboli. |
| 0.9895 | A 58 - year old patient is reported who developed an Adverse-Effectischaemic cerebrovascular accident 22 hours after successful thrombolysis with streptokinase for life - threatening pulmonary emboli. |
| Score | Text |
|---|---|
| 0.9946 | It should be recognized that Drugibuprofen may be associated with salt and water retention in the same fashion as previously described with phenylbutazone and indomethacin. |
| 0.9847 | It should be recognized that ibuprofen may be associated with salt and water retention in the same fashion as previously described with phenylbutazone and Drugindomethacin . |
| 0.9761 | It should be recognized that ibuprofen may be associated with salt and water retention in the same fashion as previously described with Drugphenylbutazone and indomethacin. |
| 0.9695 | It should be recognized that ibuprofen may be associated with Adverse-Effectsalt and water retention in the same fashion as previously described with phenylbutazone and indomethacin. |
| Score | Text |
|---|---|
| 0.9994 | To our knowledge, we describe the first reported case of isolated paresthesia and peripheral neuropathy, without systemic involvement, secondary to Drugsulindac administration. |
| 0.9868 | To our knowledge, we describe the first reported case of isolated paresthesia and Adverse-Effectperipheral neuropathy , without systemic involvement, secondary to sulindac administration. |
| 0.9867 | To our knowledge, we describe the first reported case of Adverse-Effectisolated paresthesia and peripheral neuropathy, without systemic involvement, secondary to sulindac administration. |
| Score | Text |
|---|---|
| 0.9995 | DrugMetoclopramide - induced parkinsonism is not rare, and appropriate dose reduction in patients with renal failure will help reduce the incidence of this morbidity. |
| 0.9981 | Metoclopramide - induced Adverse-Effectparkinsonism is not rare, and appropriate dose reduction in patients with renal failure will help reduce the incidence of this morbidity. |
| Score | Text |
|---|---|
| 0.9993 | DISCUSSION : DrugPhenolphthalein is the active ingredient in several over - the - counter laxative preparations and has only rarely been reported to cause TEN. |
| 0.9988 | DISCUSSION : Phenolphthalein is the active ingredient in several over - the - counter laxative preparations and has only rarely been reported to cause Adverse-EffectTEN . |
| Score | Text |
|---|---|
| 0.9992 | Charcoal haemoperfusion and cysteamine therapy led to the rapid removal of the Drugparacetamol from the body and consequently prevented the development of severe hepatic necrosis. |
| 0.9792 | Charcoal haemoperfusion and cysteamine therapy led to the rapid removal of the paracetamol from the body and consequently prevented the development of Adverse-Effectsevere hepatic necrosis . |
| Score | Text |
|---|---|
| 0.9993 | We report on three patients with acute schizophrenia, who developed severe akathisia during treatment with Drugolanzapine ( 20 - 25 mg / d ). |
| 0.8542 | We report on three patients with acute schizophrenia, who developed Adverse-Effectsevere akathisia during treatment with olanzapine ( 20 - 25 mg / d ). |
| 0.5390 | We report on three patients with acute schizophrenia, who developed severe Adverse-Effectakathisia during treatment with olanzapine ( 20 - 25 mg / d ). |
| Score | Text |
|---|---|
| 0.9995 | Multiple syncopal episodes started to occur during Drugthalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia. |
| 0.9852 | Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of Adverse-Effectsustained ventricular tachycardia . |
| 0.9796 | Adverse-EffectMultiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia. |
| Score | Text |
|---|---|
| 0.9994 | He had an immediate hypersensitivity reaction during the initiation of the DrugMTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness. |
| 0.9871 | He had an immediate Adverse-Effecthypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness. |
| 0.9805 | He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, Adverse-Effectcough , and chest tightness. |
| 0.9527 | He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, Adverse-Effectfacial swelling , cough, and chest tightness. |
| 0.8906 | He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and Adverse-Effectchest tightness . |
| 0.7855 | He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with Adverse-Effectdiffuse urticaria , facial swelling, cough, and chest tightness. |
| Score | Text |
|---|---|
| 0.9921 | This report presents a case of Adverse-Effectcolon perforation which occurred 4 months after treatment with intraperitoneal chromic phosphate for stage IB ovarian papillary serous cystadenocarcinoma. |
| 0.9833 | This report presents a case of colon perforation which occurred 4 months after treatment with intraperitoneal Drugchromic phosphate for stage IB ovarian papillary serous cystadenocarcinoma. |
| Score | Text |
|---|---|
| 0.9991 | We suggest that Drugitraconazole should be added to the list of drugs that may be responsible for a drug - induced vanishing bile duct syndrome. |
| 0.9851 | We suggest that itraconazole should be added to the list of drugs that may be responsible for a drug - induced Adverse-Effectvanishing bile duct syndrome . |
| Score | Text |
|---|---|
| 0.9949 | AIM : Report of a case of a woman patient who developed celiac disease after pegylated interferon alpha - 2a and Drugribavirin use for chronic hepatitis C. |
| 0.9935 | AIM : Report of a case of a woman patient who developed Adverse-Effectceliac disease after pegylated interferon alpha - 2a and ribavirin use for chronic hepatitis C. |
| 0.9709 | AIM : Report of a case of a woman patient who developed celiac disease after Drugpegylated interferon alpha - 2a and ribavirin use for chronic hepatitis C. |
| Score | Text |
|---|---|
| 0.9978 | These findings suggest that Adverse-Effectbicytopenia in this patient was caused by D - Pen and may be due to different sensitivities in the hematopoietic lineage. |
| 0.9778 | These findings suggest that bicytopenia in this patient was caused by DrugD - Pen and may be due to different sensitivities in the hematopoietic lineage. |
| Score | Text |
|---|---|
| 0.9811 | We describe a case of needle - track Adverse-Effectcutaneous seeding of hepatocellular carcinoma ( HCC ) after sonographically guided percutaneous ethanol injection ( PEI ). |
| 0.9315 | We describe a case of needle - track cutaneous seeding of hepatocellular carcinoma ( HCC ) after sonographically guided percutaneous Drugethanol injection ( PEI ). |
| 0.9771 | We describe a case of needle - track cutaneous seeding of hepatocellular carcinoma ( HCC ) after sonographically guided percutaneous Drugethanol injection ( PEI ). |
| 0.9610 | We describe a case of needle - track cutaneous seeding of hepatocellular carcinoma ( HCC ) after sonographically guided percutaneous ethanol injection ( DrugPEI ). |
| 0.6429 | We describe a case of needle - track cutaneous seeding of hepatocellular carcinoma ( DrugHCC ) after sonographically guided percutaneous ethanol injection ( PEI ). |
| Score | Text |
|---|---|
| 0.9995 | This article reports the occurrence of Drugrifampin - associated thrombocytopenia in an indigent patient after a four - month lapse in therapy for pulmonary tuberculosis. |
| 0.9977 | This article reports the occurrence of rifampin - associated Adverse-Effectthrombocytopenia in an indigent patient after a four - month lapse in therapy for pulmonary tuberculosis. |
| Score | Text |
|---|---|
| 0.9736 | Recent studies have shown that under experimental conditions Drugferrous sulfate may reduce the gastrointestinal absorption of orally administered levothyroxine sodium in patients with primary hypothyroidism. |
| Recent studies have shown that under experimental conditions ferrous sulfate may Adverse-Effectreduce the gastrointestinal absorption of orally administered levothyroxine sodium in patients with primary hypothyroidism. | |
| Score | Text |
|---|---|
| 0.9989 | We postulate that Drugcyclosporin , possibly together with ganciclovir, can produce transient brain stem or neuromuscular dysfunction with eye movement abnormality in occasional patients. |
| 0.9982 | We postulate that cyclosporin, possibly together with Drugganciclovir , can produce transient brain stem or neuromuscular dysfunction with eye movement abnormality in occasional patients. |
| 0.9757 | We postulate that cyclosporin, possibly together with ganciclovir, can produce Adverse-Effecttransient brain stem or neuromuscular dysfunction with eye movement abnormality in occasional patients. |
| 0.9659 | We postulate that cyclosporin, possibly together with ganciclovir, can produce transient brain stem or neuromuscular dysfunction with Adverse-Effecteye movement abnormality in occasional patients. |
| Score | Text |
|---|---|
| 0.9957 | We believe that this is the first description of acute hepatitis caused by an idiosyncratic adverse reaction to Druggliclazide or to one of its metabolites. |
| 0.9893 | We believe that this is the first description of Adverse-Effectacute hepatitis caused by an idiosyncratic adverse reaction to gliclazide or to one of its metabolites. |
| Score | Text |
|---|---|
| 0.9994 | The second is a 29 - year - old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with Druginfliximab . |
| 0.9791 | The second is a 29 - year - old man with CD in whom Adverse-Effectnodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab. |
| Score | Text |
|---|---|
| 0.9992 | Five personal observations of an acute amnestic episode in younger individuals after intake of Drugclioquinol are described together with three observations from the medical literature. |
| 0.9850 | Five personal observations of an Adverse-Effectacute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature. |
| Score | Text |
|---|---|
| 0.9982 | In this case, interferon alpha induced Adverse-Effectpolymyositis and cardiomyopathy is diagnosed in a 33 - yr - old male patient with history of chronic hepatitis B. |
| 0.9978 | In this case, interferon alpha induced polymyositis and Adverse-Effectcardiomyopathy is diagnosed in a 33 - yr - old male patient with history of chronic hepatitis B. |
| 0.9854 | In this case, Druginterferon alpha induced polymyositis and cardiomyopathy is diagnosed in a 33 - yr - old male patient with history of chronic hepatitis B. |
| Score | Text |
|---|---|
| 0.9995 | Case 3 : A 29 - year - old female alcoholic complained of general fatigue and a slight fever after 1. 5 years of abstinence with Drugcyanamide treatment. |
| 0.9889 | Case 3 : A 29 - year - old female alcoholic complained of general fatigue and a slight Adverse-Effectfever after 1. 5 years of abstinence with cyanamide treatment. |
| 0.9954 | Case 3 : A 29 - year - old female alcoholic complained of Adverse-Effectgeneral fatigue and a slight fever after 1. 5 years of abstinence with cyanamide treatment. |
| Case 3 : A 29 - year - old female alcoholic complained of general Adverse-Effectfatigue and a slight fever after 1. 5 years of abstinence with cyanamide treatment. | |
| Score | Text |
|---|---|
| 0.9995 | A twelve year - old - girl with idiopathic partial epilepsy with secondary generalization, developed acute psychosis 10 days after the administration of Druglevetiracetam . |
| 0.9931 | A twelve year - old - girl with idiopathic partial epilepsy with secondary generalization, developed Adverse-Effectacute psychosis 10 days after the administration of levetiracetam. |
| Score | Text |
|---|---|
| 0.9995 | In addition to disease refractoriness, rare instances of disease progression from chronic phase to blast crisis during Drugimatinib therapy have recently been anecdotally reported. |
| 0.9883 | In addition to disease refractoriness, rare instances of disease progression from chronic phase to Adverse-Effectblast crisis during imatinib therapy have recently been anecdotally reported. |
| Score | Text |
|---|---|
| 0.9784 | The authors suggest that in patients with corneal ulcers refractory to conventional treatment who are receiving Drugcolchicine , cessation of colchicine therapy should be considered. |
| 0.8307 | The authors suggest that in patients with Adverse-Effectcorneal ulcers refractory to conventional treatment who are receiving colchicine, cessation of colchicine therapy should be considered. |
| 0.9561 | The authors suggest that in patients with corneal ulcers refractory to conventional treatment who are receiving colchicine, cessation of Drugcolchicine therapy should be considered. |
| Score | Text |
|---|---|
| 0.9983 | OBJECTIVE : To describe a case of cefazolin - induced Adverse-Effectleukopenia in a critically ill patient who developed this adverse reaction upon rechallenge with cefoxitin. |
| 0.9862 | OBJECTIVE : To describe a case of Drugcefazolin - induced leukopenia in a critically ill patient who developed this adverse reaction upon rechallenge with cefoxitin. |
| Score | Text |
|---|---|
| 0.9979 | We describe a case of infection with Mycobacterium abscessus in a 67 - year - old woman receiving Druginfliximab as a component of her therapy for RA. |
| 0.9534 | We describe a case of infection with Adverse-EffectMycobacterium abscessus in a 67 - year - old woman receiving infliximab as a component of her therapy for RA. |
| Score | Text |
|---|---|
| 0.9899 | This case study is the second report of localized purpura after prolonged Druglamotrigine treatment suggesting this may be an atypical lamotrigine - induced drug reaction. |
| 0.9793 | This case study is the second report of Adverse-Effectlocalized purpura after prolonged lamotrigine treatment suggesting this may be an atypical lamotrigine - induced drug reaction. |
| Score | Text |
|---|---|
| 0.9993 | After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with Drugmetamizole use. |
| 0.9883 | After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming Adverse-Effectsepsis associated with metamizole use. |
| Score | Text |
|---|---|
| 0.9915 | Although a few case reports link Drugmetronidazole with the development of pseudomembranous colitis, albendazole has not been associated with the development of this condition. |
| 0.9905 | Although a few case reports link metronidazole with the development of Adverse-Effectpseudomembranous colitis , albendazole has not been associated with the development of this condition. |
| Score | Text |
|---|---|
| 0.9801 | Three cases of Adverse-Effectpseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L - asparaginase. |
| 0.9680 | Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous DrugL - asparaginase . |
| Score | Text |
|---|---|
| 0.9995 | The oligohidrosis caused by Drugzonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration. |
| 0.9972 | The Adverse-Effectoligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration. |
| Score | Text |
|---|---|
| 0.9991 | Massive DrugCBZ OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst - suppression EEG pattern, and cranial nerve areflexia. |
| 0.9888 | Massive CBZ OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst - suppression EEG pattern, and Adverse-Effectcranial nerve areflexia . |
| 0.9797 | Massive CBZ OD may produce a reversible encephalopathy that includes Adverse-Effectcortical hyperexcitability , a profound burst - suppression EEG pattern, and cranial nerve areflexia. |
| 0.9629 | Massive CBZ OD may produce a Adverse-Effectreversible encephalopathy that includes cortical hyperexcitability, a profound burst - suppression EEG pattern, and cranial nerve areflexia. |
| 0.9536 | Massive CBZ OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a Adverse-Effectprofound burst - suppression EEG pattern , and cranial nerve areflexia. |
| 0.9789 | Massive CBZ OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst - suppression EEG pattern, and cranial Adverse-Effectnerve areflexia . |
| Score | Text |
|---|---|
| 0.9995 | Progressive interstitial fibrosis with roentgenographic honeycombing developed in the case of a psoriatic patient who had been on a regimen of Drugmethotrexate for 18 years. |
| 0.9827 | Adverse-EffectProgressive interstitial fibrosis with roentgenographic honeycombing developed in the case of a psoriatic patient who had been on a regimen of methotrexate for 18 years. |
| Score | Text |
|---|---|
| 0.9990 | Case 4 : A 61 - year - old male alcoholic who remained completely abstinent while taking Drugcyanamide for 3 years showed slight elevation of serum transaminases. |
| 0.9789 | Case 4 : A 61 - year - old male alcoholic who remained completely abstinent while taking cyanamide for 3 years showed slight Adverse-Effectelevation of serum transaminases . |
| Score | Text |
|---|---|
| 0.9985 | A retrospective review of TTP patients with Drugquinine - associated thrombotic microangiopathy ( TMA ) for whom ADAMTS13 was measured before plasma exchange was performed. |
| 0.9840 | A retrospective review of TTP patients with quinine - associated Adverse-Effectthrombotic microangiopathy ( TMA ) for whom ADAMTS13 was measured before plasma exchange was performed. |
| 0.9279 | A retrospective review of TTP patients with quinine - associated thrombotic microangiopathy ( Adverse-EffectTMA ) for whom ADAMTS13 was measured before plasma exchange was performed. |
| Score | Text |
|---|---|
| 0.9967 | We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug - seeking behavior or anticholinergic symptoms with the use of Drugdiphenhydramine . |
| 0.9918 | We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug - seeking behavior or Adverse-Effectanticholinergic symptoms with the use of diphenhydramine. |
| 0.9884 | We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited Adverse-Effectdrug - seeking behavior or anticholinergic symptoms with the use of diphenhydramine. |
| Score | Text |
|---|---|
| 0.9995 | Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after DrugBCNU infusion. |
| 0.9902 | Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of Adverse-Effectmyocardial ischemia during and immediately after BCNU infusion. |
| Score | Text |
|---|---|
| 0.9994 | No cases of renal acidosis, and only one case of nephrogenic diabetes insipidus, has been previously reported as a complication of Drugfoscarnet treatment. |
| 0.9704 | No cases of renal acidosis, and only one case of Adverse-Effectnephrogenic diabetes insipidus , has been previously reported as a complication of foscarnet treatment. |
| 0.9803 | No cases of Adverse-Effectrenal acidosis , and only one case of nephrogenic diabetes insipidus, has been previously reported as a complication of foscarnet treatment. |
| Score | Text |
|---|---|
| 0.9982 | Clinicians have been aware of lithium toxicity for many years and traditionally have administered thiazide diuretics for lithium - induced Adverse-Effectpolyuria and nephrogenic diabetes insipidus. |
| 0.9819 | Clinicians have been aware of Druglithium toxicity for many years and traditionally have administered thiazide diuretics for lithium - induced polyuria and nephrogenic diabetes insipidus. |
| 0.9818 | Clinicians have been aware of lithium toxicity for many years and traditionally have administered thiazide diuretics for lithium - induced polyuria and Adverse-Effectnephrogenic diabetes insipidus . |
| 0.9728 | Clinicians have been aware of lithium toxicity for many years and traditionally have administered thiazide diuretics for Druglithium - induced polyuria and nephrogenic diabetes insipidus. |
| 0.9717 | Clinicians have been aware of lithium toxicity for many years and traditionally have administered Drugthiazide diuretics for lithium - induced polyuria and nephrogenic diabetes insipidus. |
| Clinicians have been aware of Adverse-Effectlithium toxicity for many years and traditionally have administered thiazide diuretics for lithium - induced polyuria and nephrogenic diabetes insipidus. | |
| Score | Text |
|---|---|
| 0.9983 | Thrombotic thrombocytopenic purpura ( TTP ) developed in a patient with seropositive rheumatoid arthritis ( RA ) after 2 1 / 2 months of treatment with Drugpenicillamine . |
| 0.9961 | Thrombotic thrombocytopenic purpura ( Adverse-EffectTTP ) developed in a patient with seropositive rheumatoid arthritis ( RA ) after 2 1 / 2 months of treatment with penicillamine. |
| 0.9884 | Adverse-EffectThrombotic thrombocytopenic purpura ( TTP ) developed in a patient with seropositive rheumatoid arthritis ( RA ) after 2 1 / 2 months of treatment with penicillamine. |
| Score | Text |
|---|---|
| 0.9748 | These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the DrugM - CSF treatment and macrophage - related glomerular injury. |
| 0.9547 | These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the M - CSF treatment and Adverse-Effectmacrophage - related glomerular injury . |
| Score | Text |
|---|---|
| 0.9976 | A previous review described data on 15 patients who experienced acute hemoglobinemia or Adverse-Effecthemoglobinuria following anti - D IGIV administration for ITP or secondary thrombocytopenia. |
| 0.9878 | A previous review described data on 15 patients who experienced Adverse-Effectacute hemoglobinemia or hemoglobinuria following anti - D IGIV administration for ITP or secondary thrombocytopenia. |
| 0.9721 | A previous review described data on 15 patients who experienced acute hemoglobinemia or hemoglobinuria following Druganti - D IGIV administration for ITP or secondary thrombocytopenia. |
| 0.6501 | A previous review described data on 15 patients who experienced acute hemoglobinemia or hemoglobinuria following Druganti - D IGIV administration for ITP or secondary thrombocytopenia. |
| Score | Text |
|---|---|
| 0.9992 | This is an image and brief case report of a 13 - year - old boy who presented with severe rash and systemic symptoms after starting Drugoxcarbazepine . |
| 0.9814 | This is an image and brief case report of a 13 - year - old boy who presented with Adverse-Effectsevere rash and systemic symptoms after starting oxcarbazepine. |
| Score | Text |
|---|---|
| 0.9974 | The authors describe a case of oral - facial dyskinesia that occurred after discontinuation of Drugamoxapine , and antidepressant which may also have neuroleptic effects. |
| 0.9843 | The authors describe a case of Adverse-Effectoral - facial dyskinesia that occurred after discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects. |
| Score | Text |
|---|---|
| 0.9858 | After gastric - outlet obstruction was recognized in several infants who received Drugprostaglandin E1 , we studied the association between the drug and this complication. |
| 0.9812 | After Adverse-Effectgastric - outlet obstruction was recognized in several infants who received prostaglandin E1, we studied the association between the drug and this complication. |
| Score | Text |
|---|---|
| 0.9986 | Adverse-EffectGynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered. |
| 0.9940 | Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and Drugphenytoin already being administered. |
| 0.9939 | Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the Drugphenobarbital and phenytoin already being administered. |
| 0.9909 | Gynecomastia developed in two epileptic patients some months after the addition of oral Drugfluoresone 750 mg daily to the phenobarbital and phenytoin already being administered. |
| Score | Text |
|---|---|
| 0.9995 | We report a case admitted with a first - detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self - medication with Drugvardenafil . |
| 0.9776 | We report a case admitted with a first - detected, Adverse-Effectsymptomatic paroxysmal atrial fibrillation in a healthy patient after self - medication with vardenafil. |
| Score | Text |
|---|---|
| 0.9994 | CONCLUSIONS : We present a case of a patient with CML who developed KS 12 months after starting treatment with Drugimatinib 400 mg / d. |
| 0.9972 | CONCLUSIONS : We present a case of a patient with CML who developed Adverse-EffectKS 12 months after starting treatment with imatinib 400 mg / d. |
| Score | Text |
|---|---|
| 0.9814 | The probable proarrhythmic action of Drugamiodarone , although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy. |
| 0.8363 | The probable Adverse-Effectproarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy. |
| Score | Text |
|---|---|
| 0.9976 | We report three cases of IFN beta induced Adverse-Effecthepatitis in MS and discuss the pathology findings and possible mechanisms of drug - induced liver injury. |
| 0.9874 | We report three cases of DrugIFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug - induced liver injury. |
| 0.9768 | We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug - induced Adverse-Effectliver injury . |
| Score | Text |
|---|---|
| 0.9981 | We conclude that low - dose DrugHU therapy in patients with thalassemia intermedia may increase total Hb levels sufficiently to eliminate the need for transfusions. |
| 0.8792 | We conclude that low - dose HU therapy in patients with thalassemia intermedia may Adverse-Effectincrease total Hb levels sufficiently to eliminate the need for transfusions. |
| 0.9514 | We conclude that low - dose HU therapy in patients with thalassemia intermedia may Adverse-Effectincrease total Hb levels sufficiently to eliminate the need for transfusions. |
| Score | Text |
|---|---|
| 0.9994 | This case report describes the development of asymptomatic visual field defects ( VFDs ) in a psychiatric patient with bipolar disorder receiving adjunctive Drugtiagabine treatment. |
| 0.9841 | This case report describes the development of asymptomatic visual field defects ( Adverse-EffectVFDs ) in a psychiatric patient with bipolar disorder receiving adjunctive tiagabine treatment. |
| 0.9103 | This case report describes the development of asymptomatic Adverse-Effectvisual field defects ( VFDs ) in a psychiatric patient with bipolar disorder receiving adjunctive tiagabine treatment. |
| 0.9584 | This case report describes the development of Adverse-Effectasymptomatic visual field defects ( VFDs ) in a psychiatric patient with bipolar disorder receiving adjunctive tiagabine treatment. |
| Score | Text |
|---|---|
| 0.9991 | DrugAmiodarone was the third drug to induce AVT in this patient ; she received 200 mg / day six days per week for six months. |
| 0.9985 | Amiodarone was the third drug to induce Adverse-EffectAVT in this patient ; she received 200 mg / day six days per week for six months. |
| Score | Text |
|---|---|
| 0.9991 | Three days after receiving intravitreal injection of Drugbevacizumab ( 1. 25 mg in 0. 1 ml ), he developed acute vision loss and change of consciousness. |
| 0.9926 | Three days after receiving intravitreal injection of bevacizumab ( 1. 25 mg in 0. 1 ml ), he developed Adverse-Effectacute vision loss and change of consciousness. |
| 0.9875 | Three days after receiving intravitreal injection of bevacizumab ( 1. 25 mg in 0. 1 ml ), he developed acute vision loss and Adverse-Effectchange of consciousness . |
| Score | Text |
|---|---|
| 0.9993 | Two of these patients, who also received the anti - emetic Drugprochlorperazine , lost consciousness for 48 - 72 h and then fully recovered. |
| 0.9810 | Two of these patients, who also received the anti - emetic prochlorperazine, Adverse-Effectlost consciousness for 48 - 72 h and then fully recovered. |
| Score | Text |
|---|---|
| 0.9853 | CONCLUSIONS : This is the second case report that describes gemcitabine - induced Adverse-Effectradiation recall in rectus abdominus muscles after gemcitabine - based radiation therapy. |
| 0.9669 | CONCLUSIONS : This is the second case report that describes Druggemcitabine - induced radiation recall in rectus abdominus muscles after gemcitabine - based radiation therapy. |
| 0.5815 | CONCLUSIONS : This is the second case report that describes gemcitabine - induced radiation recall in rectus abdominus muscles after Druggemcitabine - based radiation therapy. |
| Score | Text |
|---|---|
| 0.9995 | The 5 patients had severe renovascular disease which might thus represent a significant risk factor in the development of Drugcaptopril - induced acute renal failure. |
| 0.9877 | The 5 patients had severe renovascular disease which might thus represent a significant risk factor in the development of captopril - induced Adverse-Effectacute renal failure . |
| Score | Text |
|---|---|
| 0.9994 | Although vasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of Drugcladribine treatment. |
| 0.9971 | Although Adverse-Effectvasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of cladribine treatment. |
| Score | Text |
|---|---|
| 0.9937 | Treatment of ELP in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of Drugmineral oil . |
| 0.9804 | Treatment of Adverse-EffectELP in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of mineral oil. |
| 0.9758 | Treatment of ELP in children is generally supportive, with the symptoms and Adverse-Effectroentgenographic abnormalities resolving within months after stopping the use of mineral oil. |
| Score | Text |
|---|---|
| 0.9993 | This case illustrates that the hemophagocytic syndrome associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking Drugsulfasalazine . |
| 0.9916 | This case illustrates that the Adverse-Effecthemophagocytic syndrome associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking sulfasalazine. |
| Score | Text |
|---|---|
| 0.9826 | One patient was an 80 - year - old woman who was admitted for Adverse-EffectStaphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids. |
| 0.9816 | One patient was an 80 - year - old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and Drugcorticosteroids . |
| 0.9768 | One patient was an 80 - year - old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of Drugsodium hyaluronate and corticosteroids. |
| Score | Text |
|---|---|
| 0.9996 | The incidence of oral - Drugverapamil - induced hypotension in the presence of concomitant beta - adrenergic blockade by the oral route is quite rare. |
| 0.9985 | The incidence of oral - verapamil - induced Adverse-Effecthypotension in the presence of concomitant beta - adrenergic blockade by the oral route is quite rare. |
| Score | Text |
|---|---|
| 0.9633 | Painful neutrophilic skin lesions were observed in two children receiving Druggranulocyte colony - stimulating factor ( G - CSF ) for treatment of idiopathic neutropenia. |
| 0.9536 | Painful neutrophilic skin lesions were observed in two children receiving granulocyte colony - stimulating factor ( DrugG - CSF ) for treatment of idiopathic neutropenia. |
| 0.7585 | Painful Adverse-Effectneutrophilic skin lesions were observed in two children receiving granulocyte colony - stimulating factor ( G - CSF ) for treatment of idiopathic neutropenia. |
| 0.6853 | Adverse-EffectPainful neutrophilic skin lesions were observed in two children receiving granulocyte colony - stimulating factor ( G - CSF ) for treatment of idiopathic neutropenia. |
| Adverse-EffectPainful neutrophilic skin lesions were observed in two children receiving granulocyte colony - stimulating factor ( G - CSF ) for treatment of idiopathic neutropenia. | |
| Score | Text |
|---|---|
| 0.9994 | This case had radiation fibrosis, so we suggest that radiation fibrosis may be another contributor of the occurrence of ILD in patients taking Drugerlotinib . |
| 0.9980 | This case had radiation fibrosis, so we suggest that radiation fibrosis may be another contributor of the occurrence of Adverse-EffectILD in patients taking erlotinib. |
| 0.9485 | This case had radiation fibrosis, so we suggest that Adverse-Effectradiation fibrosis may be another contributor of the occurrence of ILD in patients taking erlotinib. |
| 0.7059 | This case had Adverse-Effectradiation fibrosis , so we suggest that radiation fibrosis may be another contributor of the occurrence of ILD in patients taking erlotinib. |
| Score | Text |
|---|---|
| 0.9996 | We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic Drugcibenzoline intoxication. |
| 0.9943 | We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and Adverse-Effectcardiac failure due to chronic cibenzoline intoxication. |
| 0.9922 | We cared for a patient with progressive renal impairment who presented with Adverse-Effectblurred vision , QRS broadening and cardiac failure due to chronic cibenzoline intoxication. |
| 0.9908 | We cared for a patient with progressive renal impairment who presented with blurred vision, Adverse-EffectQRS broadening and cardiac failure due to chronic cibenzoline intoxication. |
| 0.7055 | We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic Adverse-Effectcibenzoline intoxication . |
| Score | Text |
|---|---|
| 0.9987 | Adverse-EffectSeizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta - 1a and clomipramine. |
| 0.9956 | Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta - 1a and Drugclomipramine . |
| 0.9927 | Seizures and Adverse-Effectextrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta - 1a and clomipramine. |
| 0.9684 | Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with Druginterferon beta - 1a and clomipramine. |
| Score | Text |
|---|---|
| 0.9995 | BACKGROUND : DrugColchicine has a known adverse effect on wound healing through its inhibitory effect on tubulin - dependent cell functions and through collagenase activation. |
| 0.8963 | BACKGROUND : Colchicine has a known adverse effect on Adverse-Effectwound healing through its inhibitory effect on tubulin - dependent cell functions and through collagenase activation. |
| BACKGROUND : Colchicine has a known Adverse-Effectadverse effect on wound healing through its inhibitory effect on tubulin - dependent cell functions and through collagenase activation. | |
| BACKGROUND : Colchicine has a known adverse effect on wound healing through its inhibitory effect on tubulin - dependent cell functions and through Adverse-Effectcollagenase activation . | |
| Score | Text |
|---|---|
| 0.9969 | Thrombolytic therapy with tissue plasminogen activator ( DrugtPA ) for acute myocardial infarction may result in major bleeding complications such as gastrointestinal or intracranial bleeding. |
| 0.9784 | Thrombolytic therapy with Drugtissue plasminogen activator ( tPA ) for acute myocardial infarction may result in major bleeding complications such as gastrointestinal or intracranial bleeding. |
| 0.9465 | Thrombolytic therapy with tissue plasminogen activator ( tPA ) for acute myocardial infarction may result in major bleeding complications such as Adverse-Effectgastrointestinal or intracranial bleeding . |
| Score | Text |
|---|---|
| 0.9994 | We describe the development of cutaneous scleroderma in 3 patients coincident with the use of Drugbleomycin in low cumulative doses of less than 100 U. |
| 0.9882 | We describe the development of Adverse-Effectcutaneous scleroderma in 3 patients coincident with the use of bleomycin in low cumulative doses of less than 100 U. |
| Score | Text |
|---|---|
| 0.9983 | Drug - induced Adverse-Effectpsychosis resulted from the administration of quinacrine hydrochloride at a dosage of 100 mg twice daily for the treatment of discoid lupus. |
| 0.9849 | Drug - induced psychosis resulted from the administration of Drugquinacrine hydrochloride at a dosage of 100 mg twice daily for the treatment of discoid lupus. |
| Score | Text |
|---|---|
| 0.9767 | The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated Adverse-Effectvascular retinopathy . |
| 0.9662 | The interval between initiating treatment with interferon alfa and onset of Adverse-Effectanterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy. |
| 0.9128 | The interval between initiating treatment with Druginterferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy. |
| 0.7067 | The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of Druginterferon - associated vascular retinopathy. |
| Score | Text |
|---|---|
| 0.9995 | We report a case of AILD in an 80 - year - old male who presented with a generalized pruritic maculopapular eruption and fever following Drugdoxycycline administration. |
| 0.9955 | We report a case of Adverse-EffectAILD in an 80 - year - old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration. |
| 0.9864 | We report a case of AILD in an 80 - year - old male who presented with a Adverse-Effectgeneralized pruritic maculopapular eruption and fever following doxycycline administration. |
| 0.9852 | We report a case of AILD in an 80 - year - old male who presented with a generalized pruritic maculopapular eruption and Adverse-Effectfever following doxycycline administration. |
| Score | Text |
|---|---|
| 0.9955 | Post marketing studies of Interferon - beta ( IFN beta ) therapy in multiple sclerosis ( MS ) have demonstrated surprisingly high rates of Adverse-Effecthepatotoxicity . |
| 0.9825 | Post marketing studies of Interferon - beta ( DrugIFN beta ) therapy in multiple sclerosis ( MS ) have demonstrated surprisingly high rates of hepatotoxicity. |
| 0.9743 | Post marketing studies of DrugInterferon - beta ( IFN beta ) therapy in multiple sclerosis ( MS ) have demonstrated surprisingly high rates of hepatotoxicity. |
| Score | Text |
|---|---|
| 0.9975 | Hypersensitivity to Drugcarboplatin has been reported in up to 44 % of patients receiving this antineoplastic agent, usually occurring after several courses of treatment. |
| 0.9918 | Adverse-EffectHypersensitivity to carboplatin has been reported in up to 44 % of patients receiving this antineoplastic agent, usually occurring after several courses of treatment. |
| Score | Text |
|---|---|
| 0.9989 | During her third cycle, she again received Drugcisplatin 100 mg / m2 over 30 minutes and developed palmar pruritus, urticaria, and edema. |
| 0.9982 | During her third cycle, she again received cisplatin 100 mg / m2 over 30 minutes and developed palmar pruritus, Adverse-Effecturticaria , and edema. |
| 0.9977 | During her third cycle, she again received cisplatin 100 mg / m2 over 30 minutes and developed palmar pruritus, urticaria, and Adverse-Effectedema . |
| 0.9900 | During her third cycle, she again received cisplatin 100 mg / m2 over 30 minutes and developed Adverse-Effectpalmar pruritus , urticaria, and edema. |
| 0.7446 | During her third cycle, she again received cisplatin Adverse-Effect100 mg / m2 over 30 minutes and developed palmar pruritus, urticaria, and edema. |
| Score | Text |
|---|---|
| 0.9995 | The authors report a further case of Drugmethimazole - associated liver damage and present a brief review of eleven previous cases found in the literature. |
| 0.9951 | The authors report a further case of methimazole - associated Adverse-Effectliver damage and present a brief review of eleven previous cases found in the literature. |
| Score | Text |
|---|---|
| 0.9992 | We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six - hourly intravenous Drugmetoclopramide . |
| 0.5220 | We report a case of fulminant Adverse-Effectneuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six - hourly intravenous metoclopramide. |
| 0.9537 | We report a case of Adverse-Effectfulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six - hourly intravenous metoclopramide. |
| Score | Text |
|---|---|
| 0.9946 | We describe 3 AS patients treated with Drugetanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept. |
| 0.9921 | We describe 3 AS patients treated with etanercept for active AS who developed new onset of Adverse-EffectCD while AS related symptoms responded well to etanercept. |
| Score | Text |
|---|---|
| 0.9866 | After a two - month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same Adverse-Effectneurological manifestations . |
| 0.9798 | After a two - month interruption of interferon administration, natural Druginterferon alpha was given but followed by another episode of the same neurological manifestations. |
| Score | Text |
|---|---|
| 0.9994 | We describe a patient with androgen - independent prostate cancer in whom PSA continued to decrease for a period of 15 months after Drugflutamide withdrawal. |
| 0.9241 | We describe a patient with androgen - independent prostate cancer in whom Adverse-EffectPSA continued to decrease for a period of 15 months after flutamide withdrawal. |
| Score | Text |
|---|---|
| 0.9834 | 46 - year - old woman developed painful ulcers over her lower abdomen in the form of Adverse-Effectreticulate erythema after injecting interferon beta - 1b subcutaneously for multiple sclerosis. |
| 0.9788 | 46 - year - old woman developed Adverse-Effectpainful ulcers over her lower abdomen in the form of reticulate erythema after injecting interferon beta - 1b subcutaneously for multiple sclerosis. |
| 0.9670 | 46 - year - old woman developed painful ulcers over her lower abdomen in the form of reticulate erythema after injecting Druginterferon beta - 1b subcutaneously for multiple sclerosis. |
| Score | Text |
|---|---|
| 0.9994 | We report a case of SJS in a 14 - year - old male with nephrotic syndrome, who was treated with oral Drugprednisolone for 6 weeks. |
| 0.9971 | We report a case of Adverse-EffectSJS in a 14 - year - old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks. |
| Score | Text |
|---|---|
| 0.9994 | Data have been published regarding the possibility that Drugtamoxifen may be responsible for the subsequent development of carcinoma of the corpus uteri in these patients. |
| 0.9835 | Data have been published regarding the possibility that tamoxifen may be responsible for the subsequent development of Adverse-Effectcarcinoma of the corpus uteri in these patients. |
| Score | Text |
|---|---|
| 0.9995 | A 56 - year - old Caucasian man who received concomitant chemotherapy and radiation for head and neck cancer developed fever concurrent with the administration of Drugamifostine . |
| 0.9982 | A 56 - year - old Caucasian man who received concomitant chemotherapy and radiation for head and neck cancer developed Adverse-Effectfever concurrent with the administration of amifostine. |
| Score | Text |
|---|---|
| 0.9988 | DrugCalcipotriol ( Daivonex R ; Leo Pharmaceuticals, Zurich, Switzerland ) may cause irritation of the skin, whereas allergic reactions are less common. |
| 0.9753 | Calcipotriol ( Daivonex R ; Leo Pharmaceuticals, Zurich, Switzerland ) may cause irritation of the skin, whereas Adverse-Effectallergic reactions are less common. |
| 0.9738 | Calcipotriol ( Daivonex R ; Leo Pharmaceuticals, Zurich, Switzerland ) may cause Adverse-Effectirritation of the skin , whereas allergic reactions are less common. |
| Score | Text |
|---|---|
| 0.9874 | CONCLUSION : Patients with Druginsulin allergy may not have complete resolution of their symptoms after standard desensitization, particularly those patients with concomitant protamine allergy. |
| 0.9622 | CONCLUSION : Patients with insulin allergy may not have complete resolution of their symptoms after standard desensitization, particularly those patients with concomitant Adverse-Effectprotamine allergy . |
| Score | Text |
|---|---|
| 0.9768 | OBJECTIVE : To report a case of toxin - positive Clostridium difficile - induced colitis ( CDIC ) after use of Drugclindamycin phosphate vaginal cream. |
| 0.9418 | OBJECTIVE : To report a case of Adverse-Effecttoxin - positive Clostridium difficile - induced colitis ( CDIC ) after use of clindamycin phosphate vaginal cream. |
| 0.9773 | OBJECTIVE : To report a case of toxin - positive Clostridium difficile - induced colitis ( Adverse-EffectCDIC ) after use of clindamycin phosphate vaginal cream. |
| Score | Text |
|---|---|
| 0.9848 | Pathogenesis of methotrexate - induced Adverse-Effectpapular eruption in psoriasis may involve immune mechanisms other than those of methotrexate - induced cutaneous vasculitis in collagen vascular disease. |
| 0.9829 | Pathogenesis of methotrexate - induced papular eruption in psoriasis may involve immune mechanisms other than those of methotrexate - induced Adverse-Effectcutaneous vasculitis in collagen vascular disease. |
| 0.9612 | Pathogenesis of Drugmethotrexate - induced papular eruption in psoriasis may involve immune mechanisms other than those of methotrexate - induced cutaneous vasculitis in collagen vascular disease. |
| 0.9563 | Pathogenesis of methotrexate - induced papular eruption in psoriasis may involve immune mechanisms other than those of Drugmethotrexate - induced cutaneous vasculitis in collagen vascular disease. |
| Score | Text |
|---|---|
| 0.9874 | Two of the five patients who worsened motorically also developed encephalopathy during Drugrisperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment. |
| 0.9865 | Two of the five patients who worsened motorically also developed Adverse-Effectencephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment. |
| 0.8941 | Two of the five patients who Adverse-Effectworsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment. |
| 0.9381 | Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to Drugclozapine treatment. |
| 0.9062 | Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the Adverse-Effectencephalopathy resolved when the patients were switched to clozapine treatment. |
| Score | Text |
|---|---|
| 0.9994 | Acute ocular ischemic change may be associated with intravitreal injection of Drugbevacizumab in patients with vascular compromised diabetic retinopathy and / or underlying stenosis of the carotid artery. |
| 0.9851 | Adverse-EffectAcute ocular ischemic change may be associated with intravitreal injection of bevacizumab in patients with vascular compromised diabetic retinopathy and / or underlying stenosis of the carotid artery. |
| Score | Text |
|---|---|
| 0.9976 | She was receiving phenytoin sodium 300 mg / day ; carbamazepine 200 mg four times daily had been discontinued four days before admission because of Adverse-Effectleukopenia . |
| 0.9923 | She was receiving phenytoin sodium 300 mg / day ; Drugcarbamazepine 200 mg four times daily had been discontinued four days before admission because of leukopenia. |
| 0.9733 | She was receiving Drugphenytoin sodium 300 mg / day ; carbamazepine 200 mg four times daily had been discontinued four days before admission because of leukopenia. |
| Score | Text |
|---|---|
| 0.9956 | His impaired memory was found to be due to the Drugatenolol he was on and he made a complete recovery on withdrawing the beta - blocker. |
| 0.9726 | His Adverse-Effectimpaired memory was found to be due to the atenolol he was on and he made a complete recovery on withdrawing the beta - blocker. |
| Score | Text |
|---|---|
| 0.9971 | OBJECTIVE : To describe two cases of Adverse-Effectrhabdomyolysis in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and azithromycin. |
| 0.9961 | OBJECTIVE : To describe two cases of rhabdomyolysis in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and Drugazithromycin . |
| 0.9958 | OBJECTIVE : To describe two cases of rhabdomyolysis in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics Drugclarithromycin and azithromycin. |
| 0.9941 | OBJECTIVE : To describe two cases of rhabdomyolysis in patients taking Druglovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and azithromycin. |
| Score | Text |
|---|---|
| 0.9983 | This experience supports the hypothesis that heparin can be readministered early to patients with heparin - associated thrombocytopenia and Adverse-Effectthrombosis , provided antiplatelet therapy is given. |
| 0.9978 | This experience supports the hypothesis that heparin can be readministered early to patients with heparin - associated Adverse-Effectthrombocytopenia and thrombosis, provided antiplatelet therapy is given. |
| 0.9930 | This experience supports the hypothesis that heparin can be readministered early to patients with Drugheparin - associated thrombocytopenia and thrombosis, provided antiplatelet therapy is given. |
| Score | Text |
|---|---|
| 0.9993 | The frequency and relationship of granulocytopenia caused by sustained - release Drugprocainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed. |
| 0.9966 | The frequency and relationship of Adverse-Effectgranulocytopenia caused by sustained - release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed. |
| Score | Text |
|---|---|
| 0.9975 | To our knowledge, this is the first report of significant hypotension associated with intravenous Drugvalproate in the treatment of status epilepticus in the pediatric population. |
| 0.9974 | To our knowledge, this is the first report of significant Adverse-Effecthypotension associated with intravenous valproate in the treatment of status epilepticus in the pediatric population. |
| Score | Text |
|---|---|
| 0.9952 | We describe a patient with rheumatoid arthritis treated with Druggold salts, who developed bilateral interstitial pulmonary abnormalities and showed a dramatic response on corticosteroid therapy. |
| 0.9887 | We describe a patient with rheumatoid arthritis treated with gold salts, who developed Adverse-Effectbilateral interstitial pulmonary abnormalities and showed a dramatic response on corticosteroid therapy. |
| Score | Text |
|---|---|
| 0.9994 | In this case, discontinuing Drugpiroxicam , a nonsteroidal anti - inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers. |
| 0.9888 | In this case, discontinuing piroxicam, a nonsteroidal anti - inflammatory drug, and starting a palliative treatment plan helped resolve a patient's Adverse-Effectulcers . |
| Score | Text |
|---|---|
| 0.9991 | We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre - excited atrial fibrillation and were given 12 mg of Drugadenosine . |
| 0.9921 | We observed Adverse-Effectventricular fibrillation in 2 patients who presented to the emergency department with pre - excited atrial fibrillation and were given 12 mg of adenosine. |
| Score | Text |
|---|---|
| 0.9987 | On the 3rd day, an inferior vena cava ( IVC ) filter was placed with a Drugheparin flush, after which massive IVC thrombosis developed. |
| 0.9291 | On the 3rd day, an inferior vena cava ( IVC ) filter was placed with a heparin flush, after which massive Adverse-EffectIVC thrombosis developed. |
| Score | Text |
|---|---|
| 0.9991 | An 8 - year - old girl, who had been vaccinated with DrugBCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later. |
| 0.9464 | An 8 - year - old girl, who had been vaccinated with BCG without subsequent regional reactions, developed Adverse-Effectosteomyelitis in the left calcaneus 7 months later. |
| 0.5934 | An 8 - year - old girl, who had been vaccinated with BCG without subsequent regional reactions, developed Adverse-Effectosteomyelitis in the left calcaneus 7 months later. |
| Score | Text |
|---|---|
| 0.9993 | In a female with acute lymphoblastic leukemia, inadvertent Drugdoxorubicin administration intrathecally caused severe, life - threatening, acute encephalopathy with high - pressure hydrocephalus. |
| 0.9537 | In a female with acute lymphoblastic leukemia, inadvertent doxorubicin administration intrathecally caused severe, life - threatening, acute encephalopathy with Adverse-Effecthigh - pressure hydrocephalus . |
| 0.9390 | In a female with acute lymphoblastic leukemia, inadvertent doxorubicin administration intrathecally caused severe, life - threatening, Adverse-Effectacute encephalopathy with high - pressure hydrocephalus. |
| Score | Text |
|---|---|
| 0.9992 | In conclusion, this case strongly suggests that Druggliclazide can induce acute icteric liver necro - inflammation which may be misdiagnosed clinically as acute viral hepatitis. |
| 0.9802 | In conclusion, this case strongly suggests that gliclazide can induce Adverse-Effectacute icteric liver necro - inflammation which may be misdiagnosed clinically as acute viral hepatitis. |
| Score | Text |
|---|---|
| 0.9983 | We report a case of reversible DKA and new - onset DM that developed in a demented patient who was treated with Drugquetiapine for 14 days. |
| 0.9913 | We report a case of reversible Adverse-EffectDKA and new - onset DM that developed in a demented patient who was treated with quetiapine for 14 days. |
| 0.9697 | We report a case of reversible DKA and new - onset Adverse-EffectDM that developed in a demented patient who was treated with quetiapine for 14 days. |
| Score | Text |
|---|---|
| 0.9986 | Mean time between initiation of gemcitabine therapy and onset of Adverse-EffectHUS was 7. 4 + / - 3. 5 months, or 21. 9 + / - 10. 9 doses of gemcitabine. |
| 0.9946 | Mean time between initiation of Druggemcitabine therapy and onset of HUS was 7. 4 + / - 3. 5 months, or 21. 9 + / - 10. 9 doses of gemcitabine. |
| 0.9920 | Mean time between initiation of gemcitabine therapy and onset of HUS was 7. 4 + / - 3. 5 months, or 21. 9 + / - 10. 9 doses of Druggemcitabine . |
| Score | Text |
|---|---|
| 0.9398 | DrugSodium phenylbutyrate was added to treatment with HU in two patients, but failed to produce an increase in total Hb despite increasing Hb F levels. |
| 0.9037 | Sodium phenylbutyrate was added to treatment with HU in two patients, but failed to produce an increase in total Hb despite Adverse-Effectincreasing Hb F levels. |
| 0.8309 | Sodium phenylbutyrate was added to treatment with DrugHU in two patients, but failed to produce an increase in total Hb despite increasing Hb F levels. |
| 0.9138 | Sodium phenylbutyrate was added to treatment with HU in two patients, but failed to produce an Adverse-Effectincrease in total Hb despite increasing Hb F levels. |
| Score | Text |
|---|---|
| 0.9893 | INTERVENTIONS AND RESULTS : Adverse-EffectCardiac complications were observed in five pediatric patients who received between 4. 6 and 40. 8 mg / kg / d of amphotericin B. |
| 0.9824 | INTERVENTIONS AND RESULTS : Cardiac complications were observed in five pediatric patients who received between 4. 6 and 40. 8 mg / kg / d of Drugamphotericin B . |
| Score | Text |
|---|---|
| 0.9954 | We describe the case of a nonatopic 17 - year - old girl with bronchial asthma and aspirin intolerance who developed a dramatic anaphylactic reaction to oral Drugprednisone . |
| 0.9857 | We describe the case of a nonatopic 17 - year - old girl with bronchial asthma and aspirin intolerance who developed a dramatic Adverse-Effectanaphylactic reaction to oral prednisone. |
| Score | Text |
|---|---|
| 0.9989 | There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with Drugheparin - induced thrombocytopenia, especially in children. |
| 0.9977 | There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin - induced Adverse-Effectthrombocytopenia , especially in children. |
| Score | Text |
|---|---|
| 0.9993 | Renal failure is a rare complication associated with the use of Drugrifampicin for the treatment of tuberculosis, usually occurring well into the course of therapy. |
| 0.9941 | Adverse-EffectRenal failure is a rare complication associated with the use of rifampicin for the treatment of tuberculosis, usually occurring well into the course of therapy. |
| Score | Text |
|---|---|
| 0.9966 | Of the four patients who responded to DrugHU with an increase in total Hb, all reported symptomatic improvement and three have not required further transfusions. |
| 0.9670 | Of the four patients who responded to HU with an Adverse-Effectincrease in total Hb , all reported symptomatic improvement and three have not required further transfusions. |
| Score | Text |
|---|---|
| 0.9992 | Although moderate myelosuppression is not uncommonly seen in patients treated with Druglenalidomide , aplastic anemia has not previously been reported to be associated with this agent. |
| 0.9920 | Although moderate myelosuppression is not uncommonly seen in patients treated with lenalidomide, Adverse-Effectaplastic anemia has not previously been reported to be associated with this agent. |
| Score | Text |
|---|---|
| 0.9987 | The disease - modifying drugs he was taking, cyclosporin and Drugmethotrexate , were stopped, and the lymphoma resolved spontaneously without the use of chemotherapy. |
| 0.9984 | The disease - modifying drugs he was taking, Drugcyclosporin and methotrexate, were stopped, and the lymphoma resolved spontaneously without the use of chemotherapy. |
| 0.9970 | The disease - modifying drugs he was taking, cyclosporin and methotrexate, were stopped, and the Adverse-Effectlymphoma resolved spontaneously without the use of chemotherapy. |
| Score | Text |
|---|---|
| 0.9994 | The results clearly demonstrate that DrugCPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism. |
| 0.9632 | The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical Adverse-Effecthypercortisolism . |
| The results clearly demonstrate that CPH82 was associated with Adverse-Effectsuppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism. | |
| Score | Text |
|---|---|
| 0.9994 | However, peripheral neuropathy and bone marrow depression led to Druglinezolid withdrawal in seven patients, and neuropathy may not be fully reversible in all patients. |
| 0.9940 | However, peripheral neuropathy and bone marrow depression led to linezolid withdrawal in seven patients, and Adverse-Effectneuropathy may not be fully reversible in all patients. |
| 0.9862 | However, peripheral neuropathy and Adverse-Effectbone marrow depression led to linezolid withdrawal in seven patients, and neuropathy may not be fully reversible in all patients. |
| 0.9855 | However, Adverse-Effectperipheral neuropathy and bone marrow depression led to linezolid withdrawal in seven patients, and neuropathy may not be fully reversible in all patients. |
| Score | Text |
|---|---|
| 0.9994 | DrugDocetaxel induced Meibomian duct inflammation and blockage is the likely cause of this presentation in a patient with no history of eyelid masses in the past. |
| 0.9856 | Docetaxel induced Adverse-EffectMeibomian duct inflammation and blockage is the likely cause of this presentation in a patient with no history of eyelid masses in the past. |
| Score | Text |
|---|---|
| 0.9996 | We present a case of stroke after DrugPPA ingestion that occurred 4 months after the recall in an 8 - year - old boy on chronic peritoneal dialysis. |
| 0.9957 | We present a case of Adverse-Effectstroke after PPA ingestion that occurred 4 months after the recall in an 8 - year - old boy on chronic peritoneal dialysis. |
| Score | Text |
|---|---|
| 0.9974 | The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, Adverse-Effectmutism , and development of irreversible tardive dyskinesia. |
| 0.9968 | The authors describe a case of combined lithium and haloperidol toxicity characterized by Adverse-Effecthyperpyrexia , severe rigidity, mutism, and development of irreversible tardive dyskinesia. |
| 0.9953 | The authors describe a case of combined lithium and Drughaloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia. |
| 0.9934 | The authors describe a case of combined Druglithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia. |
| 0.9774 | The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, Adverse-Effectsevere rigidity , mutism, and development of irreversible tardive dyskinesia. |
| 0.9378 | The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of Adverse-Effectirreversible tardive dyskinesia . |
| Score | Text |
|---|---|
| 0.9992 | We report a child with yolk sac tumor who developed localized pigmentation after the first course of chemotherapy regimen that included cisplatin, etoposide and Drugbleomycin . |
| 0.9992 | We report a child with yolk sac tumor who developed localized pigmentation after the first course of chemotherapy regimen that included cisplatin, Drugetoposide and bleomycin. |
| 0.9992 | We report a child with yolk sac tumor who developed localized pigmentation after the first course of chemotherapy regimen that included Drugcisplatin , etoposide and bleomycin. |
| 0.9836 | We report a child with yolk sac tumor who developed Adverse-Effectlocalized pigmentation after the first course of chemotherapy regimen that included cisplatin, etoposide and bleomycin. |
| Score | Text |
|---|---|
| 0.9976 | The site of thrombosis and the chronological relationship with the Adverse-EffectIIR implicates a hypersensitivity to infliximab in the causation of the venous thrombosis in this case. |
| 0.9976 | The site of thrombosis and the chronological relationship with the IIR implicates a hypersensitivity to Druginfliximab in the causation of the venous thrombosis in this case. |
| 0.9219 | The site of thrombosis and the chronological relationship with the IIR implicates a hypersensitivity to infliximab in the causation of the Adverse-Effectvenous thrombosis in this case. |
| 0.9049 | The site of thrombosis and the chronological relationship with the IIR implicates a Adverse-Effecthypersensitivity to infliximab in the causation of the venous thrombosis in this case. |
| Score | Text |
|---|---|
| 0.9986 | The authors describe three families in whom the occurrence of Adverse-EffectFVS in all the siblings strongly suggests hereditary susceptibility to valproic acid - induced adverse outcome. |
| 0.9848 | The authors describe three families in whom the occurrence of FVS in all the siblings strongly suggests hereditary susceptibility to Drugvalproic acid - induced adverse outcome. |
| Score | Text |
|---|---|
| 0.9986 | We report the case of a 60 - year - old woman who developed erythema and erosions in the axilla and groin while on DrugPLD for breast cancer. |
| 0.9986 | We report the case of a 60 - year - old woman who developed Adverse-Effecterythema and erosions in the axilla and groin while on PLD for breast cancer. |
| 0.9094 | We report the case of a 60 - year - old woman who developed erythema and Adverse-Effecterosions in the axilla and groin while on PLD for breast cancer. |
| Score | Text |
|---|---|
| 0.9995 | A 73 - year - old woman presented with fever and cough 2 weeks after completing the third cycle of Drugfludarabine for chronic lymphocytic leukemia ( CLL ). |
| 0.9976 | A 73 - year - old woman presented with fever and Adverse-Effectcough 2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia ( CLL ). |
| 0.9962 | A 73 - year - old woman presented with Adverse-Effectfever and cough 2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia ( CLL ). |
| Score | Text |
|---|---|
| 0.9995 | We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha - glucosidase inhibitor, Drugvoglibose . |
| 0.9952 | We observed 3 diabetic patients with intolerable dizziness followed by nausea and Adverse-Effectvomiting immediately after an initial administration of the alpha - glucosidase inhibitor, voglibose. |
| 0.9922 | We observed 3 diabetic patients with intolerable dizziness followed by Adverse-Effectnausea and vomiting immediately after an initial administration of the alpha - glucosidase inhibitor, voglibose. |
| 0.9820 | We observed 3 diabetic patients with Adverse-Effectintolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha - glucosidase inhibitor, voglibose. |
| Score | Text |
|---|---|
| 0.9894 | Despite minimal short - term side effects and apparent efficacy, chronic treatment of MG with MM may be associated with increased risk of Adverse-Effectlymphoproliferative disorders . |
| 0.8707 | Despite minimal short - term side effects and apparent efficacy, chronic treatment of MG with DrugMM may be associated with increased risk of lymphoproliferative disorders. |
| Score | Text |
|---|---|
| 0.9954 | A 62 - year - old Indian with diabetic nephropathy controlled with Drugmetformin , developed miliary tuberculosis for which he was treated with rifampicin, isoniazid and ethambutol. |
| 0.9947 | A 62 - year - old Indian with diabetic nephropathy controlled with metformin, developed Adverse-Effectmiliary tuberculosis for which he was treated with rifampicin, isoniazid and ethambutol. |
| 0.9924 | A 62 - year - old Indian with diabetic nephropathy controlled with metformin, developed miliary tuberculosis for which he was treated with rifampicin, isoniazid and Drugethambutol . |
| 0.9902 | A 62 - year - old Indian with diabetic nephropathy controlled with metformin, developed miliary tuberculosis for which he was treated with Drugrifampicin , isoniazid and ethambutol. |
| 0.9891 | A 62 - year - old Indian with diabetic nephropathy controlled with metformin, developed miliary tuberculosis for which he was treated with rifampicin, Drugisoniazid and ethambutol. |
| Score | Text |
|---|---|
| 0.9917 | We present a case of Drugethylenediamine - induced delayed hypersensitivity reaction in a 46 - year - old woman who received parenteral aminophylline for an acute asthma exacerbation. |
| 0.9887 | We present a case of ethylenediamine - induced Adverse-Effectdelayed hypersensitivity reaction in a 46 - year - old woman who received parenteral aminophylline for an acute asthma exacerbation. |
| 0.9540 | We present a case of ethylenediamine - induced delayed hypersensitivity reaction in a 46 - year - old woman who received parenteral Drugaminophylline for an acute asthma exacerbation. |
| Score | Text |
|---|---|
| 0.9995 | A mentally retarded 23 - year - old woman with myoclonic astatic epilepsy developed an abnormal posture of extreme forward flexion, called camptocormia, during Drugvalproate monotherapy. |
| 0.9970 | A mentally retarded 23 - year - old woman with myoclonic astatic epilepsy developed an abnormal posture of extreme forward flexion, called Adverse-Effectcamptocormia , during valproate monotherapy. |
| 0.9276 | A mentally retarded 23 - year - old woman with myoclonic astatic epilepsy developed an Adverse-Effectabnormal posture of extreme forward flexion , called camptocormia, during valproate monotherapy. |
| Score | Text |
|---|---|
| 0.9915 | To the best of our knowledge, Adverse-Effectcorneoscleral melting in the first postoperative week after a single intraoperative application of mitomycin C has not been reported. |
| 0.9860 | To the best of our knowledge, corneoscleral melting in the first postoperative week after a single intraoperative application of Drugmitomycin C has not been reported. |
| Score | Text |
|---|---|
| 0.9988 | PURPOSE : To describe spectral - domain optical coherence tomography ( SD - OCT ) and adaptive optics ( AO ) imaging in Drughydroxychloroquine retinal toxicity. |
| 0.9103 | PURPOSE : To describe spectral - domain optical coherence tomography ( SD - OCT ) and adaptive optics ( AO ) imaging in hydroxychloroquine Adverse-Effectretinal toxicity . |
| Score | Text |
|---|---|
| 0.9995 | One patient who received Drugclindamycin had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and bile duct paucity ( ductopenia ). |
| 0.9962 | One patient who received clindamycin had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and bile duct paucity ( Adverse-Effectductopenia ). |
| 0.9903 | One patient who received clindamycin had liver biopsy findings of Adverse-Effectmarked cholestasis , portal inflammation, bile duct injury and bile duct paucity ( ductopenia ). |
| 0.9872 | One patient who received clindamycin had liver biopsy findings of marked cholestasis, Adverse-Effectportal inflammation , bile duct injury and bile duct paucity ( ductopenia ). |
| 0.9862 | One patient who received clindamycin had liver biopsy findings of marked cholestasis, portal inflammation, Adverse-Effectbile duct injury and bile duct paucity ( ductopenia ). |
| 0.9858 | One patient who received clindamycin had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and Adverse-Effectbile duct paucity ( ductopenia ). |
| Score | Text |
|---|---|
| 0.9992 | We present a case in which Drugdipyridamole induced high - grade atrioventricular ( AV ) block that responded promptly to intravenous aminophylline but not to atropine. |
| 0.9785 | We present a case in which dipyridamole induced Adverse-Effecthigh - grade atrioventricular ( AV ) block that responded promptly to intravenous aminophylline but not to atropine. |
| Score | Text |
|---|---|
| 0.9987 | We report a case of acute generalized exanthematous pustulosis ( AGEP ) in a 50 - year - old woman that was attributed to the ingestion of Drugnimesulide . |
| 0.9932 | We report a case of acute generalized exanthematous pustulosis ( Adverse-EffectAGEP ) in a 50 - year - old woman that was attributed to the ingestion of nimesulide. |
| 0.9821 | We report a case of Adverse-Effectacute generalized exanthematous pustulosis ( AGEP ) in a 50 - year - old woman that was attributed to the ingestion of nimesulide. |
| Score | Text |
|---|---|
| 0.9894 | A girl with cystic fibrosis and cyclic neutropenia developed an Adverse-Effecterythematous papular eruption without fever or neutrophilia 7 months after commencing therapy with G - CSF. |
| 0.9781 | A girl with cystic fibrosis and cyclic neutropenia developed an erythematous papular eruption without fever or neutrophilia 7 months after commencing therapy with DrugG - CSF . |
| Score | Text |
|---|---|
| 0.9983 | Life - threatening anaphylactoid reaction to Drugamifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis : a case report with literature review. |
| 0.9876 | Life - threatening Adverse-Effectanaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis : a case report with literature review. |
| Score | Text |
|---|---|
| 0.9985 | To the best of our knowledge only two previous cases of AML have been linked to treatment of HCL with purine analogs, both with Drug2 - chlorodeoxyadenosine . |
| 0.9953 | To the best of our knowledge only two previous cases of Adverse-EffectAML have been linked to treatment of HCL with purine analogs, both with 2 - chlorodeoxyadenosine. |
| Score | Text |
|---|---|
| 0.9971 | The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and Adverse-Effectendometriosis . |
| 0.9876 | The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with Adverse-Effectendometrial carcinoma and endometriosis. |
| 0.9762 | The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of Drugtamoxifen associated with endometrial carcinoma and endometriosis. |
| 0.9840 | The possible effects of Drugtamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and endometriosis. |
| Score | Text |
|---|---|
| 0.9996 | It is suggested that the patient had Drugsulfasalazine - induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms. |
| 0.9970 | It is suggested that the patient had sulfasalazine - induced Adverse-Effectlupus , which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms. |
| 0.9940 | It is suggested that the patient had sulfasalazine - induced lupus, which manifested with Adverse-Effectserositis and pulmonary parenchymal involvement in the absence of joint symptoms. |
| 0.9871 | It is suggested that the patient had sulfasalazine - induced lupus, which manifested with serositis and Adverse-Effectpulmonary parenchymal involvement in the absence of joint symptoms. |
| Score | Text |
|---|---|
| 0.9995 | The authors report a case of a patient who received Drugalteplase for acute myocardial infarction and developed spontaneous subfascial hematoma without any evidence of direct trauma. |
| 0.9861 | The authors report a case of a patient who received alteplase for acute myocardial infarction and developed spontaneous Adverse-Effectsubfascial hematoma without any evidence of direct trauma. |
| 0.9384 | The authors report a case of a patient who received alteplase for acute myocardial infarction and developed Adverse-Effectspontaneous subfascial hematoma without any evidence of direct trauma. |
| Score | Text |
|---|---|
| 0.9995 | We report five cases of restless legs syndrome ( RLS ) and periodic limb movements during sleep ( PLMS ) that were probably associated with Drugolanzapine . |
| 0.9962 | We report five cases of restless legs syndrome ( Adverse-EffectRLS ) and periodic limb movements during sleep ( PLMS ) that were probably associated with olanzapine. |
| 0.9959 | We report five cases of restless legs syndrome ( RLS ) and periodic limb movements during sleep ( Adverse-EffectPLMS ) that were probably associated with olanzapine. |
| 0.9845 | We report five cases of Adverse-Effectrestless legs syndrome ( RLS ) and periodic limb movements during sleep ( PLMS ) that were probably associated with olanzapine. |
| 0.9771 | We report five cases of restless legs syndrome ( RLS ) and Adverse-Effectperiodic limb movements during sleep ( PLMS ) that were probably associated with olanzapine. |
| Score | Text |
|---|---|
| 0.9933 | The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to DrugMTX but require this medication for specific diseases. |
| 0.9920 | The successful development and implementation of this protocol will have impact on patients who have Adverse-Effectanaphylactic reactions to MTX but require this medication for specific diseases. |
| Score | Text |
|---|---|
| 0.9990 | Rapid identification of speech loss linked to DrugFK506 may be important because reduction or cessation of the drug may be associated with reverse of speech loss. |
| 0.9513 | Rapid identification of Adverse-Effectspeech loss linked to FK506 may be important because reduction or cessation of the drug may be associated with reverse of speech loss. |
| Score | Text |
|---|---|
| 0.9927 | Adverse-EffectOcular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2. |
| 0.9619 | Ocular hypertension occurred 1 month after the second Drugranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2. |
| 0.8901 | Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first Drugranibizumab in patient 2. |
| Score | Text |
|---|---|
| 0.9993 | OBSERVATIONS : We observed aggravation and spreading of a psoriatic plaque when treated topically with the toll - like receptor ( TLR ) 7 agonist Drugimiquimod . |
| 0.9732 | OBSERVATIONS : We observed Adverse-Effectaggravation and spreading of a psoriatic plaque when treated topically with the toll - like receptor ( TLR ) 7 agonist imiquimod. |
| Score | Text |
|---|---|
| 0.9911 | A 59 - year - old woman with myasthenia gravis who received a large dose of pyridostigmine bromide developed Adverse-Effectpostoperative psychosis and was diagnosed as having bromide intoxication. |
| 0.9859 | A 59 - year - old woman with myasthenia gravis who received a large dose of Drugpyridostigmine bromide developed postoperative psychosis and was diagnosed as having bromide intoxication. |
| 0.9770 | A 59 - year - old woman with myasthenia gravis who received a large dose of pyridostigmine bromide developed postoperative psychosis and was diagnosed as having Adverse-Effectbromide intoxication . |
| Score | Text |
|---|---|
| 0.9985 | BACKGROUND : DrugHydroxyurea is a cytostatic agent used to treat myeloproliferative disorders and long - term treatment is associated with mucocutaneous adverse events and nail hyperpigmentation. |
| 0.9883 | BACKGROUND : Hydroxyurea is a cytostatic agent used to treat myeloproliferative disorders and long - term treatment is associated with mucocutaneous adverse events and Adverse-Effectnail hyperpigmentation . |
| 0.9801 | BACKGROUND : Hydroxyurea is a cytostatic agent used to treat myeloproliferative disorders and long - term treatment is associated with Adverse-Effectmucocutaneous adverse events and nail hyperpigmentation. |
| Score | Text |
|---|---|
| 0.9850 | Due to the increasing use of TMP - SMX in children, clinicians should be aware of this potentially life - threatening, Adverse-Effectimmunemediated hypersensitivity reaction . |
| 0.9692 | Due to the increasing use of DrugTMP - SMX in children, clinicians should be aware of this potentially life - threatening, immunemediated hypersensitivity reaction. |
| Score | Text |
|---|---|
| 0.9987 | We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and Drugaminotriazole . |
| 0.9985 | We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing Drugbromocil , diuron and aminotriazole. |
| 0.9978 | We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, Drugdiuron and aminotriazole. |
| 0.9724 | We report a case of Adverse-Effectgeneralized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and aminotriazole. |
| Score | Text |
|---|---|
| 0.9994 | These findings suggest that the corneal and retinal changes are the result of a toxic effect of Drugtamoxifen when used in the doses and duration described. |
| 0.9803 | These findings suggest that the Adverse-Effectcorneal and retinal changes are the result of a toxic effect of tamoxifen when used in the doses and duration described. |
| Score | Text |
|---|---|
| 0.9993 | We report a premature infant who developed seizures associated with intraventricular administration of Drugnafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics. |
| 0.9988 | We report a premature infant who developed Adverse-Effectseizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics. |
| Score | Text |
|---|---|
| 0.9994 | We report the successful treatment of Drugheparin - induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2 - year - old child with Danaparoid ( orgaran ). |
| 0.9966 | We report the successful treatment of heparin - induced Adverse-Effectthrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2 - year - old child with Danaparoid ( orgaran ). |
| 0.9921 | We report the successful treatment of heparin - induced thrombocytopenia and subsequent Adverse-Effecthemorrhagic complications postoperatively in a 2 - year - old child with Danaparoid ( orgaran ). |
| Score | Text |
|---|---|
| 0.9992 | This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on Drugdiclofenac for increasing pain in the joints. |
| 0.6239 | This patient, who had a history of osteoarthritis, had severe Adverse-Effecthepatitis 5 weeks after being started on diclofenac for increasing pain in the joints. |
| 0.9473 | This patient, who had a history of osteoarthritis, had Adverse-Effectsevere hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints. |
| Score | Text |
|---|---|
| 0.9996 | DISCUSSION : The main adverse effects of Drugleflunomide consist of diarrhea, nausea, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions. |
| 0.9987 | DISCUSSION : The main adverse effects of leflunomide consist of Adverse-Effectdiarrhea , nausea, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions. |
| 0.9985 | DISCUSSION : The main adverse effects of leflunomide consist of diarrhea, nausea, liver enzyme elevation, hypertension, Adverse-Effectalopecia , and allergic skin reactions. |
| 0.9982 | DISCUSSION : The main adverse effects of leflunomide consist of diarrhea, Adverse-Effectnausea , liver enzyme elevation, hypertension, alopecia, and allergic skin reactions. |
| 0.9980 | DISCUSSION : The main adverse effects of leflunomide consist of diarrhea, nausea, liver enzyme elevation, Adverse-Effecthypertension , alopecia, and allergic skin reactions. |
| 0.9921 | DISCUSSION : The main adverse effects of leflunomide consist of diarrhea, nausea, liver enzyme elevation, hypertension, alopecia, and Adverse-Effectallergic skin reactions . |
| 0.9852 | DISCUSSION : The main adverse effects of leflunomide consist of diarrhea, nausea, Adverse-Effectliver enzyme elevation , hypertension, alopecia, and allergic skin reactions. |
| Score | Text |
|---|---|
| 0.9990 | This case supports the view that in Druggold - induced pneumonitis a prolonged treatment with corticosteroids may be necessary, as lung function continued to improve. |
| 0.9984 | This case supports the view that in gold - induced Adverse-Effectpneumonitis a prolonged treatment with corticosteroids may be necessary, as lung function continued to improve. |
| Score | Text |
|---|---|
| 0.9971 | METHODS : A patient who developed dramatic, permanent vision loss after a 9 - month course of treatment with Drugethambutol and isoniazid for pulmonary tuberculosis is presented. |
| 0.9958 | METHODS : A patient who developed dramatic, permanent vision loss after a 9 - month course of treatment with ethambutol and Drugisoniazid for pulmonary tuberculosis is presented. |
| 0.9841 | METHODS : A patient who developed dramatic, permanent Adverse-Effectvision loss after a 9 - month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented. |
| Score | Text |
|---|---|
| 0.9994 | The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first Drugrituximab infusion and investigated aggressively. |
| 0.9853 | The occurrence of symptoms that could be ascribed to an Adverse-Effectacute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively. |
| Score | Text |
|---|---|
| 0.9895 | There have been many reports of probable lithium - induced Adverse-Effectorganic brain syndromes occurring when serum lithium levels are within or close to the therapeutic range. |
| 0.9788 | There have been many reports of probable Druglithium - induced organic brain syndromes occurring when serum lithium levels are within or close to the therapeutic range. |
| 0.7507 | There have been many reports of probable lithium - induced organic brain syndromes occurring when serum Druglithium levels are within or close to the therapeutic range. |
| Score | Text |
|---|---|
| 0.9936 | The case demonstrates that hypersensitivity reaction to pranlukast and resultant Adverse-EffectATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered. |
| 0.9554 | The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving Drugpranlukast should be considered. |
| 0.9458 | The case demonstrates that hypersensitivity reaction to Drugpranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered. |
| 0.9273 | The case demonstrates that Adverse-Effecthypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered. |
| Score | Text |
|---|---|
| 0.9996 | After 1 week of Drugnefazodone therapy the patient experienced headache, confusion, and " gray areas " in her vision, without abnormal ophthalmologic findings. |
| 0.9988 | After 1 week of nefazodone therapy the patient experienced Adverse-Effectheadache , confusion, and " gray areas " in her vision, without abnormal ophthalmologic findings. |
| 0.9948 | After 1 week of nefazodone therapy the patient experienced headache, Adverse-Effectconfusion , and " gray areas " in her vision, without abnormal ophthalmologic findings. |
| 0.9662 | After 1 week of nefazodone therapy the patient experienced headache, confusion, and " Adverse-Effectgray areas " in her vision, without abnormal ophthalmologic findings. |
| Score | Text |
|---|---|
| 0.9986 | The diagnosis was supported by the temporal course of renal deterioration during exposure to Drugcefuroxime and improvement on its discontinuation ; the pattern repeated with rechallenge. |
| 0.9841 | The diagnosis was supported by the temporal course of Adverse-Effectrenal deterioration during exposure to cefuroxime and improvement on its discontinuation ; the pattern repeated with rechallenge. |
| Score | Text |
|---|---|
| 0.9936 | Although interferon gamma has been implicated in the pathogenesis of sarcoidosis, only a few cases of Adverse-Effectsarcoidosis associated with interferon alpha therapy have been reported. |
| 0.9797 | Although interferon gamma has been implicated in the pathogenesis of sarcoidosis, only a few cases of sarcoidosis associated with Druginterferon alpha therapy have been reported. |
| 0.9740 | Although Druginterferon gamma has been implicated in the pathogenesis of sarcoidosis, only a few cases of sarcoidosis associated with interferon alpha therapy have been reported. |
| Score | Text |
|---|---|
| 0.9990 | Anti - tuberculous drugs had been stopped on the 2nd day of therapy due to development of optic neuritis secondary to Drugethambutol administration at another hospital. |
| 0.9917 | Anti - tuberculous drugs had been stopped on the 2nd day of therapy due to development of Adverse-Effectoptic neuritis secondary to ethambutol administration at another hospital. |
| Score | Text |
|---|---|
| 0.9974 | A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of Drugnefazodone , an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme. |
| 0.9575 | A case is presented of a patient who experienced Adverse-Effectbenzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme. |
| Score | Text |
|---|---|
| 0.9893 | We reported 3 patients who developed acute generalized dystonia and Adverse-Effectakinetic rigid syndrome following an initial therapy with d - penicillamine 125 - 500 mg daily. |
| 0.9856 | We reported 3 patients who developed Adverse-Effectacute generalized dystonia and akinetic rigid syndrome following an initial therapy with d - penicillamine 125 - 500 mg daily. |
| 0.9697 | We reported 3 patients who developed acute generalized dystonia and akinetic rigid syndrome following an initial therapy with Drugd - penicillamine 125 - 500 mg daily. |
| Score | Text |
|---|---|
| 0.9994 | This case presentation is of a patient who had the clinical appearance of epiglottitis, but actually had an oro - pharyngeal dystonic reaction to Drugprochlorperazine . |
| 0.9923 | This case presentation is of a patient who had the clinical appearance of Adverse-Effectepiglottitis , but actually had an oro - pharyngeal dystonic reaction to prochlorperazine. |
| 0.9795 | This case presentation is of a patient who had the clinical appearance of epiglottitis, but actually had an Adverse-Effectoro - pharyngeal dystonic reaction to prochlorperazine. |
| Score | Text |
|---|---|
| 0.9983 | Therapy with IFN - alpha may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, Adverse-Effectakathisia , seizure, and depressive disorders. |
| 0.9983 | Therapy with IFN - alpha may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, Adverse-Effectseizure , and depressive disorders. |
| 0.9961 | Therapy with IFN - alpha may be associated with a number of neuropsychiatric symptoms, such as Adverse-EffectParkinsonism , akathisia, seizure, and depressive disorders. |
| 0.9947 | Therapy with IFN - alpha may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and Adverse-Effectdepressive disorders . |
| 0.9878 | Therapy with IFN - alpha may be associated with a number of Adverse-Effectneuropsychiatric symptoms , such as Parkinsonism, akathisia, seizure, and depressive disorders. |
| 0.9755 | Therapy with DrugIFN - alpha may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and depressive disorders. |
| Score | Text |
|---|---|
| 0.9789 | CONCLUSIONS : Low dosages of Drugquinacrine used for malaria prophylaxis can be associated with a delayed, severe maculopathy indistinguishable from chloroquine maculopathy in certain patients. |
| 0.9664 | CONCLUSIONS : Low dosages of quinacrine used for malaria prophylaxis can be associated with a delayed, Adverse-Effectsevere maculopathy indistinguishable from chloroquine maculopathy in certain patients. |
| 0.6047 | CONCLUSIONS : Low dosages of quinacrine used for malaria prophylaxis can be associated with a delayed, severe maculopathy indistinguishable from chloroquine Adverse-Effectmaculopathy in certain patients. |
| 0.9483 | CONCLUSIONS : Low dosages of quinacrine used for malaria prophylaxis can be associated with a delayed, severe Adverse-Effectmaculopathy indistinguishable from chloroquine maculopathy in certain patients. |
| 0.5845 | CONCLUSIONS : Low dosages of quinacrine used for malaria prophylaxis can be associated with a delayed, severe maculopathy indistinguishable from Adverse-Effectchloroquine maculopathy in certain patients. |
| CONCLUSIONS : Low dosages of quinacrine used for malaria prophylaxis can be associated with a delayed, severe maculopathy indistinguishable from Drugchloroquine maculopathy in certain patients. | |
| Score | Text |
|---|---|
| 0.9995 | However, a recent post - marketing survey in Japan revealed that interstitial pneumonia occurred in 4 among approximately 2 000 Japanese patients treated with Drugsorafenib . |
| 0.9886 | However, a recent post - marketing survey in Japan revealed that Adverse-Effectinterstitial pneumonia occurred in 4 among approximately 2 000 Japanese patients treated with sorafenib. |
| Score | Text |
|---|---|
| 0.9994 | Three patients received respectively 190 mg, 175 mg, and 196 mg of Drugmethotrexate and developed bilateral pulmonary infiltrates without evidence of peripheral blood eosinophilia. |
| 0.9915 | Three patients received respectively 190 mg, 175 mg, and 196 mg of methotrexate and developed Adverse-Effectbilateral pulmonary infiltrates without evidence of peripheral blood eosinophilia. |
| Score | Text |
|---|---|
| 0.9984 | An infant who developed Adverse-Effectpancreatitis during meglumine antimoniate treatment for visceral leishmaniasis and who was successfully treated with a combination of allopurinol and ketoconazole is reported. |
| 0.9860 | An infant who developed pancreatitis during Drugmeglumine antimoniate treatment for visceral leishmaniasis and who was successfully treated with a combination of allopurinol and ketoconazole is reported. |
| 0.6732 | An infant who developed pancreatitis during meglumine antimoniate treatment for visceral leishmaniasis and who was successfully treated with a combination of allopurinol and Drugketoconazole is reported. |
| Score | Text |
|---|---|
| 0.9931 | Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe Drughydroxychloroquine retinopathy with 19 years follow - up. |
| 0.9361 | Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine Adverse-Effectretinopathy with 19 years follow - up. |
| 0.9688 | Normalization of generalized retinal function and Adverse-Effectprogression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow - up. |
| Score | Text |
|---|---|
| 0.9996 | However, as illustrated by these and other cases reported to date, the onset of Drugtroglitazone - induced liver injury is insidious and temporally variable. |
| 0.9934 | However, as illustrated by these and other cases reported to date, the onset of troglitazone - induced Adverse-Effectliver injury is insidious and temporally variable. |
| Score | Text |
|---|---|
| 0.9992 | A 55 - year - old woman presented an episode of acute urticaria and labial angioedema 60 minutes after ingesting 500 mg of Drugcloxacillin for a skin abscess. |
| 0.9839 | A 55 - year - old woman presented an episode of acute urticaria and Adverse-Effectlabial angioedema 60 minutes after ingesting 500 mg of cloxacillin for a skin abscess. |
| 0.9828 | A 55 - year - old woman presented an episode of Adverse-Effectacute urticaria and labial angioedema 60 minutes after ingesting 500 mg of cloxacillin for a skin abscess. |
| Score | Text |
|---|---|
| 0.9890 | These features have not previously been reported as side effects of glibenclamide therapy, but Adverse-Effectintrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent. |
| 0.9632 | These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with Drugchlorpropamide , a similar sulphonylurea agent. |
| 0.9814 | These features have not previously been reported as side effects of Drugglibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent. |
| Score | Text |
|---|---|
| 0.9899 | The relation between Drugtacrolimus treatment and staining was suggested by the appearance of pigmentation during topical tacrolimus treatment and its clinical disappearance when treatment was stopped. |
| 0.9894 | The relation between tacrolimus treatment and staining was suggested by the appearance of Adverse-Effectpigmentation during topical tacrolimus treatment and its clinical disappearance when treatment was stopped. |
| 0.9881 | The relation between tacrolimus treatment and staining was suggested by the appearance of pigmentation during topical Drugtacrolimus treatment and its clinical disappearance when treatment was stopped. |
| Score | Text |
|---|---|
| 0.9967 | The Adverse-Effecthypercalcemia responded to discontinuation of rhGH and a single dose of intravenous pamidronate disodium and has not recurred in 8 months of follow - up. |
| 0.9607 | The hypercalcemia responded to discontinuation of DrugrhGH and a single dose of intravenous pamidronate disodium and has not recurred in 8 months of follow - up. |
| 0.8482 | The hypercalcemia responded to discontinuation of rhGH and a single dose of intravenous Drugpamidronate disodium and has not recurred in 8 months of follow - up. |
| Score | Text |
|---|---|
| 0.9996 | We document the abrupt development of an extensive choroidal detachment after initiation of Drugdorzolamide therapy in a surgically untreated eye with primary open - angle glaucoma. |
| 0.9858 | We document the abrupt development of an extensive Adverse-Effectchoroidal detachment after initiation of dorzolamide therapy in a surgically untreated eye with primary open - angle glaucoma. |
| Score | Text |
|---|---|
| 0.9875 | We describe a patient with the antiphospholipid syndrome who had Adverse-Effectskin necrosis develop from low - molecular weight heparin therapy at sites distant from injection sites. |
| 0.9689 | We describe a patient with the antiphospholipid syndrome who had skin necrosis develop from Druglow - molecular weight heparin therapy at sites distant from injection sites. |
| Score | Text |
|---|---|
| 0.9827 | Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity ( Adverse-Effecttotal AV - block ) persisted. |
| 0.9123 | Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DrugDGTX toxicity ( total AV - block ) persisted. |
| 0.6429 | Since this amount of FAB was insufficient to bind all DGTX present in the serum, Adverse-Effectcardiac DGTX toxicity ( total AV - block ) persisted. |
| 0.5907 | Since this amount of FAB was insufficient to bind Drugall DGTX present in the serum, cardiac DGTX toxicity ( total AV - block ) persisted. |
| Score | Text |
|---|---|
| 0.9989 | We report four patients, three of whom first developed Adverse-Effectpsoriasis and one who had an aggravation of the condition during treatment with interferon - alpha. |
| 0.9746 | We report four patients, three of whom first developed psoriasis and one who had an aggravation of the condition during treatment with Druginterferon - alpha . |
| Score | Text |
|---|---|
| 0.9988 | Three months following splenectomy, multiple abscesses occurred in the muscles of both thighs while the patient was receiving the third course of the DrugCHOP regimen. |
| 0.9809 | Three months following splenectomy, Adverse-Effectmultiple abscesses occurred in the muscles of both thighs while the patient was receiving the third course of the CHOP regimen. |
| Score | Text |
|---|---|
| 0.9996 | The possible development of a drug - induced vasculitis or lupus - like syndrome should be added to the list of rare toxic effects of Drugvancomycin . |
| 0.9962 | The possible development of a drug - induced Adverse-Effectvasculitis or lupus - like syndrome should be added to the list of rare toxic effects of vancomycin. |
| 0.9807 | The possible development of a drug - induced vasculitis or Adverse-Effectlupus - like syndrome should be added to the list of rare toxic effects of vancomycin. |
| Score | Text |
|---|---|
| 0.9993 | CONCLUSIONS : In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of Drugrifabutin . |
| 0.9878 | CONCLUSIONS : In these 3 cases, the unique positive ocular finding was Adverse-Effectcorneal endothelial deposits , which may be related to the use of rifabutin. |
| Score | Text |
|---|---|
| 0.9973 | Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin - D ( NSC - 3053 ) and Drugmithramycin ( NSC - 24559 ). |
| 0.9779 | Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics Drugactinomycin - D ( NSC - 3053 ) and mithramycin ( NSC - 24559 ). |
| 0.9706 | Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin - D ( NSC - 3053 ) and mithramycin ( DrugNSC - 24559 ). |
| 0.9699 | Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin - D ( DrugNSC - 3053 ) and mithramycin ( NSC - 24559 ). |
| 0.8676 | Adverse-EffectExacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin - D ( NSC - 3053 ) and mithramycin ( NSC - 24559 ). |
| Score | Text |
|---|---|
| 0.9995 | A female patient with HER2 positive, metastatic breast cancer presented with pulmonary infiltrates, and a plural effusion dyspnoea after several months of Drugtrastuzumab treatment. |
| 0.9823 | A female patient with HER2 positive, metastatic breast cancer presented with Adverse-Effectpulmonary infiltrates , and a plural effusion dyspnoea after several months of trastuzumab treatment. |
| 0.9820 | A female patient with HER2 positive, metastatic breast cancer presented with pulmonary infiltrates, and a Adverse-Effectplural effusion dyspnoea after several months of trastuzumab treatment. |
| Score | Text |
|---|---|
| 0.9992 | DrugMorphine , an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed. |
| 0.9980 | Morphine, an opium alkaloid, frequently causes side effects such as Adverse-Effecthyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed. |
| 0.9812 | Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and Adverse-Effectfacial flushing , but serious cutaneous adverse drug reactions are seldom observed. |
| Score | Text |
|---|---|
| 0.9868 | CONCLUSIONS : Adverse-EffectSpontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of LMWH. |
| 0.9819 | CONCLUSIONS : Spontaneous hemothorax is a rare phenomenon in conjunction with DrugLMWH but should be considered in cases of acute respiratory distress following commencement of LMWH. |
| 0.9761 | CONCLUSIONS : Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of DrugLMWH . |
| 0.9576 | CONCLUSIONS : Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of Adverse-Effectacute respiratory distress following commencement of LMWH. |
| Score | Text |
|---|---|
| 0.9988 | A patient suffering from Drugheparin - associated thrombocytopenia ( HAT ), recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described. |
| 0.9978 | A patient suffering from heparin - associated thrombocytopenia ( HAT ), recurrent arteriothromboses, and acute renal failure after treatment with standard Drugheparin is described. |
| 0.9966 | A patient suffering from heparin - associated thrombocytopenia ( Adverse-EffectHAT ), recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described. |
| 0.9954 | A patient suffering from heparin - associated Adverse-Effectthrombocytopenia ( HAT ), recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described. |
| 0.9895 | A patient suffering from heparin - associated thrombocytopenia ( HAT ), recurrent arteriothromboses, and Adverse-Effectacute renal failure after treatment with standard heparin is described. |
| 0.9823 | A patient suffering from heparin - associated thrombocytopenia ( HAT ), Adverse-Effectrecurrent arteriothromboses , and acute renal failure after treatment with standard heparin is described. |
| Score | Text |
|---|---|
| 0.9986 | AIMS : To present a case of Adverse-Effectpiloerection after replacing fluvoxamine maleate with milnacipran hydrochloride, and to analyse this effect based on receptor occupancy theory. |
| 0.9821 | AIMS : To present a case of piloerection after replacing Drugfluvoxamine maleate with milnacipran hydrochloride, and to analyse this effect based on receptor occupancy theory. |
| 0.9788 | AIMS : To present a case of piloerection after replacing fluvoxamine maleate with Drugmilnacipran hydrochloride , and to analyse this effect based on receptor occupancy theory. |
| Score | Text |
|---|---|
| 0.9849 | PURPOSE : To determine the cause of Adverse-Effectspontaneous choroidal hemorrhage in a 67 - year - old man after a myocardial infarction and administration of tissue plasminogen activator. |
| 0.9700 | PURPOSE : To determine the cause of spontaneous choroidal hemorrhage in a 67 - year - old man after a myocardial infarction and administration of Drugtissue plasminogen activator . |
| Score | Text |
|---|---|
| 0.9876 | In one instance a Adverse-Effectsystemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide. |
| 0.9864 | In one instance a systemic hypoglycemic reaction resulting in Adverse-Effecthead trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide. |
| 0.9787 | In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of Drugacetohexamide for acetazolamide. |
| 0.9726 | In one instance a systemic hypoglycemic reaction resulting in head trauma and Adverse-Effectconfusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide. |
| Score | Text |
|---|---|
| 0.9996 | CONCLUSIONS : DrugItraconazole - induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia. |
| 0.9958 | CONCLUSIONS : Itraconazole - induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to Adverse-Effectductopenia . |
| 0.9864 | CONCLUSIONS : Itraconazole - induced Adverse-Effectliver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia. |
| 0.9822 | CONCLUSIONS : Itraconazole - induced liver injury presents with a Adverse-Effectcholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia. |
| 0.9719 | CONCLUSIONS : Itraconazole - induced liver injury presents with a cholestatic pattern of injury with Adverse-Effectdamage to the interlobular bile ducts , possibly leading to ductopenia. |
| Score | Text |
|---|---|
| 0.9991 | We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with Drugalum . |
| 0.9960 | We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed Adverse-Effectseizures while receiving continuous bladder irrigations with alum. |
| 0.9934 | We report four cases of Adverse-Effectencephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum. |
| 0.9824 | We report four cases of encephalopathy coincident with Adverse-Effectelevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum. |
| Score | Text |
|---|---|
| 0.9987 | We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in Adverse-Effecthypercalciuria and hypercalcemia. |
| 0.9985 | We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and Adverse-Effecthypercalcemia . |
| 0.9978 | We experienced a male patient with psoriasis and hypertension whose conditions were treated with Drugtacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia. |
| 0.8722 | We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and Drugthiazide , respectively, resulting in hypercalciuria and hypercalcemia. |
| Score | Text |
|---|---|
| 0.9712 | While for ribavirin antidepressant effects are not known, we suppose that antidepressants may prevent changes in serotonergic or noradrenergic neurotransmission caused by DrugIFN - alpha . |
| 0.9633 | While for ribavirin antidepressant effects are not known, we suppose that antidepressants may prevent Adverse-Effectchanges in serotonergic or noradrenergic neurotransmission caused by IFN - alpha. |
| Score | Text |
|---|---|
| 0.9988 | As Druglinezolid has been shown to have hematologic side effects, blood count monitoring is recommended in patients receiving this drug for long - term therapy. |
| 0.9700 | As linezolid has been shown to have Adverse-Effecthematologic side effects , blood count monitoring is recommended in patients receiving this drug for long - term therapy. |
| Score | Text |
|---|---|
| 0.9992 | Two patients with extrinsic asthma and coexistent insulin - dependent diabetes mellitus sustained an anaphylactoid reaction after the intravenous administration of 50 % solution of Drugdextrose . |
| 0.9932 | Two patients with extrinsic asthma and coexistent insulin - dependent diabetes mellitus sustained an Adverse-Effectanaphylactoid reaction after the intravenous administration of 50 % solution of dextrose. |
| Score | Text |
|---|---|
| 0.9994 | A patient is described who developed a rapid onset of pulmonary fibrosis following treatment with a new non - steroidal anti - inflammatory drug, Drugnabumetone . |
| 0.9895 | A patient is described who developed a rapid onset of Adverse-Effectpulmonary fibrosis following treatment with a new non - steroidal anti - inflammatory drug, nabumetone. |
| Score | Text |
|---|---|
| 0.9992 | Although its side effects are few, Drugtamoxifen increases the incidence of proliferative lesions of the endometrium, which theoretically should be preventable with progestational agents. |
| 0.9732 | Although its side effects are few, tamoxifen increases the incidence of Adverse-Effectproliferative lesions of the endometrium , which theoretically should be preventable with progestational agents. |
| Score | Text |
|---|---|
| 0.9996 | In four patients, thrombosis occurred 2 - 45 days after severe hepatic veno - occlusive disease ( HVOD ) secondary to intensive chemotherapy containing Drugbusulfan . |
| 0.9933 | In four patients, Adverse-Effectthrombosis occurred 2 - 45 days after severe hepatic veno - occlusive disease ( HVOD ) secondary to intensive chemotherapy containing busulfan. |
| 0.9930 | In four patients, thrombosis occurred 2 - 45 days after severe hepatic veno - occlusive disease ( Adverse-EffectHVOD ) secondary to intensive chemotherapy containing busulfan. |
| 0.9624 | In four patients, thrombosis occurred 2 - 45 days after severe Adverse-Effecthepatic veno - occlusive disease ( HVOD ) secondary to intensive chemotherapy containing busulfan. |
| Score | Text |
|---|---|
| 0.9992 | CONCLUSIONS : Although Drugbudesonide may be beneficial because of its anti - inflammatory effects, clinicians should be alert to its potential for causing contact dermatitis. |
| 0.9848 | CONCLUSIONS : Although budesonide may be beneficial because of its anti - inflammatory effects, clinicians should be alert to its potential for causing Adverse-Effectcontact dermatitis . |
| Score | Text |
|---|---|
| 0.9994 | The patient was found to have no motile sperm with a normal sperm count, while taking a dose of 400 mg / day of Drugcarbamazepine . |
| 0.9882 | The patient was found to have Adverse-Effectno motile sperm with a normal sperm count, while taking a dose of 400 mg / day of carbamazepine. |
| Score | Text |
|---|---|
| 0.9994 | PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing Drugbusulfan and to be associated with HVOD. |
| 0.9973 | Adverse-EffectPVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD. |
| 0.9896 | PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with Adverse-EffectHVOD . |
| Score | Text |
|---|---|
| 0.9988 | The development of cutaneous ecchymosis associated with a sudden fall in hemoglobin after the administration of Drugalteplase should strongly suggest the possibility of diffuse subfascial hematoma. |
| 0.9820 | The development of Adverse-Effectcutaneous ecchymosis associated with a sudden fall in hemoglobin after the administration of alteplase should strongly suggest the possibility of diffuse subfascial hematoma. |
| 0.9787 | The development of cutaneous ecchymosis associated with a Adverse-Effectsudden fall in hemoglobin after the administration of alteplase should strongly suggest the possibility of diffuse subfascial hematoma. |
| 0.9760 | The development of cutaneous ecchymosis associated with a sudden fall in hemoglobin after the administration of alteplase should strongly suggest the possibility of Adverse-Effectdiffuse subfascial hematoma . |
| Score | Text |
|---|---|
| 0.9993 | RESULTS : A 52 - year - old woman with Parkinson disease who had taken Drugamantadine for 6 years had bilateral corneal edema for 2 months at baseline. |
| 0.9878 | RESULTS : A 52 - year - old woman with Parkinson disease who had taken amantadine for 6 years had Adverse-Effectbilateral corneal edema for 2 months at baseline. |
| Score | Text |
|---|---|
| 0.9994 | A few recent individual case reports have suggested that a myasthenic syndrome may be associated with Drugstatin treatment, but this association is not well described. |
| 0.9941 | A few recent individual case reports have suggested that a Adverse-Effectmyasthenic syndrome may be associated with statin treatment, but this association is not well described. |
| Score | Text |
|---|---|
| 0.9990 | We report a case of Drugamiodarone - induced thyrotoxicosis of protracted duration, unresponsive to conventional thionamide therapy, with therapy limited by severe adverse drug reactions. |
| 0.9978 | We report a case of amiodarone - induced Adverse-Effectthyrotoxicosis of protracted duration, unresponsive to conventional thionamide therapy, with therapy limited by severe adverse drug reactions. |
| Score | Text |
|---|---|
| 0.9874 | We hypothesize that decreased renal elimination of DrugMTX induced by the COX - 2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV - associated lymphoproliferative disease. |
| 0.9812 | We hypothesize that decreased renal elimination of MTX induced by the COX - 2 inhibitor resulted in enhanced hematopoietic toxicity and Adverse-Effectimmunosuppression causing the EBV - associated lymphoproliferative disease. |
| 0.9789 | We hypothesize that decreased renal elimination of MTX induced by the COX - 2 inhibitor resulted in enhanced Adverse-Effecthematopoietic toxicity and immunosuppression causing the EBV - associated lymphoproliferative disease. |
| 0.9311 | We hypothesize that decreased renal elimination of MTX induced by the COX - 2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the Adverse-EffectEBV - associated lymphoproliferative disease . |
| Score | Text |
|---|---|
| 0.9995 | DrugMTX - induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis. |
| 0.9918 | MTX - induced Adverse-Effecthepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis. |
| 0.9881 | MTX - induced hepatic injury and Adverse-Effectliver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis. |
| Score | Text |
|---|---|
| 0.9995 | We herein described an additional patient with BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10 - day treatment with Drugimatinib . |
| 0.9919 | We herein described an additional patient with BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia who developed Adverse-Effecttumor lysis syndrome after 10 - day treatment with imatinib. |
| Score | Text |
|---|---|
| 0.9958 | This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and Drugcalcitriol resulting in two admissions to the hospital for milk - alkali syndrome. |
| 0.9897 | This article presents a patient with hypoparathyroidism who was treated with Drugcalcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome. |
| 0.9461 | This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for Adverse-Effectmilk - alkali syndrome . |
| Score | Text |
|---|---|
| 0.9985 | Management of hypophosphatemia induced by high - flux hemodiafiltration for the treatment of Drugvancomycin toxicity : intravenous phosphorus therapy versus use of a phosphorus - enriched dialysate. |
| 0.7735 | Management of hypophosphatemia induced by high - flux hemodiafiltration for the treatment of Adverse-Effectvancomycin toxicity : intravenous phosphorus therapy versus use of a phosphorus - enriched dialysate. |
| 0.7747 | Management of Adverse-Effecthypophosphatemia induced by high - flux hemodiafiltration for the treatment of vancomycin toxicity : intravenous phosphorus therapy versus use of a phosphorus - enriched dialysate. |
| Score | Text |
|---|---|
| 0.9958 | Although this combination agent has been associated with a hypersensitivity syndrome involving cutaneous skin eruptions, pediatric cases of TMP - SMX - induced Adverse-Effecthepatotoxicity are rare. |
| 0.9762 | Although this combination agent has been associated with a hypersensitivity syndrome involving cutaneous skin eruptions, pediatric cases of DrugTMP - SMX - induced hepatotoxicity are rare. |
| 0.9390 | Although this combination agent has been associated with a Adverse-Effecthypersensitivity syndrome involving cutaneous skin eruptions, pediatric cases of TMP - SMX - induced hepatotoxicity are rare. |
| 0.8684 | Although this combination agent has been associated with a hypersensitivity syndrome involving Adverse-Effectcutaneous skin eruptions , pediatric cases of TMP - SMX - induced hepatotoxicity are rare. |
| Score | Text |
|---|---|
| 0.9989 | The addition of intrathecal Drugmethotrexate to treatment protocols has increased survival rates in children with acute lymphoblastic leukemia but is also associated with varying degrees of neurotoxicity. |
| 0.9936 | The addition of intrathecal methotrexate to treatment protocols has increased survival rates in children with acute lymphoblastic leukemia but is also associated with varying degrees of Adverse-Effectneurotoxicity . |
| Score | Text |
|---|---|
| 0.9992 | A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody ( ANCA ) detected after she had received Drugpropylthiouracil ( PTU ) for hyperthyroidism without cutaneous vasculitis. |
| 0.9990 | A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody ( ANCA ) detected after she had received propylthiouracil ( DrugPTU ) for hyperthyroidism without cutaneous vasculitis. |
| 0.9552 | A teenage girl with crescentic glomerulonephritis had Adverse-Effectantineutrophil cytoplasmic antibody ( ANCA ) detected after she had received propylthiouracil ( PTU ) for hyperthyroidism without cutaneous vasculitis. |
| Score | Text |
|---|---|
| 0.9986 | A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for intracranial bleeding while receiving Drugaspirin and clopidogrel. |
| 0.9976 | A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for intracranial bleeding while receiving aspirin and Drugclopidogrel . |
| 0.9907 | A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for Adverse-Effectintracranial bleeding while receiving aspirin and clopidogrel. |
| Score | Text |
|---|---|
| 0.9193 | OBJECTIVE : To study therapy with indapamide impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of diabetes induced by Drugindapamide . |
| 0.9112 | OBJECTIVE : To study therapy with Drugindapamide impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of diabetes induced by indapamide. |
| 0.8895 | OBJECTIVE : To study therapy with indapamide impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of Adverse-Effectdiabetes induced by indapamide. |
| 0.7866 | OBJECTIVE : To study therapy with indapamide impairing Drugcarbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of diabetes induced by indapamide. |
| OBJECTIVE : To study therapy with indapamide Adverse-Effectimpairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of diabetes induced by indapamide. | |
| Score | Text |
|---|---|
| 0.9890 | Coadministration of antidepressant agents such as Drugnefazodone , or any other drug that inhibits the CYP3A4 isoenzyme subfamily, should be anticipated to interfere with tacrolimus metabolism. |
| 0.9434 | Coadministration of antidepressant agents such as nefazodone, or any other drug that inhibits the CYP3A4 isoenzyme subfamily, should be anticipated to interfere with Drugtacrolimus metabolism. |
| 0.7274 | Coadministration of antidepressant agents such as nefazodone, or any other drug that inhibits the CYP3A4 isoenzyme subfamily, should be anticipated to Adverse-Effectinterfere with tacrolimus metabolism . |
| Score | Text |
|---|---|
| 0.9953 | BACKGROUND : Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and Adverse-Effecthyperandrogenism seem to be common among women treated with sodium valproate for epilepsy. |
| 0.9940 | BACKGROUND : Reproductive endocrine disorders characterized by Adverse-Effectmenstrual disorders , polycystic ovaries, and hyperandrogenism seem to be common among women treated with sodium valproate for epilepsy. |
| 0.9921 | BACKGROUND : Reproductive endocrine disorders characterized by menstrual disorders, Adverse-Effectpolycystic ovaries , and hyperandrogenism seem to be common among women treated with sodium valproate for epilepsy. |
| 0.9894 | BACKGROUND : Adverse-EffectReproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism seem to be common among women treated with sodium valproate for epilepsy. |
| 0.9856 | BACKGROUND : Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism seem to be common among women treated with Drugsodium valproate for epilepsy. |
| Score | Text |
|---|---|
| 0.9989 | A 52 - year - old, white female developed low - grade fever, Adverse-Effectcough , and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis. |
| 0.9979 | A 52 - year - old, white female developed low - grade fever, cough, and Adverse-Effectdyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis. |
| 0.9884 | A 52 - year - old, white female developed Adverse-Effectlow - grade fever , cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis. |
| 0.9843 | A 52 - year - old, white female developed low - grade fever, cough, and dyspnea after 8 weeks treatment with Drugsodium aurothiomalate for rheumatoid arthritis. |
| Score | Text |
|---|---|
| 0.9990 | We report a case of a 60 - year - old woman affected by squamous lung carcinoma, who developed paroxysmal supraventricular tachycardia during cisplatin and Drugetoposide combination chemotherapy. |
| 0.9987 | We report a case of a 60 - year - old woman affected by squamous lung carcinoma, who developed paroxysmal supraventricular tachycardia during Drugcisplatin and etoposide combination chemotherapy. |
| 0.9853 | We report a case of a 60 - year - old woman affected by squamous lung carcinoma, who developed Adverse-Effectparoxysmal supraventricular tachycardia during cisplatin and etoposide combination chemotherapy. |
| Score | Text |
|---|---|
| 0.9996 | The patient experienced hallucinations, agitation, vomiting, tachycardia and seizures after ingestion of 1050 ( 48 mg / kg ) of extended - release Drugbupropion . |
| 0.9986 | The patient experienced hallucinations, agitation, vomiting, Adverse-Effecttachycardia and seizures after ingestion of 1050 ( 48 mg / kg ) of extended - release bupropion. |
| 0.9983 | The patient experienced Adverse-Effecthallucinations , agitation, vomiting, tachycardia and seizures after ingestion of 1050 ( 48 mg / kg ) of extended - release bupropion. |
| 0.9978 | The patient experienced hallucinations, agitation, vomiting, tachycardia and Adverse-Effectseizures after ingestion of 1050 ( 48 mg / kg ) of extended - release bupropion. |
| 0.9976 | The patient experienced hallucinations, agitation, Adverse-Effectvomiting , tachycardia and seizures after ingestion of 1050 ( 48 mg / kg ) of extended - release bupropion. |
| 0.9967 | The patient experienced hallucinations, Adverse-Effectagitation , vomiting, tachycardia and seizures after ingestion of 1050 ( 48 mg / kg ) of extended - release bupropion. |
| Score | Text |
|---|---|
| 0.9996 | The authors describe Drugvalproate - induced hyperammonemia and mental status changes in an 88 - year - old man, the first known reported case in an elderly patient. |
| 0.9980 | The authors describe valproate - induced Adverse-Effecthyperammonemia and mental status changes in an 88 - year - old man, the first known reported case in an elderly patient. |
| 0.9854 | The authors describe valproate - induced hyperammonemia and Adverse-Effectmental status changes in an 88 - year - old man, the first known reported case in an elderly patient. |
| Score | Text |
|---|---|
| 0.9994 | DISCUSSION : No published clinical studies in patients receiving Drugclindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea. |
| 0.9359 | DISCUSSION : No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with Adverse-Effectdiarrhea . |
| 0.9380 | DISCUSSION : No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented Adverse-EffectC. difficile toxin in stool samples of patients with diarrhea. |
| DISCUSSION : No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented Adverse-EffectC. difficile toxin in stool samples of patients with diarrhea. | |
| Score | Text |
|---|---|
| 0.9994 | When thrombosis develops during Drugheparin treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count. |
| 0.9974 | When Adverse-Effectthrombosis develops during heparin treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count. |
| Score | Text |
|---|---|
| 0.9990 | A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a Drugcyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates. |
| 0.9898 | A patient with Wegener's granulomatosis rapidly developed a Adverse-Effectcircumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates. |
| Score | Text |
|---|---|
| 0.9996 | In each of the three reported patients, alteration of eyelid appearance with deepening of the lid sulcus was evident as the result of topical Drugbimatoprost therapy. |
| 0.9832 | In each of the three reported patients, alteration of eyelid appearance with Adverse-Effectdeepening of the lid sulcus was evident as the result of topical bimatoprost therapy. |
| 0.9804 | In each of the three reported patients, Adverse-Effectalteration of eyelid appearance with deepening of the lid sulcus was evident as the result of topical bimatoprost therapy. |
| Score | Text |
|---|---|
| 0.9959 | OBJECTIVE : To evaluate the efficacy of the administration of insulin by a jet - injector device in stopping and reversing severe human insulin - induced Adverse-Effectlipoatrophy . |
| 0.9875 | OBJECTIVE : To evaluate the efficacy of the administration of insulin by a jet - injector device in stopping and reversing severe Drughuman insulin - induced lipoatrophy. |
| 0.9322 | OBJECTIVE : To evaluate the efficacy of the administration of Druginsulin by a jet - injector device in stopping and reversing severe human insulin - induced lipoatrophy. |
| Score | Text |
|---|---|
| 0.9994 | The authors intend to carry out a case - control study on patients treated with Drugtamoxifen for breast carcinoma to reveal the possible presence of endometrial carcinoma. |
| 0.9891 | The authors intend to carry out a case - control study on patients treated with tamoxifen for breast carcinoma to reveal the possible presence of Adverse-Effectendometrial carcinoma . |
| Score | Text |
|---|---|
| 0.9977 | Therefore, clinicians should pay close attention to possible onset of RD in patients with multiple risk factors for TD, even when DrugSDA therapy is used. |
| 0.9885 | Therefore, clinicians should pay close attention to possible onset of Adverse-EffectRD in patients with multiple risk factors for TD, even when SDA therapy is used. |
| Score | Text |
|---|---|
| 0.9973 | Children with acute lymphoblastic leukemia ( ALL ), treated with L - asparaginase are at risk for cerebral thrombosis or Adverse-Effecthemorrhage because of coagulation protein deficiencies. |
| 0.9780 | Children with acute lymphoblastic leukemia ( ALL ), treated with DrugL - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies. |
| 0.9725 | Children with acute lymphoblastic leukemia ( ALL ), treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of Adverse-Effectcoagulation protein deficiencies . |
| 0.9657 | Children with acute lymphoblastic leukemia ( ALL ), treated with L - asparaginase are at risk for Adverse-Effectcerebral thrombosis or hemorrhage because of coagulation protein deficiencies. |
| Score | Text |
|---|---|
| 0.9996 | We report the case of a patient with chronic lymphocytic leukemia ( CLL ) who developed fatal intravascular autoimmune hemolytic anemia ( AIHA ) after Drugfludarabine treatment. |
| 0.9965 | We report the case of a patient with chronic lymphocytic leukemia ( CLL ) who developed fatal intravascular autoimmune hemolytic anemia ( Adverse-EffectAIHA ) after fludarabine treatment. |
| 0.9853 | We report the case of a patient with chronic lymphocytic leukemia ( CLL ) who developed Adverse-Effectfatal intravascular autoimmune hemolytic anemia ( AIHA ) after fludarabine treatment. |
| Score | Text |
|---|---|
| 0.9988 | We describe two ELBW infants affected by hyperkalaemia, treated with DrugKayexalate , who developed serious hypernatraemia, that has never been reported before in preterm infants. |
| 0.9927 | We describe two ELBW infants affected by hyperkalaemia, treated with Kayexalate, who developed serious Adverse-Effecthypernatraemia , that has never been reported before in preterm infants. |
| Score | Text |
|---|---|
| 0.9997 | CONCLUSION : To the best of our knowledge, this is the first time Drugcolchicine intoxication in this age group has been described in the English literature. |
| 0.9367 | CONCLUSION : To the best of our knowledge, this is the first time Adverse-Effectcolchicine intoxication in this age group has been described in the English literature. |
| Score | Text |
|---|---|
| 0.9992 | Initial treatment with Drugheparin was substituted with thrombolysis, which resulted in clinical improvement and dissolution of right heart thrombus but was followed by fatal intracerebral haemorrhage. |
| 0.9871 | Initial treatment with heparin was substituted with thrombolysis, which resulted in clinical improvement and dissolution of right heart thrombus but was followed by Adverse-Effectfatal intracerebral haemorrhage . |
| Score | Text |
|---|---|
| 0.9991 | Nine delirious patients suffering from Druglithium intoxication were examined with the Mini - Mental State Exam ( MMS ) to describe the clinical course of the disorder. |
| 0.9738 | Nine Adverse-Effectdelirious patients suffering from lithium intoxication were examined with the Mini - Mental State Exam ( MMS ) to describe the clinical course of the disorder. |
| Score | Text |
|---|---|
| 0.9984 | Recently, some studies have also reported association between patients with juvenile rheumatoid arthritis ( JRA ) treated with DrugMethotrexate ( MTX ) and malignant lymphoma developing. |
| 0.9976 | Recently, some studies have also reported association between patients with juvenile rheumatoid arthritis ( JRA ) treated with Methotrexate ( DrugMTX ) and malignant lymphoma developing. |
| 0.9890 | Recently, some studies have also reported association between patients with juvenile rheumatoid arthritis ( JRA ) treated with Methotrexate ( MTX ) and Adverse-Effectmalignant lymphoma developing. |
| Score | Text |
|---|---|
| 0.9963 | DrugRifampin ( RFP ) increases hepatic microsomal enzyme activity, and there are case reports of RFP - induced hypothyroidism, all associated with Hashimoto's thyroiditis. |
| 0.9945 | Rifampin ( RFP ) increases hepatic microsomal enzyme activity, and there are case reports of RFP - induced Adverse-Effecthypothyroidism , all associated with Hashimoto's thyroiditis. |
| 0.9941 | Rifampin ( DrugRFP ) increases hepatic microsomal enzyme activity, and there are case reports of RFP - induced hypothyroidism, all associated with Hashimoto's thyroiditis. |
| 0.9419 | Rifampin ( RFP ) increases hepatic microsomal enzyme activity, and there are case reports of RFP - induced hypothyroidism, all associated with Adverse-EffectHashimoto's thyroiditis . |
| 0.9762 | Rifampin ( RFP ) increases hepatic microsomal enzyme activity, and there are case reports of DrugRFP - induced hypothyroidism, all associated with Hashimoto's thyroiditis. |
| Score | Text |
|---|---|
| 0.9735 | OBJECTIVE : To report the late development of Adverse-Effectimmune - mediated diabetes mellitus after completion of alfa - interferon therapy for hepatitis C in an Asian patient. |
| 0.9659 | OBJECTIVE : To report the late development of immune - mediated diabetes mellitus after completion of Drugalfa - interferon therapy for hepatitis C in an Asian patient. |
| Score | Text |
|---|---|
| 0.9995 | The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of Drugpropranolol to her neuroleptic regimen. |
| 0.9988 | The authors describe a woman with chronic schizophrenia who experienced Adverse-Effectdelirium , grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen. |
| 0.9982 | The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and Adverse-Effectphotosensitivity after the addition of propranolol to her neuroleptic regimen. |
| 0.9901 | The authors describe a woman with chronic schizophrenia who experienced delirium, Adverse-Effectgrand mal seizure , and photosensitivity after the addition of propranolol to her neuroleptic regimen. |
| Score | Text |
|---|---|
| 0.9995 | Seven patients with hematologic malignancies who were treated with Drugmiconazole for either suspected or proven fungal infections developed eight episodes of major adverse cardiorespiratory and anaphylactic reactions. |
| 0.9555 | Seven patients with hematologic malignancies who were treated with miconazole for either suspected or proven fungal infections developed eight episodes of major adverse Adverse-Effectcardiorespiratory and anaphylactic reactions . |
| 0.9013 | Seven patients with hematologic malignancies who were treated with miconazole for either suspected or proven fungal infections developed eight episodes of major Adverse-Effectadverse cardiorespiratory and anaphylactic reactions . |
| Score | Text |
|---|---|
| 0.9981 | k bipolar manic - depressive patient, developed while on Druglithium prophylaxis, akathisia at therapeutic serum lithium levels and subsequently bucco - linguo - masticatory dyskinesia. |
| 0.9910 | k bipolar manic - depressive patient, developed while on lithium prophylaxis, Adverse-Effectakathisia at therapeutic serum lithium levels and subsequently bucco - linguo - masticatory dyskinesia. |
| 0.9795 | k bipolar manic - depressive patient, developed while on lithium prophylaxis, akathisia at therapeutic serum lithium levels and subsequently Adverse-Effectbucco - linguo - masticatory dyskinesia . |
| Score | Text |
|---|---|
| 0.9874 | DrugHydroxyurea ( HU ) and sodium phenylbutyrate ( SPB ) have been shown to increase fetal hemoglobin ( Hb F ) levels in patients with thalassemia intermedia. |
| 0.9816 | Hydroxyurea ( HU ) and sodium phenylbutyrate ( SPB ) have been shown to Adverse-Effectincrease fetal hemoglobin ( Hb F ) levels in patients with thalassemia intermedia. |
| 0.9584 | Hydroxyurea ( HU ) and Drugsodium phenylbutyrate ( SPB ) have been shown to increase fetal hemoglobin ( Hb F ) levels in patients with thalassemia intermedia. |
| 0.9845 | Hydroxyurea ( DrugHU ) and sodium phenylbutyrate ( SPB ) have been shown to increase fetal hemoglobin ( Hb F ) levels in patients with thalassemia intermedia. |
| Score | Text |
|---|---|
| 0.9992 | The second was an 82 - year - old man receiving Drugticlopidine for 2 years when, during a febrile episode, he was found neutropenic with marrow aplasia. |
| 0.9827 | The second was an 82 - year - old man receiving ticlopidine for 2 years when, during a febrile episode, he was found neutropenic with Adverse-Effectmarrow aplasia . |
| 0.9818 | The second was an 82 - year - old man receiving ticlopidine for 2 years when, during a febrile episode, he was found Adverse-Effectneutropenic with marrow aplasia. |
| Score | Text |
|---|---|
| 0.9996 | A 73 - year - old woman with non - Hodgkin's lymphoma had two episodes of severe, bilateral, sensori - neural hearing loss after Drugvincristine therapy. |
| 0.9274 | A 73 - year - old woman with non - Hodgkin's lymphoma had two episodes of severe, bilateral, Adverse-Effectsensori - neural hearing loss after vincristine therapy. |
| Score | Text |
|---|---|
| 0.9990 | Fatal radiation myelopathy after high - dose Drugbusulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma : a review of the literature and implications for practice. |
| 0.9988 | Fatal radiation myelopathy after high - dose busulfan and Drugmelphalan chemotherapy and radiotherapy for Ewing's sarcoma : a review of the literature and implications for practice. |
| 0.9873 | Adverse-EffectFatal radiation myelopathy after high - dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma : a review of the literature and implications for practice. |
| Score | Text |
|---|---|
| 0.9943 | A 57 - year - old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including Druglansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease. |
| 0.9930 | A 57 - year - old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by Druglansoprazole monotherapy for gastroesophageal reflux disease. |
| 0.6179 | A 57 - year - old man developed chronic, Adverse-Effectwatery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease. |
| A 57 - year - old man developed Adverse-Effectchronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease. | |
| Score | Text |
|---|---|
| 0.9994 | BACKGROUND : DrugCyanamide , an aversive agent widely used in Japan, is known to induce various degrees of hepatic lesion with ground - glass inclusion bodies. |
| 0.8157 | BACKGROUND : Cyanamide, an aversive agent widely used in Japan, is known to induce various degrees of Adverse-Effecthepatic lesion with ground - glass inclusion bodies . |
| Score | Text |
|---|---|
| 0.9975 | BACKGROUND : To assess the nature, incidence, and risk factors of Adverse-Effectretinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients. |
| 0.9974 | BACKGROUND : To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and Drugribavirin combination therapy in chronic hepatitis C patients. |
| 0.9852 | BACKGROUND : To assess the nature, incidence, and risk factors of retinopathy associated with Drugpegylated interferon and ribavirin combination therapy in chronic hepatitis C patients. |
| Score | Text |
|---|---|
| 0.9989 | These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which Drugquetiapine was considered a significant factor. |
| 0.9962 | These cases were chosen for study because they were all Adverse-Effectdeaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor. |
| Score | Text |
|---|---|
| 0.9992 | Exposure of the fetus to Drugindomethacin by administration of the drug to the mother may cause many side effects, including premature closure of the ductus arteriosus. |
| 0.9745 | Exposure of the fetus to indomethacin by administration of the drug to the mother may cause many side effects, including Adverse-Effectpremature closure of the ductus arteriosus . |
| 0.9253 | Adverse-EffectExposure of the fetus to indomethacin by administration of the drug to the mother may cause many side effects, including premature closure of the ductus arteriosus. |
| Score | Text |
|---|---|
| 0.9826 | This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of Adverse-Effectelevated serum triglyceride levels in clozapine - treated patients. |
| 0.8909 | This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in Drugclozapine - treated patients. |
| Score | Text |
|---|---|
| 0.9990 | A case of toxic hepatitis caused by combination therapy with Drugmethotrexate and etretinate in the treatment of severe psoriasis is presented in a 47 - year - old woman. |
| 0.9988 | A case of toxic hepatitis caused by combination therapy with methotrexate and Drugetretinate in the treatment of severe psoriasis is presented in a 47 - year - old woman. |
| 0.9912 | A case of Adverse-Effecttoxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47 - year - old woman. |
| Score | Text |
|---|---|
| 0.9992 | We present a case of respiratory failure occurring in a woman at 16 weeks'gestation who was being treated with Drugnitrofurantoin for a urinary tract infection. |
| 0.9931 | We present a case of Adverse-Effectrespiratory failure occurring in a woman at 16 weeks'gestation who was being treated with nitrofurantoin for a urinary tract infection. |
| Score | Text |
|---|---|
| 0.9993 | DrugTiclopidine is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with severe bone marrow suppression, typically aplastic anemia. |
| 0.9940 | Ticlopidine is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with severe bone marrow suppression, typically Adverse-Effectaplastic anemia . |
| 0.9858 | Ticlopidine is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with Adverse-Effectsevere bone marrow suppression , typically aplastic anemia. |
| Score | Text |
|---|---|
| 0.9995 | Pellagra should be suspected whenever tuberculous patients under treatment with Drugisoniazid develop mental, neurological or gastrointestinal symptoms, even in the absence of typical pellagra dermatitis. |
| 0.9827 | Pellagra should be suspected whenever tuberculous patients under treatment with isoniazid develop Adverse-Effectmental, neurological or gastrointestinal symptoms , even in the absence of typical pellagra dermatitis. |
| Score | Text |
|---|---|
| 0.9994 | Treatment with Druginfliximab is known to produce an increase of autoantibodies ( antinuclear antibodies, anti - double - stranded DNA ), but not clinical disease. |
| 0.9907 | Treatment with infliximab is known to produce an increase of autoantibodies ( Adverse-Effectantinuclear antibodies , anti - double - stranded DNA ), but not clinical disease. |
| 0.9814 | Treatment with infliximab is known to produce an Adverse-Effectincrease of autoantibodies ( antinuclear antibodies, anti - double - stranded DNA ), but not clinical disease. |
| 0.9813 | Treatment with infliximab is known to produce an increase of autoantibodies ( antinuclear antibodies, Adverse-Effectanti - double - stranded DNA ), but not clinical disease. |
| Score | Text |
|---|---|
| 0.9984 | A 21 - year - old man with Tourette's syndrome, pedophilia, Asperger's syndrome, and multiple sclerosis experienced Adverse-Effectseizures after receiving therapy with interferon beta - 1a. |
| 0.9750 | A 21 - year - old man with Tourette's syndrome, pedophilia, Asperger's syndrome, and multiple sclerosis experienced seizures after receiving therapy with Druginterferon beta - 1a . |
| Score | Text |
|---|---|
| 0.9976 | We present a case of a 58 - year - old female patient with Graves'disease who developed AA in the third exposure to Drugmethimazole ( MMI ). |
| 0.9946 | We present a case of a 58 - year - old female patient with Graves'disease who developed Adverse-EffectAA in the third exposure to methimazole ( MMI ). |
| 0.9966 | We present a case of a 58 - year - old female patient with Graves'disease who developed AA in the third exposure to methimazole ( DrugMMI ). |
| Score | Text |
|---|---|
| 0.9845 | Adverse-EffectHypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy. |
| 0.9541 | Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with Adverse-Effecthyperacute changes on ECG whilst receiving carboplatin therapy. |
| 0.8829 | Hypersensitivity to Drugcarboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy. |
| 0.7118 | Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving Drugcarboplatin therapy. |
| 0.5981 | Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute Adverse-Effectchanges on ECG whilst receiving carboplatin therapy. |
| Score | Text |
|---|---|
| 0.9857 | ARA - C is frequently associated with Adverse-Effectdermatologic toxicity , but this is only the second case of toxic epidermal necrolysis described in connection with this drug. |
| 0.9817 | ARA - C is frequently associated with dermatologic toxicity, but this is only the second case of Adverse-Effecttoxic epidermal necrolysis described in connection with this drug. |
| 0.9771 | DrugARA - C is frequently associated with dermatologic toxicity, but this is only the second case of toxic epidermal necrolysis described in connection with this drug. |
| Score | Text |
|---|---|
| 0.9903 | After 5 days of treatment with IL - 2, the patient developed a Adverse-Effecthemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia. |
| 0.9878 | After 5 days of treatment with IL - 2, the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 Adverse-Effectpancytopenia . |
| 0.9876 | After 5 days of treatment with IL - 2, the patient developed a hemorrhagic lesion that progressed to Adverse-Effecttoxic epidermal necrolysis , as well as grade 4 pancytopenia. |
| 0.9854 | After 5 days of treatment with DrugIL - 2 , the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia. |
| Score | Text |
|---|---|
| 0.9984 | IV Drugpropranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure. |
| 0.9788 | IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a Adverse-Effectdecrease in heart rate but a paroxsymal increase in blood pressure. |
| 0.9678 | IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a Adverse-Effectparoxsymal increase in blood pressure . |
| Score | Text |
|---|---|
| 0.9985 | The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of Adverse-Effectdystonia . |
| 0.9981 | The currently available clinical and neuropharmacologic data suggest that Drugcarbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia. |
| Score | Text |
|---|---|
| 0.9981 | All developed mucocutaneous side effects within 20 weeks of beginning i m Druggold therapy, at a time when RA had improved markedly compared to pretreatment status. |
| 0.9889 | All developed Adverse-Effectmucocutaneous side effects within 20 weeks of beginning i m gold therapy, at a time when RA had improved markedly compared to pretreatment status. |
| Score | Text |
|---|---|
| 0.9989 | We present three patients with paradoxical seizures ; their serum Drugphenytoin levels were 43. 5 mcg / mL, 46. 5 mcg / mL and 38. 3 mcg / mL. |
| 0.9743 | We present three patients with paradoxical Adverse-Effectseizures ; their serum phenytoin levels were 43. 5 mcg / mL, 46. 5 mcg / mL and 38. 3 mcg / mL. |
| Score | Text |
|---|---|
| 0.9995 | Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of Drugclofazimine , showed discoloration of nail plate, subungual hyperkeratosis and onycholysis. |
| 0.9921 | Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of clofazimine, showed discoloration of nail plate, subungual hyperkeratosis and Adverse-Effectonycholysis . |
| 0.9880 | Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of clofazimine, showed discoloration of nail plate, Adverse-Effectsubungual hyperkeratosis and onycholysis. |
| 0.9809 | Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of clofazimine, showed Adverse-Effectdiscoloration of nail plate , subungual hyperkeratosis and onycholysis. |
| Score | Text |
|---|---|
| 0.9996 | CONCLUSIONS : Patients receiving intravitreal injections of Drugbevacizumab should be evaluated for potential systemic risk factors such as carotid insufficiency, coagulopathy and poorly controlled diabetes mellitus. |
| 0.9979 | CONCLUSIONS : Patients receiving intravitreal injections of bevacizumab should be evaluated for potential systemic risk factors such as carotid insufficiency, Adverse-Effectcoagulopathy and poorly controlled diabetes mellitus. |
| 0.9879 | CONCLUSIONS : Patients receiving intravitreal injections of bevacizumab should be evaluated for potential systemic risk factors such as Adverse-Effectcarotid insufficiency , coagulopathy and poorly controlled diabetes mellitus. |
| 0.9640 | CONCLUSIONS : Patients receiving intravitreal injections of bevacizumab should be evaluated for potential systemic risk factors such as carotid insufficiency, coagulopathy and Adverse-Effectpoorly controlled diabetes mellitus . |
| Score | Text |
|---|---|
| 0.9990 | A 53 - year - old man developed lower leg edema 4 weeks after Drugrosiglitazone was increased from 4 mg once / day to 4 mg twice / day. |
| 0.9867 | A 53 - year - old man developed Adverse-Effectlower leg edema 4 weeks after rosiglitazone was increased from 4 mg once / day to 4 mg twice / day. |
| Score | Text |
|---|---|
| 0.9996 | CASE SUMMARY : A 68 - year - old woman developed a dry, irritating cough within one month of starting Drugquinapril therapy for the treatment of essential hypertension. |
| 0.9778 | CASE SUMMARY : A 68 - year - old woman developed a dry, Adverse-Effectirritating cough within one month of starting quinapril therapy for the treatment of essential hypertension. |
| Score | Text |
|---|---|
| 0.9975 | Three patients who had experienced neuroleptic - induced akathisia in the past reported that the symptoms of Drugfluoxetine - induced akathisia were identical, although somewhat milder. |
| 0.9615 | Three patients who had experienced neuroleptic - induced akathisia in the past reported that the symptoms of fluoxetine - induced Adverse-Effectakathisia were identical, although somewhat milder. |
| 0.8583 | Three patients who had experienced neuroleptic - induced Adverse-Effectakathisia in the past reported that the symptoms of fluoxetine - induced akathisia were identical, although somewhat milder. |
| Score | Text |
|---|---|
| 0.9977 | Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, Adverse-Effectedema , and pain in his right forearm. |
| 0.9976 | Shortly after chemotherapy and an injection of Drugpegfilgrastim , the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm. |
| 0.9866 | Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, Adverse-Effectrapidly progressive erythema , edema, and pain in his right forearm. |
| 0.9709 | Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and Adverse-Effectpain in his right forearm . |
| Score | Text |
|---|---|
| 0.9972 | CONCLUSION : The results suggest that olanzapine may be useful in treating patients with clozapine - induced Adverse-Effectgranulocytopenia without the risk of recurrence of hematologic side effects. |
| 0.9682 | CONCLUSION : The results suggest that olanzapine may be useful in treating patients with Drugclozapine - induced granulocytopenia without the risk of recurrence of hematologic side effects. |
| Score | Text |
|---|---|
| 0.9995 | CONCLUSION : DrugGemcitabine - induced recall pneumonitis is a rarely reported phenomenon and should be taken into account even after extended time interval to the previous radiotherapy. |
| 0.9904 | CONCLUSION : Gemcitabine - induced Adverse-Effectrecall pneumonitis is a rarely reported phenomenon and should be taken into account even after extended time interval to the previous radiotherapy. |
| Score | Text |
|---|---|
| 0.9970 | In one patient, treatment with DrugDCA was associated with a decrease in blood lactate levels from 11. 2 mM before treatment to 0. 8 mM 16 h later. |
| 0.9849 | In one patient, treatment with DCA was associated with a Adverse-Effectdecrease in blood lactate levels from 11. 2 mM before treatment to 0. 8 mM 16 h later. |
| Score | Text |
|---|---|
| 0.9915 | Mitomycin - C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of Adverse-Effecthemolytic uremic syndrome . |
| 0.9646 | DrugMitomycin - C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome. |
| Score | Text |
|---|---|
| 0.9985 | Adverse-EffectPancreatitis has been noted to be a complication in 2 - 16 % of patients undergoing treatment with L - asparaginase for a variety of pediatric neoplasms. |
| 0.9694 | Pancreatitis has been noted to be a complication in 2 - 16 % of patients undergoing treatment with DrugL - asparaginase for a variety of pediatric neoplasms. |
| Score | Text |
|---|---|
| 0.9992 | RESULTS : DrugBrimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 ( strong probability ) on an adverse drug reaction probability score. |
| 0.9901 | RESULTS : Brimonidine was observed to cause Adverse-EffectIOP elevation , confirmed on rechallenge, scoring 8 ( strong probability ) on an adverse drug reaction probability score. |
| Score | Text |
|---|---|
| 0.9987 | We describe a case of Adverse-EffectPRES in a patient with collapsing focal glomeruloesclerosis ( collapsing FGS ) with complete recovery after withdrawal of cyclosporine ( CSA ). |
| 0.9985 | We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis ( collapsing FGS ) with complete recovery after withdrawal of Drugcyclosporine ( CSA ). |
| 0.9975 | We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis ( collapsing FGS ) with complete recovery after withdrawal of cyclosporine ( DrugCSA ). |
| Score | Text |
|---|---|
| 0.9995 | Three of 50 patients treated with Drugisotretinoin ( 1 mg / kg / day ) for cystic acne complained of poor night vision and / or excessive glare sensitivity. |
| 0.9809 | Three of 50 patients treated with isotretinoin ( 1 mg / kg / day ) for cystic acne complained of Adverse-Effectpoor night vision and / or excessive glare sensitivity. |
| 0.9704 | Three of 50 patients treated with isotretinoin ( 1 mg / kg / day ) for cystic acne complained of poor night vision and / or Adverse-Effectexcessive glare sensitivity . |
| Score | Text |
|---|---|
| 0.9992 | CASE REPORT : A six - year - old boy with transfusion - dependent beta - thalassaemia developed a unilateral hearing loss shortly after commencing Drugdesferrioxamine therapy. |
| 0.9912 | CASE REPORT : A six - year - old boy with transfusion - dependent beta - thalassaemia developed a Adverse-Effectunilateral hearing loss shortly after commencing desferrioxamine therapy. |
| Score | Text |
|---|---|
| 0.9991 | CASE : A malignant mixed mesodermal tumor was diagnosed in a 64 - year - old woman with a bicornuate uterus while she was taking Drugraloxifene for osteoporosis prevention. |
| 0.9855 | CASE : A Adverse-Effectmalignant mixed mesodermal tumor was diagnosed in a 64 - year - old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention. |
| Score | Text |
|---|---|
| 0.9979 | We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with Adverse-Effectirritability or angry outbursts. |
| 0.9932 | We describe two cases that illustrate the use of Druglithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts. |
| 0.9866 | We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or Adverse-Effectangry outbursts . |
| Score | Text |
|---|---|
| 0.9980 | DrugDiazepam use by pregnant women can be associated with a later presentation of withdrawal symptoms in the neonate than that induced by the use of other drugs. |
| 0.9779 | Diazepam use by pregnant women can be associated with a later presentation of Adverse-Effectwithdrawal symptoms in the neonate than that induced by the use of other drugs. |
| Score | Text |
|---|---|
| 0.9958 | She had just finished a 3 - week course of intravenous Drugtobramycin for bronchiectasis and had an elevated serum tobramycin trough level 1 week before the onset of tetany. |
| 0.9932 | She had just finished a 3 - week course of intravenous tobramycin for bronchiectasis and had an elevated serum tobramycin trough level 1 week before the onset of Adverse-Effecttetany . |
| Score | Text |
|---|---|
| 0.9568 | Although adverse reactions to protamine are reported infrequently and are usually mild, we recently observed the first fatal case of type I anaphylaxis resulting from Drugprotamine . |
| 0.9498 | Although adverse reactions to protamine are reported infrequently and are usually mild, we recently observed the first fatal case of Adverse-Effecttype I anaphylaxis resulting from protamine. |
| 0.9477 | Although adverse reactions to Drugprotamine are reported infrequently and are usually mild, we recently observed the first fatal case of type I anaphylaxis resulting from protamine. |
| 0.7569 | Although adverse reactions to protamine are reported infrequently and are usually mild, we recently observed the first Adverse-Effectfatal case of type I anaphylaxis resulting from protamine. |
| Score | Text |
|---|---|
| 0.9984 | The treatment for acidosis and hyperkalaemia should be started as soon as RTA is diagnosed, and the dosage of DrugFK506 should also be reduced if possible. |
| 0.9959 | The treatment for acidosis and hyperkalaemia should be started as soon as Adverse-EffectRTA is diagnosed, and the dosage of FK506 should also be reduced if possible. |
| Score | Text |
|---|---|
| 0.9994 | DrugLithium is known to cause acute renal failure and tubulo - interstitial disease, but the recently described association with proteinuria or nephrotic syndrome is little recognized. |
| 0.9971 | Lithium is known to cause acute renal failure and tubulo - interstitial disease, but the recently described association with Adverse-Effectproteinuria or nephrotic syndrome is little recognized. |
| 0.9913 | Lithium is known to cause acute renal failure and tubulo - interstitial disease, but the recently described association with proteinuria or Adverse-Effectnephrotic syndrome is little recognized. |
| 0.9860 | Lithium is known to cause Adverse-Effectacute renal failure and tubulo - interstitial disease, but the recently described association with proteinuria or nephrotic syndrome is little recognized. |
| 0.9834 | Lithium is known to cause acute renal failure and Adverse-Effecttubulo - interstitial disease , but the recently described association with proteinuria or nephrotic syndrome is little recognized. |
| Score | Text |
|---|---|
| 0.9992 | Awareness of this route of intoxication might be important in patients in whom neurologic or psychiatric symptoms develop while large amounts of Druglidocaine cream are being used. |
| 0.9427 | Awareness of this route of intoxication might be important in patients in whom neurologic or Adverse-Effectpsychiatric symptoms develop while large amounts of lidocaine cream are being used. |
| 0.6961 | Awareness of this route of intoxication might be important in patients in whom Adverse-Effectneurologic or psychiatric symptoms develop while large amounts of lidocaine cream are being used. |
| Score | Text |
|---|---|
| 0.9991 | We report a 4 - year - old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing Drugoxybutynin to treat enuresis. |
| 0.9963 | We report a 4 - year - old girl who presented with acute bilateral blindness, a focal seizure and Adverse-Effecthypertension 10 days after commencing oxybutynin to treat enuresis. |
| 0.9900 | We report a 4 - year - old girl who presented with acute bilateral blindness, a Adverse-Effectfocal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis. |
| 0.9863 | We report a 4 - year - old girl who presented with Adverse-Effectacute bilateral blindness , a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis. |
| Score | Text |
|---|---|
| 0.9990 | The purpose of this study was to examine the incidence and cause of Clostridium difficile colitis occurring after Drugcisplatin - based combination chemotherapy in ovarian cancer patients. |
| 0.9898 | The purpose of this study was to examine the incidence and cause of Adverse-EffectClostridium difficile colitis occurring after cisplatin - based combination chemotherapy in ovarian cancer patients. |
| Score | Text |
|---|---|
| 0.9996 | Agranulocytosis is a rare adverse effect associated with prolonged Drugvancomycin therapy, and is potentially serious, especially in end stage renal disease ( ESRD ) patients. |
| 0.9980 | Adverse-EffectAgranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease ( ESRD ) patients. |
| Score | Text |
|---|---|
| 0.9991 | Two days after administration of DrugKalimate enema, he had profuse hematochezia, and a sigmoidoscopy showed diffuse colonic mucosal necrosis in the rectum and sigmoid colon. |
| 0.9838 | Two days after administration of Kalimate enema, he had Adverse-Effectprofuse hematochezia , and a sigmoidoscopy showed diffuse colonic mucosal necrosis in the rectum and sigmoid colon. |
| 0.9154 | Two days after administration of Kalimate enema, he had profuse hematochezia, and a sigmoidoscopy showed Adverse-Effectdiffuse colonic mucosal necrosis in the rectum and sigmoid colon. |
| Two days after administration of Kalimate enema, he had profuse hematochezia, and a sigmoidoscopy showed diffuse Adverse-Effectcolonic mucosal necrosis in the rectum and sigmoid colon. | |
| Score | Text |
|---|---|
| 0.9989 | RESULTS : A 34 - year - old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of Drugtriamcinolone for diabetic macular edema. |
| 0.9891 | RESULTS : A 34 - year - old man acquired visual field defects and Adverse-Effectsevere vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema. |
| 0.9791 | RESULTS : A 34 - year - old man acquired Adverse-Effectvisual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema. |
| Score | Text |
|---|---|
| 0.9994 | METHODS : A case is presented of a 45 - year - old woman on prolonged Druggemcitabine treatment for ovarian cancer who developed HUS and recovered after drug discontinuation. |
| 0.9990 | METHODS : A case is presented of a 45 - year - old woman on prolonged gemcitabine treatment for ovarian cancer who developed Adverse-EffectHUS and recovered after drug discontinuation. |
| Score | Text |
|---|---|
| 0.9527 | The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of, or idiosyncratic response to, Drugprocainamide . |
| 0.9525 | The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported Adverse-Effectelectrophysiologic effect of, or idiosyncratic response to, procainamide. |
| Score | Text |
|---|---|
| 0.9987 | In 2 of the 3 cases the patients were also taking lithium carbonate and beta - blockers, both of which could have contributed to the Adverse-Effectincontinence . |
| 0.9920 | In 2 of the 3 cases the patients were also taking Druglithium carbonate and beta - blockers, both of which could have contributed to the incontinence. |
| Score | Text |
|---|---|
| 0.9964 | Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, Drugdoxorubicin , and mitomycin C. |
| 0.9959 | Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with Drugetoglucid , doxorubicin, and mitomycin C. |
| 0.9941 | Two cases are reported of patients who developed a Adverse-Effecthematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C. |
| 0.9917 | Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and Drugmitomycin C . |
| Score | Text |
|---|---|
| 0.9994 | Although differential diagnostic alternatives can be considered in all described cases it is very likely that Drugvincristine does cause severe visual loss in a small number of patients. |
| 0.9792 | Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause Adverse-Effectsevere visual loss in a small number of patients. |
| Score | Text |
|---|---|
| 0.9989 | OBJECTIVE : To report a case of neuroleptic malignant syndrome ( NMS ) associated with Drugfluphenazine in a schizophrenic patient and review the literature related to this condition. |
| 0.9894 | OBJECTIVE : To report a case of Adverse-Effectneuroleptic malignant syndrome ( NMS ) associated with fluphenazine in a schizophrenic patient and review the literature related to this condition. |
| 0.9874 | OBJECTIVE : To report a case of neuroleptic malignant syndrome ( Adverse-EffectNMS ) associated with fluphenazine in a schizophrenic patient and review the literature related to this condition. |
| Score | Text |
|---|---|
| 0.9802 | This latest ( third ) report suggests that the safety profile should be reexamined and at least raises the question of potential renal toxicity of Druginterferons in MS. |
| 0.9757 | This latest ( third ) report suggests that the safety profile should be reexamined and at least raises the question of potential Adverse-Effectrenal toxicity of interferons in MS. |
| Score | Text |
|---|---|
| 0.9994 | After a second dose of Drugmetoclopramide , these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension. |
| 0.9992 | After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and Adverse-Effecthypertension . |
| 0.9991 | After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, Adverse-Effecttachypnea , tachycardia, and hypertension. |
| 0.9990 | After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, Adverse-Effecttachycardia , and hypertension. |
| 0.9989 | After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, fever, Adverse-Effectdiaphoresis , tachypnea, tachycardia, and hypertension. |
| 0.9983 | After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, Adverse-Effectagitation , fever, diaphoresis, tachypnea, tachycardia, and hypertension. |
| 0.9933 | After a second dose of metoclopramide, these symptoms recurred and were associated with Adverse-Effectconfusion , agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension. |
| 0.9925 | After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, Adverse-Effectfever , diaphoresis, tachypnea, tachycardia, and hypertension. |
| Score | Text |
|---|---|
| 0.9987 | DrugSulindac ( Clinoril ), a nonsteroidal anti - inflammatory agent, has few reported neurologic toxic effects, all of which have been associated with systemic disease. |
| 0.9983 | Sulindac ( DrugClinoril ), a nonsteroidal anti - inflammatory agent, has few reported neurologic toxic effects, all of which have been associated with systemic disease. |
| 0.9816 | Sulindac ( Clinoril ), a nonsteroidal anti - inflammatory agent, has few reported Adverse-Effectneurologic toxic effects , all of which have been associated with systemic disease. |
| Score | Text |
|---|---|
| 0.9987 | We report a 59 - year - old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and Drugbusulfan . |
| 0.9986 | We report a 59 - year - old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with Drugmelphalan and busulfan. |
| 0.9732 | We report a 59 - year - old patient with chronic myeloid leukemia, who developed Adverse-Effectsevere interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan. |
| Score | Text |
|---|---|
| 0.9990 | An association of granulocytopenia, eosinophilia, skin reaction and hepatitis during Drugpropylthiouracil ( PTU ) therapy for thyrotoxicosis in a 47 year old black female is reported. |
| 0.9985 | An association of granulocytopenia, eosinophilia, skin reaction and hepatitis during propylthiouracil ( DrugPTU ) therapy for thyrotoxicosis in a 47 year old black female is reported. |
| 0.9976 | An association of granulocytopenia, Adverse-Effecteosinophilia , skin reaction and hepatitis during propylthiouracil ( PTU ) therapy for thyrotoxicosis in a 47 year old black female is reported. |
| 0.9970 | An association of granulocytopenia, eosinophilia, skin reaction and Adverse-Effecthepatitis during propylthiouracil ( PTU ) therapy for thyrotoxicosis in a 47 year old black female is reported. |
| 0.9957 | An association of Adverse-Effectgranulocytopenia , eosinophilia, skin reaction and hepatitis during propylthiouracil ( PTU ) therapy for thyrotoxicosis in a 47 year old black female is reported. |
| 0.9939 | An association of granulocytopenia, eosinophilia, Adverse-Effectskin reaction and hepatitis during propylthiouracil ( PTU ) therapy for thyrotoxicosis in a 47 year old black female is reported. |
| Score | Text |
|---|---|
| 0.9987 | The authors report five cases of Adverse-Effecttremor related to itraconazole therapy, which occurred within 1 - 12 months of initiating treatment and resolved gradually following itraconazole withdrawal. |
| 0.9680 | The authors report five cases of tremor related to Drugitraconazole therapy, which occurred within 1 - 12 months of initiating treatment and resolved gradually following itraconazole withdrawal. |
| 0.9426 | The authors report five cases of tremor related to itraconazole therapy, which occurred within 1 - 12 months of initiating treatment and resolved gradually following Drugitraconazole withdrawal. |
| Score | Text |
|---|---|
| 0.9983 | In this case, unlike those previously reported, Adverse-Effecthyponatremia recurred 5 months after switching from citalopram to mirtazapine, which is believed to be a safe antidepressant. |
| 0.9946 | In this case, unlike those previously reported, hyponatremia recurred 5 months after switching from Drugcitalopram to mirtazapine, which is believed to be a safe antidepressant. |
| 0.9937 | In this case, unlike those previously reported, hyponatremia recurred 5 months after switching from citalopram to Drugmirtazapine , which is believed to be a safe antidepressant. |
| Score | Text |
|---|---|
| 0.9985 | Torsades de Pointes induced by a combination of Druggarenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide - 4 - influencing drugs during hypokalemia due to licorice. |
| 0.9984 | Torsades de Pointes induced by a combination of garenoxacin and Drugdisopyramide and other cytochrome P450, family 3, subfamily A polypeptide - 4 - influencing drugs during hypokalemia due to licorice. |
| 0.9828 | Adverse-EffectTorsades de Pointes induced by a combination of garenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide - 4 - influencing drugs during hypokalemia due to licorice. |
| Score | Text |
|---|---|
| 0.9980 | When the data of the 57 patients are evaluated, a reversible direct cytotoxic effect of Drugticlopidine on the pluripotent / bipotent hematopoietic progenitor stem cell is proposed. |
| 0.9327 | When the data of the 57 patients are evaluated, a reversible direct Adverse-Effectcytotoxic effect of ticlopidine on the pluripotent / bipotent hematopoietic progenitor stem cell is proposed. |
| Score | Text |
|---|---|
| 0.9965 | Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far, and comprise the first cases of ( sub ) fulminant hepatitis and Adverse-Effectcirrhosis related to benzarone. |
| 0.9804 | Our cases constitute the most severe cases of Drugbenzarone hepatotoxicity reported so far, and comprise the first cases of ( sub ) fulminant hepatitis and cirrhosis related to benzarone. |
| 0.9498 | Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far, and comprise the first cases of ( sub ) fulminant hepatitis and cirrhosis related to Drugbenzarone . |
| 0.8892 | Our cases constitute the most severe cases of benzarone Adverse-Effecthepatotoxicity reported so far, and comprise the first cases of ( sub ) fulminant hepatitis and cirrhosis related to benzarone. |
| Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far, and comprise the first cases of Adverse-Effect( sub ) fulminant hepatitis and cirrhosis related to benzarone. | |
| Score | Text |
|---|---|
| 0.9989 | Case 2 demonstrated after 40 months on Drugchlorambucil the presence of a balanced translocation, t ( 1 ; 5 ) ( p36 ; q31 ) in 90 % of the cells. |
| 0.9864 | Case 2 demonstrated after 40 months on chlorambucil the presence of a Adverse-Effectbalanced translocation , t ( 1 ; 5 ) ( p36 ; q31 ) in 90 % of the cells. |
| Score | Text |
|---|---|
| 0.9943 | FDE from Drugcephalosporins has been rarely reported, and to the best of our knowledge there is no published report of ceftriaxone - induced FDE in the literature. |
| 0.9679 | Adverse-EffectFDE from cephalosporins has been rarely reported, and to the best of our knowledge there is no published report of ceftriaxone - induced FDE in the literature. |
| 0.9640 | FDE from cephalosporins has been rarely reported, and to the best of our knowledge there is no published report of ceftriaxone - induced Adverse-EffectFDE in the literature. |
| FDE from cephalosporins has been rarely reported, and to the best of our knowledge there is no published report of Drugceftriaxone - induced FDE in the literature. | |
| Score | Text |
|---|---|
| 0.9983 | CASE REPORT : We report the case of a 58 year old patient who, after 2 days of treatment with Drugroxithromycin and betamethasone, manifested acute pancreatitis. |
| 0.9981 | CASE REPORT : We report the case of a 58 year old patient who, after 2 days of treatment with roxithromycin and Drugbetamethasone , manifested acute pancreatitis. |
| 0.9888 | CASE REPORT : We report the case of a 58 year old patient who, after 2 days of treatment with roxithromycin and betamethasone, manifested Adverse-Effectacute pancreatitis . |
| Score | Text |
|---|---|
| 0.9994 | One patient had a lower average heart rate and two patients had lower average mean blood pressure values during Drugpropranolol treatment, none of which was clinically significant. |
| 0.9620 | One patient had a lower average heart rate and two patients had Adverse-Effectlower average mean blood pressure values during propranolol treatment, none of which was clinically significant. |
| 0.8549 | One patient had a Adverse-Effectlower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant. |
| 0.8186 | One patient had a lower average heart rate and two patients had Adverse-Effectlower average mean blood pressure values during propranolol treatment, none of which was clinically significant. |
| Score | Text |
|---|---|
| 0.9972 | These cases and a review of the literature suggested that Adverse-Effecthepatotoxicity , though rare, should be added to the list of adverse reactions to D - penicillamine. |
| 0.9666 | These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to DrugD - penicillamine . |
| Score | Text |
|---|---|
| 0.9944 | We report the case of a patient with multiple myeloma who developed acute life - threatening water intoxication following treatment with oral indomethacin and low dose intravenous Drugcyclophosphamide . |
| 0.9932 | We report the case of a patient with multiple myeloma who developed acute life - threatening water intoxication following treatment with oral Drugindomethacin and low dose intravenous cyclophosphamide. |
| 0.9758 | We report the case of a patient with multiple myeloma who developed acute life - threatening Adverse-Effectwater intoxication following treatment with oral indomethacin and low dose intravenous cyclophosphamide. |
| 0.5067 | We report the case of a patient with multiple myeloma who developed Adverse-Effectacute life - threatening water intoxication following treatment with oral indomethacin and low dose intravenous cyclophosphamide. |
| We report the case of a patient with multiple myeloma who developed acute Adverse-Effectlife - threatening water intoxication following treatment with oral indomethacin and low dose intravenous cyclophosphamide. | |
| Score | Text |
|---|---|
| 0.9914 | We report the occurrence of Adverse-Effectrenal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ). |
| 0.9732 | We report the occurrence of renal failure due to Adverse-Effectcholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ). |
| 0.9364 | We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( Drugt - PA ). |
| 0.9022 | We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous Drugrecombinant tissue - type plasminogen activator ( t - PA ). |
| 0.8547 | We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant Drugtissue - type plasminogen activator ( t - PA ). |
| Score | Text |
|---|---|
| 0.9989 | PURPOSE : The occurrence of Adverse-Effectmyoclonus associated with continuous i. v. infusion of dobutamine in a patient with end - stage renal disease ( ESRD ) is described. |
| 0.9985 | PURPOSE : The occurrence of myoclonus associated with continuous i. v. infusion of Drugdobutamine in a patient with end - stage renal disease ( ESRD ) is described. |
| Score | Text |
|---|---|
| 0.9987 | I saw two patients with kala - azar resistant to sodium stibogluconate who developed cardiac arrest after Drugamphotericin infusion ( in spite of tolerating a test dose ). |
| 0.9955 | I saw two patients with kala - azar resistant to sodium stibogluconate who developed Adverse-Effectcardiac arrest after amphotericin infusion ( in spite of tolerating a test dose ). |
| Score | Text |
|---|---|
| 0.9993 | However, in order to avoid neuropathic side effects, patients under Drugthalidomide therapy should be monitored every 6 months with nerve conduction studies while taking the drug. |
| 0.9569 | However, in order to avoid Adverse-Effectneuropathic side effects , patients under thalidomide therapy should be monitored every 6 months with nerve conduction studies while taking the drug. |
| Score | Text |
|---|---|
| 0.9925 | The toxicity and plasma concentrations of ifosfamide, chloroacetaldehyde, and Drug4 - hydroxyifosfamide were then determined over 24 h after a single 1. 6 g / m2 dose of ifosfamide. |
| 0.9911 | The toxicity and plasma concentrations of ifosfamide, Drugchloroacetaldehyde , and 4 - hydroxyifosfamide were then determined over 24 h after a single 1. 6 g / m2 dose of ifosfamide. |
| 0.9889 | The toxicity and plasma concentrations of Drugifosfamide , chloroacetaldehyde, and 4 - hydroxyifosfamide were then determined over 24 h after a single 1. 6 g / m2 dose of ifosfamide. |
| 0.9873 | The toxicity and plasma concentrations of ifosfamide, chloroacetaldehyde, and 4 - hydroxyifosfamide were then determined over 24 h after a single 1. 6 g / m2 dose of Drugifosfamide . |
| 0.9709 | The Adverse-Effecttoxicity and plasma concentrations of ifosfamide, chloroacetaldehyde, and 4 - hydroxyifosfamide were then determined over 24 h after a single 1. 6 g / m2 dose of ifosfamide. |
| Score | Text |
|---|---|
| 0.9990 | A brief review of reported cases of Drugchloramphenicol hypersensitivity in the English - language literature, as well as possible alternative explanations in this case, are provided. |
| 0.7951 | A brief review of reported cases of chloramphenicol Adverse-Effecthypersensitivity in the English - language literature, as well as possible alternative explanations in this case, are provided. |
| Score | Text |
|---|---|
| 0.9761 | In this paper, we report a case of 3 years - old boy who developed acute onset tetraparesia following a viral respiratory infecction and Drughepatitis B vaccination . |
| 0.9728 | In this paper, we report a case of 3 years - old boy who developed Adverse-Effectacute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination. |
| Score | Text |
|---|---|
| 0.9986 | We describe a patient who developed Adverse-EffectHUS after treatment with mitomycin C ( total dose 144 mg / m2 ) due to a carcinoma of the ascending colon. |
| 0.9900 | We describe a patient who developed HUS after treatment with Drugmitomycin C ( total dose 144 mg / m2 ) due to a carcinoma of the ascending colon. |
| Score | Text |
|---|---|
| 0.9870 | However, as the use of hepatitis B vaccination is growing, adverse side effects, including Adverse-Effectmental nerve neuropathy , should be observed with an increased frequency. |
| 0.9616 | However, as the use of Drughepatitis B vaccination is growing, adverse side effects, including mental nerve neuropathy, should be observed with an increased frequency. |
| Score | Text |
|---|---|
| 0.9838 | We describe a relatively healthy, 9 - year - old boy who developed a CA - MRSA skin and Adverse-Effectsoft tissue infection and was treated with TMP - SMX. |
| 0.9688 | We describe a relatively healthy, 9 - year - old boy who developed a CA - MRSA skin and soft tissue infection and was treated with DrugTMP - SMX . |
| 0.9540 | We describe a relatively healthy, 9 - year - old boy who developed a Adverse-EffectCA - MRSA skin and soft tissue infection and was treated with TMP - SMX. |
| Score | Text |
|---|---|
| 0.9987 | The mild immunosuppression that occurs with Drugmethotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence can not be excluded. |
| 0.9921 | The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing Adverse-Effectlymphoproliferative diseases , but coincidence can not be excluded. |
| Score | Text |
|---|---|
| 0.9993 | These are the first reported patients to show mfERG abnormalities that correspond to bitemporal visual field defects and add to the growing evidence that Drugethambutol damages the retina. |
| 0.9853 | These are the first reported patients to show Adverse-EffectmfERG abnormalities that correspond to bitemporal visual field defects and add to the growing evidence that ethambutol damages the retina. |
| 0.9824 | These are the first reported patients to show mfERG abnormalities that correspond to Adverse-Effectbitemporal visual field defects and add to the growing evidence that ethambutol damages the retina. |
| Score | Text |
|---|---|
| 0.9886 | Adverse-EffectMusculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms'tumors with ifosfamide, a derivative of cyclophosphamide. |
| 0.9884 | Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms'tumors with Drugifosfamide , a derivative of cyclophosphamide. |
| 0.9763 | Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms'tumors with ifosfamide, a derivative of Drugcyclophosphamide . |
| Score | Text |
|---|---|
| 0.9878 | This case suggests that BH - AC, a derivative of cytosine arabinoside ( 1 - beta - D - arabinofuranosylcytosine ) could be a cause of reversible Adverse-Effectencephalopathy syndrome . |
| 0.9707 | This case suggests that DrugBH - AC , a derivative of cytosine arabinoside ( 1 - beta - D - arabinofuranosylcytosine ) could be a cause of reversible encephalopathy syndrome. |
| 0.9731 | This case suggests that BH - AC, a derivative of Drugcytosine arabinoside ( 1 - beta - D - arabinofuranosylcytosine ) could be a cause of reversible encephalopathy syndrome. |
| 0.9444 | This case suggests that BH - AC, a derivative of cytosine arabinoside ( Drug1 - beta - D - arabinofuranosylcytosine ) could be a cause of reversible encephalopathy syndrome. |
| Score | Text |
|---|---|
| 0.9808 | Although the data indicate an immune - complex cause for Druggold - salt nephropathy, the incident antigen ( or antigens ) and mechanism of action remain unidentified. |
| 0.9058 | Although the data indicate an immune - complex cause for gold - salt Adverse-Effectnephropathy , the incident antigen ( or antigens ) and mechanism of action remain unidentified. |
| Score | Text |
|---|---|
| 0.9976 | A 40 - year - old man with a long standing history of rheumatoid arthritis was treated with DrugMTX over a 6 month period and developed an overwhelming hepatic necrosis. |
| 0.9819 | A 40 - year - old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an Adverse-Effectoverwhelming hepatic necrosis . |
| Score | Text |
|---|---|
| 0.9991 | We report a case of a 64 - year - old man with secondary adrenocortical insufficiency who has been on a chronic transdermal Drugfentanyl treatment because of sciatic pain syndrome. |
| 0.7641 | We report a case of a 64 - year - old man with secondary Adverse-Effectadrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome. |
| Score | Text |
|---|---|
| 0.9959 | We now report the first known cancer patient who developed life - threatening complications after treatment with topical Drug5 - FU and was shown subsequently to have profound DPD deficiency. |
| 0.9577 | We now report the first known cancer patient who developed Adverse-Effectlife - threatening complications after treatment with topical 5 - FU and was shown subsequently to have profound DPD deficiency. |
| 0.9315 | We now report the first known cancer patient who developed life - threatening complications after treatment with topical 5 - FU and was shown subsequently to have profound Adverse-EffectDPD deficiency . |
| Score | Text |
|---|---|
| 0.9991 | A 62 - year - old Caucasian man with atrial fibrillation who was taking Drugwarfarin reported an episode of hematochezia ; his international normalized ratio ( INR ) was 1. 74. |
| 0.9973 | A 62 - year - old Caucasian man with atrial fibrillation who was taking warfarin reported an episode of Adverse-Effecthematochezia ; his international normalized ratio ( INR ) was 1. 74. |
| Score | Text |
|---|---|
| 0.9993 | A 9 - year - old boy developed acute renal failure following intravenous Drugacyclovir ( 30 mg / kg per day ) administered for 6 days to treat herpetic encephalitis. |
| 0.9865 | A 9 - year - old boy developed Adverse-Effectacute renal failure following intravenous acyclovir ( 30 mg / kg per day ) administered for 6 days to treat herpetic encephalitis. |
| Score | Text |
|---|---|
| 0.9851 | We describe a patient with acute leukemia who developed Horner's syndrome and a Adverse-Effectsevere demyelinating peripheral neuropathy leading to death after receiving high - dose cytosine arabinoside. |
| 0.9824 | We describe a patient with acute leukemia who developed Adverse-EffectHorner's syndrome and a severe demyelinating peripheral neuropathy leading to death after receiving high - dose cytosine arabinoside. |
| 0.9794 | We describe a patient with acute leukemia who developed Horner's syndrome and a severe demyelinating peripheral neuropathy leading to death after receiving high - dose Drugcytosine arabinoside . |
| 0.8386 | We describe a patient with acute leukemia who developed Horner's syndrome and a severe demyelinating peripheral neuropathy leading to Adverse-Effectdeath after receiving high - dose cytosine arabinoside. |
| Score | Text |
|---|---|
| 0.9995 | We report a case of a 23 - year - old man who developed a Drugvancomycin - induced anaphylactic reaction in the treatment of methicillin - resistant Staphylococcus aureus infection. |
| 0.9936 | We report a case of a 23 - year - old man who developed a vancomycin - induced Adverse-Effectanaphylactic reaction in the treatment of methicillin - resistant Staphylococcus aureus infection. |
| Score | Text |
|---|---|
| 0.9994 | We observed 2 cases of hepatotoxicity after a high - dose Drugmethylprednisolone treatment of a demyelinating disease and evaluated the potential relationship in the light of available evidence. |
| 0.9976 | We observed 2 cases of Adverse-Effecthepatotoxicity after a high - dose methylprednisolone treatment of a demyelinating disease and evaluated the potential relationship in the light of available evidence. |
| Score | Text |
|---|---|
| 0.9991 | Masculinization of a female fetus occurred in 5 of 39 ( 12. 8 % ) exposed to Drugnorethisterone ; all were cases of clitoral hypertrophy not requiring surgical treatment. |
| 0.9859 | Masculinization of a female fetus occurred in 5 of 39 ( 12. 8 % ) exposed to norethisterone ; all were cases of Adverse-Effectclitoral hypertrophy not requiring surgical treatment. |
| 0.9709 | Adverse-EffectMasculinization of a female fetus occurred in 5 of 39 ( 12. 8 % ) exposed to norethisterone ; all were cases of clitoral hypertrophy not requiring surgical treatment. |
| Score | Text |
|---|---|
| 0.9968 | Observations in our patient suggest that the Adverse-Effectleukoencephalopathy that developed in previously reported patients who received 5 - fluorouracil and levamisole may have been caused at least partly by levamisole. |
| 0.9939 | Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received Drug5 - fluorouracil and levamisole may have been caused at least partly by levamisole. |
| 0.9926 | Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5 - fluorouracil and Druglevamisole may have been caused at least partly by levamisole. |
| 0.9838 | Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5 - fluorouracil and levamisole may have been caused at least partly by Druglevamisole . |
| Score | Text |
|---|---|
| 0.9992 | CONCLUSION : In some abstainers who take Drugcyanamide for several years, thin septum - like liver fibrosis progresses along with the emergence of ground - glass hepatocytes. |
| 0.9803 | CONCLUSION : In some abstainers who take cyanamide for several years, thin septum - like liver fibrosis progresses along with the emergence of Adverse-Effectground - glass hepatocytes . |
| 0.9541 | CONCLUSION : In some abstainers who take cyanamide for several years, thin Adverse-Effectseptum - like liver fibrosis progresses along with the emergence of ground - glass hepatocytes. |
| Score | Text |
|---|---|
| 0.9989 | DrugArgatroban is hepatically cleared and may be the preferred direct thrombin inhibitor in the presence of significant renal impairment, but conversely has prolonged effects in hepatic failure. |
| 0.9714 | Argatroban is hepatically cleared and may be the preferred direct thrombin inhibitor in the presence of significant renal impairment, but conversely has prolonged effects in Adverse-Effecthepatic failure . |
| 0.9274 | Argatroban is hepatically cleared and may be the preferred direct thrombin inhibitor in the presence of significant Adverse-Effectrenal impairment , but conversely has prolonged effects in hepatic failure. |
| Score | Text |
|---|---|
| 0.9986 | In patients with cirrhosis, the metabolism of Drugmeperidine is decreased, leading to accumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy. |
| 0.9782 | In patients with cirrhosis, the metabolism of meperidine is decreased, leading to Adverse-Effectaccumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy. |
| 0.9626 | In patients with cirrhosis, the metabolism of meperidine is decreased, leading to accumulation of the parent drug and possible Adverse-EffectCNS depressive effects similar to hepatic encephalopathy. |
| Score | Text |
|---|---|
| 0.9995 | We report a case of hepatolithiasis ( intrahepatic stone ) complicated by gram - negative sepsis in a 37 year old male with acromegaly being treated with Drugoctreotide . |
| 0.9982 | We report a case of Adverse-Effecthepatolithiasis ( intrahepatic stone ) complicated by gram - negative sepsis in a 37 year old male with acromegaly being treated with octreotide. |
| Score | Text |
|---|---|
| 0.9978 | The Adverse-Effectrash seen in this patient, who was treated with cephalexin, may be similar to the rash seen with ampicillin treatment of patients with infectious mononucleosis. |
| 0.9975 | The rash seen in this patient, who was treated with Drugcephalexin , may be similar to the rash seen with ampicillin treatment of patients with infectious mononucleosis. |
| 0.9425 | The rash seen in this patient, who was treated with cephalexin, may be similar to the Adverse-Effectrash seen with ampicillin treatment of patients with infectious mononucleosis. |
| The rash seen in this patient, who was treated with cephalexin, may be similar to the rash seen with Drugampicillin treatment of patients with infectious mononucleosis. | |
| Score | Text |
|---|---|
| 0.9931 | We report on three observations of parkinsonian patients with levo - dopa - induced Adverse-Effectdiphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements. |
| 0.9686 | We report on three observations of parkinsonian patients with Druglevo - dopa - induced diphasic dyskinesias, who received subcutaneous apomorphine to reduce the duration of abnormal movements. |
| Score | Text |
|---|---|
| 0.9996 | We describe two cases of Drugsulfadiazine - induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis. |
| 0.9978 | We describe two cases of sulfadiazine - induced Adverse-Effectcrystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis. |
| 0.9945 | We describe two cases of sulfadiazine - induced crystalluria and Adverse-Effectrenal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis. |
| Score | Text |
|---|---|
| 0.9946 | Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and calcitriol are secondary hyperparathyroidism and vitamin D intoxication, Adverse-Effectpotassium loss also should be kept in mind. |
| 0.9897 | Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and Drugcalcitriol are secondary hyperparathyroidism and vitamin D intoxication, potassium loss also should be kept in mind. |
| 0.9873 | Although major hazards of treatment of hypophosphatemic osteomalacia with Drugphosphate and calcitriol are secondary hyperparathyroidism and vitamin D intoxication, potassium loss also should be kept in mind. |
| 0.9812 | Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and calcitriol are secondary hyperparathyroidism and Adverse-Effectvitamin D intoxication , potassium loss also should be kept in mind. |
| 0.9535 | Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and calcitriol are Adverse-Effectsecondary hyperparathyroidism and vitamin D intoxication, potassium loss also should be kept in mind. |
| Score | Text |
|---|---|
| 0.9979 | After 39 hours on Drugargatroban , the infusion was stopped when minor bleeding was observed with a concurrent activated partial thromboplastin time ( aPTT ) of 100 seconds. |
| 0.9948 | After 39 hours on argatroban, the infusion was stopped when minor Adverse-Effectbleeding was observed with a concurrent activated partial thromboplastin time ( aPTT ) of 100 seconds. |
| Score | Text |
|---|---|
| 0.9992 | This report rules out other causes of toxic epidermal necrolysis and implicates Drugofloxacin in what appears to be an atypical presentation of drug - induced toxic epidermal necrolysis. |
| 0.9707 | This report rules out other causes of Adverse-Effecttoxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug - induced toxic epidermal necrolysis. |
| 0.9668 | This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug - induced Adverse-Effecttoxic epidermal necrolysis . |
| Score | Text |
|---|---|
| 0.9995 | Sensorineural hearing loss due to Drugquinine therapy for malaria has frequently been mentioned in the literature but has not been a subject of research during the last decades. |
| 0.9894 | Adverse-EffectSensorineural hearing loss due to quinine therapy for malaria has frequently been mentioned in the literature but has not been a subject of research during the last decades. |
| Score | Text |
|---|---|
| 0.9989 | A 31 - year - old female developed multiple episodes of grand mal seizures after combination chemotherapy with cisplatin, vinblastine and Drugbleomycin for germ cell ovarian cancer stage Ic. |
| 0.9988 | A 31 - year - old female developed multiple episodes of grand mal seizures after combination chemotherapy with Drugcisplatin , vinblastine and bleomycin for germ cell ovarian cancer stage Ic. |
| 0.9986 | A 31 - year - old female developed multiple episodes of grand mal seizures after combination chemotherapy with cisplatin, Drugvinblastine and bleomycin for germ cell ovarian cancer stage Ic. |
| 0.9868 | A 31 - year - old female developed multiple episodes of Adverse-Effectgrand mal seizures after combination chemotherapy with cisplatin, vinblastine and bleomycin for germ cell ovarian cancer stage Ic. |
| Score | Text |
|---|---|
| 0.9992 | A 12 year old patient with atrial flutter is presented, in whom intravenous Drugadenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia. |
| 0.9869 | A 12 year old patient with atrial flutter is presented, in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous Adverse-Effectarrhythmia . |
| 0.9808 | A 12 year old patient with atrial flutter is presented, in whom intravenous adenosine was followed by Adverse-Effectacceleration of the heart rate to a potentially dangerous arrhythmia. |
| Score | Text |
|---|---|
| 0.9987 | We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low - dose Drugaspirin for 16 months. |
| 0.9985 | We report a case in which Adverse-Effecthemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low - dose aspirin for 16 months. |
| Score | Text |
|---|---|
| 0.9997 | We report a case of hypoglycaemia after Drugmefloquine therapy ( 1, 500 mg over two days ) for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea. |
| 0.9975 | We report a case of Adverse-Effecthypoglycaemia after mefloquine therapy ( 1, 500 mg over two days ) for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea. |
| Score | Text |
|---|---|
| 0.9869 | This report describes a case of paradoxical, intravenous valproic acid - induced Adverse-Effectseizure exacerbation in a child with juvenile absence epilepsy, documented by video - electroencephalography. |
| 0.9765 | This report describes a case of paradoxical, intravenous Drugvalproic acid - induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video - electroencephalography. |
| 0.7924 | This report describes a case of Drugparadoxical , intravenous valproic acid - induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video - electroencephalography. |
| Score | Text |
|---|---|
| 0.9969 | That review suggested that patients receiving anti - D IGIV be monitored for those and other potential complications of Adverse-Effecthemoglobinemia , particularly disseminated intravascular coagulation ( DIC ). |
| 0.9856 | That review suggested that patients receiving anti - D IGIV be monitored for those and other potential complications of hemoglobinemia, particularly Adverse-Effectdisseminated intravascular coagulation ( DIC ). |
| 0.9740 | That review suggested that patients receiving anti - D IGIV be monitored for those and other potential complications of hemoglobinemia, particularly disseminated intravascular coagulation ( Adverse-EffectDIC ). |
| 0.9717 | That review suggested that patients receiving Druganti - D IGIV be monitored for those and other potential complications of hemoglobinemia, particularly disseminated intravascular coagulation ( DIC ). |
| Score | Text |
|---|---|
| 0.9968 | Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine - induced Adverse-Effectphotosensitivity may be due to a relatively low dosage of the drug. |
| 0.9585 | Mequitazine seemed to play a part similar to chlorpromazine, and absence of Drugmequitazine - induced photosensitivity may be due to a relatively low dosage of the drug. |
| Score | Text |
|---|---|
| 0.9991 | The authors suggest that Drugrisperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase. |
| 0.9613 | The authors suggest that risperidone may Adverse-Effectincrease affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase. |
| Score | Text |
|---|---|
| 0.9889 | The risk of new - onset diabetic ketoacidosis in patients with diabetic risk factors who are taking Drugperospirone hydrochloride or other atypical antipsychotics should be kept in mind. |
| 0.9716 | The risk of new - onset Adverse-Effectdiabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind. |
| Score | Text |
|---|---|
| 0.9980 | CONCLUSIONS : Among the many presentations of Drugifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent. |
| 0.9026 | CONCLUSIONS : Among the many presentations of ifosfamide Adverse-Effectneurotoxicity , clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent. |
| 0.8477 | CONCLUSIONS : Among the many presentations of ifosfamide neurotoxicity, clinicians should consider Adverse-EffectNCSE as a possible explanation for changes in consciousness in a patient receiving this agent. |
| Score | Text |
|---|---|
| 0.9986 | This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies, and then the occurrence of Graves'hyperthyroidism during DrugIFN therapy. |
| 0.9878 | This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies, and then the occurrence of Adverse-EffectGraves'hyperthyroidism during IFN therapy. |
| Score | Text |
|---|---|
| 0.9995 | A transient tonic pupillary response, denervation supersensitivity, and abnormal visual - evoked potentials in Drugquinine toxicity, to our knowledge, have not been previously reported. |
| 0.9855 | A transient tonic pupillary response, Adverse-Effectdenervation supersensitivity , and abnormal visual - evoked potentials in quinine toxicity, to our knowledge, have not been previously reported. |
| 0.9842 | A Adverse-Effecttransient tonic pupillary response , denervation supersensitivity, and abnormal visual - evoked potentials in quinine toxicity, to our knowledge, have not been previously reported. |
| 0.9572 | A transient tonic pupillary response, denervation supersensitivity, and Adverse-Effectabnormal visual - evoked potentials in quinine toxicity, to our knowledge, have not been previously reported. |
| Score | Text |
|---|---|
| 0.9972 | An encephalopathy and cardiomyopathy developed in a seventeen - year - old girl with chemotherapy - induced renal failure while receiving an intravesical Drugaluminum infusion for hemorrhagic cystitis. |
| 0.9959 | An Adverse-Effectencephalopathy and cardiomyopathy developed in a seventeen - year - old girl with chemotherapy - induced renal failure while receiving an intravesical aluminum infusion for hemorrhagic cystitis. |
| 0.9952 | An encephalopathy and Adverse-Effectcardiomyopathy developed in a seventeen - year - old girl with chemotherapy - induced renal failure while receiving an intravesical aluminum infusion for hemorrhagic cystitis. |
| 0.9324 | An encephalopathy and cardiomyopathy developed in a seventeen - year - old girl with chemotherapy - induced Adverse-Effectrenal failure while receiving an intravesical aluminum infusion for hemorrhagic cystitis. |
| Score | Text |
|---|---|
| 0.9967 | Adverse-EffectPancreatitis is a very rare adverse effect associated with the use of amiodarone, and only four cases of amiodarone - induced pancreatitis have been reported in literature. |
| 0.9892 | Pancreatitis is a very rare adverse effect associated with the use of amiodarone, and only four cases of amiodarone - induced Adverse-Effectpancreatitis have been reported in literature. |
| 0.9256 | Pancreatitis is a very rare adverse effect associated with the use of amiodarone, and only four cases of Drugamiodarone - induced pancreatitis have been reported in literature. |
| 0.9211 | Pancreatitis is a very rare adverse effect associated with the use of Drugamiodarone , and only four cases of amiodarone - induced pancreatitis have been reported in literature. |
| Score | Text |
|---|---|
| 0.9745 | CONTEXT : Previous investigators have reported discrepancies between hematologic, marrow morphologic, and cytogenetic responses to Drugimatinib mesylate among patients with chronic myeloid leukemia ( CML ). |
| 0.9723 | CONTEXT : Previous investigators have reported Adverse-Effectdiscrepancies between hematologic, marrow morphologic, and cytogenetic responses to imatinib mesylate among patients with chronic myeloid leukemia ( CML ). |
| Score | Text |
|---|---|
| 0.9982 | CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of Adverse-Effecthemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment. |
| 0.9706 | CONCLUSION : The administration of Drugtissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment. |
| 0.9649 | CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of Adverse-Effecthemorrhagic choroidal detachment . |
| Score | Text |
|---|---|
| 0.9994 | PURPOSE : To describe transient structured visual hallucinations in a patient with vascular age - related macular degeneration ( AMD ), following an intravitreal DrugAvastin - injection. |
| 0.9456 | PURPOSE : To describe Adverse-Effecttransient structured visual hallucinations in a patient with vascular age - related macular degeneration ( AMD ), following an intravitreal Avastin - injection. |
| Score | Text |
|---|---|
| 0.9996 | Ataxia caused by Drugpropafenone has been reported to the pharmaceutical companies and drug monitoring agencies, but has not been well described or emphasized in the medical literature. |
| 0.9978 | Adverse-EffectAtaxia caused by propafenone has been reported to the pharmaceutical companies and drug monitoring agencies, but has not been well described or emphasized in the medical literature. |
| Score | Text |
|---|---|
| 0.9979 | A 16 - year - old boy developed fever, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with Drugolanzapine and lithium. |
| 0.9968 | A 16 - year - old boy developed fever, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and Druglithium . |
| 0.9939 | A 16 - year - old boy developed fever, generalized rigidity, Adverse-Effectleukocytosis , and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium. |
| 0.9911 | A 16 - year - old boy developed Adverse-Effectfever , generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium. |
| 0.9864 | A 16 - year - old boy developed fever, Adverse-Effectgeneralized rigidity , leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium. |
| 0.8507 | A 16 - year - old boy developed fever, generalized rigidity, leukocytosis, and Adverse-Effectincreased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium. |
| 0.9130 | A 16 - year - old boy developed fever, generalized rigidity, leukocytosis, and Adverse-Effectincreased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium. |
| 0.8753 | A 16 - year - old boy developed fever, generalized rigidity, leukocytosis, and Adverse-Effectincreased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium. |
| 0.6954 | A 16 - year - old boy developed fever, generalized rigidity, leukocytosis, and Adverse-Effectincreased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium. |
| 0.6932 | A 16 - year - old boy developed fever, generalized rigidity, leukocytosis, and Adverse-Effectincreased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium. |
| Score | Text |
|---|---|
| 0.9636 | We suggest adding this side effect to the list of untoward effects of lidocaine and to the differential diagnosis of fixed Adverse-Effectdilated pupils in neonates treated with lidocaine. |
| 0.9033 | We suggest adding this side effect to the list of untoward effects of lidocaine and to the differential diagnosis of fixed dilated pupils in neonates treated with Druglidocaine . |
| 0.9411 | We suggest adding this side effect to the list of untoward effects of Druglidocaine and to the differential diagnosis of fixed dilated pupils in neonates treated with lidocaine. |
| Score | Text |
|---|---|
| 0.9979 | We conclude that myocardial infarction may develop in patients treated with high - dose Drugglucocorticoids for Graves'ophthalmopathy, and increased blood pressure may herald this complication. |
| 0.9883 | We conclude that Adverse-Effectmyocardial infarction may develop in patients treated with high - dose glucocorticoids for Graves'ophthalmopathy, and increased blood pressure may herald this complication. |
| Score | Text |
|---|---|
| 0.9981 | After intravitreal injection of triamcinolone acetonide, Adverse-Effectcataract may rapidly develop in eyes that have been intensively treated, topically and systemically, by corticosteroids for several years. |
| 0.9705 | After intravitreal injection of Drugtriamcinolone acetonide , cataract may rapidly develop in eyes that have been intensively treated, topically and systemically, by corticosteroids for several years. |
| Score | Text |
|---|---|
| 0.9996 | The current study investigated the visual fields and visual electrophysiology of eight patients with known Drugvigabatrin - attributed visual field loss, three of whom were reported previously. |
| 0.9881 | The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin - attributed Adverse-Effectvisual field loss , three of whom were reported previously. |
| Score | Text |
|---|---|
| 0.9992 | DrugQuinapril is an angiotensin - converting enzyme inhibitor ( ACE - inhibitor ) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment. |
| 0.9818 | Quinapril is an angiotensin - converting enzyme inhibitor ( ACE - inhibitor ) and overdose can lead to Adverse-Effectprolonged hypotension and, less frequently, transient renal impairment. |
| 0.9784 | Quinapril is an angiotensin - converting enzyme inhibitor ( ACE - inhibitor ) and overdose can lead to prolonged hypotension and, less frequently, Adverse-Effecttransient renal impairment . |
| Score | Text |
|---|---|
| 0.9992 | A 60 - year - old woman with diabetes mellitus ( type 2 ) developed an acute icteric hepatitis - like illness 6 weeks after the initiation of Druggliclazide therapy. |
| 0.9838 | A 60 - year - old woman with diabetes mellitus ( type 2 ) developed an Adverse-Effectacute icteric hepatitis - like illness 6 weeks after the initiation of gliclazide therapy. |
| Score | Text |
|---|---|
| 0.9993 | A 58 - yr - old male patient with essential thrombocythaemia ( ET ) developed chronic myeloid leukaemia ( CML ) after continuous uneventful treatment with Drughydroxyurea for 18 yr. |
| 0.9920 | A 58 - yr - old male patient with essential thrombocythaemia ( ET ) developed chronic myeloid leukaemia ( Adverse-EffectCML ) after continuous uneventful treatment with hydroxyurea for 18 yr. |
| 0.9888 | A 58 - yr - old male patient with essential thrombocythaemia ( ET ) developed Adverse-Effectchronic myeloid leukaemia ( CML ) after continuous uneventful treatment with hydroxyurea for 18 yr. |
| Score | Text |
|---|---|
| 0.7894 | The purpose of this report is to document a new case of in utero CP exposure with Adverse-Effectmultiple congenital anomalies and to establish an apparent CP embryopathy phenotype. |
| 0.9804 | The purpose of this report is to document a new case of in utero CP exposure with multiple congenital anomalies and to establish an apparent Adverse-EffectCP embryopathy phenotype. |
| The purpose of this report is to document a new case of in utero CP exposure with multiple congenital anomalies and to establish an apparent CP Adverse-Effectembryopathy phenotype. | |
| The purpose of this report is to document a new case of in utero DrugCP exposure with multiple congenital anomalies and to establish an apparent CP embryopathy phenotype. | |
| The purpose of this report is to document a new case of in utero CP exposure with multiple congenital anomalies and to establish an apparent DrugCP embryopathy phenotype. | |
| Score | Text |
|---|---|
| 0.9995 | OBJECTIVE : To report a case of Drugcalcineurin - induced pain syndrome ( CIPS ) in a child undergoing his second hematopoietic stem cell transplant ( HSCT ). |
| 0.9914 | OBJECTIVE : To report a case of calcineurin - induced Adverse-Effectpain syndrome ( CIPS ) in a child undergoing his second hematopoietic stem cell transplant ( HSCT ). |
| 0.7659 | OBJECTIVE : To report a case of calcineurin - induced pain syndrome ( Adverse-EffectCIPS ) in a child undergoing his second hematopoietic stem cell transplant ( HSCT ). |
| Score | Text |
|---|---|
| 0.9997 | A 58 - year - old woman with rheumatoid arthritis ( RA ) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with Drugsulfasalazine . |
| 0.9984 | A 58 - year - old woman with rheumatoid arthritis ( RA ) developed fever, skin eruptions, leukocytopenia, and Adverse-Effectthrombocytopenia , 3 weeks after treatment with sulfasalazine. |
| 0.9981 | A 58 - year - old woman with rheumatoid arthritis ( RA ) developed fever, skin eruptions, Adverse-Effectleukocytopenia , and thrombocytopenia, 3 weeks after treatment with sulfasalazine. |
| 0.9937 | A 58 - year - old woman with rheumatoid arthritis ( RA ) developed fever, Adverse-Effectskin eruptions , leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine. |
| 0.9899 | A 58 - year - old woman with rheumatoid arthritis ( RA ) developed Adverse-Effectfever , skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine. |
| Score | Text |
|---|---|
| 0.9922 | In deciding if tamoxifen therapy is warranted, all potentially life - threatening adverse events associated with tamoxifen should be considered, including endometrial adenocarcinoma or Adverse-Effectuterine sarcoma . |
| 0.9914 | In deciding if tamoxifen therapy is warranted, all potentially life - threatening adverse events associated with tamoxifen should be considered, including Adverse-Effectendometrial adenocarcinoma or uterine sarcoma. |
| 0.9910 | In deciding if tamoxifen therapy is warranted, all potentially life - threatening adverse events associated with Drugtamoxifen should be considered, including endometrial adenocarcinoma or uterine sarcoma. |
| 0.9757 | In deciding if Drugtamoxifen therapy is warranted, all potentially life - threatening adverse events associated with tamoxifen should be considered, including endometrial adenocarcinoma or uterine sarcoma. |
| Score | Text |
|---|---|
| 0.9995 | Although various manifestations of Drugpentamidine - induced cardiotoxicity have been reported, to our knowledge, second - degree heart block associated with this agent has not been described. |
| 0.9954 | Although various manifestations of pentamidine - induced Adverse-Effectcardiotoxicity have been reported, to our knowledge, second - degree heart block associated with this agent has not been described. |
| 0.9781 | Although various manifestations of pentamidine - induced cardiotoxicity have been reported, to our knowledge, Adverse-Effectsecond - degree heart block associated with this agent has not been described. |
| Score | Text |
|---|---|
| 0.9991 | We report the syndrome of inappropriate antidiuresis as a much earlier side - effect of Drugcarbamazepine administration in a 29 - year Nigerian female patient with generalized tonic - elonic seizures. |
| We report the syndrome of inappropriate Adverse-Effectantidiuresis as a much earlier side - effect of carbamazepine administration in a 29 - year Nigerian female patient with generalized tonic - elonic seizures. | |
| Score | Text |
|---|---|
| 0.9987 | Amphotericin B ( AmB ) is effective, but its use is limited by toxicity : renal impairment, anaemia, fever, malaise, and Adverse-Effecthypokalaemia are common. |
| 0.9985 | Amphotericin B ( AmB ) is effective, but its use is limited by toxicity : renal impairment, Adverse-Effectanaemia , fever, malaise, and hypokalaemia are common. |
| 0.9975 | Amphotericin B ( AmB ) is effective, but its use is limited by toxicity : renal impairment, anaemia, fever, Adverse-Effectmalaise , and hypokalaemia are common. |
| 0.9955 | Amphotericin B ( DrugAmB ) is effective, but its use is limited by toxicity : renal impairment, anaemia, fever, malaise, and hypokalaemia are common. |
| 0.9917 | Amphotericin B ( AmB ) is effective, but its use is limited by toxicity : renal impairment, anaemia, Adverse-Effectfever , malaise, and hypokalaemia are common. |
| 0.9889 | Amphotericin B ( AmB ) is effective, but its use is limited by toxicity : Adverse-Effectrenal impairment , anaemia, fever, malaise, and hypokalaemia are common. |
| 0.9844 | DrugAmphotericin B ( AmB ) is effective, but its use is limited by toxicity : renal impairment, anaemia, fever, malaise, and hypokalaemia are common. |
| Score | Text |
|---|---|
| 0.9991 | This case suggests that sarcoidosis and Drugpravastatin , two entities not frequently associated with myotonia, may interact in a synergistic manner to produce severe clinical myotonia in humans. |
| 0.9572 | This case suggests that sarcoidosis and pravastatin, two entities not frequently associated with myotonia, may interact in a synergistic manner to produce severe clinical Adverse-Effectmyotonia in humans. |
| 0.8355 | This case suggests that sarcoidosis and pravastatin, two entities not frequently associated with Adverse-Effectmyotonia , may interact in a synergistic manner to produce severe clinical myotonia in humans. |
| Score | Text |
|---|---|
| 0.9981 | We present two cases of Adverse-Effectanaphylaxis under anaesthesia where return of spontaneous circulation was refractory to epinephrine, but occurred following the administration of the alpha - agonist metaraminol. |
| 0.9951 | We present two cases of anaphylaxis under anaesthesia where return of spontaneous circulation was refractory to epinephrine, but occurred following the administration of the alpha - agonist Drugmetaraminol . |
| Score | Text |
|---|---|
| 0.9902 | We present the cases of two female patients diagnosed with relapsing - remitting multiple sclerosis ( RRMS ) who developed Adverse-Effectinflammatory musculoskeletal manifestations , following IFN - beta therapy. |
| 0.9748 | We present the cases of two female patients diagnosed with relapsing - remitting multiple sclerosis ( RRMS ) who developed inflammatory musculoskeletal manifestations, following DrugIFN - beta therapy. |
| Score | Text |
|---|---|
| 0.9948 | OBSERVATIONS : A 48 - year - old woman presented with disfiguring facial edema 10 weeks after she began antiviral therapy with peginterferon alfa - 2a and Drugribavirin for chronic hepatitis C infection. |
| 0.9767 | OBSERVATIONS : A 48 - year - old woman presented with Adverse-Effectdisfiguring facial edema 10 weeks after she began antiviral therapy with peginterferon alfa - 2a and ribavirin for chronic hepatitis C infection. |
| 0.9699 | OBSERVATIONS : A 48 - year - old woman presented with disfiguring facial edema 10 weeks after she began antiviral therapy with Drugpeginterferon alfa - 2a and ribavirin for chronic hepatitis C infection. |
| Score | Text |
|---|---|
| 0.9986 | Adverse-EffectAkathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta - adrenergic antagonist propranolol, dose reduction, or both. |
| 0.9881 | Akathisia appeared to be a common side effect of Drugfluoxetine and generally responded well to treatment with the beta - adrenergic antagonist propranolol, dose reduction, or both. |
| Score | Text |
|---|---|
| 0.9994 | We report a 45 - year - old Chinese man with CML and chronic hepatitis B virus infection, on Drugimatinib treatment, presenting with herpetic rash and acute liver failure. |
| 0.9942 | We report a 45 - year - old Chinese man with CML and chronic hepatitis B virus infection, on imatinib treatment, presenting with Adverse-Effectherpetic rash and acute liver failure. |
| 0.9918 | We report a 45 - year - old Chinese man with CML and chronic hepatitis B virus infection, on imatinib treatment, presenting with herpetic rash and Adverse-Effectacute liver failure . |
| Score | Text |
|---|---|
| 0.9995 | Fatal agranulocytosis in an Indian male receiving 100 mg of Drugdapsone daily, hospitalized for mid - borderline leprosy in type I reaction with triple nerve paralysis is reported. |
| 0.9888 | Adverse-EffectFatal agranulocytosis in an Indian male receiving 100 mg of dapsone daily, hospitalized for mid - borderline leprosy in type I reaction with triple nerve paralysis is reported. |
| Score | Text |
|---|---|
| 0.9976 | We believe that mucositis was a contributing factor to this case of fatal hyperkalemia after administration of Drugsuccinylcholine , with a mechanism similar to that reported with thermal injury. |
| 0.9855 | We believe that mucositis was a contributing factor to this case of Adverse-Effectfatal hyperkalemia after administration of succinylcholine, with a mechanism similar to that reported with thermal injury. |
| 0.9806 | We believe that Adverse-Effectmucositis was a contributing factor to this case of fatal hyperkalemia after administration of succinylcholine, with a mechanism similar to that reported with thermal injury. |
| Score | Text |
|---|---|
| 0.9990 | In eight patients, a mean decrease in serum Na + of 8. 25 + / - 3. 2 mEq / L was observed after a single 200 mg intravenous dose of Druglorcainide . |
| 0.9843 | In eight patients, a mean Adverse-Effectdecrease in serum Na + of 8. 25 + / - 3. 2 mEq / L was observed after a single 200 mg intravenous dose of lorcainide. |
| Score | Text |
|---|---|
| 0.9792 | Since early symptoms of the toxic effects of theophylline can mimic Adverse-Effectpeptic ulcer disease , cimetidine might be prescribed for the gastrointestinal symptoms with subsequent worsening of theophylline poisoning. |
| 0.9246 | Since early symptoms of the toxic effects of Drugtheophylline can mimic peptic ulcer disease, cimetidine might be prescribed for the gastrointestinal symptoms with subsequent worsening of theophylline poisoning. |
| 0.8747 | Since early symptoms of the toxic effects of theophylline can mimic peptic ulcer disease, cimetidine might be prescribed for the gastrointestinal symptoms with subsequent worsening of Drugtheophylline poisoning. |
| Score | Text |
|---|---|
| 0.9995 | Clinicians should be aware of the signs and symptoms of neurotoxicity during treatment, as well as predisposing factors that put patients receiving Drugmethotrexate at risk for neurotoxic effects. |
| 0.9962 | Clinicians should be aware of the signs and symptoms of Adverse-Effectneurotoxicity during treatment, as well as predisposing factors that put patients receiving methotrexate at risk for neurotoxic effects. |
| Score | Text |
|---|---|
| 0.9993 | This case describes a 52 - year - old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, Drugbevacizumab , for metastatic ovarian cancer treatment. |
| 0.9877 | This case describes a 52 - year - old white woman who developed a Adverse-Effectspontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment. |
| Score | Text |
|---|---|
| 0.9997 | This is the first report of a Drugfluoxetine - related death in a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism. |
| 0.9892 | This is the first report of a fluoxetine - related Adverse-Effectdeath in a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism. |
| Score | Text |
|---|---|
| 0.9916 | Adverse-EffectCutaneous necrosis as a result of interferon alfa is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune - mediated inflammatory process might be involved. |
| 0.9874 | Cutaneous necrosis as a result of Druginterferon alfa is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune - mediated inflammatory process might be involved. |
| Score | Text |
|---|---|
| 0.9909 | There have been more than 20 observations of the appearance or aggravation of this granulomatosis with Druginterferon alfa and more recently with the combination of interferon alfa plus ribavirin. |
| 0.9897 | There have been more than 20 observations of the appearance or aggravation of this Adverse-Effectgranulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin. |
| 0.9873 | There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of Druginterferon alfa plus ribavirin. |
| 0.9851 | There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus Drugribavirin . |
| Score | Text |
|---|---|
| 0.9759 | We describe a patient with Wilson's disease who presented with neurologic disease, was treated with DrugD - penicillamine , and suffered sudden neurologic deterioration coincident with therapy. |
| 0.9724 | We describe a patient with Wilson's disease who presented with neurologic disease, was treated with D - penicillamine, and suffered sudden Adverse-Effectneurologic deterioration coincident with therapy. |
| Score | Text |
|---|---|
| 0.9995 | This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to hypoxia and thus was more susceptible to ductal closure in response to Drugindomethacin exposure. |
| 0.9933 | This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to Adverse-Effecthypoxia and thus was more susceptible to ductal closure in response to indomethacin exposure. |
| 0.9889 | This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to hypoxia and thus was more susceptible to Adverse-Effectductal closure in response to indomethacin exposure. |
| Score | Text |
|---|---|
| 0.9927 | This Adverse-Effecteruption emerged after 1 month of therapy with salsalate, persisted for as long as salsalate was administered, and cleared within 3 weeks of discontinuing the medication. |
| 0.9647 | This eruption emerged after 1 month of therapy with Drugsalsalate , persisted for as long as salsalate was administered, and cleared within 3 weeks of discontinuing the medication. |
| 0.8928 | This eruption emerged after 1 month of therapy with salsalate, persisted for as long as Drugsalsalate was administered, and cleared within 3 weeks of discontinuing the medication. |
| Score | Text |
|---|---|
| 0.9984 | We report a case of Adverse-Effectcough following the administration of quinapril, with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension. |
| 0.9982 | We report a case of cough following the administration of Drugquinapril , with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension. |
| Score | Text |
|---|---|
| 0.9986 | Recent reports have shown that Decadron ( dexamethasone ; Merck Sharp & Dohme, West Point, Pa ) has a significant antiemetic effect on cisplatin - induced Adverse-Effectvomiting . |
| 0.9929 | Recent reports have shown that Decadron ( dexamethasone ; Merck Sharp & Dohme, West Point, Pa ) has a significant antiemetic effect on Drugcisplatin - induced vomiting. |
| Score | Text |
|---|---|
| 0.9324 | Prick tests and intradermal tests with a series of dilutions of carboplatin and cisplatin were performed on three patients who had exhibited medium and severe hypersensitivity reactions to Drugcarboplatin . |
| 0.9173 | Prick tests and intradermal tests with a series of dilutions of carboplatin and Drugcisplatin were performed on three patients who had exhibited medium and severe hypersensitivity reactions to carboplatin. |
| 0.9097 | Prick tests and intradermal tests with a series of dilutions of Drugcarboplatin and cisplatin were performed on three patients who had exhibited medium and severe hypersensitivity reactions to carboplatin. |
| 0.5704 | Prick tests and intradermal tests with a series of dilutions of carboplatin and cisplatin were performed on three patients who had exhibited medium and Adverse-Effectsevere hypersensitivity reactions to carboplatin. |
| Prick tests and intradermal tests with a series of dilutions of carboplatin and cisplatin were performed on three patients who had exhibited medium and Adverse-Effectsevere hypersensitivity reactions to carboplatin. | |
| Score | Text |
|---|---|
| 0.9992 | We believe that this represents an unusual case of moderate - dose DrugMTX - induced neurotoxicity in a patient with gastric cancer, which has not previously been reported. |
| 0.9973 | We believe that this represents an unusual case of moderate - dose MTX - induced Adverse-Effectneurotoxicity in a patient with gastric cancer, which has not previously been reported. |
| Score | Text |
|---|---|
| 0.9971 | The chemotherapeutics, including vincristine, actinomycin D, and epirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the Adverse-Effecthepatotoxicity developed. |
| 0.9950 | The chemotherapeutics, including vincristine, actinomycin D, and Drugepirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the hepatotoxicity developed. |
| 0.9948 | The chemotherapeutics, including Drugvincristine , actinomycin D, and epirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the hepatotoxicity developed. |
| 0.9928 | The chemotherapeutics, including vincristine, actinomycin D, and epirubicin in case 1 and Drugvincristine and actinomycin D in case 2, were given before the hepatotoxicity developed. |
| 0.9870 | The chemotherapeutics, including vincristine, Drugactinomycin D , and epirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the hepatotoxicity developed. |
| 0.9828 | The chemotherapeutics, including vincristine, actinomycin D, and epirubicin in case 1 and vincristine and Drugactinomycin D in case 2, were given before the hepatotoxicity developed. |
| Score | Text |
|---|---|
| 0.9994 | We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of Drugcaptopril . |
| 0.9928 | We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with Adverse-Effecttransient anuria after the administration of captopril. |
| 0.9739 | We report on a patient with renal artery stenosis who had only 1 kidney and in whom Adverse-Effectacute renal impairment developed with transient anuria after the administration of captopril. |
| Score | Text |
|---|---|
| 0.9989 | Sweet's syndrome is an acute febrile neutrophilic dermatosis that is a known complication of the administration of Drugfilgrastim , a drug that causes increased neutrophil proliferation and differentiation. |
| 0.9761 | Adverse-EffectSweet's syndrome is an acute febrile neutrophilic dermatosis that is a known complication of the administration of filgrastim, a drug that causes increased neutrophil proliferation and differentiation. |
| 0.9732 | Sweet's syndrome is an Adverse-Effectacute febrile neutrophilic dermatosis that is a known complication of the administration of filgrastim, a drug that causes increased neutrophil proliferation and differentiation. |
| Score | Text |
|---|---|
| 0.9908 | Metformin - associated Adverse-Effectlactic acidosis ( MALA ) is a serious metabolic complication that occurs because of metformin accumulation in patients who become dehydrated or developed acute renal failure. |
| 0.9851 | DrugMetformin - associated lactic acidosis ( MALA ) is a serious metabolic complication that occurs because of metformin accumulation in patients who become dehydrated or developed acute renal failure. |
| 0.9825 | Metformin - associated lactic acidosis ( MALA ) is a serious metabolic complication that occurs because of Drugmetformin accumulation in patients who become dehydrated or developed acute renal failure. |
| 0.9635 | Metformin - associated lactic acidosis ( Adverse-EffectMALA ) is a serious metabolic complication that occurs because of metformin accumulation in patients who become dehydrated or developed acute renal failure. |
| Score | Text |
|---|---|
| 0.9995 | However, a new episode of neutropenia, with a WBC count of 2. 8 x 10 ( 3 ) / mm3 and ANC of 0. 448 x 10 ( 3 ) / mm3, occurred 11 days after Drugteicoplanin initiation. |
| 0.9983 | However, a new episode of Adverse-Effectneutropenia , with a WBC count of 2. 8 x 10 ( 3 ) / mm3 and ANC of 0. 448 x 10 ( 3 ) / mm3, occurred 11 days after teicoplanin initiation. |
| Score | Text |
|---|---|
| 0.9830 | We report a case of severe anemia, which responded well to steroid therapy, in a patient receiving DrugIL - 2 plus IFN - alpha for metastatic renal cell carcinoma. |
| 0.9801 | We report a case of Adverse-Effectsevere anemia , which responded well to steroid therapy, in a patient receiving IL - 2 plus IFN - alpha for metastatic renal cell carcinoma. |
| 0.9735 | We report a case of severe anemia, which responded well to steroid therapy, in a patient receiving IL - 2 plus DrugIFN - alpha for metastatic renal cell carcinoma. |
| Score | Text |
|---|---|
| 0.9986 | After extensive neurological'work up ', we realized that the anisocoria was related to the transdermal Drugscopolamine patch that we had prescribed for weaning off the opioid. |
| 0.9980 | After extensive neurological'work up ', we realized that the Adverse-Effectanisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid. |
| Score | Text |
|---|---|
| 0.9963 | We report a patient in whom the anti - depressant trazodone hydrochloride ( DrugMolipaxin , Roussel ), a serotonin antagonist, provoked generalized pustular psoriasis ( GPP ). |
| 0.9888 | We report a patient in whom the anti - depressant trazodone hydrochloride ( Molipaxin, Roussel ), a serotonin antagonist, provoked Adverse-Effectgeneralized pustular psoriasis ( GPP ). |
| 0.9820 | We report a patient in whom the anti - depressant Drugtrazodone hydrochloride ( Molipaxin, Roussel ), a serotonin antagonist, provoked generalized pustular psoriasis ( GPP ). |
| 0.9701 | We report a patient in whom the anti - depressant trazodone hydrochloride ( Molipaxin, Roussel ), a serotonin antagonist, provoked generalized pustular psoriasis ( Adverse-EffectGPP ). |
| Score | Text |
|---|---|
| 0.9993 | In addition, there is a report on prolonged ECT seizure related to Drugciprofloxacin , which has an epileptogenic property with a similar action to beta - lactam antibiotics. |
| 0.9655 | In addition, there is a report on Adverse-Effectprolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta - lactam antibiotics. |
| Score | Text |
|---|---|
| 0.9995 | Here, we present a case of Drugsirolimus - associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids. |
| 0.9881 | Here, we present a case of sirolimus - associated Adverse-Effectinterstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids. |
| Score | Text |
|---|---|
| 0.9965 | In rare cases mitomycin C ( MMC ) may induce cancer - associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, Adverse-Effectthrombocytopenia and progressive renal failure. |
| 0.9946 | In rare cases mitomycin C ( MMC ) may induce cancer - associated hemolytic uremic syndrome, which is characterized by Adverse-Effecthemolytic anemia , thrombocytopenia and progressive renal failure. |
| 0.9939 | In rare cases mitomycin C ( DrugMMC ) may induce cancer - associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure. |
| 0.9904 | In rare cases Drugmitomycin C ( MMC ) may induce cancer - associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure. |
| 0.9886 | In rare cases mitomycin C ( MMC ) may induce cancer - associated Adverse-Effecthemolytic uremic syndrome , which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure. |
| 0.9862 | In rare cases mitomycin C ( MMC ) may induce cancer - associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and Adverse-Effectprogressive renal failure . |
| 0.5171 | In rare cases mitomycin C ( MMC ) may induce Drugcancer - associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure. |
| Score | Text |
|---|---|
| 0.9982 | DrugBisphosphonate - related osteonecrosis of the jaw ( BRONJ ) is reported in up to 18. 6 % of patients treated with intravenous bisphosphonates and can result in significant morbidity. |
| 0.9872 | Bisphosphonate - related Adverse-Effectosteonecrosis of the jaw ( BRONJ ) is reported in up to 18. 6 % of patients treated with intravenous bisphosphonates and can result in significant morbidity. |
| Score | Text |
|---|---|
| 0.9991 | CONCLUSION : Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of Drugtobramycin by inhalation or by intravenous administration. |
| 0.9832 | CONCLUSION : Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and Adverse-Effectdeterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration. |
| 0.9785 | CONCLUSION : Hypersensitivity reaction should be considered in patients who develop Adverse-Effectrecurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration. |
| Score | Text |
|---|---|
| 0.9996 | Finally, Drugreserpine toxicity, in particular central nervous system ( CNS ) disturbances, was reported more frequently in patients also receiving barbiturates, suggesting additive CNS effects. |
| 0.8364 | Finally, Adverse-Effectreserpine toxicity , in particular central nervous system ( CNS ) disturbances, was reported more frequently in patients also receiving barbiturates, suggesting additive CNS effects. |
| Score | Text |
|---|---|
| 0.9974 | RESULTS : At our institution, no children appeared with acute DrugINH neurotoxicity in the period 1985 through 1990, whereas seven patients were treated from 1991 through 1993. |
| 0.9388 | RESULTS : At our institution, no children appeared with acute INH Adverse-Effectneurotoxicity in the period 1985 through 1990, whereas seven patients were treated from 1991 through 1993. |
| Score | Text |
|---|---|
| 0.9965 | An 83 - year - old man receiving glipizide 10 mg bid developed symptomatic hypoglycemia within three days of adding trimethoprim / Drugsulfamethoxazole ( TMP / SMX ) to his regimen. |
| 0.9960 | An 83 - year - old man receiving glipizide 10 mg bid developed symptomatic hypoglycemia within three days of adding Drugtrimethoprim / sulfamethoxazole ( TMP / SMX ) to his regimen. |
| 0.9957 | An 83 - year - old man receiving glipizide 10 mg bid developed symptomatic hypoglycemia within three days of adding trimethoprim / sulfamethoxazole ( DrugTMP / SMX ) to his regimen. |
| 0.9954 | An 83 - year - old man receiving glipizide 10 mg bid developed symptomatic hypoglycemia within three days of adding trimethoprim / sulfamethoxazole ( TMP / DrugSMX ) to his regimen. |
| 0.9944 | An 83 - year - old man receiving Drugglipizide 10 mg bid developed symptomatic hypoglycemia within three days of adding trimethoprim / sulfamethoxazole ( TMP / SMX ) to his regimen. |
| 0.9889 | An 83 - year - old man receiving glipizide 10 mg bid developed Adverse-Effectsymptomatic hypoglycemia within three days of adding trimethoprim / sulfamethoxazole ( TMP / SMX ) to his regimen. |
| Score | Text |
|---|---|
| 0.9994 | The authors present a case of t - AML that developed in a child with metastatic neuroblastoma 18 months after he received oral Drugetoposide , given for palliation purpose. |
| 0.9874 | The authors present a case of Adverse-Effectt - AML that developed in a child with metastatic neuroblastoma 18 months after he received oral etoposide, given for palliation purpose. |
| Score | Text |
|---|---|
| 0.9988 | We describe the case of a 50 - year - old woman with advanced non - small cell lung cancer who developed status epilepticus shortly after receiving Drugcisplatin and gemcitabine chemotherapy. |
| 0.9986 | We describe the case of a 50 - year - old woman with advanced non - small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and Druggemcitabine chemotherapy. |
| 0.9855 | We describe the case of a 50 - year - old woman with advanced non - small cell lung cancer who developed Adverse-Effectstatus epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy. |
| Score | Text |
|---|---|
| 0.9871 | We report a rare case of Adverse-Effectcolonic mucosal necrosis following Kalimate ( calcium polystryrene sulfonate ), an analogue of Kayexalate without sorbitol in a 34 - yr - old man. |
| 0.9755 | We report a rare case of colonic mucosal necrosis following Kalimate ( Drugcalcium polystryrene sulfonate ), an analogue of Kayexalate without sorbitol in a 34 - yr - old man. |
| 0.9755 | We report a rare case of colonic mucosal necrosis following DrugKalimate ( calcium polystryrene sulfonate ), an analogue of Kayexalate without sorbitol in a 34 - yr - old man. |
| 0.9532 | We report a rare case of colonic mucosal necrosis following Kalimate ( calcium polystryrene sulfonate ), an analogue of DrugKayexalate without sorbitol in a 34 - yr - old man. |
| Score | Text |
|---|---|
| 0.9992 | The most likely cause of liver failure in this patient was, therefore, Drugclarithromycin , which undergoes hepatic metabolism and has been reported to cause fulminant hepatic failure. |
| 0.9841 | The most likely cause of liver failure in this patient was, therefore, clarithromycin, which undergoes hepatic metabolism and has been reported to cause Adverse-Effectfulminant hepatic failure . |
| 0.9797 | The most likely cause of Adverse-Effectliver failure in this patient was, therefore, clarithromycin, which undergoes hepatic metabolism and has been reported to cause fulminant hepatic failure. |
| Score | Text |
|---|---|
| 0.9990 | The development of an IgG lambda - type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on Drugdiphenylhydantoin ( DILANTIN ) therapy for 20 years is reported. |
| 0.9986 | The development of an IgG lambda - type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin ( DrugDILANTIN ) therapy for 20 years is reported. |
| 0.9913 | The development of an IgG lambda - type monoclonal gammopathy and subsequent Adverse-Effectmultiple myeloma in an epilepsy patient on diphenylhydantoin ( DILANTIN ) therapy for 20 years is reported. |
| 0.9763 | The development of an Adverse-EffectIgG lambda - type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin ( DILANTIN ) therapy for 20 years is reported. |
| Score | Text |
|---|---|
| 0.9920 | In all three cases, autopsy revealed gross and microscopic features indistinguishable from those seen in the Hamman - Rich syndrome, and Drugmethotrexate hepatotoxicity was present in one. |
| 0.8369 | In all three cases, autopsy revealed gross and microscopic features indistinguishable from those seen in the Hamman - Rich syndrome, and methotrexate Adverse-Effecthepatotoxicity was present in one. |
| Score | Text |
|---|---|
| 0.9990 | We report a 44 - year - old woman with t - MDS ( refractory anemia with excess blasts ) following treatment of recurrent anaplastic astrocytoma with Drugtemozolomide ( TMZ ). |
| 0.9987 | We report a 44 - year - old woman with t - MDS ( refractory anemia with excess blasts ) following treatment of recurrent anaplastic astrocytoma with temozolomide ( DrugTMZ ). |
| 0.9689 | We report a 44 - year - old woman with t - MDS ( Adverse-Effectrefractory anemia with excess blasts ) following treatment of recurrent anaplastic astrocytoma with temozolomide ( TMZ ). |
| Score | Text |
|---|---|
| 0.9984 | PURPOSE : To report a case of severe corticosteroid - induced Adverse-Effectglaucoma after intravitreal injection of triamcinolone acetate in a 34 - year - old man without a history of glaucoma. |
| 0.9703 | PURPOSE : To report a case of severe Drugcorticosteroid - induced glaucoma after intravitreal injection of triamcinolone acetate in a 34 - year - old man without a history of glaucoma. |
| 0.8089 | PURPOSE : To report a case of severe corticosteroid - induced glaucoma after intravitreal injection of Drugtriamcinolone acetate in a 34 - year - old man without a history of glaucoma. |
| Score | Text |
|---|---|
| 0.9970 | We present two children with acute lymphocytic leukemia who developed Adverse-Effectleukoencephalopathy following administration of a combination of intravenous ara = C and methotrexate during the consolidation phase of chemotherapy. |
| 0.9948 | We present two children with acute lymphocytic leukemia who developed leukoencephalopathy following administration of a combination of intravenous ara = C and Drugmethotrexate during the consolidation phase of chemotherapy. |
| 0.9744 | We present two children with acute lymphocytic leukemia who developed leukoencephalopathy following administration of a combination of intravenous Drugara = C and methotrexate during the consolidation phase of chemotherapy. |
| Score | Text |
|---|---|
| 0.9994 | On the second day of hospitalization, it was noted that the patient's dyspnea and sinus bradycardia could be related to a recent increase in his Drugtimolol dosage. |
| 0.9929 | On the second day of hospitalization, it was noted that the patient's Adverse-Effectdyspnea and sinus bradycardia could be related to a recent increase in his timolol dosage. |
| 0.9882 | On the second day of hospitalization, it was noted that the patient's dyspnea and Adverse-Effectsinus bradycardia could be related to a recent increase in his timolol dosage. |
| Score | Text |
|---|---|
| 0.9993 | Clinicians should be aware that an erythematous and exfoliative rash may be induced by Drugtemozolomide , and be familiar with the pharmacologic and supportive measures necessary for its treatment. |
| 0.9873 | Clinicians should be aware that an erythematous and Adverse-Effectexfoliative rash may be induced by temozolomide, and be familiar with the pharmacologic and supportive measures necessary for its treatment. |
| 0.9976 | Clinicians should be aware that an Adverse-Effecterythematous and exfoliative rash may be induced by temozolomide, and be familiar with the pharmacologic and supportive measures necessary for its treatment. |
| Score | Text |
|---|---|
| 0.9994 | Physicians should be aware of the potential for the development of RS among children who are receiving long - term Drugaspirin therapy for the treatment of systemic inflammatory illnesses. |
| 0.9925 | Physicians should be aware of the potential for the development of Adverse-EffectRS among children who are receiving long - term aspirin therapy for the treatment of systemic inflammatory illnesses. |
| Score | Text |
|---|---|
| 0.9996 | A review of the literature found 11 children and 2 adults in whom intranasal Drugdesmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status. |
| 0.9983 | A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced Adverse-Effectseizures or altered mental status. |
| 0.9958 | A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with Adverse-Effecthyponatremia , all of whom experienced seizures or altered mental status. |
| 0.9834 | A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or Adverse-Effectaltered mental status . |
| Score | Text |
|---|---|
| 0.9989 | OBJECTIVE : To describe a case of severe skin necrosis resulting from peripheral intravenous administration of low - dose Drugvasopressin in a patient with catecholamine - resistant septic shock. |
| 0.8246 | OBJECTIVE : To describe a case of severe Adverse-Effectskin necrosis resulting from peripheral intravenous administration of low - dose vasopressin in a patient with catecholamine - resistant septic shock. |
| 0.8866 | OBJECTIVE : To describe a case of Adverse-Effectsevere skin necrosis resulting from peripheral intravenous administration of low - dose vasopressin in a patient with catecholamine - resistant septic shock. |
| Score | Text |
|---|---|
| 0.9986 | Clinicians who manage cachectic patients, particularly those with protracted diarrhoea and / or receiving anti - malarial drugs including Drugmefloquine , should be aware of the risk of severe hypoglycaemia. |
| 0.9719 | Clinicians who manage cachectic patients, particularly those with protracted diarrhoea and / or receiving anti - malarial drugs including mefloquine, should be aware of the risk of Adverse-Effectsevere hypoglycaemia . |
| Score | Text |
|---|---|
| 0.9994 | CASE SUMMARY : A 25 - year - old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with Drugclindamycin vaginal cream for bacterial vaginosis. |
| 0.9919 | CASE SUMMARY : A 25 - year - old postpartum white woman developed multiple watery stools and Adverse-Effectabdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis. |
| 0.9853 | CASE SUMMARY : A 25 - year - old postpartum white woman developed Adverse-Effectmultiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis. |
| Score | Text |
|---|---|
| 0.9991 | CONCLUSIONS : Clinicians should be aware of this adverse reaction when facing similar complex neurologic symptoms in patients who are receiving the antibiotic treatment described here, especially Drugvancomycin . |
| 0.9765 | CONCLUSIONS : Clinicians should be aware of this adverse reaction when facing similar complex Adverse-Effectneurologic symptoms in patients who are receiving the antibiotic treatment described here, especially vancomycin. |
| Score | Text |
|---|---|
| 0.9991 | It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and Drug5 - fluorouracil regimens. |
| 0.9990 | It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with Drugoxaliplatinum and 5 - fluorouracil regimens. |
| 0.9893 | It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a Adverse-Effectpulmonary adverse reaction , a feature never previously associated with oxaliplatinum and 5 - fluorouracil regimens. |
| Score | Text |
|---|---|
| 0.9941 | For patients who suffer from osteogenic sarcoma and have anaphylactic reactions to DrugMTX , this desensitization protocol will allow these patients to continue with needed therapeutic or palliative chemotherapy. |
| 0.9914 | For patients who suffer from osteogenic sarcoma and have Adverse-Effectanaphylactic reactions to MTX, this desensitization protocol will allow these patients to continue with needed therapeutic or palliative chemotherapy. |
| Score | Text |
|---|---|
| 0.9952 | Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and Drugribavirin . |
| 0.9814 | Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with Druginterferon alpha and ribavirin. |
| 0.9777 | Here we present the case of a Adverse-Effectgeneralized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin. |
| Score | Text |
|---|---|
| 0.9992 | First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine ( DrugZyprexa ) reported in a total of 24 publications. |
| 0.9991 | First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with Drugolanzapine ( Zyprexa ) reported in a total of 24 publications. |
| 0.9980 | First, a review of the literature produced 41 anecdotic cases of Adverse-Effectneutropenia or agranulocytosis during treatment with olanzapine ( Zyprexa ) reported in a total of 24 publications. |
| 0.9976 | First, a review of the literature produced 41 anecdotic cases of neutropenia or Adverse-Effectagranulocytosis during treatment with olanzapine ( Zyprexa ) reported in a total of 24 publications. |
| Score | Text |
|---|---|
| 0.9995 | DrugCisplatin - induced syndrome of inappropriate antidiuretic hormone ( SIADH ) in a patient with neuroendocrine tumor of the cervix : a case report and review of the literature. |
| 0.9924 | Cisplatin - induced syndrome of inappropriate antidiuretic hormone ( Adverse-EffectSIADH ) in a patient with neuroendocrine tumor of the cervix : a case report and review of the literature. |
| 0.9769 | Cisplatin - induced Adverse-Effectsyndrome of inappropriate antidiuretic hormone ( SIADH ) in a patient with neuroendocrine tumor of the cervix : a case report and review of the literature. |
| Score | Text |
|---|---|
| 0.9995 | A 21 - year - old woman suffering from bipolar affective disorder developed systemic lupus erythematosus ( SLE ) with characteristic laboratory findings, 18 months after starting Drugcarbamazepine maintenance treatment. |
| 0.9944 | A 21 - year - old woman suffering from bipolar affective disorder developed systemic lupus erythematosus ( Adverse-EffectSLE ) with characteristic laboratory findings, 18 months after starting carbamazepine maintenance treatment. |
| 0.9836 | A 21 - year - old woman suffering from bipolar affective disorder developed Adverse-Effectsystemic lupus erythematosus ( SLE ) with characteristic laboratory findings, 18 months after starting carbamazepine maintenance treatment. |
| Score | Text |
|---|---|
| 0.9982 | DISCUSSION : To our knowledge, this is the first case report illustrating neuralgic amyotrophy triggered by exposure to the antibiotics vancomycin, Drugtobramycin , and piperacillin / tazobactam. |
| 0.9982 | DISCUSSION : To our knowledge, this is the first case report illustrating neuralgic amyotrophy triggered by exposure to the antibiotics Drugvancomycin , tobramycin, and piperacillin / tazobactam. |
| 0.9980 | DISCUSSION : To our knowledge, this is the first case report illustrating neuralgic amyotrophy triggered by exposure to the antibiotics vancomycin, tobramycin, and piperacillin / Drugtazobactam . |
| 0.9977 | DISCUSSION : To our knowledge, this is the first case report illustrating neuralgic amyotrophy triggered by exposure to the antibiotics vancomycin, tobramycin, and Drugpiperacillin / tazobactam. |
| 0.9897 | DISCUSSION : To our knowledge, this is the first case report illustrating Adverse-Effectneuralgic amyotrophy triggered by exposure to the antibiotics vancomycin, tobramycin, and piperacillin / tazobactam. |
| Score | Text |
|---|---|
| 0.9996 | CASE REPORT : We hereby report a case of radiation recall dermatitis and myositis occurring on Druggemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer. |
| 0.9974 | CASE REPORT : We hereby report a case of radiation recall dermatitis and Adverse-Effectmyositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer. |
| 0.9889 | CASE REPORT : We hereby report a case of Adverse-Effectradiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer. |
| Score | Text |
|---|---|
| 0.9995 | Caution in longterm usage and early recognition of Drugpentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug - induced fibrous myopathy and localized neuropathy. |
| 0.9940 | Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug - induced fibrous myopathy and localized Adverse-Effectneuropathy . |
| 0.9824 | Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug - induced Adverse-Effectfibrous myopathy and localized neuropathy. |
| 0.9652 | Caution in longterm usage and early recognition of pentazocine toxicity as a Adverse-Effectneuromuscular complication are important in order to prevent irreversible drug - induced fibrous myopathy and localized neuropathy. |
| 0.5672 | Caution in longterm usage and early recognition of Adverse-Effectpentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug - induced fibrous myopathy and localized neuropathy. |
| Score | Text |
|---|---|
| 0.9992 | A 40 - year - old man with advanced HIV infection and Mycobacterium avium complex infection experienced rapid cognitive decline after commencement of Drugethambutol , and symptoms fully resolved with cessation. |
| 0.9746 | A 40 - year - old man with advanced HIV infection and Mycobacterium avium complex infection experienced Adverse-Effectrapid cognitive decline after commencement of ethambutol, and symptoms fully resolved with cessation. |
| Score | Text |
|---|---|
| 0.9993 | He was started on Drugdigoxin , 0. 25 mg daily, because of echocardiographically demonstrated left ventricular dilatation and functional impairment ; he died of ventricular fibrillation 15 days later. |
| 0.9861 | He was started on digoxin, 0. 25 mg daily, because of echocardiographically demonstrated Adverse-Effectleft ventricular dilatation and functional impairment ; he died of ventricular fibrillation 15 days later. |
| 0.9860 | He was started on digoxin, 0. 25 mg daily, because of echocardiographically demonstrated left ventricular dilatation and functional impairment ; he died of Adverse-Effectventricular fibrillation 15 days later. |
| 0.9646 | He was started on digoxin, 0. 25 mg daily, because of echocardiographically demonstrated left ventricular dilatation and Adverse-Effectfunctional impairment ; he died of ventricular fibrillation 15 days later. |
| Score | Text |
|---|---|
| 0.9996 | We report a case of DrugMMC - related hemolytic uremic syndrome, and discuss the etiologic parameters, clinical aspects, prognosis and treatment modalities of this severe syndrome. |
| 0.9913 | We report a case of MMC - related Adverse-Effecthemolytic uremic syndrome , and discuss the etiologic parameters, clinical aspects, prognosis and treatment modalities of this severe syndrome. |
| Score | Text |
|---|---|
| 0.9989 | An obese patient, not diabetic, treated with Drugmetformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum. |
| 0.9653 | An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with Adverse-Effectsevere inferior digestive hemorrhage , diagnosed with Meckel's diverticulum. |
| 0.6656 | An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Adverse-EffectMeckel's diverticulum . |
| Score | Text |
|---|---|
| 0.9992 | A 61 - year - old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia developed generalized erythema with high fever 3 weeks after taking Drugsulfamethoxazole / trimethoprim. |
| 0.9992 | A 61 - year - old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia developed generalized erythema with high fever 3 weeks after taking sulfamethoxazole / Drugtrimethoprim . |
| 0.9904 | A 61 - year - old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia developed Adverse-Effectgeneralized erythema with high fever 3 weeks after taking sulfamethoxazole / trimethoprim. |
| Score | Text |
|---|---|
| 0.9985 | The patient had recurrence of Adverse-Effecturticaria and angioedema a year and a half later, at which point the NPH was stopped and she was desensitized to regular insulin. |
| 0.9984 | The patient had recurrence of urticaria and Adverse-Effectangioedema a year and a half later, at which point the NPH was stopped and she was desensitized to regular insulin. |
| 0.9696 | The patient had recurrence of urticaria and angioedema a year and a half later, at which point the NPH was stopped and she was desensitized to regular Druginsulin . |
| 0.8994 | The patient had recurrence of urticaria and angioedema a year and a half later, at which point the DrugNPH was stopped and she was desensitized to regular insulin. |
| Score | Text |
|---|---|
| 0.9969 | The patient was positive for antibody against complexes of heparin and platelet factor 4, and was diagnosed as heparin - induced Adverse-Effectthrombocytopenia with thrombosis syndrome ( HITTS ). |
| 0.9931 | The patient was positive for antibody against complexes of heparin and platelet factor 4, and was diagnosed as heparin - induced thrombocytopenia with Adverse-Effectthrombosis syndrome ( HITTS ). |
| 0.9914 | The patient was positive for antibody against complexes of heparin and platelet factor 4, and was diagnosed as Drugheparin - induced thrombocytopenia with thrombosis syndrome ( HITTS ). |
| 0.9852 | The patient was positive for antibody against complexes of Drugheparin and platelet factor 4, and was diagnosed as heparin - induced thrombocytopenia with thrombosis syndrome ( HITTS ). |
| Score | Text |
|---|---|
| 0.9996 | A 73 year - old patient with Wolff - Parkinson - White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of Drugflecainide . |
| 0.9806 | A 73 year - old patient with Wolff - Parkinson - White syndrome and paroxysmic supraventricular tachycardia developed an Adverse-Effectacute reversible encephalopathy within 15 days of initiation of flecainide. |
| Score | Text |
|---|---|
| 0.9987 | To the best of our knowledge, this is the first reported patient with captopril - induced Adverse-Effectpemphigus in whom no new lesions developed after subsequent treatment with enalapril. |
| 0.9937 | To the best of our knowledge, this is the first reported patient with Drugcaptopril - induced pemphigus in whom no new lesions developed after subsequent treatment with enalapril. |
| Score | Text |
|---|---|
| 0.9990 | Although Drugpraziquantel administration may have been effective in killing the parasite in both patients, we are concerned about the production of marked inflammation as a result of treatment. |
| 0.9809 | Although praziquantel administration may have been effective in killing the parasite in both patients, we are concerned about the production of marked Adverse-Effectinflammation as a result of treatment. |
| Score | Text |
|---|---|
| 0.9869 | OBJECTIVE : To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with Druginterferon alfa and to consider the possible underlying mechanisms for this association. |
| 0.9799 | OBJECTIVE : To report the occurrence of Adverse-Effectanterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association. |
| Score | Text |
|---|---|
| 0.9891 | The authors describe a patient with hemiparesis who developed the syndrome of irreversible lithium - effectuated Adverse-Effectneurotoxicity ( SILENT ) while being treated with lithium for a manic episode. |
| 0.9797 | The authors describe a patient with hemiparesis who developed the syndrome of irreversible Druglithium - effectuated neurotoxicity ( SILENT ) while being treated with lithium for a manic episode. |
| 0.9638 | The authors describe a patient with hemiparesis who developed the syndrome of irreversible lithium - effectuated neurotoxicity ( SILENT ) while being treated with Druglithium for a manic episode. |
| Score | Text |
|---|---|
| 0.9993 | We report a case of unintentional overdose of oral Drugpilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome. |
| 0.9972 | We report a case of unintentional overdose of oral pilocarpine tablets that resulted in Adverse-Effectbradycardia , mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome. |
| 0.9937 | We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and Adverse-Effectmuscarinic symptoms in a patient with Sjogren's syndrome. |
| 0.9930 | We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, Adverse-Effectmild hypotension , and muscarinic symptoms in a patient with Sjogren's syndrome. |
| Score | Text |
|---|---|
| 0.9765 | Gold - salt therapy may result in Adverse-Effectdamage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy. |
| 0.9753 | DrugGold - salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy. |
| 0.9707 | Gold - salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an Adverse-Effectautoimmune membranous nephropathy . |
| Score | Text |
|---|---|
| 0.9993 | In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of Drugcyclosporine . |
| 0.9814 | In the present paper, we describe two patients with active UC who developed a Adverse-Effectsevere systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine. |
| Score | Text |
|---|---|
| 0.9936 | When the acute manic state is characterized by marked psychotic symptoms and intense anxiety, it may be associated with increased vulnerability to the development of severe Druglithium neurotoxicity. |
| 0.9359 | When the acute manic state is characterized by marked Adverse-Effectpsychotic symptoms and intense anxiety, it may be associated with increased vulnerability to the development of severe lithium neurotoxicity. |
| 0.9228 | When the acute manic state is characterized by marked psychotic symptoms and intense anxiety, it may be associated with increased vulnerability to the development of severe lithium Adverse-Effectneurotoxicity . |
| 0.9206 | When the acute manic state is characterized by marked psychotic symptoms and Adverse-Effectintense anxiety , it may be associated with increased vulnerability to the development of severe lithium neurotoxicity. |
| Score | Text |
|---|---|
| 0.9994 | We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of Drugvinblastine . |
| 0.5115 | We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of Adverse-Effectinappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine. |
| 0.7647 | We report on a patient with an embryonal teratocarcinoma of the testicle who had the Adverse-Effectsyndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine. |
| Score | Text |
|---|---|
| 0.9986 | Although a lot of Drugamiodarone - induced torsades de pointe have been published, a review of all these cases and the underlying risk - factors has never been made. |
| 0.9807 | Although a lot of amiodarone - induced Adverse-Effecttorsades de pointe have been published, a review of all these cases and the underlying risk - factors has never been made. |
| Score | Text |
|---|---|
| 0.9958 | Type II heparin - induced Adverse-Effectthrombocytopenia ( HIT ) is an immunological disorder characterized by antibodies to heparin - platelet factor 4 complexes and a high risk of thrombotic complications. |
| 0.9869 | Type II Drugheparin - induced thrombocytopenia ( HIT ) is an immunological disorder characterized by antibodies to heparin - platelet factor 4 complexes and a high risk of thrombotic complications. |
| 0.8332 | Type II heparin - induced thrombocytopenia ( Adverse-EffectHIT ) is an immunological disorder characterized by antibodies to heparin - platelet factor 4 complexes and a high risk of thrombotic complications. |
| Score | Text |
|---|---|
| 0.9674 | Immobilization, while Paget's bone disease was present, and perhaps enhanced activation of dihydrotachysterol by rifampicin, could have led to Adverse-Effectincreased calcium - release into the circulation. |
| 0.9523 | Immobilization, while Paget's bone disease was present, and perhaps enhanced activation of Drugdihydrotachysterol by rifampicin, could have led to increased calcium - release into the circulation. |
| 0.7241 | Immobilization, while Paget's bone disease was present, and perhaps enhanced activation of dihydrotachysterol by Drugrifampicin , could have led to increased calcium - release into the circulation. |
| Score | Text |
|---|---|
| 0.9992 | Although useful in the management of chronic alcoholism, disulfiram is being increasingly associated with a wide spectrum of side effects and untoward medical sequelae, which now include Adverse-Effectcatatonia . |
| 0.9984 | Although useful in the management of chronic alcoholism, Drugdisulfiram is being increasingly associated with a wide spectrum of side effects and untoward medical sequelae, which now include catatonia. |
| Score | Text |
|---|---|
| 0.9994 | The patient was enrolled in a weight - loss clinic, and his diabetes medications were adjusted. Subsequently, Drugolanzapine was discontinued because of weight gain and uncontrolled diabetes. |
| 0.9874 | The patient was enrolled in a weight - loss clinic, and his diabetes medications were adjusted. Subsequently, olanzapine was discontinued because of Adverse-Effectweight gain and uncontrolled diabetes. |
| 0.9508 | The patient was enrolled in a weight - loss clinic, and his diabetes medications were adjusted. Subsequently, olanzapine was discontinued because of weight gain and Adverse-Effectuncontrolled diabetes . |
| Score | Text |
|---|---|
| 0.9994 | I report a 35 - year - old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first - time dose of subcutaneous Drugsumatriptan for migraine. |
| 0.9960 | I report a 35 - year - old woman with occult coronary artery disease who experienced Adverse-Effectcardiac arrest within minutes after receiving a first - time dose of subcutaneous sumatriptan for migraine. |
| Score | Text |
|---|---|
| 0.9995 | Despite a hematologic response in all 3 patients, none of them achieved cytogenetic remission, and all progressed to blast crisis at 7 to 10 months of Drugimatinib therapy. |
| 0.9939 | Despite a hematologic response in all 3 patients, none of them achieved cytogenetic remission, and all progressed to Adverse-Effectblast crisis at 7 to 10 months of imatinib therapy. |
| Score | Text |
|---|---|
| 0.9880 | Because sumatriptan can cause Adverse-Effectcoronary artery vasospasm , patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan. |
| 0.9415 | Because Drugsumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan. |
| 0.5781 | Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of Drugsumatriptan . |
| Score | Text |
|---|---|
| 0.9982 | We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a Adverse-Effectseizure during consolidation treatment with L - asparaginase. |
| 0.9904 | We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated Adverse-Effecttransient ischemic attacks followed by a seizure during consolidation treatment with L - asparaginase. |
| 0.9710 | We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with DrugL - asparaginase . |
| Score | Text |
|---|---|
| 0.9692 | Adverse-EffectProliferation of abnormal bone marrow histiocytes , an undesired effect of granulocyte macrophage - colony - stimulating factor therapy in a patient with Hurler's syndrome undergoing bone marrow transplantation. |
| 0.9576 | Proliferation of abnormal bone marrow histiocytes, an undesired effect of Druggranulocyte macrophage - colony - stimulating factor therapy in a patient with Hurler's syndrome undergoing bone marrow transplantation. |
| Score | Text |
|---|---|
| 0.9996 | The diagnosis was based on the rapid onset of renal failure, presence of eosinophilia, skin rash, and characteristic renal biopsy finding, following the administration of Drugampicillin . |
| 0.9947 | The diagnosis was based on the rapid onset of renal failure, presence of eosinophilia, Adverse-Effectskin rash , and characteristic renal biopsy finding, following the administration of ampicillin. |
| 0.9939 | The diagnosis was based on the rapid onset of renal failure, presence of Adverse-Effecteosinophilia , skin rash, and characteristic renal biopsy finding, following the administration of ampicillin. |
| 0.9915 | The diagnosis was based on the rapid onset of Adverse-Effectrenal failure , presence of eosinophilia, skin rash, and characteristic renal biopsy finding, following the administration of ampicillin. |
| Score | Text |
|---|---|
| 0.9830 | Monitoring of liver function tests should be mandatory in patients receiving high doses of Drugcyproterone acetate ; the drug should be withdrawn immediately if abnormal liver function tests are found. |
| 0.8997 | Monitoring of liver function tests should be mandatory in patients receiving high doses of cyproterone acetate ; the drug should be withdrawn immediately if Adverse-Effectabnormal liver function tests are found. |
| Score | Text |
|---|---|
| 0.9982 | The first patient developed a Adverse-Effectmonoarthritis 2 weeks after initiation of IFN - beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication. |
| 0.9801 | The first patient developed a monoarthritis 2 weeks after initiation of DrugIFN - beta , which persisted during the 14 months of therapy and resolved with discontinuation of the medication. |
| Score | Text |
|---|---|
| 0.9994 | DrugNaproxen , the most common offender, has been associated with a dimorphic clinical pattern : a PCT - like presentation and one simulating erythropoietic protoporphyria in the pediatric population. |
| 0.9881 | Naproxen, the most common offender, has been associated with a dimorphic clinical pattern : a PCT - like presentation and one simulating Adverse-Effecterythropoietic protoporphyria in the pediatric population. |
| Score | Text |
|---|---|
| 0.9866 | Parenteral pyridoxine, the specific antidote for INH - induced Adverse-Effectrefractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB. |
| 0.9734 | Parenteral pyridoxine, the specific antidote for DrugINH - induced refractory seizures, should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB. |
| 0.9381 | Parenteral Drugpyridoxine , the specific antidote for INH - induced refractory seizures, should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB. |
| Score | Text |
|---|---|
| 0.9994 | Alternating sinus rhythm and intermittent sinoatrial ( S - A ) block was observed in a 57 - year - old woman, under treatment for angina with 80 mg Drugpropranolol daily. |
| 0.9756 | Adverse-EffectAlternating sinus rhythm and intermittent sinoatrial ( S - A ) block was observed in a 57 - year - old woman, under treatment for angina with 80 mg propranolol daily. |
| 0.9669 | Alternating sinus rhythm and Adverse-Effectintermittent sinoatrial ( S - A ) block was observed in a 57 - year - old woman, under treatment for angina with 80 mg propranolol daily. |
| Score | Text |
|---|---|
| 0.9925 | We describe the development of Adverse-Effectischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome. |
| 0.9918 | We describe the development of ischemic colitis in a woman who was treated with Drugtegaserod and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome. |
| 0.9892 | We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among Adverse-Effectischemic colitis , tegaserod use, and irritable bowel syndrome. |
| 0.9864 | We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis, Drugtegaserod use, and irritable bowel syndrome. |
| 0.9860 | We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis, tegaserod use, and Adverse-Effectirritable bowel syndrome . |
| Score | Text |
|---|---|
| 0.9992 | A 7 - year - old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3. 5 years of almost continuous treatment with Drugazathioprine and / or prednisone for idiopathic auto - immune haemolytic anaemia. |
| 0.9991 | A 7 - year - old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3. 5 years of almost continuous treatment with azathioprine and / or Drugprednisone for idiopathic auto - immune haemolytic anaemia. |
| 0.9933 | A 7 - year - old girl developed Adverse-Effectdiabetes mellitus and exocrine pancreatic insufficiency after 3. 5 years of almost continuous treatment with azathioprine and / or prednisone for idiopathic auto - immune haemolytic anaemia. |
| 0.9909 | A 7 - year - old girl developed diabetes mellitus and Adverse-Effectexocrine pancreatic insufficiency after 3. 5 years of almost continuous treatment with azathioprine and / or prednisone for idiopathic auto - immune haemolytic anaemia. |
| Score | Text |
|---|---|
| 0.9929 | Flare of Kaposi's sarcoma ( KS ) is well described in immunosuppressed patients treated with corticosteroids and Drugrituximab , but has not yet been reported during treatment with imatinib. |
| 0.9687 | Flare of Kaposi's sarcoma ( Adverse-EffectKS ) is well described in immunosuppressed patients treated with corticosteroids and rituximab, but has not yet been reported during treatment with imatinib. |
| 0.9619 | Flare of Adverse-EffectKaposi's sarcoma ( KS ) is well described in immunosuppressed patients treated with corticosteroids and rituximab, but has not yet been reported during treatment with imatinib. |
| Score | Text |
|---|---|
| 0.9984 | The uncomplicated long - term use of adequately - dosed AZA and stable non - toxic metabolite levels could not acknowledge TPMT deficiency as a primary cause of the Adverse-Effectleukopenia . |
| 0.9962 | The uncomplicated long - term use of adequately - dosed DrugAZA and stable non - toxic metabolite levels could not acknowledge TPMT deficiency as a primary cause of the leukopenia. |
| Score | Text |
|---|---|
| 0.9963 | Theoretical basal ganglia toxicologic mechanisms of Drugmethanol poisoning are reviewed, and the role of brain imaging studies will regard to diagnosis, prognosis and impact on management is discussed. |
| 0.9101 | Theoretical basal ganglia toxicologic mechanisms of Adverse-Effectmethanol poisoning are reviewed, and the role of brain imaging studies will regard to diagnosis, prognosis and impact on management is discussed. |
| Score | Text |
|---|---|
| 0.9994 | We report a case of biopsy - proven acute tubulointerstitial nephritis associated with a second course of Drugflurbiprofen , a nonsteroidal anti - inflammatory drug of the propionic acid class. |
| 0.9842 | We report a case of biopsy - proven Adverse-Effectacute tubulointerstitial nephritis associated with a second course of flurbiprofen, a nonsteroidal anti - inflammatory drug of the propionic acid class. |
| Score | Text |
|---|---|
| 0.9990 | A 17 - year - old boy with refractory psoriatic arthritis and alpha - 1 antitrypsin deficiency who developed a syringotropic hypersensitivity reaction after 9 months of therapy with Druginfliximab and leflunomide is described. |
| 0.9989 | A 17 - year - old boy with refractory psoriatic arthritis and alpha - 1 antitrypsin deficiency who developed a syringotropic hypersensitivity reaction after 9 months of therapy with infliximab and Drugleflunomide is described. |
| 0.9929 | A 17 - year - old boy with refractory psoriatic arthritis and alpha - 1 antitrypsin deficiency who developed a Adverse-Effectsyringotropic hypersensitivity reaction after 9 months of therapy with infliximab and leflunomide is described. |
| 0.6391 | A 17 - year - old boy with refractory psoriatic arthritis and alpha - 1 antitrypsin deficiency who developed a Adverse-Effectsyringotropic hypersensitivity reaction after 9 months of therapy with infliximab and leflunomide is described. |
| Score | Text |
|---|---|
| 0.9987 | DrugDipyrone , also known as metamizole, is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with agranulocytosis. |
| 0.9980 | Dipyrone, also known as metamizole, is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with Adverse-Effectagranulocytosis . |
| 0.9980 | Dipyrone, also known as Drugmetamizole , is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with agranulocytosis. |
| Score | Text |
|---|---|
| 0.9988 | This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and Drugmethimazole in the same patient. |
| 0.9988 | This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both Drugpropylthiouracil and methimazole in the same patient. |
| 0.9973 | This is, to the best of our knowledge, the first report of a case in which Adverse-Effectagranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient. |
| Score | Text |
|---|---|
| 0.9992 | Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of Drugmethotrexate therapy in both patients. |
| 0.9910 | Although they had only a few nodules at diagnosis, the Adverse-Effectnodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients. |
| 0.9867 | Although they had only a few Adverse-Effectnodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients. |
| Score | Text |
|---|---|
| 0.9908 | CASE : We present an 11 - year old male with Budd - Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from Drugtacrolimus to sirolimus. |
| 0.9905 | CASE : We present an 11 - year old male with Budd - Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to Drugsirolimus . |
| 0.9717 | CASE : We present an 11 - year old male with Budd - Chiari syndrome who experienced profound Adverse-Effectworsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus. |
| Score | Text |
|---|---|
| 0.9995 | Though hypotension, dry mouth, and constipation are well - documented possible adverse effects, the possibility of Drugclonidine - induced bradycardia is less well recognized and is rare. |
| 0.9975 | Though hypotension, dry mouth, and constipation are well - documented possible adverse effects, the possibility of clonidine - induced Adverse-Effectbradycardia is less well recognized and is rare. |
| 0.9961 | Though Adverse-Effecthypotension , dry mouth, and constipation are well - documented possible adverse effects, the possibility of clonidine - induced bradycardia is less well recognized and is rare. |
| 0.9953 | Though hypotension, dry mouth, and Adverse-Effectconstipation are well - documented possible adverse effects, the possibility of clonidine - induced bradycardia is less well recognized and is rare. |
| 0.9935 | Though hypotension, Adverse-Effectdry mouth , and constipation are well - documented possible adverse effects, the possibility of clonidine - induced bradycardia is less well recognized and is rare. |
| Score | Text |
|---|---|
| 0.9993 | CASES : " A " was an 8 - year - old boy with attention deficit and chronic tic disorder who developed obsessive - compulsive symptoms within 2 weeks of starting Drugrisperidone . |
| 0.9893 | CASES : " A " was an 8 - year - old boy with attention deficit and chronic tic disorder who developed Adverse-Effectobsessive - compulsive symptoms within 2 weeks of starting risperidone. |
| Score | Text |
|---|---|
| 0.9996 | We report a 71 - year male with castration - resistant metastatic prostate cancer who was treated with weekly Drugdocetaxel for 12 weeks and developed significant eye irritation and dryness during treatment. |
| 0.9916 | We report a 71 - year male with castration - resistant metastatic prostate cancer who was treated with weekly docetaxel for 12 weeks and developed significant Adverse-Effecteye irritation and dryness during treatment. |
| Score | Text |
|---|---|
| 0.9985 | CONCLUSION : All doctors need to be aware of the need to review the indications for Druggabapentin use during periods of acute illness, especially with regard to renal impairment. |
| 0.9878 | CONCLUSION : All doctors need to be aware of the need to review the indications for gabapentin use during periods of acute illness, especially with regard to Adverse-Effectrenal impairment . |
| Score | Text |
|---|---|
| 0.9983 | In the presented case fluvoxamine - induced Adverse-Effectakathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden, and was successfully treated with the 5 - HT2A / 5 - HT2C antagonist mianserin. |
| 0.9959 | In the presented case Drugfluvoxamine - induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden, and was successfully treated with the 5 - HT2A / 5 - HT2C antagonist mianserin. |
| Score | Text |
|---|---|
| 0.9752 | The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to Drugphenytoin toxicity. |
| 0.9657 | The wide use of Drugphenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity. |
| 0.9326 | The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to Adverse-Effectphenytoin toxicity . |
| Score | Text |
|---|---|
| 0.9995 | Review of the literature relating to Drugmethicillin - induced nephropathy suggests a hypersensitivity origin for this disorder, but immunologic and ultrastructural investigation to date has failed to elucidate pathogenesis. |
| 0.9973 | Review of the literature relating to methicillin - induced Adverse-Effectnephropathy suggests a hypersensitivity origin for this disorder, but immunologic and ultrastructural investigation to date has failed to elucidate pathogenesis. |
| 0.7600 | Review of the literature relating to methicillin - induced nephropathy suggests a Adverse-Effecthypersensitivity origin for this disorder, but immunologic and ultrastructural investigation to date has failed to elucidate pathogenesis. |
| Score | Text |
|---|---|
| 0.9993 | We hypothesize that Drugcaffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis. |
| 0.9461 | We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the Adverse-Effectpotassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis. |
| 0.9234 | We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe Adverse-Effectrhabdomyolysis . |
| 0.9000 | We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the Adverse-Effectcoexisting hyponatremia , to result in unusually severe rhabdomyolysis. |
| 0.5221 | We hypothesize that Adverse-Effectcaffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis. |
| We hypothesize that caffeine toxicity Adverse-Effectinjured the muscle cells , which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis. | |
| Score | Text |
|---|---|
| 0.9985 | In conclusion, Adverse-EffectRSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug ( CyA or tacrolimus ), even under monotherapy or with a low steroid dose. |
| 0.9980 | In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug ( CyA or Drugtacrolimus ), even under monotherapy or with a low steroid dose. |
| 0.9973 | In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug ( DrugCyA or tacrolimus ), even under monotherapy or with a low steroid dose. |
| Score | Text |
|---|---|
| 0.9971 | We report a case of interstitial pneumonitis induced by Drugbicalutamide and / or leuprorelin acetate given as therapy for prostate cancer, in which the pneumonitis was successfully managed by steroid treatment. |
| 0.9853 | We report a case of Adverse-Effectinterstitial pneumonitis induced by bicalutamide and / or leuprorelin acetate given as therapy for prostate cancer, in which the pneumonitis was successfully managed by steroid treatment. |
| 0.9826 | We report a case of interstitial pneumonitis induced by bicalutamide and / or Drugleuprorelin acetate given as therapy for prostate cancer, in which the pneumonitis was successfully managed by steroid treatment. |
| Score | Text |
|---|---|
| 0.9939 | This case report describes a patient who was previously prescribed Drugalendronate ( Fosamax ) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho - Soda. |
| 0.9938 | This case report describes a patient who was previously prescribed alendronate ( Fosamax ) and presented with postoperative hypophosphatemia and Adverse-Effecthypocalcemic tetany after bowel preparation with Fleet Phospho - Soda. |
| 0.9888 | This case report describes a patient who was previously prescribed alendronate ( Fosamax ) and presented with postoperative Adverse-Effecthypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho - Soda. |
| 0.9818 | This case report describes a patient who was previously prescribed alendronate ( DrugFosamax ) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho - Soda. |
| 0.9491 | This case report describes a patient who was previously prescribed alendronate ( Fosamax ) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with DrugFleet Phospho - Soda . |
| 0.9310 | This case report describes a patient who was previously prescribed alendronate ( Fosamax ) and presented with Adverse-Effectpostoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho - Soda. |
| Score | Text |
|---|---|
| 0.9995 | Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long - term Drugprednisone for graft - versus - host disease. |
| 0.9916 | Patients from endemic areas referred to transplant centers may be at high risk for Adverse-Effectdisseminated histoplasmosis when treated with long - term prednisone for graft - versus - host disease. |
| Score | Text |
|---|---|
| 0.9978 | The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from Adverse-EffectRLS at nighttime. |
| 0.9857 | The third patient had been suffering from serious akathisia while on Drugrisperidone , and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime. |
| 0.9589 | The third patient had been suffering from serious Adverse-Effectakathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime. |
| 0.8136 | The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to Drugolanzapine , but thereafter the patient suffered from RLS at nighttime. |
| Score | Text |
|---|---|
| 0.9993 | RESULTS : We recently experienced a case of fatal Drugerlotinib - induced ILD, diagnosed based on clinical and radiologic findings, which occurred in a patient with radiation fibrosis. |
| 0.9984 | RESULTS : We recently experienced a case of fatal erlotinib - induced Adverse-EffectILD , diagnosed based on clinical and radiologic findings, which occurred in a patient with radiation fibrosis. |
| Score | Text |
|---|---|
| 0.9989 | In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of Drugbretylium maintenance therapy for complex ventricular ectopy. |
| 0.9899 | In the second case, five cardiac arrests due to ventricular tachycardia and Adverse-Effectfibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy. |
| 0.9855 | In the second case, five Adverse-Effectcardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy. |
| 0.9651 | In the second case, five cardiac arrests due to Adverse-Effectventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy. |
| Score | Text |
|---|---|
| 0.9997 | However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of DrugCBDCA . |
| 0.9988 | However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and Adverse-Effecttachycardia soon after administration of CBDCA. |
| 0.9987 | However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, Adverse-Effecthypotension , and tachycardia soon after administration of CBDCA. |
| 0.9976 | However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed Adverse-Effecteruptions , hypotension, and tachycardia soon after administration of CBDCA. |
| 0.9965 | However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and Adverse-Effectapnea , and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA. |
| 0.9909 | However, one patient exhibited severe hypersensitivity reactions including Adverse-Effectcardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA. |
| 0.9823 | However, one patient exhibited Adverse-Effectsevere hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA. |
| Score | Text |
|---|---|
| 0.9980 | A patient with chronic myeloid leukaemia treated with busulphan for 4 - 5 years, developed signs of busulphan toxicity and portal hypertension with ascites, oesophageal varices and Adverse-Effectjaundice . |
| 0.9967 | A patient with chronic myeloid leukaemia treated with busulphan for 4 - 5 years, developed signs of busulphan toxicity and portal hypertension with Adverse-Effectascites , oesophageal varices and jaundice. |
| 0.9901 | A patient with chronic myeloid leukaemia treated with busulphan for 4 - 5 years, developed signs of busulphan toxicity and portal hypertension with ascites, Adverse-Effectoesophageal varices and jaundice. |
| 0.9873 | A patient with chronic myeloid leukaemia treated with busulphan for 4 - 5 years, developed signs of busulphan toxicity and Adverse-Effectportal hypertension with ascites, oesophageal varices and jaundice. |
| 0.9861 | A patient with chronic myeloid leukaemia treated with Drugbusulphan for 4 - 5 years, developed signs of busulphan toxicity and portal hypertension with ascites, oesophageal varices and jaundice. |
| 0.9385 | A patient with chronic myeloid leukaemia treated with busulphan for 4 - 5 years, developed signs of Adverse-Effectbusulphan toxicity and portal hypertension with ascites, oesophageal varices and jaundice. |
| 0.7703 | A patient with chronic myeloid leukaemia treated with busulphan for 4 - 5 years, developed signs of Drugbusulphan toxicity and portal hypertension with ascites, oesophageal varices and jaundice. |
| Score | Text |
|---|---|
| 0.9988 | A 65 - year - old woman, in the intensive care unit because of septic shock and acute renal failure, had a small - bowel obstruction due to DrugAmphojel concretions. |
| 0.9776 | A 65 - year - old woman, in the intensive care unit because of septic shock and acute renal failure, had a Adverse-Effectsmall - bowel obstruction due to Amphojel concretions. |
| Score | Text |
|---|---|
| 0.9995 | To our knowledge, this is the first case report that demonstrates the occurrence of fever with low - dose Drugamifostine therapy without the manifestation of accompanying rash or hypotension. |
| 0.9963 | To our knowledge, this is the first case report that demonstrates the occurrence of Adverse-Effectfever with low - dose amifostine therapy without the manifestation of accompanying rash or hypotension. |
| Score | Text |
|---|---|
| 0.9990 | A 17 - year - old boy with acute lymphoblastic leukemia developed acute renal failure within 48 h of an intravenous high - dose Drugmethotrexate ( 5 g / m2 ) infusion. |
| 0.9919 | A 17 - year - old boy with acute lymphoblastic leukemia developed Adverse-Effectacute renal failure within 48 h of an intravenous high - dose methotrexate ( 5 g / m2 ) infusion. |
| Score | Text |
|---|---|
| 0.9995 | We report the case of a 17 - year - old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of Drugmethylphenidate . |
| 0.9933 | We report the case of a 17 - year - old male who developed Adverse-Effectchest pain , elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate. |
| 0.9867 | We report the case of a 17 - year - old male who developed chest pain, elevated cardiac biomarkers, and Adverse-Effectacute left ventricular dysfunction following a single dose of methylphenidate. |
| 0.9820 | We report the case of a 17 - year - old male who developed chest pain, Adverse-Effectelevated cardiac biomarkers , and acute left ventricular dysfunction following a single dose of methylphenidate. |
| Score | Text |
|---|---|
| 0.9966 | A fatal pancytopenia occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with Druglevomepromazine , diazepam and lithium carbonate. |
| 0.9962 | A fatal pancytopenia occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with levomepromazine, Drugdiazepam and lithium carbonate. |
| 0.9930 | A fatal pancytopenia occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with levomepromazine, diazepam and Druglithium carbonate . |
| 0.9889 | A Adverse-Effectfatal pancytopenia occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with levomepromazine, diazepam and lithium carbonate. |
| Score | Text |
|---|---|
| 0.9980 | Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with Drugsulpiride , a selective D2 - receptor antagonist. |
| 0.9860 | Although Adverse-Effecttardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with sulpiride, a selective D2 - receptor antagonist. |
| Score | Text |
|---|---|
| 0.9941 | A 58 - year - old woman developed unilateral acute angle - closure glaucoma four days after the application of a patch of transdermal Drugscopolamine delivery system ( TRANSDERM - V ). |
| 0.9735 | A 58 - year - old woman developed Adverse-Effectunilateral acute angle - closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system ( TRANSDERM - V ). |
| Score | Text |
|---|---|
| 0.9995 | At the end of his fifth cycle of Drugsunitinib therapy, the patient complained of the development of abnormally large mammary glands associated with pain and peri - areolar erythema. |
| 0.9901 | At the end of his fifth cycle of sunitinib therapy, the patient complained of the development of abnormally large mammary glands associated with Adverse-Effectpain and peri - areolar erythema. |
| 0.9892 | At the end of his fifth cycle of sunitinib therapy, the patient complained of the development of abnormally large mammary glands associated with pain and Adverse-Effectperi - areolar erythema . |
| 0.6407 | At the end of his fifth cycle of sunitinib therapy, the patient complained of the Adverse-Effectdevelopment of abnormally large mammary glands associated with pain and peri - areolar erythema. |
| 0.5423 | At the end of his fifth cycle of sunitinib therapy, the patient complained of the development of Adverse-Effectabnormally large mammary glands associated with pain and peri - areolar erythema. |
| Score | Text |
|---|---|
| 0.9893 | CONCLUSIONS : This observation of " on - off " risperidone treatment suggests that Drugrisperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent. |
| 0.9854 | CONCLUSIONS : This observation of " on - off " Drugrisperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent. |
| 0.8998 | CONCLUSIONS : This observation of " on - off " risperidone treatment suggests that risperidone may have worsened both Adverse-Effectpsychiatric and physical manifestations of the mitochondrial disorder in this adolescent. |
| Score | Text |
|---|---|
| 0.9995 | A 50 - year - old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of Drugzolmitriptan . |
| 0.9903 | A 50 - year - old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a Adverse-Effectspinal cord lesion following the use of zolmitriptan. |
| Score | Text |
|---|---|
| 0.9979 | CONCLUSION : Healthcare professionals should be aware of the possible development of serotonin syndrome as a complication of initiation of Drugfentanyl and other phenylpiperidine opioids in patients treated with SSRIs. |
| 0.9947 | CONCLUSION : Healthcare professionals should be aware of the possible development of Adverse-Effectserotonin syndrome as a complication of initiation of fentanyl and other phenylpiperidine opioids in patients treated with SSRIs. |
| Score | Text |
|---|---|
| 0.9972 | This report describes a case of acute compromise of renal function associated with Adverse-Effecthypotension in a 7 - year - old boy treated with the ACE inhibitor lisinopril and the ARB losartan. |
| 0.9923 | This report describes a case of acute compromise of renal function associated with hypotension in a 7 - year - old boy treated with the ACE inhibitor lisinopril and the ARB Druglosartan . |
| 0.9916 | This report describes a case of acute compromise of renal function associated with hypotension in a 7 - year - old boy treated with the ACE inhibitor Druglisinopril and the ARB losartan. |
| 0.7035 | This report describes a case of Adverse-Effectacute compromise of renal function associated with hypotension in a 7 - year - old boy treated with the ACE inhibitor lisinopril and the ARB losartan. |
| Score | Text |
|---|---|
| 0.9970 | The first patient developed mild nitritoid symptoms and pain in a band - like distribution, corresponding to T10 - T12 dermatomes, shortly after gold sodium thiomalate ( DrugGSTM ) injection. |
| 0.9910 | The first patient developed Adverse-Effectmild nitritoid symptoms and pain in a band - like distribution, corresponding to T10 - T12 dermatomes, shortly after gold sodium thiomalate ( GSTM ) injection. |
| 0.9863 | The first patient developed mild nitritoid symptoms and pain in a band - like distribution, corresponding to Adverse-EffectT10 - T12 dermatomes , shortly after gold sodium thiomalate ( GSTM ) injection. |
| 0.9847 | The first patient developed mild nitritoid symptoms and pain in a band - like distribution, corresponding to T10 - T12 dermatomes, shortly after Druggold sodium thiomalate ( GSTM ) injection. |
| 0.9826 | The first patient developed mild nitritoid symptoms and Adverse-Effectpain in a band - like distribution, corresponding to T10 - T12 dermatomes, shortly after gold sodium thiomalate ( GSTM ) injection. |
| Score | Text |
|---|---|
| 0.9985 | We report the case of an 11 - month - old female infant with a depressed level of consciousness after ingestion of Drugibuprofen whose mental status markedly improved with administration of naloxone. |
| 0.9382 | We report the case of an 11 - month - old female infant with a Adverse-Effectdepressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone. |
| Score | Text |
|---|---|
| 0.9677 | Acute DrugINH neurotoxicity was not suspected on the first admission ; however, when readmitted 4 weeks later with another seizure, the diagnosis of acute INH neurotoxicity was made. |
| 0.9501 | Acute INH neurotoxicity was not suspected on the first admission ; however, when readmitted 4 weeks later with another seizure, the diagnosis of acute DrugINH neurotoxicity was made. |
| 0.9229 | Acute INH neurotoxicity was not suspected on the first admission ; however, when readmitted 4 weeks later with another seizure, the diagnosis of acute INH Adverse-Effectneurotoxicity was made. |
| 0.9032 | Acute INH Adverse-Effectneurotoxicity was not suspected on the first admission ; however, when readmitted 4 weeks later with another seizure, the diagnosis of acute INH neurotoxicity was made. |
| 0.8507 | Acute INH neurotoxicity was not suspected on the first admission ; however, when readmitted 4 weeks later with another Adverse-Effectseizure , the diagnosis of acute INH neurotoxicity was made. |
| 0.5362 | Acute INH neurotoxicity was not suspected on the first admission ; however, when readmitted 4 weeks later with another seizure, the diagnosis of acute Adverse-EffectINH neurotoxicity was made. |
| Score | Text |
|---|---|
| 0.9995 | A 58 - year - old man with advanced renal cell carcinoma developed grade 3 proteinuria ( 8. 5 g / 24 h ) without microscopic hematuria or renal insufficiency five days after Drugtemsirolimus infusion. |
| 0.9339 | A 58 - year - old man with advanced renal cell carcinoma developed grade 3 Adverse-Effectproteinuria ( 8. 5 g / 24 h ) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion. |
| Score | Text |
|---|---|
| 0.9996 | Two patients treated for chronic myeloid leukemia with high doses of DrugCCNU ( 1100 mg / m2 and 1240 mg / m2, respectively ) developed a fatal pulmonary fibrosis. |
| 0.9898 | Two patients treated for chronic myeloid leukemia with high doses of CCNU ( 1100 mg / m2 and 1240 mg / m2, respectively ) developed a Adverse-Effectfatal pulmonary fibrosis . |
| Score | Text |
|---|---|
| 0.9994 | We report the cases of two patients who developed acute hepatitis after taking Drugriluzole at the recommended dose ( 100 mg daily ) for 7 and 4 weeks, respectively. |
| 0.9892 | We report the cases of two patients who developed Adverse-Effectacute hepatitis after taking riluzole at the recommended dose ( 100 mg daily ) for 7 and 4 weeks, respectively. |
| We report the cases of two patients who developed acute Adverse-Effecthepatitis after taking riluzole at the recommended dose ( 100 mg daily ) for 7 and 4 weeks, respectively. | |
| Score | Text |
|---|---|
| 0.9993 | CONCLUSION : A 37 - year - old African - American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim - Drugsulfamethoxazole . |
| 0.9990 | CONCLUSION : A 37 - year - old African - American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using Drugtrimethoprim - sulfamethoxazole. |
| 0.9978 | CONCLUSION : A 37 - year - old African - American man with G6PD deficiency developed hemolytic anemia, Adverse-Effecthepatitis , orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim - sulfamethoxazole. |
| 0.9954 | CONCLUSION : A 37 - year - old African - American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and Adverse-Effectaseptic meningitis simultaneously after using trimethoprim - sulfamethoxazole. |
| 0.9952 | CONCLUSION : A 37 - year - old African - American man with G6PD deficiency developed Adverse-Effecthemolytic anemia , hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim - sulfamethoxazole. |
| 0.9912 | CONCLUSION : A 37 - year - old African - American man with G6PD deficiency developed hemolytic anemia, hepatitis, Adverse-Effectorthostatic hypotension , and aseptic meningitis simultaneously after using trimethoprim - sulfamethoxazole. |
| Score | Text |
|---|---|
| 0.9863 | Adverse-EffectHashimoto's disease during interferon - alpha therapy in a patient with pre - treatment negative anti - thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease. |
| 0.9686 | Hashimoto's disease during Druginterferon - alpha therapy in a patient with pre - treatment negative anti - thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease. |
| Score | Text |
|---|---|
| 0.9945 | It should be emphasized that the recurrence of Adverse-Effectnephrotic syndrome was observed after the following chemotherapy, including M - CSF, whereas the bone marrow still remained completely remitted. |
| 0.9752 | It should be emphasized that the recurrence of nephrotic syndrome was observed after the following chemotherapy, including DrugM - CSF , whereas the bone marrow still remained completely remitted. |
| Score | Text |
|---|---|
| 0.9824 | Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of ceftriaxone with elevated hepato - biliary enzymes and Adverse-Effecttransient biliary stasis . |
| 0.9807 | Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of ceftriaxone with Adverse-Effectelevated hepato - biliary enzymes and transient biliary stasis. |
| 0.9580 | Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of Drugceftriaxone with elevated hepato - biliary enzymes and transient biliary stasis. |
| 0.6878 | DrugCeftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of ceftriaxone with elevated hepato - biliary enzymes and transient biliary stasis. |
| Score | Text |
|---|---|
| 0.9992 | We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking Drugraloxifene , which is also a selective estrogen receptor modulator. |
| 0.9818 | We report a case of a women in whom a Adverse-Effectmalignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator. |
| Score | Text |
|---|---|
| 0.9986 | CONCLUSIONS : The risk of drug - induced rhabdomyolysis due to the potential interaction between lovastatin and Drugazithromycin or clarithromycin should be considered before the concomitant use of these agents. |
| 0.9986 | CONCLUSIONS : The risk of drug - induced rhabdomyolysis due to the potential interaction between lovastatin and azithromycin or Drugclarithromycin should be considered before the concomitant use of these agents. |
| 0.9985 | CONCLUSIONS : The risk of drug - induced rhabdomyolysis due to the potential interaction between Druglovastatin and azithromycin or clarithromycin should be considered before the concomitant use of these agents. |
| 0.9980 | CONCLUSIONS : The risk of drug - induced Adverse-Effectrhabdomyolysis due to the potential interaction between lovastatin and azithromycin or clarithromycin should be considered before the concomitant use of these agents. |
| Score | Text |
|---|---|
| 0.9820 | Four days after the initial injection of 3. 6 mg of Druggoserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa, which was considered as a flare - up. |
| 0.9780 | Four days after the initial injection of 3. 6 mg of goserelin acetate, severe dyspnea developed due to Adverse-Effectworsening pleuritis carcinomatosa , which was considered as a flare - up. |
| 0.9712 | Four days after the initial injection of 3. 6 mg of goserelin acetate, Adverse-Effectsevere dyspnea developed due to worsening pleuritis carcinomatosa, which was considered as a flare - up. |
| 0.9286 | Four days after the initial injection of 3. 6 mg of goserelin acetate, severe dyspnea developed due to worsening pleuritis carcinomatosa, which was considered as a Adverse-Effectflare - up . |
| Score | Text |
|---|---|
| 0.9934 | A 43 - year - old woman with multiple sclerosis ( MS ) had Adverse-Effectnephrotic syndrome 21 months after starting treatment with interferon ( IFN ) - beta - 1b ( subcutaneous administration ). |
| 0.8030 | A 43 - year - old woman with multiple sclerosis ( MS ) had nephrotic syndrome 21 months after starting treatment with Druginterferon ( IFN ) - beta - 1b ( subcutaneous administration ). |
| Score | Text |
|---|---|
| 0.9963 | BACKGROUND : Interferon ( IFN ) - associated Adverse-Effectretinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained. |
| 0.9949 | BACKGROUND : DrugInterferon ( IFN ) - associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained. |
| 0.9936 | BACKGROUND : Interferon ( DrugIFN ) - associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained. |
| 0.9920 | BACKGROUND : Interferon ( IFN ) - associated retinopathy is typically characterized by Adverse-Effectretinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained. |
| 0.9893 | BACKGROUND : Interferon ( IFN ) - associated retinopathy is typically characterized by retinal hemorrhages and Adverse-Effectcotton wool spots at the posterior fundus, but visual function is usually maintained. |
| Score | Text |
|---|---|
| 0.9995 | Four months after receiving an orthotopic liver transplant, a 51 - year - old man was admitted for progressive liver failure and severe hepatocellular necrosis thought to be due to Drugtacrolimus . |
| 0.9819 | Four months after receiving an orthotopic liver transplant, a 51 - year - old man was admitted for progressive liver failure and Adverse-Effectsevere hepatocellular necrosis thought to be due to tacrolimus. |
| 0.9799 | Four months after receiving an orthotopic liver transplant, a 51 - year - old man was admitted for Adverse-Effectprogressive liver failure and severe hepatocellular necrosis thought to be due to tacrolimus. |
| Score | Text |
|---|---|
| 0.9980 | We present a case of a 20 - year - old woman who ingested 900 mg of Drugglyburide causing refractory hypoglycemia resistant to treatment with intravenous dextrose, glucagon, and diazoxide. |
| 0.5399 | We present a case of a 20 - year - old woman who ingested 900 mg of glyburide causing refractory Adverse-Effecthypoglycemia resistant to treatment with intravenous dextrose, glucagon, and diazoxide. |
| Score | Text |
|---|---|
| 0.9990 | A 25 - year - old man with a history of mid - borderline ( BB ) Hansen's disease developing a reversal reaction after starting Drugdapsone and rifampin therapy is presented. |
| 0.9990 | A 25 - year - old man with a history of mid - borderline ( BB ) Hansen's disease developing a reversal reaction after starting dapsone and Drugrifampin therapy is presented. |
| 0.9922 | A 25 - year - old man with a history of mid - borderline ( BB ) Hansen's disease developing a Adverse-Effectreversal reaction after starting dapsone and rifampin therapy is presented. |
| Score | Text |
|---|---|
| 0.9992 | One of these was Drugclofazimine , an aniline aposafranine derivative known to produce a ceroid - like pigment in the tissues of patients treated with this drug or lepromatous leprosy. |
| 0.9862 | One of these was clofazimine, an aniline aposafranine derivative known to produce a Adverse-Effectceroid - like pigment in the tissues of patients treated with this drug or lepromatous leprosy. |
| Score | Text |
|---|---|
| 0.9911 | It was restarted 6 weeks later, and 10 weeks after that, the patient presented with Adverse-Effectfulminant hepatic failure , which resolved rapidly after cessation of nicotinic acid therapy. |
| 0.9821 | It was restarted 6 weeks later, and 10 weeks after that, the patient presented with fulminant hepatic failure, which resolved rapidly after cessation of Drugnicotinic acid therapy. |
| Score | Text |
|---|---|
| 0.9993 | We report a case of an infant with complex congenital heart disease who was placed on Drugcaptopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia. |
| 0.9663 | We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed Adverse-Effectpulmonary infiltrates with eosinophilia . |
| Score | Text |
|---|---|
| 0.9893 | We report a case of a child with neurodevelopmental delay with chronic constipation and a history of chronic Drugmineral oil ingestion presenting as asymptomatic exogenous lipoid pneumonia ( ELP ). |
| 0.9643 | We report a case of a child with neurodevelopmental delay with chronic constipation and a history of chronic mineral oil ingestion presenting as asymptomatic exogenous lipoid pneumonia ( Adverse-EffectELP ). |
| 0.7882 | We report a case of a child with neurodevelopmental delay with chronic constipation and a history of chronic mineral oil ingestion presenting as asymptomatic Adverse-Effectexogenous lipoid pneumonia ( ELP ). |
| 0.9698 | We report a case of a child with neurodevelopmental delay with chronic constipation and a history of chronic mineral oil ingestion presenting as Adverse-Effectasymptomatic exogenous lipoid pneumonia ( ELP ). |
| Score | Text |
|---|---|
| 0.9965 | We report a case of a previously healthy, postmenopausal woman who developed anticonvulsant hypersensitivity syndrome while taking Bellamine S ( belladonna alkaloids ; Drugergotamine ; phenobarbital ) for hot flashes. |
| 0.9960 | We report a case of a previously healthy, postmenopausal woman who developed anticonvulsant hypersensitivity syndrome while taking Bellamine S ( belladonna alkaloids ; ergotamine ; Drugphenobarbital ) for hot flashes. |
| 0.9920 | We report a case of a previously healthy, postmenopausal woman who developed anticonvulsant hypersensitivity syndrome while taking DrugBellamine S ( belladonna alkaloids ; ergotamine ; phenobarbital ) for hot flashes. |
| 0.9690 | We report a case of a previously healthy, postmenopausal woman who developed anticonvulsant hypersensitivity syndrome while taking Bellamine S ( Drugbelladonna alkaloids ; ergotamine ; phenobarbital ) for hot flashes. |
| 0.9592 | We report a case of a previously healthy, postmenopausal woman who developed Adverse-Effectanticonvulsant hypersensitivity syndrome while taking Bellamine S ( belladonna alkaloids ; ergotamine ; phenobarbital ) for hot flashes. |
| 0.5447 | We report a case of a previously healthy, postmenopausal woman who developed anticonvulsant Adverse-Effecthypersensitivity syndrome while taking Bellamine S ( belladonna alkaloids ; ergotamine ; phenobarbital ) for hot flashes. |
| Score | Text |
|---|---|
| 0.9836 | Adverse-EffectPortal vein thrombosis in a patient with severe haemophilia A and F V G1691A mutation during continuous infusion of F VIII after intramural jejunal bleeding - - successful thrombolysis under heparin therapy. |
| 0.9348 | Portal vein thrombosis in a patient with severe haemophilia A and F V G1691A mutation during continuous infusion of DrugF VIII after intramural jejunal bleeding - - successful thrombolysis under heparin therapy. |
| Score | Text |
|---|---|
| 0.9995 | Oncologists supervising future clinical trials for lung cancer should be alert to the fact that Drugsorafenib can potentially induce serious interstitial lung disease, although this might depend on racial differences. |
| 0.9715 | Oncologists supervising future clinical trials for lung cancer should be alert to the fact that sorafenib can potentially induce serious Adverse-Effectinterstitial lung disease , although this might depend on racial differences. |
| Score | Text |
|---|---|
| 0.9986 | Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate tachycardia in the control state but tachycardia was always reinitiated by an identical escape sequence after Drugprocainamide . |
| 0.9795 | Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate tachycardia in the control state but Adverse-Effecttachycardia was always reinitiated by an identical escape sequence after procainamide. |
| 0.8849 | Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate Adverse-Effecttachycardia in the control state but tachycardia was always reinitiated by an identical escape sequence after procainamide. |
| Score | Text |
|---|---|
| 0.9862 | Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis may be at particular risk for Drugerlotinib pulmonary toxicity. |
| 0.8683 | Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis may be at particular risk for erlotinib Adverse-Effectpulmonary toxicity . |
| 0.7944 | Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known Adverse-Effectpulmonary fibrosis may be at particular risk for erlotinib pulmonary toxicity. |
| 0.9414 | Similar to reports in patients receiving Druggefitinib , those with pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis may be at particular risk for erlotinib pulmonary toxicity. |
| Score | Text |
|---|---|
| 0.9990 | We describe a patient who experienced chronic nausea and an episode of confusion while treated with a small, stable dose of oral Drugmorphine in the setting of mild renal insufficiency. |
| 0.9926 | We describe a patient who experienced chronic nausea and an episode of Adverse-Effectconfusion while treated with a small, stable dose of oral morphine in the setting of mild renal insufficiency. |
| 0.9751 | We describe a patient who experienced Adverse-Effectchronic nausea and an episode of confusion while treated with a small, stable dose of oral morphine in the setting of mild renal insufficiency. |
| 0.5491 | We describe a patient who experienced chronic Adverse-Effectnausea and an episode of confusion while treated with a small, stable dose of oral morphine in the setting of mild renal insufficiency. |
| Score | Text |
|---|---|
| 0.9992 | A 22 - year - old drug - abuser injected Drugflunitrazepam tablets dissolved in tap water into her left femoral artery and presented with clinical signs of acute ischaemia of the left leg. |
| 0.9692 | A 22 - year - old drug - abuser injected flunitrazepam tablets dissolved in tap water into her left femoral artery and presented with clinical signs of Adverse-Effectacute ischaemia of the left leg . |
| Score | Text |
|---|---|
| 0.9992 | We report four cases of hemodynamically significant pericardial effusion in patients with refractory lymphoma who were receiving Druggemcitabine , all of whom had a history of mediastinal radiation without subcarinal blocking. |
| 0.9878 | We report four cases of hemodynamically significant Adverse-Effectpericardial effusion in patients with refractory lymphoma who were receiving gemcitabine, all of whom had a history of mediastinal radiation without subcarinal blocking. |
| Score | Text |
|---|---|
| 0.9969 | Adverse-EffectHyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department. |
| 0.9964 | Hyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of Adverse-Effectlethargy in the postictal patient who presents to the emergency department. |
| 0.9867 | Hyperammonemia has been described as a complication of Drugvalproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department. |
| Score | Text |
|---|---|
| 0.9963 | A 66 - year - old mand suffering from severe coronary heart disease took Drugdigoxin with suicidal intent an was treated for the ensuing complete atrioventricular block with digoxin - specific antibody fragments. |
| 0.9755 | A 66 - year - old mand suffering from severe coronary heart disease took digoxin with suicidal intent an was treated for the ensuing Adverse-Effectcomplete atrioventricular block with digoxin - specific antibody fragments. |
| Score | Text |
|---|---|
| 0.9993 | We described a very atypical case of a high stage, high grade endometrial cancer associated with Drugtamoxifen in a 64 - year - old woman with a past history of breast cancer. |
| 0.9572 | We described a very atypical case of a high stage, high grade Adverse-Effectendometrial cancer associated with tamoxifen in a 64 - year - old woman with a past history of breast cancer. |
| Score | Text |
|---|---|
| 0.9964 | We report the first case of an acute flare of eosinophilic cystitis in a 51 - year - old woman after bladder instillation with dimethyl sulfoxide ( DrugDMSO ) for presumed interstitial cystitis. |
| 0.9908 | We report the first case of an acute flare of Adverse-Effecteosinophilic cystitis in a 51 - year - old woman after bladder instillation with dimethyl sulfoxide ( DMSO ) for presumed interstitial cystitis. |
| 0.9846 | We report the first case of an acute flare of eosinophilic cystitis in a 51 - year - old woman after bladder instillation with Drugdimethyl sulfoxide ( DMSO ) for presumed interstitial cystitis. |
| Score | Text |
|---|---|
| 0.9956 | We conclude that vincristine and actinomycin D were the cause of this rare from of Adverse-Effecthepatotoxicity and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery. |
| 0.9906 | We conclude that Drugvincristine and actinomycin D were the cause of this rare from of hepatotoxicity and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery. |
| 0.9885 | We conclude that vincristine and Drugactinomycin D were the cause of this rare from of hepatotoxicity and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery. |
| Score | Text |
|---|---|
| 0.9804 | Adverse-EffectTransient anuria following administration of angiotensin I - converting enzyme inhibitor ( SQ 14225 ) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation. |
| 0.9771 | Transient anuria following administration of angiotensin I - converting enzyme inhibitor ( DrugSQ 14225 ) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation. |
| Score | Text |
|---|---|
| 0.9990 | DrugFlutamide withdrawal syndrome is characterized by a decrease in prostate - specific antigen ( PSA ) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate. |
| 0.9990 | Flutamide withdrawal syndrome is characterized by a decrease in prostate - specific antigen ( PSA ) after Drugflutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate. |
| 0.9792 | Flutamide withdrawal syndrome is characterized by a Adverse-Effectdecrease in prostate - specific antigen ( PSA ) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate. |
| 0.6990 | Flutamide Adverse-Effectwithdrawal syndrome is characterized by a decrease in prostate - specific antigen ( PSA ) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate. |
| Adverse-EffectFlutamide withdrawal syndrome is characterized by a decrease in prostate - specific antigen ( PSA ) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate. | |
| Score | Text |
|---|---|
| 0.9990 | All patients had taken Drugphenytoin for variable time periods ( range 16 - 80 days ; mean : 40 ) and were on the medication when the skin lesions first appeared. |
| 0.9902 | All patients had taken phenytoin for variable time periods ( range 16 - 80 days ; mean : 40 ) and were on the medication when the Adverse-Effectskin lesions first appeared. |
| Score | Text |
|---|---|
| 0.9996 | On day 7 of Druglinezolid treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis. |
| 0.9948 | On day 7 of linezolid treatment, the patient developed severe pruritus, macular rash, facial edema, Adverse-Effecteosinophilia , marked increase in serum creatinine level, and mild hepatitis. |
| 0.9929 | On day 7 of linezolid treatment, the patient developed Adverse-Effectsevere pruritus , macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis. |
| 0.9928 | On day 7 of linezolid treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and Adverse-Effectmild hepatitis . |
| 0.9923 | On day 7 of linezolid treatment, the patient developed severe pruritus, Adverse-Effectmacular rash , facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis. |
| 0.9920 | On day 7 of linezolid treatment, the patient developed severe pruritus, macular rash, Adverse-Effectfacial edema , eosinophilia, marked increase in serum creatinine level, and mild hepatitis. |
| 0.9796 | On day 7 of linezolid treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, Adverse-Effectmarked increase in serum creatinine level , and mild hepatitis. |
| 0.7861 | On day 7 of linezolid treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, marked Adverse-Effectincrease in serum creatinine level , and mild hepatitis. |
| Score | Text |
|---|---|
| 0.9993 | DrugGemcitabine is a known risk factor for hemolytic uremic syndrome ( HUS ), which can often have a rapidly fatal clinical course despite intervention with steroids, plasmapheresis and hemodialysis. |
| 0.9865 | Gemcitabine is a known risk factor for Adverse-Effecthemolytic uremic syndrome ( HUS ), which can often have a rapidly fatal clinical course despite intervention with steroids, plasmapheresis and hemodialysis. |
| 0.9864 | Gemcitabine is a known risk factor for hemolytic uremic syndrome ( Adverse-EffectHUS ), which can often have a rapidly fatal clinical course despite intervention with steroids, plasmapheresis and hemodialysis. |
| Score | Text |
|---|---|
| 0.9979 | CASE : We report a case of a woman with severe human insulin - induced Adverse-Effectlipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM. |
| 0.9834 | CASE : We report a case of a woman with severe Drughuman insulin - induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM. |
| 0.8819 | CASE : We report a case of a woman with severe human insulin - induced lipoatrophy who has been treated exclusively with Drugrecombinant DNA human insulin since the onset of IDDM. |
| 0.9853 | CASE : We report a case of a woman with severe human insulin - induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of Adverse-EffectIDDM . |
| Score | Text |
|---|---|
| 0.9990 | We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of Druglevofloxacin in the absence of other etiologies known to cause these arrhythmias. |
| 0.9853 | We report the first case of Adverse-Effectpolymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias. |
| Score | Text |
|---|---|
| 0.9993 | In this case, it was suspected that a combination of cigarette smoking, pulmonary fibrosis, and low - dose Drugmethotrexate therapy might have promoted the development of lung cancer. |
| 0.9949 | In this case, it was suspected that a combination of cigarette smoking, pulmonary fibrosis, and low - dose methotrexate therapy might have promoted the development of Adverse-Effectlung cancer . |
| Score | Text |
|---|---|
| 0.9836 | Based on our experience and on previously published data, serum ammonia levels appear to be indicated in all ED patients on valproic acid therapy who present with Adverse-Effectaltered mental status . |
| 0.9812 | Based on our experience and on previously published data, serum ammonia levels appear to be indicated in all ED patients on Drugvalproic acid therapy who present with altered mental status. |
| Score | Text |
|---|---|
| 0.9934 | CONCLUSIONS : Optic neuritis in combination with other Adverse-Effectneurological signs , simulating multiple sclerosis, should be included in the list of adverse effects of recombinant and natural interferon alpha administration. |
| 0.9933 | CONCLUSIONS : Adverse-EffectOptic neuritis in combination with other neurological signs, simulating multiple sclerosis, should be included in the list of adverse effects of recombinant and natural interferon alpha administration. |
| 0.9885 | CONCLUSIONS : Optic neuritis in combination with other neurological signs, simulating multiple sclerosis, should be included in the list of adverse effects of recombinant and natural Druginterferon alpha administration. |
| 0.5303 | CONCLUSIONS : Optic neuritis in combination with other neurological signs, simulating Adverse-Effectmultiple sclerosis , should be included in the list of adverse effects of recombinant and natural interferon alpha administration. |
| Score | Text |
|---|---|
| 0.9994 | In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low - dose Drugmethotrexate : an acute megaloblastic anaemia and a pneumonitis. |
| 0.9985 | In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low - dose methotrexate : an acute megaloblastic anaemia and a Adverse-Effectpneumonitis . |
| 0.9906 | In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low - dose methotrexate : an Adverse-Effectacute megaloblastic anaemia and a pneumonitis. |
| Score | Text |
|---|---|
| 0.9984 | Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, Adverse-Effectsynovitis , and possible vasculitis, after receiving all - trans retinoic acid therapy. |
| 0.9913 | Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and Adverse-Effectpossible vasculitis , after receiving all - trans retinoic acid therapy. |
| 0.9910 | Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed Adverse-Effectacute focal myositis , synovitis, and possible vasculitis, after receiving all - trans retinoic acid therapy. |
| 0.9749 | Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving Drugall - trans retinoic acid therapy. |
| Score | Text |
|---|---|
| 0.9969 | CASE REPORT : We report a case of intracerebral hemorrhage occurring in a middle - aged man who suffered from chronic sinusitis and had been ingesting Drugpseudoephedrine daily for one year. |
| 0.9906 | CASE REPORT : We report a case of Adverse-Effectintracerebral hemorrhage occurring in a middle - aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year. |
| Score | Text |
|---|---|
| 0.9955 | In addition, an immediate erythematous macule was observed on the photopatch test site of Drugmequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy. |
| 0.9911 | In addition, an immediate Adverse-Effecterythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy. |
| 0.9686 | In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate Adverse-Effecterythema noted in chlorpromazine photoallergy. |
| In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the Adverse-Effectimmediate erythema noted in chlorpromazine photoallergy. | |
| Score | Text |
|---|---|
| 0.9994 | We present here a female patient who developed acute bilateral parotitis within minutes of i. v. Drugenalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment. |
| 0.9848 | We present here a female patient who developed Adverse-Effectacute bilateral parotitis within minutes of i. v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment. |
| Score | Text |
|---|---|
| 0.9994 | A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed fatal cerebral edema and brainstem herniation after she received a single dose of intravenous Drugmethotrexate . |
| 0.9940 | A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed fatal cerebral edema and Adverse-Effectbrainstem herniation after she received a single dose of intravenous methotrexate. |
| 0.9931 | A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed Adverse-Effectfatal cerebral edema and brainstem herniation after she received a single dose of intravenous methotrexate. |
| Score | Text |
|---|---|
| 0.9993 | We report the case of a 20 - year - old female with polyarteritis nodosa ( PAN ) who developed bilateral sensorineural hearing loss 25 minutes after receiving 30 mg of intravenous Drugketoralac . |
| 0.9898 | We report the case of a 20 - year - old female with polyarteritis nodosa ( PAN ) who developed Adverse-Effectbilateral sensorineural hearing loss 25 minutes after receiving 30 mg of intravenous ketoralac. |
| Score | Text |
|---|---|
| 0.9974 | CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 Druglevothyroxine product to another. |
| 0.9820 | CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with Adverse-Effectincreased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 levothyroxine product to another. |
| 0.9917 | CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of Adverse-Effecthypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 levothyroxine product to another. |
| 0.9689 | CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( Adverse-EffectTSH ) concentrations after switching from 1 levothyroxine product to another. |
| Score | Text |
|---|---|
| 0.9992 | A search of the United States Food and Drug Administration's Adverse Event Reporting System identified nine cases of Drugoxcarbazepine - associated angioedema in pediatric patients aged 16 years and younger. |
| 0.9977 | A search of the United States Food and Drug Administration's Adverse Event Reporting System identified nine cases of oxcarbazepine - associated Adverse-Effectangioedema in pediatric patients aged 16 years and younger. |
| Score | Text |
|---|---|
| 0.9988 | This fourth type of cutaneous Drugminocycline hyperpigmentation may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity. |
| 0.9338 | This fourth type of cutaneous minocycline Adverse-Effecthyperpigmentation may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity. |
| Score | Text |
|---|---|
| 0.9994 | This report presents a case of acute lung injury developing within hours after administration of Drugmefloquine for a low - level Plasmodium falciparum malaria, which was persistent despite halofantrine therapy. |
| 0.9878 | This report presents a case of Adverse-Effectacute lung injury developing within hours after administration of mefloquine for a low - level Plasmodium falciparum malaria, which was persistent despite halofantrine therapy. |
| Score | Text |
|---|---|
| 0.9991 | An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with Drugvalproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment. |
| 0.9871 | An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop Adverse-Effectmenstrual cycle disturbances during treatment. |
| Score | Text |
|---|---|
| 0.9931 | We speculate that platelet activation induced by pFVIII may have contributed to Adverse-Effectthrombosis and suggest that pFVIII be used with caution in elderly patients with pre - existing cardiovascular risk factors. |
| 0.9759 | We speculate that platelet activation induced by DrugpFVIII may have contributed to thrombosis and suggest that pFVIII be used with caution in elderly patients with pre - existing cardiovascular risk factors. |
| 0.9420 | We speculate that Adverse-Effectplatelet activation induced by pFVIII may have contributed to thrombosis and suggest that pFVIII be used with caution in elderly patients with pre - existing cardiovascular risk factors. |
| Score | Text |
|---|---|
| 0.9932 | We strongly suspect that this Adverse-Effectlethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension. |
| 0.9851 | We strongly suspect that this lethal anuria was mainly due to Drugifosfamide , occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension. |
| 0.8521 | We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous Drugcisplatin chemotherapy and with poor kidney perfusion due to transient hypotension. |
| Score | Text |
|---|---|
| 0.9968 | A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of Adverse-Effectulcer formation in patients being treated with these medications for asthma. |
| 0.9966 | A study following large patient groups on Drugtheophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma. |
| 0.9954 | A study following large patient groups on theophylline and a combination of Drugtheophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma. |
| Score | Text |
|---|---|
| 0.9988 | CONCLUSION : The chronic use of DrugHCQ for rheumatic diseases, or as an anti - malarial drug, should be balanced against the risk of developing potentially lethal cardiac arrhythmias. |
| 0.8899 | CONCLUSION : The chronic use of HCQ for rheumatic diseases, or as an anti - malarial drug, should be balanced against the risk of developing potentially lethal Adverse-Effectcardiac arrhythmias . |
| 0.9846 | CONCLUSION : The chronic use of HCQ for rheumatic diseases, or as an anti - malarial drug, should be balanced against the risk of developing potentially Adverse-Effectlethal cardiac arrhythmias . |
| Score | Text |
|---|---|
| 0.9989 | When the patient was treated again with Drugfludarabine nine months later, the DAT became positive with anti - IgG and anti - C3d antiglobulins after the second course of treatment. |
| 0.8390 | When the patient was treated again with fludarabine nine months later, the Adverse-EffectDAT became positive with anti - IgG and anti - C3d antiglobulins after the second course of treatment. |
| When the patient was treated again with fludarabine nine months later, the Adverse-EffectDAT became positive with anti - IgG and anti - C3d antiglobulins after the second course of treatment. | |
| Score | Text |
|---|---|
| 0.9952 | CASE SUMMARIES : While conducting a protocol evaluating the efficacy of intraperitoneal Drugcisplatin and hyperthermia in the treatment of recurrent ovarian cancer, 3 patients were noted to exhibit anaphylactoid reactions. |
| 0.9944 | CASE SUMMARIES : While conducting a protocol evaluating the efficacy of intraperitoneal cisplatin and hyperthermia in the treatment of recurrent ovarian cancer, 3 patients were noted to exhibit Adverse-Effectanaphylactoid reactions . |
| Score | Text |
|---|---|
| 0.9582 | DrugRecombinant human interferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may exacerbate psoriasis or trigger off its onset. |
| 0.6680 | Recombinant human interferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may Adverse-Effectexacerbate psoriasis or trigger off its onset . |
| 0.9408 | Recombinant human interferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may Adverse-Effectexacerbate psoriasis or trigger off its onset. |
| 0.6653 | Recombinant human Druginterferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may exacerbate psoriasis or trigger off its onset. |
| 0.6299 | Recombinant Drughuman interferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may exacerbate psoriasis or trigger off its onset. |
| 0.5541 | Recombinant human interferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may Adverse-Effectexacerbate psoriasis or trigger off its onset. |
| 0.5372 | Recombinant human interferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may Adverse-Effectexacerbate psoriasis or trigger off its onset. |
| 0.5354 | Recombinant human interferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may Adverse-Effectexacerbate psoriasis or trigger off its onset. |
| Score | Text |
|---|---|
| 0.9987 | CONCLUSIONS : The value of multihormonal therapy in breast carcinoma is not established, and the addition of progestogens to Drugtamoxifen may not reduce of developing endometrial lesions, including carcinoma. |
| 0.9980 | CONCLUSIONS : The value of multihormonal therapy in breast carcinoma is not established, and the addition of progestogens to tamoxifen may not reduce of developing endometrial lesions, including Adverse-Effectcarcinoma . |
| 0.9831 | CONCLUSIONS : The value of multihormonal therapy in breast carcinoma is not established, and the addition of progestogens to tamoxifen may not reduce of developing Adverse-Effectendometrial lesions , including carcinoma. |
| Score | Text |
|---|---|
| 0.9953 | CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and Drug5 - FU to a previous regimen of warfarin alone. |
| 0.9941 | CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of Druglevamisole and 5 - FU to a previous regimen of warfarin alone. |
| 0.9936 | CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5 - FU to a previous regimen of Drugwarfarin alone. |
| 0.9879 | CONCLUSIONS : This case describes the clinically significant Adverse-Effectincrease of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5 - FU to a previous regimen of warfarin alone. |
| Score | Text |
|---|---|
| 0.9982 | In addition, a 31 - year - old man with obsessive - compulsive disorder developed Adverse-EffectRBD soon after starting fluoxetine therapy, which persisted at PSG study 19 months after fluoxetine discontinuation. |
| 0.9962 | In addition, a 31 - year - old man with obsessive - compulsive disorder developed RBD soon after starting Drugfluoxetine therapy, which persisted at PSG study 19 months after fluoxetine discontinuation. |
| 0.9952 | In addition, a 31 - year - old man with obsessive - compulsive disorder developed RBD soon after starting fluoxetine therapy, which persisted at PSG study 19 months after Drugfluoxetine discontinuation. |
| Score | Text |
|---|---|
| 0.9976 | Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin - induced Adverse-Effectthrombocytopenia ( HIT ) postoperatively. |
| 0.9916 | Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing Drugheparin - induced thrombocytopenia ( HIT ) postoperatively. |
| 0.9882 | Most cardiac surgical patients have had previous exposure to Drugheparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin - induced thrombocytopenia ( HIT ) postoperatively. |
| 0.8503 | Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin - induced thrombocytopenia ( Adverse-EffectHIT ) postoperatively. |
| Score | Text |
|---|---|
| 0.9861 | However, given the clinically significant result to the interaction between tolazoline and cimetidine we report, the use of cimetidine in tolazoline induced Adverse-Effectupper gastrointestinal hemorrhage should deserve more attention. |
| 0.9545 | However, given the clinically significant result to the interaction between tolazoline and Drugcimetidine we report, the use of cimetidine in tolazoline induced upper gastrointestinal hemorrhage should deserve more attention. |
| 0.9466 | However, given the clinically significant result to the interaction between Drugtolazoline and cimetidine we report, the use of cimetidine in tolazoline induced upper gastrointestinal hemorrhage should deserve more attention. |
| 0.9460 | However, given the clinically significant result to the interaction between tolazoline and cimetidine we report, the use of Drugcimetidine in tolazoline induced upper gastrointestinal hemorrhage should deserve more attention. |
| 0.9430 | However, given the clinically significant result to the interaction between tolazoline and cimetidine we report, the use of cimetidine in Drugtolazoline induced upper gastrointestinal hemorrhage should deserve more attention. |
| Score | Text |
|---|---|
| 0.9916 | In this case report, we present clinical and laboratory findings of a case with chronic hepatitis B that developed Adverse-Effectacute dystonia soon after the first dose of pegylated interferon alpha. |
| 0.9721 | In this case report, we present clinical and laboratory findings of a case with chronic hepatitis B that developed acute dystonia soon after the first dose of Drugpegylated interferon alpha . |
| 0.9156 | In this case report, we present clinical and laboratory findings of a case with chronic Drughepatitis B that developed acute dystonia soon after the first dose of pegylated interferon alpha. |
| Score | Text |
|---|---|
| 0.9978 | The induced hyperglycaemia could not be controlled sufficiently, despite a high dose of insulin ( > 110 units / day ), suggesting the existence of insulin insensitivity and Adverse-Effecthyperinsulinaemia . |
| 0.9889 | The induced hyperglycaemia could not be controlled sufficiently, despite a high dose of Druginsulin ( > 110 units / day ), suggesting the existence of insulin insensitivity and hyperinsulinaemia. |
| 0.7782 | The induced hyperglycaemia could not be controlled sufficiently, despite a high dose of insulin ( > 110 units / day ), suggesting the existence of Adverse-Effectinsulin insensitivity and hyperinsulinaemia. |
| 0.9952 | The induced Adverse-Effecthyperglycaemia could not be controlled sufficiently, despite a high dose of insulin ( > 110 units / day ), suggesting the existence of insulin insensitivity and hyperinsulinaemia. |
| Score | Text |
|---|---|
| 0.9992 | Continuous EEG monitoring is helpful in managing seizures that occur as a complication of DrugCBZ OD, after the course of recovery or worsening, and in providing assistance with prognosis. |
| 0.9971 | Continuous EEG monitoring is helpful in managing Adverse-Effectseizures that occur as a complication of CBZ OD, after the course of recovery or worsening, and in providing assistance with prognosis. |
| Score | Text |
|---|---|
| 0.9943 | A 57 - year - old woman with right bundle branch block + LPH and ventricular premature contractions developed complete heart block ( CHB ) following administration of disopyramide phosphate ( DrugNorpace ). |
| 0.9934 | A 57 - year - old woman with right bundle branch block + LPH and ventricular premature contractions developed complete heart block ( Adverse-EffectCHB ) following administration of disopyramide phosphate ( Norpace ). |
| 0.9890 | A 57 - year - old woman with right bundle branch block + LPH and ventricular premature contractions developed Adverse-Effectcomplete heart block ( CHB ) following administration of disopyramide phosphate ( Norpace ). |
| 0.9789 | A 57 - year - old woman with right bundle branch block + LPH and ventricular premature contractions developed complete heart block ( CHB ) following administration of Drugdisopyramide phosphate ( Norpace ). |
| Score | Text |
|---|---|
| 0.9980 | Use of the Naranjo adverse drug reaction probability scale indicated a probable relationship ( score of 5 ) between the patient's development of Adverse-Effecthepatotoxicity and the TMP - SMX therapy. |
| 0.9789 | Use of the Naranjo adverse drug reaction probability scale indicated a probable relationship ( score of 5 ) between the patient's development of hepatotoxicity and the DrugTMP - SMX therapy. |
| Score | Text |
|---|---|
| 0.9996 | A 40 - year - old man with relapsing - remitting multiple sclerosis ( MS ) developed primary central nervous system lymphoma ( PCNSL ) after having received 21 doses of Drugnatalizumab monotherapy. |
| 0.9951 | A 40 - year - old man with relapsing - remitting multiple sclerosis ( MS ) developed primary central nervous system lymphoma ( Adverse-EffectPCNSL ) after having received 21 doses of natalizumab monotherapy. |
| 0.9865 | A 40 - year - old man with relapsing - remitting multiple sclerosis ( MS ) developed Adverse-Effectprimary central nervous system lymphoma ( PCNSL ) after having received 21 doses of natalizumab monotherapy. |
| Score | Text |
|---|---|
| 0.9971 | DrugWarfarin - associated bleeding generally is considered deleterious ; however, in our patient it unmasked an early stage of colon cancer and thus may have saved the patient's life. |
| 0.9627 | Warfarin - associated Adverse-Effectbleeding generally is considered deleterious ; however, in our patient it unmasked an early stage of colon cancer and thus may have saved the patient's life. |
| 0.9891 | Warfarin - associated bleeding generally is considered Adverse-Effectdeleterious ; however, in our patient it unmasked an early stage of colon cancer and thus may have saved the patient's life. |
| Score | Text |
|---|---|
| 0.9975 | A 44 - year - old woman is described in whom amiodarone, Drugdisopyramide , and quinidine, administered alone separately, induced atypical ventricular tachycardia ( AVT, torsade de pointes ). |
| 0.9974 | A 44 - year - old woman is described in whom Drugamiodarone , disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia ( AVT, torsade de pointes ). |
| 0.9972 | A 44 - year - old woman is described in whom amiodarone, disopyramide, and Drugquinidine , administered alone separately, induced atypical ventricular tachycardia ( AVT, torsade de pointes ). |
| 0.9941 | A 44 - year - old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia ( Adverse-EffectAVT , torsade de pointes ). |
| 0.9922 | A 44 - year - old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced Adverse-Effectatypical ventricular tachycardia ( AVT, torsade de pointes ). |
| 0.9908 | A 44 - year - old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia ( AVT, Adverse-Effecttorsade de pointes ). |
| Score | Text |
|---|---|
| 0.9993 | We report four cases of sensorimotor axonal neuropathy in children aged 10 - 15 years, treated with Drugthalidomide for myxopapillary ependymoma, Crohn's disease and recurrent giant aphthous ulceration. |
| 0.9877 | We report four cases of Adverse-Effectsensorimotor axonal neuropathy in children aged 10 - 15 years, treated with thalidomide for myxopapillary ependymoma, Crohn's disease and recurrent giant aphthous ulceration. |
| Score | Text |
|---|---|
| 0.9943 | OBJECTIVE : To report a case of Adverse-Effectserotonin syndrome associated with interaction between fentanyl and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl. |
| 0.9896 | OBJECTIVE : To report a case of serotonin syndrome associated with interaction between fentanyl and Drugcitalopram , as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl. |
| 0.9875 | OBJECTIVE : To report a case of serotonin syndrome associated with interaction between Drugfentanyl and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl. |
| 0.9780 | OBJECTIVE : To report a case of serotonin syndrome associated with interaction between fentanyl and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of Drugfentanyl . |
| Score | Text |
|---|---|
| 0.9933 | We review the literature on previously reported cases of Adverse-Effectcutaneous necrosis after injection of standard interferon alfa or pegylated interferon alfa - 2b and discuss the different pathophysiologic mechanisms that might be involved. |
| 0.9810 | We review the literature on previously reported cases of cutaneous necrosis after injection of standard Druginterferon alfa or pegylated interferon alfa - 2b and discuss the different pathophysiologic mechanisms that might be involved. |
| 0.9614 | We review the literature on previously reported cases of cutaneous necrosis after injection of standard interferon alfa or Drugpegylated interferon alfa - 2b and discuss the different pathophysiologic mechanisms that might be involved. |
| Score | Text |
|---|---|
| 0.9923 | We present a pediatric patient with leukemia and a severe, L - asparaginase - induced Adverse-Effectnecrotizing pancreatitis , treated successfully with percutaneous drainage used to flush the infected necrotic parts. |
| 0.9800 | We present a pediatric patient with leukemia and a severe, DrugL - asparaginase - induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts. |
| Score | Text |
|---|---|
| 0.9964 | The authors postulate that two types of combined lithium - neuroleptic toxicity occur : a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily Drugthioridazine . |
| 0.9913 | The authors postulate that two types of combined lithium - neuroleptic toxicity occur : a Adverse-Effectneuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine. |
| 0.9829 | The authors postulate that two types of combined lithium - neuroleptic toxicity occur : a neuroleptic malignant extrapyramidal syndrome and a Druglithium toxicity that occurs in combination with phenothiazines, primarily thioridazine. |
| 0.6940 | The authors postulate that two types of combined lithium - neuroleptic toxicity occur : a neuroleptic malignant extrapyramidal syndrome and a Adverse-Effectlithium toxicity that occurs in combination with phenothiazines, primarily thioridazine. |
| 0.9964 | The authors postulate that two types of combined lithium - neuroleptic toxicity occur : a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with Drugphenothiazines , primarily thioridazine. |
| 0.9789 | The authors postulate that two types of combined Druglithium - neuroleptic toxicity occur : a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine. |
| Score | Text |
|---|---|
| 0.9911 | The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of Adverse-Effectnephrotic syndrome . |
| 0.9756 | The possibility can be raised that M - CSF accelerated the underlying Adverse-Effectrenal disease in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of nephrotic syndrome. |
| 0.9732 | The possibility can be raised that DrugM - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of nephrotic syndrome. |
| Score | Text |
|---|---|
| 0.9842 | We report here on a heretofore undescribed respiratory syncytial virus ( RSV ) infection in a patient with a long - standing history of refractory CLL that was treated with Drugfludarabine phosphate . |
| 0.9733 | We report here on a heretofore undescribed Adverse-Effectrespiratory syncytial virus ( RSV ) infection in a patient with a long - standing history of refractory CLL that was treated with fludarabine phosphate. |
| Score | Text |
|---|---|
| 0.9995 | We report a case of hyponatremia associated with a grand mal seizure in a 28 month - old child after intra - nasal Drugdesmopressin administration for high fluid intake with nocturnal enuresis. |
| 0.9985 | We report a case of Adverse-Effecthyponatremia associated with a grand mal seizure in a 28 month - old child after intra - nasal desmopressin administration for high fluid intake with nocturnal enuresis. |
| 0.9855 | We report a case of hyponatremia associated with a Adverse-Effectgrand mal seizure in a 28 month - old child after intra - nasal desmopressin administration for high fluid intake with nocturnal enuresis. |
| Score | Text |
|---|---|
| 0.9995 | We report an additional case of Drugisotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts. |
| 0.9888 | We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, Adverse-Effecthydrocephalus , and abnormalities of the corticospinal tracts. |
| 0.9731 | We report an additional case of isotretinoin Adverse-Effectteratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts. |
| 0.9681 | We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, Adverse-Effectmultiple leptomeningeal neuroglial heterotopias , hydrocephalus, and abnormalities of the corticospinal tracts. |
| 0.9655 | We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and Adverse-Effectabnormalities of the corticospinal tracts . |
| 0.9535 | We report an additional case of isotretinoin teratogenicity in which the patient had Adverse-Effectagenesis of the cerebellar vermis , multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts. |
| Score | Text |
|---|---|
| 0.9985 | However, continued low - dose DrugMTX led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and death in 1 of our patients. |
| 0.9909 | However, continued low - dose MTX led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and Adverse-Effectdeath in 1 of our patients. |
| 0.9891 | However, continued low - dose MTX led, in spite of normal liver tests, 8 years after the last biopsy to Adverse-Effectliver failure and death in 1 of our patients. |
| Score | Text |
|---|---|
| 0.9980 | A 56 - year - old woman with scleroderma developed rapidly progressive glomerulonephritis with epithelial crescents associated with Adverse-Effecthemoptysis after 27 months of D - penicillamine therapy and a cumulative dose of 1, 200 g. |
| 0.9849 | A 56 - year - old woman with scleroderma developed rapidly progressive glomerulonephritis with Adverse-Effectepithelial crescents associated with hemoptysis after 27 months of D - penicillamine therapy and a cumulative dose of 1, 200 g. |
| 0.9815 | A 56 - year - old woman with scleroderma developed rapidly progressive glomerulonephritis with epithelial crescents associated with hemoptysis after 27 months of DrugD - penicillamine therapy and a cumulative dose of 1, 200 g. |
| 0.9771 | A 56 - year - old woman with scleroderma developed Adverse-Effectrapidly progressive glomerulonephritis with epithelial crescents associated with hemoptysis after 27 months of D - penicillamine therapy and a cumulative dose of 1, 200 g. |
| Score | Text |
|---|---|
| 0.9990 | In a phase II study of Drughycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug - related deaths. |
| 0.9840 | In a phase II study of hycanthone in patients with breast cancer we have recently observed Adverse-Effectsevere hepatotoxicity , even at lower doses, which resulted in two drug - related deaths. |
| Score | Text |
|---|---|
| 0.9954 | The development of systemic lupus erythematosus ( Adverse-EffectSLE ) after 38 months of therapy with recombinant human interferon gamma ( rIFN - gamma ) was observed in a patient with rheumatoid arthritis. |
| 0.9859 | The development of Adverse-Effectsystemic lupus erythematosus ( SLE ) after 38 months of therapy with recombinant human interferon gamma ( rIFN - gamma ) was observed in a patient with rheumatoid arthritis. |
| 0.9705 | The development of systemic lupus erythematosus ( SLE ) after 38 months of therapy with Drugrecombinant human interferon gamma ( rIFN - gamma ) was observed in a patient with rheumatoid arthritis. |
| 0.9688 | The development of systemic lupus erythematosus ( SLE ) after 38 months of therapy with recombinant human interferon gamma ( DrugrIFN - gamma ) was observed in a patient with rheumatoid arthritis. |
| Score | Text |
|---|---|
| 0.9986 | We report 2 cases of maculopapular eruption and fever in patients infected with human immunodeficiency virus ( HIV ) on the 2nd day of first administration of Drugritonavir , a protease inhibitor. |
| 0.9946 | We report 2 cases of Adverse-Effectmaculopapular eruption and fever in patients infected with human immunodeficiency virus ( HIV ) on the 2nd day of first administration of ritonavir, a protease inhibitor. |
| 0.9838 | We report 2 cases of maculopapular eruption and Adverse-Effectfever in patients infected with human immunodeficiency virus ( HIV ) on the 2nd day of first administration of ritonavir, a protease inhibitor. |
| Score | Text |
|---|---|
| 0.9953 | Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of Drugquinine - induced thrombocytopenia. |
| 0.9877 | Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine - induced Adverse-Effectthrombocytopenia . |
| 0.6847 | Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe Adverse-Effectthrombocytopenia , and confirmed the etiology of quinine - induced thrombocytopenia. |
| 0.8572 | Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of Adverse-Effectsevere thrombocytopenia , and confirmed the etiology of quinine - induced thrombocytopenia. |
| Even after a strict warning, he took another Drugquinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine - induced thrombocytopenia. | |
| Score | Text |
|---|---|
| 0.9994 | Six patients developed peripheral neuropathy and five patients bone marrow depression, blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of Druglinezolid . |
| 0.9895 | Six patients developed Adverse-Effectperipheral neuropathy and five patients bone marrow depression, blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of linezolid. |
| 0.9588 | Six patients developed peripheral neuropathy and five patients Adverse-Effectbone marrow depression , blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of linezolid. |
| Score | Text |
|---|---|
| 0.9934 | Herein is reported an unusual case of coexistent warfarin - induced skin necrosis and heparin - induced Adverse-Effectthrombocytopenia following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma. |
| 0.9478 | Herein is reported an unusual case of coexistent warfarin - induced Adverse-Effectskin necrosis and heparin - induced thrombocytopenia following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma. |
| 0.9430 | Herein is reported an unusual case of coexistent Drugwarfarin - induced skin necrosis and heparin - induced thrombocytopenia following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma. |
| 0.9001 | Herein is reported an unusual case of coexistent warfarin - induced skin necrosis and Drugheparin - induced thrombocytopenia following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma. |
| Score | Text |
|---|---|
| 0.9966 | BACKGROUND : We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis ( ASPPC ) that developed after intravitreal triamcinolone acetonide ( DrugIVTA ) injection. |
| 0.9950 | BACKGROUND : We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis ( Adverse-EffectASPPC ) that developed after intravitreal triamcinolone acetonide ( IVTA ) injection. |
| 0.9837 | BACKGROUND : We describe the ophthalmic features and clinical course of two cases of Adverse-Effectacute syphilitic posterior placoid chorioretinitis ( ASPPC ) that developed after intravitreal triamcinolone acetonide ( IVTA ) injection. |
| 0.9816 | BACKGROUND : We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis ( ASPPC ) that developed after intravitreal Drugtriamcinolone acetonide ( IVTA ) injection. |
| Score | Text |
|---|---|
| 0.9986 | We describe a case of intraoperative gelatine - induced Adverse-Effectanaphylaxis whose diagnosis was delayed as the use of gelatine during surgical procedures was omitted for two times in patient's medical records. |
| 0.9838 | We describe a case of intraoperative Druggelatine - induced anaphylaxis whose diagnosis was delayed as the use of gelatine during surgical procedures was omitted for two times in patient's medical records. |
| 0.7594 | We describe a case of intraoperative gelatine - induced anaphylaxis whose diagnosis was delayed as the use of Druggelatine during surgical procedures was omitted for two times in patient's medical records. |
| Score | Text |
|---|---|
| 0.9806 | Here, we describe a case of Vogt - Koyanagi - Harada disease occurring 4 months after the start of Druginterferon alpha treatment, probably induced by the immunomodulatory effects of interferon. |
| 0.9800 | Here, we describe a case of Adverse-EffectVogt - Koyanagi - Harada disease occurring 4 months after the start of interferon alpha treatment, probably induced by the immunomodulatory effects of interferon. |
| 0.6867 | Here, we describe a case of Vogt - Koyanagi - Harada disease occurring 4 months after the start of interferon alpha treatment, probably induced by the immunomodulatory effects of Druginterferon . |
| Score | Text |
|---|---|
| 0.9987 | Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, Druglansoprazole , or pantoprazole for 7 - 15 days for peptic acid diseases in recommended standard doses. |
| 0.9986 | Pheripheral edema was observed in five female patients after taking proton pump inhibitors Drugomeprazole , lansoprazole, or pantoprazole for 7 - 15 days for peptic acid diseases in recommended standard doses. |
| 0.9986 | Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or Drugpantoprazole for 7 - 15 days for peptic acid diseases in recommended standard doses. |
| 0.9930 | Adverse-EffectPheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7 - 15 days for peptic acid diseases in recommended standard doses. |
| Score | Text |
|---|---|
| 0.9996 | We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of Drugmethotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation. |
| 0.9142 | We describe two patients in whom Adverse-Effectpainful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation. |
| 0.7013 | We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of Adverse-Effectmethotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation. |
| 0.5585 | We describe two patients in whom painful Adverse-Effecterosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation. |
| Score | Text |
|---|---|
| 0.9911 | We recommend that a TMA in association with quinine be consistently referred to as quinine - associated Adverse-Effectthrombotic microangiopathy ( quinine - TMA ) to better distinguish this entity from idiopathic TTP. |
| 0.9613 | We recommend that a TMA in association with quinine be consistently referred to as Drugquinine - associated thrombotic microangiopathy ( quinine - TMA ) to better distinguish this entity from idiopathic TTP. |
| Score | Text |
|---|---|
| 0.9992 | A 77 - year - old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous Drugmorphine for back pain relating to vertebral metastasis of a malignant lymphoma. |
| 0.9870 | A 77 - year - old woman with no history of epilepsy presented a probable Adverse-Effectnonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma. |
| Score | Text |
|---|---|
| 0.9990 | We present a case of the syndrome of inappropriate antidiuretic hormone ( SIADH ) secondary to Drugcisplatin therapy in a patient with advanced - stage large cell neuroendocrine carcinoma of the cervix. |
| 0.9967 | We present a case of the syndrome of inappropriate antidiuretic hormone ( Adverse-EffectSIADH ) secondary to cisplatin therapy in a patient with advanced - stage large cell neuroendocrine carcinoma of the cervix. |
| 0.9786 | We present a case of the Adverse-Effectsyndrome of inappropriate antidiuretic hormone ( SIADH ) secondary to cisplatin therapy in a patient with advanced - stage large cell neuroendocrine carcinoma of the cervix. |
| Score | Text |
|---|---|
| 0.9992 | Prenatal cytomegalovirus ( CMV ) infection associated with severe brain damage was detected in an infant whose mother had been treated with Drugprednisolone and azathioprine for systemic lupus erythematosus ( SLE ). |
| 0.9992 | Prenatal cytomegalovirus ( CMV ) infection associated with severe brain damage was detected in an infant whose mother had been treated with prednisolone and Drugazathioprine for systemic lupus erythematosus ( SLE ). |
| 0.9539 | Adverse-EffectPrenatal cytomegalovirus ( CMV ) infection associated with severe brain damage was detected in an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus ( SLE ). |
| 0.7261 | Prenatal cytomegalovirus ( CMV ) infection associated with severe Adverse-Effectbrain damage was detected in an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus ( SLE ). |
| 0.9338 | Prenatal cytomegalovirus ( CMV ) infection associated with Adverse-Effectsevere brain damage was detected in an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus ( SLE ). |
| Score | Text |
|---|---|
| 0.9984 | We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with Drugbupivacaine and additional injection of lidocaine in the operative field. |
| 0.9979 | We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant Adverse-Effectmethemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field. |
| 0.9977 | We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of Druglidocaine in the operative field. |
| Score | Text |
|---|---|
| 0.9633 | Review of this and previously reported cases indicates the need for early diagnosis of Drugamiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery. |
| 0.9510 | Review of this and previously reported cases indicates the need for early diagnosis of amiodarone Adverse-Effectpneumonitis , immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery. |
| Score | Text |
|---|---|
| 0.9961 | Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg / day, AVT with Adverse-Effectsyncope occurred ; isoproterenol abolished the arrhythmia instantly. |
| 0.9955 | Two years later, 24 hours following an increase in the dose of Drugdisopyramide from 300 to 600 mg / day, AVT with syncope occurred ; isoproterenol abolished the arrhythmia instantly. |
| 0.9908 | Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg / day, Adverse-EffectAVT with syncope occurred ; isoproterenol abolished the arrhythmia instantly. |
| Score | Text |
|---|---|
| 0.9858 | A 74 - year - old patient with idiopathic Parkinson's disease was evaluated for Adverse-Effectunintended sleep episodes that occurred after long - term treatment with 400 mg / day of L - dopa. |
| 0.9734 | A 74 - year - old patient with idiopathic Parkinson's disease was evaluated for unintended sleep episodes that occurred after long - term treatment with 400 mg / day of DrugL - dopa . |
| Score | Text |
|---|---|
| 0.9986 | Prior to surgery, Druglevodopa induced dyskinesia had improved ( < or = 50 % ) under treatment with amantadine ( 400 mg / day, po ) in all three patients. |
| 0.9985 | Prior to surgery, levodopa induced Adverse-Effectdyskinesia had improved ( < or = 50 % ) under treatment with amantadine ( 400 mg / day, po ) in all three patients. |
| Score | Text |
|---|---|
| 0.9981 | We report on a patient with acromegaly who developed severe drug - induced Adverse-Effecthepatitis during combined treatment with the long - acting somatostatin - analog octreotide and the GH receptor antagonist pegvisomant. |
| 0.9957 | We report on a patient with acromegaly who developed severe drug - induced hepatitis during combined treatment with the long - acting somatostatin - analog Drugoctreotide and the GH receptor antagonist pegvisomant. |
| 0.9957 | We report on a patient with acromegaly who developed severe drug - induced hepatitis during combined treatment with the long - acting somatostatin - analog octreotide and the GH receptor antagonist Drugpegvisomant . |
| Score | Text |
|---|---|
| 0.9995 | CONCLUSIONS : DrugTopiramate may be associated with ciliochoroidal effusion with forward displacement of the lens - iris diaphragm and anterior chamber shallowing, resulting in acute myopia and angle - closure glaucoma. |
| 0.9925 | CONCLUSIONS : Topiramate may be associated with ciliochoroidal effusion with forward displacement of the lens - iris diaphragm and anterior chamber shallowing, resulting in Adverse-Effectacute myopia and angle - closure glaucoma. |
| 0.9817 | CONCLUSIONS : Topiramate may be associated with ciliochoroidal effusion with forward displacement of the lens - iris diaphragm and anterior chamber shallowing, resulting in acute myopia and Adverse-Effectangle - closure glaucoma . |
| 0.9489 | CONCLUSIONS : Topiramate may be associated with ciliochoroidal effusion with forward Adverse-Effectdisplacement of the lens - iris diaphragm and anterior chamber shallowing, resulting in acute myopia and angle - closure glaucoma. |
| 0.8171 | CONCLUSIONS : Topiramate may be associated with ciliochoroidal effusion with forward displacement of the lens - iris diaphragm and Adverse-Effectanterior chamber shallowing , resulting in acute myopia and angle - closure glaucoma. |
| 0.5967 | CONCLUSIONS : Topiramate may be associated with Adverse-Effectciliochoroidal effusion with forward displacement of the lens - iris diaphragm and anterior chamber shallowing, resulting in acute myopia and angle - closure glaucoma. |
| Score | Text |
|---|---|
| 0.9994 | A case of high - grade endometrial stromal sarcoma, confined into an intrauterine polypoid growth, in a woman with a history of breast cancer who was treated with adjuvant Drugtamoxifen . |
| 0.9696 | A case of Adverse-Effecthigh - grade endometrial stromal sarcoma , confined into an intrauterine polypoid growth, in a woman with a history of breast cancer who was treated with adjuvant tamoxifen. |
| 0.9365 | A case of high - grade endometrial stromal sarcoma, confined into an Adverse-Effectintrauterine polypoid growth , in a woman with a history of breast cancer who was treated with adjuvant tamoxifen. |
| Score | Text |
|---|---|
| 0.9993 | Because of serious side effects of an increase in the QT interval causing torsades de pointes, Drugdofetilide must be initiated with close monitoring of the QT interval in an inpatient setting. |
| 0.9839 | Because of serious side effects of an increase in the QT interval causing Adverse-Effecttorsades de pointes , dofetilide must be initiated with close monitoring of the QT interval in an inpatient setting. |
| 0.9439 | Because of serious side effects of an Adverse-Effectincrease in the QT interval causing torsades de pointes, dofetilide must be initiated with close monitoring of the QT interval in an inpatient setting. |
| Score | Text |
|---|---|
| 0.9997 | The typical Drugfluoxetine - induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic - induced akathisia. |
| 0.9959 | The typical fluoxetine - induced symptoms of Adverse-Effectrestlessness , constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic - induced akathisia. |
| 0.9941 | The typical fluoxetine - induced symptoms of restlessness, Adverse-Effectconstant pacing , purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic - induced akathisia. |
| 0.9929 | The typical fluoxetine - induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and Adverse-Effectmarked anxiety were indistinguishable from those of neuroleptic - induced akathisia. |
| 0.9809 | The typical fluoxetine - induced symptoms of restlessness, constant pacing, Adverse-Effectpurposeless movements of the feet and legs , and marked anxiety were indistinguishable from those of neuroleptic - induced akathisia. |
| 0.7438 | The typical fluoxetine - induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic - induced Adverse-Effectakathisia . |
| Score | Text |
|---|---|
| 0.9996 | OBJECTIVE : To report a case of Drugphenolphthalein - induced toxic epidermal necrolysis ( TEN ) in a patient maintained on several other medications more commonly known to be associated with TEN. |
| 0.9948 | OBJECTIVE : To report a case of phenolphthalein - induced toxic epidermal necrolysis ( Adverse-EffectTEN ) in a patient maintained on several other medications more commonly known to be associated with TEN. |
| 0.9934 | OBJECTIVE : To report a case of phenolphthalein - induced toxic epidermal necrolysis ( TEN ) in a patient maintained on several other medications more commonly known to be associated with Adverse-EffectTEN . |
| 0.9872 | OBJECTIVE : To report a case of phenolphthalein - induced Adverse-Effecttoxic epidermal necrolysis ( TEN ) in a patient maintained on several other medications more commonly known to be associated with TEN. |
| Score | Text |
|---|---|
| 0.9966 | After Druginfliximab treatment, additional sleep studies revealed an increase in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea. |
| 0.9904 | After infliximab treatment, additional sleep studies revealed an increase in the number of apneic events and Adverse-EffectSaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea. |
| 0.9787 | After infliximab treatment, additional sleep studies revealed an Adverse-Effectincrease in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea. |
| Score | Text |
|---|---|
| 0.9994 | OBJECTIVE : We report a patient who developed neutropenia on Drugclozapine , but behind the cell count decrease showed to be a diurnal variation of the white blood cells ( WBC ). |
| 0.9768 | OBJECTIVE : We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a Adverse-Effectdiurnal variation of the white blood cells ( WBC ). |
| Score | Text |
|---|---|
| 0.9988 | An infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and Drugpropranolol . |
| 0.9987 | An infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with Drugmethimazole and propranolol. |
| 0.9897 | An infant girl with choanal atresia, Adverse-Effectathelia , minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and propranolol. |
| 0.9710 | An infant girl with Adverse-Effectchoanal atresia , athelia, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and propranolol. |
| An infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate Adverse-Effectmental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and propranolol. | |
| Score | Text |
|---|---|
| 0.9927 | Acute Drugnitrite toxicity results from industrial exposure, accidental ingestion ( e. g., abuse of organic nitrites as an aphrodisiac, especially in the male homosexual population ), and suicidal ingestion. |
| 0.7057 | Acute Adverse-Effectnitrite toxicity results from industrial exposure, accidental ingestion ( e. g., abuse of organic nitrites as an aphrodisiac, especially in the male homosexual population ), and suicidal ingestion. |
| Score | Text |
|---|---|
| 0.9995 | Severe rash, including the Stevens - Johnson syndrome ( SJS ), is the major toxicity of Drugnevirapine and is described in the package labeling with a prominent, boxed warning. |
| 0.9896 | Adverse-EffectSevere rash , including the Stevens - Johnson syndrome ( SJS ), is the major toxicity of nevirapine and is described in the package labeling with a prominent, boxed warning. |
| 0.9818 | Severe rash, including the Stevens - Johnson syndrome ( Adverse-EffectSJS ), is the major toxicity of nevirapine and is described in the package labeling with a prominent, boxed warning. |
| 0.9789 | Severe rash, including the Adverse-EffectStevens - Johnson syndrome ( SJS ), is the major toxicity of nevirapine and is described in the package labeling with a prominent, boxed warning. |
| Score | Text |
|---|---|
| 0.9971 | Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of Drugsulphasalazine ( SASP ) therapy developed a severe and lasting psoriasis - like skin reaction. |
| 0.9923 | Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine ( DrugSASP ) therapy developed a severe and lasting psoriasis - like skin reaction. |
| 0.9744 | Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine ( SASP ) therapy developed a severe and lasting Adverse-Effectpsoriasis - like skin reaction . |
| Score | Text |
|---|---|
| 0.9803 | A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone ( PTH ) concentration, resulted from the therapeutic use of Drugmagnesium sulfate for toxemia of pregnancy. |
| 0.9782 | A case is reported in which severe hypocalcemia, with a Adverse-Effectlow plasma parathyroid hormone ( PTH ) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy. |
| 0.9750 | A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone ( Adverse-EffectPTH ) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy. |
| 0.9620 | A case is reported in which Adverse-Effectsevere hypocalcemia , with a low plasma parathyroid hormone ( PTH ) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy. |
| Score | Text |
|---|---|
| 0.9819 | The electrocardiogram ( ECG ), which was read as normal prior to ritodrine infusion, demonstrated a Adverse-Effecttype I second - degree AV block which disappeared upon discontinuation of ritodrine therapy. |
| 0.9733 | The electrocardiogram ( ECG ), which was read as normal prior to Drugritodrine infusion, demonstrated a type I second - degree AV block which disappeared upon discontinuation of ritodrine therapy. |
| 0.9537 | The electrocardiogram ( ECG ), which was read as normal prior to ritodrine infusion, demonstrated a type I second - degree AV block which disappeared upon discontinuation of Drugritodrine therapy. |
| Score | Text |
|---|---|
| 0.9947 | A case is reported of an elderly woman who developed febrile agranulocytosis several weeks after commencing Drugticlopidine but who had a favorable outcome after cessation of that drug and treatment with filgastrim. |
| 0.9901 | A case is reported of an elderly woman who developed Adverse-Effectfebrile agranulocytosis several weeks after commencing ticlopidine but who had a favorable outcome after cessation of that drug and treatment with filgastrim. |
| Score | Text |
|---|---|
| 0.9993 | METHODS : Two patients with exudative age - related macular degeneration were treated sequentially with an intravitreal injection of Drugbevacizumab and developed signs of severe but painless infectious endophthalmitis 2 days later. |
| 0.7485 | METHODS : Two patients with exudative age - related macular degeneration were treated sequentially with an intravitreal injection of bevacizumab and developed signs of severe but Adverse-Effectpainless infectious endophthalmitis 2 days later. |
| 0.9840 | METHODS : Two patients with exudative age - related Adverse-Effectmacular degeneration were treated sequentially with an intravitreal injection of bevacizumab and developed signs of severe but painless infectious endophthalmitis 2 days later. |
| METHODS : Two patients with exudative Adverse-Effectage - related macular degeneration were treated sequentially with an intravitreal injection of bevacizumab and developed signs of severe but painless infectious endophthalmitis 2 days later. | |
| Score | Text |
|---|---|
| 0.9789 | 3. Thus, the Adverse-Effectdecreased plasma cortisol level during alprazolam treatment of panic disorder was suggested to be caused not by symptom alleviation due to alprazolam but by alprazolam administration itself. |
| 0.9456 | 3. Thus, the decreased plasma cortisol level during Drugalprazolam treatment of panic disorder was suggested to be caused not by symptom alleviation due to alprazolam but by alprazolam administration itself. |
| Score | Text |
|---|---|
| 0.9995 | Although the t - AML developed following oral Drugetoposide therapy, the child had previously received high - dose, multiagent chemotherapy, and rearrangement of the MLL gene was not demonstrated. |
| 0.9842 | Although the Adverse-Effectt - AML developed following oral etoposide therapy, the child had previously received high - dose, multiagent chemotherapy, and rearrangement of the MLL gene was not demonstrated. |
| Score | Text |
|---|---|
| 0.9990 | A 66 - year - old Japanese woman with severe scleroderma developed Adverse-Effectanemia and thrombocytopenia due to D - penicillamine ( D - Pen ) treatment, although the leukopenia was not markedly severe. |
| 0.9956 | A 66 - year - old Japanese woman with severe scleroderma developed anemia and Adverse-Effectthrombocytopenia due to D - penicillamine ( D - Pen ) treatment, although the leukopenia was not markedly severe. |
| 0.9812 | A 66 - year - old Japanese woman with severe scleroderma developed anemia and thrombocytopenia due to DrugD - penicillamine ( D - Pen ) treatment, although the leukopenia was not markedly severe. |
| 0.9798 | A 66 - year - old Japanese woman with severe scleroderma developed anemia and thrombocytopenia due to D - penicillamine ( DrugD - Pen ) treatment, although the leukopenia was not markedly severe. |
| Score | Text |
|---|---|
| 0.9980 | While Drugdoxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum. |
| 0.9945 | While doxorubicin was administered, the patient presented Adverse-Effectthoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum. |
| 0.9888 | While doxorubicin was administered, the patient presented thoracic pain and Adverse-Effectbreathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum. |
| Score | Text |
|---|---|
| 0.9995 | A 67 - year - old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of Drugazathioprine therapy. |
| 0.9870 | A 67 - year - old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of Adverse-Effectsevere cholestasis 3 months after initiation of azathioprine therapy. |
| Score | Text |
|---|---|
| 0.9990 | We describe a life threatening side effect of acute Drugepoprostenol infusion ( pulmonary edema ) in a patient with pulmonary hypertension associated with limited scleroderma and discuss its management and potential etiology. |
| 0.9898 | We describe a life threatening side effect of acute epoprostenol infusion ( Adverse-Effectpulmonary edema ) in a patient with pulmonary hypertension associated with limited scleroderma and discuss its management and potential etiology. |
| Score | Text |
|---|---|
| 0.9962 | Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia / Adverse-Effectinfarction shortly after cis - diamine - dichloroplatinum II ( cisplatin ) - based chemotherapy. |
| 0.9948 | Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia / infarction shortly after cis - diamine - dichloroplatinum II ( Drugcisplatin ) - based chemotherapy. |
| 0.9916 | Six patients with no previous signs or symptoms suggestive of coronary artery disease developed Adverse-Effectacute coronary ischemia / infarction shortly after cis - diamine - dichloroplatinum II ( cisplatin ) - based chemotherapy. |
| 0.9582 | Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia / infarction shortly after Drugcis - diamine - dichloroplatinum II ( cisplatin ) - based chemotherapy. |
| 0.8872 | Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia / infarction shortly after Drugcis - diamine - dichloroplatinum II ( cisplatin ) - based chemotherapy. |
| Score | Text |
|---|---|
| 0.9989 | In three of these patients the infection was clinically unsuspected ; in the fourth, cutaneous herpes zoster developed after administration of 300 mg of Drugcytarabine daily for the preceding five days. |
| 0.9882 | In three of these patients the infection was clinically unsuspected ; in the fourth, Adverse-Effectcutaneous herpes zoster developed after administration of 300 mg of cytarabine daily for the preceding five days. |
| Score | Text |
|---|---|
| 0.9974 | INTRODUCTION - The aim of this case report is to present a 15 - year follow - up of a patient with Drugphenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH ). |
| 0.9944 | INTRODUCTION - The aim of this case report is to present a 15 - year follow - up of a patient with phenytoin ( DrugPHT ) intoxication with unilateral gingival hyperplasia ( GH ). |
| 0.9761 | INTRODUCTION - The aim of this case report is to present a 15 - year follow - up of a patient with phenytoin ( PHT ) intoxication with Adverse-Effectunilateral gingival hyperplasia ( GH ). |
| Score | Text |
|---|---|
| 0.9995 | Though physicians treating large populations of patients with HIV are well aware of this complication, only one other report of Drugnevirapine - associated SJS has been documented in the dermatology literature. |
| 0.9977 | Though physicians treating large populations of patients with HIV are well aware of this complication, only one other report of nevirapine - associated Adverse-EffectSJS has been documented in the dermatology literature. |
| Score | Text |
|---|---|
| 0.9861 | Grade 3 hepatotoxicity ( AST and ALT > 5 to 20 upper limit normal ) or higher has been observed in as many as 1. 4 % of MS patients on DrugIFN beta . |
| 0.9722 | Adverse-EffectGrade 3 hepatotoxicity ( AST and ALT > 5 to 20 upper limit normal ) or higher has been observed in as many as 1. 4 % of MS patients on IFN beta. |
| Score | Text |
|---|---|
| 0.9994 | OBJECTIVES : To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking Drugimatinib and to perform a review of the literature. |
| 0.9927 | OBJECTIVES : To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to Adverse-Effectblast crisis while taking imatinib and to perform a review of the literature. |
| Score | Text |
|---|---|
| 0.9930 | The purpose of this review is to increase awareness among physicians and other health care professionals that Adverse-EffectDIC may be a rare but potentially severe complication of anti - D IGIV treatment. |
| 0.9769 | The purpose of this review is to increase awareness among physicians and other health care professionals that DIC may be a rare but potentially severe complication of Druganti - D IGIV treatment. |
| Score | Text |
|---|---|
| 0.9995 | Our patient was a 72 - year - old man with advanced Parkinson's disease ( PD ) who received Druglevodopa and anti - cholinergic drugs and whose head had become almost completely bald. |
| 0.9933 | Our patient was a 72 - year - old man with advanced Parkinson's disease ( PD ) who received levodopa and anti - cholinergic drugs and whose head had become almost Adverse-Effectcompletely bald . |
| Score | Text |
|---|---|
| 0.9995 | CONCLUSIONS : These results suggest that Drugclozapine may cause TD ; however, the prevalence is low and the severity is relatively mild, with no or mild self - reported discomfort. |
| 0.9985 | CONCLUSIONS : These results suggest that clozapine may cause TD ; however, the prevalence is low and the severity is relatively mild, with no or mild self - reported Adverse-Effectdiscomfort . |
| 0.9892 | CONCLUSIONS : These results suggest that clozapine may cause Adverse-EffectTD ; however, the prevalence is low and the severity is relatively mild, with no or mild self - reported discomfort. |
| Score | Text |
|---|---|
| 0.9969 | CONCLUSIONS : The observation that Adverse-Effectneurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases. |
| 0.9940 | CONCLUSIONS : The observation that neurotoxicity developed with a delay of 24 to 48 hours after Drugacyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases. |
| 0.9934 | CONCLUSIONS : The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of Drugacyclovir levels reported in similar cases. |
| Score | Text |
|---|---|
| 0.9993 | We highlight two instances of systemic allergic reaction, and discuss the potential side effects of local Drugaprotinin injections in the orthopaedic setting as well as the evidence base for its use. |
| 0.9886 | We highlight two instances of Adverse-Effectsystemic allergic reaction , and discuss the potential side effects of local aprotinin injections in the orthopaedic setting as well as the evidence base for its use. |
| Score | Text |
|---|---|
| 0.9987 | Diarrhoea, T - CD4 + lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with Drugoxaliplatinum and 5 - fluorouracil for unresectable rectum carcinoma. |
| 0.9984 | Adverse-EffectDiarrhoea , T - CD4 + lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5 - fluorouracil for unresectable rectum carcinoma. |
| 0.9977 | Diarrhoea, T - CD4 + lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and Drug5 - fluorouracil for unresectable rectum carcinoma. |
| 0.9817 | Diarrhoea, T - CD4 + lymphopenia and Adverse-Effectbilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5 - fluorouracil for unresectable rectum carcinoma. |
| 0.9729 | Diarrhoea, Adverse-EffectT - CD4 + lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5 - fluorouracil for unresectable rectum carcinoma. |
| Score | Text |
|---|---|
| 0.9901 | Several cases of Druglithium - induced Creutzfeldt - Jakob syndrome have been reported to date ; all of them were elderly patients and a half had " therapeutic " lithium serum levels. |
| 0.9891 | Several cases of lithium - induced Adverse-EffectCreutzfeldt - Jakob syndrome have been reported to date ; all of them were elderly patients and a half had " therapeutic " lithium serum levels. |
| 0.9800 | Several cases of lithium - induced Creutzfeldt - Jakob syndrome have been reported to date ; all of them were elderly patients and a half had " therapeutic " Druglithium serum levels. |
| Score | Text |
|---|---|
| 0.9994 | We report a case of fulminant hepatic failure associated with Drugdidanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously. |
| 0.9862 | We report a case of Adverse-Effectfulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously. |
| Score | Text |
|---|---|
| 0.9993 | We report the case of a 43 - year - old man with ITP refractory to steroids and intravenous immunoglobulin who developed acute respiratory distress syndrome ( ARDS ) after a single infusion of Drugrituximab . |
| 0.9941 | We report the case of a 43 - year - old man with ITP refractory to steroids and intravenous immunoglobulin who developed acute respiratory distress syndrome ( Adverse-EffectARDS ) after a single infusion of rituximab. |
| 0.9903 | We report the case of a 43 - year - old man with ITP refractory to steroids and intravenous immunoglobulin who developed Adverse-Effectacute respiratory distress syndrome ( ARDS ) after a single infusion of rituximab. |
| Score | Text |
|---|---|
| 0.9993 | We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic Drugcyclophosphamide therapy for nonHodgkin's lymphoma. |
| 0.9724 | We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and Adverse-Effectdistal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin's lymphoma. |
| 0.9704 | We report an unusual case of simultaneous Adverse-Effecttransitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin's lymphoma. |
| Score | Text |
|---|---|
| 0.9995 | One week after the initial - dose of Drugadalimumab ( 160 mg ), which was initiated due to an acute exacerbation of Crohn's disease, the patient developed a fulminant cardiomyopathy. |
| 0.9925 | One week after the initial - dose of adalimumab ( 160 mg ), which was initiated due to an acute exacerbation of Crohn's disease, the patient developed a Adverse-Effectfulminant cardiomyopathy . |
| Score | Text |
|---|---|
| 0.9961 | Because there were no other obvious causes of renal failure in either patient, we propose that skeletal muscle ischemia developed during Drugvasopressin infusion, followed by release of myoglobin and renal damage. |
| 0.9856 | Because there were no other obvious causes of renal failure in either patient, we propose that Adverse-Effectskeletal muscle ischemia developed during vasopressin infusion, followed by release of myoglobin and renal damage. |
| 0.8323 | Because there were no other obvious causes of renal failure in either patient, we propose that skeletal muscle ischemia developed during vasopressin infusion, followed by release of myoglobin and Adverse-Effectrenal damage . |
| 0.6772 | Because there were no other obvious causes of Adverse-Effectrenal failure in either patient, we propose that skeletal muscle ischemia developed during vasopressin infusion, followed by release of myoglobin and renal damage. |
| 0.5440 | Because there were no other obvious causes of renal failure in either patient, we propose that skeletal muscle ischemia developed during vasopressin infusion, followed by release of Drugmyoglobin and renal damage. |
| Score | Text |
|---|---|
| 0.9992 | The authors describe a case of valvular heart disease in a 48 - year - old woman receiving Drugbenfluorex ( 150 mg t. i. d. for 8 years ) and leading to surgical mitral valve replacement. |
| 0.9897 | The authors describe a case of Adverse-Effectvalvular heart disease in a 48 - year - old woman receiving benfluorex ( 150 mg t. i. d. for 8 years ) and leading to surgical mitral valve replacement. |
| Score | Text |
|---|---|
| 0.9996 | CD20 - negative T - cell - rich B - cell lymphoma as a progression of a nodular lymphocyte - predominant Hodgkin's lymphoma treated with Drugrituximab : a molecular analysis using laser capture microdissection. |
| 0.9352 | Adverse-EffectCD20 - negative T - cell - rich B - cell lymphoma as a progression of a nodular lymphocyte - predominant Hodgkin's lymphoma treated with rituximab : a molecular analysis using laser capture microdissection. |
| Score | Text |
|---|---|
| 0.9991 | A 65 - year - old man on Drugwarfarin therapy with a sudden spontaneous onset of sub - conjunctival haematoma associated with bloody tears was assessed in the clinic following a referral from an optometrist. |
| 0.9917 | A 65 - year - old man on warfarin therapy with a sudden spontaneous onset of sub - conjunctival haematoma associated with Adverse-Effectbloody tears was assessed in the clinic following a referral from an optometrist. |
| 0.9752 | A 65 - year - old man on warfarin therapy with a sudden spontaneous onset of Adverse-Effectsub - conjunctival haematoma associated with bloody tears was assessed in the clinic following a referral from an optometrist. |
| Score | Text |
|---|---|
| 0.9929 | We describe the clinical response, as determined by increases in total Hb and decreased transfusion needs, in five patients with thalassemia intermedia treated with DrugHU alone or in combination with SPB. |
| 0.9903 | We describe the clinical response, as determined by increases in total Hb and decreased transfusion needs, in five patients with thalassemia intermedia treated with HU alone or in combination with DrugSPB . |
| 0.9841 | We describe the clinical response, as determined by Adverse-Effectincreases in total Hb and decreased transfusion needs, in five patients with thalassemia intermedia treated with HU alone or in combination with SPB. |
| 0.5968 | We describe the clinical response, as determined by increases in total Hb and Adverse-Effectdecreased transfusion needs , in five patients with thalassemia intermedia treated with HU alone or in combination with SPB. |
| Score | Text |
|---|---|
| 0.9996 | We report a 31 - year - old women with recurrent Hodgkin's lymphoma and unrecognized HMSN - 1 who developed severe motor neuropathy 3 weeks after the first cycle of treatment including 2 mg of Drugvincristine . |
| 0.9866 | We report a 31 - year - old women with recurrent Hodgkin's lymphoma and unrecognized HMSN - 1 who developed Adverse-Effectsevere motor neuropathy 3 weeks after the first cycle of treatment including 2 mg of vincristine. |
| Score | Text |
|---|---|
| 0.9965 | This paper reports an autopsy case of a 78 - year - old male with multiple nodules in the liver developed after long - termed administration of phosphate diethylstilbestrol ( DrugPDES ) for prostatic cancer. |
| 0.9776 | This paper reports an autopsy case of a 78 - year - old male with multiple nodules in the liver developed after long - termed administration of Drugphosphate diethylstilbestrol ( PDES ) for prostatic cancer. |
| 0.9434 | This paper reports an autopsy case of a 78 - year - old male with Adverse-Effectmultiple nodules in the liver developed after long - termed administration of phosphate diethylstilbestrol ( PDES ) for prostatic cancer. |
| Score | Text |
|---|---|
| 0.9997 | In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement ( true thymic hyperplasia ), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under DrugEtanercept treatment. |
| 0.9987 | In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement ( true thymic hyperplasia ), mediastinal lymphadenopathy and Adverse-Effectpleurisy associated with systemic symptoms under Etanercept treatment. |
| 0.9914 | In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement ( true thymic hyperplasia ), Adverse-Effectmediastinal lymphadenopathy and pleurisy associated with systemic symptoms under Etanercept treatment. |
| 0.9895 | In this report we described a case of juvenile idiopathic arthritis patient who developed Adverse-Effectthymic enlargement ( true thymic hyperplasia ), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under Etanercept treatment. |
| 0.9810 | In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement ( true Adverse-Effectthymic hyperplasia ), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under Etanercept treatment. |
| Score | Text |
|---|---|
| 0.9981 | However, the use of Druglithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity. |
| 0.9760 | However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of Adverse-Effectcardiac toxicity . |
| 0.9744 | However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the Adverse-Effectloss of intracellular potassium , thereby increasing the risk of cardiac toxicity. |
| Score | Text |
|---|---|
| 0.9969 | CONCLUSIONS : This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects ( eg, Adverse-Effectdizziness , falls ) and mimicked coronary artery disease. |
| 0.9924 | CONCLUSIONS : This is the first report of a possible interaction between propafenone and Drugcitalopram , which caused propafenone adverse effects ( eg, dizziness, falls ) and mimicked coronary artery disease. |
| 0.9870 | CONCLUSIONS : This is the first report of a possible interaction between Drugpropafenone and citalopram, which caused propafenone adverse effects ( eg, dizziness, falls ) and mimicked coronary artery disease. |
| 0.9715 | CONCLUSIONS : This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects ( eg, dizziness, Adverse-Effectfalls ) and mimicked coronary artery disease. |
| 0.9321 | CONCLUSIONS : This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects ( eg, dizziness, falls ) and mimicked Adverse-Effectcoronary artery disease . |
| 0.9903 | CONCLUSIONS : This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects ( Adverse-Effecteg , dizziness, falls ) and mimicked coronary artery disease. |
| 0.9842 | CONCLUSIONS : This is the first report of a possible interaction between propafenone and citalopram, which caused Drugpropafenone adverse effects ( eg, dizziness, falls ) and mimicked coronary artery disease. |
| Score | Text |
|---|---|
| 0.9996 | A 61 - year - old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus ( LE ) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of Drugprocainamide therapy. |
| 0.9898 | A 61 - year - old man developed Adverse-Effectclinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus ( LE ) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy. |
| 0.9876 | A 61 - year - old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus ( LE ) cell preparation, and Adverse-Effectdiffuse proliferative glomerulonephritis following 26 months of procainamide therapy. |
| 0.9848 | A 61 - year - old man developed clinical lupus syndrome with positive antinuclear antibody, Adverse-Effectpositive lupus erythematosus ( LE ) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy. |
| 0.9777 | A 61 - year - old man developed clinical lupus syndrome with Adverse-Effectpositive antinuclear antibody , positive lupus erythematosus ( LE ) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy. |
| 0.5631 | A 61 - year - old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus ( Adverse-EffectLE ) cell preparation , and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy. |
| A 61 - year - old man developed clinical lupus syndrome with positive antinuclear antibody, positive Adverse-Effectlupus erythematosus ( LE ) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy. | |
| Score | Text |
|---|---|
| 0.9997 | This report describes a case of Drugflucytosine - associated ulcerating enteritis in which the small bowel x - ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel. |
| 0.9949 | This report describes a case of flucytosine - associated ulcerating enteritis in which the small bowel x - ray demonstrated severe luminal narrowing, Adverse-Effectulceration , and marked separation of loops of bowel. |
| 0.9912 | This report describes a case of flucytosine - associated Adverse-Effectulcerating enteritis in which the small bowel x - ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel. |
| 0.9825 | This report describes a case of flucytosine - associated ulcerating enteritis in which the small bowel x - ray demonstrated Adverse-Effectsevere luminal narrowing , ulceration, and marked separation of loops of bowel. |
| 0.9651 | This report describes a case of flucytosine - associated ulcerating enteritis in which the small bowel x - ray demonstrated severe luminal narrowing, ulceration, and Adverse-Effectmarked separation of loops of bowel . |
| Score | Text |
|---|---|
| 0.9994 | The pro - arrhythmic effects of Drugprocainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway. |
| 0.9656 | The Adverse-Effectpro - arrhythmic effects of procainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway. |
| 0.6640 | The pro - arrhythmic effects of procainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by Adverse-Effectprolongation of refractoriness in the accessory pathway . |
| Score | Text |
|---|---|
| 0.9993 | When Drugpilsicainide is prescribed in patients with coronary artery disease or renal dysfunction, close attention must be paid to avoid life - threatening arrhythmias due to high plasma concentrations of the drug. |
| 0.9646 | When pilsicainide is prescribed in patients with coronary artery disease or renal dysfunction, close attention must be paid to avoid Adverse-Effectlife - threatening arrhythmias due to high plasma concentrations of the drug. |
| Score | Text |
|---|---|
| 0.9961 | Sodium valproate and Drugcarbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce psoriasiform eruptions. |
| 0.9944 | Sodium valproate and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce Adverse-Effectpsoriasiform eruptions . |
| 0.9811 | DrugSodium valproate and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce psoriasiform eruptions. |
| Score | Text |
|---|---|
| 0.9993 | Fatal pulmonary fibrosis associated with DrugBCNU : the relative role of platelet - derived growth factor - B, insulin - like growth factor I, transforming growth factor - beta1 and cyclooxygenase - 2. |
| 0.9870 | Adverse-EffectFatal pulmonary fibrosis associated with BCNU : the relative role of platelet - derived growth factor - B, insulin - like growth factor I, transforming growth factor - beta1 and cyclooxygenase - 2. |
| Score | Text |
|---|---|
| 0.9976 | We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia ( APL ) within 10 days of treatment with DrugATRA at a dose of 40 mg orally twice daily. |
| 0.9931 | We report the development of Adverse-Effectscrotal ulcer in a patient with acute promyleocytic leukemia ( APL ) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily. |
| Score | Text |
|---|---|
| 0.9989 | We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) following systemic chemotherapy with Drugcisplatin ( CDDP ) and vindesine ( VDS ). |
| 0.9988 | We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) following systemic chemotherapy with cisplatin ( CDDP ) and Drugvindesine ( VDS ). |
| 0.9987 | We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) following systemic chemotherapy with cisplatin ( CDDP ) and vindesine ( DrugVDS ). |
| 0.9985 | We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) following systemic chemotherapy with cisplatin ( DrugCDDP ) and vindesine ( VDS ). |
| 0.9936 | We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone ( Adverse-EffectSIADH ) following systemic chemotherapy with cisplatin ( CDDP ) and vindesine ( VDS ). |
| 0.9500 | We report a patient with pulmonary adenocarcinoma complicated by the Adverse-Effectsyndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) following systemic chemotherapy with cisplatin ( CDDP ) and vindesine ( VDS ). |
| Score | Text |
|---|---|
| 0.9994 | A 60 - year - old white man with chronic bronchitis was noted to develop acute respiratory failure and metabolic acidosis four days after being started on Drugmethazolamide ( Neptazane ) for an ophthalmologic problem. |
| 0.9993 | A 60 - year - old white man with chronic bronchitis was noted to develop acute respiratory failure and metabolic acidosis four days after being started on methazolamide ( DrugNeptazane ) for an ophthalmologic problem. |
| 0.9922 | A 60 - year - old white man with chronic bronchitis was noted to develop acute respiratory failure and Adverse-Effectmetabolic acidosis four days after being started on methazolamide ( Neptazane ) for an ophthalmologic problem. |
| 0.9914 | A 60 - year - old white man with chronic bronchitis was noted to develop Adverse-Effectacute respiratory failure and metabolic acidosis four days after being started on methazolamide ( Neptazane ) for an ophthalmologic problem. |
| Score | Text |
|---|---|
| 0.9992 | METHODS : A 76 - year - old woman with primary open - angle glaucoma and no history of ocular surgery developed a choroidal detachment 12 hours after initiation of therapy with Drugdorzolamide eye drops. |
| 0.9952 | METHODS : A 76 - year - old woman with primary open - angle glaucoma and no history of ocular surgery developed a Adverse-Effectchoroidal detachment 12 hours after initiation of therapy with dorzolamide eye drops. |
| Score | Text |
|---|---|
| 0.9938 | This case report describes an adolescent with severe lupus erythematosus who received Drugcyclophosphamide ( CY ) paired with taste ( cod liver oil ) and smell ( rose perfume ) as conditioned stimuli. |
| 0.9708 | This case report describes an adolescent with severe lupus erythematosus who received cyclophosphamide ( DrugCY ) paired with taste ( cod liver oil ) and smell ( rose perfume ) as conditioned stimuli. |
| 0.8589 | This case report describes an adolescent with Adverse-Effectsevere lupus erythematosus who received cyclophosphamide ( CY ) paired with taste ( cod liver oil ) and smell ( rose perfume ) as conditioned stimuli. |
| 0.6009 | This case report describes an adolescent with severe Adverse-Effectlupus erythematosus who received cyclophosphamide ( CY ) paired with taste ( cod liver oil ) and smell ( rose perfume ) as conditioned stimuli. |
| Score | Text |
|---|---|
| 0.9978 | Adverse-EffectARDS has been associated with the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines. |
| 0.9958 | ARDS has been associated with the administration of other monoclonal antibodies, such as Druginfliximab , gemtuzumab ozogamicin, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines. |
| 0.9906 | ARDS has been associated with the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and DrugOKT3 and is believed to be directly mediated by release of proinflammatory cytokines. |
| 0.9767 | ARDS has been associated with the administration of other monoclonal antibodies, such as infliximab, Druggemtuzumab ozogamicin , and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines. |
| Score | Text |
|---|---|
| 0.9995 | Well - differentiated endometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion occurred in a postmenopausal patient on Drugtamoxifen therapy 5 years after mastectomy for breast carcinoma. |
| 0.9743 | Well - differentiated Adverse-Effectendometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma. |
| Score | Text |
|---|---|
| 0.9810 | A case of severe acute hepatitis caused by Drugcyproterone acetate in a 71 year old man with prostatic carcinoma is reported with a review of the literature on hepatic reactions to this drug. |
| 0.9629 | A case of Adverse-Effectsevere acute hepatitis caused by cyproterone acetate in a 71 year old man with prostatic carcinoma is reported with a review of the literature on hepatic reactions to this drug. |
| Score | Text |
|---|---|
| 0.9988 | We report the case of an 11 - year - old female treated for mediastinal T - cell lymphoma who presented renal failure following the second cycle of high - dose Drugmethotrexate ( HDMTX ). |
| 0.9982 | We report the case of an 11 - year - old female treated for mediastinal T - cell lymphoma who presented renal failure following the second cycle of high - dose methotrexate ( DrugHDMTX ). |
| 0.9925 | We report the case of an 11 - year - old female treated for mediastinal T - cell lymphoma who presented Adverse-Effectrenal failure following the second cycle of high - dose methotrexate ( HDMTX ). |
| Score | Text |
|---|---|
| 0.9893 | Since ethambutol is actively excreted via the renal system, compromise of renal function such as due to renal tuberculosis may lead to serum concentration elevations of ethambutol sufficient to produce Adverse-Effectoptic neuropathy . |
| 0.9822 | Since Drugethambutol is actively excreted via the renal system, compromise of renal function such as due to renal tuberculosis may lead to serum concentration elevations of ethambutol sufficient to produce optic neuropathy. |
| 0.9641 | Since ethambutol is actively excreted via the renal system, compromise of renal function such as due to renal tuberculosis may lead to serum concentration elevations of Drugethambutol sufficient to produce optic neuropathy. |
| Score | Text |
|---|---|
| 0.9969 | Autopsy evidence of herpesvirus infection was found in visceral organs of four leukemic patients who had received large doses of Drugcytarabine ( cytosine arabinoside ; Ara - C ) shortly before their death. |
| 0.9906 | Autopsy evidence of Adverse-Effectherpesvirus infection was found in visceral organs of four leukemic patients who had received large doses of cytarabine ( cytosine arabinoside ; Ara - C ) shortly before their death. |
| 0.9793 | Autopsy evidence of herpesvirus infection was found in visceral organs of four leukemic patients who had received large doses of cytarabine ( cytosine arabinoside ; DrugAra - C ) shortly before their death. |
| 0.9701 | Autopsy evidence of herpesvirus infection was found in visceral organs of four leukemic patients who had received large doses of cytarabine ( Drugcytosine arabinoside ; Ara - C ) shortly before their death. |
| Score | Text |
|---|---|
| 0.9995 | We report three patients, all of whom had preexisting diabetic dyslipidemia, who showed a profound reduction in plasma HDL cholesterol and apolipoprotein AI levels soon after the initiation of Drugrosiglitazone therapy. |
| 0.9725 | We report three patients, all of whom had preexisting diabetic dyslipidemia, who showed a profound Adverse-Effectreduction in plasma HDL cholesterol and apolipoprotein AI levels soon after the initiation of rosiglitazone therapy. |
| Score | Text |
|---|---|
| 0.9995 | We report marked QT prolongation and torsades de pointes in a setting of flash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with Drugdofetilide for atrial fibrillation. |
| 0.9860 | We report marked QT prolongation and torsades de pointes in a setting of flash pulmonary edema resulting from Adverse-Effectacute myocardial ischemia in a patient who was being treated with dofetilide for atrial fibrillation. |
| 0.9812 | We report marked QT prolongation and Adverse-Effecttorsades de pointes in a setting of flash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with dofetilide for atrial fibrillation. |
| 0.9776 | We report marked Adverse-EffectQT prolongation and torsades de pointes in a setting of flash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with dofetilide for atrial fibrillation. |
| 0.9664 | We report marked QT prolongation and torsades de pointes in a setting of Adverse-Effectflash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with dofetilide for atrial fibrillation. |
| Score | Text |
|---|---|
| 0.9845 | CONCLUSIONS : Clinicians should be aware of a risk of Adverse-Effectserotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when metoclopramide is coadministered even in a single, conventional dose. |
| 0.9783 | CONCLUSIONS : Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or Drugvenlafaxine when metoclopramide is coadministered even in a single, conventional dose. |
| 0.9721 | CONCLUSIONS : Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving Drugsertraline or venlafaxine when metoclopramide is coadministered even in a single, conventional dose. |
| 0.9655 | CONCLUSIONS : Clinicians should be aware of a risk of serotonin syndrome with serious Adverse-Effectextrapyramidal reactions in patients receiving sertraline or venlafaxine when metoclopramide is coadministered even in a single, conventional dose. |
| 0.9423 | CONCLUSIONS : Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when Drugmetoclopramide is coadministered even in a single, conventional dose. |
| Score | Text |
|---|---|
| 0.9899 | Although both patients recovered from the colitis after the administration of vancomycin, the first case demonstrated a relapse of the Adverse-Effectcolitis after receiving a subsequent course of the same chemotherapy with cisplatin. |
| 0.9043 | Although both patients recovered from the colitis after the administration of vancomycin, the first case demonstrated a relapse of the colitis after receiving a subsequent course of the same chemotherapy with Drugcisplatin . |
| 0.9586 | Although both patients recovered from the colitis after the administration of Drugvancomycin , the first case demonstrated a relapse of the colitis after receiving a subsequent course of the same chemotherapy with cisplatin. |
| Score | Text |
|---|---|
| 0.9810 | Three nephrotic patients who had reduced renal function and active renal disease with progressive deterioration of renal function prior to the use of DrugMP developed transient renal failure following an MP pulse therapy. |
| 0.9800 | Three nephrotic patients who had reduced renal function and active renal disease with progressive deterioration of renal function prior to the use of MP developed Adverse-Effecttransient renal failure following an MP pulse therapy. |
| 0.9679 | Three nephrotic patients who had reduced renal function and active renal disease with progressive deterioration of renal function prior to the use of MP developed transient renal failure following an DrugMP pulse therapy. |
| Score | Text |
|---|---|
| 0.9997 | We discuss a patient who developed severe renal tubular dysfunction secondary to short - term therapy with DrugAmikacin , resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria. |
| 0.9980 | We discuss a patient who developed severe renal tubular dysfunction secondary to short - term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and Adverse-Effectpolyuria . |
| 0.9955 | We discuss a patient who developed severe renal tubular dysfunction secondary to short - term therapy with Amikacin, resulting in refractory hypokalemia, Adverse-Effecthypocalcemia , hypomagnesemia, metabolic alkalosis, and polyuria. |
| 0.9945 | We discuss a patient who developed severe renal tubular dysfunction secondary to short - term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, Adverse-Effecthypomagnesemia , metabolic alkalosis, and polyuria. |
| 0.9859 | We discuss a patient who developed severe renal tubular dysfunction secondary to short - term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, Adverse-Effectmetabolic alkalosis , and polyuria. |
| 0.9808 | We discuss a patient who developed Adverse-Effectsevere renal tubular dysfunction secondary to short - term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria. |
| 0.9804 | We discuss a patient who developed severe renal tubular dysfunction secondary to short - term therapy with Amikacin, resulting in Adverse-Effectrefractory hypokalemia , hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria. |
| Score | Text |
|---|---|
| 0.9992 | The most serious dental side effect of Drugbisphosphonate treatment ( particularly when it is administered intravenously ) is, paradoxically, osteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone. |
| 0.9829 | The most serious dental side effect of bisphosphonate treatment ( particularly when it is administered intravenously ) is, paradoxically, Adverse-Effectosteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone. |
| Score | Text |
|---|---|
| 0.9994 | DrugThrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy ; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient. |
| 0.9851 | Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy ; however, it is a vasospastic agent and may have been responsible for the Adverse-Effectcerebral infarctions in one patient. |
| Score | Text |
|---|---|
| 0.9970 | We suggest that Adverse-Effectsarcoidosis may develop in chronic hepatitis C patients during interferon alpha and / or ribavirin treatment, and diagnostic tests for this adverse effect should be performed during the follow - ups. |
| 0.9961 | We suggest that sarcoidosis may develop in chronic hepatitis C patients during interferon alpha and / or Drugribavirin treatment, and diagnostic tests for this adverse effect should be performed during the follow - ups. |
| 0.9885 | We suggest that sarcoidosis may develop in chronic hepatitis C patients during Druginterferon alpha and / or ribavirin treatment, and diagnostic tests for this adverse effect should be performed during the follow - ups. |
| Score | Text |
|---|---|
| 0.9921 | We postulate that gastritis caused by dexamethasone, Adverse-Effectmucositis caused by doxorubicin, and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event. |
| 0.9747 | We postulate that Adverse-Effectgastritis caused by dexamethasone, mucositis caused by doxorubicin, and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event. |
| 0.9420 | We postulate that gastritis caused by dexamethasone, mucositis caused by Drugdoxorubicin , and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event. |
| 0.7907 | We postulate that gastritis caused by Drugdexamethasone , mucositis caused by doxorubicin, and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event. |
| Score | Text |
|---|---|
| 0.9996 | We present two cases of Drugnitrofurantoin - induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis. |
| 0.9943 | We present two cases of nitrofurantoin - induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established Adverse-Effectfibrosis . |
| 0.9895 | We present two cases of nitrofurantoin - induced Adverse-Effectpulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis. |
| 0.9767 | We present two cases of nitrofurantoin - induced pulmonary toxicity in which the initial HRCT showed a Adverse-Effectwidespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis. |
| 0.9753 | We present two cases of nitrofurantoin - induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated Adverse-Effectdistortion of the lung parenchyma , thought to represent established fibrosis. |
| Score | Text |
|---|---|
| 0.9961 | OBJECTIVE : To describe a case of exacerbated mania potentially related to an interaction between lopinavir / ritonavir and valproic acid ( DrugVPA ) and propose a mechanism of action for this interaction. |
| 0.9961 | OBJECTIVE : To describe a case of exacerbated mania potentially related to an interaction between Druglopinavir / ritonavir and valproic acid ( VPA ) and propose a mechanism of action for this interaction. |
| 0.9956 | OBJECTIVE : To describe a case of exacerbated mania potentially related to an interaction between lopinavir / Drugritonavir and valproic acid ( VPA ) and propose a mechanism of action for this interaction. |
| 0.9877 | OBJECTIVE : To describe a case of exacerbated mania potentially related to an interaction between lopinavir / ritonavir and Drugvalproic acid ( VPA ) and propose a mechanism of action for this interaction. |
| 0.9824 | OBJECTIVE : To describe a case of exacerbated Adverse-Effectmania potentially related to an interaction between lopinavir / ritonavir and valproic acid ( VPA ) and propose a mechanism of action for this interaction. |
| Score | Text |
|---|---|
| 0.9853 | Transtubular potassium gradient ( TTKG ) also decreased and an inverse correlation was found between TTKG and doses of Drugphosphate ( r = - 0. 37 ; p < 0. 02 ; N = 38 ). |
| 0.8880 | Adverse-EffectTranstubular potassium gradient ( TTKG ) also decreased and an inverse correlation was found between TTKG and doses of phosphate ( r = - 0. 37 ; p < 0. 02 ; N = 38 ). |
| Score | Text |
|---|---|
| 0.9994 | The first known report of Drugquetiapine exacerbating OCS in a 43 - year - old man with obsessive - compulsive disorder ( OCD ), trichotillomania, delusional disorder and bipolar II disorder is presented. |
| 0.9273 | The first known report of quetiapine Adverse-Effectexacerbating OCS in a 43 - year - old man with obsessive - compulsive disorder ( OCD ), trichotillomania, delusional disorder and bipolar II disorder is presented. |
| Score | Text |
|---|---|
| 0.9992 | METHODS : A 79 - year - old woman being treated with Drugimiquimod 5 days per week for a nodular basal cell developed a verrucous plaque over the treatment area after 7 weeks of therapy. |
| 0.9962 | METHODS : A 79 - year - old woman being treated with imiquimod 5 days per week for a nodular basal cell developed a Adverse-Effectverrucous plaque over the treatment area after 7 weeks of therapy. |
| Score | Text |
|---|---|
| 0.9981 | CASE SUMMARY : A 57 - year - old female with cardiomyopathy and " sulfa " ( trimethoprim / sulfamethoxazole ) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of Drugfurosemide . |
| 0.9944 | CASE SUMMARY : A 57 - year - old female with cardiomyopathy and " sulfa " ( trimethoprim / sulfamethoxazole ) allergy documented as pancreatitis presented with symptoms consistent with Adverse-Effectpancreatitis after use of furosemide. |
| Score | Text |
|---|---|
| 0.9989 | We thus concluded that an excessive dose of DrugAZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis. |
| 0.9934 | We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of Adverse-Effecthemorrhagic gastritis . |
| 0.9331 | We thus concluded that an excessive dose of AZ had probably Adverse-Effectdestroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis. |
| 0.6110 | We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or Adverse-Effectthrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis. |
| We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or Adverse-Effectthrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis. | |
| Score | Text |
|---|---|
| 0.9963 | In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of Drug8 - methoxypsoralen solution as a suntanning agent. |
| 0.9841 | In this article, we present the case of a vitiligo patient who was admitted to our facility with an Adverse-Effectintense burn after the topical use of 8 - methoxypsoralen solution as a suntanning agent. |
| Score | Text |
|---|---|
| 0.9974 | A 36 - year - old man being treated with cisplatinum, vinblastine, and Drugbleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome. |
| 0.9966 | A 36 - year - old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, Adverse-Effectencephalopathy , and a partial nondominant parietal lobe syndrome. |
| 0.9964 | A 36 - year - old man being treated with cisplatinum, Drugvinblastine , and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome. |
| 0.9957 | A 36 - year - old man being treated with Drugcisplatinum , vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome. |
| 0.9721 | A 36 - year - old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense Adverse-Effectleft homonymous hemianopsia , encephalopathy, and a partial nondominant parietal lobe syndrome. |
| 0.9400 | A 36 - year - old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a Adverse-Effectpartial nondominant parietal lobe syndrome . |
| Score | Text |
|---|---|
| 0.9995 | CASE SUMMARIES : In each case, the patients were treated over 5 years with Druglovastatin and developed rhabdomyolysis that coincided with the completion of a prescribed regimen of a newer macrolide antibiotic. |
| 0.9985 | CASE SUMMARIES : In each case, the patients were treated over 5 years with lovastatin and developed Adverse-Effectrhabdomyolysis that coincided with the completion of a prescribed regimen of a newer macrolide antibiotic. |
| Score | Text |
|---|---|
| 0.9994 | Retinal abnormalities, including retinal hemorrhage and " cotton - wool " spots, often occur within the first 8 weeks in the course of Druginterferon therapy in patients with chronic hepatitis C. |
| 0.9929 | Retinal abnormalities, including Adverse-Effectretinal hemorrhage and " cotton - wool " spots, often occur within the first 8 weeks in the course of interferon therapy in patients with chronic hepatitis C. |
| 0.9910 | Adverse-EffectRetinal abnormalities , including retinal hemorrhage and " cotton - wool " spots, often occur within the first 8 weeks in the course of interferon therapy in patients with chronic hepatitis C. |
| 0.7523 | Retinal abnormalities, including retinal hemorrhage and Adverse-Effect" cotton - wool " spots , often occur within the first 8 weeks in the course of interferon therapy in patients with chronic hepatitis C. |
| 0.8342 | Retinal abnormalities, including retinal hemorrhage and " Adverse-Effectcotton - wool " spots , often occur within the first 8 weeks in the course of interferon therapy in patients with chronic hepatitis C. |
| Score | Text |
|---|---|
| 0.9987 | To date, only three cases of Adverse-Effectseizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect. |
| 0.9851 | To date, only three cases of seizures associated with Drugamphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect. |
| Score | Text |
|---|---|
| 0.9985 | DrugZolpidem ( Ambien ), a relatively new nonbenzodiazepine sedative - hypnotic, was involved in the death of a 39 - year - old obese male who was being treated for depression and insomnia. |
| 0.9971 | Zolpidem ( DrugAmbien ), a relatively new nonbenzodiazepine sedative - hypnotic, was involved in the death of a 39 - year - old obese male who was being treated for depression and insomnia. |
| 0.9915 | Zolpidem ( Ambien ), a relatively new nonbenzodiazepine sedative - hypnotic, was involved in the Adverse-Effectdeath of a 39 - year - old obese male who was being treated for depression and insomnia. |
| Score | Text |
|---|---|
| 0.9911 | A 45 - year - old woman with steroid - dependent Crohn's colitis, successfully managed with maintenance Druginfliximab infusions and methotrexate, developed a lupus - like syndrome eight months after her initial infusion. |
| 0.9905 | A 45 - year - old woman with steroid - dependent Crohn's colitis, successfully managed with maintenance infliximab infusions and Drugmethotrexate , developed a lupus - like syndrome eight months after her initial infusion. |
| 0.9890 | A 45 - year - old woman with steroid - dependent Crohn's colitis, successfully managed with maintenance infliximab infusions and methotrexate, developed a Adverse-Effectlupus - like syndrome eight months after her initial infusion. |
| Score | Text |
|---|---|
| 0.9996 | Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis ; therefore, we report 2 patients with Drugdasatinib - induced pleural effusion with complete pleural fluid analysis. |
| 0.9905 | Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis ; therefore, we report 2 patients with dasatinib - induced Adverse-Effectpleural effusion with complete pleural fluid analysis. |
| Score | Text |
|---|---|
| 0.9993 | A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of Drugcarbamazepine respectively. |
| 0.9876 | A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete Adverse-Effectright bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively. |
| Score | Text |
|---|---|
| 0.9996 | A 65 - year - old female patient presented with jaundice followed 2 days later by severe dyspnea and tachypnea which worsened when patient was lying flat, 1 week after the fourth dose of Drugadalimumab . |
| 0.9983 | A 65 - year - old female patient presented with Adverse-Effectjaundice followed 2 days later by severe dyspnea and tachypnea which worsened when patient was lying flat, 1 week after the fourth dose of adalimumab. |
| 0.9981 | A 65 - year - old female patient presented with jaundice followed 2 days later by severe dyspnea and Adverse-Effecttachypnea which worsened when patient was lying flat, 1 week after the fourth dose of adalimumab. |
| 0.9934 | A 65 - year - old female patient presented with jaundice followed 2 days later by Adverse-Effectsevere dyspnea and tachypnea which worsened when patient was lying flat, 1 week after the fourth dose of adalimumab. |
| Score | Text |
|---|---|
| 0.9990 | CASE PRESENTATION : We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative - free Drugtobramycin by inhalation, beginning at 16 months of age. |
| 0.9820 | CASE PRESENTATION : We report a patient with CF who developed recurrent eosinophilia and Adverse-Effectsevere persistent bronchospasm following repeated administration of preservative - free tobramycin by inhalation, beginning at 16 months of age. |
| 0.9650 | CASE PRESENTATION : We report a patient with CF who developed Adverse-Effectrecurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative - free tobramycin by inhalation, beginning at 16 months of age. |
| Score | Text |
|---|---|
| 0.9847 | Three patients with niacin - induced visual symptoms had Adverse-Effectcystoid maculopathy without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of visual symptoms upon discontinuation of niacin. |
| 0.9495 | Three patients with Drugniacin - induced visual symptoms had cystoid maculopathy without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of visual symptoms upon discontinuation of niacin. |
| 0.9452 | Three patients with niacin - induced Adverse-Effectvisual symptoms had cystoid maculopathy without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of visual symptoms upon discontinuation of niacin. |
| 0.9033 | Three patients with niacin - induced visual symptoms had cystoid maculopathy without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of visual symptoms upon discontinuation of Drugniacin . |
| 0.8715 | Three patients with niacin - induced visual symptoms had cystoid maculopathy without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of Adverse-Effectvisual symptoms upon discontinuation of niacin. |
| 0.8169 | Three patients with niacin - induced visual symptoms had cystoid maculopathy without leakage on Drugfluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of visual symptoms upon discontinuation of niacin. |
| Score | Text |
|---|---|
| 0.9888 | After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU - induced Adverse-Effectfulminant hepatitis . |
| 0.9728 | After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with DrugPTU - induced fulminant hepatitis. |
| 0.9277 | After an extensive review of the literature, we believe that this is the first communication of the successful use of Drugamiodarone to control hyperthyroidism in a patient with PTU - induced fulminant hepatitis. |
| Score | Text |
|---|---|
| 0.9992 | The authors present a case study of a mentally healthy man who repeatedly experienced short - lived, obsessional - like suicidal ideas and images after ingestion of the anti - fungal drug Drugketoconazole . |
| 0.9792 | The authors present a case study of a mentally healthy man who repeatedly experienced short - lived, Adverse-Effectobsessional - like suicidal ideas and images after ingestion of the anti - fungal drug ketoconazole. |
| Score | Text |
|---|---|
| 0.9955 | A 50 - year - old diabetic and hypertensive male patient is reported who had Drugticlopidine - induced marrow aplasia partially responsive to colony - stimulating factors and corticosteroids, but experienced complete recovery with cyclosporine. |
| 0.9943 | A 50 - year - old diabetic and hypertensive male patient is reported who had ticlopidine - induced Adverse-Effectmarrow aplasia partially responsive to colony - stimulating factors and corticosteroids, but experienced complete recovery with cyclosporine. |
| Score | Text |
|---|---|
| 0.9963 | In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of Druginfliximab due to an unrecognized HBs - antigen carrier state. |
| 0.9894 | In this case report, we have described a patient with Crohn's disease who developed Adverse-Effectsubfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs - antigen carrier state. |
| Score | Text |
|---|---|
| 0.9854 | Although Drugretinoic acid is well tolerated by the majority of patients with this disease, a potentially fatal complication of this kind of treatment has been reported : " the retinoic acid syndrome ". |
| 0.9839 | Although retinoic acid is well tolerated by the majority of patients with this disease, a potentially fatal complication of this kind of treatment has been reported : " the Adverse-Effectretinoic acid syndrome ". |
| 0.9687 | Although retinoic acid is well tolerated by the majority of patients with this disease, a potentially Adverse-Effectfatal complication of this kind of treatment has been reported : " the retinoic acid syndrome ". |
| Score | Text |
|---|---|
| 0.9990 | Preliminary results suggest that the higher concentrations of Drugdextrose induce increased histamine release from blood cells, and that this phenomenon is more marked in diabetic, and particularly diabetic - allergic, individuals. |
| 0.9841 | Preliminary results suggest that the higher concentrations of dextrose induce Adverse-Effectincreased histamine release from blood cells, and that this phenomenon is more marked in diabetic, and particularly diabetic - allergic, individuals. |
| Score | Text |
|---|---|
| 0.9711 | The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism ( s ) of mannitol Adverse-Effectnephrotoxicity are discussed. |
| 0.9427 | The literature is also reviewed for ARF associated with Drugmannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism ( s ) of mannitol nephrotoxicity are discussed. |
| 0.9339 | The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism ( s ) of Drugmannitol nephrotoxicity are discussed. |
| 0.8458 | The literature is also reviewed for Adverse-EffectARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism ( s ) of mannitol nephrotoxicity are discussed. |
| 0.7561 | The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism ( s ) of Adverse-Effectmannitol nephrotoxicity are discussed. |
| Score | Text |
|---|---|
| 0.9966 | INTRODUCTION : We describe the neurointensive care ( NIC ) management of a patient with severe cerebral swelling and raised intracranial pressure ( ICP ) after severe sodium valproic acid ( DrugVPA ) intoxication. |
| 0.9830 | INTRODUCTION : We describe the neurointensive care ( NIC ) management of a patient with severe cerebral swelling and Adverse-Effectraised intracranial pressure ( ICP ) after severe sodium valproic acid ( VPA ) intoxication. |
| 0.9816 | INTRODUCTION : We describe the neurointensive care ( NIC ) management of a patient with severe cerebral swelling and raised intracranial pressure ( ICP ) after severe Drugsodium valproic acid ( VPA ) intoxication. |
| 0.9752 | INTRODUCTION : We describe the neurointensive care ( NIC ) management of a patient with Adverse-Effectsevere cerebral swelling and raised intracranial pressure ( ICP ) after severe sodium valproic acid ( VPA ) intoxication. |
| Score | Text |
|---|---|
| 0.9836 | Four years after the beginning of DrugIFN therapy, he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody, and then 28 units / day of insulin injection was started. |
| 0.9808 | Four years after the beginning of IFN therapy, he acutely developed moderate hyperglycemia and Adverse-Effectsevere ketonuria with positive islet cell antibody, and then 28 units / day of insulin injection was started. |
| 0.9719 | Four years after the beginning of IFN therapy, he acutely developed Adverse-Effectmoderate hyperglycemia and severe ketonuria with positive islet cell antibody, and then 28 units / day of insulin injection was started. |
| 0.7638 | Four years after the beginning of IFN therapy, he acutely developed moderate hyperglycemia and severe ketonuria with Adverse-Effectpositive islet cell antibody , and then 28 units / day of insulin injection was started. |
| 0.6875 | Four years after the beginning of IFN therapy, he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody, and then 28 units / day of Druginsulin injection was started. |
| Score | Text |
|---|---|
| 0.9969 | Adverse-EffectARDS is rarely associated with rituximab infusion for lympho - proliferative disorders, but it should be considered by those administering rituximab, especially when a patient develops severe pulmonary symptoms soon after infusion. |
| 0.9670 | ARDS is rarely associated with Drugrituximab infusion for lympho - proliferative disorders, but it should be considered by those administering rituximab, especially when a patient develops severe pulmonary symptoms soon after infusion. |
| 0.9628 | ARDS is rarely associated with rituximab infusion for lympho - proliferative disorders, but it should be considered by those administering rituximab, especially when a patient develops Adverse-Effectsevere pulmonary symptoms soon after infusion. |
| 0.9591 | ARDS is rarely associated with rituximab infusion for lympho - proliferative disorders, but it should be considered by those administering Drugrituximab , especially when a patient develops severe pulmonary symptoms soon after infusion. |
| Score | Text |
|---|---|
| 0.9994 | However, a large case - control study included three cases of either Stevens - Johnson syndrome or toxic epidermal necrolysis associated with Drugofloxacin use, but no details of the cases were given. |
| 0.9872 | However, a large case - control study included three cases of either Stevens - Johnson syndrome or Adverse-Effecttoxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given. |
| 0.9809 | However, a large case - control study included three cases of either Adverse-EffectStevens - Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given. |
| Score | Text |
|---|---|
| 0.9992 | The reported case represents an unusual association between medication with the proton pump inhibitor Druglansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis. |
| 0.9938 | The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of Adverse-Effectcollagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis. |
| Score | Text |
|---|---|
| 0.9996 | This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of Drugetanercept therapy. |
| 0.9937 | This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of Adverse-Effectpulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy. |
| This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of Adverse-Effectpulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy. | |
| Score | Text |
|---|---|
| 0.9497 | The former patient had complained once that his visual acuity had decreased after the termination of DrugIFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased. |
| 0.9263 | The former patient had complained once that his Adverse-Effectvisual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased. |
| 0.9261 | The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his Adverse-Effectvisual acuity had decreased . |
| 0.8416 | The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during DrugIFN therapy that his visual acuity had decreased. |
| Score | Text |
|---|---|
| 0.9971 | CASE SUMMARY : A 39 - year - old white Jewish schizophrenic man treated with Drugolanzapine developed an elevated serum CK concentration with a peak concentration of 4000 IU / L ( normal < 230 ). |
| 0.9868 | CASE SUMMARY : A 39 - year - old white Jewish schizophrenic man treated with olanzapine developed an Adverse-Effectelevated serum CK concentration with a peak concentration of 4000 IU / L ( normal < 230 ). |
| Score | Text |
|---|---|
| 0.9995 | We are concerned that the macular lesion was a retinal toxic effect of Druggentamicin because of the recent description of similar lesions occurring after the inadvertent intraocular injection of massive doses of this drug. |
| 0.9919 | We are concerned that the Adverse-Effectmacular lesion was a retinal toxic effect of gentamicin because of the recent description of similar lesions occurring after the inadvertent intraocular injection of massive doses of this drug. |
| 0.5271 | We are concerned that the macular lesion was a Adverse-Effectretinal toxic effect of gentamicin because of the recent description of similar lesions occurring after the inadvertent intraocular injection of massive doses of this drug. |
| Score | Text |
|---|---|
| 0.9987 | Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on Drugphenytoin and 11. 6 % of these had blood levels in the toxic range. |
| 0.9649 | Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11. 6 % of these had Adverse-Effectblood levels in the toxic range . |
| Score | Text |
|---|---|
| 0.9802 | We describe a case of Adverse-Effectpoisoning with 3, 4 - methylenedioxymet - amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported. |
| 0.9203 | We describe a case of poisoning with Drug3, 4 - methylenedioxymet - amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported. |
| Score | Text |
|---|---|
| 0.9860 | Total blindness with a transient tonic pupillary response, Adverse-Effectdenervation supersensitivity , and abnormal visual - evoked potentials developed in a 54 - year - old man after the use of quinine sulfate for leg cramps. |
| 0.9856 | Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual - evoked potentials developed in a 54 - year - old man after the use of Drugquinine sulfate for leg cramps. |
| 0.9837 | Total blindness with a transient tonic pupillary response, denervation supersensitivity, and Adverse-Effectabnormal visual - evoked potentials developed in a 54 - year - old man after the use of quinine sulfate for leg cramps. |
| 0.9921 | Adverse-EffectTotal blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual - evoked potentials developed in a 54 - year - old man after the use of quinine sulfate for leg cramps. |
| 0.9798 | Total blindness with a Adverse-Effecttransient tonic pupillary response , denervation supersensitivity, and abnormal visual - evoked potentials developed in a 54 - year - old man after the use of quinine sulfate for leg cramps. |
| Adverse-EffectTotal blindness with a transient tonic pupillary response , denervation supersensitivity, and abnormal visual - evoked potentials developed in a 54 - year - old man after the use of quinine sulfate for leg cramps. | |
| Score | Text |
|---|---|
| 0.9985 | We report the case of a patient who developed polyserositis ( pericardial effusion, pleural effusion, and Adverse-Effectpericarditis ) after being started on clozapine, and whose symptoms remitted upon discontinuation of clozapine. |
| 0.9980 | We report the case of a patient who developed Adverse-Effectpolyserositis ( pericardial effusion, pleural effusion, and pericarditis ) after being started on clozapine, and whose symptoms remitted upon discontinuation of clozapine. |
| 0.9950 | We report the case of a patient who developed polyserositis ( pericardial effusion, pleural effusion, and pericarditis ) after being started on Drugclozapine , and whose symptoms remitted upon discontinuation of clozapine. |
| 0.9932 | We report the case of a patient who developed polyserositis ( pericardial effusion, pleural effusion, and pericarditis ) after being started on clozapine, and whose symptoms remitted upon discontinuation of Drugclozapine . |
| 0.9881 | We report the case of a patient who developed polyserositis ( Adverse-Effectpericardial effusion , pleural effusion, and pericarditis ) after being started on clozapine, and whose symptoms remitted upon discontinuation of clozapine. |
| 0.9881 | We report the case of a patient who developed polyserositis ( pericardial effusion, Adverse-Effectpleural effusion , and pericarditis ) after being started on clozapine, and whose symptoms remitted upon discontinuation of clozapine. |
| Score | Text |
|---|---|
| 0.9983 | This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of Drugnaproxen and reviews the literature on NSAID - related permanent sensorineural hearing loss. |
| 0.9892 | This article reports the case of an otherwise healthy patient who experienced permanent Adverse-Effectsensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID - related permanent sensorineural hearing loss. |
| 0.9817 | This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID - related permanent Adverse-Effectsensorineural hearing loss . |
| Score | Text |
|---|---|
| 0.9988 | Hypo - oestrogenic and anabolic / androgenic side - effects of Drugdanazol are well known by the gynaecologist and some of them are present in > 50 % of patients being treated for endometriosis. |
| 0.9810 | Adverse-EffectHypo - oestrogenic and anabolic / androgenic side - effects of danazol are well known by the gynaecologist and some of them are present in > 50 % of patients being treated for endometriosis. |
| Score | Text |
|---|---|
| 0.9994 | A 7 - year - old with congenital toxoplasmosis who took Drugpyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines. |
| 0.9993 | A 7 - year - old with congenital toxoplasmosis who took pyrimethamine and Drugsulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines. |
| 0.9990 | A 7 - year - old with congenital toxoplasmosis who took pyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, Adverse-Effectswelling , abdominal pain and transaminitis, persisting weeks after withholding medicines. |
| 0.9976 | A 7 - year - old with congenital toxoplasmosis who took pyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, Adverse-Effectabdominal pain and transaminitis, persisting weeks after withholding medicines. |
| 0.9970 | A 7 - year - old with congenital toxoplasmosis who took pyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and Adverse-Effecttransaminitis , persisting weeks after withholding medicines. |
| 0.9923 | A 7 - year - old with congenital toxoplasmosis who took pyrimethamine and sulfadiazine for reactivated chorioretinitis developed Adverse-Effectfever , severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines. |
| 0.9885 | A 7 - year - old with congenital toxoplasmosis who took pyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever, Adverse-Effectsevere cutaneous involvement , swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines. |
| Score | Text |
|---|---|
| 0.9945 | The case reported here is of a child given a large dose of intravenous Drugiron sucrose ( 16 mg / kg ) over 3 hours, who subsequently developed features of systemic iron toxicity. |
| 0.9828 | The case reported here is of a child given a large dose of intravenous iron sucrose ( 16 mg / kg ) over 3 hours, who subsequently developed features of Adverse-Effectsystemic iron toxicity . |
| Score | Text |
|---|---|
| 0.9994 | The first patient was a 61 - year - old man with a 30 - year history of fistulizing CD in whom B - cell non - Hodgkin's lymphoma was diagnosed 9 months after treatment with Druginfliximab . |
| 0.9731 | The first patient was a 61 - year - old man with a 30 - year history of fistulizing CD in whom Adverse-EffectB - cell non - Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab. |
| Score | Text |
|---|---|
| 0.9994 | The authors report a case of focal myocardial necrosis, presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug, Drugamsacrine , in a patient without coronary artery disease. |
| 0.9880 | The authors report a case of Adverse-Effectfocal myocardial necrosis , presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug, amsacrine, in a patient without coronary artery disease. |
| 0.9722 | The authors report a case of focal myocardial necrosis, presenting clinically as an Adverse-Effectacute myocardial infarction during the administration of the antineoplastic drug, amsacrine, in a patient without coronary artery disease. |
| Score | Text |
|---|---|
| 0.9993 | OBJECTIVE : The authors described a case of Druginterferon - induced psychosis as a framework to review the literature and discuss the decision to pursue antiviral treatment in psychiatrically ill patients with hepatitis C. |
| 0.9987 | OBJECTIVE : The authors described a case of interferon - induced Adverse-Effectpsychosis as a framework to review the literature and discuss the decision to pursue antiviral treatment in psychiatrically ill patients with hepatitis C. |
| Score | Text |
|---|---|
| 0.9949 | Although gabapentin withdrawal has been previously reported and usually consists of anxiety, Adverse-Effectdiaphoresis , and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal. |
| 0.9937 | Although gabapentin withdrawal has been previously reported and usually consists of Adverse-Effectanxiety , diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal. |
| 0.9895 | Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with Adverse-Effectgeneralized seizures and status epilepticus secondary to gabapentin withdrawal. |
| 0.9756 | Although Druggabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal. |
| 0.9624 | Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to Druggabapentin withdrawal. |
| 0.9586 | Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and Adverse-Effectpalpitations , this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal. |
| 0.8399 | Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and Adverse-Effectstatus epilepticus secondary to gabapentin withdrawal. |
| Score | Text |
|---|---|
| 0.9994 | The possibility of deep vein thrombosis caused by the compression of the veins by necrotic tumor should be considered in patients with abdominal or pelvic metastases of GIST, including patients treated with Drugimatinib . |
| 0.9865 | The possibility of Adverse-Effectdeep vein thrombosis caused by the compression of the veins by necrotic tumor should be considered in patients with abdominal or pelvic metastases of GIST, including patients treated with imatinib. |
| 0.7946 | The possibility of deep vein thrombosis caused by the Adverse-Effectcompression of the veins by necrotic tumor should be considered in patients with abdominal or pelvic metastases of GIST, including patients treated with imatinib. |
| Score | Text |
|---|---|
| 0.9972 | Though Adverse-Effectproteinuria and nephrotic syndrome is a rare adverse effect of IFN - beta - 1b therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings. |
| 0.9940 | Though proteinuria and Adverse-Effectnephrotic syndrome is a rare adverse effect of IFN - beta - 1b therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings. |
| 0.9705 | Though proteinuria and nephrotic syndrome is a rare adverse effect of DrugIFN - beta - 1b therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings. |
| Score | Text |
|---|---|
| 0.9977 | Possible mechanisms by which clonidine decreases spasticity are described, probable mechanisms of induced Adverse-Effectbradycardia are reviewed, and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented. |
| 0.9750 | Possible mechanisms by which Drugclonidine decreases spasticity are described, probable mechanisms of induced bradycardia are reviewed, and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented. |
| 0.9295 | Possible mechanisms by which clonidine decreases spasticity are described, probable mechanisms of induced bradycardia are reviewed, and specific treatment recommendations for the use of Drugclonidine in spinal cord injured patients are presented. |
| Score | Text |
|---|---|
| 0.9967 | None of them had a history of cardiac disease, and with the possible exception of one case of cardiac arrest, where the patient received Drugdoxorubicin , no predisposing factors could be found. |
| 0.9952 | None of them had a history of cardiac disease, and with the possible exception of one case of Adverse-Effectcardiac arrest , where the patient received doxorubicin, no predisposing factors could be found. |
| Score | Text |
|---|---|
| 0.9990 | Interestingly, the use of carboplatin ( CBDCA ) and VDS in the subsequent treatment course was well tolerated indicating that the SIADH was most likely to have been induced by administration of DrugCDDP . |
| 0.9972 | Interestingly, the use of carboplatin ( CBDCA ) and VDS in the subsequent treatment course was well tolerated indicating that the Adverse-EffectSIADH was most likely to have been induced by administration of CDDP. |
| Score | Text |
|---|---|
| 0.9696 | A woman 38 - year - old, suffering for about ten years from multiple sclerosis and treated with repeated therapy cycles of intrathecal DrugDepo - Medrol , developed a spastic paraparesis at the lower limbs. |
| 0.9069 | A woman 38 - year - old, suffering for about ten years from multiple sclerosis and treated with repeated therapy cycles of intrathecal Depo - Medrol, developed a Adverse-Effectspastic paraparesis at the lower limbs . |
| Score | Text |
|---|---|
| 0.9949 | We describe a patient with acute myeloblastic leukemia ( AML ) who developed Adverse-Effectnephrotic syndrome after receiving several courses of chemotherapy, including macrophage - colony - stimulating factor ( M - CSF ). |
| 0.9580 | We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy, including macrophage - colony - stimulating factor ( DrugM - CSF ). |
| 0.9563 | We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy, including Drugmacrophage - colony - stimulating factor ( M - CSF ). |
| Score | Text |
|---|---|
| 0.9987 | Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take Drugquinine for night leg cramps. |
| 0.9410 | Only after three subsequent episodes of severe, symptomatic Adverse-Effectthrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps. |
| Score | Text |
|---|---|
| 0.9993 | DrugCaptopril is an angiotensin - converting enzyme ( ACE ) inhibitor and their cutaneous side - effects are documented, but little has been published concerning the usefulness of patch test when they occur. |
| 0.9734 | Captopril is an angiotensin - converting enzyme ( ACE ) inhibitor and their Adverse-Effectcutaneous side - effects are documented, but little has been published concerning the usefulness of patch test when they occur. |
| Score | Text |
|---|---|
| 0.9985 | Slow acetylators, who comprise roughly 50 % of the South African population, are likely to develop clinical and biochemical features of Drugphenytoin toxicity when this drug is given together with antituberculosis therapy. |
| 0.9449 | Slow acetylators, who comprise roughly 50 % of the South African population, are likely to develop clinical and biochemical features of Adverse-Effectphenytoin toxicity when this drug is given together with antituberculosis therapy. |
| Score | Text |
|---|---|
| 0.9995 | During intravenous treatment with Drugterlipressin for recurrent gastrointestinal ( GI ) bleeding, a 50 - year - old male with no history of heart disease developed a newly prolonged QT interval and torsade de pointes. |
| 0.9839 | During intravenous treatment with terlipressin for recurrent gastrointestinal ( GI ) bleeding, a 50 - year - old male with no history of heart disease developed a newly prolonged QT interval and Adverse-Effecttorsade de pointes . |
| 0.9837 | During intravenous treatment with terlipressin for recurrent gastrointestinal ( GI ) bleeding, a 50 - year - old male with no history of heart disease developed a newly Adverse-Effectprolonged QT interval and torsade de pointes. |
| Score | Text |
|---|---|
| 0.9994 | OBJECTIVE : To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis ( AIN ) due to Drugpantoprazole . |
| 0.9805 | OBJECTIVE : To describe what is believed, as of November 4, 2003, to be the first case published in the literature of Adverse-Effectacute interstitial nephritis ( AIN ) due to pantoprazole. |
| 0.9896 | OBJECTIVE : To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis ( Adverse-EffectAIN ) due to pantoprazole. |
| Score | Text |
|---|---|
| 0.9833 | A 33 - year - old male presented with Adverse-Effectbrown discolouration of the fingernails following the application of 4 % hydroquinone in sorbolene cream and 0. 1 % tretinoin cream to the face intermittently for 9 months. |
| 0.9158 | A 33 - year - old male presented with brown discolouration of the fingernails following the application of Drug4 % hydroquinone in sorbolene cream and 0. 1 % tretinoin cream to the face intermittently for 9 months. |
| 0.7524 | A 33 - year - old male presented with brown discolouration of the fingernails following the application of 4 % hydroquinone in sorbolene cream and Drug0. 1 % tretinoin cream to the face intermittently for 9 months. |
| A 33 - year - old male presented with brown discolouration of the fingernails following the application of 4 % hydroquinone in sorbolene cream and Drug0. 1 % tretinoin cream to the face intermittently for 9 months. | |
| Score | Text |
|---|---|
| 0.9944 | CONCLUSION : This report describes a case of a probable interaction between topical Drugeconazole lotion 1 % and acenocoumarol that resulted in overanticoagulation and a life - threatening laryngeal hematoma in this elderly patient. |
| 0.9931 | CONCLUSION : This report describes a case of a probable interaction between topical econazole lotion 1 % and Drugacenocoumarol that resulted in overanticoagulation and a life - threatening laryngeal hematoma in this elderly patient. |
| 0.9593 | CONCLUSION : This report describes a case of a probable interaction between topical econazole lotion 1 % and acenocoumarol that resulted in overanticoagulation and a life - threatening Adverse-Effectlaryngeal hematoma in this elderly patient. |
| 0.9815 | CONCLUSION : This report describes a case of a probable interaction between topical econazole lotion 1 % and acenocoumarol that resulted in Adverse-Effectoveranticoagulation and a life - threatening laryngeal hematoma in this elderly patient. |
| Score | Text |
|---|---|
| 0.9986 | CASE REPORT : We report a patient who developed a DAT - positive hemolytic episode after a red cell ( RBC ) transfusion was delivered during the infusion of her 17th cycle of Drugoxaliplatin . |
| 0.9819 | CASE REPORT : We report a patient who developed a Adverse-EffectDAT - positive hemolytic episode after a red cell ( RBC ) transfusion was delivered during the infusion of her 17th cycle of oxaliplatin. |
| Score | Text |
|---|---|
| 0.9995 | We report the case of a patient with the acquired immunodeficiency syndrome treated with Drugrifampicin who had a'normal'screening test for adrenal insufficiency, yet had clinical evidence of adrenal failure. |
| 0.9897 | We report the case of a patient with the acquired immunodeficiency syndrome treated with rifampicin who had a'normal'screening test for adrenal insufficiency, yet had clinical evidence of Adverse-Effectadrenal failure . |
| Score | Text |
|---|---|
| 0.9987 | Adverse-EffectParaplegia following prophylactic intrathecal cytosine arabinoside ( Ara - C ) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg / m2 / d for 5 consecutive days. |
| 0.9844 | Paraplegia following prophylactic intrathecal Drugcytosine arabinoside ( Ara - C ) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg / m2 / d for 5 consecutive days. |
| 0.9814 | Paraplegia following prophylactic intrathecal cytosine arabinoside ( DrugAra - C ) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg / m2 / d for 5 consecutive days. |
| Score | Text |
|---|---|
| 0.9985 | Infants are particularly susceptible to chronic nitrate - induced Adverse-Effectmethemoglobinemia because of their low stomach acid production, large numbers of nitrite - reducing bacteria, and the relatively easy oxidation of fetal hemoglobin. |
| 0.9895 | Infants are particularly susceptible to chronic Drugnitrate - induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite - reducing bacteria, and the relatively easy oxidation of fetal hemoglobin. |
| 0.5902 | Infants are particularly susceptible to chronic nitrate - induced methemoglobinemia because of their low stomach acid production, large numbers of Drugnitrite - reducing bacteria, and the relatively easy oxidation of fetal hemoglobin. |
| Score | Text |
|---|---|
| 0.9810 | In this study, we report on three individual patients who received BTX - B and who subsequently developed Adverse-Effectparasympathetic dysfunction of the visual system after injections of BTX - B at remote sites. |
| 0.9733 | In this study, we report on three individual patients who received DrugBTX - B and who subsequently developed parasympathetic dysfunction of the visual system after injections of BTX - B at remote sites. |
| 0.9658 | In this study, we report on three individual patients who received BTX - B and who subsequently developed parasympathetic dysfunction of the visual system after injections of DrugBTX - B at remote sites. |
| Score | Text |
|---|---|
| 0.9978 | Reversible valproic acid - induced Adverse-Effectdementia was documented in a 21 - year - old man with epilepsy who had a 3 - year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies. |
| 0.9842 | Reversible Drugvalproic acid - induced dementia was documented in a 21 - year - old man with epilepsy who had a 3 - year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies. |
| Score | Text |
|---|---|
| 0.9995 | We report on a patient with subarachnoid haemorrhage who developed an acute life - threatening pseudo - obstruction of the colon, a variant of adynamic ileus, while being treated with intravenous Drugnimodipine . |
| 0.9866 | We report on a patient with subarachnoid haemorrhage who developed an acute life - threatening pseudo - obstruction of the colon, a variant of Adverse-Effectadynamic ileus , while being treated with intravenous nimodipine. |
| 0.9563 | We report on a patient with subarachnoid haemorrhage who developed an acute life - threatening Adverse-Effectpseudo - obstruction of the colon , a variant of adynamic ileus, while being treated with intravenous nimodipine. |
| Score | Text |
|---|---|
| 0.9989 | Although high - dose Drugmethotrexate has been shown to be useful in the treatment of primary osteogenic sarcoma, the tumoricidal effects of therapy appear to have caused a fatal rise in intracranial pressure. |
| 0.9825 | Although high - dose methotrexate has been shown to be useful in the treatment of primary osteogenic sarcoma, the tumoricidal effects of therapy appear to have caused a Adverse-Effectfatal rise in intracranial pressure . |
| Score | Text |
|---|---|
| 0.9992 | Five and one - half years after the diagnosis of myeloma, while in remission on Drugcyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma. |
| 0.9652 | Five and one - half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe Adverse-Effectabdominal right lower quadrant pain due to a large cecal lymphoma. |
| 0.9526 | Five and one - half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large Adverse-Effectcecal lymphoma . |
| 0.8321 | Five and one - half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced Adverse-Effectsevere abdominal right lower quadrant pain due to a large cecal lymphoma. |
| Score | Text |
|---|---|
| 0.9996 | We describe the exceptional development of AML and lung cancer in a patient with previously diagnosed CLL in minimal residual disease status after Drugfludarabine treatment followed by autologous peripheral blood stem - cell transplantation. |
| 0.9986 | We describe the exceptional development of Adverse-EffectAML and lung cancer in a patient with previously diagnosed CLL in minimal residual disease status after fludarabine treatment followed by autologous peripheral blood stem - cell transplantation. |
| 0.9957 | We describe the exceptional development of AML and Adverse-Effectlung cancer in a patient with previously diagnosed CLL in minimal residual disease status after fludarabine treatment followed by autologous peripheral blood stem - cell transplantation. |
| Score | Text |
|---|---|
| 0.9930 | Three of these patients had convulsions attributed to imipenem / cilastatin ; 3. 6 % of the patients had Adverse-Effectseizure , or 2 % of imipenem / cilastatin administrations was followed by a seizure attack. |
| 0.9735 | Three of these patients had Adverse-Effectconvulsions attributed to imipenem / cilastatin ; 3. 6 % of the patients had seizure, or 2 % of imipenem / cilastatin administrations was followed by a seizure attack. |
| 0.9703 | Three of these patients had convulsions attributed to imipenem / Drugcilastatin ; 3. 6 % of the patients had seizure, or 2 % of imipenem / cilastatin administrations was followed by a seizure attack. |
| 0.9473 | Three of these patients had convulsions attributed to Drugimipenem / cilastatin ; 3. 6 % of the patients had seizure, or 2 % of imipenem / cilastatin administrations was followed by a seizure attack. |
| 0.9295 | Three of these patients had convulsions attributed to imipenem / cilastatin ; 3. 6 % of the patients had seizure, or 2 % of imipenem / Drugcilastatin administrations was followed by a seizure attack. |
| 0.9275 | Three of these patients had convulsions attributed to imipenem / cilastatin ; 3. 6 % of the patients had seizure, or 2 % of imipenem / cilastatin administrations was followed by a Adverse-Effectseizure attack. |
| 0.8937 | Three of these patients had convulsions attributed to imipenem / cilastatin ; 3. 6 % of the patients had seizure, or 2 % of Drugimipenem / cilastatin administrations was followed by a seizure attack. |
| 0.8805 | Three of these patients had convulsions attributed to imipenem / cilastatin ; 3. 6 % of the patients had seizure, or 2 % of imipenem / cilastatin administrations was followed by a Adverse-Effectseizure attack . |
| Score | Text |
|---|---|
| 0.9995 | Since elevated cortisol levels in Cushing's disease poses a threat for pancreatitis, there is a possibility that patients with Cushing's disease might be more prone to acute pancreatitis following Drugpropofol administration. |
| 0.9314 | Since elevated cortisol levels in Cushing's disease poses a threat for pancreatitis, there is a possibility that patients with Cushing's disease might be more prone to Adverse-Effectacute pancreatitis following propofol administration. |
| 0.7611 | Since elevated cortisol levels in Cushing's disease poses a threat for Adverse-Effectpancreatitis , there is a possibility that patients with Cushing's disease might be more prone to acute pancreatitis following propofol administration. |
| Score | Text |
|---|---|
| 0.9968 | We report a case of torsade de pointes following a single oral dose of Drugamiodarone ( 1400 mg or 30 mg kg - 1 ) administered after short intravenous loading for prevention of paroxysmal atrial flutter. |
| 0.9872 | We report a case of Adverse-Effecttorsade de pointes following a single oral dose of amiodarone ( 1400 mg or 30 mg kg - 1 ) administered after short intravenous loading for prevention of paroxysmal atrial flutter. |
| Score | Text |
|---|---|
| 0.9993 | Eighty - two patients with various malignancies who received imipenem / Drugcilastatin 143 times for neutropenic fever between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified. |
| 0.9993 | Eighty - two patients with various malignancies who received Drugimipenem / cilastatin 143 times for neutropenic fever between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified. |
| 0.9729 | Eighty - two patients with various malignancies who received imipenem / cilastatin 143 times for Adverse-Effectneutropenic fever between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified. |
| Score | Text |
|---|---|
| 0.9979 | A 36 - y - o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became Adverse-Effectdelirious and was admitted to a psychiatric hospital. |
| 0.9851 | A 36 - y - o patient with schizophrenia, who had consumed gradually increasing quantities of Drugoolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital. |
| Score | Text |
|---|---|
| 0.9996 | In this report, two cases of ET which evolved into AL without prior exposure to radiation or alkylating agents, and which were treated with long - term Drughydroxyurea therapy, are described. |
| 0.9908 | In this report, two cases of ET which evolved into Adverse-EffectAL without prior exposure to radiation or alkylating agents, and which were treated with long - term hydroxyurea therapy, are described. |
| 0.9448 | In this report, two cases of Adverse-EffectET which evolved into AL without prior exposure to radiation or alkylating agents, and which were treated with long - term hydroxyurea therapy, are described. |
| Score | Text |
|---|---|
| 0.9980 | Animals treated with DrugHAL showed a highly significant 32 % - 46 % loss of tyrosine hydroxylase ( TH ) immunoreactive neurons in the substantia nigra, and 20 % contraction of the TH stained dendritic arbour. |
| 0.8830 | Animals treated with HAL showed a highly significant 32 % - 46 % Adverse-Effectloss of tyrosine hydroxylase ( TH ) immunoreactive neurons in the substantia nigra, and 20 % contraction of the TH stained dendritic arbour. |
| 0.7269 | Animals treated with HAL showed a highly significant 32 % - 46 Adverse-Effect% loss of tyrosine hydroxylase ( TH ) immunoreactive neurons in the substantia nigra, and 20 % contraction of the TH stained dendritic arbour. |
| Animals treated with HAL showed a highly Adverse-Effectsignificant 32 % - 46 % loss of tyrosine hydroxylase ( TH ) immunoreactive neurons in the substantia nigra, and 20 % contraction of the TH stained dendritic arbour. | |
| Score | Text |
|---|---|
| 0.9984 | The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that Drugbarbiturates can be added to the list of agents which can cause submassive hepatic necrosis. |
| 0.9875 | The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that barbiturates can be added to the list of agents which can cause Adverse-Effectsubmassive hepatic necrosis . |
| Score | Text |
|---|---|
| 0.9995 | Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43 - year - old man, who was receiving long - term Drugsulfasalazine therapy for chronic ulcerative colitis. |
| 0.9984 | Adverse-EffectPneumonitis , bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43 - year - old man, who was receiving long - term sulfasalazine therapy for chronic ulcerative colitis. |
| 0.9866 | Pneumonitis, Adverse-Effectbilateral pleural effusions , echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43 - year - old man, who was receiving long - term sulfasalazine therapy for chronic ulcerative colitis. |
| 0.9847 | Pneumonitis, bilateral pleural effusions, echocardiographic evidence of Adverse-Effectcardiac tamponade , and positive autoantibodies developed in a 43 - year - old man, who was receiving long - term sulfasalazine therapy for chronic ulcerative colitis. |
| 0.9836 | Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and Adverse-Effectpositive autoantibodies developed in a 43 - year - old man, who was receiving long - term sulfasalazine therapy for chronic ulcerative colitis. |
| Score | Text |
|---|---|
| 0.9062 | The present report illustrates a rare case of refractory akathisia after Druginterferon - alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon - alpha. |
| 0.8896 | The present report illustrates a rare case of refractory akathisia after interferon - alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with Druginterferon - alpha . |
| 0.8640 | The present report illustrates a rare case of refractory akathisia after interferon - alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the Adverse-Effectneurotoxicity associated with interferon - alpha. |
| 0.8309 | The present report illustrates a rare case of refractory Adverse-Effectakathisia after interferon - alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon - alpha. |
| 0.7730 | The present report illustrates a rare case of Adverse-Effectrefractory akathisia after interferon - alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon - alpha. |
| 0.5569 | The present report illustrates a rare case of refractory akathisia after interferon - alpha treatment and also that Druglevodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon - alpha. |
| Score | Text |
|---|---|
| 0.9988 | OBJECTIVE : To report the case of a young woman with Graves'disease in whom ototoxicity developed because of Drugpropylthiouracil ( PTU ) - induced antineutrophil cytoplasmic antibody ( ANCA ) - associated vasculitis. |
| 0.9984 | OBJECTIVE : To report the case of a young woman with Graves'disease in whom ototoxicity developed because of propylthiouracil ( DrugPTU ) - induced antineutrophil cytoplasmic antibody ( ANCA ) - associated vasculitis. |
| 0.9904 | OBJECTIVE : To report the case of a young woman with Graves'disease in whom Adverse-Effectototoxicity developed because of propylthiouracil ( PTU ) - induced antineutrophil cytoplasmic antibody ( ANCA ) - associated vasculitis. |
| 0.9409 | OBJECTIVE : To report the case of a young woman with Graves'disease in whom ototoxicity developed because of propylthiouracil ( PTU ) - induced Adverse-Effectantineutrophil cytoplasmic antibody ( ANCA ) - associated vasculitis . |
| Score | Text |
|---|---|
| 0.9986 | We report the case of a 20 - year - old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of Drugivermectin . |
| 0.9912 | We report the case of a 20 - year - old woman originally from Cameroon who was infected by the L. loa parasite and developed Adverse-Effectsevere hepatitis , identified 1 month after a single dose of ivermectin. |
| Score | Text |
|---|---|
| 0.9988 | Rapamycin / sirolimus ( SR ), trade named Rapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with myelosuppression, Adverse-Effecthypertension , hyperlipidemia, and infection. |
| 0.9987 | DrugRapamycin / sirolimus ( SR ), trade named Rapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection. |
| 0.9986 | Rapamycin / sirolimus ( SR ), trade named Rapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with myelosuppression, hypertension, Adverse-Effecthyperlipidemia , and infection. |
| 0.9975 | Rapamycin / Drugsirolimus ( SR ), trade named Rapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection. |
| 0.9960 | Rapamycin / sirolimus ( SR ), trade named DrugRapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection. |
| 0.9949 | Rapamycin / sirolimus ( SR ), trade named Rapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with Adverse-Effectmyelosuppression , hypertension, hyperlipidemia, and infection. |
| 0.9882 | Rapamycin / sirolimus ( SR ), trade named Rapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and Adverse-Effectinfection . |
| Rapamycin / sirolimus ( DrugSR ), trade named Rapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection. | |
| Score | Text |
|---|---|
| 0.9926 | The main side - effects of Lp - TAE combined with HT were low - grade fever, localized pain, Adverse-Effectmyelo - suppression and liver dysfunction, but these were transient and eventually disappeared. |
| 0.9869 | The main side - effects of Lp - TAE combined with HT were low - grade fever, Adverse-Effectlocalized pain , myelo - suppression and liver dysfunction, but these were transient and eventually disappeared. |
| 0.9865 | The main side - effects of Lp - TAE combined with HT were low - grade fever, localized pain, myelo - suppression and Adverse-Effectliver dysfunction , but these were transient and eventually disappeared. |
| 0.9843 | The main side - effects of Lp - TAE combined with HT were Adverse-Effectlow - grade fever , localized pain, myelo - suppression and liver dysfunction, but these were transient and eventually disappeared. |
| 0.9744 | The main side - effects of DrugLp - TAE combined with HT were low - grade fever, localized pain, myelo - suppression and liver dysfunction, but these were transient and eventually disappeared. |
| 0.9245 | The main side - effects of Lp - TAE combined with DrugHT were low - grade fever, localized pain, myelo - suppression and liver dysfunction, but these were transient and eventually disappeared. |
| Score | Text |
|---|---|
| 0.9982 | Adverse-EffectHyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved. |
| 0.9875 | Hyperkalaemia with Adverse-Effectrenal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved. |
| 0.9608 | Hyperkalaemia with renal tubular dysfunction by oral therapy of Drugsulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved. |
| 0.9591 | Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( Drugco - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved. |
| Score | Text |
|---|---|
| 0.9900 | A young diamond dealer developed Adverse-Effectvisual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five - drug antiemetic regimen for cisplatin - associated nausea. |
| 0.9804 | A young diamond dealer developed visual impairment attributed to Adverse-Effectbilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five - drug antiemetic regimen for cisplatin - associated nausea. |
| 0.9571 | A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent DrugDecadron used as part of a five - drug antiemetic regimen for cisplatin - associated nausea. |
| 0.8132 | A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five - drug antiemetic regimen for Drugcisplatin - associated nausea. |
| A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five - drug antiemetic regimen for cisplatin - associated Adverse-Effectnausea . | |
| Score | Text |
|---|---|
| 0.9997 | A 22 - year - old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting Drugminocycline therapy for acne. |
| 0.9990 | A 22 - year - old black man developed fever, chills, Adverse-Effectfatigue , night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne. |
| 0.9981 | A 22 - year - old black man developed fever, Adverse-Effectchills , fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne. |
| 0.9915 | A 22 - year - old black man developed Adverse-Effectfever , chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne. |
| 0.9887 | A 22 - year - old black man developed fever, chills, fatigue, Adverse-Effectnight sweats , tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne. |
| 0.9528 | A 22 - year - old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a Adverse-Effectgeneralized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne. |
| 0.9927 | A 22 - year - old black man developed fever, chills, fatigue, night sweats, Adverse-Effecttender lymphadenopathy , and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne. |
| Score | Text |
|---|---|
| 0.9933 | OBJECTIVE : To report a case of chronic, nonproductive cough secondary to the angiotensin - converting enzyme ( ACE ) inhibitor Drugquinapril , with complete resolution after switching to another ACE inhibitor, fosinopril. |
| 0.9732 | OBJECTIVE : To report a case of chronic, nonproductive Adverse-Effectcough secondary to the angiotensin - converting enzyme ( ACE ) inhibitor quinapril, with complete resolution after switching to another ACE inhibitor, fosinopril. |
| 0.9727 | OBJECTIVE : To report a case of chronic, nonproductive cough secondary to the angiotensin - converting enzyme ( ACE ) inhibitor quinapril, with complete resolution after switching to another ACE inhibitor, Drugfosinopril . |
| Score | Text |
|---|---|
| 0.9972 | We have described three patients with hepatitis C for whom IFN - alpha and Drugribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by hyperthryroidism relapse due to Graves'disease. |
| 0.9934 | We have described three patients with hepatitis C for whom IFN - alpha and ribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by Adverse-Effecthyperthryroidism relapse due to Graves'disease. |
| 0.9829 | We have described three patients with hepatitis C for whom DrugIFN - alpha and ribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by hyperthryroidism relapse due to Graves'disease. |
| 0.9473 | We have described three patients with hepatitis C for whom IFN - alpha and ribavirin were prescribed and who developed two successive phases of silent Adverse-Effectthyroiditis followed by hyperthryroidism relapse due to Graves'disease. |
| 0.6484 | We have described three patients with hepatitis C for whom IFN - alpha and ribavirin were prescribed and who developed two successive phases of Adverse-Effectsilent thyroiditis followed by hyperthryroidism relapse due to Graves'disease. |
| Score | Text |
|---|---|
| 0.9966 | In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of Adverse-EffectELP should be considered in the differential diagnoses if mineral oil use has occurred. |
| 0.9931 | In patients with swallowing dysfunction and pneumonia, a history of Drugmineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred. |
| 0.9920 | In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if Drugmineral oil use has occurred. |
| 0.9604 | In patients with swallowing dysfunction and Adverse-Effectpneumonia , a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred. |
| 0.8637 | In patients with Adverse-Effectswallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred. |
| Score | Text |
|---|---|
| 0.9989 | CONCLUSIONS : Life - threatening adrenal suppression, requiring hydrocortisone supplementation and intensive therapy, was observed and successfully treated in a newborn, whose mother had received high - dose Drugmethylprednisolone in late pregnancy. |
| 0.9919 | CONCLUSIONS : Life - threatening Adverse-Effectadrenal suppression , requiring hydrocortisone supplementation and intensive therapy, was observed and successfully treated in a newborn, whose mother had received high - dose methylprednisolone in late pregnancy. |
| Score | Text |
|---|---|
| 0.9949 | We believe the temporal association of the abnormal liver enzymes in this patient, in the absence of other offending agents, argues strongly in favor of Drug6 - TG as a cause of liver enzyme abnormalities. |
| 0.9863 | We believe the temporal association of the Adverse-Effectabnormal liver enzymes in this patient, in the absence of other offending agents, argues strongly in favor of 6 - TG as a cause of liver enzyme abnormalities. |
| 0.9546 | We believe the temporal association of the abnormal liver enzymes in this patient, in the absence of other offending agents, argues strongly in favor of 6 - TG as a cause of Adverse-Effectliver enzyme abnormalities . |
| Score | Text |
|---|---|
| 0.9991 | Two patients with imminent gangrene of the extremities caused by Drugergot - induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement. |
| 0.9945 | Two patients with imminent gangrene of the extremities caused by ergot - induced Adverse-Effectarteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement. |
| 0.9390 | Two patients with imminent Adverse-Effectgangrene of the extremities caused by ergot - induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement. |
| Score | Text |
|---|---|
| 0.9995 | Patients receiving Drugamifostine who develop only fever should be evaluated for an adverse drug reaction, as well as for sepsis and fevers of neutropenia, and it may be necessary to discontinue the drug. |
| 0.9974 | Patients receiving amifostine who develop only fever should be evaluated for an adverse drug reaction, as well as for Adverse-Effectsepsis and fevers of neutropenia, and it may be necessary to discontinue the drug. |
| 0.9918 | Patients receiving amifostine who develop only Adverse-Effectfever should be evaluated for an adverse drug reaction, as well as for sepsis and fevers of neutropenia, and it may be necessary to discontinue the drug. |
| 0.9885 | Patients receiving amifostine who develop only fever should be evaluated for an adverse drug reaction, as well as for sepsis and Adverse-Effectfevers of neutropenia , and it may be necessary to discontinue the drug. |
| Score | Text |
|---|---|
| 0.9889 | Retrospectively, bucillamine was believed to be the cause of the Adverse-Effectgiant hypertrophy because of its structural similarity to D - penicillamine, which was the subject of an abundance of reports of mammary hyperplasia. |
| 0.9656 | Retrospectively, bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to DrugD - penicillamine , which was the subject of an abundance of reports of mammary hyperplasia. |
| 0.8397 | Retrospectively, bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to D - penicillamine, which was the subject of an abundance of reports of Adverse-Effectmammary hyperplasia . |
| 0.6269 | Retrospectively, Drugbucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to D - penicillamine, which was the subject of an abundance of reports of mammary hyperplasia. |
| 0.7644 | Retrospectively, bucillamine was believed to be the cause of the Adverse-Effectgiant hypertrophy because of its structural similarity to D - penicillamine, which was the subject of an abundance of reports of mammary hyperplasia. |
| 0.7590 | Retrospectively, bucillamine was believed to be the cause of the Adverse-Effectgiant hypertrophy because of its structural similarity to D - penicillamine, which was the subject of an abundance of reports of mammary hyperplasia. |
| 0.7498 | Retrospectively, bucillamine was believed to be the cause of the Adverse-Effectgiant hypertrophy because of its structural similarity to D - penicillamine, which was the subject of an abundance of reports of mammary hyperplasia. |
| 0.7281 | Retrospectively, bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to D - penicillamine, which was the subject of an abundance of reports of Drugmammary hyperplasia. |
| 0.6168 | Retrospectively, bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity Drugto D - penicillamine , which was the subject of an abundance of reports of mammary hyperplasia. |
| 0.5533 | Retrospectively, bucillamine was believed to be the cause of the Adverse-Effectgiant hypertrophy because of its structural similarity to D - penicillamine, which was the subject of an abundance of reports of mammary hyperplasia. |
| 0.5524 | Retrospectively, bucillamine was believed to be the cause of the Adverse-Effectgiant hypertrophy because of its structural similarity to D - penicillamine, which was the subject of an abundance of reports of mammary hyperplasia. |
| Score | Text |
|---|---|
| 0.9954 | Both patients were then treated with a carboplatin alternative to cisplatin in the following courses, which resulted in neither a relapse of the Adverse-Effectcolitis nor a recurrence of the malignancies up to this time. |
| 0.9635 | Both patients were then treated with a carboplatin alternative to Drugcisplatin in the following courses, which resulted in neither a relapse of the colitis nor a recurrence of the malignancies up to this time. |
| 0.9636 | Both patients were then treated with a Drugcarboplatin alternative to cisplatin in the following courses, which resulted in neither a relapse of the colitis nor a recurrence of the malignancies up to this time. |
| 0.9510 | Both patients were then treated with a carboplatin alternative to cisplatin in the following courses, which resulted in neither a relapse of the colitis nor a recurrence of the Adverse-Effectmalignancies up to this time. |
| Score | Text |
|---|---|
| 0.9991 | PURPOSE / OBJECTIVES : To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase ( DPD ) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following Drug5 - fluorouracil ( 5 - FU ) - based chemotherapy. |
| 0.9989 | PURPOSE / OBJECTIVES : To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase ( DPD ) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5 - fluorouracil ( Drug5 - FU ) - based chemotherapy. |
| 0.9603 | PURPOSE / OBJECTIVES : To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase ( DPD ) deficiency, which predisposes patients with cancer to potentially Adverse-Effectlethal adverse reactions following 5 - fluorouracil ( 5 - FU ) - based chemotherapy. |
| Score | Text |
|---|---|
| 0.9995 | The aim of this report is to describe the clinical and electroencephalographic findings seen in an elderly woman without previous history of seizures who developed a nonconvulsive generalized status epilepticus following acute withdrawal of Druglorazepam . |
| 0.9855 | The aim of this report is to describe the clinical and electroencephalographic findings seen in an elderly woman without previous history of seizures who developed a Adverse-Effectnonconvulsive generalized status epilepticus following acute withdrawal of lorazepam. |
| Score | Text |
|---|---|
| 0.9994 | A 71 - year - old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained - release Drugprocainamide ( 750 mg / day ). |
| 0.9974 | A 71 - year - old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited Adverse-Effectgranulocytopenia 8 days following the administration of oral sustained - release procainamide ( 750 mg / day ). |
| Score | Text |
|---|---|
| 0.9994 | We describe a continuous ambulatory peritoneal dialysis ( CAPD ) patient that developed Drugvancomycin - induced agranulocytosis during treatment for methicillin - resistant Staphylococcus aureus ( MRSA ) - associated external cuff infection and pneumonia. |
| 0.9967 | We describe a continuous ambulatory peritoneal dialysis ( CAPD ) patient that developed vancomycin - induced Adverse-Effectagranulocytosis during treatment for methicillin - resistant Staphylococcus aureus ( MRSA ) - associated external cuff infection and pneumonia. |
| Score | Text |
|---|---|
| 0.9993 | Although Drugisradipine has been associated with hepatocellular injury, there are no reports of fulminant liver failure with this agent, and our patient had been treated for > 2 years without signs of toxicity. |
| 0.9749 | Although isradipine has been associated with Adverse-Effecthepatocellular injury , there are no reports of fulminant liver failure with this agent, and our patient had been treated for > 2 years without signs of toxicity. |
| 0.9888 | Although isradipine has been associated with hepatocellular injury, there are no reports of Adverse-Effectfulminant liver failure with this agent, and our patient had been treated for > 2 years without signs of toxicity. |
| Score | Text |
|---|---|
| 0.9996 | We describe a patient with CREST syndrome ( calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia ) who paradoxically experienced worsening of Raynaud's phenomenon when using Drugyohimbine for ED. |
| 0.9826 | We describe a patient with CREST syndrome ( calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia ) who paradoxically experienced Adverse-Effectworsening of Raynaud's phenomenon when using yohimbine for ED. |
| Score | Text |
|---|---|
| 0.9996 | A patient is described with the characteristic features of Drugphenytoin hypersensitivity syndrome ( PHS ) including fever, erythroderma, tibial and facial oedema, pinhead - sized facial pustules and abnormal liver function tests. |
| 0.9975 | A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever, Adverse-Effecterythroderma , tibial and facial oedema, pinhead - sized facial pustules and abnormal liver function tests. |
| 0.9906 | A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including Adverse-Effectfever , erythroderma, tibial and facial oedema, pinhead - sized facial pustules and abnormal liver function tests. |
| 0.9893 | A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever, erythroderma, tibial and facial oedema, pinhead - sized facial pustules and Adverse-Effectabnormal liver function tests . |
| 0.9836 | A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever, erythroderma, tibial and facial oedema, Adverse-Effectpinhead - sized facial pustules and abnormal liver function tests. |
| 0.9707 | A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever, erythroderma, Adverse-Effecttibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests. |
| A patient is described with the characteristic features of Adverse-Effectphenytoin hypersensitivity syndrome ( PHS ) including fever, erythroderma, tibial and facial oedema, pinhead - sized facial pustules and abnormal liver function tests. | |
| Score | Text |
|---|---|
| 0.9991 | Although transient increases in ectopy after Drugbretylium therapy have been described, presumably due to catecholamine release, the occurrence of life - threatening ventricular arrhythmia leading to cardiac arrest has not previously been emphasized. |
| 0.9943 | Although transient increases in ectopy after bretylium therapy have been described, presumably due to catecholamine release, the occurrence of life - threatening ventricular arrhythmia leading to Adverse-Effectcardiac arrest has not previously been emphasized. |
| 0.9178 | Although transient increases in ectopy after bretylium therapy have been described, presumably due to catecholamine release, the occurrence of life - threatening Adverse-Effectventricular arrhythmia leading to cardiac arrest has not previously been emphasized. |
| Score | Text |
|---|---|
| 0.9980 | We report a case of Adverse-Effectpancytopenia in a 23 - year - old man with Crohn's disease who was treated with 5 - aminosalicylic acid ( Pentasa ; Nisshin, Tokyo, Japan ) 3. 0 g / day. |
| 0.9923 | We report a case of pancytopenia in a 23 - year - old man with Crohn's disease who was treated with 5 - aminosalicylic acid ( DrugPentasa ; Nisshin, Tokyo, Japan ) 3. 0 g / day. |
| 0.9805 | We report a case of pancytopenia in a 23 - year - old man with Crohn's disease who was treated with Drug5 - aminosalicylic acid ( Pentasa ; Nisshin, Tokyo, Japan ) 3. 0 g / day. |
| 0.9508 | We report a case of pancytopenia in a 23 - year - old man with Crohn's disease who was treated with 5 - aminosalicylic acid ( Pentasa ; DrugNisshin , Tokyo, Japan ) 3. 0 g / day. |
| Score | Text |
|---|---|
| 0.9984 | Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ), i. e. fluoxetine and Drugsertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ). |
| 0.9983 | Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ), i. e. Drugfluoxetine and sertraline, have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ). |
| 0.9894 | Adverse-EffectExtrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ), i. e. fluoxetine and sertraline, have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ). |
| Score | Text |
|---|---|
| 0.9995 | Because Drugetoposide - induced pulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible. |
| 0.9923 | Because etoposide - induced Adverse-Effectpulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible. |
| Score | Text |
|---|---|
| 0.9887 | Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following Drugnitrous oxide anesthesia. |
| 0.9759 | Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency developed Adverse-Effectsubacute combined degeneration of the spinal cord following nitrous oxide anesthesia. |
| Score | Text |
|---|---|
| 0.9992 | We describe a case of a man treated with an EGFR - inhibitor ( Drugerlotinib ) for a cell lung cancer who developed skin manifestations localized in an uncommon area and with an atypical evolution. |
| 0.9979 | We describe a case of a man treated with an EGFR - inhibitor ( erlotinib ) for a cell lung cancer who developed Adverse-Effectskin manifestations localized in an uncommon area and with an atypical evolution. |
| Score | Text |
|---|---|
| 0.9941 | Physicians should be cognizant of this potential complication in patients receiving thalidomide or thalidomide - like drugs who present with Adverse-Effectfever and pulmonary infiltrates and fail to improve despite treatment with broad - spectrum antibiotics. |
| 0.9925 | Physicians should be cognizant of this potential complication in patients receiving thalidomide or thalidomide - like drugs who present with fever and Adverse-Effectpulmonary infiltrates and fail to improve despite treatment with broad - spectrum antibiotics. |
| 0.9746 | Physicians should be cognizant of this potential complication in patients receiving Drugthalidomide or thalidomide - like drugs who present with fever and pulmonary infiltrates and fail to improve despite treatment with broad - spectrum antibiotics. |
| 0.9239 | Physicians should be cognizant of this potential complication in patients receiving thalidomide or Drugthalidomide - like drugs who present with fever and pulmonary infiltrates and fail to improve despite treatment with broad - spectrum antibiotics. |
| Score | Text |
|---|---|
| 0.9913 | This article describes two cases of Adverse-Effectaplastic anemia , at least one of which was almost certainly induced by the use of methazolamide, and one case of agranulocytosis related to the use of methazolamide. |
| 0.9767 | This article describes two cases of aplastic anemia, at least one of which was almost certainly induced by the use of methazolamide, and one case of Adverse-Effectagranulocytosis related to the use of methazolamide. |
| 0.9263 | This article describes two cases of aplastic anemia, at least one of which was almost certainly induced by the use of Drugmethazolamide , and one case of agranulocytosis related to the use of methazolamide. |
| 0.8911 | This article describes two cases of aplastic anemia, at least one of which was almost certainly induced by the use of methazolamide, and one case of agranulocytosis related to the use of Drugmethazolamide . |
| Score | Text |
|---|---|
| 0.9996 | Common adverse events ( frequency 10 % ) of Druglacosamide doses up to 600 mg / day include nonspecific central nervous system effects ( e. g., dizziness, ataxia, diplopia, and somnolence ). |
| 0.9988 | Common adverse events ( frequency 10 % ) of lacosamide doses up to 600 mg / day include nonspecific central nervous system effects ( e. g., dizziness, ataxia, Adverse-Effectdiplopia , and somnolence ). |
| 0.9988 | Common adverse events ( frequency 10 % ) of lacosamide doses up to 600 mg / day include nonspecific central nervous system effects ( e. g., dizziness, ataxia, diplopia, and Adverse-Effectsomnolence ). |
| 0.9986 | Common adverse events ( frequency 10 % ) of lacosamide doses up to 600 mg / day include nonspecific central nervous system effects ( e. g., Adverse-Effectdizziness , ataxia, diplopia, and somnolence ). |
| 0.9984 | Common adverse events ( frequency 10 % ) of lacosamide doses up to 600 mg / day include nonspecific central nervous system effects ( e. g., dizziness, Adverse-Effectataxia , diplopia, and somnolence ). |
| 0.7731 | Common adverse events ( frequency 10 % ) of lacosamide doses up to 600 mg / day include Adverse-Effectnonspecific central nervous system effects ( e. g., dizziness, ataxia, diplopia, and somnolence ). |
| 0.5843 | Common adverse events ( frequency 10 % ) of lacosamide doses up to 600 mg / day include nonspecific Adverse-Effectcentral nervous system effects ( e. g., dizziness, ataxia, diplopia, and somnolence ). |
| Score | Text |
|---|---|
| 0.9995 | In this healthy population, the relative risk of developing endometrial carcinoma in the Drugtamoxifen arm was 2. 54, although when stratified by age, in women over 50, the risk grew to 4. 01. |
| 0.9883 | In this healthy population, the relative risk of developing Adverse-Effectendometrial carcinoma in the tamoxifen arm was 2. 54, although when stratified by age, in women over 50, the risk grew to 4. 01. |
| Score | Text |
|---|---|
| 0.9994 | METHODS : We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with Drugleflunomide between November 1998 and January 2000. |
| 0.9938 | METHODS : We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if Adverse-Effectweight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000. |
| Score | Text |
|---|---|
| 0.9955 | A sixty - year - old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with Adverse-Effectanuria , the day after 5 g / m2 bolus ifosfamide. |
| 0.9898 | A sixty - year - old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g / m2 bolus Drugifosfamide . |
| 0.8648 | A sixty - year - old woman with advanced breast cancer, previously treated with cisplatin, developed an Adverse-Effectirreversible lethal renal failure with anuria, the day after 5 g / m2 bolus ifosfamide. |
| 0.9600 | A sixty - year - old woman with advanced breast cancer, previously treated with Drugcisplatin , developed an irreversible lethal renal failure with anuria, the day after 5 g / m2 bolus ifosfamide. |
| 0.6471 | A sixty - year - old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible Adverse-Effectlethal renal failure with anuria, the day after 5 g / m2 bolus ifosfamide. |
| Score | Text |
|---|---|
| 0.9790 | Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of Druglithium toxicity and measuring serum lithium levels every second or third day. |
| 0.9683 | Until additional data are available, if intravenous Drugacyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day. |
| 0.9379 | Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of Adverse-Effectlithium toxicity and measuring serum lithium levels every second or third day. |
| 0.9518 | Until additional data are available, if intravenous acyclovir is administered concurrently with Druglithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day. |
| Score | Text |
|---|---|
| 0.9928 | Although they had complex medical problems, the high serum concentrations of ampicillin at the time of seizures without their recurrence after discontinuing the antibiotic suggest that the seizures were related to the Drugampicillin therapy. |
| 0.9922 | Although they had complex medical problems, the high serum concentrations of ampicillin at the time of seizures without their recurrence after discontinuing the antibiotic suggest that the Adverse-Effectseizures were related to the ampicillin therapy. |
| 0.9806 | Although they had complex medical problems, the high serum concentrations of Drugampicillin at the time of seizures without their recurrence after discontinuing the antibiotic suggest that the seizures were related to the ampicillin therapy. |
| 0.8843 | Although they had complex medical problems, the high serum concentrations of ampicillin at the time of Adverse-Effectseizures without their recurrence after discontinuing the antibiotic suggest that the seizures were related to the ampicillin therapy. |
| Score | Text |
|---|---|
| 0.9994 | We present a case of an elderly woman with a pre - existing history of ischaemic heart disease, who was treated with Drugvenlafaxine , and developed acute myocardial ischaemia within the first week of treatment. |
| 0.9918 | We present a case of an elderly woman with a pre - existing history of ischaemic heart disease, who was treated with venlafaxine, and developed Adverse-Effectacute myocardial ischaemia within the first week of treatment. |
| Score | Text |
|---|---|
| 0.9995 | We report a patient with recurrent, increasingly severe episodes of PPE, ultimately complicated by a severe bullous eruption, following successive cycles of high - dose Drugcytarabine for the treatment of acute lymphoblastic leukaemia. |
| 0.9820 | We report a patient with recurrent, increasingly severe episodes of Adverse-EffectPPE , ultimately complicated by a severe bullous eruption, following successive cycles of high - dose cytarabine for the treatment of acute lymphoblastic leukaemia. |
| 0.9107 | We report a patient with recurrent, increasingly severe episodes of PPE, ultimately complicated by a severe Adverse-Effectbullous eruption , following successive cycles of high - dose cytarabine for the treatment of acute lymphoblastic leukaemia. |
| 0.9060 | We report a patient with recurrent, increasingly severe episodes of PPE, ultimately complicated by a Adverse-Effectsevere bullous eruption , following successive cycles of high - dose cytarabine for the treatment of acute lymphoblastic leukaemia. |
| Score | Text |
|---|---|
| 0.9852 | The evidence of high plasmatic levels of DrugCBZ and the absence of other aetiologic factors lead the authors to conclude that the overdose of CBZ could have represented the precipitating of the episode of acute pancreatitis. |
| 0.9837 | The evidence of high plasmatic levels of CBZ and the absence of other aetiologic factors lead the authors to conclude that the overdose of DrugCBZ could have represented the precipitating of the episode of acute pancreatitis. |
| 0.9707 | The evidence of high plasmatic levels of CBZ and the absence of other aetiologic factors lead the authors to conclude that the overdose of CBZ could have represented the precipitating of the episode of Adverse-Effectacute pancreatitis . |
| Score | Text |
|---|---|
| 0.9980 | Assessment of cortisol response was by insulin - induced Adverse-Effecthypoglycaemia in three cases, by short tetracosactrin test in two, and by low - dose tetracosactrin and 24 - hour urinary cortisol / creatinine ratio in one. |
| 0.9907 | Assessment of cortisol response was by Druginsulin - induced hypoglycaemia in three cases, by short tetracosactrin test in two, and by low - dose tetracosactrin and 24 - hour urinary cortisol / creatinine ratio in one. |
| Score | Text |
|---|---|
| 0.9992 | A case of anaphylactoid reaction due solely to the use of DrugGelofusine in a patient with non - haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery. |
| 0.9931 | A case of Adverse-Effectanaphylactoid reaction due solely to the use of Gelofusine in a patient with non - haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery. |
| Score | Text |
|---|---|
| 0.9896 | CONCLUSION : While Adverse-Effectthrombosis has been reported with GnRH - a therapy in men with prostate cancer, its association with treatment in this benign case may have been a consequence of the massive tumor size. |
| 0.9708 | CONCLUSION : While thrombosis has been reported with DrugGnRH - a therapy in men with prostate cancer, its association with treatment in this benign case may have been a consequence of the massive tumor size. |
| 0.9480 | CONCLUSION : While thrombosis has been reported with GnRH - a therapy in men with prostate cancer, its association with treatment in this benign case may have been a consequence of the Adverse-Effectmassive tumor size . |
| Score | Text |
|---|---|
| 0.9795 | Idiosyncratic factors involving vasopressin receptor affinity and distribution, vasopressin - associated vasodilation in some vascular beds, and the effect of vasopressin on the renin - angiotensin system may further contribute to Adverse-Effectimpaired tissue perfusion . |
| 0.9307 | Idiosyncratic factors involving vasopressin receptor affinity and distribution, vasopressin - associated Adverse-Effectvasodilation in some vascular beds, and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion. |
| 0.8983 | Idiosyncratic factors involving vasopressin receptor affinity and distribution, Drugvasopressin - associated vasodilation in some vascular beds, and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion. |
| 0.7965 | Idiosyncratic factors involving vasopressin receptor affinity and distribution, vasopressin - associated vasodilation in some vascular beds, and the effect of Drugvasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion. |
| Score | Text |
|---|---|
| 0.9992 | A 35 - year - old woman presented with neurotoxicity correlated to an i. v. regimen of Drug5 - fluorouracil as episodes of acute confusional state and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum. |
| 0.9966 | A 35 - year - old woman presented with Adverse-Effectneurotoxicity correlated to an i. v. regimen of 5 - fluorouracil as episodes of acute confusional state and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum. |
| 0.9662 | A 35 - year - old woman presented with neurotoxicity correlated to an i. v. regimen of 5 - fluorouracil as episodes of Adverse-Effectacute confusional state and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum. |
| Score | Text |
|---|---|
| 0.9991 | Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice - a - day application of Drugdipivefrin . |
| 0.9924 | Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of Adverse-Effectcicatricial entropion after at least 2 years of twice - a - day application of dipivefrin. |
| Score | Text |
|---|---|
| 0.9994 | DrugMethotrexate - associated nephropathy is a rare complication in pediatric oncology, and a review of the literature suggests that exposure to nephrotoxic agents may be a significant but perhaps underrecognized risk factor for its development. |
| 0.9976 | Methotrexate - associated Adverse-Effectnephropathy is a rare complication in pediatric oncology, and a review of the literature suggests that exposure to nephrotoxic agents may be a significant but perhaps underrecognized risk factor for its development. |
| Score | Text |
|---|---|
| 0.9656 | In this paper, we report a case of severe hypercalcemia of immobilization in a 40 - year - old hemodialyzed woman treated by Drugcinacalcet HCl for a severe HPTH - II ( PTH > 1, 000 pg / mL ). |
| 0.9524 | In this paper, we report a case of Adverse-Effectsevere hypercalcemia of immobilization in a 40 - year - old hemodialyzed woman treated by cinacalcet HCl for a severe HPTH - II ( PTH > 1, 000 pg / mL ). |
| Score | Text |
|---|---|
| 0.9987 | Although combinations of belladonna, Drugergotamine , and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with anticonvulsant hypersensitivity syndrome. |
| 0.9987 | Although combinations of Drugbelladonna , ergotamine, and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with anticonvulsant hypersensitivity syndrome. |
| 0.9984 | Although combinations of belladonna, ergotamine, and Drugphenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with anticonvulsant hypersensitivity syndrome. |
| 0.9887 | Although combinations of belladonna, ergotamine, and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with Adverse-Effectanticonvulsant hypersensitivity syndrome . |
| 0.7510 | Although combinations of belladonna, ergotamine, and phenobarbital have been used for medical treatment of Adverse-Effectmenopausal symptoms since the 1960s, this is the first known case report of its association with anticonvulsant hypersensitivity syndrome. |
| Score | Text |
|---|---|
| 0.9816 | OBJECTIVE : To report the occurrence of Adverse-Effectacute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole - induced hepatitis. |
| 0.9615 | OBJECTIVE : To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole - induced Adverse-Effecthepatitis . |
| 0.9457 | OBJECTIVE : To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of Drugitraconazole - induced hepatitis. |
| 0.9008 | OBJECTIVE : To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse Drugitraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole - induced hepatitis. |
| Score | Text |
|---|---|
| 0.9966 | INTRODUCTION : In resource limited settings patients on antiretroviral treatment who develop stavudine induced Adverse-Effecthyperlactatemia are often switched to zidovudine on the basis of published studies that demonstrate that this agent can be a safe alternative. |
| 0.9955 | INTRODUCTION : In resource limited settings patients on antiretroviral treatment who develop Drugstavudine induced hyperlactatemia are often switched to zidovudine on the basis of published studies that demonstrate that this agent can be a safe alternative. |
| Score | Text |
|---|---|
| 0.9996 | CONCLUSIONS : Although Drugmirtazapine offers clinicians a combination of strong efficacy and good safety, we suggest bearing SS in mind when prescribing this drug, especially in frail, elderly patients with underlying chronic conditions. |
| 0.9947 | CONCLUSIONS : Although mirtazapine offers clinicians a combination of strong efficacy and good safety, we suggest bearing Adverse-EffectSS in mind when prescribing this drug, especially in frail, elderly patients with underlying chronic conditions. |
| Score | Text |
|---|---|
| 0.9992 | The first reported case, in an adult, of Drugcholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria. |
| 0.9874 | The first reported case, in an adult, of cholestyramine induced Adverse-Effecthyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria. |
| Score | Text |
|---|---|
| 0.9855 | We have successfully overcome severe neutropenia in an RA patient treated with Druggold salts, using granulocyte colony - stimulating factor ( G - CSF ), reducing the duration of neutropenia and risk of infection. |
| 0.9778 | We have successfully overcome Adverse-Effectsevere neutropenia in an RA patient treated with gold salts, using granulocyte colony - stimulating factor ( G - CSF ), reducing the duration of neutropenia and risk of infection. |
| Score | Text |
|---|---|
| 0.9985 | We report the case of a lung cancer patient with bronquiloalveolar carcinoma ( BAC ) presenting with BOOP after chemotherapy with Drugdocetaxel and gemcitabine producing severe respiratory insufficiency, and simulating a progression of the tumor. |
| 0.9985 | We report the case of a lung cancer patient with bronquiloalveolar carcinoma ( BAC ) presenting with BOOP after chemotherapy with docetaxel and Druggemcitabine producing severe respiratory insufficiency, and simulating a progression of the tumor. |
| 0.9981 | We report the case of a lung cancer patient with bronquiloalveolar carcinoma ( BAC ) presenting with Adverse-EffectBOOP after chemotherapy with docetaxel and gemcitabine producing severe respiratory insufficiency, and simulating a progression of the tumor. |
| 0.9711 | We report the case of a lung cancer patient with bronquiloalveolar carcinoma ( BAC ) presenting with BOOP after chemotherapy with docetaxel and gemcitabine producing Adverse-Effectsevere respiratory insufficiency , and simulating a progression of the tumor. |
| 0.9681 | We report the case of a lung cancer patient with bronquiloalveolar carcinoma ( BAC ) presenting with BOOP after chemotherapy with docetaxel and gemcitabine producing severe respiratory insufficiency, and simulating a Adverse-Effectprogression of the tumor . |
| Score | Text |
|---|---|
| 0.9835 | This report details a case of Adverse-Effectbilateral avascular necrosis of the femoral heads in a patient receiving'standard'doses of dexamethasone as part of the antiemetic regimen used in cisplatin - based combination chemotherapy. |
| 0.9750 | This report details a case of bilateral avascular necrosis of the femoral heads in a patient receiving'standard'doses of Drugdexamethasone as part of the antiemetic regimen used in cisplatin - based combination chemotherapy. |
| 0.7590 | This report details a case of bilateral avascular necrosis of the femoral heads in a patient receiving'standard'doses of dexamethasone as part of the antiemetic regimen used in Drugcisplatin - based combination chemotherapy. |
| Score | Text |
|---|---|
| 0.9985 | In the present paper the authors describe 2 female patients who developed Adverse-Effectincontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine. |
| 0.9967 | In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on Drugvenlafaxine . |
| 0.9959 | In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and Drugsertraline , as well as a third who developed this side effect on venlafaxine. |
| 0.9941 | In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors Drugparoxetine and sertraline, as well as a third who developed this side effect on venlafaxine. |
| Score | Text |
|---|---|
| 0.9987 | Exacerbation of Drug5 - FU dermatologic toxicities in patients with preexisting conditions suggests the importance of aggressive ocular prophylaxis, using frequent ocular lubrication and topical steroid preparations with concurrent medical management of pre - existing dermatologic conditions. |
| 0.9518 | Exacerbation of 5 - FU Adverse-Effectdermatologic toxicities in patients with preexisting conditions suggests the importance of aggressive ocular prophylaxis, using frequent ocular lubrication and topical steroid preparations with concurrent medical management of pre - existing dermatologic conditions. |
| Score | Text |
|---|---|
| 0.9904 | In this report, two newborns with congenital heart anomalies demonstrated the Adverse-Effectharlequin color change , one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association. |
| 0.9868 | In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic Drugprostaglandin E1 , suggesting a possible association. |
| Score | Text |
|---|---|
| 0.9975 | One explanation for the noted increase in the Drugtheophylline level is that metabolism occurs mainly by cytochrome P450 ( CYP 1A2 ), an enzyme that is known to be inhibited with high concentrations of zafirlukast. |
| 0.9972 | One explanation for the noted increase in the theophylline level is that metabolism occurs mainly by cytochrome P450 ( CYP 1A2 ), an enzyme that is known to be inhibited with high concentrations of Drugzafirlukast . |
| 0.6536 | One explanation for the noted Adverse-Effectincrease in the theophylline level is that metabolism occurs mainly by cytochrome P450 ( CYP 1A2 ), an enzyme that is known to be inhibited with high concentrations of zafirlukast. |
| Score | Text |
|---|---|
| 0.9948 | With the use of optical coherence tomography ( OCT ), two patients with IFN - associated retinopathy who had developed Adverse-Effectmacular edema and reduced visual acuity during the clinical course of IFN therapy were observed. |
| 0.9931 | With the use of optical coherence tomography ( OCT ), two patients with IFN - associated Adverse-Effectretinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed. |
| 0.9920 | With the use of optical coherence tomography ( OCT ), two patients with IFN - associated retinopathy who had developed macular edema and Adverse-Effectreduced visual acuity during the clinical course of IFN therapy were observed. |
| 0.9810 | With the use of optical coherence tomography ( OCT ), two patients with DrugIFN - associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed. |
| 0.9626 | With the use of optical coherence tomography ( OCT ), two patients with IFN - associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of DrugIFN therapy were observed. |
| Score | Text |
|---|---|
| 0.9983 | A case of sideroblastic anemia is presented in a patient with a left ventricular assist device drive - line infection who was receiving Druglinezolid , an antibiotic used for serious infections with gram - positive organisms. |
| 0.9912 | A case of Adverse-Effectsideroblastic anemia is presented in a patient with a left ventricular assist device drive - line infection who was receiving linezolid, an antibiotic used for serious infections with gram - positive organisms. |
| Score | Text |
|---|---|
| 0.9989 | We introduce a case of a sixty years old woman with several previous episodes of Adverse-Effectrhinitis , conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration ( Calsynar ). |
| 0.9978 | We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and Adverse-Effectperspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration ( Calsynar ). |
| 0.9973 | We introduce a case of a sixty years old woman with several previous episodes of rhinitis, Adverse-Effectconjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration ( Calsynar ). |
| 0.9971 | We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration ( DrugCalsynar ). |
| 0.9969 | We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and perspiration immediately after the administration of salmon Drugcalcitonin with nasal spray or intramuscular administration ( Calsynar ). |
| Score | Text |
|---|---|
| 0.9995 | Videopolysomnographic and pharmacokinetic studies with monitoring of plasma Druglevodopa levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia. |
| 0.9922 | Videopolysomnographic and pharmacokinetic studies with monitoring of plasma levodopa levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with Adverse-Effectpainful dysesthesia . |
| 0.9893 | Videopolysomnographic and pharmacokinetic studies with monitoring of plasma levodopa levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and Adverse-Effectflexor spasms , associated with painful dysesthesia. |
| 0.9863 | Videopolysomnographic and pharmacokinetic studies with monitoring of plasma levodopa levels demonstrated Adverse-Effectmarked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia. |
| 0.9809 | Videopolysomnographic and pharmacokinetic studies with monitoring of plasma levodopa levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, Adverse-Effecttonic grouped discharges and flexor spasms, associated with painful dysesthesia. |
| 0.9806 | Videopolysomnographic and pharmacokinetic studies with monitoring of plasma levodopa levels demonstrated marked motor hyperactivity during augmentation, with Adverse-Effectanarchic discharges of motor unit potentials , tonic grouped discharges and flexor spasms, associated with painful dysesthesia. |
| Score | Text |
|---|---|
| 0.9989 | Currently the use of Drugzidovudine is one of the few specific measures available, and as a potentially teratogenic and fetotoxic agent, any decision for its use requires evaluation of the potential for fetal damage. |
| 0.9924 | Currently the use of zidovudine is one of the few specific measures available, and as a potentially Adverse-Effectteratogenic and fetotoxic agent, any decision for its use requires evaluation of the potential for fetal damage. |
| 0.9832 | Currently the use of zidovudine is one of the few specific measures available, and as a potentially teratogenic and fetotoxic agent, any decision for its use requires evaluation of the potential for Adverse-Effectfetal damage . |
| 0.8788 | Currently the use of zidovudine is one of the few specific measures available, and as a potentially teratogenic and Adverse-Effectfetotoxic agent, any decision for its use requires evaluation of the potential for fetal damage. |
| Score | Text |
|---|---|
| 0.9989 | A patient is presented with typical hyperthyroidism, who developed a severe proximal muscle weakness and a raised creatine phosphokinase after treatment for hyperthyroidism with Drugpropylthiouracil ( 100 mg orally, three times a day ). |
| 0.9894 | A patient is presented with typical hyperthyroidism, who developed a Adverse-Effectsevere proximal muscle weakness and a raised creatine phosphokinase after treatment for hyperthyroidism with propylthiouracil ( 100 mg orally, three times a day ). |
| 0.9891 | A patient is presented with typical hyperthyroidism, who developed a severe proximal muscle weakness and a Adverse-Effectraised creatine phosphokinase after treatment for hyperthyroidism with propylthiouracil ( 100 mg orally, three times a day ). |
| 0.8606 | A patient is presented with typical Adverse-Effecthyperthyroidism , who developed a severe proximal muscle weakness and a raised creatine phosphokinase after treatment for hyperthyroidism with propylthiouracil ( 100 mg orally, three times a day ). |
| Score | Text |
|---|---|
| 0.9885 | After a six - week course of low - dose Drugcyclosporine A , she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels. |
| 0.9701 | After a six - week course of low - dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and Adverse-Effecteffective renal plasma flow despite of low cyclosporine A plasma levels. |
| 0.9527 | After a six - week course of low - dose cyclosporine A, she developed a severe but reversible Adverse-Effectloss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels. |
| 0.8603 | After a six - week course of low - dose cyclosporine A, she developed a severe but Adverse-Effectreversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels. |
| Score | Text |
|---|---|
| 0.9996 | We suggest that the previous classification of Drugnitrofurantoin induced lung injury into " acute " and " chronic " injury is an oversimplification in view of the wide variety of pathological entities that have subsequently emerged. |
| 0.9733 | We suggest that the previous classification of nitrofurantoin induced Adverse-Effectlung injury into " acute " and " chronic " injury is an oversimplification in view of the wide variety of pathological entities that have subsequently emerged. |
| We suggest that the previous classification of Adverse-Effectnitrofurantoin induced lung injury into " acute " and " chronic " injury is an oversimplification in view of the wide variety of pathological entities that have subsequently emerged. | |
| Score | Text |
|---|---|
| 0.9904 | OBJECTIVE : To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a Adverse-Effectfatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity. |
| 0.9873 | OBJECTIVE : To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of Drugamphotericin B and to review its toxicity. |
| Score | Text |
|---|---|
| 0.9989 | The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of Drugolanzapine to metabolic changes manifested as uncontrolled diabetes mellitus and weight gain. |
| 0.9949 | The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of olanzapine to metabolic changes manifested as uncontrolled diabetes mellitus and Adverse-Effectweight gain . |
| 0.9765 | The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of olanzapine to metabolic changes manifested as Adverse-Effectuncontrolled diabetes mellitus and weight gain. |
| Score | Text |
|---|---|
| 0.9969 | We consider asterixis to be an easily overlooked sign of Adverse-Effectneurotoxicity , which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ. |
| 0.9964 | We consider Adverse-Effectasterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ. |
| 0.9940 | We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or Drugclozapine are used in combination with CBZ. |
| 0.9933 | We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with DrugCBZ . |
| 0.9886 | We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as Druglithium or clozapine are used in combination with CBZ. |
| Score | Text |
|---|---|
| 0.9827 | It was hypothesized that Drugvalproic acid may interfere with glucuronidation of lamotrigine, leading to increased serum lamotrigine levels, or perhaps alter the drug's metabolism, resulting in accumulation of a toxic intermediate metabolite. |
| 0.9764 | It was hypothesized that valproic acid may interfere with glucuronidation of lamotrigine, leading to Adverse-Effectincreased serum lamotrigine levels , or perhaps alter the drug's metabolism, resulting in accumulation of a toxic intermediate metabolite. |
| 0.9634 | It was hypothesized that valproic acid may interfere with glucuronidation of lamotrigine, leading to increased serum lamotrigine levels, or perhaps alter the drug's metabolism, resulting in Adverse-Effectaccumulation of a toxic intermediate metabolite . |
| 0.8991 | It was hypothesized that valproic acid may interfere with glucuronidation of Druglamotrigine , leading to increased serum lamotrigine levels, or perhaps alter the drug's metabolism, resulting in accumulation of a toxic intermediate metabolite. |
| Score | Text |
|---|---|
| 0.9990 | METHODS : A retrospective report of the first case of gemcitabine - related Adverse-EffectHUS , in a patient with metastatic pancreatic adenocarcinoma, treated with a variety of standard therapies in addition to rituximab is presented. |
| 0.9915 | METHODS : A retrospective report of the first case of Druggemcitabine - related HUS, in a patient with metastatic pancreatic adenocarcinoma, treated with a variety of standard therapies in addition to rituximab is presented. |
| Score | Text |
|---|---|
| 0.9990 | We present a case of HUS in an advanced ovarian cancer patient treated with carboplatin and Druggemcitabine , and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow - up. |
| 0.9988 | We present a case of Adverse-EffectHUS in an advanced ovarian cancer patient treated with carboplatin and gemcitabine, and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow - up. |
| 0.9987 | We present a case of HUS in an advanced ovarian cancer patient treated with Drugcarboplatin and gemcitabine, and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow - up. |
| Score | Text |
|---|---|
| 0.9979 | We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with Drugpiritrexim , a methotrexate analog. |
| 0.9919 | We describe a patient with transitional cell carcinoma of the renal pelvis who developed Adverse-Effectrespiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog. |
| 0.9764 | We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an Adverse-Effectabnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog. |
| 0.9954 | We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a Drugmethotrexate analog. |
| Score | Text |
|---|---|
| 0.9972 | CONCLUSIONS : The Adverse-Effectpiloerection observed after the replacement of fluvoxamine with milnacipran in this patient appears to have been due to an increase in the alpha ( 1 ) - adrenoceptor occupancy by endogenous norepinephrine induced by milnacipran. |
| 0.9329 | CONCLUSIONS : The piloerection observed after the replacement of fluvoxamine with Drugmilnacipran in this patient appears to have been due to an increase in the alpha ( 1 ) - adrenoceptor occupancy by endogenous norepinephrine induced by milnacipran. |
| 0.9269 | CONCLUSIONS : The piloerection observed after the replacement of Drugfluvoxamine with milnacipran in this patient appears to have been due to an increase in the alpha ( 1 ) - adrenoceptor occupancy by endogenous norepinephrine induced by milnacipran. |
| 0.8895 | CONCLUSIONS : The piloerection observed after the replacement of fluvoxamine with milnacipran in this patient appears to have been due to an increase in the alpha ( 1 ) - adrenoceptor occupancy by endogenous Drugnorepinephrine induced by milnacipran. |
| 0.8802 | CONCLUSIONS : The piloerection observed after the replacement of fluvoxamine with milnacipran in this patient appears to have been due to an increase in the alpha ( 1 ) - adrenoceptor occupancy by endogenous norepinephrine induced by Drugmilnacipran . |
| Score | Text |
|---|---|
| 0.9986 | In summary, we report herein the first case of SIADH believed to be an adverse effect of Drugmizoribin , which may therefore needed to be added to the list of drugs which can induce SIADH. |
| 0.9967 | In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce Adverse-EffectSIADH . |
| 0.9967 | In summary, we report herein the first case of Adverse-EffectSIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH. |
| Score | Text |
|---|---|
| 0.9829 | During the first days of Drugarsenic trioxide treatment a rapid decrease in the D - dimers was seen ( normal values reached until day 7 ), together with a slight decrease in peripheral blood leukocytes. |
| 0.9535 | During the first days of arsenic trioxide treatment a rapid Adverse-Effectdecrease in the D - dimers was seen ( normal values reached until day 7 ), together with a slight decrease in peripheral blood leukocytes. |
| 0.6664 | During the first days of arsenic trioxide treatment a rapid decrease in the D - dimers was seen ( normal values reached until day 7 ), together with a Adverse-Effectslight decrease in peripheral blood leukocytes . |
| 0.8466 | During the first days of arsenic trioxide treatment a rapid decrease in the D - dimers was seen ( normal values reached until day 7 ), together with a slight Adverse-Effectdecrease in peripheral blood leukocytes . |
| Score | Text |
|---|---|
| 0.9993 | Therefore, although Druggarenoxacin reportedly causes fewer adverse reactions for cardiac rhythms than third - generation quinolone antibiotics, one must be cautious of the interference of other drugs during hypokalemia in order to prevent TdP. |
| 0.9747 | Therefore, although garenoxacin reportedly causes fewer adverse reactions for cardiac rhythms than third - generation quinolone antibiotics, one must be cautious of the interference of other drugs during Adverse-Effecthypokalemia in order to prevent TdP. |
| 0.9475 | Therefore, although garenoxacin reportedly causes fewer adverse reactions for Adverse-Effectcardiac rhythms than third - generation quinolone antibiotics, one must be cautious of the interference of other drugs during hypokalemia in order to prevent TdP. |
| Score | Text |
|---|---|
| 0.9995 | Two children, 1 with idiopathic nephrotic syndrome and 1 with endo - extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i. v. pulse Drugmethylprednisolone ( IVPMP ) treatment. |
| 0.9986 | Two children, 1 with idiopathic nephrotic syndrome and 1 with endo - extracapillary glomerulonephritis, presented an episode of Adverse-Effectseizures and transient blindness at different times after i. v. pulse methylprednisolone ( IVPMP ) treatment. |
| 0.9934 | Two children, 1 with idiopathic nephrotic syndrome and 1 with endo - extracapillary glomerulonephritis, presented an episode of seizures and Adverse-Effecttransient blindness at different times after i. v. pulse methylprednisolone ( IVPMP ) treatment. |
| 0.9993 | Two children, 1 with idiopathic nephrotic syndrome and 1 with endo - extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i. v. pulse methylprednisolone ( DrugIVPMP ) treatment. |
| Score | Text |
|---|---|
| 0.9996 | A Drugdapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy. |
| 0.9983 | A dapsone hypersensitivity syndrome, consisting of fever, Adverse-Effectheadache , nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy. |
| 0.9980 | A dapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, Adverse-Effecthepatitis , hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy. |
| 0.9979 | A dapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, Adverse-Effectleukopenia , and mononucleosis, has been described in patients treated with the drug for leprosy. |
| 0.9976 | A dapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, Adverse-Effecthemolysis , leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy. |
| 0.9971 | A dapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and Adverse-Effectmononucleosis , has been described in patients treated with the drug for leprosy. |
| 0.9970 | A dapsone hypersensitivity syndrome, consisting of fever, headache, nausea, Adverse-Effectvomiting , lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy. |
| 0.9970 | A dapsone hypersensitivity syndrome, consisting of fever, headache, Adverse-Effectnausea , vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy. |
| 0.9952 | A dapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, Adverse-Effectlymphadenopathy , hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy. |
| 0.9884 | A dapsone hypersensitivity syndrome, consisting of Adverse-Effectfever , headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy. |
| 0.9586 | A dapsone Adverse-Effecthypersensitivity syndrome , consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy. |
| Score | Text |
|---|---|
| 0.9093 | Cardiac glycosides are thought to prevent doxorubicin Adverse-Effectcardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin. |
| 0.8555 | Cardiac glycosides are thought to prevent Drugdoxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin. |
| Score | Text |
|---|---|
| 0.9870 | OBJECTIVE : The purpose of this study was to determine whether desensitization to NPH insulin, as well as standard insulin desensitization, could control Adverse-Effectallergic symptoms in a patient allergic to both NPH and regular insulin. |
| 0.9800 | OBJECTIVE : The purpose of this study was to determine whether desensitization to NPH insulin, as well as standard Druginsulin desensitization, could control allergic symptoms in a patient allergic to both NPH and regular insulin. |
| 0.9769 | OBJECTIVE : The purpose of this study was to determine whether desensitization to DrugNPH insulin , as well as standard insulin desensitization, could control allergic symptoms in a patient allergic to both NPH and regular insulin. |
| 0.9754 | OBJECTIVE : The purpose of this study was to determine whether desensitization to NPH insulin, as well as standard insulin desensitization, could control allergic symptoms in a patient allergic to both NPH and regular Druginsulin . |
| 0.9130 | OBJECTIVE : The purpose of this study was to determine whether desensitization to NPH insulin, as well as standard insulin desensitization, could control allergic symptoms in a patient allergic to both DrugNPH and regular insulin. |
| Score | Text |
|---|---|
| 0.9996 | The authors present an elderly patient with mixed dementia who developed TD at multiple sites, ( including respiratory dyskinesia [ RD ], limb dyskinesia, and orofacial dyskinesia ) following abrupt withdrawal of Drugrisperidone therapy. |
| 0.9942 | The authors present an elderly patient with mixed dementia who developed TD at multiple sites, ( including respiratory dyskinesia [ RD ], limb dyskinesia, and Adverse-Effectorofacial dyskinesia ) following abrupt withdrawal of risperidone therapy. |
| 0.9933 | The authors present an elderly patient with mixed dementia who developed TD at multiple sites, ( including Adverse-Effectrespiratory dyskinesia [ RD ], limb dyskinesia, and orofacial dyskinesia ) following abrupt withdrawal of risperidone therapy. |
| 0.9929 | The authors present an elderly patient with mixed dementia who developed TD at multiple sites, ( including respiratory dyskinesia [ RD ], Adverse-Effectlimb dyskinesia , and orofacial dyskinesia ) following abrupt withdrawal of risperidone therapy. |
| 0.9918 | The authors present an elderly patient with mixed dementia who developed Adverse-EffectTD at multiple sites, ( including respiratory dyskinesia [ RD ], limb dyskinesia, and orofacial dyskinesia ) following abrupt withdrawal of risperidone therapy. |
| 0.9883 | The authors present an elderly patient with mixed dementia who developed TD at multiple sites, ( including respiratory dyskinesia [ Adverse-EffectRD ], limb dyskinesia, and orofacial dyskinesia ) following abrupt withdrawal of risperidone therapy. |
| Score | Text |
|---|---|
| 0.9982 | We conjectured that the side effects of insulin, such as anti - natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and Adverse-Effecthypoalbuminaemia . |
| 0.9981 | We conjectured that the side effects of insulin, such as anti - natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, Adverse-Effecthyperinsulinaemia and hypoalbuminaemia. |
| 0.9887 | We conjectured that the side effects of Druginsulin , such as anti - natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia. |
| 0.9722 | We conjectured that the side effects of insulin, such as anti - natriuresis and Adverse-Effectincreased vascular permeability , might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia. |
| 0.9636 | We conjectured that the side effects of insulin, such as Adverse-Effectanti - natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia. |
| 0.7991 | We conjectured that the side effects of insulin, such as anti - natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies Adverse-Effectinsulin insensitivity , hyperinsulinaemia and hypoalbuminaemia. |
| Score | Text |
|---|---|
| 0.9972 | We present two cases in which both patients suffered with Adverse-EffectCLS , which we believe was caused following administration of granulocyte colony - stimulating factor, to our knowledge not described in the intensive care patient previously. |
| 0.9679 | We present two cases in which both patients suffered with CLS, which we believe was caused following administration of Druggranulocyte colony - stimulating factor , to our knowledge not described in the intensive care patient previously. |
| Score | Text |
|---|---|
| 0.9931 | The principle treatment for DPD - deficient patients with severe acute 5 - FU reactions is supportive care ; however, the administration of thymidine potentially may reverse severe 5 - FU - induced neurologic symptoms such as Adverse-Effectencephalopathy and coma. |
| 0.9809 | The principle treatment for DPD - deficient patients with severe acute Drug5 - FU reactions is supportive care ; however, the administration of thymidine potentially may reverse severe 5 - FU - induced neurologic symptoms such as encephalopathy and coma. |
| 0.9795 | The principle treatment for DPD - deficient patients with severe acute 5 - FU reactions is supportive care ; however, the administration of thymidine potentially may reverse severe 5 - FU - induced neurologic symptoms such as encephalopathy and Adverse-Effectcoma . |
| 0.9782 | The principle treatment for DPD - deficient patients with severe acute 5 - FU reactions is supportive care ; however, the administration of thymidine potentially may reverse severe Drug5 - FU - induced neurologic symptoms such as encephalopathy and coma. |
| 0.9483 | The principle treatment for DPD - deficient patients with severe acute 5 - FU reactions is supportive care ; however, the administration of thymidine potentially may reverse severe 5 - FU - induced Adverse-Effectneurologic symptoms such as encephalopathy and coma. |
| The principle treatment for DPD - deficient patients with Adverse-Effectsevere acute 5 - FU reactions is supportive care ; however, the administration of thymidine potentially may reverse severe 5 - FU - induced neurologic symptoms such as encephalopathy and coma. | |
| Score | Text |
|---|---|
| 0.9882 | A case report is presented concerning the administration of ketanserin in the treatment of pulmonary vasoconstriction and Adverse-Effectright ventricular failure following the infusion of protamine in a patient undergoing coronary artery bypass surgery and mitral valve replacement. |
| 0.9529 | A case report is presented concerning the administration of ketanserin in the treatment of Adverse-Effectpulmonary vasoconstriction and right ventricular failure following the infusion of protamine in a patient undergoing coronary artery bypass surgery and mitral valve replacement. |
| 0.7969 | A case report is presented concerning the administration of ketanserin in the treatment of pulmonary vasoconstriction and right ventricular failure following the infusion of Drugprotamine in a patient undergoing coronary artery bypass surgery and mitral valve replacement. |
| 0.9246 | A case report is presented concerning the administration of Drugketanserin in the treatment of pulmonary vasoconstriction and right ventricular failure following the infusion of protamine in a patient undergoing coronary artery bypass surgery and mitral valve replacement. |
| Score | Text |
|---|---|
| 0.9979 | This patient developed sequential symptoms including alternative hemiparesis, Adverse-Effectdysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue. |
| 0.9952 | This patient developed sequential symptoms including alternative hemiparesis, dysarthria and Adverse-Effectaltered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue. |
| 0.9912 | This patient developed sequential symptoms including alternative Adverse-Effecthemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue. |
| 0.9775 | This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of DrugHD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue. |
| 0.5907 | This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with Drugleucovorin rescue. |
| Score | Text |
|---|---|
| 0.9988 | DrugFK506 , which began to be administered 12 days earlier, rose to a level of 44 ng / mL ( normal range, 10 - 20 ng / mL ) 1 day before neurologic abnormalities began. |
| 0.9872 | FK506, which began to be administered 12 days earlier, rose to a level of 44 ng / mL ( normal range, 10 - 20 ng / mL ) 1 day before Adverse-Effectneurologic abnormalities began. |
| Score | Text |
|---|---|
| 0.9873 | From 1996 to 2002 several medications were changed due to their adverse effects : indinavir ( renal colic and fever ), nelfinavir ( cutaneous rash ), and efavirenz ( Adverse-Effectnausea and temporary memory loss ). |
| 0.9793 | From 1996 to 2002 several medications were changed due to their adverse effects : indinavir ( renal colic and fever ), nelfinavir ( cutaneous rash ), and efavirenz ( nausea and Adverse-Effecttemporary memory loss ). |
| 0.9471 | From 1996 to 2002 several medications were changed due to their adverse effects : indinavir ( Adverse-Effectrenal colic and fever ), nelfinavir ( cutaneous rash ), and efavirenz ( nausea and temporary memory loss ). |
| 0.9285 | From 1996 to 2002 several medications were changed due to their adverse effects : indinavir ( renal colic and fever ), nelfinavir ( Adverse-Effectcutaneous rash ), and efavirenz ( nausea and temporary memory loss ). |
| 0.5549 | From 1996 to 2002 several medications were changed due to their adverse effects : indinavir ( renal colic and Adverse-Effectfever ), nelfinavir ( cutaneous rash ), and efavirenz ( nausea and temporary memory loss ). |
| 0.4701 | From 1996 to 2002 several medications were changed due to their adverse effects : Drugindinavir ( renal colic and fever ), nelfinavir ( cutaneous rash ), and efavirenz ( nausea and temporary memory loss ). |
| 0.9925 | From 1996 to 2002 several medications were changed due to their adverse effects : indinavir ( renal colic and fever ), nelfinavir ( cutaneous rash ), and Adverse-Effectefavirenz ( nausea and temporary memory loss ). |
| From 1996 to 2002 several medications were changed due to their adverse effects : indinavir ( renal colic and fever ), Drugnelfinavir ( cutaneous rash ), and efavirenz ( nausea and temporary memory loss ). | |
| From 1996 to 2002 several medications were changed due to their adverse effects : indinavir ( renal colic and fever ), nelfinavir ( cutaneous rash ), and Drugefavirenz ( nausea and temporary memory loss ). | |
| Score | Text |
|---|---|
| 0.9995 | A 74 - year - old man received oral administration of Drugpilsicainide , a pure sodium channel blocker with slow recovery kinetics, to convert paroxysmal atrial fibrillation to sinus rhythm and developed loss of consciousness two days later. |
| 0.9939 | A 74 - year - old man received oral administration of pilsicainide, a pure sodium channel blocker with slow recovery kinetics, to convert paroxysmal atrial fibrillation to sinus rhythm and developed Adverse-Effectloss of consciousness two days later. |
| Score | Text |
|---|---|
| 0.9766 | Based on the Naranjo algorithm, the adverse reaction observed was probably related to the hydroxyurea treatment ( score = 6 ) ; however, the Drughydroxyurea chemotherapy could not be discontinued because of the myeloproliferative disorder. |
| 0.9755 | Based on the Naranjo algorithm, the adverse reaction observed was probably related to the hydroxyurea treatment ( score = 6 ) ; however, the hydroxyurea chemotherapy could not be discontinued because of the Adverse-Effectmyeloproliferative disorder . |
| 0.9872 | Based on the Naranjo algorithm, the adverse reaction observed was probably related to the Drughydroxyurea treatment ( score = 6 ) ; however, the hydroxyurea chemotherapy could not be discontinued because of the myeloproliferative disorder. |
| Score | Text |
|---|---|
| 0.9912 | Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving Drugouabain , and none of the 16 who were receiving digoxin. |
| 0.9861 | Adverse-EffectMinor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin. |
| 0.9850 | Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving Drugdigoxin . |
| Score | Text |
|---|---|
| 0.9966 | Phenytoin was discontinued after admission ; however, phenytoin 1 g i. v. was given for a tonic - clonic seizure two days after admission, after which swelling of the face and legs and Adverse-Effectpruritus developed. |
| 0.9770 | Phenytoin was discontinued after admission ; however, Drugphenytoin 1 g i. v. was given for a tonic - clonic seizure two days after admission, after which swelling of the face and legs and pruritus developed. |
| 0.9644 | Phenytoin was discontinued after admission ; however, phenytoin 1 g i. v. was given for a tonic - clonic seizure two days after admission, after which Adverse-Effectswelling of the face and legs and pruritus developed. |
| 0.9764 | DrugPhenytoin was discontinued after admission ; however, phenytoin 1 g i. v. was given for a tonic - clonic seizure two days after admission, after which swelling of the face and legs and pruritus developed. |
| Score | Text |
|---|---|
| 0.9896 | It is concluded that ' Adverse-Effectcerebral atrophy ' on CT scans may represent an accumulative effect of ACTH and that ACTH should be given with the utmost discretion, and in as low a dose as possible. |
| 0.9607 | It is concluded that'cerebral atrophy'on CT scans may represent an accumulative effect of DrugACTH and that ACTH should be given with the utmost discretion, and in as low a dose as possible. |
| 0.7045 | It is concluded that'cerebral atrophy'on CT scans may represent an accumulative effect of ACTH and that DrugACTH should be given with the utmost discretion, and in as low a dose as possible. |
| Score | Text |
|---|---|
| 0.9994 | We describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly Drugtaxol ( 80 mg / m ( 2 ) x3 ). |
| 0.9954 | We describe a case of advanced ovarian carcinoma who developed Adverse-Effectdifficulty walking because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly taxol ( 80 mg / m ( 2 ) x3 ). |
| 0.9886 | We describe a case of advanced ovarian carcinoma who developed difficulty walking because of Adverse-Effectmarked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly taxol ( 80 mg / m ( 2 ) x3 ). |
| 0.9857 | We describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and Adverse-Effectloss of proprioception 25 days after treatment with weekly taxol ( 80 mg / m ( 2 ) x3 ). |
| Score | Text |
|---|---|
| 0.9994 | We report here a 26 - year - old female with diffuse large B - cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high - dose DrugBCNU ( 600 mg / m2 ). |
| 0.9802 | We report here a 26 - year - old female with diffuse large B - cell lymphoma who died of Adverse-Effectsevere pulmonary fibrosis 81 days after the administration of high - dose BCNU ( 600 mg / m2 ). |
| Score | Text |
|---|---|
| 0.9918 | Symptoms and signs of Adverse-Effectaugmentation were related to low plasma levodopa levels, abating 75 minutes after oral levodopa administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma levodopa concentration. |
| 0.9686 | Symptoms and signs of augmentation were related to low plasma levodopa levels, abating 75 minutes after oral Druglevodopa administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma levodopa concentration. |
| 0.9677 | Symptoms and signs of augmentation were related to low plasma Druglevodopa levels, abating 75 minutes after oral levodopa administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma levodopa concentration. |
| 0.9323 | Symptoms and signs of augmentation were related to low plasma levodopa levels, abating 75 minutes after oral levodopa administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma Druglevodopa concentration. |
| Score | Text |
|---|---|
| 0.9950 | METHODS : Double - blind, placebo - controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1. 5 hours after challenges with DrugViokase and Pancrease MT 16, but not with placebo. |
| 0.9860 | METHODS : Double - blind, placebo - controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1. 5 hours after challenges with Viokase and DrugPancrease MT 16 , but not with placebo. |
| 0.9847 | METHODS : Double - blind, placebo - controlled titrated oral challenges with pancreatic enzymes resulted in definite Adverse-Effectvomiting within 1 to 1. 5 hours after challenges with Viokase and Pancrease MT 16, but not with placebo. |
| Score | Text |
|---|---|
| 0.9946 | After ruling out a hydrotelluric source of fluorine, the patient's Adverse-Effectfluorosis was linked to chronic use of niflumic acid, following the publication in 1978 of the 2 previously reported cases affected by this drug. |
| 0.9834 | After ruling out a hydrotelluric source of fluorine, the patient's fluorosis was linked to chronic use of Drugniflumic acid , following the publication in 1978 of the 2 previously reported cases affected by this drug. |
| Score | Text |
|---|---|
| 0.9949 | PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced Adverse-Effectneurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir. |
| 0.9661 | PURPOSE : To investigate the concentration - side effect relationship in a patient with severe Drugacyclovir - induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir. |
| 0.8867 | PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced neurotoxicity and to summarize the information available in the literature about Adverse-Effectcentral nervous system side effects due to acyclovir. |
| 0.8498 | PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to Drugacyclovir . |
| Score | Text |
|---|---|
| 0.9719 | We report a 5 - year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to Adverse-Effectsubmucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy. |
| 0.9688 | We report a 5 - year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon, secondary to Drughigh - lipase pancreatin therapy. |
| 0.9520 | We report a 5 - year - old boy with CF who had a stricture of the Adverse-Effecthepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon, secondary to high - lipase pancreatin therapy. |
| 0.5492 | We report a 5 - year - old boy with CF who had a stricture of Adverse-Effectthe hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon, secondary to high - lipase pancreatin therapy. |
| 0.5194 | We report a 5 - year - old boy with CF who had a stricture Adverse-Effectof the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon, secondary to high - lipase pancreatin therapy. |
| We report a 5 - year - old boy with CF who had a Adverse-Effectstricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon, secondary to high - lipase pancreatin therapy. | |
| Score | Text |
|---|---|
| 0.9920 | The presented patient was treated with 200 mg TCA and developed Adverse-EffectCushing's syndrome 6 weeks later ( cortisol and ACTH concentrations were below limits of detection, TCA concentrations were > 3 micrograms / l ). |
| 0.9809 | The presented patient was treated with 200 mg DrugTCA and developed Cushing's syndrome 6 weeks later ( cortisol and ACTH concentrations were below limits of detection, TCA concentrations were > 3 micrograms / l ). |
| Score | Text |
|---|---|
| 0.9993 | Such a rapid and relentless progression of Drugmethyldopa - induced liver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy. |
| 0.9901 | Such a rapid and relentless progression of methyldopa - induced Adverse-Effectliver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy. |
| 0.9716 | Such a rapid and relentless progression of methyldopa - induced liver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit Adverse-Effectliver function abnormalities early in the course of therapy. |
| Score | Text |
|---|---|
| 0.9996 | We report an HIV - infected woman who developed mild leukopenia as the first sign of a Drugnevirapine - related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia. |
| 0.9596 | We report an HIV - infected woman who developed mild leukopenia as the first sign of a nevirapine - related adverse event, which was followed by skin and hepatic toxicity associated with a more severe Adverse-Effectleukopenia . |
| 0.9490 | We report an HIV - infected woman who developed mild leukopenia as the first sign of a nevirapine - related adverse event, which was followed by Adverse-Effectskin and hepatic toxicity associated with a more severe leukopenia. |
| 0.8606 | We report an HIV - infected woman who developed mild Adverse-Effectleukopenia as the first sign of a nevirapine - related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia. |
| 0.6739 | We report an HIV - infected woman who developed Adverse-Effectmild leukopenia as the first sign of a nevirapine - related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia. |
| Score | Text |
|---|---|
| 0.9911 | An 11 - year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( DrugLevemepromazine ) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome. |
| 0.9908 | An 11 - year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from Adverse-Effectrespiratory distress syndrome . |
| 0.9854 | An 11 - year - old boy who was treated with a relatively high dose of Drugmethotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome. |
| Score | Text |
|---|---|
| 0.9970 | The day after clozapine was stopped, while he was still receiving clomipramine 150 mg / d, he began behaving oddly, started sweating profusely, Adverse-Effectshivering , and became tremulous, agitated, and confused. |
| 0.9966 | The day after clozapine was stopped, while he was still receiving clomipramine 150 mg / d, he began behaving oddly, started sweating profusely, shivering, and became Adverse-Effecttremulous , agitated, and confused. |
| 0.9957 | The day after Drugclozapine was stopped, while he was still receiving clomipramine 150 mg / d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused. |
| 0.9935 | The day after clozapine was stopped, while he was still receiving clomipramine 150 mg / d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, Adverse-Effectagitated , and confused. |
| 0.9911 | The day after clozapine was stopped, while he was still receiving clomipramine 150 mg / d, he began behaving oddly, started Adverse-Effectsweating profusely , shivering, and became tremulous, agitated, and confused. |
| 0.9853 | The day after clozapine was stopped, while he was still receiving Drugclomipramine 150 mg / d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused. |
| 0.9833 | The day after clozapine was stopped, while he was still receiving clomipramine 150 mg / d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and Adverse-Effectconfused . |
| 0.9829 | The day after clozapine was stopped, while he was still receiving clomipramine 150 mg / d, he began Adverse-Effectbehaving oddly , started sweating profusely, shivering, and became tremulous, agitated, and confused. |
| Score | Text |
|---|---|
| 0.9932 | PATIENTS : Two patients, ages 40 and 51 years, undergoing treatment with Druginterferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc - related field defects and segmental optic disc edema. |
| 0.8637 | PATIENTS : Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced Adverse-Effectsudden bilateral, sequential visual loss with disc - related field defects and segmental optic disc edema. |
| 0.6427 | PATIENTS : Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, Adverse-Effectsequential visual loss with disc - related field defects and segmental optic disc edema. |
| Score | Text |
|---|---|
| 0.9952 | We present the case of a patient who had undergone cholecystectomy previously, but in whom morphine given in the Emergency Department precipitated pain consistent with Adverse-Effectbiliary colic ; the pain resolved promptly after administration of naloxone. |
| 0.9838 | We present the case of a patient who had undergone cholecystectomy previously, but in whom Drugmorphine given in the Emergency Department precipitated pain consistent with biliary colic ; the pain resolved promptly after administration of naloxone. |
| 0.9823 | We present the case of a patient who had undergone cholecystectomy previously, but in whom morphine given in the Emergency Department precipitated Adverse-Effectpain consistent with biliary colic ; the pain resolved promptly after administration of naloxone. |
| Score | Text |
|---|---|
| 0.9990 | We describe a 74 - year - old man with rheumatoid arthritis ( RA ) who developed syndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) 1. 5 months after commencement of Drugmizoribin prescription when his arthritis was improved. |
| 0.9978 | We describe a 74 - year - old man with rheumatoid arthritis ( RA ) who developed syndrome of inappropriate secretion of antidiuretic hormone ( Adverse-EffectSIADH ) 1. 5 months after commencement of mizoribin prescription when his arthritis was improved. |
| 0.9810 | We describe a 74 - year - old man with rheumatoid arthritis ( RA ) who developed Adverse-Effectsyndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) 1. 5 months after commencement of mizoribin prescription when his arthritis was improved. |
| Score | Text |
|---|---|
| 0.9979 | DrugRapamycin / sirolimus - induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart - lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy. |
| 0.9978 | Rapamycin / sirolimus - induced Adverse-Effectpneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart - lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy. |
| 0.9971 | Rapamycin / Drugsirolimus - induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart - lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy. |
| 0.9814 | Rapamycin / sirolimus - induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart - lung transplant recipient who developed a Adverse-Effectpulmonary infiltrate that reversed after ceasing SR therapy. |
| Rapamycin / sirolimus - induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart - lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing DrugSR therapy. | |
| Score | Text |
|---|---|
| 0.9984 | We report the case of a 14 - year - old female with acute promyelocytic leukemia who developed symptomatic cardiomyopathy only 4 months into treatment with a combination of Drugdaunomycin and all - trans retinoic acid ( ATRA ). |
| 0.9962 | We report the case of a 14 - year - old female with acute promyelocytic leukemia who developed symptomatic cardiomyopathy only 4 months into treatment with a combination of daunomycin and all - trans retinoic acid ( DrugATRA ). |
| 0.9894 | We report the case of a 14 - year - old female with acute promyelocytic leukemia who developed Adverse-Effectsymptomatic cardiomyopathy only 4 months into treatment with a combination of daunomycin and all - trans retinoic acid ( ATRA ). |
| 0.9481 | We report the case of a 14 - year - old female with acute promyelocytic leukemia who developed symptomatic cardiomyopathy only 4 months into treatment with a combination of daunomycin and Drugall - trans retinoic acid ( ATRA ). |
| Score | Text |
|---|---|
| 0.9715 | The authors report a longitudinal case study of a woman with a history of bipolar affective disorder in which DrugL - dopa shortened the manic - depressive cycle length when administered in a double - blind trial. |
| 0.8270 | The authors report a longitudinal case study of a woman with a history of bipolar affective disorder in which L - dopa Adverse-Effectshortened the manic - depressive cycle length when administered in a double - blind trial. |
| 0.7032 | The authors report a longitudinal case study of a woman with a history of bipolar affective disorder in which L - Adverse-Effectdopa shortened the manic - depressive cycle length when administered in a double - blind trial. |
| 0.6379 | The authors report a longitudinal case study of a woman with a history of bipolar affective disorder in which Adverse-EffectL - dopa shortened the manic - depressive cycle length when administered in a double - blind trial. |
| 0.5053 | The authors report a longitudinal case study of a woman with a history of bipolar affective disorder in which L Adverse-Effect- dopa shortened the manic - depressive cycle length when administered in a double - blind trial. |
| Score | Text |
|---|---|
| 0.9991 | Purple glove syndrome, named for its distinctive purple discoloration and swelling of the hands in the distribution of a glove, is an uncommon complication of intravenous Drugphenytoin administration through small dorsal veins of the hands. |
| 0.9907 | Adverse-EffectPurple glove syndrome , named for its distinctive purple discoloration and swelling of the hands in the distribution of a glove, is an uncommon complication of intravenous phenytoin administration through small dorsal veins of the hands. |
| 0.9652 | Purple glove syndrome, named for its distinctive purple discoloration and Adverse-Effectswelling of the hands in the distribution of a glove, is an uncommon complication of intravenous phenytoin administration through small dorsal veins of the hands. |
| 0.9569 | Purple glove syndrome, named for its distinctive Adverse-Effectpurple discoloration and swelling of the hands in the distribution of a glove, is an uncommon complication of intravenous phenytoin administration through small dorsal veins of the hands. |
| Score | Text |
|---|---|
| 0.9896 | In this report, we present a case of Adverse-Effecthypoglycaemic coma associated with SP, an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of SP increases. |
| 0.9795 | In this report, we present a case of hypoglycaemic coma associated with DrugSP , an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of SP increases. |
| 0.9130 | In this report, we present a case of hypoglycaemic coma associated with SP, an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of DrugSP increases. |
| Score | Text |
|---|---|
| 0.9990 | Administration of intravenous Drugnitroglycerin in a patient with idiopathic pulmonary hypertension resulted in an increase in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an increase in pulmonary vascular resistance. |
| 0.9815 | Administration of intravenous nitroglycerin in a patient with idiopathic pulmonary hypertension resulted in an increase in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an Adverse-Effectincrease in pulmonary vascular resistance . |
| 0.9783 | Administration of intravenous nitroglycerin in a patient with idiopathic pulmonary hypertension resulted in an Adverse-Effectincrease in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an increase in pulmonary vascular resistance. |
| 0.9590 | Administration of intravenous nitroglycerin in a patient with idiopathic pulmonary hypertension resulted in an increase in pulmonary artery pressure associated with a Adverse-Effectdecrease in blood flow that is best explained by an increase in pulmonary vascular resistance. |
| Score | Text |
|---|---|
| 0.9986 | It was postulated that the allergic reaction was most likely caused by Drugcapecitabine or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well - tolerance of fluorouracil. |
| 0.9889 | It was postulated that the Adverse-Effectallergic reaction was most likely caused by capecitabine or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well - tolerance of fluorouracil. |
| Score | Text |
|---|---|
| 0.9978 | Prolonged responses were achieved with low doses of DrugHU ( 3 - 10 mg / kg / day ) and higher doses were associated with mild reversible hematologic or hepatic toxicity and no further increases in Hb. |
| 0.9408 | Prolonged responses were achieved with low doses of HU ( 3 - 10 mg / kg / day ) and higher doses were associated with mild reversible hematologic or Adverse-Effecthepatic toxicity and no further increases in Hb. |
| Prolonged responses were achieved with low doses of HU ( 3 - 10 mg / kg / day ) and higher doses were associated with Adverse-Effectmild reversible hematologic or hepatic toxicity and no further increases in Hb. | |
| Score | Text |
|---|---|
| 0.9881 | This Adverse-Effectpanic anxiety was not relieved by taking etizolam and flunitrazepam again, but subsided rapidly by the re - administration of mianserin 30 mg / day, and because of that the depressive symptom also disappeared. |
| 0.9720 | This panic anxiety was not relieved by taking etizolam and flunitrazepam again, but subsided rapidly by the re - administration of Drugmianserin 30 mg / day, and because of that the depressive symptom also disappeared. |
| 0.9914 | This panic anxiety was not relieved by taking etizolam and Drugflunitrazepam again, but subsided rapidly by the re - administration of mianserin 30 mg / day, and because of that the depressive symptom also disappeared. |
| 0.9890 | This panic anxiety was not relieved by taking Drugetizolam and flunitrazepam again, but subsided rapidly by the re - administration of mianserin 30 mg / day, and because of that the depressive symptom also disappeared. |
| Score | Text |
|---|---|
| 0.9990 | Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after Drugzonisamide treatment was begun or its dosage increased. |
| 0.9900 | Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and Adverse-Effectaltered mental status after zonisamide treatment was begun or its dosage increased. |
| 0.9113 | Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex Adverse-Effectvisual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased. |
| Score | Text |
|---|---|
| 0.9996 | A child in whom a Drugphenobarbital hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein - losing enteropathy, myositis, and nephritis, is described. |
| 0.9986 | A child in whom a phenobarbital hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein - losing enteropathy, myositis, and Adverse-Effectnephritis , is described. |
| 0.9982 | A child in whom a phenobarbital hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, Adverse-Effectalopecia , icterus, protein - losing enteropathy, myositis, and nephritis, is described. |
| 0.9973 | A child in whom a phenobarbital hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, Adverse-Effecticterus , protein - losing enteropathy, myositis, and nephritis, is described. |
| 0.9971 | A child in whom a phenobarbital hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein - losing enteropathy, Adverse-Effectmyositis , and nephritis, is described. |
| 0.9888 | A child in whom a phenobarbital hypersensitivity drug reaction developed which consisted of Adverse-Effectfever , a pruritic desquamating erythrodermic rash, alopecia, icterus, protein - losing enteropathy, myositis, and nephritis, is described. |
| 0.9695 | A child in whom a phenobarbital hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, Adverse-Effectprotein - losing enteropathy , myositis, and nephritis, is described. |
| 0.8898 | A child in whom a phenobarbital Adverse-Effecthypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein - losing enteropathy, myositis, and nephritis, is described. |
| 0.8131 | A child in whom a phenobarbital hypersensitivity drug reaction developed which consisted of fever, Adverse-Effecta pruritic desquamating erythrodermic rash , alopecia, icterus, protein - losing enteropathy, myositis, and nephritis, is described. |
| 0.8421 | A child in whom a phenobarbital Adverse-Effecthypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein - losing enteropathy, myositis, and nephritis, is described. |
| 0.8150 | A child in whom a phenobarbital Adverse-Effecthypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein - losing enteropathy, myositis, and nephritis, is described. |
| 0.7748 | A child in whom a phenobarbital hypersensitivity drug reaction developed which consisted of fever, a Adverse-Effectpruritic desquamating erythrodermic rash , alopecia, icterus, protein - losing enteropathy, myositis, and nephritis, is described. |
| Score | Text |
|---|---|
| 0.9963 | We observed 5 reactions in 3 patients that appear to be related to a high dose - infusion time ratio, indicating that dose and rate of infusion may be important factors in precipitating anaphylactoid reactions with Drugcisplatin . |
| 0.9854 | We observed 5 reactions in 3 patients that appear to be related to a high dose - infusion time ratio, indicating that dose and rate of infusion may be important factors in precipitating Adverse-Effectanaphylactoid reactions with cisplatin. |
| Score | Text |
|---|---|
| 0.9994 | The present observation suggests, that a batch of different testing doses, including lower testing doses may help to differentiate between an allergic type of contact dermatitis and an irritant type of reaction after treatment with Drugcalcipotriol . |
| 0.9721 | The present observation suggests, that a batch of different testing doses, including lower testing doses may help to differentiate between an allergic type of contact dermatitis and an Adverse-Effectirritant type of reaction after treatment with calcipotriol. |
| Score | Text |
|---|---|
| 0.9993 | DISCUSSION : Rhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure Several drugs have been associated with rhabdomyolysis, including Druglovastatin , a hydroxymethylglutaryl - coenzyme A reductase inhibitor. |
| 0.9832 | DISCUSSION : Rhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure Several drugs have been associated with Adverse-Effectrhabdomyolysis , including lovastatin, a hydroxymethylglutaryl - coenzyme A reductase inhibitor. |
| 0.9945 | DISCUSSION : Adverse-EffectRhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure Several drugs have been associated with rhabdomyolysis, including lovastatin, a hydroxymethylglutaryl - coenzyme A reductase inhibitor. |
| 0.8083 | DISCUSSION : Rhabdomyolysis is a clinical syndrome resulting from the Adverse-Effectdestruction of skeletal muscle that may progress to renal failure Several drugs have been associated with rhabdomyolysis, including lovastatin, a hydroxymethylglutaryl - coenzyme A reductase inhibitor. |
| Score | Text |
|---|---|
| 0.9942 | After initiation of topical Drugvitamin D3 ointment ( 20 micro g / g of tacalcitol ) 10 g / day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually. |
| 0.9635 | After initiation of topical vitamin D3 ointment ( 20 micro g / g of Drugtacalcitol ) 10 g / day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually. |
| 0.7802 | After initiation of topical vitamin D3 ointment ( 20 micro g / g of tacalcitol ) 10 g / day for the skin lesions, both the Adverse-Effectserum level of calcium and urinary excretion of calcium increased gradually. |
| After initiation of topical vitamin D3 ointment ( 20 micro g / g of tacalcitol ) 10 g / day for the skin lesions, both the Adverse-Effectserum level of calcium and urinary excretion of calcium increased gradually. | |
| Score | Text |
|---|---|
| 0.9958 | The use of Drugmethotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease. |
| 0.9956 | The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which DrugMTX appeared to potentiate opportunistic infections and accelerate HIV disease. |
| 0.9930 | The use of methotrexate ( DrugMTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease. |
| 0.9685 | The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and Adverse-Effectaccelerate HIV disease . |
| 0.9613 | The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to Adverse-Effectpotentiate opportunistic infections and accelerate HIV disease. |
| Score | Text |
|---|---|
| 0.9987 | During clarithromycin coadministration, four out of the seven patients developed moderate - to - severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and Adverse-Effectataxia , which resolved within 5 days after clarithromycin discontinuation. |
| 0.9986 | During clarithromycin coadministration, four out of the seven patients developed moderate - to - severe toxic symptoms of carbamazepine, such as drowsiness, Adverse-Effectdizziness , and ataxia, which resolved within 5 days after clarithromycin discontinuation. |
| 0.9983 | During clarithromycin coadministration, four out of the seven patients developed moderate - to - severe toxic symptoms of carbamazepine, such as Adverse-Effectdrowsiness , dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation. |
| 0.9972 | During clarithromycin coadministration, four out of the seven patients developed moderate - to - severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after Drugclarithromycin discontinuation. |
| 0.9970 | During Drugclarithromycin coadministration, four out of the seven patients developed moderate - to - severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation. |
| 0.9955 | During clarithromycin coadministration, four out of the seven patients developed moderate - to - severe toxic symptoms of Drugcarbamazepine , such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation. |
| 0.8147 | During clarithromycin coadministration, four out of the seven patients developed moderate - to - severe Adverse-Effecttoxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation. |
| Score | Text |
|---|---|
| 0.9996 | CASE SUMMARY : We report the case of a 31 - year - old patient hospitalized due to behavioral alterations and treated with oral Drugzuclopenthixol , an antipsychotic from the thioxanthene family, who developed an acute, painful erection. |
| 0.8751 | CASE SUMMARY : We report the case of a 31 - year - old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, Adverse-Effectpainful erection . |
| Score | Text |
|---|---|
| 0.9997 | DIAGNOSIS : Severe Drugtemozolomide - induced immunosuppression, exacerbated by corticosteroids, with profound T - cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma. |
| 0.9935 | DIAGNOSIS : Severe temozolomide - induced Adverse-Effectimmunosuppression , exacerbated by corticosteroids, with profound T - cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma. |
| 0.9721 | DIAGNOSIS : Severe temozolomide - induced immunosuppression, exacerbated by corticosteroids, with profound T - cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and Adverse-Effectcutaneous Kaposi's sarcoma . |
| 0.9697 | DIAGNOSIS : Severe temozolomide - induced immunosuppression, exacerbated by corticosteroids, with profound T - cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, Adverse-Effectbrain abscess with Listeria monocytogenes , and cutaneous Kaposi's sarcoma. |
| 0.9233 | DIAGNOSIS : Severe temozolomide - induced immunosuppression, exacerbated by corticosteroids, with profound T - cell lymphocytopenia and simultaneous opportunistic Adverse-Effectinfections with Pneumocystis jiroveci pneumonia , brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma. |
| 0.9170 | DIAGNOSIS : Severe temozolomide - induced immunosuppression, exacerbated by corticosteroids, with profound Adverse-EffectT - cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma. |
| 0.9311 | DIAGNOSIS : Severe temozolomide - induced immunosuppression, exacerbated by corticosteroids, with profound T - cell lymphocytopenia and simultaneous Adverse-Effectopportunistic infections with Pneumocystis jiroveci pneumonia , brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma. |
| 0.8217 | DIAGNOSIS : Severe temozolomide - induced immunosuppression, exacerbated by corticosteroids, with profound T - cell lymphocytopenia and Adverse-Effectsimultaneous opportunistic infections with Pneumocystis jiroveci pneumonia , brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma. |
| 0.6133 | DIAGNOSIS : Severe temozolomide - induced immunosuppression, Adverse-Effectexacerbated by corticosteroids , with profound T - cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma. |
| Score | Text |
|---|---|
| 0.9974 | Many clinicians appear to be concerned about the potential hepatotoxicity of the opiate antagonist Drugnaltrexone ( NTX ) and this may be one reason why it is not used more widely in treating both heroin and alcohol abusers. |
| 0.9966 | Many clinicians appear to be concerned about the potential hepatotoxicity of the opiate antagonist naltrexone ( DrugNTX ) and this may be one reason why it is not used more widely in treating both heroin and alcohol abusers. |
| 0.9958 | Many clinicians appear to be concerned about the potential Adverse-Effecthepatotoxicity of the opiate antagonist naltrexone ( NTX ) and this may be one reason why it is not used more widely in treating both heroin and alcohol abusers. |
| Score | Text |
|---|---|
| 0.9988 | Our review of 194 RA patients and 38 PsA patients receiving MTX has identified four RA patients and one PsA patient with MTX - induced Adverse-Effectpneumonitis , giving a prevalence of 2. 1 % and 0. 03 %, respectively. |
| 0.9842 | Our review of 194 RA patients and 38 PsA patients receiving MTX has identified four RA patients and one PsA patient with DrugMTX - induced pneumonitis, giving a prevalence of 2. 1 % and 0. 03 %, respectively. |
| 0.9841 | Our review of 194 RA patients and 38 PsA patients receiving DrugMTX has identified four RA patients and one PsA patient with MTX - induced pneumonitis, giving a prevalence of 2. 1 % and 0. 03 %, respectively. |
| Score | Text |
|---|---|
| 0.9911 | A 7 - year - old boy developed a severe unilateral grand mal seizure at the age of 5 years ( Drugphenobarbitone therapy ) ; 1. 5 years later valproate ( 2 - propylpentanoic acid, VPA ) was added to the therapy. |
| 0.9897 | A 7 - year - old boy developed a severe unilateral grand mal seizure at the age of 5 years ( phenobarbitone therapy ) ; 1. 5 years later Drugvalproate ( 2 - propylpentanoic acid, VPA ) was added to the therapy. |
| 0.9881 | A 7 - year - old boy developed a severe unilateral grand mal seizure at the age of 5 years ( phenobarbitone therapy ) ; 1. 5 years later valproate ( 2 - propylpentanoic acid, DrugVPA ) was added to the therapy. |
| 0.9852 | A 7 - year - old boy developed a Adverse-Effectsevere unilateral grand mal seizure at the age of 5 years ( phenobarbitone therapy ) ; 1. 5 years later valproate ( 2 - propylpentanoic acid, VPA ) was added to the therapy. |
| 0.9728 | A 7 - year - old boy developed a severe unilateral grand mal seizure at the age of 5 years ( phenobarbitone therapy ) ; 1. 5 years later valproate ( Drug2 - propylpentanoic acid , VPA ) was added to the therapy. |
| Score | Text |
|---|---|
| 0.9705 | The authors suggest that fluoxetine - induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine - induced Adverse-Effectakathisia and tricyclic antidepressant - induced " jitteriness " may be identical. |
| 0.9557 | The authors suggest that fluoxetine - induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of Drugfluoxetine - induced akathisia and tricyclic antidepressant - induced " jitteriness " may be identical. |
| 0.9474 | The authors suggest that fluoxetine - induced Adverse-Effectakathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine - induced akathisia and tricyclic antidepressant - induced " jitteriness " may be identical. |
| 0.9402 | The authors suggest that Drugfluoxetine - induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine - induced akathisia and tricyclic antidepressant - induced " jitteriness " may be identical. |
| 0.9625 | The authors suggest that fluoxetine - induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine - induced akathisia and tricyclic antidepressant - induced " Adverse-Effectjitteriness " may be identical. |
| 0.5098 | The authors suggest that fluoxetine - induced akathisia may be caused by Adverse-Effectserotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine - induced akathisia and tricyclic antidepressant - induced " jitteriness " may be identical. |
| Score | Text |
|---|---|
| 0.9776 | Given that discontinuation of nitrofurantoin and introduction of methylprednisolon therapy significantly lowered liver enzyme levels, restoring most of them to normal, we concluded that this was probably the case of toxic liver damage caused by Drugnitrofurantoin . |
| 0.9738 | Given that discontinuation of nitrofurantoin and introduction of methylprednisolon therapy significantly lowered liver enzyme levels, restoring most of them to normal, we concluded that this was probably the case of Adverse-Effecttoxic liver damage caused by nitrofurantoin. |
| 0.9672 | Given that discontinuation of nitrofurantoin and introduction of Drugmethylprednisolon therapy significantly lowered liver enzyme levels, restoring most of them to normal, we concluded that this was probably the case of toxic liver damage caused by nitrofurantoin. |
| 0.9579 | Given that discontinuation of Drugnitrofurantoin and introduction of methylprednisolon therapy significantly lowered liver enzyme levels, restoring most of them to normal, we concluded that this was probably the case of toxic liver damage caused by nitrofurantoin. |
| Score | Text |
|---|---|
| 0.9994 | In this report we present four patients treated with a combination of different psychotropic drugs, in whom asterixis was triggered either by adding Drugcarbamazepine ( CBZ ) to a treatment regimen, or by increasing its dosage. |
| 0.9992 | In this report we present four patients treated with a combination of different psychotropic drugs, in whom asterixis was triggered either by adding carbamazepine ( DrugCBZ ) to a treatment regimen, or by increasing its dosage. |
| 0.9982 | In this report we present four patients treated with a combination of different psychotropic drugs, in whom Adverse-Effectasterixis was triggered either by adding carbamazepine ( CBZ ) to a treatment regimen, or by increasing its dosage. |
| Score | Text |
|---|---|
| 0.9945 | Approximately 15 min after the first administration of nebulised Drugmorphine the patient became markedly bradypneic ( respiratory rate : 4 - 5 bpm ), hypotensive ( BP 70 / 40 mmHg ), and responded only partially to command. |
| 0.9924 | Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic ( respiratory rate : 4 - 5 bpm ), Adverse-Effecthypotensive ( BP 70 / 40 mmHg ), and responded only partially to command. |
| 0.9894 | Approximately 15 min after the first administration of nebulised morphine the patient became markedly Adverse-Effectbradypneic ( respiratory rate : 4 - 5 bpm ), hypotensive ( BP 70 / 40 mmHg ), and responded only partially to command. |
| Score | Text |
|---|---|
| 0.9985 | Replicate brain magnetic resonance imaging examinations after six weeks and 11 months of Drugpenicillamine therapy documented the development of new brain lesions during this period, while liver biopsy specimen data disclosed that excellent hepatic decoppering had occurred. |
| 0.9913 | Replicate brain magnetic resonance imaging examinations after six weeks and 11 months of penicillamine therapy documented the development of new Adverse-Effectbrain lesions during this period, while liver biopsy specimen data disclosed that excellent hepatic decoppering had occurred. |
| Score | Text |
|---|---|
| 0.9986 | This case emphasizes the importance of the evaluation of Druglithium - associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management. |
| 0.9985 | This case emphasizes the importance of the evaluation of lithium - associated Adverse-Effectpolyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management. |
| Score | Text |
|---|---|
| 0.9874 | We report a 50 - year - old male patient with a 15 - year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a Adverse-Effectgeneralised pustular exacerbation and a aggravation of the joint condition. |
| 0.9859 | We report a 50 - year - old male patient with a 15 - year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of Drugcyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition. |
| 0.9844 | We report a 50 - year - old male patient with a 15 - year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a Adverse-Effectaggravation of the joint condition . |
| Score | Text |
|---|---|
| 0.9844 | An objective causality assessment indicated a probable relationship between Adverse-Effectclotting abnormality and warfarin administration, although the degree of elevation of the INR was unusual in the light of the daily warfarin dose and duration of its exposure. |
| 0.9641 | An objective causality assessment indicated a probable relationship between clotting abnormality and Drugwarfarin administration, although the degree of elevation of the INR was unusual in the light of the daily warfarin dose and duration of its exposure. |
| 0.5896 | An objective causality assessment indicated a probable relationship between clotting abnormality and warfarin administration, although the degree of elevation of the INR was unusual in the light of the daily Drugwarfarin dose and duration of its exposure. |
| Score | Text |
|---|---|
| 0.9995 | Even though only a few cases of this adverse event have been reported in the literature, severe Drugdocetaxel - induced pulmonary toxicity needs to be considered in the differential diagnosis when such patients present with respiratory symptoms. |
| 0.9887 | Even though only a few cases of this adverse event have been reported in the literature, severe docetaxel - induced Adverse-Effectpulmonary toxicity needs to be considered in the differential diagnosis when such patients present with respiratory symptoms. |
| 0.9657 | Even though only a few cases of this adverse event have been reported in the literature, severe docetaxel - induced pulmonary toxicity needs to be considered in the differential diagnosis when such patients present with Adverse-Effectrespiratory symptoms . |
| Score | Text |
|---|---|
| 0.9970 | METHODS : A 68 - year - old man developed intense conjunctival hyperemia and cystoid macula edema after switching from Druglatanoprost to bimatoprost 9 months after cataract surgery in an eye at low - risk for this cystoid macular edema. |
| 0.9966 | METHODS : A 68 - year - old man developed intense conjunctival hyperemia and cystoid macula edema after switching from latanoprost to Drugbimatoprost 9 months after cataract surgery in an eye at low - risk for this cystoid macular edema. |
| 0.9870 | METHODS : A 68 - year - old man developed intense conjunctival hyperemia and Adverse-Effectcystoid macula edema after switching from latanoprost to bimatoprost 9 months after cataract surgery in an eye at low - risk for this cystoid macular edema. |
| 0.9826 | METHODS : A 68 - year - old man developed Adverse-Effectintense conjunctival hyperemia and cystoid macula edema after switching from latanoprost to bimatoprost 9 months after cataract surgery in an eye at low - risk for this cystoid macular edema. |
| 0.9742 | METHODS : A 68 - year - old man developed intense conjunctival hyperemia and cystoid macula edema after switching from latanoprost to bimatoprost 9 months after cataract surgery in an eye at low - risk for this Adverse-Effectcystoid macular edema . |
| Score | Text |
|---|---|
| 0.9993 | CASE REPORT : A woman of 80 years, on long - term Drugwarfarin therapy presented with an acute dissecting thoracic aortic aneurysm ; on investigation the only precipitating factor found was an international normalised ratio of 4. 8. |
| 0.9842 | CASE REPORT : A woman of 80 years, on long - term warfarin therapy presented with an Adverse-Effectacute dissecting thoracic aortic aneurysm ; on investigation the only precipitating factor found was an international normalised ratio of 4. 8. |
| Score | Text |
|---|---|
| 0.9987 | We describe a 57 - year - old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy ( Drugbleomycin and methotrexate ) used to treat a metastatic squamous cell carcinoma of the hypopharynx. |
| 0.9987 | We describe a 57 - year - old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy ( bleomycin and Drugmethotrexate ) used to treat a metastatic squamous cell carcinoma of the hypopharynx. |
| 0.9978 | We describe a 57 - year - old man with acral erythrocyanosis progressing to acute digital ischemia and Adverse-Effectgangrene that developed after combined chemotherapy ( bleomycin and methotrexate ) used to treat a metastatic squamous cell carcinoma of the hypopharynx. |
| 0.9871 | We describe a 57 - year - old man with acral erythrocyanosis progressing to Adverse-Effectacute digital ischemia and gangrene that developed after combined chemotherapy ( bleomycin and methotrexate ) used to treat a metastatic squamous cell carcinoma of the hypopharynx. |
| Score | Text |
|---|---|
| 0.9867 | One patient required nursing home placement and a Adverse-Effectfeeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine. |
| 0.9850 | One patient required nursing home placement and a feeding gastrostomy as a result of the Adverse-Effectworsening parkinsonism during risperidone treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine. |
| 0.9736 | One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during Drugrisperidone treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine. |
| 0.8691 | One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment, but was able to return home and have the gastrostomy removed after switching from Drugrisperidone to clozapine. |
| 0.9060 | One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to Drugclozapine . |
| Score | Text |
|---|---|
| 0.9993 | We report the case of an 87 - year - old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and Adverse-Effecthyperkalemia shortly after completing a course of intravenous immunoglobulin ( IVIG ). |
| 0.9991 | We report the case of an 87 - year - old white woman with myasthenia gravis who presented with nausea, shortness of breath, Adverse-Effectazotemia , and hyperkalemia shortly after completing a course of intravenous immunoglobulin ( IVIG ). |
| 0.9987 | We report the case of an 87 - year - old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous Drugimmunoglobulin ( IVIG ). |
| 0.9985 | We report the case of an 87 - year - old white woman with myasthenia gravis who presented with Adverse-Effectnausea , shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin ( IVIG ). |
| 0.9980 | We report the case of an 87 - year - old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin ( DrugIVIG ). |
| 0.9839 | We report the case of an 87 - year - old white woman with myasthenia gravis who presented with nausea, Adverse-Effectshortness of breath , azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin ( IVIG ). |
| Score | Text |
|---|---|
| 0.9977 | After therapy for diabetic coma with insulin ( containing the preservative Drugcresol ) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and lost consciousness. |
| 0.9968 | After therapy for diabetic coma with insulin ( containing the preservative cresol ) and electrolyte solutions was started, the patient complained of Adverse-Effectincreasing myalgia , developed a high fever and respiratory and metabolic acidosis and lost consciousness. |
| 0.9959 | After therapy for diabetic coma with Druginsulin ( containing the preservative cresol ) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and lost consciousness. |
| 0.9936 | After therapy for diabetic coma with insulin ( containing the preservative cresol ) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and Adverse-Effectlost consciousness . |
| 0.9802 | After therapy for diabetic coma with insulin ( containing the preservative cresol ) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and Adverse-Effectrespiratory and metabolic acidosis and lost consciousness. |
| 0.9795 | After therapy for diabetic coma with insulin ( containing the preservative cresol ) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a Adverse-Effecthigh fever and respiratory and metabolic acidosis and lost consciousness. |
| Score | Text |
|---|---|
| 0.9988 | A study of in vitro reactivity to L - T4, as assessed by peripheral blood lymphocyte transformation, was carried out in a patient with Hashimoto's disease who developed Adverse-Effectleukopenia during treatment with L - T4. |
| 0.9727 | A study of in vitro reactivity to L - T4, as assessed by peripheral blood lymphocyte transformation, was carried out in a patient with Hashimoto's disease who developed leukopenia during treatment with DrugL - T4 . |
| 0.9632 | A study of in vitro reactivity to DrugL - T4 , as assessed by peripheral blood lymphocyte transformation, was carried out in a patient with Hashimoto's disease who developed leukopenia during treatment with L - T4. |
| Score | Text |
|---|---|
| 0.9994 | The clinical course suggests that Drugcaffeine , which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions. |
| 0.9967 | The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause Adverse-Effectrhabdomyolysis on rare occasions. |
| 0.9963 | The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the Adverse-Effectrhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions. |
| 0.9941 | The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the Adverse-Effectdelirium , although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions. |
| 0.8331 | The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe Adverse-Effecthyponatremia has been reported to cause rhabdomyolysis on rare occasions. |
| 0.8092 | The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although Adverse-Effectsevere hyponatremia has been reported to cause rhabdomyolysis on rare occasions. |
| Score | Text |
|---|---|
| 0.9974 | A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and Adverse-Effectataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate. |
| 0.9954 | A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of Drugpentobarbital and pyrilamine maleate. |
| 0.9904 | A Adverse-Effecttoxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate. |
| 0.9865 | A toxic encephalopathy characterized by Adverse-Effectdepressed level of consciousness , marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate. |
| 0.9854 | A toxic encephalopathy characterized by depressed level of consciousness, Adverse-Effectmarked irritability , and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate. |
| 0.9739 | A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and Drugpyrilamine maleate . |
| Score | Text |
|---|---|
| 0.9889 | Careful follow - up of so - called " self - limited " Druginsulin edema is encouraged, and the early institution of diuretic therapy is advocated in elderly patients to prevent the development of overt cardiac failure. |
| 0.6581 | Careful follow - up of so - called " self - limited " insulin Adverse-Effectedema is encouraged, and the early institution of diuretic therapy is advocated in elderly patients to prevent the development of overt cardiac failure. |
| 0.6294 | Careful follow - up of so - called " self - limited " Adverse-Effectinsulin edema is encouraged, and the early institution of diuretic therapy is advocated in elderly patients to prevent the development of overt cardiac failure. |
| Score | Text |
|---|---|
| 0.9984 | We present a 46 - year - old African - American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of meningitis after using trimethoprim / Drugsulfamethoxazole ( TMP / SMX ). |
| 0.9983 | We present a 46 - year - old African - American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of meningitis after using Drugtrimethoprim / sulfamethoxazole ( TMP / SMX ). |
| 0.9978 | We present a 46 - year - old African - American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of meningitis after using trimethoprim / sulfamethoxazole ( TMP / DrugSMX ). |
| 0.9974 | We present a 46 - year - old African - American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of meningitis after using trimethoprim / sulfamethoxazole ( DrugTMP / SMX ). |
| 0.9969 | We present a 46 - year - old African - American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of Adverse-Effectmeningitis after using trimethoprim / sulfamethoxazole ( TMP / SMX ). |
| Score | Text |
|---|---|
| 0.9994 | We report ( to our knowledge, for the first time in a child ) the emergence of psychosis in a 12 - year old white girl with an increased Drugefavirenz concentration and heterozygous gene polymorphism of the CYP2B6 - G516 T. |
| 0.9984 | We report ( to our knowledge, for the first time in a child ) the emergence of Adverse-Effectpsychosis in a 12 - year old white girl with an increased efavirenz concentration and heterozygous gene polymorphism of the CYP2B6 - G516 T. |
| Score | Text |
|---|---|
| 0.9994 | We report the first case of a human immunodeficiency virus type 1 ( HIV - 1 ) - infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural Drugtriamcinolone injections. |
| 0.9934 | We report the first case of a human immunodeficiency virus type 1 ( HIV - 1 ) - infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Adverse-EffectCushing syndrome with profound complications after epidural triamcinolone injections. |
| Score | Text |
|---|---|
| 0.9990 | After seven months'continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine - year - old boy developed Adverse-Effectpolyarthritis , rash and hepatitis in association with anti - native DNA antibodies and positive antinuclear factor. |
| 0.9989 | After seven months'continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine - year - old boy developed polyarthritis, rash and Adverse-Effecthepatitis in association with anti - native DNA antibodies and positive antinuclear factor. |
| 0.9981 | After seven months'continuous treatment for suspected tuberculosis with rifampicin and Drugethambutol a nine - year - old boy developed polyarthritis, rash and hepatitis in association with anti - native DNA antibodies and positive antinuclear factor. |
| 0.9967 | After seven months'continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine - year - old boy developed polyarthritis, Adverse-Effectrash and hepatitis in association with anti - native DNA antibodies and positive antinuclear factor. |
| 0.9836 | After seven months'continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine - year - old boy developed polyarthritis, rash and hepatitis in association with Adverse-Effectanti - native DNA antibodies and positive antinuclear factor. |
| 0.9985 | After seven months'continuous treatment for suspected tuberculosis with Drugrifampicin and ethambutol a nine - year - old boy developed polyarthritis, rash and hepatitis in association with anti - native DNA antibodies and positive antinuclear factor. |
| 0.9863 | After seven months'continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine - year - old boy developed polyarthritis, rash and hepatitis in association with anti - native DNA antibodies and Adverse-Effectpositive antinuclear factor . |
| Score | Text |
|---|---|
| 0.9984 | We report a 43 - year - old woman who developed sore throat, swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of Drugbudesonide spray ( Budefat ) for treatment of bronchial asthma. |
| 0.9967 | We report a 43 - year - old woman who developed sore throat, swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of budesonide spray ( DrugBudefat ) for treatment of bronchial asthma. |
| 0.9952 | We report a 43 - year - old woman who developed sore throat, swelling of the lips and oral cavity and Adverse-Effectdysphagia , 2 weeks after the use of budesonide spray ( Budefat ) for treatment of bronchial asthma. |
| 0.9925 | We report a 43 - year - old woman who developed Adverse-Effectsore throat , swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of budesonide spray ( Budefat ) for treatment of bronchial asthma. |
| 0.9803 | We report a 43 - year - old woman who developed sore throat, Adverse-Effectswelling of the lips and oral cavity and dysphagia, 2 weeks after the use of budesonide spray ( Budefat ) for treatment of bronchial asthma. |
| Score | Text |
|---|---|
| 0.9994 | However, in the mid - to - late 1980s, a series of letters to the editor and case reports announced an association between Drugtamoxifen therapy in women with breast cancer and the development of endometrial carcinoma. |
| 0.9922 | However, in the mid - to - late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of Adverse-Effectendometrial carcinoma . |
| Score | Text |
|---|---|
| 0.9579 | We report a cae of Adverse-Effectparanoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines. |
| 0.9461 | We report a cae of paranoid psychosis following use of a decongestant containing DrugPPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines. |
| 0.9443 | We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to DrugPPA in which doses were known and stated to be within recommended guidelines. |
| We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of Adverse-Effectpsychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines. | |
| Score | Text |
|---|---|
| 0.9995 | OBJECTIVE : To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new - onset psychotic and increased mood symptoms during treatment with Drugrisperidone . |
| 0.6814 | OBJECTIVE : To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new - onset psychotic and Adverse-Effectincreased mood symptoms during treatment with risperidone. |
| 0.6389 | OBJECTIVE : To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new - onset Adverse-Effectpsychotic and increased mood symptoms during treatment with risperidone. |
| Score | Text |
|---|---|
| 0.9995 | Ten days after Drugitraconazole was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities. |
| 0.9943 | Ten days after itraconazole was started, he developed Adverse-Effectparalytic ileus , neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities. |
| 0.9924 | Ten days after itraconazole was started, he developed paralytic ileus, Adverse-Effectneurogenic bladder , mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities. |
| 0.9874 | Ten days after itraconazole was started, he developed paralytic ileus, neurogenic bladder, Adverse-Effectmild left ptosis , and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities. |
| 0.9768 | Ten days after itraconazole was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and Adverse-Effectmild weakness of the upper extremities . |
| 0.9768 | Ten days after itraconazole was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with Adverse-Effectsevere paralysis of the lower extremities and mild weakness of the upper extremities. |
| 0.9610 | Ten days after itraconazole was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and Adverse-Effectabsence of deep reflexes , with severe paralysis of the lower extremities and mild weakness of the upper extremities. |
| Score | Text |
|---|---|
| 0.9784 | Administration of intrathecal DrugAra - C in the same dose over longer intervals within 3 - 5 days between consecutive doses resulted in mild, transient neurological symptoms ( paresthesias ) in only one of 30 patients so treated. |
| 0.9619 | Administration of intrathecal Ara - C in the same dose over longer intervals within 3 - 5 days between consecutive doses resulted in mild, transient neurological symptoms ( Adverse-Effectparesthesias ) in only one of 30 patients so treated. |
| 0.5662 | Administration of intrathecal Ara - C in the same dose over longer intervals within 3 - 5 days between consecutive doses resulted in Adverse-Effectmild, transient neurological symptoms ( paresthesias ) in only one of 30 patients so treated. |
| Score | Text |
|---|---|
| 0.9992 | PATIENT AND METHOD : A 34 - year - old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha - 2a and ribavirin for 6 months, developed progressive malaise and Adverse-Effectanemia 6 months after the end of treatment. |
| 0.9974 | PATIENT AND METHOD : A 34 - year - old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha - 2a and Drugribavirin for 6 months, developed progressive malaise and anemia 6 months after the end of treatment. |
| 0.9962 | PATIENT AND METHOD : A 34 - year - old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha - 2a and ribavirin for 6 months, developed Adverse-Effectprogressive malaise and anemia 6 months after the end of treatment. |
| 0.9746 | PATIENT AND METHOD : A 34 - year - old woman with chronic hepatitis C, genotype 3, receiving Drugpegylated interferon alpha - 2a and ribavirin for 6 months, developed progressive malaise and anemia 6 months after the end of treatment. |
| Score | Text |
|---|---|
| 0.9842 | CASE SUMMARY : A 46 - year - old African - American man experienced recurrent grand mal seizures during intravenous infusion of Drugamphotericin B , then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time. |
| 0.9319 | CASE SUMMARY : A 46 - year - old African - American man experienced recurrent Adverse-Effectgrand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time. |
| 0.9157 | CASE SUMMARY : A 46 - year - old African - American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then Adverse-Effectpetit mal seizures as the infusion was stopped and the drug concentrations decreased with time. |
| 0.7613 | CASE SUMMARY : A 46 - year - old African - American man experienced Adverse-Effectrecurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time. |
| Score | Text |
|---|---|
| 0.9997 | We report the case of a young man, affected by rheumatoid arthritis who developed a rapid - onset short - of - breath, hemoptysis, and severe weakness, about 2 weeks after the administration of Drugleflunomide . |
| 0.9990 | We report the case of a young man, affected by rheumatoid arthritis who developed a rapid - onset short - of - breath, Adverse-Effecthemoptysis , and severe weakness, about 2 weeks after the administration of leflunomide. |
| 0.9970 | We report the case of a young man, affected by rheumatoid arthritis who developed a rapid - onset short - of - breath, hemoptysis, and Adverse-Effectsevere weakness , about 2 weeks after the administration of leflunomide. |
| 0.9780 | We report the case of a young man, affected by rheumatoid arthritis who developed a rapid - onset Adverse-Effectshort - of - breath , hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide. |
| Score | Text |
|---|---|
| 0.9965 | It is thought that the clinico - pathological features and chronology of this case bore the hallmarks of the so - called " 3 - week sulphasalazine syndrome ", a rare, but often fatal, immunoallergic reaction to Drugsulphasalazine . |
| 0.9690 | It is thought that the clinico - pathological features and chronology of this case bore the hallmarks of the so - called " 3 - week Drugsulphasalazine syndrome ", a rare, but often fatal, immunoallergic reaction to sulphasalazine. |
| 0.9331 | It is thought that the clinico - pathological features and chronology of this case bore the hallmarks of the so - called " 3 - week sulphasalazine syndrome ", a rare, but often Adverse-Effectfatal , immunoallergic reaction to sulphasalazine. |
| 0.9288 | It is thought that the clinico - pathological features and chronology of this case bore the hallmarks of the so - called " 3 - week Adverse-Effectsulphasalazine syndrome ", a rare, but often fatal, immunoallergic reaction to sulphasalazine. |
| 0.9157 | It is thought that the clinico - pathological features and chronology of this case bore the hallmarks of the so - called " 3 - week sulphasalazine syndrome ", a rare, but often fatal, Adverse-Effectimmunoallergic reaction to sulphasalazine. |
| Score | Text |
|---|---|
| 0.9342 | After several unrevealing medical work - ups, he was found to have a high blood Druglead level ( 122 microg / dL ) ; he has a history of scraping and sanding lead paint without adequate protective measures. |
| 0.8937 | After several unrevealing medical work - ups, he was found to have a Adverse-Effecthigh blood lead level ( 122 microg / dL ) ; he has a history of scraping and sanding lead paint without adequate protective measures. |
| 0.6641 | After several unrevealing medical work - ups, he was found to have a high blood lead level ( 122 microg / dL ) ; he has a history of scraping and sanding Druglead paint without adequate protective measures. |
| Score | Text |
|---|---|
| 0.9815 | OBJECTIVES : The authors described a case of Adverse-EffectHashimoto's disease during interferon - alpha ( IFN - alpha ) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease. |
| 0.9746 | OBJECTIVES : The authors described a case of Hashimoto's disease during Druginterferon - alpha ( IFN - alpha ) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease. |
| 0.9712 | OBJECTIVES : The authors described a case of Hashimoto's disease during interferon - alpha ( DrugIFN - alpha ) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease. |
| Score | Text |
|---|---|
| 0.9996 | A high dose of Drugcotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious. |
| 0.9980 | A high dose of cotrimoxazole induced Adverse-Effecthyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious. |
| 0.9820 | A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea, and Adverse-Effectincreased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious. |
| 0.9766 | A high dose of cotrimoxazole induced hyperkalaemia with the Adverse-Effectelevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious. |
| 0.8553 | A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; Adverse-Effectone patient became unconscious . |
| 0.9823 | A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became Adverse-Effectunconscious . |
| 0.9818 | A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient Adverse-Effectbecame unconscious . |
| 0.9028 | A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one Adverse-Effectpatient became unconscious . |
| Score | Text |
|---|---|
| 0.9991 | We report on 7 patients ( 2 women, 5 men ) with chronic renal failure, who developed under a high dosage of the new diuretic Drugmuzolimine ( range 240 to 1440 mg per day ) fatal neuromyeloencephalopathy. |
| 0.9821 | We report on 7 patients ( 2 women, 5 men ) with chronic renal failure, who developed under a high dosage of the new diuretic muzolimine ( range 240 to 1440 mg per day ) Adverse-Effectfatal neuromyeloencephalopathy . |
| Score | Text |
|---|---|
| 0.9962 | We report the first case of fulminant adult respiratory distress syndrome ( ARDS ) associated with pegylated interferon alpha - 2a ( pegIFNalpha - 2a ) and Drugribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure. |
| 0.9929 | We report the first case of fulminant adult respiratory distress syndrome ( Adverse-EffectARDS ) associated with pegylated interferon alpha - 2a ( pegIFNalpha - 2a ) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure. |
| 0.9806 | We report the first case of fulminant adult respiratory distress syndrome ( ARDS ) associated with Drugpegylated interferon alpha - 2a ( pegIFNalpha - 2a ) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure. |
| 0.9805 | We report the first case of fulminant adult respiratory distress syndrome ( ARDS ) associated with pegylated interferon alpha - 2a ( DrugpegIFNalpha - 2a ) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure. |
| 0.9157 | We report the first case of fulminant Adverse-Effectadult respiratory distress syndrome ( ARDS ) associated with pegylated interferon alpha - 2a ( pegIFNalpha - 2a ) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure. |
| 0.9590 | We report the first case of Adverse-Effectfulminant adult respiratory distress syndrome ( ARDS ) associated with pegylated interferon alpha - 2a ( pegIFNalpha - 2a ) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure. |
| Score | Text |
|---|---|
| 0.9977 | Here we describe a patient with Crohn's disease who developed a severe Druginfliximab infusion reaction ( IIR ), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion. |
| 0.9966 | Here we describe a patient with Crohn's disease who developed a severe infliximab infusion reaction ( IIR ), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of Druginfliximab infusion. |
| 0.9921 | Here we describe a patient with Crohn's disease who developed a severe infliximab infusion reaction ( Adverse-EffectIIR ), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion. |
| 0.9704 | Here we describe a patient with Crohn's disease who developed a severe infliximab infusion reaction ( IIR ), complicated 1 day later by Adverse-Effectsevere swelling of the forearm and hand ipsilateral to the site of infliximab infusion. |
| Here we describe a patient with Crohn's disease who developed a Adverse-Effectsevere infliximab infusion reaction ( IIR ), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion. | |
| Score | Text |
|---|---|
| 0.9993 | However, there remain questions concerning whether these drugs, especially Drugmethimazole ( MMI ), may be associated with aplasia cutis congenita ( ACC ) and how best to avoid impairment of fetal thyroid function during their use. |
| 0.9858 | However, there remain questions concerning whether these drugs, especially methimazole ( MMI ), may be associated with Adverse-Effectaplasia cutis congenita ( ACC ) and how best to avoid impairment of fetal thyroid function during their use. |
| 0.9736 | However, there remain questions concerning whether these drugs, especially methimazole ( MMI ), may be associated with aplasia cutis congenita ( Adverse-EffectACC ) and how best to avoid impairment of fetal thyroid function during their use. |
| 0.9585 | However, there remain questions concerning whether these drugs, especially methimazole ( DrugMMI ), may be associated with aplasia cutis congenita ( ACC ) and how best to avoid impairment of fetal thyroid function during their use. |
| 0.9516 | However, there remain questions concerning whether these drugs, especially methimazole ( MMI ), may be associated with aplasia cutis congenita ( ACC ) and how best to avoid Adverse-Effectimpairment of fetal thyroid function during their use. |
| Score | Text |
|---|---|
| 0.9927 | Case 2, a 29 - year - old woman, developed Adverse-Effectbilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22 - month use of recombinant interferon alpha - 2b for chronic myelogenous leukemia. |
| 0.9902 | Case 2, a 29 - year - old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as Adverse-Effectbowel and bladder dysfunction after a 22 - month use of recombinant interferon alpha - 2b for chronic myelogenous leukemia. |
| 0.9861 | Case 2, a 29 - year - old woman, developed bilateral optic neuritis combined with Adverse-Effectnumbness of the lower extremities as well as bowel and bladder dysfunction after a 22 - month use of recombinant interferon alpha - 2b for chronic myelogenous leukemia. |
| 0.9627 | Case 2, a 29 - year - old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22 - month use of Drugrecombinant interferon alpha - 2b for chronic myelogenous leukemia. |
| Score | Text |
|---|---|
| 0.9940 | We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed Adverse-Effectacute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis. |
| 0.9677 | We report a case of a patient with mild chronic renal insufficiency who had been taking Drugsimvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis. |
| 0.9392 | We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with Drugcolchicine for acute gouty bursitis. |
| We report a case of a patient with Adverse-Effectmild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis. | |
| Score | Text |
|---|---|
| 0.9996 | We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with Drugepoprostenol , presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever. |
| 0.9979 | We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and Adverse-Effectvomiting , and fever. |
| 0.9975 | We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, Adverse-Effectscaling , nausea and vomiting, and fever. |
| 0.9962 | We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, Adverse-Effectnausea and vomiting, and fever. |
| 0.9917 | We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with Adverse-Effectrapidly progressive erythema , scaling, nausea and vomiting, and fever. |
| 0.9895 | We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and Adverse-Effectfever . |
| Score | Text |
|---|---|
| 0.9863 | CONCLUSIONS : This case report showed that the clinical appearance of Adverse-EffectHashimoto's disease after IFN - alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition ( DR5 ) for this pathology. |
| 0.9779 | CONCLUSIONS : This case report showed that the clinical appearance of Hashimoto's disease after DrugIFN - alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition ( DR5 ) for this pathology. |
| Score | Text |
|---|---|
| 0.9995 | We report a case of a patient with rheumatoid arthritis treated with low - dose Drugmethotrexate ( 15 mg / week ) who developed infection with both M. tuberculosis and M. chelonae after the revision of a prosthetic hip. |
| 0.9391 | We report a case of a patient with rheumatoid arthritis treated with low - dose methotrexate ( 15 mg / week ) who developed Adverse-Effectinfection with both M. tuberculosis and M. chelonae after the revision of a prosthetic hip. |
| Score | Text |
|---|---|
| 0.9996 | The case histories are presented of two patients who developed lung disease associated with the use of Drugnitrofurantoin with histological features of bronchiolitis obliterans organising pneumonia ( BOOP ), a rare but recognised form of drug induced injury. |
| 0.9925 | The case histories are presented of two patients who developed Adverse-Effectlung disease associated with the use of nitrofurantoin with histological features of bronchiolitis obliterans organising pneumonia ( BOOP ), a rare but recognised form of drug induced injury. |
| 0.9907 | The case histories are presented of two patients who developed lung disease associated with the use of nitrofurantoin with histological features of bronchiolitis obliterans organising pneumonia ( Adverse-EffectBOOP ), a rare but recognised form of drug induced injury. |
| 0.9764 | The case histories are presented of two patients who developed lung disease associated with the use of nitrofurantoin with histological features of Adverse-Effectbronchiolitis obliterans organising pneumonia ( BOOP ), a rare but recognised form of drug induced injury. |
| Score | Text |
|---|---|
| 0.9994 | A selective association between Drugfluoxetine and extensive, prominent eye movements in nonrapid eye movement ( NREM ) sleep was detected, utilizing Fisher's exact one - tailed statistic ( p less than 0. 00001 for each comparison ). |
| 0.9590 | A selective association between fluoxetine and extensive, prominent Adverse-Effecteye movements in nonrapid eye movement ( NREM ) sleep was detected, utilizing Fisher's exact one - tailed statistic ( p less than 0. 00001 for each comparison ). |
| Score | Text |
|---|---|
| 0.9980 | Our findings suggest that Adverse-Effecthyperkalemia can develop with the use of low - dose heparin, within seven days of initiating heparin therapy, and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication. |
| 0.9920 | Our findings suggest that hyperkalemia can develop with the use of low - dose heparin, within seven days of initiating Drugheparin therapy, and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication. |
| 0.9914 | Our findings suggest that hyperkalemia can develop with the use of low - dose Drugheparin , within seven days of initiating heparin therapy, and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication. |
| Score | Text |
|---|---|
| 0.9998 | We describe a case of disseminated muscular cysticercosis followed by myositis ( fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci ) induced by Drugpraziquantel therapy, an event not described previously. |
| 0.9990 | We describe a case of disseminated muscular cysticercosis followed by Adverse-Effectmyositis ( fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci ) induced by praziquantel therapy, an event not described previously. |
| 0.9923 | We describe a case of disseminated muscular cysticercosis followed by myositis ( fever, Adverse-Effectdiffuse myalgia , weakness of the lower limbs, and inflammatory reaction around dying cysticerci ) induced by praziquantel therapy, an event not described previously. |
| 0.9909 | We describe a case of disseminated muscular cysticercosis followed by myositis ( Adverse-Effectfever , diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci ) induced by praziquantel therapy, an event not described previously. |
| 0.9835 | We describe a case of disseminated muscular cysticercosis followed by myositis ( fever, diffuse myalgia, Adverse-Effectweakness of the lower limbs , and inflammatory reaction around dying cysticerci ) induced by praziquantel therapy, an event not described previously. |
| 0.9784 | We describe a case of disseminated muscular cysticercosis followed by myositis ( fever, diffuse myalgia, weakness of the lower limbs, and Adverse-Effectinflammatory reaction around dying cysticerci ) induced by praziquantel therapy, an event not described previously. |
| 0.9708 | We describe a case of Adverse-Effectdisseminated muscular cysticercosis followed by myositis ( fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci ) induced by praziquantel therapy, an event not described previously. |
| Score | Text |
|---|---|
| 0.9887 | A 51 - yr - old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed attacks of asthma when captopril was added to the nadolol and Drugdyazide treatment for his high blood pressure. |
| 0.9853 | A 51 - yr - old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed attacks of asthma when captopril was added to the Drugnadolol and dyazide treatment for his high blood pressure. |
| 0.9797 | A 51 - yr - old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed Adverse-Effectattacks of asthma when captopril was added to the nadolol and dyazide treatment for his high blood pressure. |
| 0.9542 | A 51 - yr - old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed attacks of asthma when Drugcaptopril was added to the nadolol and dyazide treatment for his high blood pressure. |
| Score | Text |
|---|---|
| 0.9924 | Despite a response of the meningeal tumor the patient developed in the third week of DrugMTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara - C treatment and led to death within 3 weeks. |
| 0.9873 | Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and Adverse-Effectloss of consciousness which worsened during subsequent Ara - C treatment and led to death within 3 weeks. |
| 0.9860 | Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent DrugAra - C treatment and led to death within 3 weeks. |
| 0.9828 | Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a Adverse-Effectprogressive visual loss and loss of consciousness which worsened during subsequent Ara - C treatment and led to death within 3 weeks. |
| 0.8956 | Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara - C treatment and led to Adverse-Effectdeath within 3 weeks. |
| Score | Text |
|---|---|
| 0.9961 | A 32 - year - old man with a family history of type 2 diabetes mellitus presented with Adverse-Effectcirculatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan. |
| 0.9948 | A 32 - year - old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and Adverse-Effectdeep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan. |
| 0.9825 | A 32 - year - old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with Drugperospirone hydrochloride , a recently developed atypical antipsychotic agent available only in Japan. |
| Score | Text |
|---|---|
| 0.9995 | A woman with a 20 - year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs, developed a B - cell lymphoma of the lip following 4 1 / 2 years of treatment with Drugrazoxane . |
| 0.9775 | A woman with a 20 - year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs, developed a Adverse-EffectB - cell lymphoma of the lip following 4 1 / 2 years of treatment with razoxane. |
| Score | Text |
|---|---|
| 0.9981 | Fatal lung fibrosis caused by Drugpaclitaxel toxicity has not been reported In this report, we describe the case of a 62 - year - old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer. |
| 0.9967 | Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62 - year - old woman who received six cycles of Drugpaclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer. |
| 0.9966 | Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62 - year - old woman who received six cycles of paclitaxel and Drugcarboplatin as combination chemotherapy for advanced ovarian cancer. |
| 0.9882 | Adverse-EffectFatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62 - year - old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer. |
| Score | Text |
|---|---|
| 0.9994 | Since Drugimiquimod induces large amounts of type I interferon production from TLR7 - expressing plasmacytoid dendritic cell precursors ( PDCs ), the natural interferon - producing cells of the peripheral blood, we asked whether PDCs are present in psoriatic skin. |
| 0.9749 | Since imiquimod induces Adverse-Effectlarge amounts of type I interferon production from TLR7 - expressing plasmacytoid dendritic cell precursors ( PDCs ), the natural interferon - producing cells of the peripheral blood, we asked whether PDCs are present in psoriatic skin. |
| Score | Text |
|---|---|
| 0.9891 | As this relapse coincided with development of a strong delayed - type hypersensitivity response to Drugtuberculin and improved after treatment with the anti - inflammatory agent oxpentifylline, it was probably caused by restoration of pathogen - specific cellular immunity. |
| 0.9561 | As this relapse coincided with development of a strong delayed - type Adverse-Effecthypersensitivity response to tuberculin and improved after treatment with the anti - inflammatory agent oxpentifylline, it was probably caused by restoration of pathogen - specific cellular immunity. |
| Score | Text |
|---|---|
| 0.9993 | In view of our experience in the present case, it should be stressed that close monitoring of coagulation capacity is necessary in critically ill patients in order to avoid fatal haemorrhage after initiating Drugwarfarin therapy regardless of the dosage. |
| 0.9926 | In view of our experience in the present case, it should be stressed that close monitoring of coagulation capacity is necessary in critically ill patients in order to avoid Adverse-Effectfatal haemorrhage after initiating warfarin therapy regardless of the dosage. |
| Score | Text |
|---|---|
| 0.9993 | On day 4, following 3 doses of Drugdalteparin , the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography ( CTPA ) and intercostal drainage of 1500 mL of frank blood. |
| 0.9902 | On day 4, following 3 doses of dalteparin, the patient developed Adverse-Effectacute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography ( CTPA ) and intercostal drainage of 1500 mL of frank blood. |
| Score | Text |
|---|---|
| 0.9993 | We report an 82 - year - old man who developed ventricular tachycardia and Torsades de Pointes ( TdP ) after oral administration of Druggarenoxacin , a novel quinolone antibiotic agent that differs from the third - generation quinolones, for pneumonia. |
| 0.9974 | We report an 82 - year - old man who developed ventricular tachycardia and Torsades de Pointes ( Adverse-EffectTdP ) after oral administration of garenoxacin, a novel quinolone antibiotic agent that differs from the third - generation quinolones, for pneumonia. |
| 0.9913 | We report an 82 - year - old man who developed Adverse-Effectventricular tachycardia and Torsades de Pointes ( TdP ) after oral administration of garenoxacin, a novel quinolone antibiotic agent that differs from the third - generation quinolones, for pneumonia. |
| 0.9838 | We report an 82 - year - old man who developed ventricular tachycardia and Adverse-EffectTorsades de Pointes ( TdP ) after oral administration of garenoxacin, a novel quinolone antibiotic agent that differs from the third - generation quinolones, for pneumonia. |
| Score | Text |
|---|---|
| 0.9983 | After the dose of Drugmethylprednisolone was reduced from 40 mg to 20 mg i. v. q6h and shifted to other anti - asthma treatment by procaterol metered dose inhaler via spacer, the psychotic reaction disappeared a few hours later. |
| 0.9915 | After the dose of methylprednisolone was reduced from 40 mg to 20 mg i. v. q6h and shifted to other anti - asthma treatment by procaterol metered dose inhaler via spacer, the Adverse-Effectpsychotic reaction disappeared a few hours later. |
| Score | Text |
|---|---|
| 0.9987 | The cases are important in documenting that drug - induced dystonias do occur in patients with dementia, that Drugrisperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification. |
| 0.9970 | The cases are important in documenting that drug - induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to Adverse-Effectdystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification. |
| 0.9968 | The cases are important in documenting that drug - induced Adverse-Effectdystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification. |
| Score | Text |
|---|---|
| 0.9994 | He was started on oral Druglansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10 ( 3 ) / mm ( 3 ) ; on hospital day 3, the platelet count was 36 x 10 ( 3 ) / mm ( 3 ). |
| 0.9585 | He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his Adverse-Effectplatelet count decreased to 102 x 10 ( 3 ) / mm ( 3 ) ; on hospital day 3, the platelet count was 36 x 10 ( 3 ) / mm ( 3 ). |
| Score | Text |
|---|---|
| 0.9995 | Here we present the case of a woman who received high doses of Drugmethylprednisolone ( 1 g iv daily ) for active Graves'ophthalmopathy, and developed severe hypertension followed by myocardial infarction on the fifth day of treatment. |
| 0.9934 | Here we present the case of a woman who received high doses of methylprednisolone ( 1 g iv daily ) for active Graves'ophthalmopathy, and developed severe hypertension followed by Adverse-Effectmyocardial infarction on the fifth day of treatment. |
| 0.9921 | Here we present the case of a woman who received high doses of methylprednisolone ( 1 g iv daily ) for active Graves'ophthalmopathy, and developed Adverse-Effectsevere hypertension followed by myocardial infarction on the fifth day of treatment. |
| Score | Text |
|---|---|
| 0.9778 | We report on three cases wherein treatment of dexmedetomidine - induced bradycardia with i. v. glycopyrrolate ( 5. 0 microg / kg ) not only resulting in resolution of bradycardia but also resulting in an Adverse-Effectexaggerated increase of arterial blood pressure . |
| 0.9760 | We report on three cases wherein treatment of Drugdexmedetomidine - induced bradycardia with i. v. glycopyrrolate ( 5. 0 microg / kg ) not only resulting in resolution of bradycardia but also resulting in an exaggerated increase of arterial blood pressure. |
| 0.9292 | We report on three cases wherein treatment of dexmedetomidine - induced Adverse-Effectbradycardia with i. v. glycopyrrolate ( 5. 0 microg / kg ) not only resulting in resolution of bradycardia but also resulting in an exaggerated increase of arterial blood pressure. |
| 0.6511 | We report on three cases wherein treatment of dexmedetomidine - induced bradycardia with i. v. Drugglycopyrrolate ( 5. 0 microg / kg ) not only resulting in resolution of bradycardia but also resulting in an exaggerated increase of arterial blood pressure. |
| Score | Text |
|---|---|
| 0.9951 | While the introduction of carmustine wafers ( Gliadel wafers ) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant Adverse-Effectcerebral edema is a potential adverse effect. |
| 0.9917 | While the introduction of Drugcarmustine wafers ( Gliadel wafers ) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect. |
| 0.9846 | While the introduction of carmustine wafers ( DrugGliadel wafers ) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect. |
| Score | Text |
|---|---|
| 0.9924 | CASE REPORT : We present a case of a 28 - yr - old male who developed a severe case of Adverse-Effectnephrotic syndrome while being treated for relapsing / remitting Multiple Sclerosis ( RRMS ) with weekly injections of interferon beta 1a. |
| 0.9792 | CASE REPORT : We present a case of a 28 - yr - old male who developed a severe case of nephrotic syndrome while being treated for relapsing / remitting Multiple Sclerosis ( RRMS ) with weekly injections of Druginterferon beta 1a . |
| Score | Text |
|---|---|
| 0.9788 | We report a case of ST elevation in right precordial leads compatible with Adverse-Effecttype 1 Brugada syndrome following administration of propafenone in a patient with Wolff - Parkinson - White syndrome who was receiving lithium at concentrations within therapeutic levels. |
| 0.9671 | We report a case of ST elevation in right precordial leads compatible with type 1 Brugada syndrome following administration of Drugpropafenone in a patient with Wolff - Parkinson - White syndrome who was receiving lithium at concentrations within therapeutic levels. |
| 0.9350 | We report a case of Adverse-EffectST elevation in right precordial leads compatible with type 1 Brugada syndrome following administration of propafenone in a patient with Wolff - Parkinson - White syndrome who was receiving lithium at concentrations within therapeutic levels. |
| 0.8434 | We report a case of ST elevation in right precordial leads compatible with type 1 Brugada syndrome following administration of propafenone in a patient with Wolff - Parkinson - White syndrome who was receiving Druglithium at concentrations within therapeutic levels. |
| Score | Text |
|---|---|
| 0.9991 | The authors report a case of acute pancreatitis ( AP ) occurring in a patient under treatment with Drugcarbamazepine ( CBZ ) for post - traumatic petit mal epilepsy, and review the current literature of drug - induced AP. |
| 0.9986 | The authors report a case of acute pancreatitis ( AP ) occurring in a patient under treatment with carbamazepine ( DrugCBZ ) for post - traumatic petit mal epilepsy, and review the current literature of drug - induced AP. |
| 0.9867 | The authors report a case of Adverse-Effectacute pancreatitis ( AP ) occurring in a patient under treatment with carbamazepine ( CBZ ) for post - traumatic petit mal epilepsy, and review the current literature of drug - induced AP. |
| 0.6259 | The authors report a case of acute pancreatitis ( Adverse-EffectAP ) occurring in a patient under treatment with carbamazepine ( CBZ ) for post - traumatic petit mal epilepsy, and review the current literature of drug - induced AP. |
| The authors report a case of acute Adverse-Effectpancreatitis ( AP ) occurring in a patient under treatment with carbamazepine ( CBZ ) for post - traumatic petit mal epilepsy, and review the current literature of drug - induced AP. | |
| Score | Text |
|---|---|
| 0.9995 | These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course : 3 of these patients died of PCP occurring during the first month of treatment with Drugprednisone . |
| 0.9547 | These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course : 3 of these patients Adverse-Effectdied of PCP occurring during the first month of treatment with prednisone. |
| 0.9821 | These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course : 3 of these patients died of Adverse-EffectPCP occurring during the first month of treatment with prednisone. |
| Score | Text |
|---|---|
| 0.9741 | A small initial dose of Drugprazosin ranging from 0. 5 to 1 mg has been recommended to avoid the first - dose phenomenon characterized by a sudden and severe drop in blood pressure after the administration of the first dose of prazosin. |
| 0.9274 | A small initial dose of prazosin ranging from 0. 5 to 1 mg has been recommended to avoid the first - dose phenomenon characterized by a sudden and severe drop in blood pressure after the administration of the first dose of Drugprazosin . |
| 0.8738 | A small initial dose of prazosin ranging from 0. 5 to 1 mg has been recommended to avoid the first - dose phenomenon characterized by a sudden and Adverse-Effectsevere drop in blood pressure after the administration of the first dose of prazosin. |
| 0.9458 | A small initial dose of prazosin ranging from 0. 5 to 1 mg has been recommended to avoid the first - dose phenomenon characterized by a sudden and severe Adverse-Effectdrop in blood pressure after the administration of the first dose of prazosin. |
| Score | Text |
|---|---|
| 0.9980 | In a postural challenge test after administration of isosorbide dinitrate ( 5 mg ), blood pressure decreased from 120 / 67 to 65 / 35 mmHg, followed by Adverse-Effectsyncope with a sudden decrease in pulse rate from 85 to 60 beats / min. |
| 0.9807 | In a postural challenge test after administration of isosorbide dinitrate ( 5 mg ), blood pressure decreased from 120 / 67 to 65 / 35 mmHg, followed by syncope with a Adverse-Effectsudden decrease in pulse rate from 85 to 60 beats / min. |
| 0.9806 | In a postural challenge test after administration of Drugisosorbide dinitrate ( 5 mg ), blood pressure decreased from 120 / 67 to 65 / 35 mmHg, followed by syncope with a sudden decrease in pulse rate from 85 to 60 beats / min. |
| 0.9667 | In a postural challenge test after administration of isosorbide dinitrate ( 5 mg ), Adverse-Effectblood pressure decreased from 120 / 67 to 65 / 35 mmHg, followed by syncope with a sudden decrease in pulse rate from 85 to 60 beats / min. |
| Score | Text |
|---|---|
| 0.9976 | CONCLUSIONS : This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of Adverse-Effectdiarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin. |
| 0.9912 | CONCLUSIONS : This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and Drugclindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin. |
| 0.9861 | CONCLUSIONS : This report indicates clindamycin phosphate vaginal cream as the most probable cause of Adverse-EffectCDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin. |
| 0.9839 | CONCLUSIONS : This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of Adverse-EffectC. difficile toxin . |
| 0.9818 | CONCLUSIONS : This report indicates Drugclindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin. |
| Score | Text |
|---|---|
| 0.9978 | DISCUSSION : Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and Adverse-Effectbradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates. |
| 0.9934 | DISCUSSION : Amphotericin B deoxycholate has been reported to produce significant Adverse-Effectcardiac toxicity , with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates. |
| 0.9928 | DISCUSSION : Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with Adverse-Effectventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates. |
| 0.9762 | DISCUSSION : DrugAmphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates. |
| Score | Text |
|---|---|
| 0.9987 | This report suggests that Adverse-Effectanemia can occur due to MMF, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used. |
| 0.9768 | This report suggests that anemia can occur due to MMF, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, Drugcyclosporine and prednisone is used. |
| 0.9743 | This report suggests that anemia can occur due to MMF, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and Drugprednisone is used. |
| 0.9704 | This report suggests that anemia can occur due to DrugMMF , in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used. |
| 0.9683 | This report suggests that anemia can occur due to MMF, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of DrugMMF , cyclosporine and prednisone is used. |
| 0.9602 | This report suggests that anemia can occur due to MMF, in particular when it is given with Drugprednisone , a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used. |
| Score | Text |
|---|---|
| 0.9996 | A 79 - year - old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with Drugcolchicine . |
| 0.9991 | A 79 - year - old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of Adverse-Effectfatigue , myalgia, and leg weakness, shortly after starting treatment with colchicine. |
| 0.9991 | A 79 - year - old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, Adverse-Effectmyalgia , and leg weakness, shortly after starting treatment with colchicine. |
| 0.9963 | A 79 - year - old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and Adverse-Effectleg weakness , shortly after starting treatment with colchicine. |
| Score | Text |
|---|---|
| 0.9998 | RESULTS : In a 22 - year - old Thai woman with Graves'disease, tinnitus, hearing impairment in the left ear ( with progression to the right ear ), and vertigo developed after 3 years of therapy with DrugPTU . |
| 0.9991 | RESULTS : In a 22 - year - old Thai woman with Graves'disease, Adverse-Effecttinnitus , hearing impairment in the left ear ( with progression to the right ear ), and vertigo developed after 3 years of therapy with PTU. |
| 0.9989 | RESULTS : In a 22 - year - old Thai woman with Graves'disease, tinnitus, hearing impairment in the left ear ( with progression to the right ear ), and Adverse-Effectvertigo developed after 3 years of therapy with PTU. |
| 0.9095 | RESULTS : In a 22 - year - old Thai woman with Graves'disease, tinnitus, Adverse-Effecthearing impairment in the left ear ( with progression to the right ear ), and vertigo developed after 3 years of therapy with PTU. |
| 0.8594 | RESULTS : In a 22 - year - old Thai woman with Graves'disease, tinnitus, hearing impairment in the left ear ( with Adverse-Effectprogression to the right ear ), and vertigo developed after 3 years of therapy with PTU. |
| RESULTS : In a 22 - year - old Thai woman with Graves'disease, tinnitus, Adverse-Effecthearing impairment in the left ear ( with progression to the right ear ) , and vertigo developed after 3 years of therapy with PTU. | |
| Score | Text |
|---|---|
| 0.9921 | This case is remarkable since 1 ) ECM developed after subcutaneous and not after intramuscular injection, 2 ) the injection was given by the patient himself, and 3 ) glatiramer acetate can induce Adverse-Effectskin necrosis as a side effect. |
| 0.9758 | This case is remarkable since 1 ) ECM developed after subcutaneous and not after intramuscular injection, 2 ) the injection was given by the patient himself, and 3 ) Drugglatiramer acetate can induce skin necrosis as a side effect. |
| 0.9928 | This case is remarkable since 1 ) Adverse-EffectECM developed after subcutaneous and not after intramuscular injection, 2 ) the injection was given by the patient himself, and 3 ) glatiramer acetate can induce skin necrosis as a side effect. |
| Score | Text |
|---|---|
| 0.9961 | Subsequent in vivo / vitro studies clearly demonstrated that the neurological effects were due to a synergistic action of desferrioxamine and Drugprochlorperazine , probably resulting in exceptional fluxes of intra / extra cellular iron / copper disturbing noradrenergic and serotonergic systems. |
| 0.9949 | Subsequent in vivo / vitro studies clearly demonstrated that the neurological effects were due to a synergistic action of Drugdesferrioxamine and prochlorperazine, probably resulting in exceptional fluxes of intra / extra cellular iron / copper disturbing noradrenergic and serotonergic systems. |
| 0.9885 | Subsequent in vivo / vitro studies clearly demonstrated that the Adverse-Effectneurological effects were due to a synergistic action of desferrioxamine and prochlorperazine, probably resulting in exceptional fluxes of intra / extra cellular iron / copper disturbing noradrenergic and serotonergic systems. |
| Score | Text |
|---|---|
| 0.9996 | We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom Druginfliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other. |
| 0.9838 | We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to Adverse-Effectnecrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other. |
| 0.9826 | We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to Adverse-Effectprogression of preexisting mononeuritis multiplex in the other. |
| 0.9810 | We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with Adverse-Effectperipheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other. |
| Score | Text |
|---|---|
| 0.9930 | Adverse-EffectMI related to the use of activated and non - activated PCCs predominantly affects young patients who often have no preceding history of, or risk factors for, MI and tends to be associated with large cumulative doses of concentrate. |
| 0.9841 | MI related to the use of activated and non - activated DrugPCCs predominantly affects young patients who often have no preceding history of, or risk factors for, MI and tends to be associated with large cumulative doses of concentrate. |
| Score | Text |
|---|---|
| 0.9993 | We report on a 56 - year - old female who exhibited drug refractory paroxysmal atrial fibrillation, in which marked prolongation of the QT interval and T wave inversion on electrocardiogram was demonstrated reproducibly shortly after the administration of oral Drugpirmenol therapy. |
| 0.9846 | We report on a 56 - year - old female who exhibited drug refractory paroxysmal atrial fibrillation, in which marked prolongation of the QT interval and Adverse-EffectT wave inversion on electrocardiogram was demonstrated reproducibly shortly after the administration of oral pirmenol therapy. |
| 0.9759 | We report on a 56 - year - old female who exhibited drug refractory paroxysmal atrial fibrillation, in which marked Adverse-Effectprolongation of the QT interval and T wave inversion on electrocardiogram was demonstrated reproducibly shortly after the administration of oral pirmenol therapy. |
| 0.9441 | We report on a 56 - year - old female who exhibited Adverse-Effectdrug refractory paroxysmal atrial fibrillation , in which marked prolongation of the QT interval and T wave inversion on electrocardiogram was demonstrated reproducibly shortly after the administration of oral pirmenol therapy. |
| Score | Text |
|---|---|
| 0.9942 | This case of Druglinezolid - associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms ( DRESS ) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug. |
| 0.9907 | This case of linezolid - associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms ( Adverse-EffectDRESS ) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug. |
| 0.9892 | This case of linezolid - associated Adverse-Effectacute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms ( DRESS ) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug. |
| 0.9770 | This case of linezolid - associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms ( DRESS ) syndrome in a patient treated with Druglinezolid raises concerns about the presumed renal safety of this drug. |
| 0.9585 | This case of linezolid - associated acute interstitial nephritis within the context of a Adverse-Effectdrug rash with eosinophilia and systemic symptoms ( DRESS ) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug. |
| Score | Text |
|---|---|
| 0.9937 | INTRODUCTION : Although gefitinib used for the treatment of non - small - cell lung cancer is a well - known cause of interstitial lung disease ( Adverse-EffectILD ), few case reports on erlotinib - induced ILD have been issued. |
| 0.9496 | INTRODUCTION : Although gefitinib used for the treatment of non - small - cell lung cancer is a well - known cause of Adverse-Effectinterstitial lung disease ( ILD ), few case reports on erlotinib - induced ILD have been issued. |
| 0.9470 | INTRODUCTION : Although gefitinib used for the treatment of non - small - cell lung cancer is a well - known cause of interstitial lung disease ( ILD ), few case reports on Drugerlotinib - induced ILD have been issued. |
| 0.9456 | INTRODUCTION : Although Druggefitinib used for the treatment of non - small - cell lung cancer is a well - known cause of interstitial lung disease ( ILD ), few case reports on erlotinib - induced ILD have been issued. |
| 0.6495 | INTRODUCTION : Although gefitinib used for the treatment of non - small - cell lung cancer is a well - known cause of interstitial lung disease ( ILD ), few case reports on erlotinib - induced Adverse-EffectILD have been issued. |
| Score | Text |
|---|---|
| 0.9987 | RESULTS : A 44 - year - old man taking Drugnaproxen for chronic low back pain and a 20 - year - old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands. |
| 0.9982 | RESULTS : A 44 - year - old man taking naproxen for chronic low back pain and a 20 - year - old woman on Drugoxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands. |
| 0.9930 | RESULTS : A 44 - year - old man taking naproxen for chronic low back pain and a 20 - year - old woman on oxaprozin for rheumatoid arthritis presented with Adverse-Effecttense bullae and cutaneous fragility on the face and the back of the hands. |
| 0.9890 | RESULTS : A 44 - year - old man taking naproxen for chronic low back pain and a 20 - year - old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and Adverse-Effectcutaneous fragility on the face and the back of the hands. |
| Score | Text |
|---|---|
| 0.9983 | The patient's previous rash and the temporal relation of this event and the ingestion of phenolphthalein, as well as the similarity of this case to other reports, point to phenolphthalein as the cause of Adverse-EffectTEN in this patient. |
| 0.9529 | The patient's previous Adverse-Effectrash and the temporal relation of this event and the ingestion of phenolphthalein, as well as the similarity of this case to other reports, point to phenolphthalein as the cause of TEN in this patient. |
| 0.9477 | The patient's previous rash and the temporal relation of this event and the ingestion of Drugphenolphthalein , as well as the similarity of this case to other reports, point to phenolphthalein as the cause of TEN in this patient. |
| 0.8471 | The patient's previous rash and the temporal relation of this event and the ingestion of phenolphthalein, as well as the similarity of this case to other reports, point to Drugphenolphthalein as the cause of TEN in this patient. |
| Score | Text |
|---|---|
| 0.9972 | The case history confirms that Druggold treatment, even in the same patient, can give rise to a wide range of skin disturbances, which in many cases do not break out until long after the drug has been withdrawn. |
| 0.9880 | The case history confirms that gold treatment, even in the same patient, can give rise to a wide range of Adverse-Effectskin disturbances , which in many cases do not break out until long after the drug has been withdrawn. |
| Score | Text |
|---|---|
| 0.9996 | A patient receiving Drugvancomycin for a serious staphylococcal infection had a lupus - like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips. |
| 0.9929 | A patient receiving vancomycin for a serious staphylococcal infection had a lupus - like syndrome characterized by a Adverse-Effectmalar rash , pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips. |
| 0.9896 | A patient receiving vancomycin for a serious staphylococcal infection had a lupus - like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and Adverse-Effecttender erythematous and hemorrhagic lesions of the finger tips. |
| 0.9854 | A patient receiving vancomycin for a serious staphylococcal infection had a Adverse-Effectlupus - like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips. |
| 0.9825 | A patient receiving vancomycin for a serious staphylococcal infection had a lupus - like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and Adverse-Effecthemorrhagic lesions of the finger tips . |
| 0.9744 | A patient receiving vancomycin for a serious staphylococcal infection had a lupus - like syndrome characterized by a malar rash, pain and Adverse-Effecterythema of the cartilage of both ears , and tender erythematous and hemorrhagic lesions of the finger tips. |
| 0.9693 | A patient receiving vancomycin for a serious staphylococcal infection had a lupus - like syndrome characterized by a malar rash, Adverse-Effectpain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips. |
| Score | Text |
|---|---|
| 0.9994 | Because the combination of Drugbleomycin and vinca alkaloids is commonly used for the treatment of AIDS - related Kaposi's sarcoma, clinicians should be aware of the risk of provoking acral necrosis in patients who develop Raynaud's phenomenon under chemotherapy. |
| 0.9795 | Because the combination of bleomycin and vinca alkaloids is commonly used for the treatment of AIDS - related Kaposi's sarcoma, clinicians should be aware of the risk of provoking Adverse-Effectacral necrosis in patients who develop Raynaud's phenomenon under chemotherapy. |
| 0.9789 | Because the combination of bleomycin and vinca alkaloids is commonly used for the treatment of AIDS - related Kaposi's sarcoma, clinicians should be aware of the risk of provoking acral necrosis in patients who develop Adverse-EffectRaynaud's phenomenon under chemotherapy. |
| 0.8321 | Because the combination of bleomycin and vinca alkaloids is commonly used for the treatment of AIDS - related Adverse-EffectKaposi's sarcoma , clinicians should be aware of the risk of provoking acral necrosis in patients who develop Raynaud's phenomenon under chemotherapy. |
| Score | Text |
|---|---|
| 0.9957 | DrugMethotrexate ( MTX ) is a commonly used second line agent for RA, and there have been several recent reports of Epstein - Barr virus ( EBV ) - associated polyclonal B cell lymphoproliferative disorder in MTX - treated RA patients. |
| 0.9953 | Methotrexate ( DrugMTX ) is a commonly used second line agent for RA, and there have been several recent reports of Epstein - Barr virus ( EBV ) - associated polyclonal B cell lymphoproliferative disorder in MTX - treated RA patients. |
| 0.9933 | Methotrexate ( MTX ) is a commonly used second line agent for RA, and there have been several recent reports of Epstein - Barr virus ( EBV ) - associated polyclonal B cell lymphoproliferative disorder in DrugMTX - treated RA patients. |
| Methotrexate ( MTX ) is a commonly used second line agent for RA, and there have been several recent reports of Adverse-EffectEpstein - Barr virus ( EBV ) - associated polyclonal B cell lymphoproliferative disorder in MTX - treated RA patients. | |
| Score | Text |
|---|---|
| 0.9377 | We present a case of acute Drugepinephrine toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed severe allergic reaction to intravenous immunoglobulin, and was subsequently given epinephrine by mistake intravenously rather than subcutaneously. |
| 0.8940 | We present a case of acute epinephrine toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed Adverse-Effectsevere allergic reaction to intravenous immunoglobulin, and was subsequently given epinephrine by mistake intravenously rather than subcutaneously. |
| 0.7045 | We present a case of acute epinephrine toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed severe allergic reaction to intravenous immunoglobulin, and was subsequently given Drugepinephrine by mistake intravenously rather than subcutaneously. |
| 0.5201 | We present a case of acute epinephrine toxicity resulting in Adverse-Effectacute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed severe allergic reaction to intravenous immunoglobulin, and was subsequently given epinephrine by mistake intravenously rather than subcutaneously. |
| 0.5517 | We present a case of acute Adverse-Effectepinephrine toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed severe allergic reaction to intravenous immunoglobulin, and was subsequently given epinephrine by mistake intravenously rather than subcutaneously. |
| Score | Text |
|---|---|
| 0.9996 | We report a myeloma patient who developed severe paralytic ileus during Drugbortezomib therapy, which presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation, suggesting a direct causal relationship. |
| 0.9801 | We report a myeloma patient who developed Adverse-Effectsevere paralytic ileus during bortezomib therapy, which presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation, suggesting a direct causal relationship. |
| Score | Text |
|---|---|
| 0.9898 | These in vitro findings and clinical course suggest that TRAb / TBII without thyroid - stimulating activity may develop in patients with Drugamiodarone - induced destructive thyroiditis, as reported in patients with destructive thyroiditis, such as subacute and silent thyroiditis. |
| 0.9669 | These in vitro findings and clinical course suggest that TRAb / TBII without thyroid - stimulating activity may develop in patients with amiodarone - induced Adverse-Effectdestructive thyroiditis , as reported in patients with destructive thyroiditis, such as subacute and silent thyroiditis. |
| 0.9589 | These in vitro findings and clinical course suggest that TRAb / TBII without thyroid - stimulating activity may develop in patients with amiodarone - induced destructive thyroiditis, as reported in patients with Adverse-Effectdestructive thyroiditis , such as subacute and silent thyroiditis. |
| 0.7556 | These in vitro findings and clinical course suggest that TRAb / TBII without thyroid - stimulating activity may develop in patients with amiodarone - induced destructive thyroiditis, as reported in patients with destructive thyroiditis, such as subacute and silent Adverse-Effectthyroiditis . |
| 0.6746 | These in vitro findings and clinical course suggest that DrugTRAb / TBII without thyroid - stimulating activity may develop in patients with amiodarone - induced destructive thyroiditis, as reported in patients with destructive thyroiditis, such as subacute and silent thyroiditis. |
| 0.5879 | These in vitro findings and clinical course suggest that TRAb / TBII without thyroid - stimulating activity may develop in patients with amiodarone - induced destructive thyroiditis, as reported in patients with destructive Adverse-Effectthyroiditis , such as subacute and silent thyroiditis. |
| These in vitro findings and clinical course suggest that Adverse-EffectTRAb / TBII without thyroid - stimulating activity may develop in patients with amiodarone - induced destructive thyroiditis, as reported in patients with destructive thyroiditis, such as subacute and silent thyroiditis. | |
| Score | Text |
|---|---|
| 0.9974 | When SASP was changed to 5 - aminosalicylic acid ( 5 - ASA ), his skin eruptions were resolved, however, he developed weakness and Adverse-Effectatrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance. |
| 0.9970 | When SASP was changed to 5 - aminosalicylic acid ( 5 - ASA ), his skin eruptions were resolved, however, he developed Adverse-Effectweakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance. |
| 0.9888 | When SASP was changed to 5 - aminosalicylic acid ( Drug5 - ASA ), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance. |
| 0.9886 | When SASP was changed to 5 - aminosalicylic acid ( 5 - ASA ), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and Adverse-Effectgait disturbance . |
| 0.9783 | When SASP was changed to Drug5 - aminosalicylic acid ( 5 - ASA ), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance. |
| 0.9765 | When SASP was changed to 5 - aminosalicylic acid ( 5 - ASA ), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive Adverse-Effectworsening of the dysesthesia in his legs and gait disturbance. |
| 0.9423 | When DrugSASP was changed to 5 - aminosalicylic acid ( 5 - ASA ), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance. |
| 0.9215 | When SASP was changed to 5 - aminosalicylic acid ( 5 - ASA ), his Adverse-Effectskin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance. |
| Score | Text |
|---|---|
| 0.9981 | CASE REPORT : Soon after initiation of amiodarone HCl ( 200 mg / day ), a 76 - year - old man came to us with symptoms of visual " shining, " Adverse-Effectglare , color vision anomalies, and gradually decreased vision. |
| 0.9943 | CASE REPORT : Soon after initiation of amiodarone HCl ( 200 mg / day ), a 76 - year - old man came to us with symptoms of visual " shining, " glare, color vision anomalies, and gradually Adverse-Effectdecreased vision . |
| 0.9893 | CASE REPORT : Soon after initiation of Drugamiodarone HCl ( 200 mg / day ), a 76 - year - old man came to us with symptoms of visual " shining, " glare, color vision anomalies, and gradually decreased vision. |
| 0.9874 | CASE REPORT : Soon after initiation of amiodarone HCl ( 200 mg / day ), a 76 - year - old man came to us with symptoms of visual " shining, " glare, Adverse-Effectcolor vision anomalies , and gradually decreased vision. |
| 0.9863 | CASE REPORT : Soon after initiation of amiodarone HCl ( 200 mg / day ), a 76 - year - old man came to us with symptoms of Adverse-Effectvisual " shining , " glare, color vision anomalies, and gradually decreased vision. |
| Score | Text |
|---|---|
| 0.9940 | The mechanism of the decrease in plasma potassium induced by Drugphosphate treatment was investigated in a 24 - year - old hypertensive patient with hypophosphatemic osteomalacia, who was the youngest of four patients, belonging to a 23 number kindred of five generations. |
| 0.9791 | The mechanism of the Adverse-Effectdecrease in plasma potassium induced by phosphate treatment was investigated in a 24 - year - old hypertensive patient with hypophosphatemic osteomalacia, who was the youngest of four patients, belonging to a 23 number kindred of five generations. |
| Score | Text |
|---|---|
| 0.9976 | A 16 - year - old white male with acute biphenotypic leukemia developed evidence of the eosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing Drugtryptophan , which were given during his initial induction chemotherapy and also after autologous marrow transplantation. |
| 0.9902 | A 16 - year - old white male with acute biphenotypic leukemia developed evidence of the Adverse-Effecteosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing tryptophan, which were given during his initial induction chemotherapy and also after autologous marrow transplantation. |
| Score | Text |
|---|---|
| 0.9984 | Subsequently, he developed Adverse-Effecthyperglycemia ( fasting blood glucose 138 mg / dL ) that resolved when olanzapine was stopped and recurred ( fasting blood glucose 150 mg / dL ) after 2 days of rechallenge with olanzapine 2. 5 mg twice daily. |
| 0.9851 | Subsequently, he developed hyperglycemia ( fasting blood glucose 138 mg / dL ) that resolved when Drugolanzapine was stopped and recurred ( fasting blood glucose 150 mg / dL ) after 2 days of rechallenge with olanzapine 2. 5 mg twice daily. |
| 0.9757 | Subsequently, he developed hyperglycemia ( fasting blood glucose 138 mg / dL ) that resolved when olanzapine was stopped and recurred ( fasting blood glucose 150 mg / dL ) after 2 days of rechallenge with Drugolanzapine 2. 5 mg twice daily. |
| Score | Text |
|---|---|
| 0.9985 | The potential development of SJS / Adverse-EffectTEN , a severe life - threatening illness, emphasizes the need for judicious use of TMP - Sx and close monitoring and follow - up for patients who were given TMP - Sx for SSTIs. |
| 0.9979 | The potential development of Adverse-EffectSJS / TEN, a severe life - threatening illness, emphasizes the need for judicious use of TMP - Sx and close monitoring and follow - up for patients who were given TMP - Sx for SSTIs. |
| 0.9772 | The potential development of SJS / TEN, a severe life - threatening illness, emphasizes the need for judicious use of DrugTMP - Sx and close monitoring and follow - up for patients who were given TMP - Sx for SSTIs. |
| 0.9793 | The potential development of SJS / TEN, a severe life - threatening illness, emphasizes the need for judicious use of TMP - Sx and close monitoring and follow - up for patients who were given DrugTMP - Sx for SSTIs. |
| Score | Text |
|---|---|
| 0.9976 | We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor - alpha blocking agent Drugetanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen. |
| 0.9771 | We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor - alpha blocking agent etanercept for severe plaque psoriasis, experienced Adverse-Effectpersistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen. |
| Score | Text |
|---|---|
| 0.9915 | Case 1, a 62 - year - old woman, developed Adverse-Effectbilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven - month use of recombinant interferon alpha - 2a for chronic active hepatitis C. |
| 0.9862 | Case 1, a 62 - year - old woman, developed bilateral optic neuritis with decreased sensation of vibration and Adverse-Effectincreased deep tendon reflex in the lower extremities after a seven - month use of recombinant interferon alpha - 2a for chronic active hepatitis C. |
| 0.9844 | Case 1, a 62 - year - old woman, developed bilateral optic neuritis with Adverse-Effectdecreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven - month use of recombinant interferon alpha - 2a for chronic active hepatitis C. |
| 0.9653 | Case 1, a 62 - year - old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven - month use of Drugrecombinant interferon alpha - 2a for chronic active hepatitis C. |
| Score | Text |
|---|---|
| 0.9925 | In all cases, drugs in addition to quetiapine were detected, but in cases # 1 and # 2, the cause of Adverse-Effectdeath was considered to be a quetiapine overdose and the other drugs were not considered to be contributory. |
| 0.9814 | In all cases, drugs in addition to quetiapine were detected, but in cases # 1 and # 2, the cause of death was considered to be a Drugquetiapine overdose and the other drugs were not considered to be contributory. |
| 0.9714 | In all cases, drugs in addition to Drugquetiapine were detected, but in cases # 1 and # 2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory. |
| Score | Text |
|---|---|
| 0.9992 | Of particular interest in this patient is the fluctuation of the QT interval at a stable dose of Drugmethadone , suggesting that a single normal electrocardiogram ( ECG ) does not guarantee that the patient is not at risk of ventricular arrhythmias. |
| 0.9889 | Of particular interest in this patient is the Adverse-Effectfluctuation of the QT interval at a stable dose of methadone, suggesting that a single normal electrocardiogram ( ECG ) does not guarantee that the patient is not at risk of ventricular arrhythmias. |
| Score | Text |
|---|---|
| 0.9880 | Ethambutol is frequently used in the treatment of tuberculosis, and, although Adverse-Effectoptic neuropathies have been reported with the use of ethambutol, this adverse side effect has been considered to be rare and generally reversible with discontinuation of the medication. |
| 0.9794 | DrugEthambutol is frequently used in the treatment of tuberculosis, and, although optic neuropathies have been reported with the use of ethambutol, this adverse side effect has been considered to be rare and generally reversible with discontinuation of the medication. |
| Score | Text |
|---|---|
| 0.9967 | The authors suggest that in the absence of any proven benefit of Drugitraconazole prophylaxis, and given the interaction of this drug with vincristine leading to severe and even potentially fatal toxicities, the combination use of these drugs should be avoided. |
| 0.9953 | The authors suggest that in the absence of any proven benefit of itraconazole prophylaxis, and given the interaction of this drug with Drugvincristine leading to severe and even potentially fatal toxicities, the combination use of these drugs should be avoided. |
| 0.8764 | The authors suggest that in the absence of any proven benefit of itraconazole prophylaxis, and given the interaction of this drug with vincristine leading to severe and even potentially Adverse-Effectfatal toxicities , the combination use of these drugs should be avoided. |
| Score | Text |
|---|---|
| 0.9686 | Two 65 - year - old white men with coronary heart disease, given Drugniacin therapy for dyslipidemia for 5 months, developed intense dental and gingival pain that was associated with increases in dose and that was relieved with discontinuance of niacin treatment. |
| 0.9530 | Two 65 - year - old white men with coronary heart disease, given niacin therapy for dyslipidemia for 5 months, developed intense dental and gingival pain that was associated with increases in dose and that was relieved with discontinuance of Drugniacin treatment. |
| 0.9488 | Two 65 - year - old white men with coronary heart disease, given niacin therapy for dyslipidemia for 5 months, developed Adverse-Effectintense dental and gingival pain that was associated with increases in dose and that was relieved with discontinuance of niacin treatment. |
| 0.6884 | Two 65 - year - old white men with coronary heart disease, given niacin therapy for dyslipidemia for 5 months, developed intense Adverse-Effectdental and gingival pain that was associated with increases in dose and that was relieved with discontinuance of niacin treatment. |
| Score | Text |
|---|---|
| 0.9990 | A 62 - year - old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy - related hemolytic - uremic syndrome during the second cycle of neoadjuvant chemotherapy consisting of cisplatin, Drugbleomycin , and methotrexate. |
| 0.9990 | A 62 - year - old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy - related hemolytic - uremic syndrome during the second cycle of neoadjuvant chemotherapy consisting of cisplatin, bleomycin, and Drugmethotrexate . |
| 0.9990 | A 62 - year - old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy - related hemolytic - uremic syndrome during the second cycle of neoadjuvant chemotherapy consisting of Drugcisplatin , bleomycin, and methotrexate. |
| 0.9893 | A 62 - year - old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy - related Adverse-Effecthemolytic - uremic syndrome during the second cycle of neoadjuvant chemotherapy consisting of cisplatin, bleomycin, and methotrexate. |
| Score | Text |
|---|---|
| 0.9882 | A case of Adverse-Effectskeletal fluorosis induced by prolonged treatment with niflumic acid, a fast - acting non - steroid antiinflammatory agent, is reported in a 35 - year - old woman suffering from rheumatoid arthritis and treated, in addition, with corticosteroids. |
| 0.9791 | A case of skeletal fluorosis induced by prolonged treatment with Drugniflumic acid , a fast - acting non - steroid antiinflammatory agent, is reported in a 35 - year - old woman suffering from rheumatoid arthritis and treated, in addition, with corticosteroids. |
| Score | Text |
|---|---|
| 0.9996 | The reported cases of in utero exposure to Drugcyclosposphamide shared the following manifestations with our patient : growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly. |
| 0.9969 | The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient : growth deficiency, developmental delay, craniosynostosis, Adverse-Effectblepharophimosis , flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly. |
| 0.9965 | The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient : growth deficiency, developmental delay, Adverse-Effectcraniosynostosis , blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly. |
| 0.9961 | The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient : growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and Adverse-Effectoligodactyly . |
| 0.9931 | The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient : growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including Adverse-Effecthypoplastic thumbs and oligodactyly. |
| 0.9921 | The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient : growth deficiency, Adverse-Effectdevelopmental delay , craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly. |
| 0.9907 | The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient : growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and Adverse-Effectdistal limb defects including hypoplastic thumbs and oligodactyly. |
| 0.9901 | The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient : growth deficiency, developmental delay, craniosynostosis, blepharophimosis, Adverse-Effectflat nasal bridge , abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly. |
| 0.9924 | The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient : growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, Adverse-Effectabnormal ears , and distal limb defects including hypoplastic thumbs and oligodactyly. |
| 0.9907 | The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient : Adverse-Effectgrowth deficiency , developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly. |
| Score | Text |
|---|---|
| 0.9996 | Seven of the eight cases of acute leukemia occurred in a series of 553 patients treated with DrugTreosulfan for ovarian cancer in the period from 1970 to 1977 and followed closely for a total of 1159 patient - years up to February 1978. |
| 0.9921 | Seven of the eight cases of Adverse-Effectacute leukemia occurred in a series of 553 patients treated with Treosulfan for ovarian cancer in the period from 1970 to 1977 and followed closely for a total of 1159 patient - years up to February 1978. |
| Score | Text |
|---|---|
| 0.9967 | In addition, while cases of loop diuretic - induced Adverse-Effectpancreatitis , including furosemide, have been published, the allergic manifestations with both sulfonamide antibiotics and non - antibiotics in our patient suggest possible cross - reactivity between these 2 drug classes. |
| 0.9911 | In addition, while cases of loop diuretic - induced pancreatitis, including Drugfurosemide , have been published, the allergic manifestations with both sulfonamide antibiotics and non - antibiotics in our patient suggest possible cross - reactivity between these 2 drug classes. |
| 0.9625 | In addition, while cases of loop diuretic - induced pancreatitis, including furosemide, have been published, the allergic manifestations with both Drugsulfonamide antibiotics and non - antibiotics in our patient suggest possible cross - reactivity between these 2 drug classes. |
| 0.8826 | In addition, while cases of loop diuretic - induced pancreatitis, including furosemide, have been published, the Adverse-Effectallergic manifestations with both sulfonamide antibiotics and non - antibiotics in our patient suggest possible cross - reactivity between these 2 drug classes. |
| Score | Text |
|---|---|
| 0.9995 | The cause of these previously unreported side effects of Drugniacin therapy is uncertain but may be related to prostaglandin - mediated vasodilatation, hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of pain to the teeth. |
| 0.9878 | The cause of these previously unreported side effects of niacin therapy is uncertain but may be related to prostaglandin - mediated vasodilatation, Adverse-Effecthyperalgesia of sensory nerve receptors , and potentiation of inflammation in the gingiva with referral of pain to the teeth. |
| 0.9878 | The cause of these previously unreported side effects of niacin therapy is uncertain but may be related to Adverse-Effectprostaglandin - mediated vasodilatation , hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of pain to the teeth. |
| 0.9858 | The cause of these previously unreported side effects of niacin therapy is uncertain but may be related to prostaglandin - mediated vasodilatation, hyperalgesia of sensory nerve receptors, and Adverse-Effectpotentiation of inflammation in the gingiva with referral of pain to the teeth. |
| 0.9166 | The cause of these previously unreported side effects of niacin therapy is uncertain but may be related to prostaglandin - mediated vasodilatation, hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of Adverse-Effectpain to the teeth . |
| Score | Text |
|---|---|
| 0.9996 | OBJECTIVE : To document a case of serotonin syndrome ( SS ) associated with Drugmirtazapine monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction. |
| 0.9944 | OBJECTIVE : To document a case of Adverse-Effectserotonin syndrome ( SS ) associated with mirtazapine monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction. |
| 0.9084 | OBJECTIVE : To document a case of serotonin syndrome ( Adverse-EffectSS ) associated with mirtazapine monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction. |
| 0.5599 | OBJECTIVE : To document a case of serotonin syndrome ( SS ) associated with mirtazapine monotherapy, review the previously reported cases of Adverse-EffectSS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction. |
| Score | Text |
|---|---|
| 0.9995 | A variety of movement disorders are known to occur in association with Drugcarbamazepine ( CBZ ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders. |
| 0.9993 | A variety of movement disorders are known to occur in association with carbamazepine ( DrugCBZ ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders. |
| 0.9971 | A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children, but development of Adverse-Effecttics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders. |
| 0.9918 | A variety of Adverse-Effectmovement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders. |
| Score | Text |
|---|---|
| 0.9975 | Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of Adverse-Effectmethemoglobinemia . |
| 0.9947 | Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of Druglidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia. |
| 0.9086 | Although the two local anesthetics usually do not cause Adverse-Effectmethemoglobinemia , we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia. |
| Score | Text |
|---|---|
| 0.9976 | Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, Drugvincristine , cyclophosphamide, doxorubicin, and rituximab ( R - EPOCH ) for diffuse large B - cell lymphoma. |
| 0.9976 | Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and Drugrituximab ( R - EPOCH ) for diffuse large B - cell lymphoma. |
| 0.9975 | Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, Drugprednisone , vincristine, cyclophosphamide, doxorubicin, and rituximab ( R - EPOCH ) for diffuse large B - cell lymphoma. |
| 0.9975 | Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, Drugcyclophosphamide , doxorubicin, and rituximab ( R - EPOCH ) for diffuse large B - cell lymphoma. |
| 0.9974 | Herein, we describe a patient with AIDS who presented to medical attention with Adverse-Effectpancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab ( R - EPOCH ) for diffuse large B - cell lymphoma. |
| 0.9974 | Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, Drugdoxorubicin , and rituximab ( R - EPOCH ) for diffuse large B - cell lymphoma. |
| 0.9974 | Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with Drugetoposide , prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab ( R - EPOCH ) for diffuse large B - cell lymphoma. |
| 0.5104 | Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab ( DrugR - EPOCH ) for diffuse large B - cell lymphoma. |
| Score | Text |
|---|---|
| 0.9864 | We report five cases of Drugcarboplatin ( CBDCA ) hypersensitivity after weekly low - dose paclitaxel ( 60 mg / m2 ) / CBDCA ( area under the concentration curve = 2 ) therapy in patients with recurrent ovarian cancer receiving multiple platinum - based chemotherapy. |
| 0.9829 | We report five cases of carboplatin ( CBDCA ) hypersensitivity after weekly low - dose Drugpaclitaxel ( 60 mg / m2 ) / CBDCA ( area under the concentration curve = 2 ) therapy in patients with recurrent ovarian cancer receiving multiple platinum - based chemotherapy. |
| 0.9803 | We report five cases of carboplatin ( DrugCBDCA ) hypersensitivity after weekly low - dose paclitaxel ( 60 mg / m2 ) / CBDCA ( area under the concentration curve = 2 ) therapy in patients with recurrent ovarian cancer receiving multiple platinum - based chemotherapy. |
| 0.9605 | We report five cases of carboplatin ( CBDCA ) Adverse-Effecthypersensitivity after weekly low - dose paclitaxel ( 60 mg / m2 ) / CBDCA ( area under the concentration curve = 2 ) therapy in patients with recurrent ovarian cancer receiving multiple platinum - based chemotherapy. |
| Score | Text |
|---|---|
| 0.9988 | However, we recently saw two patients with renal tuberculosis treated with Drugethambutol in whom visual loss from toxic optic neuropathies was severe and irreversible despite careful ophthalmological monitoring and prompt discontinuation of the agent at the first sign of impaired visual function. |
| 0.9868 | However, we recently saw two patients with renal tuberculosis treated with ethambutol in whom Adverse-Effectvisual loss from toxic optic neuropathies was severe and irreversible despite careful ophthalmological monitoring and prompt discontinuation of the agent at the first sign of impaired visual function. |
| 0.9653 | However, we recently saw two patients with renal tuberculosis treated with ethambutol in whom visual loss from Adverse-Effecttoxic optic neuropathies was severe and irreversible despite careful ophthalmological monitoring and prompt discontinuation of the agent at the first sign of impaired visual function. |
| Score | Text |
|---|---|
| 0.9995 | The aim of this paper is to report the case of rosaceiform eruption induced by Drugerlotinib in an 81 - year - old - man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping. |
| 0.9911 | The aim of this paper is to report the case of Adverse-Effectrosaceiform eruption induced by erlotinib in an 81 - year - old - man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping. |
| Score | Text |
|---|---|
| 0.9930 | Recently, her serum Drugtheophylline levels had increased to the toxic range ( 133. 2 micromol / L [ 24 microg / mL ] ) shortly after the addition of zafirlukast ( Accolate, Zeneca Pharmaceuticals, Wilmington, Del ) to her regimen. |
| 0.9923 | Recently, her serum theophylline levels had increased to the toxic range ( 133. 2 micromol / L [ 24 microg / mL ] ) shortly after the addition of Drugzafirlukast ( Accolate, Zeneca Pharmaceuticals, Wilmington, Del ) to her regimen. |
| 0.9891 | Recently, her serum theophylline levels had increased to the toxic range ( 133. 2 micromol / L [ 24 microg / mL ] ) shortly after the addition of zafirlukast ( DrugAccolate , Zeneca Pharmaceuticals, Wilmington, Del ) to her regimen. |
| 0.6396 | Recently, her serum Adverse-Effecttheophylline levels had increased to the toxic range ( 133. 2 micromol / L [ 24 microg / mL ] ) shortly after the addition of zafirlukast ( Accolate, Zeneca Pharmaceuticals, Wilmington, Del ) to her regimen. |
| 0.9195 | Recently, her serum theophylline Adverse-Effectlevels had increased to the toxic range ( 133. 2 micromol / L [ 24 microg / mL ] ) shortly after the addition of zafirlukast ( Accolate, Zeneca Pharmaceuticals, Wilmington, Del ) to her regimen. |
| 0.8657 | Recently, her serum theophylline levels Adverse-Effecthad increased to the toxic range ( 133. 2 micromol / L [ 24 microg / mL ] ) shortly after the addition of zafirlukast ( Accolate, Zeneca Pharmaceuticals, Wilmington, Del ) to her regimen. |
| 0.8644 | Recently, her serum theophylline levels had Adverse-Effectincreased to the toxic range ( 133. 2 micromol / L [ 24 microg / mL ] ) shortly after the addition of zafirlukast ( Accolate, Zeneca Pharmaceuticals, Wilmington, Del ) to her regimen. |
| Score | Text |
|---|---|
| 0.9996 | The current report describes a man who was prescribed Drugzonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high - grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus - 6 immunoglobulin G titer. |
| 0.9978 | The current report describes a man who was prescribed zonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high - grade fever, Adverse-Effecteosinophilia , liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus - 6 immunoglobulin G titer. |
| 0.9965 | The current report describes a man who was prescribed zonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high - grade fever, eosinophilia, liver dysfunction, Adverse-Effectlymphadenopathy and an increase in antihuman herpesvirus - 6 immunoglobulin G titer. |
| 0.9953 | The current report describes a man who was prescribed zonisamide for epilepsy and subsequently developed widespread Adverse-Effectskin rash , acute kidney injury, high - grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus - 6 immunoglobulin G titer. |
| 0.9907 | The current report describes a man who was prescribed zonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high - grade fever, eosinophilia, Adverse-Effectliver dysfunction , lymphadenopathy and an increase in antihuman herpesvirus - 6 immunoglobulin G titer. |
| 0.9898 | The current report describes a man who was prescribed zonisamide for epilepsy and subsequently developed widespread skin rash, Adverse-Effectacute kidney injury , high - grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus - 6 immunoglobulin G titer. |
| 0.9859 | The current report describes a man who was prescribed zonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, Adverse-Effecthigh - grade fever , eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus - 6 immunoglobulin G titer. |
| 0.8632 | The current report describes a man who was prescribed zonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high - grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus - 6 Adverse-Effectimmunoglobulin G titer . |
| The current report describes a man who was prescribed zonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high - grade fever, eosinophilia, liver dysfunction, lymphadenopathy and Adverse-Effectan increase in antihuman herpesvirus - 6 immunoglobulin G titer . | |
| Score | Text |
|---|---|
| 0.9995 | DrugOxcarbazepine - associated angioedema manifested by swelling of the face, eyes, lips, or tongue or difficulty swallowing or breathing ( or both ) is a rare but potentially life - threatening reaction for which early recognition and management are vital. |
| 0.9983 | Oxcarbazepine - associated Adverse-Effectangioedema manifested by swelling of the face, eyes, lips, or tongue or difficulty swallowing or breathing ( or both ) is a rare but potentially life - threatening reaction for which early recognition and management are vital. |
| Score | Text |
|---|---|
| 0.9911 | CASE REPORT : We describe here a case of a 60 year old female that experienced a relapse of Adverse-Effectsymptomatic hyperlactatemia after being switched from stavudine to zidovudine and how the case was managed at the Infectious Diseases Institute, Kampala, Uganda. |
| 0.9823 | CASE REPORT : We describe here a case of a 60 year old female that experienced a relapse of symptomatic hyperlactatemia after being switched from stavudine to Drugzidovudine and how the case was managed at the Infectious Diseases Institute, Kampala, Uganda. |
| 0.9787 | CASE REPORT : We describe here a case of a 60 year old female that experienced a relapse of symptomatic hyperlactatemia after being switched from Drugstavudine to zidovudine and how the case was managed at the Infectious Diseases Institute, Kampala, Uganda. |
| Score | Text |
|---|---|
| 0.9995 | CONCLUSIONS : SD - OCT and AO detected abnormalities that correlate topographically with visual field loss from Drughydroxychloroquine toxicity as demonstrated by HVF 10 - 2 and may be useful in the detection of subclinical abnormalities that precede symptoms or objective visual field loss. |
| 0.9823 | CONCLUSIONS : SD - OCT and AO detected abnormalities that correlate topographically with Adverse-Effectvisual field loss from hydroxychloroquine toxicity as demonstrated by HVF 10 - 2 and may be useful in the detection of subclinical abnormalities that precede symptoms or objective visual field loss. |
| 0.9797 | CONCLUSIONS : SD - OCT and AO detected abnormalities that correlate topographically with visual field loss from hydroxychloroquine toxicity as demonstrated by HVF 10 - 2 and may be useful in the detection of subclinical abnormalities that precede symptoms or Adverse-Effectobjective visual field loss . |
| 0.6693 | CONCLUSIONS : SD - OCT and AO detected Adverse-Effectabnormalities that correlate topographically with visual field loss from hydroxychloroquine toxicity as demonstrated by HVF 10 - 2 and may be useful in the detection of subclinical abnormalities that precede symptoms or objective visual field loss. |
| Score | Text |
|---|---|
| 0.9993 | A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and bone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg / m2 Drugmethotrexate ( MTX ). |
| 0.9991 | A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and bone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg / m2 methotrexate ( DrugMTX ). |
| 0.9943 | A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed Adverse-Effectsevere skin rash and bone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg / m2 methotrexate ( MTX ). |
| 0.9921 | A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and Adverse-Effectbone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg / m2 methotrexate ( MTX ). |
| Score | Text |
|---|---|
| 0.9836 | The clinical course suggested that recombinant alpha - 2b peginterferon plus ribavirin provoked Adverse-Effecttype 1 diabetes mellitus , therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment. |
| 0.9827 | The clinical course suggested that recombinant alpha - 2b peginterferon plus Drugribavirin provoked type 1 diabetes mellitus, therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment. |
| 0.9108 | The clinical course suggested that Drugrecombinant alpha - 2b peginterferon plus ribavirin provoked type 1 diabetes mellitus, therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment. |
| 0.5594 | The clinical course suggested that recombinant Drugalpha - 2b peginterferon plus ribavirin provoked type 1 diabetes mellitus, therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment. |
| Score | Text |
|---|---|
| 0.9971 | An episode of leukoencephalopathy is reported in a 13 - year - old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4 - hour infusion of 500 mg / m2 Drugmethotrexate and 12 mg intrathecal methotrexate. |
| 0.9971 | An episode of leukoencephalopathy is reported in a 13 - year - old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4 - hour infusion of 500 mg / m2 methotrexate and 12 mg intrathecal Drugmethotrexate . |
| 0.9965 | An episode of Adverse-Effectleukoencephalopathy is reported in a 13 - year - old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4 - hour infusion of 500 mg / m2 methotrexate and 12 mg intrathecal methotrexate. |
| Score | Text |
|---|---|
| 0.9987 | In this report, one patient who developed gangrene after Drugbleomycin and vincristine / vinblastine chemotherapy for AIDS - related Kaposi's sarcoma and another HIV - infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented. |
| 0.9981 | In this report, one patient who developed gangrene after bleomycin and Drugvincristine / vinblastine chemotherapy for AIDS - related Kaposi's sarcoma and another HIV - infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented. |
| 0.9981 | In this report, one patient who developed Adverse-Effectgangrene after bleomycin and vincristine / vinblastine chemotherapy for AIDS - related Kaposi's sarcoma and another HIV - infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented. |
| 0.9977 | In this report, one patient who developed gangrene after bleomycin and vincristine / Drugvinblastine chemotherapy for AIDS - related Kaposi's sarcoma and another HIV - infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented. |
| 0.9677 | In this report, one patient who developed gangrene after bleomycin and vincristine / vinblastine chemotherapy for AIDS - related Kaposi's sarcoma and another HIV - infected patient who exhibited symptoms of Adverse-Effectsevere Raynaud's phenomenon related to the same regimen are presented. |
| Score | Text |
|---|---|
| 0.9989 | The polycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued, and the 2 women who had gained weight and developed Adverse-Effectamenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication. |
| 0.9695 | The polycystic changes disappeared from the ovaries in 2 of the women after Drugvalproate therapy was discontinued, and the 2 women who had gained weight and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication. |
| 0.9484 | The polycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued, and the 2 women who had gained weight and developed amenorrhea while being treated with Drugvalproate lost weight and resumed menstruating after the change in medication. |
| 0.9431 | The Adverse-Effectpolycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued, and the 2 women who had gained weight and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication. |
| The polycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued, and the 2 women who had Adverse-Effectgained weight and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication. | |
| Score | Text |
|---|---|
| 0.9993 | Six of 13 outpatients with schizophrenia who participated in a ten - week open trial of Drugrisperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia. |
| 0.9992 | Six of 13 outpatients with schizophrenia who participated in a ten - week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and Adverse-Effectinsomnia . |
| 0.9937 | Six of 13 outpatients with schizophrenia who participated in a ten - week open trial of risperidone had an initial good response to the medication followed by development of Adverse-Effectintolerable affect , including feelings of agitation and depression and periods of crying and insomnia. |
| 0.9884 | Six of 13 outpatients with schizophrenia who participated in a ten - week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and Adverse-Effectdepression and periods of crying and insomnia. |
| 0.9871 | Six of 13 outpatients with schizophrenia who participated in a ten - week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including Adverse-Effectfeelings of agitation and depression and periods of crying and insomnia. |
| 0.9855 | Six of 13 outpatients with schizophrenia who participated in a ten - week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and Adverse-Effectperiods of crying and insomnia. |
| Score | Text |
|---|---|
| 0.9979 | We report a case of drug - induced Kaposi's sarcoma ( KS ) on the sole of the right foot in a 71 - year - old man, treated for 6 months with corticosteroid therapy ( Drugprednisolone 25 mg / day ) for pericardial effusion. |
| 0.9875 | We report a case of drug - induced Adverse-EffectKaposi's sarcoma ( KS ) on the sole of the right foot in a 71 - year - old man, treated for 6 months with corticosteroid therapy ( prednisolone 25 mg / day ) for pericardial effusion. |
| 0.8086 | We report a case of drug - induced Kaposi's sarcoma ( Adverse-EffectKS ) on the sole of the right foot in a 71 - year - old man, treated for 6 months with corticosteroid therapy ( prednisolone 25 mg / day ) for pericardial effusion. |
| Score | Text |
|---|---|
| 0.9992 | In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of Drugcyclosporin , prednisone and azathioprine, developed thrombosis of the central retinal vein 5 years following the transplantation. |
| 0.9990 | In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, Drugprednisone and azathioprine, developed thrombosis of the central retinal vein 5 years following the transplantation. |
| 0.9990 | In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, prednisone and Drugazathioprine , developed thrombosis of the central retinal vein 5 years following the transplantation. |
| 0.9191 | In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, prednisone and azathioprine, developed Adverse-Effectthrombosis of the central retinal vein 5 years following the transplantation. |
| 0.8910 | In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, prednisone and azathioprine, developed Adverse-Effectthrombosis of the central retinal vein 5 years following the transplantation. |
| Score | Text |
|---|---|
| 0.9854 | Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc - dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and / or interstitium are the main targets for Drugcyclosporine A nephrotoxicity. |
| 0.9368 | Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc - dimercaptosuccinic acid and the Adverse-Effectincrease in proteinuria , we suggest that in this case the tubules and / or interstitium are the main targets for cyclosporine A nephrotoxicity. |
| 0.9236 | Based upon the observed Adverse-Effectfall of the filtration fraction , the rise in the relative clearance of 99Tc - dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and / or interstitium are the main targets for cyclosporine A nephrotoxicity. |
| 0.8919 | Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc - dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and / or interstitium are the main targets for cyclosporine A Adverse-Effectnephrotoxicity . |
| 0.6234 | Based upon the observed fall of the filtration fraction, the Adverse-Effectrise in the relative clearance of 99Tc - dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and / or interstitium are the main targets for cyclosporine A nephrotoxicity. |
| 0.9291 | Based upon the observed fall of the filtration fraction, the rise in the relative clearance of Drug99Tc - dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and / or interstitium are the main targets for cyclosporine A nephrotoxicity. |
| 0.8073 | Based upon the observed fall of the filtration fraction, the Adverse-Effectrise in the relative clearance of 99Tc - dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and / or interstitium are the main targets for cyclosporine A nephrotoxicity. |
| 0.7881 | Based upon the observed fall of the filtration fraction, the Adverse-Effectrise in the relative clearance of 99Tc - dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and / or interstitium are the main targets for cyclosporine A nephrotoxicity. |
| Score | Text |
|---|---|
| 0.9720 | Although there is one case report of Adverse-Effectcholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321 : 1270, 1989 ), this is the first reported case of atheroembolic acute renal failure following t - PA therapy. |
| 0.9646 | Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321 : 1270, 1989 ), this is the first reported case of Adverse-Effectatheroembolic acute renal failure following t - PA therapy. |
| 0.9172 | Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321 : 1270, 1989 ), this is the first reported case of atheroembolic acute renal failure following Drugt - PA therapy. |
| 0.9064 | Although there is one case report of cholesterol crystal embolization following Drugt - PA therapy with only extrarenal manifestations ( N Engl J Med 321 : 1270, 1989 ), this is the first reported case of atheroembolic acute renal failure following t - PA therapy. |
| 0.7432 | Although there is one case report of cholesterol crystal embolization following t - PA therapy with only Adverse-Effectextrarenal manifestations ( N Engl J Med 321 : 1270, 1989 ), this is the first reported case of atheroembolic acute renal failure following t - PA therapy. |
| 0.5435 | Although there is one case report of cholesterol crystal embolization following t Drug- PA therapy with only extrarenal manifestations ( N Engl J Med 321 : 1270, 1989 ), this is the first reported case of atheroembolic acute renal failure following t - PA therapy. |
| Score | Text |
|---|---|
| 0.9600 | Rebound hyperglycemia was observed with both intermediate ( neutral protamine hagedorn ) and long - acting ( Drugprotamine zinc iletin ) insulins, and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat. |
| 0.9530 | Rebound hyperglycemia was observed with both intermediate ( neutral Drugprotamine hagedorn ) and long - acting ( protamine zinc iletin ) insulins, and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat. |
| 0.8618 | Rebound hyperglycemia was observed with both intermediate ( Drugneutral protamine hagedorn ) and long - acting ( protamine zinc iletin ) insulins, and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat. |
| 0.8416 | Rebound Adverse-Effecthyperglycemia was observed with both intermediate ( neutral protamine hagedorn ) and long - acting ( protamine zinc iletin ) insulins, and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat. |
| Adverse-EffectRebound hyperglycemia was observed with both intermediate ( neutral protamine hagedorn ) and long - acting ( protamine zinc iletin ) insulins, and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat. | |
| Score | Text |
|---|---|
| 0.9982 | The goal of this study is to describe three patients diagnosed with migraine and epilepsy ( both under control ) who evolved into status migrainosus after the introduction of Drugoxcarbazepine ( OXC ), as part of a switch off from carbamazepine ( CBZ ). |
| 0.9981 | The goal of this study is to describe three patients diagnosed with migraine and epilepsy ( both under control ) who evolved into status migrainosus after the introduction of oxcarbazepine ( OXC ), as part of a switch off from Drugcarbamazepine ( CBZ ). |
| 0.9979 | The goal of this study is to describe three patients diagnosed with migraine and epilepsy ( both under control ) who evolved into status migrainosus after the introduction of oxcarbazepine ( OXC ), as part of a switch off from carbamazepine ( DrugCBZ ). |
| 0.9978 | The goal of this study is to describe three patients diagnosed with migraine and epilepsy ( both under control ) who evolved into status migrainosus after the introduction of oxcarbazepine ( DrugOXC ), as part of a switch off from carbamazepine ( CBZ ). |
| 0.9941 | The goal of this study is to describe three patients diagnosed with migraine and epilepsy ( both under control ) who evolved into Adverse-Effectstatus migrainosus after the introduction of oxcarbazepine ( OXC ), as part of a switch off from carbamazepine ( CBZ ). |
| Score | Text |
|---|---|
| 0.9886 | Physicians should be aware of the risk of severe Adverse-EffectAIHA in CLL patients with a history of AIHA or positivation of the DAT during previous fludarabine administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment. |
| 0.9861 | Physicians should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or positivation of the DAT during previous fludarabine administration, or in case of secondary fixation of complement to the red cell membrane occurring during Drugfludarabine treatment. |
| 0.9794 | Physicians should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or positivation of the DAT during previous Drugfludarabine administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment. |
| 0.9770 | Physicians should be aware of the risk of severe AIHA in CLL patients with a history of Adverse-EffectAIHA or positivation of the DAT during previous fludarabine administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment. |
| 0.9758 | Physicians should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or Adverse-Effectpositivation of the DAT during previous fludarabine administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment. |
| Score | Text |
|---|---|
| 0.9923 | We report a case of Stevens - Johnson syndrome / toxic epidermal necrolysis ( SJS / Adverse-EffectTEN ) secondary to trimethoprim - sulfamethoxazole ( TMP - Sx ) therapy for presumed community - associated methicillin - resistant Staphylococcus aureus ( CA - MRSA ) infection. |
| 0.9868 | We report a case of Stevens - Johnson syndrome / Adverse-Effecttoxic epidermal necrolysis ( SJS / TEN ) secondary to trimethoprim - sulfamethoxazole ( TMP - Sx ) therapy for presumed community - associated methicillin - resistant Staphylococcus aureus ( CA - MRSA ) infection. |
| 0.9853 | We report a case of Adverse-EffectStevens - Johnson syndrome / toxic epidermal necrolysis ( SJS / TEN ) secondary to trimethoprim - sulfamethoxazole ( TMP - Sx ) therapy for presumed community - associated methicillin - resistant Staphylococcus aureus ( CA - MRSA ) infection. |
| 0.9645 | We report a case of Stevens - Johnson syndrome / toxic epidermal necrolysis ( SJS / TEN ) secondary to trimethoprim - sulfamethoxazole ( DrugTMP - Sx ) therapy for presumed community - associated methicillin - resistant Staphylococcus aureus ( CA - MRSA ) infection. |
| 0.9631 | We report a case of Stevens - Johnson syndrome / toxic epidermal necrolysis ( Adverse-EffectSJS / TEN ) secondary to trimethoprim - sulfamethoxazole ( TMP - Sx ) therapy for presumed community - associated methicillin - resistant Staphylococcus aureus ( CA - MRSA ) infection. |
| 0.8906 | We report a case of Stevens - Johnson syndrome / toxic epidermal necrolysis ( SJS / TEN ) secondary to Drugtrimethoprim - sulfamethoxazole ( TMP - Sx ) therapy for presumed community - associated methicillin - resistant Staphylococcus aureus ( CA - MRSA ) infection. |
| Score | Text |
|---|---|
| 0.9883 | CONCLUSIONS : Sustained - release verapamil is thought to be the cause of the Adverse-Effectasthma attack in this patient because she was not taking any other preparations ; the symptoms started with the administration of sustained - release verapamil and were relieved after its discontinuation. |
| 0.9817 | CONCLUSIONS : Sustained - release Drugverapamil is thought to be the cause of the asthma attack in this patient because she was not taking any other preparations ; the symptoms started with the administration of sustained - release verapamil and were relieved after its discontinuation. |
| 0.9765 | CONCLUSIONS : Sustained - release verapamil is thought to be the cause of the asthma attack in this patient because she was not taking any other preparations ; the symptoms started with the administration of sustained - release Drugverapamil and were relieved after its discontinuation. |
| Score | Text |
|---|---|
| 0.9888 | Further studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop autoimmune thyroiditis, in order to make a early diagnosis of Adverse-Effectthyroid disorders during the IFN - alpha treatment. |
| 0.9874 | Further studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop Adverse-Effectautoimmune thyroiditis , in order to make a early diagnosis of thyroid disorders during the IFN - alpha treatment. |
| 0.9760 | Further studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop autoimmune thyroiditis, in order to make a early diagnosis of thyroid disorders during the DrugIFN - alpha treatment. |
| Score | Text |
|---|---|
| 0.9994 | A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed postprandial hyperglycemia and glycosuria during a period of topical administration of a corticosteroid cream, Drughalcinonide cream 0. 1 %, under occlusion. |
| 0.9989 | A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed postprandial hyperglycemia and Adverse-Effectglycosuria during a period of topical administration of a corticosteroid cream, halcinonide cream 0. 1 %, under occlusion. |
| 0.9918 | A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed Adverse-Effectpostprandial hyperglycemia and glycosuria during a period of topical administration of a corticosteroid cream, halcinonide cream 0. 1 %, under occlusion. |
| Score | Text |
|---|---|
| 0.9992 | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, rash, fever, leukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of Drugcarbamazepine ( CBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| 0.9990 | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, rash, fever, leukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( DrugCBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| 0.9990 | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, rash, fever, leukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( CBZ ; DrugTegretol ) used against benign Rolandic epilepsy. |
| 0.9988 | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, rash, fever, Adverse-Effectleukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( CBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| 0.9980 | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, Adverse-Effectrash , fever, leukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( CBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| 0.9903 | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, rash, Adverse-Effectfever , leukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( CBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| 0.9831 | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, rash, fever, leukopenia and Adverse-Effectpositive anti - nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( CBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| 0.6825 | A 14 - year - old female developed Adverse-Effectsystemic lupus erythematosus ( SLE ) - like symptoms , rash, fever, leukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( CBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| 0.9772 | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, rash, fever, leukopenia and positive anti - nuclear antibody ( Adverse-EffectANA ) two weeks after administration of carbamazepine ( CBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| 0.6003 | A 14 - year - old female developed systemic lupus erythematosus ( Adverse-EffectSLE ) - like symptoms , rash, fever, leukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( CBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| Score | Text |
|---|---|
| 0.9982 | Since the thrombocyte count started to increase immediately after initiation and dropped immediately after discontinuation of ciprofloxacin and Drugtazobactam / piperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative. |
| 0.9982 | Since the thrombocyte count started to increase immediately after initiation and dropped immediately after discontinuation of ciprofloxacin and tazobactam / Drugpiperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative. |
| 0.9981 | Since the thrombocyte count started to increase immediately after initiation and dropped immediately after discontinuation of Drugciprofloxacin and tazobactam / piperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative. |
| 0.9587 | Since the Adverse-Effectthrombocyte count started to increase immediately after initiation and dropped immediately after discontinuation of ciprofloxacin and tazobactam / piperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative. |
| Score | Text |
|---|---|
| 0.9837 | Our findings suggest that significant Adverse-Effectprogression of marrow reticulin fibrosis during imatinib therapy can be an indicator for a return or progression of CML and, in some patients with CML, imatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment. |
| 0.9745 | Our findings suggest that significant progression of marrow reticulin fibrosis during Drugimatinib therapy can be an indicator for a return or progression of CML and, in some patients with CML, imatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment. |
| 0.8985 | Our findings suggest that significant progression of marrow reticulin fibrosis during imatinib therapy can be an indicator for a return or progression of CML and, in some patients with CML, Drugimatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment. |
| Score | Text |
|---|---|
| 0.9932 | Ciprofloxacin is among the standard treatments for infected ischemic ulcers ; in the rare case of ciprofloxacin - induced Adverse-Effecthemorrhagic vasculitis , it might be interpreted as progression of infection, instead of a complication of the treatment, thus leading to faulty diagnosis and treatment. |
| 0.9852 | Ciprofloxacin is among the standard treatments for infected ischemic ulcers ; in the rare case of Drugciprofloxacin - induced hemorrhagic vasculitis, it might be interpreted as progression of infection, instead of a complication of the treatment, thus leading to faulty diagnosis and treatment. |
| 0.9555 | Ciprofloxacin is among the standard treatments for infected ischemic ulcers ; in the rare case of ciprofloxacin - induced hemorrhagic vasculitis, it might be interpreted as Adverse-Effectprogression of infection , instead of a complication of the treatment, thus leading to faulty diagnosis and treatment. |
| 0.8797 | DrugCiprofloxacin is among the standard treatments for infected ischemic ulcers ; in the rare case of ciprofloxacin - induced hemorrhagic vasculitis, it might be interpreted as progression of infection, instead of a complication of the treatment, thus leading to faulty diagnosis and treatment. |
| Score | Text |
|---|---|
| 0.9992 | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including Adverse-Effectheadache , dizziness and insomnia. |
| 0.9991 | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including headache, dizziness and Adverse-Effectinsomnia . |
| 0.9989 | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including headache, Adverse-Effectdizziness and insomnia. |
| 0.9989 | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, grepafloxacin, Drugtrovafloxacin , gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including headache, dizziness and insomnia. |
| 0.9988 | CONCLUSION : The new quinolone derivatives ( Druglevofloxacin , sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including headache, dizziness and insomnia. |
| 0.9988 | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, Druggrepafloxacin , trovafloxacin, gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including headache, dizziness and insomnia. |
| 0.9988 | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, Druggatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including headache, dizziness and insomnia. |
| 0.9987 | CONCLUSION : The new quinolone derivatives ( levofloxacin, Drugsparfloxacin , grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including headache, dizziness and insomnia. |
| 0.9986 | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and Drugmoxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including headache, dizziness and insomnia. |
| 0.7192 | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause Adverse-Effectcentral nervous system - related adverse effects , including headache, dizziness and insomnia. |
| Score | Text |
|---|---|
| 0.9851 | CONCLUSIONS : In our reported case, a local hyperproduction of TNF - alpha from macrophages that was induced by the injected Druginsulin could explain the dedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone. |
| 0.9248 | CONCLUSIONS : In our reported case, a local hyperproduction of TNF - alpha from macrophages that was induced by the injected insulin could explain the Adverse-Effectdedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone. |
| 0.9757 | CONCLUSIONS : In our reported case, a local hyperproduction of TNF - alpha from macrophages that was induced by the injected insulin could explain the dedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of Drugdexamethasone . |
| 0.6449 | CONCLUSIONS : In our reported case, a local hyperproduction of TNF - alpha from macrophages that was induced by the injected insulin could explain the dedifferentiation of the adipocytes of the subcutaneous tissue and the Adverse-Effectreversion that was induced by the local injection of dexamethasone. |
| 0.6189 | CONCLUSIONS : In our reported case, a local hyperproduction of TNF - alpha from macrophages that was induced by the injected insulin could explain the Adverse-Effectdedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone. |
| CONCLUSIONS : In our reported case, a local Adverse-Effecthyperproduction of TNF - alpha from macrophages that was induced by the injected insulin could explain the dedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone. | |
| Score | Text |
|---|---|
| 0.9687 | Factors that suggested an association between the severe angioedematous reaction and DrugBP topical application include the strong reaction to BP in the patch - test, the temporal relationship, the complete resolution of symptoms after the drug was withdrawn and the absence of other identified explanations. |
| 0.9656 | Factors that suggested an association between the Adverse-Effectsevere angioedematous reaction and BP topical application include the strong reaction to BP in the patch - test, the temporal relationship, the complete resolution of symptoms after the drug was withdrawn and the absence of other identified explanations. |
| Score | Text |
|---|---|
| 0.9328 | To develop information on the relative rarity or frequency of Adverse-Effectneurologic worsening with the initiation of penicillamine therapy, we conducted a retrospective survey of 25 additional patients with Wilson's disease who met the criteria of presenting with neurologic disease and having been treated with penicillamine. |
| 0.9303 | To develop information on the relative rarity or frequency of neurologic worsening with the initiation of Drugpenicillamine therapy, we conducted a retrospective survey of 25 additional patients with Wilson's disease who met the criteria of presenting with neurologic disease and having been treated with penicillamine. |
| 0.8400 | To develop information on the relative rarity or frequency of neurologic worsening with the initiation of penicillamine therapy, we conducted a retrospective survey of 25 additional patients with Wilson's disease who met the criteria of presenting with neurologic disease and having been treated with Drugpenicillamine . |
| 0.8649 | To develop information on the Adverse-Effectrelative rarity or frequency of neurologic worsening with the initiation of penicillamine therapy, we conducted a retrospective survey of 25 additional patients with Wilson's disease who met the criteria of presenting with neurologic disease and having been treated with penicillamine. |
| To develop information on the relative rarity or frequency of neurologic worsening with the initiation of penicillamine therapy, we conducted a retrospective survey of 25 additional patients with Wilson's disease who met the criteria of presenting with Adverse-Effectneurologic disease and having been treated with penicillamine. | |
| Score | Text |
|---|---|
| 0.9987 | The risk of developing Adverse-EffectsAML is estimated to be between 1 % and 5 %, 2 - 20 years after exposure to etoposide but may also be related to cumulative drug doses, treatment schedules, host factors and co - administration of other antineoplastic agents. |
| 0.9967 | The risk of developing sAML is estimated to be between 1 % and 5 %, 2 - 20 years after exposure to Drugetoposide but may also be related to cumulative drug doses, treatment schedules, host factors and co - administration of other antineoplastic agents. |
| Score | Text |
|---|---|
| 0.9994 | The presence of a lymphocyte alveolitis with a predominance of CD4 + T cells in 3 RA patients and CD8 + T cells with a concomitant increase in neutrophils in another case suggests that immunologically mediated reactions may be one damage mechanism in DrugMTX - induced pneumonitis. |
| 0.9988 | The presence of a lymphocyte alveolitis with a predominance of CD4 + T cells in 3 RA patients and CD8 + T cells with a concomitant increase in neutrophils in another case suggests that immunologically mediated reactions may be one damage mechanism in MTX - induced Adverse-Effectpneumonitis . |
| Score | Text |
|---|---|
| 0.9996 | Renal failure appeared 8 to 17 days after beginning Druggentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min, urine to plasma creatinine ratios less than 20, urinary sodium concentrations 16 to 60 mEq / liter, proteinuria, and cylindruria. |
| 0.9953 | Adverse-EffectRenal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min, urine to plasma creatinine ratios less than 20, urinary sodium concentrations 16 to 60 mEq / liter, proteinuria, and cylindruria. |
| Score | Text |
|---|---|
| 0.9986 | He had been taking trimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of Adverse-Effectheadaches , dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.9981 | He had been taking trimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, Adverse-Effectdizziness , difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.9942 | He had been taking trimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a Adverse-Effectmaculopapular rash was noted. |
| 0.9936 | He had been taking trimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, Adverse-Effectweakness , and itching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.9855 | He had been taking trimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, Adverse-Effectdifficulty with speech , weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.9141 | He had been taking Drugtrimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.6019 | He had been taking trimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and Adverse-Effectitching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.5630 | He had been taking trimethoprim - Drugsulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.9767 | He had been taking trimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and Adverse-Effectitching on the trunk of his body and legs , where a maculopapular rash was noted. |
| 0.5527 | He had been taking trimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and Adverse-Effectitching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.5433 | He had been taking trimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and Adverse-Effectitching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.5404 | He had been taking trimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and Adverse-Effectitching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.5174 | He had been taking trimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and Adverse-Effectitching on the trunk of his body and legs, where a maculopapular rash was noted. |
| Score | Text |
|---|---|
| 0.9892 | A clinically atypical, neuropathologically verified case of Adverse-EffectCreutzfeldt - Jakob disease is described in a 32 - year - old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence ( 1970 to 1973 ) with human growth hormone processed from pooled cadaveric pituitary glands. |
| 0.9819 | A clinically atypical, neuropathologically verified case of Creutzfeldt - Jakob disease is described in a 32 - year - old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence ( 1970 to 1973 ) with Drughuman growth hormone processed from pooled cadaveric pituitary glands. |
| Score | Text |
|---|---|
| 0.9994 | In a series of 104 cases of intentional or inadvertent use of Drugzidovudine at differing gestations in pregnancy, there were eight spontaneous first trimester abortions, eight therapeutic terminations, and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed. |
| 0.9945 | In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy, there were eight spontaneous first trimester abortions, eight therapeutic terminations, and eight cases of Adverse-Effectfetal abnormality occurring among a total of 88 cases where the pregnancy progressed. |
| 0.8856 | In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy, there were eight spontaneous Adverse-Effectfirst trimester abortions , eight therapeutic terminations, and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed. |
| 0.5700 | In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy, there were eight Adverse-Effectspontaneous first trimester abortions , eight therapeutic terminations, and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed. |
| Score | Text |
|---|---|
| 0.9963 | This is the first reported case of Adverse-EffectBOOP associated with single - agent rituximab, and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab - based combinations, strengthens the possibility of a causal relationship. |
| 0.9960 | This is the first reported case of BOOP associated with single - agent rituximab, and along with two other patients we describe, as well as two prior reports of Adverse-EffectBOOP in NHL patients receiving rituximab - based combinations, strengthens the possibility of a causal relationship. |
| 0.9610 | This is the first reported case of BOOP associated with single - agent Drugrituximab , and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab - based combinations, strengthens the possibility of a causal relationship. |
| 0.9025 | This is the first reported case of BOOP associated with single - agent rituximab, and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving Drugrituximab - based combinations, strengthens the possibility of a causal relationship. |
| Score | Text |
|---|---|
| 0.9995 | The patient completed a 10 - month follow - up, maintaining a complete resolution of the treated skin lesions ; however, the development of a painful hand ulcer, possibly associated with the Drughydroxyurea , and new skin cancers were observed at the last follow - up visit. |
| 0.9921 | The patient completed a 10 - month follow - up, maintaining a complete resolution of the treated skin lesions ; however, the development of a painful hand ulcer, possibly associated with the hydroxyurea, and new Adverse-Effectskin cancers were observed at the last follow - up visit. |
| 0.9703 | The patient completed a 10 - month follow - up, maintaining a complete resolution of the treated skin lesions ; however, the development of a Adverse-Effectpainful hand ulcer , possibly associated with the hydroxyurea, and new skin cancers were observed at the last follow - up visit. |
| Score | Text |
|---|---|
| 0.9987 | The case is presented of a 72 - year - old man with hormone - refractory prostate cancer and weekly administration of 30 mg / m2 Drugdocetaxel who developed subacute interstitial pneumonitis - related pulmonary fibrosis after seven doses and died despite mechanical ventilation and high - dose corticosteroid treatment. |
| 0.9792 | The case is presented of a 72 - year - old man with hormone - refractory prostate cancer and weekly administration of 30 mg / m2 docetaxel who developed Adverse-Effectsubacute interstitial pneumonitis - related pulmonary fibrosis after seven doses and died despite mechanical ventilation and high - dose corticosteroid treatment. |
| Score | Text |
|---|---|
| 0.9878 | Therefore, it is reasonable to conclude that : 1 ) 2 - CdA can induce durable complete remission in MCD patients but unfortunately it can not cure the disease ; 2 ) the possibility that Drug2 - CdA may accelerate the transformation of MCD to NHL can not be ruled out. |
| 0.6904 | Therefore, it is reasonable to conclude that : 1 ) 2 - CdA can induce durable complete remission in MCD patients but unfortunately it can not cure the disease ; 2 ) the possibility that 2 - CdA may accelerate the Adverse-Effecttransformation of MCD to NHL can not be ruled out. |
| 0.9923 | Therefore, it is reasonable to conclude that : 1 ) Drug2 - CdA can induce durable complete remission in MCD patients but unfortunately it can not cure the disease ; 2 ) the possibility that 2 - CdA may accelerate the transformation of MCD to NHL can not be ruled out. |
| Score | Text |
|---|---|
| 0.9994 | A 26 - year - old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of Drugsalazosulfapyridine . |
| 0.9982 | A 26 - year - old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, Adverse-Effectmalaise , and fever up to 39 degrees C one day after the administration of salazosulfapyridine. |
| 0.9943 | A 26 - year - old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and Adverse-Effectpustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine. |
| 0.9941 | A 26 - year - old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with Adverse-Effectdiffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine. |
| 0.9780 | A 26 - year - old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and Adverse-Effectfever up to 39 degrees C one day after the administration of salazosulfapyridine. |
| Score | Text |
|---|---|
| 0.9995 | We present a case report of a patient with alveolar hydatid disease, whose treatment with Drugmebendazole was brief due to side effects of alopecia and granulocytopenia ; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia. |
| 0.9987 | We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and Adverse-Effectgranulocytopenia ; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia. |
| 0.9987 | We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of Adverse-Effectalopecia and granulocytopenia ; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia. |
| Score | Text |
|---|---|
| 0.9987 | We describe 2 male patients, a 49 - year - old with psoriatic arthritis and impaired renal function and a 43 - year - old renal transplant recipient, who both sustained a marked decline in glomerular filtration rate in conjunction with a selective inhibitor of cyclooxygenase - 2 ( COX - 2 ), Drugrofecoxib . |
| 0.9776 | We describe 2 male patients, a 49 - year - old with psoriatic arthritis and impaired renal function and a 43 - year - old renal transplant recipient, who both sustained a marked Adverse-Effectdecline in glomerular filtration rate in conjunction with a selective inhibitor of cyclooxygenase - 2 ( COX - 2 ), rofecoxib. |
| Score | Text |
|---|---|
| 0.9996 | The main clinical features of this 58 - year - old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg Drugmethimazole daily. |
| 0.9975 | The main clinical features of this 58 - year - old female patient were laboratory evidence of Adverse-Effectleucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg methimazole daily. |
| 0.9958 | The main clinical features of this 58 - year - old female patient were laboratory evidence of leucopenia and Adverse-Effectcholestasis , and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg methimazole daily. |
| 0.9890 | The main clinical features of this 58 - year - old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and Adverse-Effectbile stasis , demonstrated 20 days after the initiation of antithyroid therapy with 20 mg methimazole daily. |
| 0.9884 | The main clinical features of this 58 - year - old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with Adverse-Effectgranulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg methimazole daily. |
| 0.9881 | The main clinical features of this 58 - year - old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of Adverse-Effectfatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg methimazole daily. |
| Score | Text |
|---|---|
| 0.9955 | On the fifth day after administration of a high dose of ARA - C ( 2 g / m2 intravenously every 12 hours ), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, Adverse-Effectsepsis , and death on the 22nd day. |
| 0.9897 | On the fifth day after administration of a high dose of ARA - C ( 2 g / m2 intravenously every 12 hours ), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and Adverse-Effectdeath on the 22nd day. |
| 0.9823 | On the fifth day after administration of a high dose of DrugARA - C ( 2 g / m2 intravenously every 12 hours ), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and death on the 22nd day. |
| 0.9461 | On the fifth day after administration of a high dose of ARA - C ( 2 g / m2 intravenously every 12 hours ), she developed Adverse-Effectbullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and death on the 22nd day. |
| 0.9248 | On the fifth day after administration of a high dose of ARA - C ( 2 g / m2 intravenously every 12 hours ), she developed bullous lesions on the hands and soles that disseminated, evolving to Adverse-Effectnecrosis , sepsis, and death on the 22nd day. |
| On the fifth day after administration of a high dose of ARA - C ( 2 g / m2 intravenously every 12 hours ), she developed Adverse-Effectbullous lesions on the hands and soles that disseminated, evolving to necrosis , sepsis, and death on the 22nd day. | |
| Score | Text |
|---|---|
| 0.9891 | It is presumed that her hyperchloremic metabolic acidosis was secondary to Drugcholestyramine because of the similarity to pediatric reports ; the rapid and lasting response to intravenous sodium bicarbonate ; the absence of another etiology ; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery. |
| 0.9850 | It is presumed that her Adverse-Effecthyperchloremic metabolic acidosis was secondary to cholestyramine because of the similarity to pediatric reports ; the rapid and lasting response to intravenous sodium bicarbonate ; the absence of another etiology ; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery. |
| Score | Text |
|---|---|
| 0.9995 | Previous studies have demonstrated the interaction of DrugMTX and a variety of non - steroidal, anti - inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia. |
| 0.9989 | Previous studies have demonstrated the interaction of MTX and a variety of non - steroidal, anti - inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and Adverse-Effectpyrexia . |
| 0.9987 | Previous studies have demonstrated the interaction of MTX and a variety of non - steroidal, anti - inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, Adverse-Effectdiarrhea , elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia. |
| 0.9985 | Previous studies have demonstrated the interaction of MTX and a variety of non - steroidal, anti - inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, Adverse-Effectjaundice , mucosal ulcerations, and pyrexia. |
| 0.9983 | Previous studies have demonstrated the interaction of MTX and a variety of non - steroidal, anti - inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure, pancytopenia, Adverse-Effectvomiting , diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia. |
| 0.9982 | Previous studies have demonstrated the interaction of MTX and a variety of non - steroidal, anti - inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure, Adverse-Effectpancytopenia , vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia. |
| 0.9919 | Previous studies have demonstrated the interaction of MTX and a variety of non - steroidal, anti - inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, Adverse-Effectmucosal ulcerations , and pyrexia. |
| 0.9884 | Previous studies have demonstrated the interaction of MTX and a variety of non - steroidal, anti - inflammatory drugs ( NSAIDs ) with various clinical manifestations including Adverse-Effectacute renal failure , pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia. |
| 0.9884 | Previous studies have demonstrated the interaction of MTX and a variety of non - steroidal, anti - inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, Adverse-Effectelevated liver transaminases , jaundice, mucosal ulcerations, and pyrexia. |
| Score | Text |
|---|---|
| 0.9984 | METHOD : Case analysis of a poly - drug overdose ( Drugvenlafaxine , topiramate, divalproex sodium, risperidone, and carbamazepine ) presenting with mixed SS / NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS / NMS in critical care settings. |
| 0.9979 | METHOD : Case analysis of a poly - drug overdose ( venlafaxine, topiramate, divalproex sodium, Drugrisperidone , and carbamazepine ) presenting with mixed SS / NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS / NMS in critical care settings. |
| 0.9977 | METHOD : Case analysis of a poly - drug overdose ( venlafaxine, Drugtopiramate , divalproex sodium, risperidone, and carbamazepine ) presenting with mixed SS / NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS / NMS in critical care settings. |
| 0.9977 | METHOD : Case analysis of a poly - drug overdose ( venlafaxine, topiramate, divalproex sodium, risperidone, and Drugcarbamazepine ) presenting with mixed SS / NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS / NMS in critical care settings. |
| 0.9933 | METHOD : Case analysis of a poly - drug overdose ( venlafaxine, topiramate, Drugdivalproex sodium , risperidone, and carbamazepine ) presenting with mixed SS / NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS / NMS in critical care settings. |
| 0.8617 | METHOD : Case analysis of a poly - drug overdose ( venlafaxine, topiramate, divalproex sodium, risperidone, and carbamazepine ) presenting with mixed Adverse-EffectSS / NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS / NMS in critical care settings. |
| 0.8041 | METHOD : Case analysis of a poly - drug overdose ( venlafaxine, topiramate, divalproex sodium, risperidone, and carbamazepine ) presenting with mixed SS / Adverse-EffectNMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS / NMS in critical care settings. |
| Score | Text |
|---|---|
| 0.9983 | After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long - acting somatostatin analog or the combination of these two drugs was responsible for this case of drug - induced Adverse-Effecthepatitis . |
| 0.9818 | After rechallenge with monotherapy pegvisomant, however, the Adverse-Effecthepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long - acting somatostatin analog or the combination of these two drugs was responsible for this case of drug - induced hepatitis. |
| 0.9616 | After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely Drugpegvisomant alone and not the long - acting somatostatin analog or the combination of these two drugs was responsible for this case of drug - induced hepatitis. |
| 0.9667 | After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long - acting Drugsomatostatin analog or the combination of these two drugs was responsible for this case of drug - induced hepatitis. |
| After rechallenge with monotherapy Drugpegvisomant , however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long - acting somatostatin analog or the combination of these two drugs was responsible for this case of drug - induced hepatitis. | |
| Score | Text |
|---|---|
| 0.9983 | Possible pathophysiological mechanisms which may have been operative in this case include : a direct central nervous system ( CNS ) toxic effect of valproic acid ; a paradoxical epileptogenic effect secondary to the drug ; and an indirect CNS toxic effect mediated through valproic acid - induced Adverse-Effecthyperammonemia . |
| 0.9852 | Possible pathophysiological mechanisms which may have been operative in this case include : a direct central nervous system ( CNS ) toxic effect of valproic acid ; a paradoxical epileptogenic effect secondary to the drug ; and an indirect CNS toxic effect mediated through Drugvalproic acid - induced hyperammonemia. |
| 0.8988 | Possible pathophysiological mechanisms which may have been operative in this case include : a direct central nervous system ( CNS ) toxic effect of Drugvalproic acid ; a paradoxical epileptogenic effect secondary to the drug ; and an indirect CNS toxic effect mediated through valproic acid - induced hyperammonemia. |
| Score | Text |
|---|---|
| 0.9995 | The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to Druggemcitabine and were discussed in the current study to 13. |
| 0.9941 | The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed Adverse-Effectradiation recall to gemcitabine and were discussed in the current study to 13. |
| 0.9935 | The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of Adverse-Effectradiation recall , thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13. |
| 0.9821 | The authors also determined that their case of Adverse-Effectmyositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13. |
| Score | Text |
|---|---|
| 0.9995 | These findings suggest that Drugclozapine - induced seizures can be successfully treated, that gradual dose titration can reduce the likelihood of further episodes of seizures and that concomitant use of a suitable mood stabilizer / anti - epileptic medication can improve the outcome of treatment - resistant schizophrenia. |
| 0.9980 | These findings suggest that clozapine - induced Adverse-Effectseizures can be successfully treated, that gradual dose titration can reduce the likelihood of further episodes of seizures and that concomitant use of a suitable mood stabilizer / anti - epileptic medication can improve the outcome of treatment - resistant schizophrenia. |
| 0.9946 | These findings suggest that clozapine - induced seizures can be successfully treated, that gradual dose titration can reduce the likelihood of further episodes of Adverse-Effectseizures and that concomitant use of a suitable mood stabilizer / anti - epileptic medication can improve the outcome of treatment - resistant schizophrenia. |
| Score | Text |
|---|---|
| 0.9883 | We report the case histories of two patients with histologically confirmed adenocarcinoma of the prostate, both of whom had been treated with steroidal anti - androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation, and who subsequently developed Adverse-Effectfemoral head avascular necrosis . |
| 0.9827 | We report the case histories of two patients with histologically confirmed adenocarcinoma of the prostate, both of whom had been treated with steroidal anti - androgen therapy in the form of Drugcyproterone acetate prior to radical or palliative pelvic irradiation, and who subsequently developed femoral head avascular necrosis. |
| 0.9094 | We report the case histories of two patients with histologically confirmed Adverse-Effectadenocarcinoma of the prostate , both of whom had been treated with steroidal anti - androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation, and who subsequently developed femoral head avascular necrosis. |
| Score | Text |
|---|---|
| 0.9995 | Postoperatively, the first two patients treated with 1 to 2 cc of Drugthrombin were slow to awaken ; one had evidence of vasospasm by transcranial Doppler ultrasound studies and multiple infarcts on cranial computerized tomography, while the other had a moderate - sized frontal hematoma with intracranial hypertension. |
| 0.9963 | Postoperatively, the first two patients treated with 1 to 2 cc of thrombin were slow to awaken ; one had evidence of Adverse-Effectvasospasm by transcranial Doppler ultrasound studies and multiple infarcts on cranial computerized tomography, while the other had a moderate - sized frontal hematoma with intracranial hypertension. |
| 0.9842 | Postoperatively, the first two patients treated with 1 to 2 cc of thrombin were slow to awaken ; one had evidence of vasospasm by transcranial Doppler ultrasound studies and Adverse-Effectmultiple infarcts on cranial computerized tomography, while the other had a moderate - sized frontal hematoma with intracranial hypertension. |
| 0.8962 | Postoperatively, the first two patients treated with 1 to 2 cc of thrombin were Adverse-Effectslow to awaken ; one had evidence of vasospasm by transcranial Doppler ultrasound studies and multiple infarcts on cranial computerized tomography, while the other had a moderate - sized frontal hematoma with intracranial hypertension. |
| 0.7154 | Postoperatively, the first two patients treated with 1 to 2 cc of thrombin were slow to awaken ; one had evidence of vasospasm by transcranial Doppler ultrasound studies and multiple infarcts on cranial computerized tomography, while the other had a moderate - sized frontal hematoma with Adverse-Effectintracranial hypertension . |
| 0.7072 | Postoperatively, the first two patients treated with 1 to 2 cc of thrombin were slow to awaken ; one had evidence of vasospasm by transcranial Doppler ultrasound studies and multiple infarcts on cranial computerized tomography, while the other had a moderate - sized Adverse-Effectfrontal hematoma with intracranial hypertension. |
| Score | Text |
|---|---|
| 0.9979 | RESULTS : The estimated number of Accutane prescriptions for reproductive - aged women has more than doubled in the past 10 years ; it is the most widely used Adverse-Effectteratogenic drug in the United States, with approximately 2. 5 per 1, 000 reproductive - aged women exposed to Accutane in 1999. |
| 0.9942 | RESULTS : The estimated number of DrugAccutane prescriptions for reproductive - aged women has more than doubled in the past 10 years ; it is the most widely used teratogenic drug in the United States, with approximately 2. 5 per 1, 000 reproductive - aged women exposed to Accutane in 1999. |
| Score | Text |
|---|---|
| 0.9984 | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and Adverse-Effecteosinophilia two weeks after receiving trimethoprim ( TMP ) - sulfamethoxazole ( SMX ) treatment. |
| 0.9974 | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim ( TMP ) - sulfamethoxazole ( DrugSMX ) treatment. |
| 0.9966 | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, Adverse-Effectskin eruptions , cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim ( TMP ) - sulfamethoxazole ( SMX ) treatment. |
| 0.9955 | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, Adverse-Effecthepatosplenomegaly , atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim ( TMP ) - sulfamethoxazole ( SMX ) treatment. |
| 0.9948 | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, Adverse-Effectcervical lymphadenopathy , hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim ( TMP ) - sulfamethoxazole ( SMX ) treatment. |
| 0.9935 | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with Adverse-Effectfever , skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim ( TMP ) - sulfamethoxazole ( SMX ) treatment. |
| 0.9923 | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim ( TMP ) - Drugsulfamethoxazole ( SMX ) treatment. |
| 0.9889 | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, Adverse-Effectatypical lymphocytosis , and eosinophilia two weeks after receiving trimethoprim ( TMP ) - sulfamethoxazole ( SMX ) treatment. |
| 0.9466 | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving Drugtrimethoprim ( TMP ) - sulfamethoxazole ( SMX ) treatment. |
| 0.8080 | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim ( DrugTMP ) - sulfamethoxazole ( SMX ) treatment. |
| Score | Text |
|---|---|
| 0.9972 | Although it is difficult to be certain of the direct link of amiodarone on the basis of a single case, it is reasonable to presume that this histopathology is associated with amiodarone - induced Adverse-Effecthypothyroidism and that involution changes represent the hypofunctional status of this drug - induced disorder. |
| 0.9558 | Although it is difficult to be certain of the direct link of amiodarone on the basis of a single case, it is reasonable to presume that this histopathology is associated with Drugamiodarone - induced hypothyroidism and that involution changes represent the hypofunctional status of this drug - induced disorder. |
| 0.8922 | Although it is difficult to be certain of the direct link of Drugamiodarone on the basis of a single case, it is reasonable to presume that this histopathology is associated with amiodarone - induced hypothyroidism and that involution changes represent the hypofunctional status of this drug - induced disorder. |
| 0.5120 | Although it is difficult to be certain of the direct link of amiodarone on the basis of a single case, it is reasonable to presume that this histopathology is associated with amiodarone - induced hypothyroidism and that involution changes represent the Adverse-Effecthypofunctional status of this drug - induced disorder. |
| Score | Text |
|---|---|
| 0.9973 | It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of Adverse-Effecthypertension , and raises the issue of whether lead - induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium. |
| 0.9359 | It also highlights a current major etiologic question, that is, whether and to what degree Druglead exposure contributes to the development of hypertension, and raises the issue of whether lead - induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium. |
| 0.9083 | It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether Druglead - induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium. |
| 0.9609 | It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether lead - induced hypertension constitutes a subset of Adverse-Effecthypertension that is especially amenable to therapy with dietary calcium. |
| 0.9577 | It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether lead - induced Adverse-Effecthypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium. |
| It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether Adverse-Effectlead - induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium. | |
| Score | Text |
|---|---|
| 0.9994 | DrugRisperidone is a frequently used member of a new class of atypical antipsychotics - the serotonin - dopamine antagonists ( SDAs ) - due to its comparatively high efficacy and low D2 / 5HT2 binding ratio, which results in a low incidence of extrapyramidal side effects including tardive dyskinesia ( TD ). |
| 0.9920 | Risperidone is a frequently used member of a new class of atypical antipsychotics - the serotonin - dopamine antagonists ( SDAs ) - due to its comparatively high efficacy and low D2 / 5HT2 binding ratio, which results in a low incidence of extrapyramidal side effects including Adverse-Effecttardive dyskinesia ( TD ). |
| 0.9844 | Risperidone is a frequently used member of a new class of atypical antipsychotics - the serotonin - dopamine antagonists ( SDAs ) - due to its comparatively high efficacy and low D2 / 5HT2 binding ratio, which results in a low incidence of extrapyramidal side effects including tardive dyskinesia ( Adverse-EffectTD ). |
| 0.9011 | Risperidone is a frequently used member of a new class of atypical antipsychotics - the serotonin - dopamine antagonists ( SDAs ) - due to its comparatively high efficacy and low D2 / 5HT2 binding ratio, which results in a low incidence of Adverse-Effectextrapyramidal side effects including tardive dyskinesia ( TD ). |
| Score | Text |
|---|---|
| 0.9996 | DrugVancomycin is widely used against methicillin - resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as " red man syndrome " and anaphylaxis. |
| 0.9988 | Vancomycin is widely used against methicillin - resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as " red man syndrome " and Adverse-Effectanaphylaxis . |
| 0.9984 | Vancomycin is widely used against methicillin - resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as Adverse-Effectnephrotoxicity , ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as " red man syndrome " and anaphylaxis. |
| 0.9983 | Vancomycin is widely used against methicillin - resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, Adverse-Effectototoxicity , gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as " red man syndrome " and anaphylaxis. |
| 0.9958 | Vancomycin is widely used against methicillin - resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, Adverse-Effectblood disorders , and two types of hypersensitivity reactions - an anaphylactoid reaction known as " red man syndrome " and anaphylaxis. |
| 0.9923 | Vancomycin is widely used against methicillin - resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as " Adverse-Effectred man syndrome " and anaphylaxis. |
| 0.9920 | Vancomycin is widely used against methicillin - resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, Adverse-Effectgastrointestinal disturbances , blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as " red man syndrome " and anaphylaxis. |
| 0.9797 | Vancomycin is widely used against methicillin - resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of Adverse-Effecthypersensitivity reactions - an anaphylactoid reaction known as " red man syndrome " and anaphylaxis. |
| 0.5081 | Vancomycin is widely used against methicillin - resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an Adverse-Effectanaphylactoid reaction known as " red man syndrome " and anaphylaxis. |
| 0.9930 | Vancomycin is widely used against methicillin - resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an Adverse-Effectanaphylactoid reaction known as " red man syndrome " and anaphylaxis. |
| Score | Text |
|---|---|
| 0.9996 | Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking Drugamiodarone for 4 years, developed thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin ( TSH ) receptor antibody ( TRAb ), or thyrotropin - binding inhibiting immunoglobulin ( TBII ). |
| 0.9983 | Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking amiodarone for 4 years, developed Adverse-Effectthyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin ( TSH ) receptor antibody ( TRAb ), or thyrotropin - binding inhibiting immunoglobulin ( TBII ). |
| 0.9772 | Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking amiodarone for 4 years, developed thyrotoxicosis with subacute onset, accompanied by Adverse-Effecttransiently positive thyrotropin ( TSH ) receptor antibody ( TRAb ), or thyrotropin - binding inhibiting immunoglobulin ( TBII ). |
| 0.9609 | Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking amiodarone for 4 years, developed thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin ( TSH ) receptor antibody ( TRAb ), or Adverse-Effectthyrotropin - binding inhibiting immunoglobulin ( TBII ). |
| 0.9695 | Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking amiodarone for 4 years, developed thyrotoxicosis with Adverse-Effectsubacute onset , accompanied by transiently positive thyrotropin ( TSH ) receptor antibody ( TRAb ), or thyrotropin - binding inhibiting immunoglobulin ( TBII ). |
| 0.9327 | Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking amiodarone for 4 years, developed thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin ( TSH ) receptor antibody ( TRAb ), or Adverse-Effectthyrotropin - binding inhibiting immunoglobulin ( TBII ). |
| 0.9130 | Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking amiodarone for 4 years, developed thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin ( TSH ) receptor antibody ( TRAb ), or Adverse-Effectthyrotropin - binding inhibiting immunoglobulin ( TBII ). |
| 0.9045 | Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking amiodarone for 4 years, developed thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin ( TSH ) receptor antibody ( TRAb ), or Adverse-Effectthyrotropin - binding inhibiting immunoglobulin ( TBII ). |
| 0.7653 | Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking amiodarone for 4 years, developed thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin ( TSH ) receptor antibody ( Adverse-EffectTRAb ), or thyrotropin - binding inhibiting immunoglobulin ( TBII ). |
| Score | Text |
|---|---|
| 0.9916 | Adverse-EffectThrombocytopenia with or without microangiopathy following quinine is often referred to as quinine " hypersensitivity. " When schistocytes are present it is frequently termed " quinine - associated TTP / HUS. " A severe deficiency of the vWF - cleaving protease, ADAMTS13, is associated with idiopathic TTP. |
| 0.9582 | Thrombocytopenia with or without microangiopathy following Drugquinine is often referred to as quinine " hypersensitivity. " When schistocytes are present it is frequently termed " quinine - associated TTP / HUS. " A severe deficiency of the vWF - cleaving protease, ADAMTS13, is associated with idiopathic TTP. |
| 0.8918 | Thrombocytopenia with or without microangiopathy following quinine is often referred to as quinine " hypersensitivity. " When schistocytes are present it is frequently termed " Drugquinine - associated TTP / HUS. " A severe deficiency of the vWF - cleaving protease, ADAMTS13, is associated with idiopathic TTP. |
| 0.9728 | Thrombocytopenia with or without microangiopathy following quinine is often referred to as quinine " hypersensitivity. " When schistocytes are present it is frequently termed " quinine - associated TTP / Adverse-EffectHUS . " A severe deficiency of the vWF - cleaving protease, ADAMTS13, is associated with idiopathic TTP. |
| 0.9492 | Thrombocytopenia with or without microangiopathy following quinine is often referred to as Drugquinine " hypersensitivity. " When schistocytes are present it is frequently termed " quinine - associated TTP / HUS. " A severe deficiency of the vWF - cleaving protease, ADAMTS13, is associated with idiopathic TTP. |
| 0.8587 | Thrombocytopenia with or without microangiopathy following quinine is often referred to as quinine " Adverse-Effecthypersensitivity . " When schistocytes are present it is frequently termed " quinine - associated TTP / HUS. " A severe deficiency of the vWF - cleaving protease, ADAMTS13, is associated with idiopathic TTP. |
| 0.6475 | Thrombocytopenia with or without microangiopathy following quinine is often referred to as quinine " hypersensitivity. " When schistocytes are present it is frequently termed " quinine - associated TTP / HUS. " A Adverse-Effectsevere deficiency of the vWF - cleaving protease , ADAMTS13, is associated with idiopathic TTP. |
| Thrombocytopenia with or without microangiopathy following quinine is often referred to as quinine " hypersensitivity. " When schistocytes are present it is frequently termed " quinine - associated Adverse-EffectTTP / HUS . " A severe deficiency of the vWF - cleaving protease, ADAMTS13, is associated with idiopathic TTP. | |
| Score | Text |
|---|---|
| 0.9958 | Intravenous verapamil therapy in babies may cause Adverse-Effectapnea , hypotension, and bradycardia ; continued episodes of atrial flutter in a child may cause sudden death ; quinidine may be related to the death ; children with " familial seizure disorders " may in fact have the long QT interval syndrome. |
| 0.9928 | Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia ; continued episodes of atrial flutter in a child may cause Adverse-Effectsudden death ; quinidine may be related to the death ; children with " familial seizure disorders " may in fact have the long QT interval syndrome. |
| 0.9912 | Intravenous Drugverapamil therapy in babies may cause apnea, hypotension, and bradycardia ; continued episodes of atrial flutter in a child may cause sudden death ; quinidine may be related to the death ; children with " familial seizure disorders " may in fact have the long QT interval syndrome. |
| 0.9908 | Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia ; continued episodes of atrial flutter in a child may cause sudden death ; quinidine may be related to the death ; children with " familial seizure disorders " may in fact have the Adverse-Effectlong QT interval syndrome . |
| 0.9867 | Intravenous verapamil therapy in babies may cause apnea, Adverse-Effecthypotension , and bradycardia ; continued episodes of atrial flutter in a child may cause sudden death ; quinidine may be related to the death ; children with " familial seizure disorders " may in fact have the long QT interval syndrome. |
| 0.9540 | Intravenous verapamil therapy in babies may cause apnea, hypotension, and Adverse-Effectbradycardia ; continued episodes of atrial flutter in a child may cause sudden death ; quinidine may be related to the death ; children with " familial seizure disorders " may in fact have the long QT interval syndrome. |
| 0.9319 | Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia ; continued episodes of atrial flutter in a child may cause sudden death ; Drugquinidine may be related to the death ; children with " familial seizure disorders " may in fact have the long QT interval syndrome. |
| 0.5350 | Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia ; continued episodes of Adverse-Effectatrial flutter in a child may cause sudden death ; quinidine may be related to the death ; children with " familial seizure disorders " may in fact have the long QT interval syndrome. |
| Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia ; continued episodes of atrial flutter in a child may cause sudden death ; quinidine may be related to the Adverse-Effectdeath ; children with " familial seizure disorders " may in fact have the long QT interval syndrome. | |
| Score | Text |
|---|---|
| 0.9908 | The pharmaceutical company producing Halfan has reported 8 Adverse-Effectcardiac arrests , leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency. |
| 0.9890 | The pharmaceutical company producing DrugHalfan has reported 8 cardiac arrests, leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency. |
| 0.9826 | The pharmaceutical company producing Halfan has reported 8 cardiac arrests, leading to 6 Adverse-Effectdeaths , when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency. |
| 0.8201 | The pharmaceutical company producing Halfan has reported 8 cardiac arrests, leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with Drugmefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency. |
| 0.5427 | The pharmaceutical company producing Halfan has reported 8 cardiac arrests, leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre - existing Adverse-Effectprolongation of the QT interval or the patient had a thiamine deficiency. |
| Score | Text |
|---|---|
| 0.9919 | The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and Adverse-Effectsevere anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia. |
| 0.9908 | The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by Adverse-Effectacute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia. |
| 0.9884 | The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of Adverse-Effecthypoxemia . |
| 0.9482 | The administration of " Drugsweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia. |
| 0.7210 | The administration of " sweet spirits of nitre " ( Drug4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia. |
| 0.6386 | The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin Adverse-Effectdied from the consequences of hypoxemia. |
| 0.6638 | The administration of " sweet Drugspirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia. |
| Score | Text |
|---|---|
| 0.9968 | Although the literature on the use of Drugrisperidone in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency of extrapyramidal symptoms ( EPS ). |
| 0.9906 | Although the literature on the use of risperidone in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency of Adverse-Effectextrapyramidal symptoms ( EPS ). |
| 0.9854 | Although the literature on the use of risperidone in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency of extrapyramidal symptoms ( Adverse-EffectEPS ). |
| Score | Text |
|---|---|
| 0.9984 | Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin : one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and Adverse-Effecthypotension ; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever. |
| 0.9968 | Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin : one, involving intrahepatic artery infusion, manifested general erythema, Adverse-Effectdyspnea , and hypotension ; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever. |
| 0.9965 | Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin : one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension ; the other, involving intravenous infusion, manifested Adverse-Effectabdominal pain , general erythema, and fever. |
| 0.9958 | Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin : one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension ; the other, involving intravenous infusion, manifested abdominal pain, Adverse-Effectgeneral erythema , and fever. |
| 0.9953 | Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin : one, involving intrahepatic artery infusion, manifested Adverse-Effectgeneral erythema , dyspnea, and hypotension ; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever. |
| 0.9826 | Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin : one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension ; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and Adverse-Effectfever . |
| 0.9727 | Two patients with ovarian cancer who had received multiple courses of Drugcisplatin without complications experienced hypersensitivity reactions to cisplatin : one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension ; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever. |
| 0.9673 | Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to Drugcisplatin : one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension ; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever. |
| 0.9596 | Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced Adverse-Effecthypersensitivity reactions to cisplatin : one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension ; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever. |
| Score | Text |
|---|---|
| 0.9901 | We report 5 patients ( 3 patients with chronic hepatitis C treated with pegylated interferon alfa - 2b in association with oral ribavirin and two patients with chronic myelocytic leukemia ) who developed Adverse-Effectlocal cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa - 2b at different doses. |
| 0.9777 | We report 5 patients ( 3 patients with chronic hepatitis C treated with pegylated interferon alfa - 2b in association with oral ribavirin and two patients with chronic myelocytic leukemia ) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of Drugpegylated interferon alfa - 2b at different doses. |
| 0.9759 | We report 5 patients ( 3 patients with chronic hepatitis C treated with Drugpegylated interferon alfa - 2b in association with oral ribavirin and two patients with chronic myelocytic leukemia ) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa - 2b at different doses. |
| 0.9034 | We report 5 patients ( 3 patients with chronic hepatitis C treated with pegylated interferon alfa - 2b in association with oral Drugribavirin and two patients with chronic myelocytic leukemia ) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa - 2b at different doses. |
| Score | Text |
|---|---|
| 0.9884 | Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin - induced Adverse-Effecthyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients. |
| 0.9612 | Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of Drugbleomycin - induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients. |
| 0.9543 | Although this type of Adverse-Effecthyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin - induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients. |
| 0.9294 | Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving Drugbleomycin , this is, to our knowledge, the first reported case of bleomycin - induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients. |
| 0.9833 | Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin - induced hyperpigmentation in an AIDS patient and should be added to the growing list of Adverse-Effectcutaneous eruptions seen in these patients. |
| Score | Text |
|---|---|
| 0.9711 | Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum - based chemotherapy, even in platinum - sensitive cases, because DrugCBDCA hypersensitivity can occur even with low - dose CBDCA administration. |
| 0.9682 | Our report suggested that DrugCBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum - based chemotherapy, even in platinum - sensitive cases, because CBDCA hypersensitivity can occur even with low - dose CBDCA administration. |
| 0.9528 | Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum - based chemotherapy, even in platinum - sensitive cases, because CBDCA hypersensitivity can occur even with low - dose DrugCBDCA administration. |
| 0.9021 | Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum - based chemotherapy, even in platinum - sensitive cases, because CBDCA Adverse-Effecthypersensitivity can occur even with low - dose CBDCA administration. |
| 0.8476 | Our report suggested that CBDCA Adverse-Effecthypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum - based chemotherapy, even in platinum - sensitive cases, because CBDCA hypersensitivity can occur even with low - dose CBDCA administration. |
| 0.7224 | Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that DrugCBDCA should be excluded in patients who have received multiple platinum - based chemotherapy, even in platinum - sensitive cases, because CBDCA hypersensitivity can occur even with low - dose CBDCA administration. |
| Score | Text |
|---|---|
| 0.9943 | This paper reports on a 6. 9 - year - old autistic male who developed repeated episodes of Adverse-Effectacute dystonic reactions associated with pimozide administration at the doses of 0. 096 mg / kg / day and 0. 032 mg / kg / day and 32 hours following pimozide withdrawal, as well as during subsequent thioridazine administration. |
| 0.9592 | This paper reports on a 6. 9 - year - old autistic male who developed repeated episodes of acute dystonic reactions associated with Drugpimozide administration at the doses of 0. 096 mg / kg / day and 0. 032 mg / kg / day and 32 hours following pimozide withdrawal, as well as during subsequent thioridazine administration. |
| 0.9512 | This paper reports on a 6. 9 - year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0. 096 mg / kg / day and 0. 032 mg / kg / day and 32 hours following pimozide withdrawal, as well as during subsequent Drugthioridazine administration. |
| 0.9301 | This paper reports on a 6. 9 - year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0. 096 mg / kg / day and 0. 032 mg / kg / day and 32 hours following Drugpimozide withdrawal, as well as during subsequent thioridazine administration. |
| Score | Text |
|---|---|
| 0.9759 | We have seen a case of terminal malignant melanoma in which clinical manifestations, indicative of Adverse-Effectanterior spinal artery syndrome , developed following the injection of 0. 3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - - C5 level for the control of severe right arm pain. |
| 0.7603 | We have seen a case of terminal malignant melanoma in which clinical manifestations, indicative of anterior spinal artery syndrome, developed following the injection of 0. 3 ml of 10 % Drugphenol - glycerine into the cervical subarachnoid space at the C4 - - C5 level for the control of severe right arm pain. |
| 0.9850 | We have seen a case of Adverse-Effectterminal malignant melanoma in which clinical manifestations, indicative of anterior spinal artery syndrome, developed following the injection of 0. 3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - - C5 level for the control of severe right arm pain. |
| Score | Text |
|---|---|
| 0.9992 | Contrary to previous recommendations, our experience cautions against the further use of high - dose Drugcytarabine in patients who develop PPE, and is a timely reminder of the potential toxicity of this agent, which is now increasingly being used as first - line treatment in the management of haematologic malignancies. |
| 0.9974 | Contrary to previous recommendations, our experience cautions against the further use of high - dose cytarabine in patients who develop Adverse-EffectPPE , and is a timely reminder of the potential toxicity of this agent, which is now increasingly being used as first - line treatment in the management of haematologic malignancies. |
| Score | Text |
|---|---|
| 0.9819 | Attempts were made to stop and then restart the Drugtheophylline therapy at progressively lower doses ; however, with each attempt, the patient's reaction to the drug became more toxic, with serum theophylline levels ranging between 99. 9 and 149. 9 micromol / L ( 18 and 27 microg / mL ). |
| 0.9633 | Attempts were made to stop and then restart the theophylline therapy at progressively lower doses ; however, with each attempt, the patient's reaction to the drug became more toxic, with serum Drugtheophylline levels ranging between 99. 9 and 149. 9 micromol / L ( 18 and 27 microg / mL ). |
| Attempts were made to stop and then restart the theophylline therapy at progressively lower doses ; however, with each attempt, the patient's Adverse-Effectreaction to the drug became more toxic , with serum theophylline levels ranging between 99. 9 and 149. 9 micromol / L ( 18 and 27 microg / mL ). | |
| Score | Text |
|---|---|
| 0.9954 | Since recent studies have reported no negative interactions with concurrent use, we here report three cases ( one case of a prolonged seizure, a serotonin syndrome and a focal seizure ) of severe Druglithium - induced side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic. |
| 0.9915 | Since recent studies have reported no negative interactions with concurrent use, we here report three cases ( one case of a prolonged seizure, a Adverse-Effectserotonin syndrome and a focal seizure ) of severe lithium - induced side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic. |
| 0.9880 | Since recent studies have reported no negative interactions with concurrent use, we here report three cases ( one case of a prolonged seizure, a serotonin syndrome and a Adverse-Effectfocal seizure ) of severe lithium - induced side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic. |
| 0.9877 | Since recent studies have reported no negative interactions with concurrent use, we here report three cases ( one case of a Adverse-Effectprolonged seizure , a serotonin syndrome and a focal seizure ) of severe lithium - induced side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic. |
| Score | Text |
|---|---|
| 0.9996 | Eleven patients developed infection requiring hospitalization while taking Drugleflunomide including : lower respiratory tract infections ( 3 ), cellulitis ( 2 ), disseminated herpes zoster ( 2 ), probable TB liver ( 1 ), abdominal sepsis ( 1 ), mycotic aneurysm ( 1 ) and gastroenteritis ( 1 ). |
| 0.9939 | Eleven patients developed Adverse-Effectinfection requiring hospitalization while taking leflunomide including : lower respiratory tract infections ( 3 ), cellulitis ( 2 ), disseminated herpes zoster ( 2 ), probable TB liver ( 1 ), abdominal sepsis ( 1 ), mycotic aneurysm ( 1 ) and gastroenteritis ( 1 ). |
| 0.9937 | Eleven patients developed infection requiring hospitalization while taking leflunomide including : lower respiratory tract infections ( 3 ), cellulitis ( 2 ), disseminated herpes zoster ( 2 ), probable TB liver ( 1 ), abdominal sepsis ( 1 ), mycotic aneurysm ( 1 ) and Adverse-Effectgastroenteritis ( 1 ). |
| 0.9933 | Eleven patients developed infection requiring hospitalization while taking leflunomide including : lower respiratory tract infections ( 3 ), cellulitis ( 2 ), disseminated herpes zoster ( 2 ), probable Adverse-EffectTB liver ( 1 ), abdominal sepsis ( 1 ), mycotic aneurysm ( 1 ) and gastroenteritis ( 1 ). |
| 0.9920 | Eleven patients developed infection requiring hospitalization while taking leflunomide including : lower respiratory tract infections ( 3 ), cellulitis ( 2 ), disseminated herpes zoster ( 2 ), probable TB liver ( 1 ), Adverse-Effectabdominal sepsis ( 1 ), mycotic aneurysm ( 1 ) and gastroenteritis ( 1 ). |
| 0.9899 | Eleven patients developed infection requiring hospitalization while taking leflunomide including : lower respiratory tract infections ( 3 ), Adverse-Effectcellulitis ( 2 ), disseminated herpes zoster ( 2 ), probable TB liver ( 1 ), abdominal sepsis ( 1 ), mycotic aneurysm ( 1 ) and gastroenteritis ( 1 ). |
| 0.9875 | Eleven patients developed infection requiring hospitalization while taking leflunomide including : lower respiratory tract infections ( 3 ), cellulitis ( 2 ), Adverse-Effectdisseminated herpes zoster ( 2 ), probable TB liver ( 1 ), abdominal sepsis ( 1 ), mycotic aneurysm ( 1 ) and gastroenteritis ( 1 ). |
| 0.9847 | Eleven patients developed infection requiring hospitalization while taking leflunomide including : Adverse-Effectlower respiratory tract infections ( 3 ), cellulitis ( 2 ), disseminated herpes zoster ( 2 ), probable TB liver ( 1 ), abdominal sepsis ( 1 ), mycotic aneurysm ( 1 ) and gastroenteritis ( 1 ). |
| 0.9797 | Eleven patients developed infection requiring hospitalization while taking leflunomide including : lower respiratory tract infections ( 3 ), cellulitis ( 2 ), disseminated herpes zoster ( 2 ), probable TB liver ( 1 ), abdominal sepsis ( 1 ), Adverse-Effectmycotic aneurysm ( 1 ) and gastroenteritis ( 1 ). |
| Score | Text |
|---|---|
| 0.9950 | During dose - finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed Adverse-Effectperipheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. |
| 0.9765 | During dose - finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving Drugomeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. |
| 0.9666 | During dose - finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving Drugpantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. |
| 0.9809 | During dose - finding studies for intravenous proton pump inhibitors omeprazole and Drugpantoprazole , three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. |
| 0.9749 | During dose - finding studies for intravenous proton pump inhibitors Drugomeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. |
| Score | Text |
|---|---|
| 0.9980 | Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to Drugbisabolol - a component of the Aquaphor emollient they were using to treat their atopic dermatitis. |
| 0.9779 | Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential Adverse-Effectallergic contact dermatitis to bisabolol - a component of the Aquaphor emollient they were using to treat their atopic dermatitis. |
| Score | Text |
|---|---|
| 0.9764 | We describe the Adverse-Effectinfectious toxicities experienced by the first two patients in our institution treated with dexamethasone ( 10 mg / m ( 2 ) / day for 4 weeks with gradual tapering ) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone. |
| 0.9185 | We describe the infectious toxicities experienced by the first two patients in our institution treated with Drugdexamethasone ( 10 mg / m ( 2 ) / day for 4 weeks with gradual tapering ) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone. |
| 0.8319 | We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone ( 10 mg / m ( 2 ) / day for 4 weeks with gradual tapering ) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with Drugdexamethasone . |
| 0.5027 | We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone ( 10 mg / m ( 2 ) / day for 4 weeks with gradual tapering ) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of Adverse-Effectinfectious complications with dexamethasone. |
| 0.8606 | We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone ( 10 mg / m ( 2 ) / day for 4 weeks with gradual tapering ) during induction according to the Drugdexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone. |
| Score | Text |
|---|---|
| 0.9994 | We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered Drugmethotrexate and, in the second by intrathecally administered methotrexate and cranial irradiation. |
| 0.9994 | We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered methotrexate and, in the second by intrathecally administered Drugmethotrexate and cranial irradiation. |
| 0.9982 | We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and Adverse-Effecthydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered methotrexate and, in the second by intrathecally administered methotrexate and cranial irradiation. |
| 0.9977 | We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed Adverse-Effectleukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered methotrexate and, in the second by intrathecally administered methotrexate and cranial irradiation. |
| 0.9098 | We report the case histories of identical twin brothers who developed Adverse-Effectconcordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered methotrexate and, in the second by intrathecally administered methotrexate and cranial irradiation. |
| 0.8080 | We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to Adverse-Effectcentral nervous system prophylaxis by, in the first case intrathecally administered methotrexate and, in the second by intrathecally administered methotrexate and cranial irradiation. |
| Score | Text |
|---|---|
| 0.9954 | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion, agitation, tachycardia, Adverse-Effecttremors , myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl. |
| 0.9951 | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with Adverse-Effectserotonin syndrome , following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl. |
| 0.9948 | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) Drugcitalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl. |
| 0.9944 | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion, agitation, Adverse-Effecttachycardia , tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl. |
| 0.9943 | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion, Adverse-Effectagitation , tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl. |
| 0.9929 | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion, agitation, tachycardia, tremors, Adverse-Effectmyoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl. |
| 0.9922 | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and Adverse-Effectunsteady gait , consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl. |
| 0.9850 | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed Adverse-Effectconfusion , agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl. |
| 0.9763 | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of Drugfentanyl . |
| 0.9750 | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of Drugfentanyl , and all symptoms and signs resolved following discontinuation of fentanyl. |
| Score | Text |
|---|---|
| 0.9996 | We describe longitudinal diffusion - weighted MRI findings of sub - acute leukoencephalopathy following Drugmethotrexate therapy in a 24 - year - old man diagnosed with pre - B - cell acute lymphoblastic leukemia ( ALL ), presenting with right - sided paralysis and aphasia after second consolidation with intrathecal triple - drug therapy given intrathecally. |
| 0.9653 | We describe longitudinal diffusion - weighted MRI findings of Adverse-Effectsub - acute leukoencephalopathy following methotrexate therapy in a 24 - year - old man diagnosed with pre - B - cell acute lymphoblastic leukemia ( ALL ), presenting with right - sided paralysis and aphasia after second consolidation with intrathecal triple - drug therapy given intrathecally. |
| 0.6072 | We describe longitudinal diffusion - weighted MRI findings of sub - acute leukoencephalopathy following methotrexate therapy in a 24 - year - old man diagnosed with pre - B - cell acute lymphoblastic leukemia ( ALL ), presenting with right - sided paralysis and Adverse-Effectaphasia after second consolidation with intrathecal triple - drug therapy given intrathecally. |
| Score | Text |
|---|---|
| 0.9996 | This report describes an individual with mental retardation who experienced behavioral exacerbation associated with Drugclonazepam prescribed at 2 mg / day ( 0. 02 mg / kg / day ) to treat aggression, self - injurious behavior, property destruction, and screaming, which was measured with a 15 - minute partial interval recording measurement method. |
| 0.9934 | This report describes an individual with mental retardation who experienced Adverse-Effectbehavioral exacerbation associated with clonazepam prescribed at 2 mg / day ( 0. 02 mg / kg / day ) to treat aggression, self - injurious behavior, property destruction, and screaming, which was measured with a 15 - minute partial interval recording measurement method. |
| Score | Text |
|---|---|
| 0.9978 | In this article lithium is not discussed, although there are a number of concerns about lithium's potential Adverse-Effectteratogenicity , and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking lithium ; as with other medications, however, the data have specific limitations. |
| 0.9891 | In this article lithium is not discussed, although there are a number of concerns about Druglithium ' s potential teratogenicity, and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking lithium ; as with other medications, however, the data have specific limitations. |
| 0.9780 | In this article lithium is not discussed, although there are a number of concerns about lithium's potential teratogenicity, and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking Druglithium ; as with other medications, however, the data have specific limitations. |
| 0.9744 | In this article lithium is not discussed, although there are a number of concerns about lithium's potential teratogenicity, and it has been implicated in Adverse-EffectEpstein's anomaly , a congenital heart defect among infants born to women taking lithium ; as with other medications, however, the data have specific limitations. |
| 0.9843 | In this article Druglithium is not discussed, although there are a number of concerns about lithium's potential teratogenicity, and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking lithium ; as with other medications, however, the data have specific limitations. |
| 0.9689 | In this article lithium is not discussed, although there are a number of concerns about lithium's potential teratogenicity, and it has been implicated in Epstein's anomaly, a Adverse-Effectcongenital heart defect among infants born to women taking lithium ; as with other medications, however, the data have specific limitations. |
| Score | Text |
|---|---|
| 0.9995 | CASE SUMMARY : A 61 - year - old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long - term course of pulse Drugitraconazole therapy ( 200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk ) for onychomycosis. |
| 0.9920 | CASE SUMMARY : A 61 - year - old woman with no apparent risk factors for liver injury developed Adverse-Effectacute hepatitis one week after the final dose of a long - term course of pulse itraconazole therapy ( 200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk ) for onychomycosis. |
| Score | Text |
|---|---|
| 0.9957 | Thirty - six patients with AL received, in a three - month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside ( ARA - C ) ; among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and Adverse-Effectsevere myalgias . |
| 0.9946 | Thirty - six patients with AL received, in a three - month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside ( ARA - C ) ; among them, along with myelosuppression, five experienced Adverse-Effectfever , infectious complications, gastrointestinal tract symptoms and severe myalgias. |
| 0.9934 | Thirty - six patients with AL received, in a three - month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside ( ARA - C ) ; among them, along with myelosuppression, five experienced fever, infectious complications, Adverse-Effectgastrointestinal tract symptoms and severe myalgias. |
| 0.9874 | Thirty - six patients with AL received, in a three - month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside ( ARA - C ) ; among them, along with myelosuppression, five experienced fever, Adverse-Effectinfectious complications , gastrointestinal tract symptoms and severe myalgias. |
| 0.9834 | Thirty - six patients with AL received, in a three - month period, 51 cycles of combined chemotherapy which included, in all of them, Drugcytosine arabinoside ( ARA - C ) ; among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and severe myalgias. |
| 0.9826 | Thirty - six patients with AL received, in a three - month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside ( DrugARA - C ) ; among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and severe myalgias. |
| Score | Text |
|---|---|
| 0.9993 | 1. Changes in the plasma cortisol level were reported in a male patient with panic disorder during the period of low - dose Drugalprazolam treatment ( mean 0. 62 + / - 0. 15 mg / day ) compared with during the period of high - dose period ( mean 1. 08 + / - 0. 28 mg / day ). |
| 0.9762 | 1. Adverse-EffectChanges in the plasma cortisol level were reported in a male patient with panic disorder during the period of low - dose alprazolam treatment ( mean 0. 62 + / - 0. 15 mg / day ) compared with during the period of high - dose period ( mean 1. 08 + / - 0. 28 mg / day ). |
| Score | Text |
|---|---|
| 0.9813 | DISCUSSION : After exclusion of other causes, the onset of Adverse-Effectthrombocytopenia after administration of lansoprazole, the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic thrombocytopenic response to lansoprazole. |
| 0.9269 | DISCUSSION : After exclusion of other causes, the onset of thrombocytopenia after administration of Druglansoprazole , the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic thrombocytopenic response to lansoprazole. |
| 0.9200 | DISCUSSION : After exclusion of other causes, the onset of thrombocytopenia after administration of lansoprazole, the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic thrombocytopenic response to Druglansoprazole . |
| 0.5404 | DISCUSSION : After exclusion of other causes, the onset of thrombocytopenia after administration of lansoprazole, the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an Adverse-Effectidiosyncratic thrombocytopenic response to lansoprazole. |
| DISCUSSION : After exclusion of other causes, the onset of thrombocytopenia after administration of lansoprazole, the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic Adverse-Effectthrombocytopenic response to lansoprazole. | |
| Score | Text |
|---|---|
| 0.9916 | In a single practice during the 21 years 1971 - 1991, the incidence of Adverse-Effectgestational diabetes in pregnancies in which norethisterone was prescribed was 32. 4 % ( 22 of 69 ) in comparison with 7. 1 % in pregnancies in which the women did not take norethisterone ( 137 of 1, 684 ) ( p < 0. 001 ). |
| 0.9434 | In a single practice during the 21 years 1971 - 1991, the incidence of gestational diabetes in pregnancies in which Drugnorethisterone was prescribed was 32. 4 % ( 22 of 69 ) in comparison with 7. 1 % in pregnancies in which the women did not take norethisterone ( 137 of 1, 684 ) ( p < 0. 001 ). |
| 0.8606 | In a single practice during the 21 years 1971 - 1991, the incidence of gestational diabetes in pregnancies in which norethisterone was prescribed was 32. 4 % ( 22 of 69 ) in comparison with 7. 1 % in pregnancies in which the women did not take Drugnorethisterone ( 137 of 1, 684 ) ( p < 0. 001 ). |
| Score | Text |
|---|---|
| 0.9931 | These findings are consistent with an immune - complex form of glomerulopathy in which gold is neither the antigen nor a hapten in the glomerular deposits, and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by gold therapy may be a causative factor in the Adverse-Effectrenal disease associated with gold therapy in rheumatoid arthritis. |
| 0.9874 | These findings are consistent with an immune - complex form of glomerulopathy in which gold is neither the antigen nor a hapten in the glomerular deposits, and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by gold therapy may be a causative factor in the renal disease associated with Druggold therapy in rheumatoid arthritis. |
| 0.9836 | These findings are consistent with an immune - complex form of glomerulopathy in which gold is neither the antigen nor a hapten in the glomerular deposits, and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by Druggold therapy may be a causative factor in the renal disease associated with gold therapy in rheumatoid arthritis. |
| 0.9817 | These findings are consistent with an immune - complex form of glomerulopathy in which Druggold is neither the antigen nor a hapten in the glomerular deposits, and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by gold therapy may be a causative factor in the renal disease associated with gold therapy in rheumatoid arthritis. |
| Score | Text |
|---|---|
| 0.9991 | The latter form ( DrugMacrodantin ) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form - - liver damage, acute and chronic pulmonary reactions, peripheral neuropathy, blood dyscrasias and allergic reactions - - and does so just as rapidly and floridly ; one such case is reported here. |
| 0.9962 | The latter form ( Macrodantin ) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form - - liver damage, acute and chronic pulmonary reactions, peripheral neuropathy, blood dyscrasias and Adverse-Effectallergic reactions - - and does so just as rapidly and floridly ; one such case is reported here. |
| 0.9958 | The latter form ( Macrodantin ) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form - - liver damage, acute and chronic pulmonary reactions, Adverse-Effectperipheral neuropathy , blood dyscrasias and allergic reactions - - and does so just as rapidly and floridly ; one such case is reported here. |
| 0.9946 | The latter form ( Macrodantin ) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form - - Adverse-Effectliver damage , acute and chronic pulmonary reactions, peripheral neuropathy, blood dyscrasias and allergic reactions - - and does so just as rapidly and floridly ; one such case is reported here. |
| 0.9931 | The latter form ( Macrodantin ) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form - - liver damage, acute and chronic pulmonary reactions, peripheral neuropathy, Adverse-Effectblood dyscrasias and allergic reactions - - and does so just as rapidly and floridly ; one such case is reported here. |
| 0.9726 | The latter form ( Macrodantin ) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form - - liver damage, Adverse-Effectacute and chronic pulmonary reactions , peripheral neuropathy, blood dyscrasias and allergic reactions - - and does so just as rapidly and floridly ; one such case is reported here. |
| Score | Text |
|---|---|
| 0.9949 | RESULTS : After 4 - to 14 - month period of therapy with the combination of indapamide ( 2. 5 mg / day ) and Drugfosinopril ( 10 mg / day ) in three patients and 6 - month period of monotherapy with indapamide ( 2. 5 mg / day ) in one patient, glucose levels of all patients increased and achieve criteria of diabetes diagnoses. |
| 0.9934 | RESULTS : After 4 - to 14 - month period of therapy with the combination of Drugindapamide ( 2. 5 mg / day ) and fosinopril ( 10 mg / day ) in three patients and 6 - month period of monotherapy with indapamide ( 2. 5 mg / day ) in one patient, glucose levels of all patients increased and achieve criteria of diabetes diagnoses. |
| 0.9918 | RESULTS : After 4 - to 14 - month period of therapy with the combination of indapamide ( 2. 5 mg / day ) and fosinopril ( 10 mg / day ) in three patients and 6 - month period of monotherapy with Drugindapamide ( 2. 5 mg / day ) in one patient, glucose levels of all patients increased and achieve criteria of diabetes diagnoses. |
| 0.9822 | RESULTS : After 4 - to 14 - month period of therapy with the combination of indapamide ( 2. 5 mg / day ) and fosinopril ( 10 mg / day ) in three patients and 6 - month period of monotherapy with indapamide ( 2. 5 mg / day ) in one patient, glucose levels of all patients increased and achieve criteria of Adverse-Effectdiabetes diagnoses. |
| Score | Text |
|---|---|
| 0.9860 | This case demonstrates an occupational activity ( construction ) that has now become the dominant source of lead exposure for U. S. adults, the importance of a good occupational history to suspecting and making a diagnosis, the possible outcomes of chronic Druglead toxicity, and the importance of preventing further exposure and using proper methods to treat acute toxicity. |
| 0.9780 | This case demonstrates an occupational activity ( construction ) that has now become the dominant source of lead exposure for U. S. adults, the importance of a good occupational history to suspecting and making a diagnosis, the possible outcomes of chronic Adverse-Effectlead toxicity , and the importance of preventing further exposure and using proper methods to treat acute toxicity. |
| 0.9537 | This case demonstrates an occupational activity ( construction ) that has now become the dominant source of Druglead exposure for U. S. adults, the importance of a good occupational history to suspecting and making a diagnosis, the possible outcomes of chronic lead toxicity, and the importance of preventing further exposure and using proper methods to treat acute toxicity. |
| 0.5236 | This case demonstrates an occupational activity ( construction ) that has now become the dominant source of lead exposure for U. S. adults, the importance of a good occupational history to suspecting and making a diagnosis, the possible outcomes of chronic lead toxicity, and the importance of preventing further exposure and using proper methods to treat Adverse-Effectacute toxicity . |
| Score | Text |
|---|---|
| 0.9898 | By means of the in vitro heparin - induced platelet activation ( HIPA ) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin ( Sanofi Labaz, Munich, FRG ), as well as the enoxaparine Clexane ( Nattermann, Cologne, FRG ), all induced Adverse-Effectplatelet activation with the patient's serum. |
| 0.9890 | By means of the in vitro heparin - induced platelet activation ( HIPA ) assay it was shown that standard heparin and the LMW heparins Fragmin and DrugFraxiparin ( Sanofi Labaz, Munich, FRG ), as well as the enoxaparine Clexane ( Nattermann, Cologne, FRG ), all induced platelet activation with the patient's serum. |
| 0.9758 | By means of the in vitro heparin - induced platelet activation ( HIPA ) assay it was shown that standard heparin and the LMW heparins DrugFragmin and Fraxiparin ( Sanofi Labaz, Munich, FRG ), as well as the enoxaparine Clexane ( Nattermann, Cologne, FRG ), all induced platelet activation with the patient's serum. |
| 0.9658 | By means of the in vitro heparin - induced platelet activation ( HIPA ) assay it was shown that standard Drugheparin and the LMW heparins Fragmin and Fraxiparin ( Sanofi Labaz, Munich, FRG ), as well as the enoxaparine Clexane ( Nattermann, Cologne, FRG ), all induced platelet activation with the patient's serum. |
| 0.9428 | By means of the in vitro Drugheparin - induced platelet activation ( HIPA ) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin ( Sanofi Labaz, Munich, FRG ), as well as the enoxaparine Clexane ( Nattermann, Cologne, FRG ), all induced platelet activation with the patient's serum. |
| 0.9423 | By means of the in vitro heparin - induced Adverse-Effectplatelet activation ( HIPA ) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin ( Sanofi Labaz, Munich, FRG ), as well as the enoxaparine Clexane ( Nattermann, Cologne, FRG ), all induced platelet activation with the patient's serum. |
| 0.7525 | By means of the in vitro heparin - induced platelet activation ( HIPA ) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin ( DrugSanofi Labaz , Munich, FRG ), as well as the enoxaparine Clexane ( Nattermann, Cologne, FRG ), all induced platelet activation with the patient's serum. |
| 0.7161 | By means of the in vitro heparin - induced platelet activation ( HIPA ) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin ( Sanofi Labaz, Munich, FRG ), as well as the Drugenoxaparine Clexane ( Nattermann, Cologne, FRG ), all induced platelet activation with the patient's serum. |
| By means of the in vitro heparin - induced platelet activation ( HIPA ) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin ( Sanofi Labaz, Munich, FRG ), as well as the enoxaparine DrugClexane ( Nattermann, Cologne, FRG ), all induced platelet activation with the patient's serum. | |
| Score | Text |
|---|---|
| 0.9006 | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with DrugCS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS. |
| 0.9002 | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in Drugcorticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS. |
| 0.8458 | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving DrugCS . |
| 0.9730 | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with Adverse-Effectcutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS. |
| 0.8650 | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a Adverse-Effectvisceral involvement after cutaneous leishmaniasis in a man receiving CS. |
| 0.8481 | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( DrugCS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS. |
| 0.6728 | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous Drugleishmaniasis in a man receiving CS. |
| 0.5387 | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral Drugleishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS. |
| 0.4986 | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated lingual Drugleishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS. |
| CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated Adverse-Effectlingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS. | |
| CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after Adverse-Effectcutaneous leishmaniasis in a man receiving CS. | |
| CASE PRESENTATION : Three cases of Adverse-EffectLeishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS. | |
| Score | Text |
|---|---|
| 0.9996 | Although the existence of an acute pericarditis or an acute myocarditis as possible causes of the ST elevation can not be fully ruled out, the sudden onset, prominent magnitude, and brief duration of the ST elevation are perhaps more indicative of an acute ischemic event, possibly related to a transient coronary vasoconstriction induced by the Drugdopamine infusion. |
| 0.9299 | Although the existence of an acute pericarditis or an acute myocarditis as possible causes of the ST elevation can not be fully ruled out, the sudden onset, prominent magnitude, and brief duration of the ST elevation are perhaps more indicative of an acute ischemic event, possibly related to a Adverse-Effecttransient coronary vasoconstriction induced by the dopamine infusion. |
| 0.6154 | Although the existence of an acute pericarditis or an acute myocarditis as possible causes of the ST elevation can not be fully ruled out, the sudden onset, prominent magnitude, and brief duration of the ST elevation are perhaps more indicative of an Adverse-Effectacute ischemic event , possibly related to a transient coronary vasoconstriction induced by the dopamine infusion. |
| Although the existence of an acute pericarditis or an acute myocarditis as possible causes of the ST elevation can not be fully ruled out, the sudden onset, prominent magnitude, and brief duration of the ST elevation are perhaps more indicative of an acute ischemic event, possibly related to a transient Adverse-Effectcoronary vasoconstriction induced by the dopamine infusion. | |
| Score | Text |
|---|---|
| 0.9091 | Its overall toxicity is considerably less compared to standard induction chemotherapy ; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as " Drugretinoic acid syndrome. " This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis. |
| 0.8186 | Its overall toxicity is considerably less compared to standard induction chemotherapy ; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as " Adverse-Effectretinoic acid syndrome . " This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis. |
| 0.8001 | Its overall toxicity is considerably less compared to standard induction chemotherapy ; however, it is associated with a high incidence of a Adverse-Effectpotentially fatal symptom complex referred to as " retinoic acid syndrome. " This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis. |
| 0.7016 | Its overall Adverse-Effecttoxicity is considerably less compared to standard induction chemotherapy ; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as " retinoic acid syndrome. " This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis. |
| 0.9689 | Its overall toxicity is considerably less compared to standard induction chemotherapy ; however, it is associated with a high incidence of a potentially Adverse-Effectfatal symptom complex referred to as " retinoic acid syndrome. " This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis. |
| Score | Text |
|---|---|
| 0.9990 | We further used immunohistochemistry ( IHC ) to examine the relative role of platelet - derived growth factor - B ( PDGF - B ), insulin - like growth factor I ( IGF - I ), transforming growth factor - beta1 ( TGF - beta1 ) and cyclooxygenase - 2 ( COX - 2 ) in the pathogenesis of DrugBCNU - related pulmonary fibrosis. |
| 0.9848 | We further used immunohistochemistry ( IHC ) to examine the relative role of platelet - derived growth factor - B ( PDGF - B ), insulin - like growth factor I ( IGF - I ), transforming growth factor - beta1 ( TGF - beta1 ) and cyclooxygenase - 2 ( COX - 2 ) in the pathogenesis of BCNU - related Adverse-Effectpulmonary fibrosis . |
| Score | Text |
|---|---|
| 0.9751 | CONCLUSION : The present findings suggest that : ( i ) amantadine probably exerts its anti - dyskinetic effect by acting on the " indirect " pathway ; ( ii ) the pathophysiological mechanisms of subthalamotomy induced dyskinesias may differ from those involved in DrugL - dopa induced dyskinesias ; ( iii ) dyskinesias induced by STN surgery resolve spontaneously as compensatory mechanisms develop. |
| 0.9147 | CONCLUSION : The present findings suggest that : ( i ) amantadine probably exerts its anti - dyskinetic effect by acting on the " indirect " pathway ; ( ii ) the pathophysiological mechanisms of subthalamotomy induced dyskinesias may differ from those involved in L - dopa induced Adverse-Effectdyskinesias ; ( iii ) dyskinesias induced by STN surgery resolve spontaneously as compensatory mechanisms develop. |
| 0.9344 | CONCLUSION : The present findings suggest that : ( i ) Drugamantadine probably exerts its anti - dyskinetic effect by acting on the " indirect " pathway ; ( ii ) the pathophysiological mechanisms of subthalamotomy induced dyskinesias may differ from those involved in L - dopa induced dyskinesias ; ( iii ) dyskinesias induced by STN surgery resolve spontaneously as compensatory mechanisms develop. |
| 0.8067 | CONCLUSION : The present findings suggest that : ( i ) amantadine probably exerts its anti - dyskinetic effect by acting on the " indirect " pathway ; ( ii ) the pathophysiological mechanisms of subthalamotomy induced Adverse-Effectdyskinesias may differ from those involved in L - dopa induced dyskinesias ; ( iii ) dyskinesias induced by STN surgery resolve spontaneously as compensatory mechanisms develop. |
| Score | Text |
|---|---|
| 0.9990 | A 10 - year - old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4 - hour infusion of high - dose Drugmethotrexate ( MTX ) ( 12 g / m2 ), and went on to develop acute renal failure with life - threatening hyperkalemia 29 hours later. |
| 0.9988 | A 10 - year - old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4 - hour infusion of high - dose methotrexate ( DrugMTX ) ( 12 g / m2 ), and went on to develop acute renal failure with life - threatening hyperkalemia 29 hours later. |
| 0.9763 | A 10 - year - old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4 - hour infusion of high - dose methotrexate ( MTX ) ( 12 g / m2 ), and went on to develop Adverse-Effectacute renal failure with life - threatening hyperkalemia 29 hours later. |
| 0.9260 | A 10 - year - old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending Adverse-Effectrenal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4 - hour infusion of high - dose methotrexate ( MTX ) ( 12 g / m2 ), and went on to develop acute renal failure with life - threatening hyperkalemia 29 hours later. |
| 0.8893 | A 10 - year - old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme Adverse-Effectelevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4 - hour infusion of high - dose methotrexate ( MTX ) ( 12 g / m2 ), and went on to develop acute renal failure with life - threatening hyperkalemia 29 hours later. |
| 0.7199 | A 10 - year - old boy with osteosarcoma and normal renal function manifested laboratory evidence of Adverse-Effectimpending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4 - hour infusion of high - dose methotrexate ( MTX ) ( 12 g / m2 ), and went on to develop acute renal failure with life - threatening hyperkalemia 29 hours later. |
| Score | Text |
|---|---|
| 0.9911 | Although risk factors for DrugMTX - induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre - existing lung disease, represented by diffuse interstitial changes on chest X - ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of MTX pneumonitis. |
| 0.9848 | Although risk factors for MTX - induced Adverse-Effectpulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre - existing lung disease, represented by diffuse interstitial changes on chest X - ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of MTX pneumonitis. |
| 0.9533 | Although risk factors for MTX - induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre - existing lung disease, represented by diffuse interstitial changes on chest X - ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of MTX Adverse-Effectpneumonitis . |
| 0.9282 | Although risk factors for MTX - induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre - existing lung disease, represented by diffuse interstitial changes on chest X - ray, and Adverse-Effectmild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of MTX pneumonitis. |
| 0.7543 | Although risk factors for MTX - induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre - existing lung disease, represented by diffuse interstitial changes on chest X - ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of Adverse-EffectMTX pneumonitis . |
| 0.6013 | Although risk factors for MTX - induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre - existing lung disease, represented by diffuse interstitial changes on chest X - ray, and mild bronchial asthma in two RA patients and by Adverse-Effectpulmonary silicosis in the patient with PsA may account for a predisposition to the development of MTX pneumonitis. |
| Although risk factors for MTX - induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre - existing lung disease, represented by diffuse interstitial changes on chest X - ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of DrugMTX pneumonitis. | |
| Score | Text |
|---|---|
| 0.9905 | A retrospective epidemiological study of deaths from hepatic angiosarcoma ( HAS ) in the U. S. showed that during 1964 - - 74 there were 168 such cases, of which 37 ( 22 % ) were associated with previously known causes ( Drugvinyl chloride ,'Thorotrast ', and inorganic arsenic ) and 4 ( 3. 1 % ) of the remaining 131 cases with the use of androgenic - anabolic steroids. |
| 0.9893 | A retrospective epidemiological study of deaths from hepatic angiosarcoma ( HAS ) in the U. S. showed that during 1964 - - 74 there were 168 such cases, of which 37 ( 22 % ) were associated with previously known causes ( vinyl chloride, ' DrugThorotrast ', and inorganic arsenic ) and 4 ( 3. 1 % ) of the remaining 131 cases with the use of androgenic - anabolic steroids. |
| 0.9891 | A retrospective epidemiological study of deaths from hepatic angiosarcoma ( HAS ) in the U. S. showed that during 1964 - - 74 there were 168 such cases, of which 37 ( 22 % ) were associated with previously known causes ( vinyl chloride,'Thorotrast ', and Druginorganic arsenic ) and 4 ( 3. 1 % ) of the remaining 131 cases with the use of androgenic - anabolic steroids. |
| 0.8729 | A retrospective epidemiological study of deaths from Adverse-Effecthepatic angiosarcoma ( HAS ) in the U. S. showed that during 1964 - - 74 there were 168 such cases, of which 37 ( 22 % ) were associated with previously known causes ( vinyl chloride,'Thorotrast ', and inorganic arsenic ) and 4 ( 3. 1 % ) of the remaining 131 cases with the use of androgenic - anabolic steroids. |
| 0.9826 | A retrospective epidemiological study of Adverse-Effectdeaths from hepatic angiosarcoma ( HAS ) in the U. S. showed that during 1964 - - 74 there were 168 such cases, of which 37 ( 22 % ) were associated with previously known causes ( vinyl chloride,'Thorotrast ', and inorganic arsenic ) and 4 ( 3. 1 % ) of the remaining 131 cases with the use of androgenic - anabolic steroids. |
| 0.8285 | A retrospective epidemiological study of deaths from hepatic angiosarcoma ( HAS ) in the U. S. showed that during 1964 - - 74 there were 168 such cases, of which 37 ( 22 % ) were associated with previously known causes ( vinyl chloride,'Thorotrast ', and inorganic arsenic ) and 4 ( 3. 1 % ) of the remaining 131 cases with the use of Drugandrogenic - anabolic steroids . |
| Score | Text |
|---|---|
| 0.9874 | Although his renal function recovered completely with high - dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of Adverse-Effectrenal toxicity may be present as early as 2 hours after the completion of a 4 - hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4 - hour MTX infusion. |
| 0.8931 | Although his renal function recovered completely with high - dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4 - hour DrugMTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4 - hour MTX infusion. |
| 0.8830 | Although his renal function recovered completely with high - dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4 - hour MTX infusion, and to suggest that monitoring for DrugMTX toxicity should perhaps begin within a few hours after the completion of 4 - hour MTX infusion. |
| 0.8661 | Although his renal function recovered completely with high - dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4 - hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4 - hour DrugMTX infusion. |
| 0.7612 | Although his renal function recovered completely with high - dose leucovorin, hemodialysis, charcoal hemoperfusion, and Drugcarboxypeptidase G2 , we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4 - hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4 - hour MTX infusion. |
| Score | Text |
|---|---|
| 0.9929 | We suggest that nicotinic acid was the cause of his liver disease, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of nicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of Adverse-Effecthepatotoxicity . |
| 0.9837 | We suggest that nicotinic acid was the cause of his liver disease, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of Drugnicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity. |
| 0.9821 | We suggest that Drugnicotinic acid was the cause of his liver disease, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of nicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity. |
| 0.9121 | We suggest that nicotinic acid was the cause of his Adverse-Effectliver disease , that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of nicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity. |
| 0.9897 | We suggest that nicotinic acid was the cause of his liver disease, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the Adverse-Effecthepatic failure , and that the probable increased use of nicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity. |
| 0.9664 | We suggest that nicotinic acid was the cause of his liver disease, that this case is of particular note because of the rather short period of therapy before the onset of Adverse-Effectliver injury and the severity of the hepatic failure, and that the probable increased use of nicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity. |
| Score | Text |
|---|---|
| 0.9878 | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken Drugmequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross - reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| 0.9766 | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross - reaction to promethazine, decreased MED to both UVA and UVB, and Adverse-Effectpersistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| 0.9727 | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross - reaction to Drugpromethazine , decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| 0.9557 | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross - reaction to promethazine, Adverse-Effectdecreased MED to both UVA and UVB , and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| 0.9315 | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross - reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the Drugmequitazine . |
| 0.9098 | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate Adverse-Effecterythema reaction, cross - reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| 0.9955 | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate Adverse-Effecterythema reaction , cross - reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| 0.7930 | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross - reaction to promethazine, Adverse-Effectdecreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| 0.6799 | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, Adverse-Effectcross - reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| 0.5977 | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross - reaction to promethazine, Adverse-Effectdecreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, Adverse-Effectcross - reaction to promethazine , decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. | |
| Score | Text |
|---|---|
| 0.9979 | Major points illustrated are, ( 1 ) occurrence of Adverse-EffectHIT with any dose or form of heparin ; ( 2 ) misperceptions on the diagnostic criteria ; ( 3 ) correct ( thrombin inhibitors ) and incorrect ( platelet transfusions and warfarin ) management ; ( 4 ) influence of management strategy on clinical outcomes ; ( 5 ) severity of the syndrome ; and ( 6 ) potential for both anamnestic response to heparin and disappearance of HIT antibodies over time. |
| 0.9862 | Major points illustrated are, ( 1 ) occurrence of HIT with any dose or form of Drugheparin ; ( 2 ) misperceptions on the diagnostic criteria ; ( 3 ) correct ( thrombin inhibitors ) and incorrect ( platelet transfusions and warfarin ) management ; ( 4 ) influence of management strategy on clinical outcomes ; ( 5 ) severity of the syndrome ; and ( 6 ) potential for both anamnestic response to heparin and disappearance of HIT antibodies over time. |
| 0.7708 | Major points illustrated are, ( 1 ) occurrence of HIT with any dose or form of heparin ; ( 2 ) misperceptions on the diagnostic criteria ; ( 3 ) correct ( thrombin inhibitors ) and incorrect ( platelet transfusions and warfarin ) management ; ( 4 ) influence of management strategy on clinical outcomes ; ( 5 ) severity of the syndrome ; and ( 6 ) potential for both anamnestic response to Drugheparin and disappearance of HIT antibodies over time. |
| 0.5895 | Major points illustrated are, ( 1 ) occurrence of HIT with any dose or form of heparin ; ( 2 ) misperceptions on the diagnostic criteria ; ( 3 ) correct ( thrombin inhibitors ) and incorrect ( platelet transfusions and Drugwarfarin ) management ; ( 4 ) influence of management strategy on clinical outcomes ; ( 5 ) severity of the syndrome ; and ( 6 ) potential for both anamnestic response to heparin and disappearance of HIT antibodies over time. |
| Score | Text |
|---|---|
| 0.9835 | These findings mean that the effect of the MP pulse therapy on renal function depends on the clinical state of the patient and that renal deterioration after the pulse therapy may be more marked in patients who are more nephrotic and more impaired in renal function and suggest that increasing sodium and water retention during an MP therapy and the associated renal interstitial edema, proposed as one of the mechanisms of acute renal failure occurring in patients with minimal - change nephrotic syndrome, may be responsible for the DrugMP - induced transient renal failure. |
| 0.9801 | These findings mean that the effect of the MP pulse therapy on renal function depends on the clinical state of the patient and that renal deterioration after the pulse therapy may be more marked in patients who are more nephrotic and more impaired in renal function and suggest that increasing sodium and water retention during an MP therapy and the associated renal interstitial edema, proposed as one of the mechanisms of acute renal failure occurring in patients with minimal - change nephrotic syndrome, may be responsible for the MP - induced Adverse-Effecttransient renal failure . |
| 0.9742 | These findings mean that the effect of the DrugMP pulse therapy on renal function depends on the clinical state of the patient and that renal deterioration after the pulse therapy may be more marked in patients who are more nephrotic and more impaired in renal function and suggest that increasing sodium and water retention during an MP therapy and the associated renal interstitial edema, proposed as one of the mechanisms of acute renal failure occurring in patients with minimal - change nephrotic syndrome, may be responsible for the MP - induced transient renal failure. |
| 0.8577 | These findings mean that the effect of the MP pulse therapy on renal function depends on the clinical state of the patient and that renal deterioration after the pulse therapy may be more marked in patients who are more nephrotic and more impaired in renal function and suggest that increasing sodium and water retention during an DrugMP therapy and the associated renal interstitial edema, proposed as one of the mechanisms of acute renal failure occurring in patients with minimal - change nephrotic syndrome, may be responsible for the MP - induced transient renal failure. |
| 0.8011 | These findings mean that the effect of the MP pulse therapy on renal function depends on the clinical state of the patient and that renal deterioration after the pulse therapy may be more marked in patients who are more nephrotic and more impaired in renal function and suggest that increasing sodium and water retention during an MP therapy and the associated Adverse-Effectrenal interstitial edema , proposed as one of the mechanisms of acute renal failure occurring in patients with minimal - change nephrotic syndrome, may be responsible for the MP - induced transient renal failure. |